{"abt22_sentences.json": [["In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures.", -0.5], ["The Diagnostic Products segment’s products are subject to competition in technological innovation, price, convenience of use, service, instrument warranty provisions, product performance, laboratory efficiency, long-term supply contracts, and product potential for overall cost-effectiveness and productivity gains.", 0.2], ["Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.", -0.3], ["Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.", -0.3], ["Due to disruptions to the global supply chain caused in part by the COVID-19 pandemic and macroeconomic conditions such as inflationary pressures and labor shortages, Abbott has experienced availability issues with some materials and electronic components.", -0.7], ["To date, Abbott has been able to manage these challenges without significant supply disruptions or shortages for raw materials and supplies.", 0.3], ["While it is not feasible to predict with certainty the final costs related to those investigations and remediation activities, Abbott believes that such costs, together with other expenditures to maintain compliance with applicable laws and regulations concerning environmental protection, should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.", 0.1], ["Compliance with these laws and regulations is costly and materially affects Abbott’s business.", -0.6], ["Among other effects, health care regulations and significant changes thereto (such as the introduction of the Medical Devices Regulation and the In Vitro Diagnostic Medical Devices Regulation in the European Union) substantially increase the time, difficulty, and costs incurred in developing, obtaining and maintaining approval to market, and marketing newly developed and existing products.", -0.4], ["Failure to comply can delay the release of a new product or result in regulatory and enforcement actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product’s production and sale, suspension or revocation of billing privileges, and other civil or criminal sanctions, including fines and penalties.", -0.8], ["Failure to comply with these regulatory requirements can result in sanctions, including suspension, revocation, or limitation of a laboratory’s certification, which is necessary to conduct business, as well as significant fines or criminal penalties.", -1.0], ["In some cases, these studies have resulted, and may in the future result, in the discontinuation of marketing of such products in one or more countries, and may give rise to claims for damages from persons who believe they have been injured as a result of their use.", -1.0], ["Budgetary pressures on health care payors may also heighten the scope and severity of pricing pressures on Abbott’s products for the foreseeable future.", -0.8], ["DRG and PPS entitle a health care facility to a fixed reimbursement based on the diagnosis and/or procedure rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products.", -0.5], ["Failure to report appropriate data may result in civil or criminal fines and/or penalties.", -1.0], ["Policy changes or implementation of new health care legislation could result in significant changes to health care systems.", -0.8], ["Failure to comply with data privacy and security laws and regulations can result in business disruption and enforcement actions, which could include civil or criminal penalties.", -1.0], ["Abbott believes that future legislation and regulation in the markets it serves could affect the timing and expense associated with bringing health care products or services to market, access to health care products and services, increase rebates, reduce prices or reimbursements or the rate of price increases for health care products and services, change health care delivery systems, create new fees and obligations for the pharmaceutical, nutrition, diagnostic, and medical device industries, or require additional reporting and disclosure.", -0.6], ["Abbott’s business, financial condition, results of operations, or prospects could be materially adversely affected by any of these risks.", -1.0], ["Disruptions to Abbott’s global supply chain, which is large and complex, could negatively affect Abbott’s results of operations.", -1.0], ["The COVID-19 pandemic has contributed to global supply chain disruptions, which have adversely impacted the cost and availability of certain raw materials, supplies, and services.", -0.8], ["While Abbott has taken actions to offset some of these inflationary pressures in its supply chain, Abbott may not be able to completely offset all the increases in its operational costs.", -0.6], ["Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.", -0.7], ["Abbott may not be able to integrate acquisitions successfully into its existing business or transition disposed businesses efficiently, and could incur or assume significant debt and unknown or contingent liabilities.", -0.7], ["Abbott could also experience negative effects on its reported results of operations from acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets.", -0.7], ["These effects could cause a deterioration of Abbott’s credit rating, result in increased borrowing costs and interest expense, and decrease liquidity.", -0.8], ["Abbott depends on sophisticated information technology systems and maintains protected personal data, and a cyber attack or other breach affecting these information technology systems or protected data could have a material adverse effect on Abbott’s results of operations.", -0.9], ["A significant attack or other disruption could result in adverse consequences, including increased costs and expenses, manufacturing challenges or disruption, problems with product availability, functionality or safety, damage to customer relations, reputational damage, lost revenue, and legal or regulatory penalties.", -0.9], ["For additional information concerning data privacy and security regulation, see the discussion in “Regulation” under Item 1, “Business.” A breach of protected personal information could result in adverse consequences, including regulatory inquiries or litigation, increased costs and expenses, reputational damage, lost revenue, and fines or penalties.", -0.8], ["Any significant breach, attack or other disruption involving Abbott’s systems or products could have a material adverse effect on Abbott’s business.", -0.9], ["Abbott’s research and development efforts may not succeed in developing commercially successful products and technologies, which may cause Abbott’s revenue and profitability to decline.", -0.8], ["Promising new products and technologies may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.", -0.7], ["Failure to launch successful new products or technologies, or new indications or uses for existing products, may cause Abbott’s products or technologies to become obsolete, causing Abbott’s revenues and operating results to suffer.", -0.9], ["The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers or manufacturers encounters problems manufacturing products, Abbott’s business could suffer.", -0.8], ["If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.", -0.7], ["Any of these events could, among other things, lead to increased costs, lost revenue, damage to customer relations, reputational damage, time and expense spent investigating the cause and remediating the problem, if any, a production stoppage at a manufacturing facility, and depending on the cause, similar losses with respect to other lots, batches or products.", -0.8], ["To the extent Abbott or one of its suppliers or manufacturers experiences significant manufacturing problems, this could have a material adverse effect on Abbott’s revenues and profitability.", -0.9], ["Abbott has significant indebtedness, which could adversely affect its business, including decreasing its business flexibility.", -0.8], ["This consolidated indebtedness could have the effect, among other things, of reducing Abbott's flexibility to respond to changing business and economic conditions, and reducing funds available for working capital, capital expenditures, acquisitions, and other general corporate purposes.", -0.8], ["Abbott's ability to arrange additional financing or refinancing will depend on, among other factors, Abbott's financial position and performance, as well as prevailing market conditions and other factors beyond Abbott's control.", -0.7], ["Consequently, Abbott cannot assure that it will be able to obtain additional financing or refinancing on terms acceptable to Abbott or at all, which could adversely impact Abbott's ability to make scheduled payments with respect to its consolidated indebtedness and its profitability and financial condition.", -1], ["Additionally, further borrowing could cause a deterioration of Abbott's credit ratings.", -1], ["Adverse changes in Abbott's credit ratings may result in increased borrowing costs for future long-term debt or short-term borrowing facilities and may limit financing options, including access to the unsecured borrowing market.", -1], ["Delays in the receipt of, or failure to obtain, approvals for future products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and substantial additional costs.", -1], ["Any of these events could disrupt Abbott’s business and have a material adverse effect on Abbott’s revenues, profitability, cash flows, and financial condition.", -1], ["In addition, violations of these laws, or allegations of such violations, could disrupt Abbott’s business and result in a material adverse effect on Abbott’s revenues, profitability, and financial condition.", -1], ["Changes in the health care regulatory environment may adversely impact the demand for and price of Abbott’s products.", -1], ["Both in the U.S. and internationally, government authorities may enact changes in regulatory requirements, make legislative or administrative reforms to existing reimbursement programs, make adverse decisions relating to Abbott’s products’ coverage or reimbursement, or make changes to patient access to health care, all of which could adversely impact the demand for and usage of Abbott’s products or the prices that Abbott’s customers are willing to pay for them.", -1], ["Future rulemaking could affect rebates, prices or the rate of price increases for health care products and services, or required reporting and disclosure.", -1], ["The expiration or loss of intellectual property protection and licenses may affect Abbott’s future revenues and operating income.", -1], ["To the extent Abbott’s intellectual property is successfully challenged, invalidated, or circumvented or to the extent it does not allow Abbott to compete effectively, Abbott’s businesses could suffer.", -0.8], ["To the extent that countries do not enforce Abbott’s intellectual property rights, Abbott’s future revenues and operating income could be reduced.", -0.7], ["Significant safety concerns could arise for Abbott’s products, which could have a material adverse effect on Abbott’s revenues and financial condition.", -0.9], ["When new safety concerns are reported, Abbott may be required to amend the conditions of use for a product.", -0.6], ["For example, Abbott may be required to provide additional warnings on a product’s label or narrow its approved intended use, either of which could reduce the product’s market acceptance.", -0.7], ["If serious safety concerns arise with an Abbott product, sales of the product have been and could be halted by Abbott or by regulatory authorities.", -0.9], ["Product liability claims and lawsuits, safety alerts or product recalls, and other allegations of product safety or quality issues, regardless of their validity or ultimate outcome, may have a material adverse effect on Abbott’s business and reputation and on Abbott’s ability to attract and retain customers.", -0.9], ["Consequences may also include additional costs, a decrease in market share for the products, lower income or exposure to other claims.", -0.8], ["Product liability losses are self-insured and could have a material adverse effect on Abbott’s profitability, cash flows, and financial condition.", -0.9], ["Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the COVID-19 pandemic, which has had, and may continue to have, a material effect on Abbott’s business, financial condition and results of operations.", -0.8], ["As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases like the COVID-19 pandemic, may negatively impact certain of Abbott's operations.", -0.8], ["Health concerns and significant changes in political or economic conditions caused by such outbreaks can cause, and during the COVID-19 pandemic have caused, significant reductions in demand for certain products, increased difficulty in serving customers, disruptions to manufacturing and supply chains, and negative effects on certain of Abbott’s operations as well as the operations of its suppliers, distributors and other third-party partners.", -0.9], ["In addition, the COVID-19 pandemic has contributed to global supply chain disruptions, which have adversely impacted the cost and availability of certain raw materials, supplies, and services.", -0.8], ["Further, the demand for COVID-19 tests has been volatile over the last two years as the number of COVID-19 cases has fluctuated during the period.", -0.7], ["Abbott expects the COVID-19 pandemic to shift to an endemic state in 2023, which would likely result in significantly lower demand for COVID-19 tests.", -0.6], ["Due to the unpredictability of the COVID-19 pandemic, including how and when it will shift to an endemic state, the extent to which COVID-19 will continue to have a material effect on Abbott’s business, financial condition or results of operations is uncertain.", -0.9], ["Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating income.", -0.8], ["In the United States and other countries, Abbott’s businesses have experienced downward pressure on certain product pricing.", -0.7], ["Cost containment efforts by governments and private organizations are described in greater detail in the section captioned “Regulation.” To the extent these cost containment efforts are not offset by greater patient access to health care or other factors, Abbott’s future revenues and operating income will be reduced.", -0.8], ["Competitors’ intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott’s future profitability and financial condition.", -0.9], ["A successful claim of patent or other intellectual property infringement could subject Abbott to significant damages or an injunction preventing the manufacture, sale or use of affected Abbott products.", -0.8], ["Any of these events could have a material adverse effect on Abbott’s profitability and financial condition.", -0.9], ["New products and technological advances by Abbott’s competitors may negatively affect Abbott’s results of operations.", -0.7], ["Fluctuation in foreign currency exchange rates has adversely affected and may continue to adversely affect Abbott’s financial statements and its ability to realize projected sales and earnings.", -0.8], ["Abbott’s profitability is affected by movement of the U.S. dollar against other currencies.", -0.6], ["Deterioration in the economic condition and credit quality of certain countries may negatively affect Abbott’s results of operations.", -0.7], ["Financial instability and fiscal deficits in these countries may result in additional austerity measures to reduce costs, including health care.", -0.7], ["Deterioration in the quality of sovereign debt, including credit downgrades, could increase Abbott’s collection risk where a significant amount of Abbott’s receivables in these countries are with governmental health care systems or where Abbott’s customers depend on payment by government health care systems.", -0.8], ["The international nature of Abbott’s business subjects it to additional business risks that may cause its revenue and profitability to decline.", -0.8], ["Events contemplated by these risks may, individually or in the aggregate, have a material adverse effect on Abbott’s revenues and profitability.", -0.9], ["Other factors can have a material adverse effect on Abbott’s future profitability and financial condition.", -0.8], ["legal difficulties, any of which could preclude or delay commercialization of products or adversely affect profitability, including claims asserting statutory or regulatory violations, and adverse litigation decisions.", -0.9], ["To date, Abbott has been able to manage these disruptions without material impact to its results of operations.", 0.5], ["There could be additional sanctions, economic volatility, cybersecurity threats, political instability, transportation and other supply disruptions, as well as collection default risk or limited availability of resources to conduct essential business processes that could have a material adverse impact to Abbott’s operations and financial condition.", -0.7], ["October 1, 2022 — October 31, 2022    2,000,000 (1)  $    98.258     2,000,000  $  2,919,279,803 (2)", 0.2], ["2022                      800,000 (1)  $    98.103      800,000  $   2,840,797,543 (2)", 0.2], ["On December 10, 2021, Abbott announced that its board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.", 0.7], ["Sales in international markets comprise 58 percent of consolidated net sales.", 0.4], ["The coronavirus (COVID-19) pandemic affected Abbott’s diversified health care businesses in various ways over the 2020 through 2022 period.", -0.3], ["Abbott’s Diagnostics segment experienced the most significant change in sales from 2020 to 2022 as a result of the COVID-19 pandemic.", 0.1], ["In 2020 and 2021, Abbott mobilized its teams across multiple fronts to develop and launch various new diagnostic tests to detect COVID-19.", -0.1], ["Abbott’s COVID-19 testing-related sales totaled approximately $8.4 billion in 2022, $7.7 billion in 2021, and $3.9 billion in 2020, led by sales related to Abbott’s BinaxNOW, Panbio and ID NOW rapid testing platforms.", 0.8], ["Abbott expects the COVID-19 pandemic to shift to an endemic state in 2023, which would likely result in significantly lower demand for COVID-19 tests.", -0.5], ["Due to the unpredictability of the pandemic, including how and when it will shift to an endemic state, the extent to which COVID-19 will have a material effect on Abbott's business, financial condition or results of operations is uncertain.", -0.8], ["Across Abbott’s cardiovascular and neuromodulation businesses, procedure volumes were negatively impacted in 2021 and 2022 by surges of COVID- 19 in various geographies as well as intermittent COVID-19 lockdown restrictions and healthcare staffing challenges.", -0.7], ["Despite such challenges, overall volume trends improved in several cardiovascular businesses in 2021 and 2022.", 0.3], ["While Abbott’s branded generic pharmaceuticals business was also negatively affected by the pandemic in 2020 as COVID-19 spread across emerging market countries,", -0.4], ["While Abbott’s 2022 and 2021 sales were most significantly affected by the COVID-19 pandemic, the increase in total sales since 2020 also reflects the introduction of new products across various businesses as well as higher sales of various existing products.", 0.2], ["Sales in emerging markets, which represent approximately 35 percent of total company sales, increased 5.6 percent in 2022 and 19.6 percent in 2021, excluding the impact of foreign exchange.", 0.6], ["On July 1, Abbott restarted partial production at the facility beginning with its specialty formula EleCare® and metabolic formulas.", 0.5], ["Over the last three years, Abbott’s operating margin as a percentage of sales increased from 15.5 percent in 2020 to 19.6 percent in 2021 and then decreased to 19.2 percent in 2022.", -0.1], ["The decrease in 2022 from 2021 reflects the impact of the voluntary infant product recall and manufacturing stoppage in U.S. Pediatric Nutritionals and the impact of inflation and supply chain challenges on various manufacturing inputs and transportation costs across Abbott's businesses, partially offset by the favorable impact of margin improvement initiatives.", -0.5], ["The increase in 2021 from 2020 reflects the impact of sales volume increases for COVID-19 tests in Rapid Diagnostics and growth across virtually all of Abbott’s businesses due, in part, to partial recovery from the COVID-19 pandemic, partially offset by the impact of inflation and supply chain challenges on various manufacturing inputs and transportation costs and an increase in restructuring costs.", 0.2], ["While Abbott expects inflationary pressures on various raw materials, packaging materials and transportation costs to continue in 2023, the impact of such cost increases is expected to be at least partially mitigated by price increases in certain businesses and the impact of continued gross margin improvement initiatives.", 0.1], ["With respect to the performance of each reportable segment over the last three years, sales in the Medical Devices segment, excluding the impact of foreign exchange, increased 8.1 percent in 2022 and 19.4 percent in 2021.", 0.5], ["The sales increase in 2022 was driven by growth in Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure.", 0.7], ["The sales increase in 2021 was driven by double-digit growth across all of Abbott’s Medical Devices divisions, led by Diabetes Care, Structural Heart and Electrophysiology, due, in part, to a partial recovery from the COVID-19 pandemic.", 0.6], ["In 2022, operating earnings for the Medical Devices segment decreased 2.3 percent.", -0.3], ["Excluding the impact of foreign exchange, Medical Devices operating earnings increased 9.3 percent.", 0.4], ["The operating margin profile for the Medical Devices segment increased from 25.8 percent of sales in 2020 to 31.4 percent in 2021 and then decreased to 30.0 percent in 2022.", 0.2], ["The overall increase over the two years reflects the impact of higher sales volumes across the Medical Device businesses, partially offset by continued pricing pressures on drug eluting stents (DES) and other products.", -0.1], ["The decrease in 2022 from 2021 reflects various factors, including the impacts of inflationary pressures and supply chain challenges related to various manufacturing inputs and processes.", -0.6], ["In Abbott’s Diagnostics segment, sales increased 10.4 percent in 2022 and 42.7 percent in 2021, excluding the impact of foreign exchange.", 0.5], ["In 2022, operating earnings for the Diagnostics segment increased 6.6 percent.", 0.3], ["The operating margin profile increased from 34.3 percent of sales in 2020 to 40.2 percent in 2022 primarily due to higher sales in Rapid Diagnostics and the impact of increased routine diagnostics testing on Core Laboratory Diagnostics versus 2020 levels.", 0.7], ["In Abbott’s Nutritional Products segment, total pediatric nutrition sales, excluding the impact of foreign exchange, decreased 16.6 percent in 2022 as a result of the voluntary recall and manufacturing stoppage discussed above as well as challenging market dynamics in Greater China.", -0.8], ["In December 2022, Abbott initiated steps to exit its pediatric nutrition business in China.", -0.9], ["Excluding the impact of foreign exchange, total pediatric nutrition sales increased 3.3 percent in 2021 driven by the Pedialyte®, PediaSure® and Similac brands in the U.S. as well as infant and toddler product growth across several international markets, partially offset by challenging market dynamics in the Greater China infant category.", 0.2], ["Excluding the impact of foreign exchange, total adult nutrition sales increased 4.8 percent in 2022 and 12.8 percent in 2021, led by the continued growth of Ensure®, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna®, Abbott’s market-leading diabetes-specific nutrition brand, across several countries.", 0.6], ["In 2022, operating earnings for the Nutritional Products segment decreased 60.0 percent.", -0.9], ["Operating margins for the worldwide nutritional products business decreased from 22.9 percent in 2020 to 9.5 percent in 2022.", -0.8], ["Excluding the impact of foreign exchange, Established Pharmaceutical sales increased 10.6 percent in 2022 and 10.4 percent in 2021.", 0.7], ["The sales increases in 2022 and 2021 reflect higher sales in several geographies including India, China, and Brazil.", 0.6], ["In 2022, operating earnings for the Established Pharmaceutical Products segment increased 18.0 percent.", 0.8], ["Operating margins increased from 18.5 percent of sales in 2020 to 21.4 percent in 2022 primarily due to the impact of gross margin improvement initiatives and higher selling prices partially offset by inflation on various product inputs.", 0.7], ["Abbott declared dividends of $1.92 per share in 2022 and $1.82 per share in 2021, an increase of approximately 5.5 percent.", 0.5], ["Dividends paid totaled $3.309 billion in 2022 compared to $3.202 billion in 2021.", 0.1], ["The year-over-year change in the amount of dividends paid reflects the increase in the dividend rate.", 0.3], ["In December 2022, Abbott increased the company’s quarterly dividend by 8.5 percent to $0.51 per share from $0.47 per share, effective with the dividend paid in February 2023.", 0.6], ["In December 2021, Abbott increased the company’s quarterly dividend by 4.4 percent to $0.47 per share from $0.45 per share, effective with the dividend paid in February 2022.", 0.4], ["In 2023, Abbott will also focus on continuing to invest in product development areas that provide the opportunity for strong sustainable growth over the next several years.", 0.8], ["In its diagnostics business, Abbott's focus will include driving sales growth from its Alinity suite of diagnostics instruments and its portfolio of rapid diagnostic testing systems as well as continuing to meet COVID-19 test demand.", 0.7], ["In the Medical Devices segment, Abbott will focus on launching various new products and expanding its market position across the various businesses.", 0.7], ["In its nutritional business, Abbott will continue to focus on executing the actions needed to achieve a recovery in its infant formula business and growth globally.", 0.6], ["In the established pharmaceuticals business, Abbott will continue to focus on growing its business with the depth and breadth of its portfolio in emerging markets.", 0.6], ["Sales Rebates — In 2022, approximately 45 percent of Abbott’s consolidated gross revenues were subject to various forms of rebates and allowances that Abbott recorded as reductions of revenues at the time of sale.", -0.3], ["Using historical trends, adjusted for current changes, Abbott estimates the amount of the rebate that will be paid, and records the liability as a reduction of gross sales when Abbott records its sale of the product.", -0.2], ["Rebates and chargebacks charged against gross sales in 2022, 2021, and 2020 amounted to approximately", -0.4], ["$3.9 billion, $3.9 billion, and $3.3 billion, respectively, or 17.6 percent, 17.5 percent, and 20.1 percent of gross sales, respectively, based on gross sales of approximately $22.4 billion, $22.3 billion, and $16.6 billion, respectively, subject to rebate.", -0.4], ["A one-percentage point increase in the percentage of rebates to related gross sales would decrease net sales by approximately $224 million in 2022.", -0.5], ["Other allowances charged against gross sales were approximately $280 million, $268 million, and $207 million for cash discounts in 2022, 2021, and 2020, respectively, and $379 million, $211 million, and $232 million for returns in 2022, 2021, and 2020, respectively.", -0.5], ["The significant net actuarial gains for these plans in 2022 reflects the impact of higher discount rates on the measurement of plan liabilities, partially offset by lower asset returns during the year.", 0.2], ["$2.0 billion for Abbott’s defined benefit plans and net gains of $6 million for Abbott’s medical and dental plans.", 0.1], ["If the undiscounted cash flows of an intangible asset are less than the carrying value of an intangible asset, the intangible asset is written down to its fair value, which is usually the discounted cash flow amount.", -0.7], ["Amortization expense in continuing operations for intangible assets amounted to $2.0 billion in 2022 and 2021 and $2.1 billion in 2020.", -0.3], ["There was no reduction of goodwill relating to impairments in 2022, 2021, and 2020.", 0.3], ["450, loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded.", -0.6], ["As information becomes known, either the minimum loss amount is increased, resulting in additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions.", -0.6], ["Abbott estimates the range of possible loss to be from approximately $40 million to", -0.4], ["$50 million for its legal proceedings and environmental exposures.", -0.4], ["Accruals of approximately $45 million have been recorded at December 31, 2022 for these proceedings and exposures.", -0.2], ["The increase in Total Net Sales in 2022 reflects growth in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as well as growth in the Established Pharmaceutical Products and Medical Devices segments, partially offset by lower Nutritional Products sales.", 0.5], ["Abbott’s COVID-19 testing-related sales totaled approximately $8.4 billion in 2022, $7.7 billion in 2021 and $3.9 billion in 2020.", 0.4], ["Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales decreased 0.3 percent in 2022.", -0.3], ["Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 5.1 percent.", 0.5], ["Abbott’s net sales in 2022 were unfavorably impacted by changes in foreign exchange rates as the relatively stronger U.S. dollar decreased total international sales by", -0.4], ["8.2 percent and total sales by 5.1 percent.", -0.4], ["The increase in Total Net Sales in 2021 reflects volume growth across all of Abbott's segments.", 0.6], ["In 2021, excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 15.2 percent.", 0.7], ["Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 13.7 percent.", 0.7], ["The price declines related to the Diagnostic Products segment in 2022 and 2021 primarily reflect lower pricing for COVID-19 tests.", -0.5], ["Total Established Pharmaceutical Products sales increased 10.6 percent in 2022 and 10.4 percent in 2021, excluding the unfavorable impact of foreign exchange.", 0.8], ["Excluding the impact of foreign exchange, total sales in Key Emerging markets increased 11.8 percent in 2022 and 11.9 percent in 2021 due to higher sales in various geographies including India, China, and Brazil, and several therapeutic areas, including gastroenterology, central nervous system/pain management, and cardiometabolic products.", 0.9], ["Excluding the impact of foreign exchange, sales in Established Pharmaceuticals’ other emerging markets increased 7.3 percent in 2022 and 6.0 percent in 2021.", 0.7], ["Excluding the impact of foreign exchange, total Nutritional Products sales decreased 6.2 percent in 2022 compared to a 7.7 percent increase in 2021.", -0.3], ["The 28.7 percent decrease in U.S. Pediatric Nutritional sales in 2022 reflects the impact of the voluntary recall and production stoppage of certain infant powder formula products manufactured at Abbott's facility in Sturgis, Michigan, partially offset by increased demand for Abbott’s Pedialyte products.", -0.8], ["U.S. sales of infant powder formula brands associated with the recall were $479 million and $1.2 billion in 2022 and 2021, respectively.", -0.7], ["In 2021, U.S. Pediatric Nutritional sales increased 10.3 percent compared to 2020, reflecting growth in Pedialyte, Similac, and PediaSure.", 0.6], ["International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 3.9 percent in 2022 and 3.2 percent in 2021.", -0.4], ["The 2022 decrease reflects the impact of challenging market dynamics in the infant category in Greater China, partially offset by higher sales volumes in several countries in Southeast Asia and Latin America.", -0.2], ["The 2021 decrease reflects lower sales in China, the Middle East and various countries in Southeast Asia, partially offset by higher volumes sold in various countries in Latin America and Europe.", -0.2], ["International Adult Nutritional sales, excluding the effect of foreign exchange, increased 7.6 percent in 2022 and 17.0 percent in 2021, reflecting continued growth of the Ensure and Glucerna brands in various countries.", 0.8], ["Adult Nutritional sales decreased 0.5 percent as continued growth of the Ensure brand was offset by lower sales of other products and the impact of temporarily utilizing liquid manufacturing capacity to manufacture infant formula.", -0.1], ["Adult Nutritional sales increased 5.6 percent, primarily due to growth of Ensure and Glucerna.", 0.6], ["Excluding the effect of foreign exchange, Diagnostics segment sales increased 10.4 percent in 2022 and 42.7 percent in 2021, driven by demand for Abbott’s portfolio of COVID-19 tests in Rapid Diagnostics.", 0.7], ["Rapid Diagnostics sales increased 22.5 percent and", 0.5], ["93.3 percent in 2022 and 2021, respectively, excluding the effect of foreign exchange.", 0.4], ["The increases reflect COVID-19 test demand across Abbott’s rapid testing platforms, including the Panbio system, the ID NOW platform, and the BinaxNOW COVID-19 Ag Card test.", 0.6], ["Rapid Diagnostics COVID-19 testing-related sales were $7.9 billion in 2022, $6.6 billion in 2021 and $2.6 billion in 2020.", 0.7], ["In 2022, Rapid Diagnostics sales increased 15.8 percent, excluding COVID-19 testing-related sales, and 19.1 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.7], ["These increases reflect higher sales of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.", 0.8], ["In 2021, Rapid Diagnostics sales increased 10.4 percent, excluding COVID-19 testing-related sales, and 9.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.7], ["These increases reflected the recovery of routine diagnostic testing from the 2020 impact of the pandemic.", 0.5], ["In Core Laboratory Diagnostics, sales increased 1.9 percent in 2022, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing from the continued roll-out of the Alinity platform and an expanded menu of tests.", 0.6], ["These higher volumes were partially offset by lower sales of Abbott’s laboratory-based tests for the detection of COVID-19 IgG and IgM antibodies as well as intermittent market disruptions in China due to COVID-19 quarantine restrictions in various cities.", -0.2], ["Core Laboratory Diagnostics COVID-19 testing-related sales on Abbott’s ARCHITECT and Alinity i platforms were $62 million in 2022, $204 million in 2021, and $262 million in 2020.", -0.1], ["In 2022, Core Laboratory Diagnostics sales decreased 2.0 percent, excluding COVID-19 testing- related sales, and increased 4.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.3], ["In 2021, Core Laboratory Diagnostics sales increased 12.4 percent, excluding the effect of foreign exchange, as a higher volume of routine diagnostic testing performed in hospitals and other laboratories was partially offset by lower sales of tests for the detection of COVID-19 IgG and IgM antibodies.", 0.4], ["In Molecular Diagnostics, sales decreased 27.4 percent in 2022 and 2.9 percent in 2021, excluding the effect of foreign exchange.", -0.7], ["In both years, the decreases were driven by lower demand for Abbott’s laboratory-based PCR molecular tests for COVID-19, partially offset by growth in other areas from the continued roll-out of the Alinity m platform.", -0.5], ["In 2022, Molecular Diagnostics sales increased 9.0 percent, excluding COVID-19 testing-related sales, and 13.8 percent, excluding the impact of foreign exchange and COVID-19 testing- related sales.", 0.8], ["In 2021, Molecular Diagnostics sales increased 29.2 percent, excluding COVID-19 testing-related sales, and increased", 0.7], ["27.0 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.7], ["Excluding the effect of foreign exchange, total Medical Devices sales grew 8.1 percent in 2022 and 19.4 percent in 2021.", 0.8], ["In 2022 and 2021, the increase was driven by growth in Diabetes Care, Structural Heart, Electrophysiology and Heart Failure.", 0.7], ["The 2022 and 2021 growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre, Abbott’s continuous glucose monitoring system, in the U.S. and internationally.", 0.8], ["FreeStyle Libre sales totaled $4.3 billion in 2022, which reflected a 22.4 percent increase, excluding the effect of foreign exchange, over 2021.", 0.9], ["FreeStyle Libre sales totaled $3.7 billion in 2021, which reflected a 36.8 percent increase, excluding the effect of foreign exchange, over 2020 when sales totaled $2.6 billion.", 0.9], ["In 2022, while procedure volumes across Abbott’s cardiovascular and neuromodulation businesses were negatively impacted by new surges of COVID-19 in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the year, overall volumes improved in several businesses versus 2021.", -0.2], ["In Electrophysiology, the 7.3 percent growth, excluding the effect of foreign exchange, reflects the increase in procedure volumes and the continued roll‑out of Abbott’s EnSite X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across Europe.", 0.8], ["Growth in Structural Heart, excluding the effect of foreign exchange, was 13.0 percent in 2022, driven by growth across several areas of the business, including Amplatzer® Amulet® Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form and MitraClip®, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation, a leaky heart valve.", 0.8], ["In Vascular, 2022 sales decreased 1.0 percent, excluding the impact of exchange, as higher endovascular sales were offset by the negative effect of lower average selling prices globally on traditional DES and other coronary products and a lower recovery of percutaneous coronary intervention (PCI) procedures which impacted the coronary business.", -0.5], ["In 2021, while procedure volumes across Abbott’s cardiovascular and neuromodulation businesses were negatively impacted early in the year by elevated COVID-19 case rates in certain countries, including the U.S., overall volumes improved over the course of 2021 across various businesses.", 0.1], ["The year-over-year increases in the various businesses reflect a recovery from the 2020 levels when the pandemic reduced procedure volumes as well as sales growth from pre-pandemic levels in Structural Heart, Electrophysiology, and", 0.3], ["The growth in Structural Heart during 2021 was broad-based across several areas of the business, including MitraClip and TriClip®, the world’s first minimally invasive, clip-based device for repair of a leaky tricuspid heart valve.", 0.7], ["Abbott has periodically sold product rights to non-strategic products and has recorded the related gains in net sales in accordance with Abbott’s revenue recognition policies as discussed in Note 1 to the consolidated financial statements.", 0.2], ["Gross profit margins were 51.5 percent of net sales in 2022, 52.2 percent of net sales in 2021, and 50.5 percent in 2020.", 0.1], ["The decrease in 2022 reflects the impact of the voluntary infant product recall and Sturgis manufacturing stoppage as well as the prioritization of infant formula sales related to the WIC Program in the Nutritional business.", -0.7], ["The decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses.", -0.6], ["In 2021, the increase primarily reflects the effects of higher sales volume, higher manufacturing utilization, and the nonrecurrence of a 2020 impairment of intangible assets, partially offset by increases in various manufacturing costs and the impact of higher restructuring charges.", 0.2], ["The increase primarily reflects higher spending on various projects to advance products in development as well as the impairment of certain in- process R&D intangible assets partially offset by the favorable impact of foreign exchange.", -0.2], ["Selling, general and administrative (SG&A) expenses were virtually unchanged in 2022 compared to 2021 as higher selling and marketing spending to drive growth was offset by the favorable impact of foreign exchange.", 0.0], ["SG&A expenses increased 16.8 percent in 2021 due primarily to higher selling and marketing spending and the nonrecurrence of $100 million of income in 2020 from a litigation settlement.", -0.3], ["In 2022, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses.", 0.2], ["Abbott recorded employee-related severance and other charges of approximately $234 million of which approximately $59 million was recorded in Cost of products sold, approximately", -0.4], ["In addition, Abbott recognized inventory-related charges of approximately $23 million and fixed assets impairment charges of approximately $4 million related to these restructuring plans.", -0.3], ["Abbott recorded employee related severance and other charges of approximately $68 million of which approximately $16 million was recorded in Cost of products sold, approximately", -0.4], ["On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter of 2021 in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals.", -0.1], ["In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold.", -0.5], ["The charge recognized in the second quarter included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.", -0.5], ["In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly.", -0.1], ["As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter restructuring action.", 0.3], ["In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter or Abbott settled with the counterparty in the second half of 2021.", 0.1], ["Interest expense, net decreased $115 million in 2022 due to the impact of higher interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022 partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.", 0.2], ["Interest expense, net decreased $10 million in 2021 due to the reduction of interest expense driven by lower interest rates in 2021.", 0.1], ["Other (income) expense, net includes income of approximately $406 million, $270 million, and $205 million in 2022, 2021, and 2020, respectively, related to the non-service cost components of the net periodic benefit costs associated with the pension and post- retirement medical plans.", 0.4], ["Other (income) expense, net also includes equity investment impairments that totaled approximately $45 million in 2022 and $115 million in 2020 and a gain on the sale of an equity method investment in 2021.", -0.2], ["The $26 million increase to the transition tax liability was the result of the resolution of various tax positions related to prior years.", -0.3], ["This adjustment increased the cumulative net tax expense related to the TCJA to $1.53 billion.", -0.4], ["Earnings from discontinued operations, net of tax, in 2020 reflect the recognition of $24 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years.", 0.1], ["Exclusive of these discrete items, tax expense was favorably impacted by lower tax rates and tax exemptions on foreign income primarily derived from operations in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica, Singapore, and Malta.", -0.1], ["Widespread adoption of a minimum tax rate regime could have an unfavorable impact on Abbott’s future effective tax rate.", -0.7], ["Over the next several years, Abbott plans to expand its product portfolio in key therapeutic areas with the aim of addressing the health needs of more people in emerging markets and being among the first to launch new off-patent and differentiated medicines.", 0.8], ["In addition, Abbott continues to expand existing brands into new markets, implement product enhancements that provide value to patients and acquire strategic products and technology through licensing activities.", 0.7], ["The results of the last impairment test indicated that the fair value of each reporting unit was substantially in excess of its carrying value.", 0.5], ["Net cash from operating activities amounted to $9.6 billion, $10.5 billion, and $7.9 billion in 2022, 2021, and 2020, respectively.", 0.6], ["The decrease in Net cash from operating activities in 2022 was primarily due to the unfavorable cash flow impact of an increased investment in working capital partially offset by reduced expenditures related to restructuring actions and lower cash payments for income taxes.", -0.5], ["The increase in Net cash from operating activities in 2021 was primarily due to the favorable cash flow impact of higher segment operating earnings and improved working capital management partially offset by higher cash taxes paid and the net impact of litigation settlements.", 0.4], ["Abbott expects annual cash flow from operating activities to continue to exceed Abbott’s capital expenditures and cash dividends.", 0.9], ["At December 31, 2022, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s.", 0.7], ["As of December 31, 2022, Abbott's total debt outstanding was $16.8 billion, of which $2.25 billion will mature in 2023.", -0.2], ["On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.", 0.2], ["In 2021, Abbott repaid approximately $195 million on a short-term facility upon maturity.", 0.1], ["After the repayment, Abbott has no short-term debt.", 0.5], ["On June 24, 2020, Abbott completed the issuance of $1.3 billion aggregate principal amount of senior notes, consisting of", -0.1], ["On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due 2020 upon maturity.", 0.2], ["Under the program authorized in 2014, Abbott repurchased 1.6 million shares at a cost of $173 million in 2020.", 0.1], ["In 2021, Abbott repurchased 16.6 million of its common shares for $2.016 billion which fully utilized the authorization remaining under the 2014 share repurchase program and a portion of the 2019 authorization.", 0.3], ["32.3 million of its common shares for $3.65 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization.", 0.3], ["Abbott declared dividends of $1.92 per share in 2022 compared to $1.82 per share in 2021, an increase of approximately 5.5 percent.", 0.7], ["Dividends paid were $3.309 billion in 2022 compared to $3.202 billion in 2021.", -0.1], ["Working capital was $9.7 billion at December 31, 2022 and $11.1 billion at December 31, 2021.", -0.2], ["The decrease was due largely to the classification of $2.3 billion of Senior Notes due in 2023 as current liabilities, partially offset by an increase in inventory.", -0.5], ["It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future.", -0.8], ["The new standard did not have an impact on its consolidated financial statements.", 0.0], ["Abbott does not expect adoption of this new standard to have a material impact on its consolidated financial statements.", 0.0], ["A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at December 31, 2022 by approximately $2 million.", -0.3], ["Changes in the fair value of these securities are recorded in earnings.", 0.1], ["Changes in the fair value of these investments, as well as an offsetting change in the benefit obligation, are recorded in earnings.", 0.1], ["The fair value of long-term debt at December 31, 2022 and 2021 amounted to $16.3 billion and $21.2 billion, respectively (average interest rates of 3.5% and 3.4% as of December 31, 2022 and 2021, respectively) with maturities through 2046.", -0.2], ["At December 31, 2022 and 2021, the fair value of current and long-term investment securities amounted to approximately $1.1 billion and $1.3 billion, respectively.", -0.1], ["These contracts are designated as cash flow hedges of the variability of the cash flows due to changes in foreign currency exchange rates and are marked-to-market with the resulting gains or losses reflected in Accumulated other comprehensive income (loss).", 0.0], ["Gains or losses will be included in Cost of products sold at the time the products are sold, generally within the next twelve to eighteen months.", 0.1], ["The contracts are marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or gains on the foreign currency exposure being managed.", 0.1], ["The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.", 0.0], ["Net Earnings from Discontinued Operations, net of taxes", -0.2], ["Net actuarial gains (losses) and prior service cost and credits and amortization", -0.1], ["of net actuarial losses and prior service cost and credits, net of taxes of $330", -0.1], ["in 2022, $340 in 2021 and $(79) in 2020", 0.0], ["Net gains (losses) on derivative instruments designated as cash flow hedges,", -0.1], ["net of taxes of $11 in 2022, $63 in 2021 and $(87) in 2020", -0.2], ["Net actuarial (losses) and prior service (cost) and credits", -0.5], ["Cumulative gains (losses) on derivative instruments designated as cash flow", -0.3], ["Proceeds from issuance of long-term debt and debt with maturities over 3 months", 0.5], ["Repayments of long-term debt and debt with maturities over 3 months", -0.5], ["Effect of exchange rate changes on cash and cash equivalents", 0.0], ["Net Increase (Decrease) in Cash and Cash Equivalents", 0.0], ["Post-employment obligations and other long-term liabilities                         7,522       8,771 Commitments and contingencies", -0.2], ["Common shares held in treasury, at cost — Shares: 2022: 248,724,257; 2021: 221,191,228         (15,229)      (11,822) Earnings employed in the business                                      35,257       31,528", 0.3], ["Shares: 2022: 221,191,228; 2021: 209,926,622; 2020: 214,351,838      $    (11,822) $    (10,042) $    (10,147)", -0.3], ["Shares: 2022: 32,513,231; 2021: 16,914,774; 2020: 1,865,541              (3,676)      (2,051)       (193)", -0.5], ["Shares: 2022: 248,724,257; 2021: 221,191,228; 2020: 209,926,622      $    (15,229) $    (11,822) $    (10,042)", -0.7], ["Beginning of Year                                $     31,528  $     27,627  $     25,847 Impact of adoption of new accounting standards                        —         —         (5) Net earnings                                        6,933       7,071       4,495", 0.5], ["Beginning of Year                               $     (8,374) $     (8,946) $     (8,465)", -0.8], ["End of Year                                  $     (8,051) $     (8,374) $     (8,946)", -0.8], ["Actual results could differ from those amounts.", -0.2], ["Transaction gains and losses are recorded on the Net foreign exchange (gain) loss line of the Consolidated Statement of Earnings.", 0.0], ["Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements are recorded when the conditions noted above are met.", 0.2], ["Sales of product rights for marketable products are recorded as revenue upon disposition of the rights.", 0.3], ["Earnings from Continuing Operations allocated to common shares in 2022, 2021 and 2020 were $6.905 billion, $7.042 billion and $4.449 billion, respectively.", 0.6], ["Net earnings allocated to common shares in 2022, 2021 and 2020 were $6.905 billion, $7.042 billion and $4.473 billion, respectively.", -0.1], ["Investments held in a rabbi trust and investments in publicly traded equity securities are recorded at fair value and changes in fair value are recorded in earnings.", 0.0], ["Product liability losses are self-insured.", -0.5], ["Abbott’s COVID-19 testing-related sales totaled approximately $8.4 billion in 2022, $7.7 billion in 2021, and $3.9 billion in 2020.", 0.5], ["As of December 31, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4 billion in the Diagnostic Products segment and approximately $432 million in the Medical Devices segment.", 0.2], ["Other (income) expense, net, for 2022, 2021 and 2020 includes approximately $406 million, $270 million and $205 million of income, respectively, related to the non-service cost components of the net periodic benefit costs associated with the pension and post- retirement medical plans.", 0.3], ["The decrease in Abbott’s long-term investments as of December 31, 2022 versus the balance as of December 31, 2021 primarily relates to a decrease in the fair value of investments held in a rabbi trust, the impact of asset impairments and a distribution from an investment held in a joint venture, partially offset by increased investment in long-term time deposits.", -0.4], ["Includes approximately $850 million and $680 million of net unrecognized tax benefits in 2022 and 2021, respectively.", -0.2], ["Other comprehensive income (loss) before reclassifications         (980)       954       137        111", -0.6], ["Net current period other comprehensive income (loss)            (980)      1,201       351       572", -0.3], ["Balance at December 31, 2021                       (5,839)      (2,670)       135      (8,374)", -1.0], ["Other comprehensive income (loss) before reclassifications         (894)      1,007       199       312", 0.2], ["Foreign currency translation adjustments decreased goodwill by $431 million in 2022 and by $532 million in 2021.", -0.5], ["There were no reductions of goodwill relating to impairments in 2022 and 2021.", 0.5], ["In 2022, $111 million of impairment charges were recorded on the Research and development line of the Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.", -0.8], ["Foreign currency translation adjustments decreased intangible assets by $150 million in 2022 and by $197 million in 2021.", -0.5], ["In 2022, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses.", 0.7], ["Abbott recorded employee related severance and other charges of approximately $234 million of which approximately $59 million was recorded in Cost of products sold, approximately", -0.7], ["$36 million was recorded in Research and development and approximately $139 million was recorded in Selling, general and administrative expenses.", -0.7], ["In addition, Abbott recognized inventory related charges of approximately $23 million and fixed assets impairment charges of approximately $4 million related to these restructuring plans.", -0.8], ["In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold.", -0.5], ["The charge recognized in the second quarter included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.", -0.7], ["In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly.", 0.3], ["As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter restructuring action.", 0.2], ["In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter or Abbott settled with the counterparty in the second half of 2021.", 0.1], ["In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott's diagnostic, established pharmaceutical, nutritional, and medical device businesses.", 0.4], ["Abbott recorded employee related severance and other charges of approximately $68 million of which approximately $16 million was recorded in Cost of products sold, approximately", -0.4], ["$4 million was recorded in Research and development and approximately $48 million was recorded in Selling, general and administrative expenses.", -0.3], ["The fair market value of restricted stock awards and units vested in 2022, 2021 and 2020 was $639 million, $809 million and $631 million, respectively.", 0.6], ["The total intrinsic value of options exercised in 2022, 2021 and 2020 was $85 million, $393 million and $279 million, respectively.", 0.5], ["The total unrecognized compensation cost related to all share-based compensation plans at December 31, 2022 amounted to approximately $494 million, which is expected to be recognized over the next three years.", -0.1], ["Total non-cash stock compensation expense charged against income from continuing operations in 2022, 2021 and 2020 for share- based plans totaled approximately $685 million, $640 million and $546 million, respectively, and the tax benefit recognized was approximately $170 million, $267 million and $200 million, respectively.", 0.2], ["On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.", 0.0], ["On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due 2021 upon maturity.", 0.0], ["Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis.", 0.5], ["In September 2019, the board of directors approved a bond redemption authorization for the early redemption of up to $5 billion of outstanding long-term debt.", 0.3], ["In December 2021, Abbott repaid a short-term facility for approximately $195 million.", 0.0], ["Operating lease revenue represented less than 3 percent of Abbott’s total net sales in the years ended December 31, 2022, 2021 and 2020.", -0.2], ["Accumulated gains and losses as of December 31, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.", -0.3], ["The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.", -0.4], ["The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income.", -0.1], ["as cash flow hedges       $  281  $  164  $  (207) $  234  $  (252) $  102  Cost of products sold", -0.2], ["A gain of $70 million, a gain of $19 million and a loss of $171 million were recognized in 2022, 2021 and 2020, respectively, related to foreign currency forward exchange contracts not designated as hedges.", 0.1], ["Excluding such contingent consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at December 31, 2022 to be approximately $235 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.", 0.0], ["Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations.", -0.5], ["Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure.", -0.4], ["No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.", -0.3], ["Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million.", -0.6], ["(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs", -0.2], ["The $3.6 billion and $463 million of defined benefit plan gains in 2022 and 2021, respectively, that decreased the projected benefit obligations primarily reflect the year-over-year increases in the discount rates used to measure the obligations.", 0.3], ["The $437 million of medical and dental plan gains in 2022 that decreased the projected benefit obligations primarily reflect the year-over-year increase in the discount rates used to measure the obligations.", -0.1], ["Other comprehensive income (loss) for each respective year includes the amortization of actuarial losses and prior service costs (credits) as noted in the previous table.", 0.0], ["Other comprehensive income (loss) for each respective year also includes: net actuarial gains of", 0.1], ["$858 million for defined benefit plans and a gain of $374 million for medical and dental plans in 2022; net actuarial gains of $1.141 billion for defined benefit plans and a gain of $45 million for medical and dental plans in 2021, and net actuarial losses of $611 million for defined benefit plans and a gain of $23 million for medical and dental plans in 2020.", 0.2], ["The net actuarial gains in 2022 are primarily due to the year-over-year increase in discount rates partially offset by the impact of 2022 actual asset returns being less than expected returns.", 0.1], ["The net actuarial gains in 2021 are primarily due to the favorable impact of actual 2021 asset returns in excess of expected returns and the year-over-year increase in discount rates.", 0.2], ["The net actuarial losses in 2020 are primarily due to the year-over-year decline in discount rates, partially offset by the impact of actual asset returns in excess of expected returns.", -0.2], ["$290 million of the absolute return funds, redemptions are subject to a 33 percent gate and a 25 percent gate, respectively, and $70 million is subject to a lock until 2025.", -0.3], ["Abbott’s unfunded commitment in these funds was $569 million and $585 million as of December 31, 2022 and 2021, respectively.", -0.1], ["Abbott funded $413 million in 2022 and $418 million in 2021 to defined pension plans.", 0.1], ["Abbott’s contributions to this plan were $190 million in 2022, $181 million in 2021 and $164 million in 2020.", -0.1], ["In 2022, taxes on earnings from continuing operations include approximately $43 million in excess tax benefits associated with share-based compensation and approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years.", -0.2], ["In 2021, taxes on earnings from continuing operations include approximately $145 million in excess tax benefits associated with share-based compensation and approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years.", 0.1], ["In 2020, taxes on earnings from continuing operations include the recognition of approximately $170 million of tax benefits associated with the impairment of certain assets, approximately $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years, and approximately $100 million in excess tax benefits associated with share-based compensation.", 0.2], ["In 2020, taxes on earnings from continuing operations also include a $26 million increase to the transition tax liability associated with the 2017 TCJA.", -0.3], ["This adjustment increased the cumulative net tax expense related to the TCJA to $1.53 billion.", -0.4], ["Earnings from discontinued operations, net of tax, in 2020 reflect the recognition of $24 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years.", 0.1], ["Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit is so remote that the benefit is not reflected as a deferred tax asset.", -0.5], ["The 2021 increase due to prior year tax positions includes approximately $714 million of international tax positions for which a deferred tax asset has not been recorded because recognition of the future benefit is not expected.", -0.6], ["The total amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate is approximately $1.28 billion.", -0.7], ["Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by approximately $315 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.", -0.1], ["In 2022 and 2020, the impact of foreign exchange unfavorably impacted net sales and operating earnings.", -0.7], ["In 2021, the impact of foreign exchange favorably impacted net sales and unfavorably impacted operating earnings.", -0.3], ["Other, net in 2022 includes $176 million of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets.", -0.8], ["Other, net also includes integration costs associated with the acquisitions of Alere Inc. and St. Jude Medical and restructuring charges in 2022, 2021 and 2020.", -0.6], ["Charges for restructuring actions and other cost reduction initiatives were approximately $265 million in 2022, $375 million in 2021 and $125 million in 2020.", -0.5], ["At December 31, 2022 and 2021, long-lived assets totaled $14.2 billion and $13.1 billion, respectively, and in the United States such assets totaled $7.7 billion and $6.8 billion, respectively.", 0.2], ["In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.", 0.8], ["The Chief Executive Officer, Robert B. Ford, and the Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Commission under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.", 0.7]], "abt23_sentences.json": [["In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures.", -0.5], ["Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.", -0.3], ["The introduction of new products by competitors, changes in medical practices and procedures, and regulatory changes can result in product obsolescence.", -0.4], ["In addition, private label and local manufacturers’ products may increase competitive pressure.", -0.5], ["Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.", -0.3], ["After several years of challenges to the global supply chain caused in part by the COVID-19 pandemic and macroeconomic conditions such as inflationary pressures and labor shortages, Abbott's global supply chain has improved.", 0.4], ["To that end, Abbott provides market competitive compensation, healthcare benefits, continuing education benefits, pension and/or retirement savings plans, financial support for employees with student loan debt, and several programs to facilitate employees building an ownership stake in Abbott, including a global long-term incentive program for employees generally beginning at the manager level.", 0.8], ["Compliance with these laws and regulations is costly and materially affects Abbott’s business.", -0.6], ["Among other effects, health care regulations and significant changes thereto (such as the introduction of the Medical Devices Regulation and the In Vitro Diagnostic Medical Devices Regulation in the European Union) substantially increase the time, difficulty, and costs incurred in developing, obtaining and maintaining approval to market, and marketing newly developed and existing products.", -0.7], ["Failure to comply can delay the release of a new product or result in regulatory and enforcement actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product’s production and sale, suspension or revocation of billing privileges, and other civil or criminal sanctions, including fines and penalties.", -0.9], ["Failure to comply with these regulatory requirements can result in sanctions, including suspension, revocation, or limitation of a laboratory’s certification, which is necessary to conduct business, as well as significant fines or criminal penalties.", -1.0], ["In some cases, these studies have resulted, and may in the future result, in the discontinuation of marketing of such products in one or more countries, and may give rise to claims for damages from persons who believe they have been injured as a result of their use.", -1.0], ["Efforts to reduce health care costs are also being made in the private sector, notably by health care payors and providers, which have instituted various cost reduction and containment measures.", -0.5], ["Abbott expects that insurers and providers will continue attempts to reduce the cost or utilization of health care products.", -0.5], ["Budgetary pressures on health care payors may also heighten the scope and severity of pricing pressures on Abbott’s products for the foreseeable future.", -0.5], ["DRG and PPS entitle a health care facility to a fixed reimbursement based on the diagnosis and/or procedure rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products.", -0.5], ["Governmental cost containment efforts also affect Abbott’s nutritional products business.", -0.5], ["As a result, through competitive bidding states obtain rebates from manufacturers of infant formula whose products are used in the program.", 0.0], ["Failure to report appropriate data may result in civil or criminal fines and/or penalties.", -1.0], ["For example, the European Union, China, various other countries, and various U.S. states (e.g., California, Virginia, and Colorado) have enacted or are considering enacting data protection laws that contain significant compliance obligations and financial penalties for noncompliance.", -1.0], ["Failure to comply with data privacy and security laws and regulations can result in business disruption and enforcement actions, which could include civil or criminal penalties.", -1.0], ["Abbott believes that future legislation and regulation in the markets it serves could affect the timing and expense associated with bringing health care products or services to market, access to health care products and services, increase rebates, reduce prices or reimbursements or the rate of price increases for health care products and services, change health care delivery systems, create new fees and obligations for the pharmaceutical, nutrition, diagnostic, and medical device industries, or require additional reporting and disclosure.", -0.5], ["Abbott’s business, financial condition, results of operations, or prospects could be materially adversely affected by any of these risks.", -1.0], ["Disruptions to Abbott’s global supply chain, which is large and complex, could negatively affect Abbott’s results of operations.", -1.0], ["While Abbott has taken and will continue to take actions to mitigate the risks of disruptions to its global supply chain, disruptions to it could negatively affect Abbott's results of operations.", -0.8], ["For example, the COVID-19 pandemic and macroeconomic conditions such as inflationary pressures and labor shortages contributed to global supply chain challenges over the last few years, which adversely impacted the cost and availability of certain raw materials, supplies, and services.", -1.0], ["Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.", -0.8], ["Abbott may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits.", -0.8], ["If Abbott is successful in making an acquisition, the products and technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated.", -0.8], ["Abbott may not be able to integrate acquisitions successfully into its existing business or transition disposed businesses efficiently, and could incur or assume significant debt and unknown or contingent liabilities.", -0.8], ["Abbott could also experience negative effects on its reported results of operations from acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets.", -0.8], ["These effects could cause a deterioration of Abbott’s credit rating, result in increased borrowing costs and interest expense, and decrease liquidity.", -0.9], ["Abbott depends on sophisticated information systems and maintains protected personal data, and a significant cybersecurity incident or other disruption affecting these information systems or protected data could have a material adverse effect on Abbott’s business, financial condition and results of operations.", -0.9], ["A significant cybersecurity incident or other disruption could result in adverse consequences, including regulatory inquiries or litigation, increased costs and expenses, manufacturing challenges or disruption, problems with product availability, functionality or safety, damage to customer relations, reputational damage, lost revenue, and fines or penalties.", -0.9], ["For additional information concerning data privacy and security regulation, see the discussion in “Regulation” under Item 1, “Business.” A breach of protected personal information could result in adverse consequences, including regulatory inquiries or litigation, increased costs and expenses, reputational damage, lost revenue, and fines or penalties.", -0.8], ["Any significant cybersecurity incident or other disruption affecting Abbott’s information systems or products could have a material adverse effect on Abbott’s business, financial condition and results of operations.", -0.9], ["Abbott’s research and development efforts may not succeed in developing commercially successful products and technologies, which may cause Abbott’s revenue and profitability to decline.", -0.8], ["Failure to launch successful new products or technologies, or new indications or uses for existing products, may cause Abbott’s products or technologies to become obsolete, causing Abbott’s revenues and operating results to suffer.", -0.8], ["The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers or manufacturers encounters problems manufacturing products, Abbott’s business could suffer.", -0.7], ["If problems arise during the production of a lot or batch of product, those products may have to be discarded.", -0.7], ["If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.", -0.8], ["Any of these events could, among other things, lead to increased costs, lost revenue, damage to customer relations, reputational damage, time and expense spent investigating the cause and remediating the problem, if any, a production stoppage at a manufacturing facility, and depending on the cause, similar losses with respect to other lots, batches or products.", -0.9], ["To the extent Abbott or one of its suppliers or manufacturers experiences significant manufacturing problems, this could have a material adverse effect on Abbott’s revenues and profitability.", -0.9], ["Abbott has significant indebtedness, which could adversely affect its business, including decreasing its business flexibility.", -0.8], ["This consolidated indebtedness could have the effect, among other things, of reducing Abbott's flexibility to respond to changing business and economic conditions, and reducing funds available for working capital, capital expenditures, acquisitions, and other general corporate purposes.", -0.8], ["Consequently, Abbott cannot assure that it will be able to obtain additional financing or refinancing on terms acceptable to Abbott or at all, which could adversely impact Abbott's ability to make scheduled payments with respect to its consolidated indebtedness and its profitability and financial condition.", -0.8], ["Additionally, further borrowing could cause a deterioration of Abbott's credit ratings.", -0.7], ["Adverse changes in Abbott's credit ratings may result in increased borrowing costs for future long-term debt or short-term borrowing facilities and may limit financing options, including access to the unsecured borrowing market.", -0.7], ["It is costly for Abbott to comply with numerous governmental regulations and to develop compliant products and processes, and consequences for non-compliance could have a material adverse effect on Abbott's revenues, profitability, cash flows, and financial condition.", -0.8], ["Delays in the receipt of, or failure to obtain, approvals for future products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and substantial additional costs.", -0.8], ["These actions could result in, among other things, substantial modifications to Abbott’s business practices and operations; refunds, recalls, or seizures of Abbott’s products; a total or partial shutdown of production in one or more facilities while Abbott or Abbott’s suppliers remedy any actual or potential issues; the inability to obtain future pre-market approvals or marketing authorizations; and withdrawals or suspensions of current products from the market.", -0.9], ["Any of these events could disrupt Abbott’s business and have a material adverse effect on Abbott’s revenues, profitability, cash flows, and financial condition.", -0.9], ["For information on Abbott’s voluntary recall in February 2022 of certain powder infant formula products manufactured at its facility in Sturgis, Michigan, the manufacturing stoppage at such facility, and the consent decree that Abbott entered into with the FDA on May 16, 2022, see the discussion in the “Financial Review” section in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of this report.", -0.5], ["Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations, which could result in a material adverse effect on Abbott's revenues, profitability, and financial condition.", -0.8], ["In addition, violations of these laws, or allegations of such violations, could disrupt Abbott’s business and result in a material adverse effect on Abbott’s revenues, profitability, and financial condition.", -0.8], ["Changes in the health care regulatory environment may adversely impact the demand for and price of Abbott’s products.", -0.7], ["Both in the U.S. and internationally, government authorities may enact changes in regulatory requirements, make legislative or administrative reforms to existing reimbursement programs, make adverse decisions relating to Abbott’s products’ coverage or reimbursement, or make changes to patient access to health care, all of which could adversely impact the demand for and usage of Abbott’s products or the prices that Abbott’s customers are willing to pay for them.", -0.7], ["The expiration or loss of intellectual property protection and licenses may affect Abbott’s future revenues and operating income.", -0.6], ["To the extent Abbott’s intellectual property is successfully challenged, invalidated, or circumvented or to the extent it does not allow Abbott to compete effectively, Abbott’s businesses could suffer.", -0.7], ["To the extent that countries do not enforce Abbott’s intellectual property rights, Abbott’s future revenues and operating income could be reduced.", -0.6], ["Significant safety concerns could arise for Abbott’s products, which could have a material adverse effect on Abbott’s revenues and financial condition.", -1.0], ["For example, Abbott may be required to provide additional warnings on a product’s label or narrow its approved intended use, either of which could reduce the product’s market acceptance.", -0.8], ["If serious safety concerns arise with an Abbott product, sales of the product have been and could be halted by Abbott or by regulatory authorities.", -1.0], ["Product liability claims and lawsuits, safety alerts or product recalls, and other allegations of product safety or quality issues, regardless of their validity or ultimate outcome, may have a material adverse effect on Abbott’s business and reputation and on Abbott’s ability to attract and retain customers.", -1.0], ["Consequences may also include additional costs, a decrease in market share for the products, lower income or exposure to other claims.", -0.9], ["Product liability losses are self-insured and could have a material adverse effect on Abbott’s profitability, cash flows, and financial condition.", -1.0], ["Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating income.", -0.9], ["In the United States and other countries, Abbott’s businesses have experienced downward pressure on certain product pricing.", -0.8], ["Cost containment efforts by governments and private organizations are described in greater detail in the section captioned “Regulation.” To the extent these cost containment efforts are not offset by greater patient access to health care or other factors, Abbott’s future revenues and operating income will be reduced.", -0.9], ["Competitors’ intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott’s future profitability and financial condition.", -1.0], ["A successful claim of patent or other intellectual property infringement could subject Abbott to significant damages or an injunction preventing the manufacture, sale or use of affected Abbott products.", -0.8], ["Any of these events could have a material adverse effect on Abbott’s profitability and financial condition.", -0.9], ["New products and technological advances by Abbott’s competitors may negatively affect Abbott’s results of operations.", -0.7], ["Abbott’s products face intense competition from competitors' products and technological advances.", -0.6], ["Further, the development of new technology, health care products and medicines, and the development of new treatments for disease could significantly change the competitive landscape of the health care industry and negatively impact the demand for certain Abbott products.", -0.7], ["Fluctuation in foreign currency exchange rates has adversely affected and may continue to adversely affect Abbott’s financial statements and its ability to realize projected sales and earnings.", -0.8], ["Abbott’s profitability is affected by movement of the U.S. dollar against other currencies.", -0.5], ["Adverse changes in tax laws, regulations and interpretations, both in the U.S. and internationally, could have a material adverse effect on Abbott’s effective tax rate, financial condition and results of operations.", -0.9], ["Abbott is a large, global corporation, and changes in tax laws, regulations or interpretations could adversely affect Abbott’s overall tax liabilities.", -0.8], ["Changes in tax laws, regulations or interpretations, both in the U.S. and internationally, such as the two-pillared plan proposed by the Organization for Economic Cooperation & Development (OECD), could materially adversely affect Abbott’s effective tax rate, financial condition and results of operations.", -0.9], ["Deterioration in the economic condition and credit quality of certain countries may negatively affect Abbott’s results of operations.", -1.0], ["Unfavorable economic conditions in certain countries may increase the time it takes to collect outstanding trade receivables or inhibit Abbott's ability to best utilize its cash.", -0.8], ["Financial instability and fiscal deficits in these countries may result in additional austerity measures to reduce costs, including health care.", -0.9], ["Deterioration in the quality of sovereign debt, including credit downgrades, could increase Abbott’s collection risk where a significant amount of Abbott’s receivables in these countries are with governmental health care systems or where Abbott’s customers depend on payment by government health care systems.", -0.9], ["Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the COVID-19 pandemic, which had a material effect on Abbott’s business, financial condition and results of operations.", -1.0], ["As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases like the COVID-19 pandemic, may negatively impact certain Abbott's operations.", -0.9], ["Health concerns and significant changes in political or economic conditions caused by such outbreaks can cause, and during the COVID-19 pandemic caused, significant reductions in demand for certain products, increased difficulty in serving customers, disruptions to manufacturing and supply chains, and negative effects on certain of Abbott’s operations as well as the operations of its suppliers, distributors and other third-party partners.", -1.0], ["Furthermore, such widespread outbreaks may impact, and during the COVID-19 pandemic impacted, the broader economies of affected countries, including negatively impacting economic growth, the proper functioning of financial and capital markets, inflation rates, foreign currency exchange rates, and interest rates.", -1.0], ["In addition, the COVID-19 pandemic contributed to global supply chain disruptions, which adversely impacted the cost and availability of certain raw materials, supplies, and services.", -1.0], ["Further, the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.", -0.8], ["The international nature of Abbott’s business subjects it to additional business risks that may cause its revenue and profitability to decline.", -0.8], ["Events contemplated by these risks may, individually or in the aggregate, have a material adverse effect on Abbott’s revenues and profitability.", -0.9], ["Other factors can have a material adverse effect on Abbott’s future profitability and financial condition.", -0.9], ["Many other factors can affect Abbott’s profitability and its financial condition, including:", -0.7], ["legal difficulties, any of which could preclude or delay commercialization of products or adversely affect profitability, including claims asserting statutory or regulatory violations, and adverse litigation decisions.", -0.9], ["To date, Abbott has been able to manage these disruptions without material impact to its results of operations.", 0.2], ["There could be additional sanctions, economic volatility, cybersecurity threats, political instability, transportation and other supply disruptions, as well as collection default or liquidity risks or limited availability of resources to conduct essential business processes that could have a material adverse impact to Abbott’s operations and financial condition.", -0.9], ["A discussion of how Abbott’s business, results of operations, and financial condition could be materially adversely affected by risks from cybersecurity threats is contained in Item 1A.", -0.8], ["Risk Factors under “Abbott depends on sophisticated information systems and maintains protected personal data, and a significant cybersecurity incident or other disruption affecting these information systems or protected personal data could have a material adverse effect on Abbott’s business, financial condition and results of operations.\"", -0.9], ["While it is not feasible to predict the outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.", 0.1], ["On December 10, 2021, Abbott announced that its board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.", 0.5], ["Abbott’s Diagnostics segment experienced the most significant change in sales from 2020 to 2023 as a result of the COVID-19 pandemic.", 0.0], ["During the pandemic, COVID-19 testing-related sales grew to 17.8 percent and 19.2 percent of Abbott's sales in 2021 and 2022, respectively.", 0.2], ["Abbott’s COVID-19 testing-related sales totaled approximately $7.7 billion in 2021 and $8.4 billion in 2022, led by sales related to Abbott’s BinaxNOW, Panbio and ID NOW rapid testing platforms.", 0.3], ["In 2023, the pandemic shifted to an endemic state and the U.S. federal public health emergency expired, resulting in significantly lower demand for COVID-19 tests.", -0.5], ["In 2023, Abbott’s COVID-19 testing-related sales totaled approximately $1.6 billion, of which $730 million occurred in the first quarter of 2023.", -0.2], ["Across Abbott’s cardiovascular and neuromodulation businesses, procedure volumes were negatively impacted during the pandemic by surges of COVID-19 in various geographies as well as intermittent COVID-19 lockdown restrictions and healthcare staffing challenges.", -0.7], ["Despite such challenges, overall volume trends improved in several cardiovascular businesses and in routine diagnostic testing in 2022 and that growth continued in 2023.", 0.4], ["While Abbott’s branded generic pharmaceuticals business was also negatively affected by the pandemic in 2020 as COVID-19 spread across emerging market countries, volumes recovered and grew over the 2021 to 2023 period.", 0.1], ["While Abbott’s total sales over the last three years were most significantly affected by the impacts of the COVID-19 pandemic, sales over this period also reflect the introduction of new products across various businesses, as well as higher sales of various existing products.", 0.3], ["Sales in emerging markets, which represent approximately 38 percent of total company sales, increased 5.4 percent in 2023 and 5.6 percent in 2022, excluding the impact of foreign exchange.", 0.5], ["In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in Sturgis, Michigan and stopped production at the facility.", -0.8], ["In 2023, as Abbott's production of infant formula increased in the U.S., Abbott made progress toward recovering market share in this business.", 0.7], ["In the fourth quarter of 2023, Abbott returned to having the market-leading position in the U.S., as measured on a volume basis.", 0.9], ["Over the last three years, Abbott’s operating margin as a percentage of sales decreased from 19.6 percent in 2021 to 19.2 percent in 2022 and 16.2 percent in 2023.", -0.7], ["The decrease in 2023 from 2021 reflects the unfavorable effects of lower COVID-19 testing-related sales, foreign exchange, and higher costs for various manufacturing inputs.", -0.6], ["The decrease in 2022 from 2021 reflects the impact of the voluntary infant product recall and manufacturing stoppage in U.S. Pediatric Nutritionals and the impact of inflation and supply chain challenges on various manufacturing inputs and transportation costs across Abbott's businesses.", -0.7], ["In both 2023 and 2022, these unfavorable effects were partially offset by the favorable impact of margin improvement initiatives.", 0.2], ["While Abbott experienced inflationary pressures on various raw materials, packaging materials and transportation costs over the last three years, the impact of such cost increases was partially mitigated by price increases in certain businesses and the impact of continued gross margin improvement initiatives.", 0.1], ["With respect to the performance of each reportable segment over the last three years, sales in the Medical Devices segment, excluding the impact of foreign exchange, increased 15.1 percent in 2023 and 8.1 percent in 2022.", 0.8], ["The sales increases in 2023 and 2022 were driven by growth in Diabetes Care, Electrophysiology, Heart Failure, and Structural Heart.", 0.8], ["The 2023 increase was also driven by growth in Neuromodulation sales.", 0.7], ["In 2023, operating earnings for the Medical Devices segment increased 19.6 percent.", 0.9], ["The operating margin profile for the Medical Devices segment decreased from 31.3 percent in 2021 to 30.0 percent in 2022 and then increased to 31.4 percent in 2023.", 0.2], ["The decrease in 2022 from 2021 reflects various factors, including the impacts of inflationary pressures and supply chain challenges related to various manufacturing inputs and processes.", -0.6], ["The increase in 2023 from 2022 reflects the impact of higher sales volumes across the Medical Devices businesses.", 0.7], ["In Abbott’s Diagnostics segment, sales decreased 38.2 percent in 2023 and increased 10.4 percent in 2022, excluding the impact of foreign exchange.", -0.8], ["As was discussed above, the 2023 sales decrease was driven by lower demand for Abbott's COVID-19 tests, partially offset by higher routine diagnostics testing in the core laboratory business.", -0.5], ["The 2022 sales growth was driven by demand for Abbott's portfolio of rapid diagnostics tests for COVID-19 and higher routine diagnostics testing in the core laboratory business, partially offset by lower demand for Abbott’s laboratory-based tests for COVID-19 in the molecular diagnostics business.", 0.3], ["In 2023, operating earnings for the Diagnostics segment decreased 63.4 percent.", -0.9], ["The operating margin profile decreased from 40.2 percent in 2021 to 24.4 percent in 2023 primarily due to lower demand for Abbott's COVID-19 tests.", -0.5], ["In Abbott’s Nutritional Products segment, total pediatric nutrition sales, excluding the impact of foreign exchange, increased 14.8 percent in 2023, which includes market share recovery in the U.S. infant formula business following the voluntary recall of certain products in the prior year.", 0.7], ["In 2022, pediatric nutrition sales decreased 16.6 percent as a result of the voluntary recall and manufacturing stoppage discussed above, as well as challenging market dynamics in China.", -0.6], ["In December 2022, Abbott initiated steps to exit its pediatric nutrition business in China.", -0.7], ["Excluding the impact of foreign exchange, total adult nutrition sales increased 8.8 percent in 2023 and 4.8 percent in 2022, led by the continued growth of Abbott's Ensure® and Glucerna® products across several countries.", 0.6], ["In 2023, operating earnings for the Nutritional Products segment increased 88.9 percent compared to 2022.", 0.9], ["Operating margins for this segment decreased from 21.3 percent in 2021 to 9.5 percent in 2022 and then increased to 16.4 percent in 2023.", 0.2], ["The decrease in 2022 was driven by the impact of the voluntary infant product recall and manufacturing stoppage as well as higher manufacturing and distribution costs, including commodity prices, partially offset by the impact of gross margin improvement initiatives.", -0.4], ["The increase in 2023 reflects the favorable effects of higher sales and a continued focus on gross margin improvement initiatives, partially offset by higher commodity and other costs.", 0.3], ["Excluding the impact of foreign exchange, Established Pharmaceutical sales increased 10.9 percent in 2023 and 10.6 percent in 2022.", 0.8], ["The sales increases in 2023 and 2022 reflect higher sales in several geographies including India, Vietnam, and Brazil.", 0.8], ["In 2023, operating earnings for the Established Pharmaceutical Products segment increased 15.0 percent.", 1.0], ["Operating margins increased from 18.8 percent in 2021 to 23.8 percent in 2023 primarily due to the impact of gross margin improvement initiatives and higher sales, partially offset by inflation on various product inputs.", 0.9], ["Abbott declared dividends of $2.08 per share in 2023 and $1.92 per share in 2022, an increase of 8.3 percent.", 0.8], ["Dividends paid totaled $3.556 billion compared to $3.309 billion in 2022.", 0.5], ["In December 2023, Abbott increased the company’s quarterly dividend by 7.8 percent to $0.55 per share from $0.51 per share, effective with the dividend paid in February 2024.", 0.7], ["In December 2022, Abbott increased the company’s quarterly dividend by 8.5 percent to $0.51 per share from $0.47 per share, effective with the dividend paid in February 2023.", 0.7], ["Sales Rebates — In 2023, 49 percent of Abbott’s consolidated gross revenues were subject to various forms of rebates and allowances that Abbott recorded as reductions of revenues at the time of sale.", -0.3], ["A one-percentage point increase in the percentage of rebates to related gross sales would decrease net sales by approximately $227 million in 2023.", -0.7], ["The net actuarial gains for these plans in 2023 reflect the impact of actual asset returns during the year in excess of expected returns, partially offset by the impact of lower discount rates on the measurement of plan liabilities.", 0.2], ["At December 31, 2023, pretax net actuarial losses and prior service costs and (credits) recognized in Accumulated other comprehensive income (loss) were net losses of $1.8 billion for Abbott’s defined benefit plans and net losses of $40 million for Abbott’s medical and dental plans.", -0.8], ["If the undiscounted cash flows of an intangible asset are less than the carrying value of an intangible asset, the intangible asset is written down to its fair value, which is usually the discounted cash flow amount.", -0.7], ["There was no reduction of goodwill relating to impairments in 2023, 2022, and 2021.", 0.2], ["450, loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded.", -0.6], ["As information becomes known, either the minimum loss amount is increased, resulting in additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions.", -0.6], ["Abbott estimates the range of possible loss to be from approximately $30 million to", -0.5], ["$45 million for its legal proceedings and environmental exposures.", -0.5], ["Accruals of approximately $40 million have been recorded at December 31, 2023 for these proceedings and exposures.", -0.5], ["The decrease in total net sales in 2023 reflects the decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by higher sales in the Medical Devices, Established Pharmaceutical Products and Nutritional Products segments.", -0.3], ["Abbott’s COVID-19 testing-related sales totaled approximately $1.6 billion in 2023, $8.4 billion in 2022 and $7.7 billion in 2021.", 0.1], ["Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 9.2 percent in 2023.", 0.7], ["Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 11.7 percent.", 0.8], ["Abbott’s net sales in 2023 were unfavorably impacted by changes in foreign exchange rates as the relatively stronger U.S. dollar decreased total international sales by 3.5 percent and total sales by 2.0 percent.", -0.4], ["The increase in total net sales in 2022 reflects growth in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as well as growth in the Established Pharmaceutical Products and Medical Devices segments, partially offset by lower Nutritional Products sales.", 0.3], ["Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales decreased 0.3 percent in 2022.", -0.2], ["Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s 2022 total net sales increased 5.1 percent.", 0.5], ["Abbott’s net sales in 2022 were unfavorably impacted by changes in foreign exchange rates as the relatively stronger U.S. dollar decreased total international sales by 8.2 percent and total sales by 5.1 percent.", -0.6], ["The price declines related to the Diagnostic Products segment in 2023 and 2022 primarily reflect lower pricing for COVID-19 tests.", -0.3], ["Total Established Pharmaceutical Products sales increased 10.9 percent in 2023 and 10.6 percent in 2022, excluding the unfavorable impact of foreign exchange.", 0.7], ["Excluding the effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 10.3 percent in 2023 and 12.1 percent in 2022, led by growth in several countries and across several therapeutic areas, including cardiometabolic, central nervous system/pain management and respiratory.", 0.8], ["Other Emerging Markets, excluding the effect of foreign exchange, increased by 12.8 percent in 2023 and 6.1 percent in 2022.", 0.5], ["Excluding the impact of foreign exchange, total Nutritional Products sales increased 11.6 percent in 2023 compared to a 6.2 percent decrease in 2022.", 0.6], ["In U.S. Pediatric Nutritional sales, the 26.6 percent increase in 2023 reflects progress in recovering market share in 2023 following the voluntary recall of certain infant formula products in the first quarter of 2022, as well as the unfavorable 2022 impact of the recall, partially offset by a decrease in 2023 Pedialyte® sales.", 0.3], ["In 2022, U.S. Pediatric Nutritional sales decreased", -0.7], ["28.7 percent as a result of the voluntary recall and production stoppage of certain infant powder formula products, partially offset by increased demand for Abbott’s Pedialyte products.", -0.5], ["In 2022, the 3.9 percent decrease in International Pediatric Nutritional sales, excluding the effect of foreign exchange, reflects the impact of the challenging market dynamics in the infant category in China, partially offset by higher sales volumes in several countries in Southeast Asia and Latin America.", -0.2], ["Adult Nutritional sales increased 5.8 percent and decreased 0.5 percent, respectively.", 0.1], ["The growth in 2023 was led by higher Ensure® and Glucerna® product sales.", 0.7], ["In 2022, the growth of the Ensure brand was offset by lower sales of other products and the impact of temporarily utilizing liquid manufacturing capacity to manufacture infant formula.", -0.3], ["In 2023 and 2022, International Adult Nutritionals sales, excluding the effect of foreign exchange, increased 10.4 percent and 7.6 percent, respectively, led by growth of Ensure® and Glucerna® products in various countries.", 0.8], ["Excluding the effect of foreign exchange, Diagnostics segment sales decreased 38.2 percent in 2023 and increased 10.4 percent in 2022, driven by changes in demand for COVID-19 tests.", -0.5], ["Rapid Diagnostics sales decreased 62.9 percent in 2023 and increased 22.8 percent in 2022, excluding the effect of foreign exchange.", -0.6], ["The decrease in 2023 reflects lower demand for COVID-19 tests across Abbott’s rapid testing platforms.", -0.7], ["Rapid Diagnostics sales increased 1.3 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.1], ["In 2022, Rapid Diagnostics sales increased 17.0 percent, excluding COVID-19 testing-related sales, and 20.5 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.3], ["These increases reflect higher sales of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV), as well as growth in various other Rapid Diagnostics products.", 0.5], ["In Core Laboratory Diagnostics, sales increased 8.4 percent in 2023 and 1.9 percent in 2022, excluding the effect of foreign exchange.", 0.4], ["The increases in 2023 and 2022 were due to higher year-over-year volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower test sales for the detection of COVID-19 IgG and IgM antibodies.", 0.2], ["6.5 percent in 2023 and decreased 2.0 percent in 2022.", -0.1], ["Excluding the impact of foreign exchange and COVID-19 testing-related sales, Core Laboratory Diagnostics sales increased 9.4 percent in 2023 and 4.8 percent in 2022.", 0.4], ["In Molecular Diagnostics, sales decreased 41.6 percent in 2023 and 27.4 percent in 2022, excluding the effect of foreign exchange.", -0.8], ["Molecular Diagnostics COVID-19 testing-related sales were $43 million in 2023, $411 million in 2022 and $891 million in 2021.", -0.5], ["In 2023, Molecular Diagnostics sales decreased 9.2 percent, excluding COVID-19 testing-related sales, and decreased 8.1 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", -0.7], ["2023 sales were impacted by lower demand for respiratory testing compared to significantly higher-than-usual demand in 2022.", -0.6], ["In 2022, Molecular Diagnostics sales increased 9.0 percent, excluding COVID-19 testing-related sales, and 13.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.", 0.3], ["Excluding the effect of foreign exchange, total Medical Devices sales grew 15.1 percent in 2023 and 8.0 percent in 2022, led by double-digit growth in 2023 in Diabetes Care, Structural Heart, Heart Failure, Neuromodulation and Electrophysiology.", 0.7], ["Higher Diabetes Care sales were driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally.", 0.8], ["FreeStyle Libre sales totaled $5.3 billion in 2023, which reflected a 25.5 percent increase, excluding the effect of foreign exchange, over 2022 when FreeStyle Libre sales totaled $4.3 billion.", 0.9], ["In 2022, while procedure volumes across Abbott's cardiovascular and neuromodulation businesses were negatively impacted by surges of COVID-19 in various geographies, as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the year, overall volumes improved from 2021 levels.", -0.2], ["In 2023, the 15.9 percent increase in Electrophysiology sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes in the U.S., China, and various European countries.", 0.6], ["In 2022, Electrophysiology sales increased 7.3 percent, excluding the effect of foreign exchange, due to an increase in procedure volumes and the continued roll‑out of Abbott’s EnSite X® EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across Europe.", 0.7], ["In Neuromodulation, the 16.4 percent increase in 2023 sales, excluding the effect of foreign exchange, was driven by the recent launch of the Eterna® rechargeable spinal cord stimulation system for the treatment of chronic pain along with market growth compared to the prior year.", 0.8], ["In Structural Heart, excluding the effect of foreign exchange, the 14.3 percent and 13.0 percent sales increases in 2023 and 2022, respectively, reflect continued growth of the MitraClip® product as well as various other products, including Amplatzer® Amulet® Left Atrial Appendage Occluder, Navitor®, and TriClip®.", 0.8], ["In Vascular, the 9.3 percent increase in 2023 sales, excluding the impact of foreign exchange, reflects the acquisition of CSI on April 27, 2023, as well as double-digit growth in endovascular sales.", 0.7], ["In 2022, Vascular sales decreased 1.0 percent, excluding the impact of foreign exchange, as higher endovascular sales were offset by the negative effect of lower average selling prices globally on traditional drug eluting stents (DES) and other coronary products and a lower recovery of percutaneous coronary intervention (PCI) procedures which impacted the coronary business.", -0.2], ["The expiration of licenses and patent protection can affect the future revenues and operating income of Abbott.", -0.5], ["Gross profit margins were 50.3 percent of net sales in 2023, 51.5 percent of net sales in 2022, and 52.2 percent of net sales in 2021.", -0.1], ["The decrease in 2023 reflects the unfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs, partially offset by the nonrecurrence of the negative impact in 2022 of the voluntary product recall in the Nutritional business and the impact in 2023 of gross margin improvement initiatives.", -0.4], ["In 2022, the decrease reflected the impact of the voluntary infant product recall and Sturgis manufacturing stoppage, as well as the prioritization of infant formula sales related to the WIC Program in the Nutritional business.", -0.6], ["The decrease also reflected higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses.", -0.5], ["The decrease in R&D expense in 2023 was primarily driven by lower restructuring charges, lower impairment charges related to in-process R&D assets acquired in previous business combinations, and other cost reductions.", -0.2], ["The increase in 2022 versus 2021 primarily reflected higher spending on various projects to advance products in development, as well as a charge related to the impairment of certain in- process R&D intangible assets, partially offset by the favorable impact of foreign exchange.", -0.1], ["The 2023 decrease reflects the favorable impact of foreign exchange and lower restructuring charges in 2023 as well as the non- recurrence of 2022 expenses related to the voluntary product recall in the Nutritional segment.", 0.1], ["In 2023, Abbott management approved plans to restructure various operations in order to reduce costs in its medical devices, diagnostic, and established pharmaceutical businesses.", 0.0], ["Abbott recorded employee related severance and other charges of approximately", -0.3], ["In addition, Abbott recognized fixed asset impairment and inventory related charges of approximately $31 million related to these restructuring plans.", -0.3], ["In 2022, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses.", 0.0], ["Abbott recorded employee related severance and other charges of approximately $234 million of which approximately $59 million was recorded in Cost of products sold, approximately", -0.4], ["In addition, Abbott recognized inventory related charges of approximately $23 million and fixed assets impairment charges of approximately $4 million related to these restructuring plans.", -0.3], ["Charges under this plan were recorded in Cost of products sold and totaled $441 million in 2021.", -0.5], ["In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic, established pharmaceutical, nutritional, and medical device businesses.", -0.1], ["Abbott recorded employee related severance and other charges of approximately $68 million of which approximately $16 million was recorded in Cost of products sold, approximately", -0.5], ["Interest expense, net decreased from $375 million in 2022 to $252 million in 2023.", 0.3], ["The decrease was due to the favorable impact of higher interest rates on interest income, partially offset by the negative impact of interest rate hedge contracts related to certain fixed- rate debt.", -0.2], ["Interest expense, net decreased $115 million in 2022 due to the impact of higher interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022, partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.", 0.2], ["Other income, net increased from $277 million of income in 2021 and $321 million of income in 2022 to $479 million of income in 2023.", 0.5], ["Other income, net also includes equity investment impairments that totaled approximately $39 million in 2023 and $45 million in 2022; in 2023 income from a $42 million reduction in the fair value of contingent consideration related to previous business acquisitions; and a gain on the sale of an equity method investment in 2021.", -0.3], ["As a result of the resolution of various tax positions related to prior years, taxes on earnings in 2023, 2022 and 2021 also include approximately $80 million and $20 million of net tax expense and $55 million of net tax benefits, respectively.", 0.1], ["In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million.", -0.8], ["Implementation of the OECD proposal may have a material impact on Abbott’s Consolidated Financial Statements in the future.", -0.4], ["Numerous new products that build on advances in these platforms are currently under development, including clinical outcome testing, and are expected to be launched over the coming years.", 0.8], ["In addition, the Diagnostics segment is pursuing the FDA’s customary regulatory process for various COVID-19 tests for which EUAs were obtained.", 0.3], ["The results of the last impairment test indicated that the fair value of each reporting unit was substantially in excess of its carrying value.", 0.7], ["Net cash from operating activities amounted to $7.3 billion, $9.6 billion, and $10.5 billion in 2023, 2022, and 2021, respectively.", 0.5], ["The decrease in Net cash from operating activities in 2023 as compared to 2022 is primarily due to the decline in operating earnings and increased payments related to accounts payable and accrued liabilities, partially offset by lower expenditures for inventory and lower cash payments for income taxes due to lower earnings.", -0.4], ["The decrease in Net cash from operating activities in 2022 as compared to 2021 was primarily due to the unfavorable cash flow impact of an increased investment in working capital, partially offset by reduced expenditures related to restructuring actions and lower cash payments for income taxes.", -0.3], ["Abbott expects annual cash flow from operating activities to continue to exceed Abbott’s capital expenditures and cash dividends.", 0.6], ["As of December 31, 2023, Abbott's total debt outstanding was $14.7 billion, of which approximately $1.1 billion will mature in 2024.", 0.1], ["Abbott expects to repay the $655 million of notes maturing in 2024 through the use of cash on hand and to refinance the $419 million term loan in 2024.", 0.2], ["On November 30, 2023, Abbott repaid the $1.05 billion outstanding principal amount of its 3.40% Notes upon maturity.", 0.4], ["On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity.", -0.1], ["In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition.", -0.1], ["In 2021, Abbott repurchased 16.6 million of its common shares for $2.016 billion, which fully utilized the authorization remaining under the 2014 share repurchase program and a portion of the 2019 authorization.", 0.1], ["32.3 million of its common shares for $3.65 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021", 0.1], ["In 2023, Abbott repurchased approximately 9.8 million of its common shares for $1.025 billion.", 0.1], ["Abbott declared dividends of $2.08 per share in 2023 compared to $1.92 per share in 2022, an increase of 8.3 percent.", 0.3], ["Dividends paid were $3.556 billion in 2023 compared to $3.309 billion in 2022.", 0.2], ["Working capital was $8.8 billion at December 31, 2023 and $9.7 billion at December 31, 2022.", -0.2], ["The decrease was due largely to a decrease in cash and cash equivalents, partially offset by the repayment of debt due in 2023.", -0.3], ["The decrease in cash and cash equivalents from $9.9 billion at December 31, 2022 to $6.9 billion at December 31, 2023 primarily reflects the payment of dividends, the repayment of debt, capital expenditures, share repurchases, and the cost of business acquisitions, partially offset by the cash generated from operations.", -0.4], ["Capital expenditures of $2.2 billion in 2023, $1.8 billion in 2022, and $1.9 billion in 2021 were principally for upgrading and expanding manufacturing and research and development facilities and equipment in various segments, investments in information technology, and laboratory instruments placed with customers.", 0.5], ["Abbott believes that its available cash and cash equivalents along with its ability to generate operating cash flow and continued access to debt markets are sufficient to fund existing and planned cash requirements.", 0.8], ["Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings.", 0.0], ["The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s consolidated financial statements.", 0.0], ["The fair value of equity securities held by Abbott with a readily determinable fair value was approximately $12 million and $9 million as of December 31, 2023 and 2022, respectively.", 0.2], ["A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at December 31, 2023 by approximately $2 million.", -0.5], ["Changes in the fair value of these securities are recorded in earnings.", 0.1], ["Changes in the fair value of these investments, as well as an offsetting change in the benefit obligation, are recorded in earnings.", 0.1], ["These contracts are designated as cash flow hedges of the variability of the cash flows due to changes in foreign currency exchange rates and are marked-to-market with the resulting gains or losses reflected in Accumulated other comprehensive income (loss).", 0.3], ["Gains or losses will be included in Cost of products sold at the time the products are sold, generally within the next twelve to eighteen months.", 0.2], ["The contracts are marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or gains on the foreign currency exposure being managed.", -0.1], ["Net actuarial gains (losses) and prior service cost and credits and amortization", 0.0], ["Net gains (losses) on derivative instruments designated as cash flow hedges,", -0.1], ["net of taxes of $(66) in 2023, $11 in 2022 and $63 in 2021", -0.2], ["Net actuarial (losses) and prior service (cost) and credits", -0.2], ["Cumulative gains (losses) on derivative instruments designated as cash flow", -0.1], ["Repayments of long-term debt and debt with maturities over 3 months", -0.3], ["Net Increase (Decrease) in Cash and Cash Equivalents", 0.0], ["Trade receivables, less allowances of — 2023: $444; 2022: $500", 0.1], ["Common shares held in treasury, at cost — Shares: 2023: 253,807,494; 2022: 248,724,257         (15,981)      (15,229) Earnings employed in the business                                      37,554       35,257", 0.2], ["Issuance of restricted stock awards                             (552)       (520)       (490) End of Year", -0.5], ["Shares: 2023: 1,987,883,852; 2022: 1,986,519,278; 2021: 1,985,273,421    $     24,869  $     24,709  $     24,470", 0.2], ["Shares: 2023: 248,724,257; 2022: 221,191,228; 2021: 209,926,622      $    (15,229) $    (11,822) $    (10,042)", -0.7], ["Shares: 2023: 4,881,031; 2022: 4,980,202; 2021: 5,650,168                 297        269        271", 0.3], ["Shares: 2023: 9,964,268; 2022: 32,513,231; 2021: 16,914,774              (1,049)      (3,676)      (2,051)", -0.8], ["Shares: 2023: 253,807,494; 2022: 248,724,257; 2021: 221,191,228      $    (15,981) $    (15,229) $    (11,822)", -0.7], ["End of Year                                  $     (7,839) $     (8,051) $     (8,374)", -0.6], ["Beginning of Year                               $       219  $       222  $       219", 0.1], ["End of Year                                  $       224  $       219  $       222", 0.2], ["Transaction gains and losses are recorded on the Net foreign exchange (gain) loss line of the Consolidated Statement of Earnings.", 0.0], ["Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements are recorded when the conditions noted above are met.", -0.1], ["Net earnings allocated to common shares in 2023, 2022 and 2021 were $5.701 billion, $6.905 billion and $7.042 billion, respectively.", 0.2], ["Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events.", 0.0], ["The new standard did not have an impact on its consolidated financial statements.", 0.0], ["As a result,", -0.5], ["Abbott’s COVID-19 testing-related sales totaled approximately $1.6 billion in 2023, $8.4 billion in 2022 and $7.7 billion in 2021.", 0.3], ["Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded.", -0.1], ["As of December 31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.4 billion in the Diagnostic Products segment and approximately $478 million in the Medical Devices segment.", 0.1], ["Abbott expects to recognize revenue on approximately 58 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.", 0.2], ["The amounts as of December 31, 2023 and 2022 were not significant.", -0.2], ["The amounts as of December 31, 2023 and 2022 were not significant.", -0.2], ["Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.", -0.2], ["Other (income) expense, net, for 2023, 2022 and 2021 includes approximately $498 million, $406 million and $270 million of income, respectively, related to the non-service cost components of the net periodic benefit costs associated with the pension and post- retirement medical plans.", 0.5], ["The increase in Abbott’s long-term investments as of December 31, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.", 0.1], ["Includes approximately $650 million and $850 million of net unrecognized tax benefits and $430 million and $740 million of transition tax obligation related to the TCJA in 2023 and 2022, respectively.", 0.1], ["Net Actuarial Gains (Losses) and Prior Service (Costs) and Credits", 0.0], ["Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow", 0.0], ["Other comprehensive income (loss) before reclassifications         (894)      1,007       199       312", 0.1], ["Net current period other comprehensive income (loss)            (894)      1,177        40       323", 0.1], ["Other comprehensive income (loss) before reclassifications          212       127         5       344", 0.2], ["In 2023, recent business acquisitions increased goodwill by approximately $576 million.", 0.8], ["Foreign currency translation adjustments increased goodwill by $304 million in 2023 and decreased goodwill by $431 million in 2022.", 0.2], ["The gross amount of amortizable intangible assets increased by $305 million due to a recent business acquisition.", 0.7], ["Foreign currency translation adjustments increased intangible assets by $44 million in 2023 and decreased intangible assets by $150 million in 2022.", 0.1], ["In 2023, $100 million of impairment charges related to certain indefinite- lived intangible assets in the Medical Devices reportable segment were recorded on the Research and development line of the Consolidated Statement of Earnings.", -0.7], ["Recent business acquisitions increased IPR&D assets by $80 million.", 0.6], ["In 2022, $111 million of impairment charges were recorded on the Research and development line of the Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.", -0.8], ["In 2023, Abbott management approved plans to restructure various operations in order to reduce costs in its medical devices, diagnostic, and established pharmaceutical businesses.", 0.3], ["In addition, Abbott recognized fixed asset impairment and inventory related charges of approximately $31 million related to these restructuring plans.", -0.5], ["In 2022, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses.", 0.4], ["In addition, Abbott recognized inventory related charges of approximately $23 million and fixed assets impairment charges of approximately $4 million related to these restructuring plans.", -0.5], ["In 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter of 2021 in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals.", 0.2], ["Charges under this plan were recorded in Cost of products sold and totaled $441 million in 2021.", -0.7], ["In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic, established pharmaceutical, nutritional, and medical device businesses.", 0.3], ["Abbott recorded employee related severance and other charges of approximately $68 million of which approximately $16 million was recorded in Cost of products sold, approximately", -0.6], ["$4 million was recorded in Research and development and approximately $48 million was recorded in Selling, general and", -0.6], ["The fair market value of restricted stock awards and units vested in 2023, 2022 and 2021 was $536 million, $639 million and $809 million, respectively.", 0.5], ["The total intrinsic value of options exercised in 2023, 2022 and 2021 was $102 million, $85 million and $393 million, respectively.", 0.4], ["Total non-cash stock compensation expense charged against income in 2023, 2022 and 2021 for share-based plans totaled approximately $644 million, $685 million and $640 million, respectively, and the tax benefit recognized was approximately $144 million, $170 million and $267 million, respectively.", 0.3], ["On November 30, 2023, Abbott repaid the $1.05 billion outstanding principal amount of its 3.40% Notes upon maturity.", 0.2], ["On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity.", 0.0], ["The repayment equated to approximately $1.2 billion.", 0.0], ["In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition.", 0.0], ["On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.", 0.0], ["In December 2021, Abbott repaid a short-term facility for approximately $195 million.", 0.0], ["Sales-type leases are not significant.", -0.5], ["Operating lease revenue represented less than 3 percent of Abbott’s total net sales in the years ended December 31, 2023, 2022 and 2021.", -0.5], ["These contracts, with gross notional amounts totaling $7.3 billion at December 31, 2023, and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.", 0.0], ["Accumulated gains and losses as of December 31, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.", 0.0], ["The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.", 0.0], ["The decrease from 2022 was due to the maturity of $700 million of interest rate hedge contracts in 2023 in conjunction with long-term debt that also matured in 2023.", -0.2], ["A loss of $44 million and gains of $70 million and $19 million were recognized in 2023, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as hedges.", -0.1], ["The decrease in the amount of contingent consideration from December 31, 2022 reflects the impact of projected timeline changes for events that will trigger payment of contingent consideration, partially offset by additional contingent consideration assumed in a business acquisition in 2023.", -0.3], ["No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.", 0.1], ["Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $30 million to $45 million.", -0.4], ["The recorded accrual balance at December 31, 2023 for these proceedings and exposures was approximately $40 million.", -0.3], ["This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No.", 0.0], ["(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs", -0.2], ["The $458 million of defined benefit plan losses and $35 million of medical and dental plan losses in 2023 that increased the projected benefit obligations primarily reflect the year-over-year decline in the discount rates used to measure the obligations.", -0.5], ["The $3.6 billion of defined benefit plan gains and $437 million of medical and dental plan gains in 2022 that decreased the projected benefit obligations primarily reflect the year-over-year increase in the discount rates used to measure the obligations.", 0.5], ["In addition, approximately $15 million of income was recognized in 2023 related to the curtailment of a non-U.S. defined benefit plan.", -0.1], ["$182 million for defined benefit plans and a loss of $33 million for medical and dental plans in 2023; net actuarial gains of $858 million for defined benefit plans and a gain of $374 million for medical and dental plans in 2022, and net actuarial gains of $1.14 billion for defined benefit plans and a gain of $45 million for medical and dental plans in 2021.", 0.2], ["The net actuarial gains in 2023 related to defined benefit plans are primarily due to the favorable impact of actual asset returns in excess of expected returns, partially offset by the year-over-year decrease in discount rates.", 0.3], ["The net actuarial losses in 2023 related to medical and dental plans are primarily due to the year-over-year decrease in discount rates.", -0.3], ["The net actuarial gains in 2022 were primarily due to the year-over-year increase in discount rates, partially offset by the impact of 2022 actual asset returns being less than expected returns.", 0.2], ["The net actuarial gains in 2021 are primarily due to the favorable impact of actual 2021 asset returns in excess of expected returns and the year-over-year increase in discount rates.", 0.4], ["$250 million of the absolute return funds, redemptions are subject to a 33 percent gate and a 25 percent gate, respectively, and $80 million is subject to a lock until 2025.", -0.2], ["Abbott’s unfunded commitment in these funds was $555 million and $569 million as of December 31, 2023 and 2022, respectively.", 0.0], ["Abbott funded $349 million in 2023 and $413 million in 2022 to defined pension plans.", 0.1], ["Abbott’s contributions to this plan were $199 million in 2023, $190 million in 2022 and $181 million in 2021.", 0.1], ["Taxes on earnings include approximately $22 million, $43 million and $145 million in excess tax benefits associated with share- based compensation in 2023, 2022 and 2021, respectively.", -0.2], ["As a result of the resolution of various tax positions related to prior years, taxes on earnings in 2023, 2022 and 2021 also include approximately $80 million and $20 million of net tax expense and $55 million of net tax benefits, respectively.", -0.1], ["In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.", -0.8], ["Implementation of the OECD proposal may have a material impact on Abbott’s Consolidated Financial Statements in the future.", -0.5], ["Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit was, in previous reporting periods, considered so remote that the benefit was not recognized as a deferred tax asset.", -0.6], ["In 2023, Abbott concluded that the future economic benefit of the incurred losses is no longer remote and therefore, a deferred tax asset was recognized.", 0.3], ["Abbott also concluded that it is not more likely than not that the tax benefit associated with the deferred tax asset will be realized; therefore, an offsetting valuation allowance was recognized.", -0.4], ["In 2023, Abbott's unrecognized tax benefits increased by", -0.3], ["$1.3 billion to $3.32 billion, which includes $2.06 billion attributable to tax positions that, if recognized, would result in a deferred tax asset and a related valuation allowance.", -0.2], ["Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between", -0.1], ["In 2023 and 2022, foreign exchange unfavorably impacted net sales and operating earnings.", -0.5], ["In 2021, foreign exchange favorably impacted net sales and unfavorably impacted operating earnings.", 0.0], ["Charges and expenses for restructuring actions and other cost reduction initiatives were approximately $122 million in 2023, $265 million in 2022, and $375 million in 2021.", -0.5], ["Other, net in 2023 also includes charges of $100 million related to indefinite-lived intangible asset impairments, partially offset by income arising from fair value changes in contingent consideration related to previous business acquisitions.", -0.2], ["Other, net in 2022 also includes", -0.7], ["$176 million of charges related to a voluntary recall within the Nutritional products segment and $111 million of charges related to the impairment of IPR&D intangible assets.", -0.8], ["At December 31, 2023 and 2022, long-lived assets totaled $16.2 billion and $14.2 billion, respectively, and in the United States such assets totaled $8.9 billion and $7.7 billion, respectively.", 0.3], ["Description of the Matter     As described in Note 15 to the consolidated financial statements, unrecognized tax benefits were approximately $3.3 billion at December 31, 2023.", -0.3], ["During the quarter ended December 31, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.", 0.1]], "dal22_sentences.json": [["In 2022, demand for air travel accelerated significantly beginning late in the March quarter with continued improvement throughout the remainder of the year.", 0.8], ["In 2022, we continued to differentiate Delta from the industry by strengthening our competitive advantages.", 0.7], ["With our improved profitability, we returned to normal profit sharing and are planning a $563 million planned payout for eligible employees.", 0.9], ["The company also maintains a Shared Rewards program to incentivize operational performance, and in 2022 $61 million was earned by employees under this program.", 0.6], ["We delivered the best completion factor and on-time arrival and departure rates among our network carrier peers in 2022 based on preliminary data.", 0.8], ["In 2022, we were honored with the Cirium Platinum Award for global operational excellence as North America’s most on-time airline, reflecting Delta’s on-time performance.", 0.9], ["In January 2023, the Wall Street Journal named us the top airline of 2022 among the nine U.S. airlines in its annual airline scorecard for the second consecutive year, leading the industry in on-time arrivals, completion factor and involuntary denied boardings.", 0.9], ["Core hubs have strong local passenger share, a high penetration of customers loyal to Delta, a competitive cost position and strong margins.", 0.7], ["Coastal hubs provide a strong presence in large revenue markets and enable growth in premium products and international service.", 0.7], ["We increased local market share in our core hubs and plan to focus growth in 2023 in our core hubs as we complete our rebuild.", 0.8], ["In particular, the U.S. Department of Transportation (\"DOT\") granted final regulatory approval for our joint venture agreement with LATAM in 2022.", 0.8], ["We believe our continued investment in customer service and experience, operations, product, airports and technology has shaped customer perception of our brand leading to improvements in our domestic net promoter scores and increased customer loyalty compared to pre-pandemic levels.", 0.9], ["In 2022, the SkyMiles program membership accelerated with a record 8.5 million new SkyMiles Members.", 0.9], ["We believe there is opportunity to continue this trend and expect the increased value we provide customers to deliver high-margin revenue and more resilient cash flows.", 0.8], ["In 2022, we made significant progress restoring our financial foundation with strong profitability and positive free cash flow for the year.", 0.9], ["Restoring the strength of our balance sheet and reducing debt is a key financial priority.", 0.7], ["During 2022, we repaid approximately $4.5 billion in debt and finance lease obligations and the company remains committed to regaining investment grade metrics.", 0.8], ["The strength of our balance sheet supports our ability to obtain financing and was instrumental in protecting shareholders during the pandemic.", 0.8], ["Over the last decade we have fundamentally transformed our business by investing in our people, our product and our reliability to alter the commodity-like nature of air travel and improve our financial foundation.", 0.8], ["Our complementary portfolio businesses, such as our cargo business, which has grown significantly during the pandemic, and our Maintenance, Repair and Overhaul (\"MRO\") operation, where we believe we remain well-positioned for growth through contractual agreements with jet engine manufacturers, including three next generation engine platforms.", 0.8], ["Our premium yield growth has significantly outpaced main cabin with paid load factors higher in 2022 than in 2019, as demand for premium products continues to grow.", 1.0], ["In 2022, the Delta American Express co- branded card grew by 1.2 million new cardholders, with remuneration from American Express surpassing $5.5 billion.", 1.0], ["Each of our joint venture or cooperation arrangements provides for joint commercial cooperation with the relevant partner within the geographic scope of the arrangement, including the sharing of revenues and/or profits and losses generated by the parties on the joint venture routes, as well as joint marketing and sales, coordinated pricing and revenue management, network and schedule planning and other coordinated activities with respect to the parties' operations on joint venture routes.", 0.0], ["In March 2022, Grupo Aeroméxico emerged from its voluntary proceedings to reorganize under Chapter 11 of the United States bankruptcy code.", -0.5], ["Upon completion of LATAM's restructuring process in November 2022, we acquired an approximately 10% equity stake in LATAM.", 0.5], ["Through alliance arrangements with other SkyTeam carriers, we are able to link our network with the route networks of the other member airlines, providing opportunities to increase connecting traffic while offering enhanced customer service through reciprocal codesharing and loyalty program participation, airport lounge access and cargo operations.", 0.5], ["In 2022, cargo revenues increased year over year as ongoing supply chain challenges, elevated market yields and increased capacity benefited our cargo operations.", 0.5], ["In 2022, as we continued to restore our business, we hired approximately 25,000 new full-time employees across our business, including pilots, flight attendants, and customer service agents.", 0.5], ["In 2022, we made meaningful progress towards this goal by increasing the percentage of Black officers and director-level employees to 8.5% from 5.8% in 2020, although much work remains to be done to provide additional internal and external career pathways to senior leadership roles.", 0.0], ["Our results of operations are significantly impacted by changes in the price and availability of aircraft fuel.", -0.5], ["We purchase most of our aircraft fuel under contracts that establish the price based on various market indices and therefore do not provide material protection against price increases or assure the availability of our fuel supplies.", -0.5], ["We also purchase aircraft fuel on the spot market, from offshore sources and under contracts that permit the refiners to set the price.", -0.3], ["The facility is capable of refining approximately 200,000 barrels of crude oil per day and operations returned to pre-pandemic levels throughout 2022.", 0.5], ["Monroe’s sustainability ambitions include being one of the most energy efficient refineries in the country with the lowest energy intensity and GHG emissions on an absolute and per barrel basis.", 0.7], ["We closely monitor the hedge portfolio and rebalance the portfolio based on market conditions, which may result in locking in gains or losses on hedge contracts prior to their settlement dates.", 0.2], ["We currently have sufficient slots or analogous authorizations to operate our existing flights, and we have generally been able to obtain the rights to expand our operations and to change our schedules.", 0.6], ["Additional regulation could result in taxation, regulatory or permitting requirements from multiple jurisdictions for the same operations and significant costs for us and the airline industry.", -0.7], ["In addition to direct costs, such regulation could result in increased fuel costs passed through from fuel suppliers affected by any such regulations.", -0.6], ["Certain airports have also adopted, and others could in the future adopt, GHG emission or climate-related goals and requirements that could impact our operations or require us to make changes or investments in our infrastructure.", -0.4], ["While we have had sufficient scheduling flexibility to accommodate local noise restrictions in the past, our operations could be adversely impacted if locally imposed regulations become more restrictive or widespread.", -0.8], ["In addition, foreign governments may allow airports to enact similar restrictions, which could adversely impact our international operations or require significant expenditures in order for our aircraft to comply with the restrictions.", -0.8], ["For example, in 2022, to reduce noise, the Netherlands announced plans to reduce the maximum number of flights authorized annually at Amsterdam’s Schiphol Airport.", -0.5], ["Market prices for RINs have been volatile, marked by periods of sharp increases and decreases primarily in response to speculation about what the EPA and/or the U.S. Congress will do with respect to compliance obligations.", -0.6], ["The EPA's proposed ethanol mandates for 2023, 2024, and 2025 are billions of gallons above the projected ethanol demand for those years, which has resulted in an increase to already high prices for RINs.", -0.7], ["As described below, these risks could materially affect our business, financial condition or results of operations in the future.", -0.9], ["We have a significant amount of existing fixed obligations, including aircraft lease and debt financings, leases of airport property and other facilities, and other material cash obligations.", -0.8], ["In addition, we have substantial commitments for capital expenditures.", -0.7], ["We had approximately $9.4 billion in cash, cash equivalents, short-term investments and aggregate principal amount committed and available to be drawn under our revolving credit facilities (\"liquidity\") as of December 31, 2022; however, our future liquidity could be negatively affected by the risk factors discussed in this Form 10-K, and in other filings we may make from time to time with the SEC.", -0.9], ["If our liquidity is materially diminished, we might not be able to timely pay our leases and debts or comply with certain financial covenants in our financing and credit card processing agreements or with other material provisions of our contractual obligations.", -0.9], ["A decline in these coverage ratios, including due to factors that are beyond our control, could require us to post additional collateral or trigger an early amortization event.", -0.9], ["Complying with certain of the covenants in our debt agreements and other restrictive covenants that may be contained in any future debt agreements could limit our ability to operate our business and to take advantage of business opportunities that are in our long-term interest.", -0.8], ["While the covenants in our debt agreements are subject to important exceptions and qualifications, if we fail to comply with them and are unable to obtain a waiver or amendment, refinance the indebtedness subject to these covenants or take other mitigating actions, an event of default would result.", -0.9], ["If an event of default were to occur, the lenders or noteholders could, among other things, declare outstanding amounts due and payable and where applicable and subject to the terms of relevant collateral agreements, repossess collateral, including aircraft or other valuable assets.", -0.9], ["The acceleration of significant indebtedness could require us to seek to renegotiate, repay or refinance the obligations under our financing arrangements, and there is no assurance that such renegotiation or refinancing efforts would be successful.", -0.8], ["An aircraft crash or other serious accident involving our aircraft or those of our airline partners could expose Delta to significant liability.", -0.9], ["Although we believe that our insurance coverage is appropriate, we may be forced to bear substantial losses from an accident in the event that the coverage was not sufficient.", -0.8], ["In addition, any accident involving an aircraft that we operate or an aircraft that is operated by an airline that is one of our regional carriers or codeshare, alliance or joint venture partners could create a negative public perception about safety and reliability for aviation authorities and the public, which could harm our reputation, resulting in air travelers being reluctant to fly on our aircraft and therefore harm our business.", -0.9], ["If successful, these actions could cause harm to our computer systems or compromise data stored on our computer networks or those of our business partners and service providers, potentially causing us to incur remedial, legal and other costs, which could be material.", -0.8], ["In addition, as cybercriminals become more sophisticated, the cost of proactive defensive measures continues to increase.", -0.7], ["The compromise of our or our business partners’ or service providers’ technology systems resulting in the loss, interruption, disclosure, misappropriation of, or access to, our information or that of our customers, employees or business partners could result in legal claims or proceedings, liability or regulatory penalties under laws protecting the privacy and security of personal information, disruption to our operations and damage to our reputation, any or all of which could adversely affect our business.", -0.9], ["The costs to remediate breaches and similar system compromises that do occur could be material.", -0.8], ["A significant individual, sustained or repeated failure of our information technology infrastructure, including third-party networks we utilize and on which we depend, could impact our operations and our customer service, result in increased costs and damage our reputation.", -0.9], ["While we have in place initiatives to prevent disruptions and disaster recovery plans and continue to invest in improvements to these initiatives and plans, we have previously experienced infrastructure disruptions and these measures may not be adequate to prevent a future business disruption and any material adverse financial and reputational consequences to our business as recent outages of large cloud providers whom we rely on has shown.", -0.7], ["If this technology does not perform effectively, including as a result of the implementation or integration of new or upgraded technologies or systems, our business and operations would be negatively affected, which could be material.", -0.9], ["These relationships and investments involve significant challenges and risks, including that joint ventures or cooperation agreements such as our agreement with Aeroméxico may be subject to ongoing review and renewal requirements and may not generate the expected financial results, or that we may not realize a satisfactory return on our investments.", -0.8], ["The COVID-19 pandemic significantly impacted the operations of our airline partners and, similar public health threats that may arise could adversely affect the expansion of strategic relationships in the future.", -0.7], ["These carriers have incurred significant financial losses as a result of the pandemic, and some were forced to seek protection under applicable bankruptcy laws.", -0.8], ["For example, following the onset of the pandemic, Grupo Aeroméxico and LATAM filed voluntary proceedings to reorganize under Chapter 11 of the United States bankruptcy code (\"bankruptcy process\"), from which they successfully emerged in the March 2022 quarter and the December 2022 quarter, respectively, and Virgin Atlantic undertook a voluntary recapitalization process in the UK that was completed in September 2020.", 0.2], ["As discussed further in Note 4 of the Notes to the Consolidated Financial Statements, due to the effects of the COVID-19 pandemic, the carrying value of our equity investments in these three carriers was reduced to zero prior to our additional investments.", -0.6], ["In the future if any airline partner that may seek to restructure or recapitalize is unable to do so successfully or if our commercial arrangements with any of these partners are not maintained, any investments or other assets associated with those partners could become impaired, and our business and results of operations could be materially adversely affected.", -0.8], ["To the extent that the operations of a third-party on which we rely is significantly disrupted or if these third parties experience significant performance issues (including failing to satisfy any applicable performance standards) or fail to meet any applicable compliance requirements, our revenue may be reduced, our expenses may be increased and our reputation may be harmed, any or all of which could result in a material adverse effect on our business and results of operations.", -1.0], ["Some regional carriers, including our wholly owned subsidiary, Endeavor, are facing a shortage of qualified pilots and experiencing operating constraints as a result.", -0.8], ["If this shortage becomes more widespread, third-party regional carriers may not be able to comply with their obligations to us, and Endeavor may not be able to perform as expected, which could reduce our expected capacity and affect our revenue, resulting in a material adverse effect on our business and results of operations.", -0.9], ["During the fiscal year ended December 31, 2020, we recorded significant impairment and related charges resulting from the acceleration of our fleet simplification strategy and the write-down of investments in certain airline partners, stemming from the impact of the COVID-19 pandemic.", -1.0], ["We may be required to recognize losses in the future due to, among other factors, extreme fuel price volatility, tight credit markets, government regulatory changes, decline in the fair values of certain tangible or intangible assets, such as aircraft, route authorities, and airport slots, unfavorable trends in forecasted results of operations and cash flows and an uncertain economic environment, as well as other uncertainties.", -1.0], ["Further impairment charges could have a material adverse effect on our results of operations.", -1.0], ["Strikes or labor disputes with our unionized employees may have a material adverse effect on our ability to conduct business.", -1.0], ["Likewise, if third-party regional carriers with which we have contract carrier agreements are unable to reach agreement with their unionized work groups in current or future negotiations regarding the terms of their collective bargaining agreements, those carriers may be subject to work interruptions or stoppages, subject to the requirements of the Railway Labor Act, which could have a material adverse effect on our operations.", -1.0], ["The seasonal shifting of demand causes our financial results to vary on a quarterly basis.", -0.7], ["In addition, increases in the frequency, severity or duration of thunderstorms, hurricanes, typhoons, floods or other severe weather events, including from changes in the global climate and rising global temperatures, could result in increases in delays and cancellations, turbulence-related injuries and fuel consumption to avoid such weather, any of which could result in loss of revenue and higher costs.", -1.0], ["Our results of operations are significantly impacted by changes in the price of aircraft fuel.", -0.5], ["Over the last decade, fuel prices have been highly volatile and at times have increased substantially.", -0.7], ["From 2020 to 2022, our average annual fuel price per gallon has increased from", -0.3], ["$1.64 to $3.36 with significant volatility during that period.", -0.4], ["Our aircraft fuel purchase contracts alone do not provide material protection against price increases as these contracts typically establish the price based on industry standard market price indices.", -0.6], ["The competitive nature of the airline industry may affect our ability to pass along rapidly increasing fuel costs to our customers.", -0.8], ["In addition, because passengers often purchase tickets well in advance of their travel, a significant rapid increase in fuel price may result in the fare charged not covering that increase.", -0.7], ["At times in the past, we often were not able to increase our fares to offset fully the effect of increases in fuel costs, and we may not be able to do so in the future.", -0.8], ["Shortages in fuel supplies could have negative effects on our business and results of operations.", -0.9], ["The disruption or interruption of production at the refinery could have a negative impact on our ability to acquire jet fuel needed for our operations.", -0.9], ["If the refinery were to experience an interruption in operations, disruptions in fuel supplies could have negative effects on our results of operations and financial condition.", -1.0], ["In addition, the financial benefits from the operation of the refinery could be materially adversely affected (to the extent not recoverable through insurance) because of lost production and repair costs.", -1.0], ["If Monroe's cost of producing non-jet fuel products exceeds the value it receives for those products, the financial benefits we expect to achieve through the ownership of the refinery and our consolidated results of operations could be materially adversely affected.", -1.0], ["Monroe could incur substantial losses, including cleanup costs, fines and other sanctions and third-party claims, and its operations could be interrupted, as a result of such an incident.", -1.0], ["Monroe's insurance coverage does not cover all potential losses, costs or liabilities, and Monroe could suffer losses for uninsurable or uninsured risks or in amounts greater than its insurance coverage.", -1.0], ["If Monroe were to incur a significant liability for which it is not fully insured or for which insurance companies do not or are unable to provide coverage, this could have a material adverse effect on our consolidated financial results of operations or consolidated financial position.", -1.0], ["In addition, because of our ownership of Monroe, the occurrence of an environmental or other incident could result in damage to our reputation, which could have a material adverse effect on our financial results.", -1.0], ["Monroe could incur fines and other sanctions, cleanup costs and third-party claims as a result of violations of or liabilities under environmental, health and safety requirements, which if significant, could have a material adverse effect on our consolidated financial results.", -1.0], ["In addition, the enactment of new, more stringent environmental laws and regulations, including any laws or regulations relating to greenhouse gas emissions, could significantly increase the level of expenditures required for Monroe or restrict its operations.", -1.0], ["Market prices for RINs have been volatile, marked by periods of sharp increases and decreases primarily in response to speculation about what the EPA and/or the U.S. Congress will do with respect to compliance obligations.", -0.5], ["Monroe’s purchase of RINs at elevated prices in the future could have a material impact on our consolidated results of operations and cash flows.", -0.8], ["Increases in the volume of renewable fuels that must be blended into Monroe’s products could limit the refinery’s production if sufficient numbers of RINs are not available for purchase or relief from this requirement is not obtained, which could have a material adverse effect on our consolidated financial results.", -0.9], ["To the extent we are unable to respond in a timely and appropriate manner to adverse publicity, our brand and reputation may be damaged.", -0.7], ["We are continuing to develop our climate strategy and transition plan; however, our ability to execute on such a plan is subject to substantial risks and uncertainties, as it is dependent on the actions of governments and third parties and will require, among other things, significant capital investment, including from third parties, research and development from manufacturers and other stakeholders, along with government policies and incentives to reduce the cost, and incent production, of SAF and other technologies that are not presently in existence or available at scale.", -0.6], ["Significant damage to our reputation and brand could have a material adverse effect on our business and financial results, including as a result of litigation related to any of these matters.", -0.9], ["If we experience a substantial turnover in our leadership and other key employees and we are not able to replace these persons with individuals with comparable skills, or we otherwise fail to maintain our company culture, our performance could be materially adversely impacted.", -0.8], ["Furthermore, we may be unable to attract and retain additional qualified senior management and other key personnel as needed in the future.", -0.7], ["The COVID-19 pandemic, the measures governments and private parties implemented in order to stem its spread, and the general concern about the virus among travelers had a material adverse effect on the demand for worldwide air travel compared to historical levels, and consequently upon our business.", -0.9], ["Similar disease outbreaks or public health threats that may arise in the future could have similarly adverse effects on our business.", -0.8], ["Among other effects of the COVID-19 pandemic that affected air travel and our business, the pandemic led governments both in the United States and abroad to issue travel restriction or advisories, and to implement quarantines and health-related curfews or \"shelter in place\" orders; led employers to instruct employees to work from home and/or otherwise dissuaded or restricted air travel; caused business conventions, conferences, concerts, sporting events and similar events to be canceled or held with limited or no attendees; and discouraged travelers from air travel to destinations where COVID-19 was particularly virulent or due to possible enhanced COVID-19 related screening measures.", -0.8], ["These pandemic-related effects negatively impacted air travel in general, which in turn materially adversely affected our revenues, results of operations and financial condition for an extended period of time.", -1], ["Our operations have been, and could in the future be, negatively affected further if our employees are quarantined or sickened as a result of exposure to a disease outbreak such as COVID-19, or as a result of a similar public health crisis, or if they are subject to additional governmental curfews or \"shelter in place\" health orders or similar restrictions.", -1], ["Measures restricting the ability of our airport or in-flight employees to come to work negatively impact our service or operations, all of which could negatively affect our business.", -1], ["We are unable to predict the extent to which disease outbreaks or other public health threats that may arise in the future may change our customers' behavior or travel patterns, which could have a material impact on our business.", -1], ["Terrorist attacks, geopolitical conflict or security events, or the fear or threat of any of these events, could have a significant adverse effect on our business.", -1], ["In addition, the impact on our operations of avoiding areas of the world, including airspace, in which there are geopolitical conflicts and the targeting of commercial aircraft by parties to those conflicts can be significant.", -1], ["Security events, primarily from external sources but also from potential insider threats, also pose a significant risk to our passenger and cargo operations.", -1], ["Terrorist attacks, geopolitical conflict or security events, or the fear or threat of any of these events, even if not made directly on or involving the airline industry, could have a significant negative impact on us by discouraging passengers from flying, leading to decreased ticket sales and increased refunds.", -1], ["In addition, potential costs from these types of events include increased security costs, impacts from avoiding flight paths over areas in which conflict is occurring or could occur, such as flight redirections or cancellations, reputational harm and other costs.", -1], ["If any or all of these types of events occur, they could have a material adverse effect on our business, financial condition and results of operations.", -1], ["If we cannot maintain our costs at a competitive level, then our business, financial condition and results of operations could be materially adversely affected.", -1], ["Increased competition in both the domestic and international markets may have a material adverse effect on our business, financial condition and results of operations.", -1], ["An interruption or disruption at an airport where we have significant operations, whether resulting from air traffic control delays, failure of computer systems or technology infrastructure, weather events or natural disasters, or performance issues from third-party service providers, if sustained for an extended period of time, could have a material adverse effect on our business, financial condition and results of operations.", -1], ["Any significant problems associated with an aircraft or engine type that we operate, including new aircraft or engine types, such as design defects, mechanical problems, contractual performance by the manufacturers or adverse perception by the public leading to customer avoidance, or adverse actions by the FAA resulting in limitations on use or grounding could have a negative impact on our operations if we are not able to substitute or replace the affected aircraft or engine type.", -1], ["Any of the foregoing could have a material adverse effect on our financial condition and results of operations.", -1], ["Airlines are subject to extensive regulatory and legal compliance requirements that result in significant costs and may have material adverse effects on our business.", -1], ["We expect to continue incurring significant expenses to comply with the FAA’s regulations.", -1], ["In addition, a directive or other regulation that has a significant operational impact on us could have a material adverse impact on our financial results.", -1], ["Other laws, regulations, taxes and airport rates and charges have also been imposed from time to time that significantly increase the cost of airline operations, reduce revenues or otherwise impact our business.", -1], ["Additional taxes and fees, if implemented, could negatively impact our results of operations.", -1], ["Airport slot access is subject to government regulation and changes in slot regulations or allocations could impose a significant cost on the airlines operating in airports subject to such regulations or allocations or otherwise adversely affect an airline’s business.", -0.8], ["Certain of our hubs are among the most congested airports in the United States and have been, and could in the future be, the subject of regulatory action that might limit the number of flights and/or increase costs of operations at certain times or throughout the day.", -0.7], ["Failure to implement measures to improve the air traffic control system could lead to increased delays and inefficiencies in flight operations as demand for U.S. air travel increases, having a material adverse effect on our operations.", -0.9], ["Failure to update the air traffic control system in a timely manner, and the substantial funding requirements of an updated system that may be imposed on air carriers, may have an adverse impact on our financial condition and results of operations.", -0.8], ["In particular, the imposition of significant tariffs with respect to aircraft that we are not able to mitigate could substantially increase our costs, which in turn could have a material adverse effect on our financial results.", -0.9], ["Failure to comply with trade sanctions and restrictions, the Foreign Corrupt Practices Act (the \"FCPA\") and similar anti-bribery laws in non-U.S. jurisdictions, as well as other applicable laws or regulations could result in litigation, assessment of damages, imposition of penalties or other consequences, any or all of which could harm our reputation and have an adverse effect on our financial results.", -0.9], ["Although we dedicate significant resources to manage compliance with global privacy and information security obligations, this challenging regulatory environment may pose material risks to our business, including increased operational burdens and costs, regulatory enforcement, and legal claims or proceedings.", -0.7], ["Compliance with existing and future environmental laws and regulations could require capital investment and increase operational costs, and violations can lead to significant fines and penalties and reputational harm.", -0.8], ["EPA's proposed rule, once finalized, could subject airports, airlines, and refineries, among others, to potential liability for cleanup of historical PFAS contamination associated with use of PFAS-containing firefighting foam.", -0.8], ["Future regulatory action concerning climate change, aircraft emissions and noise emissions could have a significant effect on the airline industry.", -0.7], ["However, given the COVID-19 pandemic and resulting unprecedented reduction in international travel, in June 2020 ICAO removed 2020 from the baseline calculation for the first phase of CORSIA, from 2021 to 2023.", -0.5], ["However, CORSIA is expected to increase operating costs for airlines that operate internationally.", -0.3], ["In addition to CORSIA, we may face a patchwork of regulation of aircraft emissions in the U.S. and abroad and could become subject to further taxes, charges or additional requirements to obtain permits or purchase allowances or emission credits for greenhouse gas emissions in various jurisdictions.", -0.6], ["Additional regulation could result in taxation, regulatory or permitting requirements from multiple jurisdictions for the same operations and significant costs for the airline industry, including Delta.", -0.7], ["In addition to direct costs, such regulation could result in increased fuel costs passed through from fuel suppliers affected by any such regulations.", -0.4], ["While the specific nature of future actions is hard to predict, new laws or regulations related to environmental matters adopted in the U.S. or other countries could impose significant additional costs on or otherwise adversely affect our operations.", -0.8], ["Certain airports have also adopted, and others could in the future adopt, greenhouse gas emission or climate-related goals and requirements that could impact our operations or require us to make changes or investments in our infrastructure.", -0.5], ["In addition to risks from potential changes to environmental regulation and policy, the transition to lower-carbon technologies, such as SAF, or changes in consumer preferences resulting from a negative perception of the environmental impact of air travel could materially adversely affect our business and financial results.", -0.9], ["For example, lower-carbon technologies such as SAF and direct air capture technologies are currently not available at scale and may take decades to develop, and the cost to transition to them could be prohibitively expensive without appropriate government policies and incentives in place.", -0.7], ["As more businesses have publicly announced environmental sustainability goals, the cost of carbon offsets has also increased significantly and will likely continue to do so.", -0.6], ["As a result of the discretionary nature of air travel, the airline industry has been cyclical and particularly sensitive to changes in economic conditions.", -0.5], ["During periods of unfavorable or volatile economic conditions in the economy in the U.S. or abroad, including as a result of the COVID- 19 pandemic and the worldwide response to it, demand for air travel can be significantly impacted as business and leisure travelers choose not to travel, seek alternative forms of transportation for short trips or conduct business using technological alternatives.", -0.8], ["If unfavorable economic conditions occur, particularly for an extended period, our business, financial condition and results of operations may be adversely affected.", -0.9], ["In addition, significant or volatile changes in exchange rates between the U.S. dollar and other currencies, and the imposition of exchange controls or other currency restrictions, may have a material adverse effect on our liquidity, financial conditions and results of operations.", -0.8], ["Political disruptions and instability around the world can negatively impact the demand and network availability for air travel.", -0.7], ["Additionally, any deterioration in global trade relations, such as increased tariffs or other trade barriers, could result in a decrease in the demand for international air travel.", -0.6], ["As part of a multi-year effort, we have been investing in new aircraft to provide an improved customer experience, greater fuel efficiency that results in reduced carbon emissions, better operating economics and more premium products.", 0.5], ["While we have paid cash dividends to holders of our common stock on a quarterly basis, we suspended dividends in March 2020 due to the impact of the COVID-19 pandemic.", -0.4], ["During 2022, our recovery from the impact of the COVID-19 pandemic continued and is continuing into 2023.", 0.3], ["Our 2022 operating income was $3.7 billion, an improvement of $1.8 billion compared to 2021, while operating income, adjusted (a non-GAAP financial measure) which excludes restructuring charges and other items was $3.6 billion, an increase of $6.1 billion compared to 2021.", 0.8], ["The increases in operating income and operating income, adjusted were primarily due to the continued recovery in the demand for air travel during 2022, which resulted in a 69% increase in operating revenue on a 20% increase in system capacity.", 0.8], ["Our 2022 operating income decreased $3.0 billion compared to 2019 primarily due to an increase in operating costs, including a 35% increase in fuel cost, and lower passenger revenue due to system capacity that was 15% lower as we continued to restore our operations from the effects of the COVID-19 pandemic.", -0.6], ["Operating income, adjusted (a non-GAAP financial measure) decreased $3.1 billion compared to 2019.", -0.8], ["Compared to 2021, our 2022 operating revenue increased $20.7 billion, or 69%, primarily due to continued recovery in travel demand from the COVID-19 pandemic and higher refinery sales to third parties.", 0.7], ["Improvement in premium products revenue resulted from both a shift in the mix of seats on our aircraft following the retirement of certain fleets in 2020 and delivery of new aircraft since that time, as well as incremental increase in demand, particularly from leisure customers.", 0.6], ["Compared to 2019, our operating revenue increased $3.6 billion, or 8%, due primarily to higher refinery sales to third parties, partially offset by the revenue impact from 15% lower capacity.", 0.2], ["Total operating expense increased $18.9 billion, or 67%, compared to 2021, primarily resulting from higher fuel costs, due to both an increase in fuel price and increased consumption as capacity was restored, as well as higher salaries and related costs, higher volume-related expenses associated with the increase in capacity and demand and an increase in expenses related to refinery sales to third parties, reflected in ancillary business and refinery expense.", -0.7], ["The increase also resulted from $4.5 billion of PSP grants recognized during 2021, which reduced expenses in that year.", -0.3], ["excludes expenses related to refinery sales to third parties, contra-expense from the recognition of PSP grants in 2021 and other items, increased $12.8 billion, or 44%, compared to 2021.", -0.5], ["Our total operating cost per available seat mile (\"CASM\") increased 40% to 20.12 cents compared to 2021, primarily due to the higher costs discussed above.", -0.4], ["Non-fuel unit costs (\"CASM-Ex\", a non-GAAP financial measure), which excludes fuel, expenses related to refinery sales to third parties, contra-expense from the recognition of PSP grants in 2021 and other items, increased 6% to 12.87 cents.", -0.2], ["Total operating expense increased $6.5 billion, or 16%, compared to 2019, primarily resulting from higher fuel costs and an increase in expenses related to refinery sales to third parties.", -0.5], ["Total operating expense, adjusted (a non-GAAP financial measure) increased $2.0 billion, or 5% compared to 2019.", -0.3], ["Our CASM increased 37% compared to 2019, primarily due to the higher costs discussed above and a 15% decrease in capacity.", -0.7], ["CASM-Ex (a non-GAAP financial measure) increased 18% compared to 2019.", -0.4], ["During 2023, we expect non-fuel unit costs to decrease compared to 2022 as we restore our network to pre-pandemic levels, better utilizing our assets.", 0.3], ["We expect to reduce our investments in rebuilding the network as we progress through the year while improving our operational efficiency and managing inflationary pressures including labor cost increases.", 0.4], ["Total non-operating expense was $1.7 billion in 2022, $259 million higher than 2021 primarily due to higher mark-to-market losses on certain of our equity investments, partially offset by reduced losses on our equity method investments, lower interest expense as a result of our debt reduction initiatives and lower losses on extinguishment of debt.", -0.1], ["Total non-operating expense was $1.3 billion higher than 2019, primarily due to higher mark-to-market losses on certain of our equity investments and higher interest expense as a result of our increased debt balances due to the financing arrangements entered into during 2020.", -0.4], ["During 2022, operating activities provided cash flows of $6.4 billion, primarily on improving ticket sales, and incurred approximately $6.9 billion of net investing cash outflows, primarily for $6.4 billion of capital expenditures.", 0.1], ["After adjusting for strategic investments and certain other activities, these results generated $244 million of free cash flow (a non-GAAP financial measure) in 2022.", 0.5], ["Also, during 2022 we had cash outflows of approximately $4.5 billion related to repayments of our debt and finance leases, including approximately $2.3 billion for early repayments and the remainder from scheduled maturities.", -0.5], ["Our operating revenue increased $20.7 billion, or 69%, compared to the year ended December 31, 2021 due primarily to increased demand in 2022 as a result of the continued recovery from the COVID-19 pandemic and higher third-party refinery sales.", 0.7], ["The increase in operating revenue, on a 20% increase in system capacity, generated a 41% increase in total revenue per available seat mile (\"TRASM\") and a 43% increase in TRASM, adjusted (a non-GAAP financial measure) compared to 2021.", 0.6], ["Domestic passenger unit revenue (\"PRASM\") for the year ended December 31, 2022 increased 48% compared to the year ended December 31, 2021 as a result of stronger demand and higher levels of traffic due to the ongoing recovery from the COVID-19 pandemic throughout 2022.", 0.6], ["Domestic revenue in 2022 was above 2021 levels and near pre-pandemic levels, even though capacity was not fully restored, as consumers continue to return to travel.", 0.4], ["We also experienced higher growth in premium product revenue (including Delta One, First Class, Delta Premium Select and Delta Comfort+) compared to main cabin with the delivery of new aircraft that include more premium seat capacity and an increase in premium product yield compared to main cabin, as we see more consumers choosing these premium offerings.", 0.5], ["International passenger revenue for the year ended December 31, 2022 increased 147% with capacity up 47% compared to the year ended December 31, 2021, with the Atlantic region experiencing the most significant improvement, as travel to many European destinations resumed or increased.", 0.8], ["Both of these changes have had a positive impact on international demand.", 0.7], ["Most countries in our network have removed or eased travel restrictions, resulting in revenue improvement across all international regions.", 0.7], ["The Atlantic region showed strong demand improvement during 2022 as western European countries removed or eased travel restrictions in the first half of 2022.", 0.8], ["Revenue in this region was near pre-pandemic levels as travelers continue to show increased desire for transatlantic travel.", 0.9], ["This has been led by demand for leisure destinations such as Italy, Spain and Greece and improving business demand.", 0.7], ["Latin America region revenue was also near pre-pandemic levels during 2022, due to continued strong demand for leisure destinations in Mexico, the Caribbean and Central America.", 0.8], ["The Pacific region continues to be the most impacted by travel restrictions, although we experienced demand improvement during 2022 following South Korea and Australia reopening to international travelers and the recent easing of travel restrictions to Japan.", 0.3], ["We expect the increasing revenue trends in all international regions to continue into 2023 as demand for international locations continues to be strong and countries continue to reopen and remove or ease remaining travel restrictions.", 0.9], ["For example, in January 2023 China ended most of its pandemic-related travel restrictions and we expect to increase capacity based on demand during 2023.", 0.9], ["Given the impact of the COVID-19 pandemic on customer behavior and changes made in ticket validity terms, as well as the elimination of change fees for most tickets, our estimates of revenue that will be recognized from the air traffic liability for unused tickets may vary in future periods.", -0.2], ["These sales increased $1.7 billion compared to 2021.", 0.7], ["The increase in third- party refinery sales resulted from higher pricing and production during 2022 compared to 2021.", 0.7], ["On continued strength in co-brand card spend and card acquisitions, revenues from our relationship with American Express increased in 2022 compared to 2021.", 0.8], ["Compared to 2021, these transactions have increased due to the ongoing recovery of our business that continued to materialize in 2022.", 0.7], ["During 2021, travel demand began to recover from the low levels experienced during the height of the COVID-19 pandemic.", 0.3], ["This recovery in demand continued to accelerate during 2022.", 0.5], ["As a result, operating expenses increased in conjunction with the increases in demand and capacity discussed above.", -0.2], ["The continued restoration of our operations was the primary driver for the increases in most operating expense line items, particularly contracted services, aircraft maintenance materials and outside repairs, passenger commissions and other selling expenses and passenger service.", 0.4], ["We hired approximately 25,000 employees during 2022 principally in flight operations, in-flight service, reservations and customer care, TechOps and airport customer service, in order to support our operations as demand and capacity returned.", 0.6], ["These hiring actions and a 4% base pay increase effective May 1, 2022 for eligible employees resulted in the increase in salaries and related costs in 2022 compared to 2021.", 0.4], ["The increase also results from the ending of the voluntary unpaid leave of absence program we offered in response to the COVID-19 pandemic during 2021.", 0.1], ["In early 2023, we announced a 5% base pay increase for eligible employees effective April 1, 2023.", 0.5], ["In addition to various work rule changes and an 18% pay rate increase in 2023, the tentative agreement includes a provision for a one-time payment of approximately $700 million upon pilot ratification.", 0.7], ["Fuel expense increased $5.8 billion compared to 2021 primarily due to a 78% increase in the market price of jet fuel and a 23% increase in consumption as capacity was restored.", -0.6], ["Increased expenses were primarily related to refinery sales to third parties, which increased $1.7 billion compared to 2021.", -0.4], ["The increase compared to 2021 was driven by higher pricing and production during 2022.", 0.2], ["The cost of aircraft maintenance services we provide to third parties increased compared to 2021 due to the increase in flights and aircraft operated during 2022.", -0.3], ["Regional carrier expense increased compared to 2021 due to an increase in contract carrier rates and wages, while capacity was constrained due to a shortage of regional jet pilots.", -0.7], ["During 2020, we recorded restructuring charges of $8.2 billion for items such as fleet impairments and voluntary early retirement and separation programs following strategic business decisions in response to the COVID-19 pandemic.", -1.0], ["In the years ended December 31, 2022 and 2021, we recognized $124 million and $19 million, respectively, of adjustments to certain of those restructuring charges, representing changes in our estimates or the outcome of contract negotiations.", -0.5], ["Profit sharing increased by $455 million during 2022 due to higher profit during the year.", 0.8], ["For the year ended December 31, 2021, we recorded a special profit sharing expense of $108 million, based on the adjusted pre-tax profit earned during the second half of the year, to recognize the extraordinary efforts of our employees through the pandemic.", 0.5], ["During the year ended December 31, 2021, we received a total of $6.4 billion under PSP agreements with the U.S. Department of the Treasury, which we were required to use exclusively for the payment of employee wages, salaries and benefits.", -0.1], ["The support payments included grants totaling $4.5 billion that were recognized as contra-expense in 2021 over the period that the funds were used.", 0.2], ["This decreased as compared to 2021 as a result of our debt reduction initiatives during 2021 and 2022.", 0.0], ["We are reducing the total amount of interest expense by pre-paying our debt in addition to periodic amortization payments and scheduled maturities.", 0.3], ["During 2021, we made payments of approximately $5.8 billion related to our debt and finance leases, which included approximately $3.8 billion for early repayments.", 0.1], ["We have continued to pay down our debt during 2022 with $4.5 billion of payments on debt and finance lease obligations, including early repayment activities of", 0.2], ["$1.5 billion of certain notes through a cash tender offer in the September 2022 quarter and $778 million in principal for the early repurchase of various secured and unsecured notes through repurchases on the open market.", 0.1], ["Gain/(loss) on investments, net.", 0.0], ["Loss on extinguishment of debt.", -0.5], ["Loss on extinguishment of debt reflects the losses incurred in the early repayment of debt referenced above.", -0.4], ["Miscellaneous, net primarily includes charitable contributions and foreign exchange gains/(losses).", -0.1], ["As of December 31, 2022, we had approximately $5.4 billion of U.S. federal pre-tax net operating loss carryforwards, of which", 0.2], ["The jet fuel produced and procured through exchanging gasoline and diesel fuel produced by the refinery provided approximately 200,000 barrels per day, or approximately 75% of our pre-COVID-19 pandemic consumption, for use in our airline operations.", 0.3], ["Refinery revenues increased from $6.1 billion in 2021 to $10.7 billion in 2022, primarily driven by the increase in third-party refinery sales and sales to the airline segment.", 0.7], ["The increase in third-party refinery sales resulted from higher pricing and production during 2022 compared to 2021.", 0.5], ["The refinery recorded an operating loss of $2 million in 2021 compared to operating income of $777 million in 2022 mainly due to the increased production and pricing, partially offset by higher Renewable Identification Numbers (\"RINs\") compliance costs discussed below.", 0.6], ["Monroe incurred $576 million in RINs compliance costs during 2022, compared to $422 million incurred in 2021.", -0.3], ["Observable RINs prices increased through the first half of 2022 and remained at these higher rates through the second half of the year.", -0.2], ["As of December 31, 2022, we had $9.4 billion in cash, cash equivalents, short-term investments and aggregate principal amount committed and available to be drawn under our revolving credit facilities (\"liquidity\").", 0.8], ["Operating activities in 2022 provided $6.4 billion of cash flow compared to $3.3 billion in 2021.", 0.9], ["$4.5 billion in funds received from payroll support program grants.", 1.0], ["We expect to continue generating positive cash flows from operations during 2023.", 1.0], ["Beginning with the COVID-19 pandemic in the March 2020 quarter through 2021, reduced demand for air travel resulted in a lower level of advance bookings and the associated cash received than we had historically experienced, which had been impacting the typical seasonal trend of air traffic liability.", -0.5], ["However, demand improved during 2022 as consumers regained confidence to travel and increased ticket purchases for travel further in advance.", 0.5], ["As a result, air traffic liability began returning to the usual seasonal trend in 2022.", 0.5], ["The average fuel price per gallon increased substantially in 2022.", -0.5], ["While prices have recently moderated, we expect elevated jet fuel prices in comparison to historical levels to continue during the beginning of 2023 due to current market conditions, further exacerbated by geopolitical events.", -0.5], ["As capacity and demand increased throughout the year, fuel consumption was higher in 2022 than 2021 as well.", 0.0], ["However, we voluntarily contributed $1.5 billion to these plans during 2021.", 0.5], ["In 2020, we recorded a $3.4 billion charge associated with voluntary early retirement and separation programs and other employee benefit charges.", -1.0], ["Approximately $440 million, $575 million and $720 million was disbursed in cash payments to participants in the voluntary programs during 2022, 2021 and 2020 respectively.", -0.1], ["$300 million in cash payments will be made to participants in the voluntary separation programs in 2023 and the remaining payments in 2024 and beyond.", -0.2], ["Our broad-based employee profit sharing program provides that, for each year in which we have an annual pre-tax profit, as defined by the terms of the program, we will pay a specified portion of that profit to employees.", 0.5], ["To recognize the extraordinary efforts of our employees through the pandemic, we made a special profit-sharing payment of $108 million to eligible employees in February 2022, based on the adjusted pre-tax profit earned during the second half of 2021.", 0.7], ["During the year ended December 31, 2022, we recorded $563 million in profit sharing expense based on 2022 pre-tax profit, which we will pay to employees in February 2023.", 0.6], ["We have recognized a right-of-use (\"ROU\") asset and lease liability representing the fixed component of the lease payments for this facility and as the majority of the project either expands or modifies Delta’s leased premises, our lease liability will increase upon completion.", -0.3], ["As of December 31, 2022, our lease liability related to this Sublease was $2.3 billion.", -0.4], ["In 2022 we redeemed a net of $100 million in short-term investments.", 0.2], ["Our capital expenditures (i.e., property and equipment additions in our Consolidated Statements of Cash Flows (\"cash flows statement\")) were $6.4 billion and $3.2 billion in 2022 and 2021, respectively.", 0.3], ["In 2022, we achieved a significant milestone by opening the headhouse (including the Delta Sky Club), the terminal roadways and Concourse E - the second of four new concourses to be built.", 0.8], ["We currently expect our net project cost to be approximately $3.8 billion and we bear the risks of project construction, including any potential cost over-runs.", -0.5], ["$800 million to $700 million.", -0.2], ["Costs incurred in excess of the $1.8 billion maximum will not be reimbursed by the City.", -0.8], ["We currently expect our net project costs to be approximately $600 million, of which approximately $350 million has been reflected as investing activities in our cash flows statement since the project started in 2017.", 0.2], ["Given reduced passenger volumes resulting from the COVID-19 pandemic, we accelerated the construction schedule for this project in 2020.", -0.1], ["To support our international presence, during 2022 we invested an aggregate amount of $757 million in Grupo Aeroméxico and LATAM as each carrier emerged from restructuring processes.", 0.3], ["In 2022, we had cash outflows of approximately $4.5 billion related to repayments of our debt and finance leases, including approximately $2.3 billion for the early repayment of certain notes through a cash tender offer and other various secured and unsecured notes.", -0.6], ["In addition to payment of scheduled debt maturities, we expect to continue paying down our debt in 2023, and therefore reduce our future interest obligations.", 0.1], ["A hypothetical 10% increase in our estimate of the ETV of a mile would have decreased total operating revenue by less than 1% for the year ended December 31, 2022, as a result of an increase in the amount of revenue deferred associated with the miles earned.", -0.3], ["During the years ended December 31, 2022, 2021 and 2020, total cash sales from marketing agreements related to our loyalty program were $5.7 billion, $4.1 billion and $2.9 billion, respectively, which are allocated to travel and other performance obligations, as discussed below.", 0.4], ["During the COVID-19 pandemic, we experienced significant ticket cancellations, particularly in the early months of 2020.", -0.8], ["Given the impact of the COVID-19 pandemic on customer behavior and changes made in ticket validity terms, as well as the elimination of change fees for most tickets, our estimates of revenue that will be recognized from the air traffic liability for unused tickets may vary in future periods.", -0.5], ["We review flight equipment, ROU assets and other long-lived assets used in operations for impairment losses when events and circumstances indicate the assets may be impaired.", -0.6], ["Factors which could be indicators of impairment include, but are not limited to (1) a decision to permanently remove flight equipment or other long-lived assets from operations, (2) significant changes in the estimated useful life, (3) significant changes in projected cash flows, (4) permanent and significant declines in fleet fair values and (5) changes to the regulatory environment.", -0.7], ["For long-lived assets held for sale, we discontinue depreciation and record impairment losses when the carrying amount of these assets is greater than the fair value less the cost to sell.", -0.7], ["If an asset group is impaired, the impairment loss recognized is the amount by which the asset group's carrying amount exceeds its estimated fair value.", -0.7], ["We evaluated our fleet for impairment, determining that only certain fleet types were impaired, as the future cash flows from the operation of these fleet types through the respective retirement dates were lower than the carrying value.", -0.7], ["This resulted in impairment and other related charges of $4.4 billion during 2020, recorded in restructuring charges in our income statement.", -0.9], ["Due to the recovery in demand that we experienced throughout 2021 and 2022, we decided not to retire any additional aircraft and returned to service a majority of the aircraft that were temporarily parked in 2020.", 0.5], ["We recorded no further impairments during 2021 or 2022.", 0.3], ["Following the impairment charges, the aggregate net book value of these aircraft as of December 31, 2022 and December 31, 2021 was approximately $220 million and $340 million, respectively, with the reduction in 2022 primarily due to aircraft sales.", -0.5], ["Changes in certain events and circumstances could result in impairment or a change from indefinite-lived to definite-lived.", -0.7], ["Factors which could cause impairment include, but are not limited to (1) negative trends in our market capitalization, (2) reduced profitability resulting from lower passenger mile yields or higher input costs (primarily related to fuel and employees), (3) lower passenger demand as a result of weakened U.S. and global economies, global pandemics or other factors, (4) interruption to our operations due to a prolonged employee strike, terrorist attack or other reasons, (5) changes to the regulatory environment (e.g., changes in slot access and/or availability, additional Open Skies agreements or changes to antitrust approvals), (6) competitive changes by other airlines and (7) strategic changes to our operations leading to diminished utilization of the intangible assets.", -0.8], ["In the September 2022 quarter, final regulatory approval was granted for our trans-American joint venture agreement with LATAM.", 0.5], ["$1.2 billion alliance-related indefinite-lived intangible asset.", 0.2], ["We believe the LATAM joint venture agreement will generate growth opportunities, building upon Delta's and LATAM's global footprint.", 0.8], ["In 2022, we performed qualitative assessments of our goodwill and indefinite-lived intangible assets, including applicable factors noted in \"Key Assumptions\" above, and determined that there was no indication that the assets were impaired.", 0.3], ["As of December 31, 2022, the unfunded benefit obligation for these plans recorded on our balance sheets was $90 million.", -0.3], ["However, we voluntarily contributed $1.5 billion to these plans during 2021.", 0.4], ["Based on our funded status as of December 31, 2021, we modified the strategic asset allocation mix in 2022 to reduce the investment risk of the portfolio.", 0.1], ["Based on the portfolio's risk profile, we lowered the weighted average expected long-term rate of return on our defined benefit pension plan assets for 2022 net periodic benefit cost to 7.00%.", -0.2], ["Changes in life expectancy may significantly impact our benefit obligations and future net periodic benefit cost.", -0.5], ["We establish valuation allowances if it is more likely than not that we will be unable to realize our deferred income tax assets.", -0.4], ["In evaluating the likelihood of utilizing our net deferred income tax assets, the significant factors that we consider include (1) our recent history of significant profitability, (2) growth in the U.S. and global economies,", 0.3], ["Although we have cumulative losses since the onset of the pandemic, we have a history of significant earnings prior to the onset of the COVID-19 pandemic.", -0.1], ["During 2022, we returned to profitability, as our business continued to recover from the impact of the pandemic.", 0.6], ["We are expecting to generate sufficient taxable income to utilize our federal net operating loss carryforwards before any expire.", 0.5], ["However, the generation of future taxable income is dependent on many factors, including those which are out of our control, such as the demand for air travel and overall health of the economy.", -0.3], ["As such, there are no guarantees that a valuation allowance will not be required against some or all of our deferred tax assets in future periods.", -0.6], ["Therefore, we have not recorded a valuation allowance on our deferred tax assets other than the certain net realized and unrealized capital losses and certain state net operating losses that have short expiration periods.", 0.1], ["Upon adoption, we do not believe it will have a material impact on the valuation of our equity investments; however, we may be required to include additional disclosures to the extent we have material equity investments subject to contractual sale restrictions.", -0.1], ["During 2020, we recorded restructuring charges of $8.2 billion for items such as fleet impairments and voluntary early retirement and separation programs following strategic business decisions in response to the COVID-19 pandemic.", -0.8], ["In the years ended December 31, 2022 and 2021, we recognized $124 million and $19 million, respectively, of adjustments to certain of those restructuring charges, representing changes in our estimates or the outcome of contract negotiations.", -0.3], ["We recognized $4.5 billion of the grant proceeds from the payroll support program extensions as a contra-expense during 2021.", 0.2], ["To recognize the extraordinary efforts of our employees through the pandemic, we made a special profit-sharing payment to eligible employees in February 2022, based on the adjusted pre-tax profit earned during the second half of 2021.", 0.5], ["The volatility in fuel prices impacts the comparability of year-over-year financial performance.", -0.4], ["The adjustment for aircraft fuel and related taxes allows investors to better understand and analyze our non-fuel costs and year- over-year financial performance.", 0.3], ["We adjust for profit sharing because this adjustment allows investors to better understand and analyze our recurring cost performance and provides a more meaningful comparison of our core operating costs to the airline industry.", 0.4], ["Net redemptions of short-term investments represent the net purchase and sale activity of investments and marketable securities in the period, including gains and losses.", 0.0], ["Market risk is the potential negative impact of adverse changes in these prices or rates on our Consolidated Financial Statements.", -0.6], ["We expect adjustments to the fair value of financial instruments to result in ongoing volatility in earnings and stockholders' equity.", -0.5], ["Changes in fuel prices materially impact our results of operations.", -0.3], ["A one cent increase in the cost of jet fuel would result in approximately $40 million of additional annual fuel expense based on annual pre-COVID-19 pandemic consumption of approximately four billion gallons of jet fuel.", -0.4], ["As a result of the reduced capacity from the COVID-19 pandemic, our jet fuel consumption during 2022 of 3.4 billion gallons was lower than our historical and expected future consumption.", -0.2], ["Market risk associated with our variable-rate debt and variable-rate leases relates to the potential negative impact to future earnings from an increase in interest rates.", -0.6], ["At December 31, 2022, we had $17.9 billion of fixed-rate debt, $3.6 billion of variable-rate debt and $713 million of variable-rate leases.", 0.0], ["An increase of 100 basis points in average annual interest rates would have decreased the estimated fair value of our fixed-rate debt by $725 million at December 31, 2022 and would have increased the annual interest expense on our variable-rate debt and variable-rate leases by", -0.5], ["Consolidated Statements of Comprehensive Income/(Loss) for the years ended December 31, 2022, 2021 and 2020       64", -0.1], ["Note 13 - Accumulated Other Comprehensive Loss 98", 0.0], ["In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.", 0.5], ["Description of the Matter At December 31, 2022, the fair value of the Company’s benefit plan assets measured at fair value on a recurring basis totaled $15.6 billion, of which $12.3 billion do not have a readily determinable fair value and are measured at net asset value per share (\"NAV assets\") as a practical expedient.", -0.1], ["For the year ended December 31, 2022, the Company recognized $2.9 billion of revenue classified as loyalty travel awards within passenger revenue and $2.6 billion of revenue classified as loyalty program revenue within other revenue in the consolidated statement of operations.", 0.3], ["Description of the Matter At December 31, 2022, the Company had gross deferred tax assets of $8.2 billion with a related valuation allowance of $1.2 billion, and gross deferred tax liabilities of $7.9 billion.", -0.2], ["Deferred tax assets are reduced by a valuation allowance if, based on the weight of all available evidence, in management’s judgment it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.", -0.5], ["Net (Decrease)/Increase in Cash, Cash Equivalents and Restricted Cash", 0.0], ["Some of our marketing arrangements provide for the sharing of revenues and expenses.", 0.0], ["Revenues and expenses associated with collaborative arrangements are presented on a gross basis in the applicable line items on our Consolidated Statements of Operations (\"income statement\").", 0.0], ["Our short-term investments in debt securities purchased prior to October 1, 2022 are classified as fair value investments under the fair value option and unrealized gains and losses are recorded in non-operating expense.", -0.1], ["As we return to our pre-pandemic investment strategy for these assets, our short-term investments in debt securities purchased after October 1, 2022 are classified as available-for-sale investments and are stated at fair value with unrealized gains and losses recorded in accumulated other comprehensive income/(loss) (\"AOCI\").", 0.1], ["Realized gains and losses on these investments are recorded in non-operating expense.", -0.1], ["As part of our strategy to mitigate the cost of the refining margin reflected in the price of jet fuel, our wholly owned subsidiary, Monroe Energy, LLC (\"Monroe\"), operates the Trainer oil refinery.", -0.1], ["Refined products (finished goods) and feedstock and blendstock inventories (work-in-process) are both carried at the lower of cost and net realizable value.", 0.0], ["During 2022, we purchased and retired $116 million of carbon offsets which relate to a portion of our airline segment's 2021 and March 2022 quarter carbon emissions.", 0.2], ["During 2021, we purchased and retired $95 million of carbon offsets, which related to a portion of our airline segment's 2020 and 2021 carbon emissions.", 0.1], ["Changes in fuel prices, interest rates and foreign currency exchange rates impact our results of operations.", -0.3], ["Our derivative contracts are recognized at fair value on our balance sheets and had net balances of $47 million and $17 million at", 0.1], ["Depreciation and amortization expense related to our property and equipment was $2.1 billion, $2.0 billion and $2.3 billion for the years ended December 31, 2022, 2021 and 2020, respectively.", 0.0], ["Included in the depreciation and amortization expense discussed above, we recorded $307 million, $301 million and $304 million for amortization of capitalized software for the years ended December 31, 2022, 2021 and 2020, respectively.", 0.0], ["We review flight equipment, ROU assets and other long-lived assets used in operations for impairment losses when events and circumstances indicate the assets may be impaired.", -0.2], ["For long-lived assets held for sale, we discontinue depreciation and record impairment losses when the carrying amount of these assets is greater than the fair value less the cost to sell.", -0.3], ["If an asset group is impaired, the impairment loss recognized is the amount by which the asset group's carrying amount exceeds its estimated fair value.", -0.5], ["Due to the impacts of the COVID-19 pandemic, during 2020 we removed a significant portion of our mainline and regional aircraft from active service and evaluated our fleet for impairment, determining that only certain fleet types were impaired, as the future cash flows from the operation of these fleet types through the respective retirement dates were lower than the carrying value.", -0.7], ["Due to the recovery in demand that we experienced throughout 2021 and 2022, we decided not to retire any additional aircraft and returned to service a majority of the aircraft that were temporarily parked in 2020.", 0.5], ["Advertising expense was $302 million, $198 million and $119 million for the years ended December 31, 2022, 2021 and 2020, respectively.", 0.0], ["We recognized approximately $4.2 billion, $2.2 billion and $3.1 billion in passenger revenue during the years ended December 31, 2022, 2021 and 2020, respectively, that had been recorded in our air traffic liability balance at the beginning of those periods.", 0.7], ["The air traffic liability typically increases during the winter and spring months as advanced ticket sales grow prior to the summer peak travel season and decreases during the summer and fall months.", 0.0], ["Beginning with the COVID-19 pandemic in the March 2020 quarter through 2021, reduced demand for air travel resulted in a lower level of advance bookings and the associated cash received than we had historically experienced, which had been impacting the typical seasonal trend of air traffic liability.", -0.5], ["However, demand improved during 2022 as consumers regained confidence to travel and increased ticket purchases for travel further in advance.", 0.6], ["Given the impact of the COVID-19 pandemic on customer behavior and changes made in ticket validity terms, as well as the elimination of change fees for most tickets as discussed below, our estimates of revenue that will be recognized from the air traffic liability for unused tickets may vary in future periods.", -0.2], ["A change in assumptions regarding the redemption activity for miles or the estimated fair value of miles expected to be redeemed could have a material impact on our revenue in the year in which the change occurs and in future years.", -0.3], ["During the years ended December 31, 2022, 2021 and 2020, total cash sales from marketing agreements related to our loyalty program were $5.7 billion, $4.1 billion and $2.9 billion, respectively, which are allocated to travel and other performance obligations, as discussed below.", -0.1], ["In 2020, due to the COVID-19 pandemic, we recorded reserves on certain receivables, which are discussed further in Note 15, \"Government Grants and Restructuring\".", -0.7], ["During the year ended December 31, 2022 there were no material gains or losses related to investments classified as Level 3 as a result of fair value adjustments.", 0.0], ["We recognized losses of $394 million, $146 million and gains of $85 million on our fuel hedge contracts in aircraft fuel and related taxes on our income statement for the years ended December 31, 2022, 2021 and 2020, respectively.", -0.3], ["The losses recognized during 2022 were composed of $365 million of settlements on contracts and $29 million of mark-to-market adjustments.", -0.4], ["Expense from the settlement of closed contracts is offset by higher operating profits at Monroe from higher pricing.", 0.2], ["If an investment accounted for under the equity method experiences a loss in value that is determined to be other than temporary, we will reduce our carrying value of the investment to fair value and record the loss in impairments and equity method results in our income statement.", -0.6], ["In the March 2022 quarter, Grupo Aeroméxico (\"Aeroméxico\") emerged from its voluntary proceedings to reorganize under Chapter 11 of the United States bankruptcy code (\"bankruptcy process\").", -0.8], ["At the conclusion of the bankruptcy process, Aeroméxico's previously outstanding capital stock was consolidated and exchanged for less than 0.01% of new capital stock, which effectively eliminated our historical 51% ownership stake.", -0.9], ["Upon emergence, Delta received a 20% equity stake in the newly restructured Aeroméxico in exchange for (1) our receivables under Aeroméxico's debtor-in-possession financing, (2) $100 million (recorded as an investing outflow on our cash flows statement), and (3) our agreement to provide expanded commercial services to Aeroméxico in future periods.", 0.1], ["Upon emergence, Delta received full repayment of our outstanding debtor-in-possession financing.", -0.1], ["We purchased LATAM's New Convertible Notes for $657 million and subsequently converted the Notes to common stock, representing a 10% equity stake in the newly restructured LATAM.", 0.5], ["We maintain our 49% equity interest and continue to track our share of Virgin Atlantic's losses under the equity method of accounting.", -0.2], ["These previously unrecognized losses are only recorded to the extent we make additional investments in Virgin Atlantic (i.e., additional shareholder support).", -0.3], ["As of December 31, 2022, we have approximately $300 million of unrecognized equity method losses related to our 49% interest in Virgin Atlantic.", -0.4], ["If we determine that it is more likely than not that the asset may be impaired, we use the quantitative approach to assess the asset's fair value and the amount of the impairment.", -0.6], ["We recognize an impairment charge if the asset's carrying value exceeds its estimated fair value.", -0.7], ["Factors which could cause impairment include, but are not limited to (1) negative trends in our market capitalization, (2) reduced profitability resulting from lower passenger mile yields or higher input costs (primarily related to fuel and employees), (3) lower passenger demand as a result of weakened U.S. and global economies, global pandemics or other factors, (4) interruption to our operations due to a prolonged employee strike, terrorist attack or other reasons, (5) changes to the regulatory environment (e.g., changes in slot access and/or availability, additional Open Skies agreements or changes to antitrust approvals), (6) competitive changes by other airlines and (7) strategic changes to our operations leading to diminished utilization of the intangible assets.", -0.8], ["As a result of the significant impact the COVID-19 pandemic had on our market capitalization, profitability and overall travel demand, we performed a quantitative valuation of our goodwill and indefinite-lived intangible assets during the December 2020 quarter.", -0.5], ["$1.2 billion alliance-related indefinite-lived intangible asset.", 0.0], ["We believe the LATAM joint venture agreement will generate growth opportunities, building upon Delta's and LATAM's global footprint.", 0.8], ["Amortization expense was $9 million, $10 million and $10 million for the years ended December 31, 2022, 2021 and 2020, respectively.", 0.0], ["In 2022, we completed a cash tender offer for an aggregate purchase price of $1.5 billion, excluding accrued and unpaid interest, of certain of our outstanding debt securities.", 0.2], ["During 2022, in addition to the cash tender offer, we also repurchased $778 million of various secured and unsecured notes on the open market.", 0.1], ["Collectively, these payments resulted in a $100 million loss on extinguishment of debt, which is recorded in non-operating expense in our income statement.", -0.5], ["As of December 31, 2022, we had approximately $2.9 billion undrawn and available under our revolving credit facilities.", 0.5], ["Market risk associated with our fixed- and variable-rate debt relates to the potential reduction in fair value and negative impact to future earnings, respectively, from an increase in interest rates.", -0.7], ["In 2020, we entered into $2.8 billion of sale-leaseback transactions for 85 aircraft.", 0.1], ["Delta Air Lines, Inc. | 2022 10-K            82", 0.0], ["(1) Expenses are primarily classified within aircraft rent, landing fees and other rents and regional carrier expense on our income statement.", 0.0], ["We have recognized a ROU asset and lease liability representing the fixed component of the lease payments for this facility and as the majority of the project either expands or modifies Delta’s leased premises, our lease liability will increase upon completion.", -0.1], ["The revolving credit facility agreement was most recently amended in January 2023, decreasing the revolver capacity from", -0.3], ["$800 million to $700 million.", -0.2], ["Costs incurred in excess of the $1.8 billion maximum will not be reimbursed by the City.", -0.7], ["We currently expect our net project costs to be approximately $600 million, of which approximately $350 million has been reflected as investing activities in our cash flows statement since the project started in 2017.", 0.2], ["In 2022, we achieved a significant milestone by opening the headhouse (including the Delta Sky Club), the terminal roadways and Concourse E - the second of four new concourses to be built.", 0.8], ["Pursuant to the lease agreement, as amended to date, we will (1) fund (through debt issuance and existing cash) and undertake the design, management and construction of the terminal and certain off-premises supporting facilities, (2) receive a Port Authority contribution of approximately $500 million to facilitate construction of the terminal and other supporting infrastructure,", 0.3], ["Using funding primarily provided by these arrangements, we spent approximately $650 million, $950 million and $600 million during 2022, 2021, and 2020 respectively, bringing the total amount spent on the project to date to approximately $3.2 billion.", 0.1], ["The costs associated with our defined contribution pension plans were approximately", -0.2], ["As a result, we recorded a $1.3 billion special termination benefit charge and increased our postretirement healthcare obligation by $1.3 billion.", -0.8]], "dal23_sentences.json": [["In 2023, we continued to differentiate Delta from the industry by strengthening our competitive advantages.", 0.8], ["Our industry-leading profit sharing program directly aligns our employees' interests with the company's long-term success and for 2023, we are rewarding them with $1.4 billion in profit sharing payments.", 1.0], ["The company also maintains a Shared Rewards program to incentivize operational performance, and our employees earned $53 million under this program in 2023.", 0.7], ["Core hubs have strong local passenger share, a high penetration of customers loyal to Delta, a competitive cost position and strong margins.", 0.6], ["In 2023, we focused on restoring our core hubs while solidifying positions in our coastal hubs.", 0.5], ["In 2023, we took delivery of 43 aircraft, including new A321neos, A220-300s and A330-900s.", 0.7], ["Our new aircraft delivered since 2019 are on average 28% more fuel efficient per seat mile than aircraft retired since 2019.", 0.9], ["We believe our continued investment in customer service and experience, operations, product, airports and technology has shaped customer perception of our brand leading to improvements in our domestic net promoter scores and increased customer loyalty compared to pre-pandemic levels.", 0.8], ["We believe there is opportunity to continue this trend and expect the increased value we provide customers to deliver high-margin revenue and resilient cash flows.", 0.9], ["In 2023, we made significant progress restoring our financial foundation with strong profitability and $2 billion of free cash flow for the year.", 1.0], ["During 2023, we repaid approximately $4.1 billion in debt and finance lease obligations and the company remains committed to regaining investment grade metrics.", 0.8], ["We have diversified our business by growing high- margin revenue streams that leverage our competitive advantages, including:", 0.7], ["Our premium yield growth has significantly outpaced main cabin, with record paid load factors in premium cabin in 2023, as demand for premium products continues to grow.", 0.9], ["In 2023, we grew our mix of premium seats, including the continued expansion of Delta Premium Select.", 0.8], ["In 2023, 10% of revenue miles flown on Delta were from award travel, as program members redeemed miles in the loyalty program for approximately 30 million award tickets.", 0.7], ["In 2023, remuneration from American Express totaled $6.8 billion, which we expect to increase by 10% in 2024 and grow to $10 billion over the long-term.", 0.9], ["Through alliance arrangements with other SkyTeam carriers, we are able to link our route network with those of the other member airlines, providing opportunities to increase connecting traffic while offering enhanced customer service through reciprocal codesharing and loyalty program participation, airport lounge access and cargo operations.", 0.6], ["These arrangements enable us to better match capacity with demand in these markets.", 0.5], ["We are entitled to all ticket, cargo, mail, in-flight and ancillary revenues associated with the flights under these capacity purchase arrangements.", 0.6], ["We generate cargo revenues in domestic and international markets through the use of cargo space on regularly scheduled passenger aircraft.", 0.6], ["In 2023, cargo revenues decreased year over year, mostly resulting from lower yield due to decreased market demand and increased industry capacity.", -0.8], ["In 2023, the aggregate revenue from our MRO operation and Delta Vacations was approximately $840 million.", 0.5], ["Reward our people through highly competitive total compensation designed to share Delta’s success with our employees who make it possible and promote teamwork and collaboration across the business.", 0.7], ["Our results of operations are significantly impacted by changes in the price and availability of aircraft fuel.", -0.6], ["We purchase most of our aircraft fuel under contracts that establish the price based on various market indices and therefore do not provide material protection against price increases or assure the availability of our fuel supplies.", -0.7], ["We own Monroe as part of our strategy to mitigate the cost of the refining margin reflected in the price of jet fuel, as well as to maintain sufficiency of supply to our New York operations.", 0.3], ["We closely monitor the hedge portfolio and rebalance the portfolio based on market conditions, which may result in locking in gains or losses on hedge contracts prior to their settlement dates.", 0.2], ["Dormant route authorities may not be renewed in some cases, especially where another U.S. carrier indicates a willingness to provide service.", -0.5], ["Self-help includes, among other things, a strike by the union or the imposition of proposed changes to the collective bargaining agreement by the airline.", -0.9], ["However, CORSIA is expected to increase operating costs for airlines that operate internationally.", -0.4], ["Under these regulations, any airline with flights originating or landing in the European Economic Area (\"EEA\") is subject to the ETS and, beginning in 2012, was required to purchase emissions allowances if the airline exceeds the number of free allowances allocated to it under the ETS.", -0.5], ["The airline industry may face additional regulation of aircraft emissions in the U.S. and abroad and become subject to further taxes, charges or additional requirements to obtain permits or purchase allowances or emission credits for GHG emissions in various jurisdictions.", -0.7], ["This mandate is expected to increase the cost of SAF in the EU.", -0.4], ["Additional regulation could result in taxation, regulatory or permitting requirements from multiple jurisdictions for the same operations and significant costs for us and the airline industry.", -0.6], ["In addition to direct costs, such regulation could result in increased fuel costs passed through from fuel suppliers affected by any such regulations.", -0.5], ["Certain airports have also adopted, and others could in the future adopt, GHG emission or climate-related goals and requirements that could impact our operations or require us to make changes or investments in our infrastructure.", -0.4], ["While we have had sufficient scheduling flexibility to accommodate local noise restrictions in the past, our operations could be adversely impacted if locally imposed regulations become more restrictive or widespread.", -0.6], ["In addition, foreign governments may enact or allow airports to enact similar restrictions, which could adversely impact our international operations or require significant expenditures in order for our aircraft to comply with the restrictions.", -0.6], ["Because Monroe is able to blend only a small amount of renewable fuels, it must purchase the majority of its RINs requirement in the secondary market.", -0.5], ["Market prices for RINs have been volatile and marked by periods of sharp increases and decreases primarily in response to speculation about what the EPA and/or the U.S. Congress will do with respect to compliance obligations.", -0.5], ["These volume requirements are below projected production of Transportation Fuels, which has resulted in a decrease in the price of RINs.", -0.5], ["As described below, these risks could materially affect our business, financial condition or results of operations in the future.", -0.7], ["An aircraft crash or other serious accident involving our aircraft or those of our airline partners could expose us to significant liability.", -0.9], ["Although we believe that our insurance coverage is appropriate, we may be forced to bear substantial losses from an accident in the event that the coverage was not sufficient.", -0.8], ["In addition, any accident involving an aircraft that we operate or an aircraft that is operated by an airline that is one of our regional carriers or codeshare, alliance or joint venture partners could create a negative public perception about safety and reliability for aviation authorities and the public, which could harm our reputation, resulting in air travelers being reluctant to fly on our aircraft and therefore harm our business.", -0.9], ["If successful, these actions could cause harm to our computer systems or compromise data stored on our computer networks or those of our business partners and third-party service providers, potentially causing us to incur remedial, legal and other costs, which could be material.", -0.8], ["In addition, as cybercriminals become more sophisticated, the cost of proactive defensive measures continues to increase.", -0.7], ["The compromise of our or our business partners’ or third-party service providers’ technology systems resulting in the loss, interruption, disclosure, misappropriation of, or access to, our information or that of our customers, employees or business partners could result in legal claims or proceedings, liability or regulatory penalties under laws protecting the privacy and security of personal information, disruption to our operations and damage to our reputation, any or all of which could adversely affect our business.", -0.9], ["The costs to remediate breaches and similar system compromises that do occur could be material.", -0.8], ["A significant individual, sustained or repeated failure of our information technology infrastructure, including third-party networks we utilize and on which we depend, could impact our operations and our customer service, result in increased costs and damage our reputation.", -0.9], ["These measures may not be adequate to prevent a future business disruption and any material adverse financial and reputational consequences to our business as recent outages of large cloud providers whom we rely on has shown.", -0.8], ["If this technology does not perform effectively, including as a result of the implementation or integration of new or upgraded technologies or systems, our business and operations would be negatively affected, which could be material.", -0.9], ["Our results of operations are significantly impacted by changes in the price of aircraft fuel.", -0.5], ["Fuel prices are highly volatile and at times have increased substantially.", -0.6], ["Our aircraft fuel purchase contracts alone do not provide material protection against price increases as these contracts typically establish the price based on industry standard market price indices.", -0.7], ["Because passengers often purchase tickets well in advance of their travel, a significant rapid increase in fuel price may result in the fare charged not covering that increase.", -0.8], ["At times in the past, we often were not able to increase our fares to offset fully the effect of increases in fuel costs, and we may not be able to do so in the future.", -0.7], ["Shortages in fuel supplies could have negative effects on our business and results of operations.", -0.8], ["Unplanned disruptions or interruptions of production at the refinery could have a negative impact on our ability to acquire jet fuel needed for our operations.", -0.8], ["If the refinery were to experience an unexpected interruption in operations, disruptions in fuel supplies could have negative effects on our results of operations and financial condition.", -0.8], ["In addition, the financial benefits from the operation of the refinery could be materially adversely affected (to the extent not recoverable through insurance) because of lost production and repair costs.", -0.9], ["If Monroe's cost of producing non-jet fuel products significantly exceeds the value it receives for those products, the financial benefits we expect to achieve through the ownership of the refinery and our consolidated results of operations could be materially adversely affected.", -0.9], ["These relationships and investments involve significant challenges and risks, including that joint ventures or cooperation agreements may be subject to ongoing review and renewal requirements and may not generate the expected financial results, or that we may not realize a satisfactory return on our investments.", -0.8], ["To the extent that the operations of any of these carriers are disrupted over an extended period or their actions have a significant adverse effect on our operations, our results of operations could be materially adversely affected.", -0.9], ["If our commercial arrangements with any of these partners are not maintained, any investments or other assets associated with those partners could become impaired, and our business and results of operations could be materially adversely affected.", -0.9], ["To the extent that the operations of a third-party on which we rely is significantly disrupted or if these third parties experience significant performance issues (including failing to satisfy any applicable performance standards) or fail to meet any applicable compliance requirements, our revenue may be reduced, our expenses may be increased and our reputation may be harmed, any or all of which could result in a material adverse effect on our business and results of operations.", -0.9], ["Some regional carriers, including our wholly owned subsidiary, Endeavor, are facing a shortage of qualified pilots and experiencing operating constraints as a result.", -0.7], ["If this shortage becomes more widespread, third-party regional carriers may not be able to comply with their obligations to us, and Endeavor may not be able to perform as expected, which could reduce our expected capacity and affect our revenue, resulting in a material adverse effect on our business and results of operations.", -0.8], ["A decline in these coverage ratios, including due to factors that are beyond our control, could trigger an early amortization event or, if applicable, require us to post additional collateral.", -0.8], ["If an event of default were to occur, the lenders or noteholders could, among other things, declare outstanding amounts due and payable and where applicable and subject to the terms of relevant collateral agreements, repossess collateral, including aircraft or other valuable assets.", -0.9], ["In addition, an event of default or acceleration of indebtedness under one agreement could result in an event of default under other of our financing agreements.", -0.8], ["The acceleration of significant indebtedness could require us to seek to renegotiate, repay or refinance the obligations under our financing arrangements, and there is no assurance that such renegotiation or refinancing efforts would be successful.", -0.9], ["Strikes or labor disputes with our unionized employees may have a material adverse effect on our ability to conduct business.", -0.9], ["Likewise, if third-party regional carriers with which we have contract carrier agreements are unable to reach agreement with their unionized work groups in current or future negotiations regarding the terms of their collective bargaining agreements, those carriers may be subject to work interruptions or stoppages, subject to the requirements of the Railway Labor Act, which could have a material adverse effect on our operations.", -0.9], ["Our results of operations are impacted by a number of factors including seasonality and changing economic and other conditions beyond our control.", -0.6], ["Demand for air travel is typically higher in the June and September quarters, particularly in our international markets, because there is more vacation travel during these periods than during the remainder of the year.", 0.2], ["The seasonal shifting of demand causes our financial results to vary on a quarterly basis.", -0.4], ["Changes in the value of our equity investments in other airlines and airline service companies can also be significant and cause fluctuations in our results.", -0.5], ["In addition, increases in the frequency, severity or duration of thunderstorms, hurricanes, typhoons, floods or other severe weather events, including from changes in the global climate and rising global temperatures, could result in increases in delays and cancellations, turbulence-related injuries and fuel consumption to avoid such weather, any of which could result in loss of revenue and higher costs.", -0.7], ["Monroe could incur substantial losses, including cleanup costs, fines and other sanctions and third-party claims, and its operations could be interrupted, as a result of such an incident.", -0.8], ["Monroe's insurance coverage does not cover all potential losses, costs or liabilities, and Monroe could suffer losses for uninsurable or uninsured risks or in amounts greater than its insurance coverage.", -1.0], ["If Monroe were to incur a significant liability for which it is not fully insured or for which insurance companies do not or are unable to provide coverage, this could have a material adverse effect on our consolidated financial results of operations or consolidated financial position.", -1.0], ["In addition, because of our ownership of Monroe, the occurrence of an environmental or other incident could result in damage to our reputation, which could have a material adverse effect on our financial results.", -1.0], ["Monroe could incur fines and other sanctions, cleanup costs and third-party claims as a result of violations of or liabilities under environmental, health and safety requirements, which if significant, could have a material adverse effect on our consolidated financial results.", -1.0], ["In addition, the enactment of new, more stringent environmental laws and regulations, including any laws or regulations relating to greenhouse gas emissions, could significantly increase the level of expenditures required for Monroe or restrict its operations.", -1.0], ["As a result, Monroe is exposed to the market price of RINs.", -0.5], ["Market prices for RINs have been volatile, marked by periods of sharp increases and decreases primarily in response to speculation about what the EPA and/or the U.S. Congress will do with respect to compliance obligations.", -0.5], ["Monroe’s purchase of RINs at elevated prices in the future could have a material impact on our consolidated results of operations and cash flows.", -1.0], ["Increases in the volume of renewable fuels that must be blended into Monroe’s products could limit the refinery’s production if sufficient numbers of RINs are not available for purchase, or if relief from this requirement is not obtained, which could have a material adverse effect on our consolidated financial results.", -1.0], ["Significant damage to our reputation and brand could have a material adverse effect on our business and financial results, including as a result of litigation related to any of these matters.", -1.0], ["If we experience a substantial turnover in our leadership and other key employees and we are not able to replace these persons with individuals with comparable skills, or we otherwise fail to maintain our company culture, our performance could be materially adversely impacted.", -1], ["The COVID-19 pandemic, the measures governments and private parties implemented in order to stem its spread, and the general concern about the virus among travelers had a material adverse effect on the demand for worldwide air travel compared to historical levels, and consequently upon our business for an extended period.", -1], ["Similar disease outbreaks or public health threats that may arise in the future could have similarly adverse effects on our business.", -1], ["Our operations were, and could in the future be, negatively affected further if our employees are quarantined or sickened as a result of exposure to a disease outbreak, or as a result of a similar public health crisis, or if they are subject to additional governmental curfews or \"shelter in place\" health orders or similar restrictions.", -1], ["Measures restricting the ability of our airport or in-flight employees to come to work negatively impact our service or operations, all of which could negatively affect our business.", -1], ["We are unable to predict the extent to which disease outbreaks or other public health threats that may arise in the future may change our customers' behavior or travel patterns, which could have a material impact on our business.", -1], ["The degree to which any future disease outbreaks or public health threats may impact our revenues, results of operations and financial condition is uncertain and will depend on future developments.", -1], ["Terrorist attacks, geopolitical conflict or security events, or the fear or threat of any of these events, could have a significant adverse effect on our business.", -1], ["In addition, the impact on our operations of avoiding areas of the world, including airspace, in which there are geopolitical conflicts and the targeting of commercial aircraft by parties to those conflicts can be significant.", -1], ["Security events, primarily from external sources but also from potential insider threats, also pose a significant risk to our passenger and cargo operations.", -1], ["Terrorist attacks, geopolitical conflict or security events, or the fear or threat of any of these events, even if not made directly on or involving the airline industry, could have a significant negative impact on us by discouraging passengers from flying, leading to decreased ticket sales and increased refunds.", -1], ["In addition, potential costs from these types of events include increased security costs, impacts from avoiding flight paths over areas in which conflict is occurring or could occur, such as flight redirections or cancellations, reputational harm and other costs.", -1], ["If any or all of these types of events occur, they could have a material adverse effect on our business, financial condition and results of operations.", -1], ["If we cannot maintain our costs at a competitive level, then our business, financial condition and results of operations could be materially adversely affected.", -1], ["Increased competition from these sectors in both the domestic and international markets may have a material adverse effect on our business, financial condition and results of operations.", -1], ["An interruption or disruption at an airport or facility where we have significant operations, whether resulting from air traffic control delays, failure of computer systems or technology infrastructure, weather events or natural disasters, or performance issues from third-party service providers, if sustained for an extended period of time, could have a material adverse effect on our business, financial condition and results of operations.", -1], ["Any significant problems associated with an aircraft or engine type that we operate, including new aircraft or engine types, such as design defects, mechanical problems, contractual performance by the manufacturers or adverse perception by the public leading to customer avoidance, or adverse actions by the FAA resulting in limitations on use or grounding could have a negative impact on our operations if we are not able to substitute or replace the affected aircraft or engine type.", -1], ["Any of the foregoing could have a material adverse effect on our financial condition and results of operations.", -1], ["Airlines are subject to extensive regulatory and legal compliance requirements that result in significant costs and may have material adverse effects on our business.", -1], ["In addition, a directive or other regulation that has a significant operational impact on us could have a material adverse impact on our financial results.", -1], ["Other laws, regulations, taxes and airport rates and charges have also been imposed from time to time that significantly increase the cost of airline operations, reduce revenues or otherwise impact our business.", -1.0], ["Additional taxes and fees, if implemented, could negatively impact our results of operations.", -0.8], ["Airport slot access is subject to government regulation and changes in slot regulations or allocations could impose a significant cost on the airlines operating in airports subject to such regulations or allocations or otherwise adversely affect an airline’s business.", -0.9], ["Certain of our hubs are among the most congested airports in the United States and have been, and could in the future be, the subject of regulatory action that might limit the number of flights and/or increase costs of operations at certain times or throughout the day.", -0.7], ["Failure to implement measures to improve the air traffic control system could lead to increased delays and inefficiencies in flight operations as demand for U.S. air travel increases, having a material adverse effect on our operations.", -0.9], ["Failure to update the air traffic control system in a timely manner, and the substantial funding requirements of an updated system that may be imposed on air carriers, may have an adverse impact on our financial condition and results of operations.", -0.9], ["In particular, the imposition of significant tariffs with respect to aircraft that we are not able to mitigate could substantially increase our costs, which in turn could have a material adverse effect on our financial results.", -0.9], ["Failure to comply with trade sanctions and restrictions, the Foreign Corrupt Practices Act (the \"FCPA\") and similar anti-bribery laws in non-U.S. jurisdictions, as well as other applicable laws or regulations could result in litigation, assessment of damages, imposition of penalties or other consequences, any or all of which could harm our reputation and have an adverse effect on our financial results.", -0.9], ["Although we dedicate significant resources to manage compliance with global privacy and information security obligations, this challenging regulatory environment may pose material risks to our business, including increased operational burdens and costs, regulatory enforcement, and legal claims or proceedings.", -0.8], ["Compliance with existing and future environmental laws and regulations could require capital investment and increase operational costs, and violations can lead to significant fines and penalties and reputational harm.", -0.8], ["The ultimate impact and associated cost to Delta of these legislative and regulatory developments related to PFAS, including firefighting foam, cannot be predicted at this time.", -0.5], ["Future regulatory action concerning climate change, aircraft emissions and noise could have a significant effect on the airline industry.", -0.6], ["However, CORSIA is expected to increase operating costs for airlines that operate internationally.", -0.7], ["The mandate initially requires that, of the jet fuel supplied in the EU, 2% must be SAF beginning in 2025, and the percentage increases incrementally over time to 70% in 2050.", 0.1], ["This mandate is expected to increase the cost of SAF in the EU.", -0.4], ["Additional regulation could result in taxation, regulatory or permitting requirements from multiple jurisdictions for the same operations and significant costs for the airline industry, including Delta.", -0.6], ["In addition to direct costs, such regulation could result in increased fuel costs passed through from fuel suppliers affected by any such regulations.", -0.5], ["In addition to risks from potential changes to environmental regulation and policy, the transition to lower-carbon technologies, such as SAF, or changes in consumer preferences resulting from a negative perception of the environmental impact of air travel could materially adversely affect our business and financial results.", -0.8], ["As a result of the discretionary nature of air travel, the airline industry has been cyclical and particularly sensitive to changes in economic conditions.", -0.7], ["During periods of unfavorable or volatile economic conditions in the economy in the U.S. or abroad, demand for air travel can be significantly impacted as business and leisure travelers choose not to travel, seek alternative forms of transportation for short trips or conduct business using technological alternatives.", -0.9], ["If unfavorable economic conditions occur, particularly for an extended period, our business, financial condition and results of operations may be adversely affected.", -1.0], ["In addition, significant or volatile changes in exchange rates between the U.S. dollar and other currencies, and the imposition of exchange controls or other currency restrictions, may have a material adverse effect on our liquidity, financial conditions and results of operations.", -1.0], ["Political disruptions and instability around the world can negatively impact the demand and network availability for air travel.", -1.0], ["Additionally, any deterioration in global trade relations, such as increased tariffs or other trade barriers, could result in a decrease in the demand for international air travel.", -1.0], ["In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial.", 0.5], ["In 2023, we retired all remaining CRJ-200 aircraft from service.", 0.5], ["As part of a multi-year effort, we have been investing in new aircraft to provide an improved customer experience, greater fuel efficiency that results in reduced carbon emissions, better operating economics and more premium products.", 1.0], ["In January 2024, we entered into a purchase agreement with Airbus for 20 A350-1000 aircraft, with an option to purchase an additional 20 widebody aircraft.", 1.0], ["After suspending dividends in March 2020, our Board of Directors re-instated a quarterly dividend program in 2023 with $0.10 per share dividend payments in both the September and December quarters.", 1.0], ["Our 2023 operating income was $5.5 billion, an improvement of $1.9 billion compared to 2022, while operating income, adjusted (a non-GAAP financial measure) which excludes one-time pilot agreement expenses and other items was $6.3 billion, an increase of $2.8 billion compared to 2022.", 1.0], ["Operating income and operating income, adjusted increased primarily from increases in revenue as described below.", 0.5], ["Compared to 2022, our 2023 operating revenue increased $7.5 billion, or 15%, primarily due to a 17% increase in capacity driven by an increase in demand for international travel and continuing strength in demand for domestic travel and premium products.", 0.8], ["Total revenue, adjusted (a non-GAAP financial measure) increased in 2023 by $9.1 billion, or 20%, compared to 2022.", 0.7], ["Total operating expense increased $5.6 billion, or 12%, compared to 2022, primarily resulting from higher employee related costs from increased wages and profit sharing, pilot agreement and related expenses and higher volume-related expenses associated with the 17% increase in capacity, partially offset by lower expenses related to refinery sales to third parties, reflected in ancillary business and refinery expense.", -0.2], ["Total operating expense, adjusted (a non-GAAP financial measure) increased $6.3 billion, or 15%, compared to 2022.", -0.1], ["Our total operating cost per available seat mile (\"CASM\") decreased 4% compared to 2022 to 19.31 cents, primarily due to a 17% increase in capacity, as well as lower fuel expense and lower expenses related to refinery sales to third parties.", 0.4], ["Non-fuel unit costs (\"CASM-Ex\", a non-GAAP financial measure), which excludes fuel, expenses related to refinery sales to third parties, and other items, increased 2.3% to 13.17 cents.", -0.1], ["Total non-operating income was $87 million in 2023 compared to total non-operating expense of $1.7 billion in 2022 primarily due to mark-to-market gains on certain of our equity investments and lower interest expense as a result of our debt reduction initiatives, partially offset by increased pension related expenses.", 0.3], ["During 2023, operating activities provided cash flows of $6.5 billion, primarily from ticket sales.", 0.6], ["Investing activities resulted in net cash outflows of approximately $3.1 billion, primarily for $5.3 billion of capital expenditures, partially offset by $2.2 billion of net redemptions of short-term investments.", -0.3], ["After adjusting for the pilot agreement payment and certain other activities, these results generated $2.0 billion of free cash flow (a non-GAAP financial measure) in 2023.", 0.8], ["Also, during 2023 we had cash outflows of approximately $4.1 billion related to repayments of our debt and finance leases, including approximately $2.0 billion for early repayments and the remainder from scheduled maturities.", -0.5], ["Our operating revenue increased $7.5 billion, or 15%, compared to 2022 due primarily to a 17% increase in capacity driven by an increase in demand for international travel and continuing strength in demand for domestic travel, with growth in revenue from premium products outpacing main cabin.", 0.9], ["This increase was partially offset by lower third-party refinery sales recorded in other revenue.", -0.1], ["Total revenue per available seat mile (\"TRASM\") decreased 2% in large part as a result of the decline in third-party refinery sales.", -0.3], ["Domestic passenger unit revenue (\"PRASM\") for 2023 increased 2% compared to 2022 due to a 12% increase in revenue on a 10% increase in capacity and a slight increase in load factor.", 0.2], ["Domestic revenue in 2023 was above 2022 levels as we experienced strong revenue results across the domestic network, with coastal hub markets such as New York and Boston improving significantly compared to the prior year, domestic business travel revenue improving and a 10% increase in domestic capacity compared to 2022.", 0.7], ["We also experienced higher growth in premium product revenue (including Delta One, First Class, Delta Premium Select and Delta Comfort+) compared to main cabin with the delivery of new aircraft that include more premium seat capacity and an increase in yield in premium products compared to main cabin, as we see more consumers choosing these premium offerings.", 0.6], ["International passenger revenue for 2023 increased 49% with capacity up 31% compared to 2022.", 0.9], ["Passenger revenue increased in each geographic region with the Atlantic region experiencing the largest absolute improvement, as travel to many European destinations increased.", 0.8], ["Consumers showed a strong desire for transatlantic travel, driving higher revenue and passenger unit revenue during 2023 on 30% capacity growth compared to 2022.", 0.8], ["Latin America region revenue increased during 2023 compared to 2022, due to strong demand for leisure destinations in South America and the Caribbean on a 16% increase in capacity.", 0.7], ["The Pacific region benefited from improved demand for travel to the region, particularly to Japan, on 75% increased capacity following the lifting of pandemic-related travel restrictions and the performance of our joint venture with Korean Air.", 0.9], ["These sales decreased $1.6 billion compared to 2022.", -0.8], ["The decrease in third- party refinery sales resulted from lower pricing and a turnaround which was completed between September and November 2023.", -0.7], ["Revenues from our relationship with American Express increased compared to 2022 driven by co-brand card spend growth.", 0.6], ["The increase in miscellaneous is primarily due to increased revenue from Delta Sky Club access.", 0.5], ["The agreement includes numerous work rule changes and pay rate increases during the four-year term, including an initial pay rate increase of 18%.", 0.4], ["We also implemented base pay increases for eligible non-pilot employees of 5% effective April 1, 2023.", 0.3], ["Each of these actions contributed to the increase in salaries and related costs.", 0.2], ["Fuel expense decreased $413 million compared to 2022 primarily due to an 18% decrease in the market price of jet fuel partially offset by a 15% increase in consumption on a 17% increase in capacity.", -0.1], ["The decline in these expenses was primarily related to lower refinery sales to third parties, which decreased $1.6 billion compared to 2022.", -0.2], ["The decrease in third-party refinery sales resulted from lower pricing and the turnaround, which was completed between September and November 2023.", -0.3], ["Contracted services expenses increased compared to 2022 due to higher-volume related expenses associated with increased capacity, in addition to inflationary pressures.", -0.4], ["The increase in landing fees and other rents resulted from higher rates charged by airports following extensive redevelopment projects at numerous facilities and more flights compared to 2022 that contributed to our increased capacity.", -0.3], ["Aircraft maintenance materials and outside repairs increased as we continued to invest in the operational reliability of our fleet, in particular related to engine overhauls on our B-757 aircraft, in addition to higher material costs.", -0.2], ["The increase in passenger revenue in 2023, compared to 2022, directly led to increased passenger commissions and selling expenses.", 0.2], ["Passenger service expenses increased compared to 2022 due to higher volume-related expenses associated with increased traffic.", -0.1], ["Profit sharing increased by $820 million during 2023 due to higher profit during the year.", 0.8], ["Our profit sharing program pays 10% to all eligible employees for the first $2.5 billion of annual profit, as defined by the terms of the program, and 20% of annual profit above $2.5 billion.", 0.7], ["In addition to the actions in salaries and related costs described above, the ratified pilot agreement also includes a provision for a one-time payment made upon ratification during 2023 of $735 million.", 0.5], ["Additionally, we recorded adjustments to other benefit-related items of approximately $130 million.", 0.0], ["The increase in other is primarily due to higher volume-related expenses associated with increased capacity, such as flight crew and other employee travel and incidental costs, and inflationary pressures.", -0.2], ["This decreased as compared to 2022 as a result of our reduced interest expense resulting from our debt reduction initiatives and increased interest income.", 0.3], ["We are reducing the total amount of interest expense by pre-paying our debt in addition to periodic amortization payments and scheduled maturities.", 0.4], ["During 2023, we made $4.1 billion of payments on debt and finance lease obligations, including early repayment activities of $1.4 billion in principal for the early repurchase of various secured and unsecured notes and the SkyMiles Term Loan on the open market and", 0.2], ["$585 million in early principal repayments on various notes secured by aircraft.", 0.1], ["Interest income increased as a result of higher interest rates and higher short-term investment balances throughout most of 2023.", 0.4], ["The increase compared to 2022 is due to net unrealized gains on our equity investments during 2023, primarily Wheels Up, Hanjin-KAL and LATAM.", 0.5], ["During 2023, we recorded a $786 million mark-to- market gain on our investment in Wheels Up based on the closing price of its shares as traded on the New York Stock Exchange.", 0.7], ["Net unrealized losses on our equity investments during 2022 were primarily related to LATAM, Hanjin-KAL and Wheels Up.", -0.5], ["Loss on extinguishment of debt.", -1.0], ["Loss on extinguishment of debt reflects the losses incurred in the early repayment of debt referenced above.", -0.8], ["Pension and related (expense)/benefit reflects the net periodic (cost)/benefit of our pension and other postretirement and postemployment benefit plans.", -0.3], ["Miscellaneous, net primarily includes our share of net results from our equity method investments, charitable contributions and foreign exchange gains/(losses).", 0.0], ["Between mid-September 2023 and mid-November 2023, the refinery completed a turnaround and did not produce any refined products during this time.", -0.7], ["Refinery revenues decreased in 2023, primarily driven by the decrease in exchange products and third-party refinery sales.", -0.6], ["These decreases resulted from lower pricing and the turnaround, which was completed between September and November 2023.", -0.6], ["The refinery operating income decreased in 2023 mainly due to lower pricing and the turnaround.", -0.7], ["Monroe incurred $323 million in RINs compliance costs during 2023, compared to $576 million incurred in 2022.", -0.4], ["Observable RINs prices declined during 2023 and we acquired RINs assets to satisfy substantially all of our 2023 RINs obligation.", -0.5], ["As of December 31, 2023, we had $6.8 billion in cash, cash equivalents, short-term investments and aggregate principal amount committed and available to be drawn under our revolving credit facilities (\"liquidity\").", 0.8], ["Operating activities in 2023 provided $6.5 billion of cash flow compared to $6.4 billion in 2022.", 0.7], ["The air traffic liability typically increases during the winter and spring months as advanced ticket sales grow prior to the summer peak travel season and decreases during the summer and fall months.", 0.0], ["Fuel expense represented approximately 21% of our total operating expense during 2023.", -0.2], ["The average fuel price per gallon decreased in 2023.", 0.3], ["As capacity increased throughout the year, fuel consumption was higher in 2023 than 2022 as well.", 0.1], ["Our broad-based employee profit sharing program provides that, for each year in which we have an annual pre-tax profit, as defined by the terms of the program, we will pay a specified portion of that profit to employees.", 0.9], ["We paid $563 million in 2023 to our employees in recognition of their contributions toward meeting our financial goals.", 0.9], ["During the year ended December 31, 2023, we recorded $1.4 billion in profit sharing expense based on 2023 pre-tax profit, which we will pay to employees in February 2024.", 0.9], ["As of December 31, 2023 the total of these minimum amounts was $8.8 billion and range from approximately $1.3 billion to $1.6 billion on an annual basis over the next five years.", -0.1], ["As described further in Note 7 of the Notes to the Consolidated Financial Statements, as of December 31, 2023 we had a total of $9.2 billion of minimum operating lease obligations.", -0.1], ["We are enhancing and expanding our facilities at Terminal 4 of JFK to strengthen our competitive position and offer a premium travel experience for customers in New York City.", 0.5], ["In 2023, we redeemed a net of $2.2 billion in short-term investments.", 0.2], ["Our capital expenditures (i.e., property and equipment additions in our Consolidated Statements of Cash Flows (\"cash flows statement\")) were $5.3 billion and $6.4 billion in 2023 and 2022, respectively.", 0.1], ["Pursuant to the lease agreement, as amended to date, we (1) are funding (through debt issuance and existing cash) and undertaking the design, management and construction of the terminal and certain off-premises supporting facilities, (2) are receiving a Port Authority contribution of approximately $500 million to facilitate construction of the terminal and other supporting infrastructure, (3) will be responsible for all operations and maintenance during the term of the lease and (4) will have preferential rights to all gates in the terminal subject to Port Authority requirements with respect to accommodation of designated carriers.", 0.3], ["We currently expect our net project cost to be approximately $3.8 billion and we bear the risks of project construction, including any potential cost over-runs.", -0.2], ["During 2023, the revolving credit facility agreement was amended and the revolver capacity was reduced to $626 million.", -0.3], ["Costs incurred in excess of the $1.8 billion maximum will not be reimbursed by the City.", -0.4], ["In 2023, we had cash outflows of approximately $4.1 billion related to repayments of our debt and finance leases, including early repayment activities of $1.4 billion in principal for the repurchase of various secured and unsecured notes and the SkyMiles Term Loan through repurchases on the open market and $585 million in early principal repayments on various notes secured by aircraft.", -0.5], ["In the March 2023 quarter, both Fitch and S&P credit rating agencies upgraded our debt rating outlooks to stable and positive, respectively.", 0.8], ["In the September 2023 quarter, S&P upgraded our credit rating to BB+.", 0.7], ["$200 million to $400 million on an annual basis over the next five years.", 0.2], ["During 2023, we re-instated our quarterly dividend program with $0.10 per share payments in both the September 2023 and December 2023 quarters, resulting in total dividend payments during the year ended December 31, 2023 of", 0.6], ["As of December 31, 2023 we had approximately $2.9 billion undrawn and available under our revolving credit facilities.", 0.5], ["A change in assumptions regarding the redemption activity for miles or the estimated fair value of miles expected to be redeemed could have a material impact on our revenue in the year in which the change occurs and in future years.", -0.3], ["During the years ended December 31, 2023, 2022 and 2021, total cash sales from marketing agreements related to our loyalty program were $6.9 billion,", 0.4], ["$5.7 billion and $4.1 billion, respectively, which are allocated to travel and other performance obligations, as discussed below.", 0.3], ["Changes in certain events and circumstances could result in impairment or a change from indefinite-lived to definite-lived.", -0.5], ["Factors which could cause impairment include, but are not limited to (1) negative trends in our market capitalization, (2) reduced profitability resulting from lower passenger mile yields or higher input costs (primarily related to fuel and employees), (3) lower passenger demand as a result of weakened U.S. and global economies or other factors, (4) interruption to our operations due to a prolonged employee strike, terrorist attack or other reasons, (5) changes to the regulatory environment (e.g., changes in slot access and/or availability, additional Open Skies agreements or changes to antitrust approvals), (6) competitive changes by other airlines and (7) strategic changes to our operations leading to diminished utilization of the intangible assets.", -0.7], ["In 2023, we performed quantitative assessments of our goodwill and indefinite-lived intangible assets, including applicable factors noted in \"Key Assumptions\" above, and determined that there was no indication that the assets were impaired as the fair value of each asset exceeded its carrying value by at least 20%.", 0.5], ["As of December 31, 2023, the unfunded benefit obligation for these plans recorded on our balance sheets was $145 million, which is the net of our benefit obligation of $15.9 billion and plan assets of $15.8 billion.", -0.2], ["1.00% decrease in expected long-term rate of return on assets", -0.5], ["1.00% increase in expected long-term rate of return on assets", 0.5], ["Changes in life expectancy may significantly impact our benefit obligations and future net periodic cost/(benefit).", -0.3], ["While this recent legislation makes our funding obligations for these plans more predictable, factors outside our control continue to have an impact on the funding requirements.", -0.4], ["We solicit valuation updates from the investment fund managers and use their information and corroborating data from public markets to determine any needed fair value adjustments.", 0.3], ["The agreement includes a provision for a one-time payment made upon ratification in the March 2023 quarter of $735 million.", 0.2], ["Additionally, we recorded adjustments to other benefit-related items of approximately $130 million.", -0.1], ["During 2020, we recorded restructuring charges for items such as fleet impairments and voluntary early retirement and separation programs following strategic business decisions in response to the COVID-19 pandemic.", -0.8], ["During 2022, we recognized adjustments to certain of those restructuring charges, representing changes in our estimates.", -0.2], ["The volatility in fuel prices impacts the comparability of year-over-year financial performance.", -0.5], ["The adjustment for aircraft fuel and related taxes allows investors to better understand and analyze our non-fuel costs and year- over-year financial performance.", 0.3], ["Profit sharing.", 0.5], ["We adjust for profit sharing because this adjustment allows investors to better understand and analyze our recurring cost performance and provides a more meaningful comparison of our core operating costs to the airline industry.", 0.4], ["Net redemptions of short-term investments represent the net purchase and sale activity of investments and marketable securities in the period, including gains and losses.", 0.0], ["Pilot agreement payment.", 0.2], ["The agreement includes a provision for a one-time payment made upon ratification in the March 2023 quarter of $735 million.", 0.3], ["We have market risk exposure related to fuel prices, interest rates, foreign currency exchange rates and changes in the market value of equity investments.", -0.4], ["Market risk is the potential negative impact of adverse changes in these prices or rates on our Consolidated Financial Statements.", -0.6], ["We expect adjustments to the fair value of financial instruments to result in ongoing volatility in earnings and stockholders' equity.", -0.5], ["Changes in fuel prices materially impact our results of operations.", -0.3], ["A one cent increase in the cost of jet fuel per gallon would result in approximately $40 million of additional annual fuel expense based on annual consumption of approximately four billion gallons of jet fuel.", -0.4], ["Market risk associated with our variable-rate debt and variable-rate leases relates to the potential negative impact to future earnings from an increase in interest rates.", -0.6], ["An increase of 100 basis points in average annual interest rates would have decreased the estimated fair value of our fixed-rate debt by $716 million at December 31, 2023 and would have increased the annual interest expense on our variable-rate debt and variable-rate leases by $25 million.", -0.5], ["We often hold our equity securities for long periods and short-term price volatility has occurred in the past and will occur in the future, impacting the volatility of our financial results.", -0.4], ["As of December 31, 2023, we have long-term investments recorded at fair value of $2.9 billion and, therefore, a 10% change in the fair value of these investments would have an approximately $290 million impact on our financial results.", 0.1], ["Note 13 - Accumulated Other Comprehensive Loss 94", 0.0], ["In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.", 0.8], ["Description of the Matter At December 31, 2023 the Company’s aggregate current and noncurrent loyalty program deferred revenue balance was $8.4 billion.", 0.2], ["For the year ended December 31, 2023, the Company recognized $3.5 billion of revenue classified as loyalty travel awards within passenger revenue and $3.1 billion of revenue classified as loyalty program revenue within other revenue in the consolidated statement of operations.", 0.8], ["Pension, postretirement and postemployment payments greater than expense", 0.1], ["Net Decrease in Cash, Cash Equivalents and Restricted Cash", -0.5], ["Other comprehensive income               —    —     —       —     1,908   —    —   1,908", 0.2], ["Net income                        —    —     —       280       —   —     —    280", 0.3], ["Net income                        —    —     —      1,318       —   —     —   1,318", 0.7], ["Other comprehensive income               —    —     —       —      1,329   —    —   1,329", 0.6], ["Net income                        —    —     —      4,609       —   —     —   4,609", 1.0], ["Other comprehensive loss                 —    —     —       —       (44)   —    —    (44)", -0.3], ["Dividends declared ($0.20 per share)            —    —     —      (129)       —   —    —   (129)", -0.2], ["Some of our marketing arrangements provide for the sharing of revenues and expenses.", -0.1], ["Revenues and expenses associated with collaborative arrangements are presented on a gross basis in the applicable line items on our Consolidated Statements of Operations (\"income statement\").", 0.0], ["Our short-term investments in debt securities purchased prior to October 1, 2022 are classified as fair value investments under the fair value option and unrealized gains and losses are recorded in non-operating expense.", -0.2], ["Our short-term investments in debt securities purchased on or after October 1, 2022 are classified as available-for-sale investments and are stated at fair value with unrealized gains and losses recorded in accumulated other comprehensive income/(loss) (\"AOCI\").", 0.0], ["Realized gains and losses on these investments are recorded in non-operating expense.", -0.2], ["As part of our strategy to mitigate the cost of the refining margin reflected in the price of jet fuel, our wholly owned subsidiary, Monroe Energy, LLC (\"Monroe\"), operates the Trainer oil refinery.", 0.1], ["Changes in fuel prices, interest rates and foreign currency exchange rates impact our results of operations.", -0.3], ["Our derivative contracts are recognized at fair value on our balance sheets and had net balances of $5 million and $47 million at", 0.0], ["Depreciation and amortization expense related to our property and equipment was $2.3 billion, $2.1 billion and $2.0 billion for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.1], ["Included in the depreciation and amortization expense discussed above, we recorded $340 million, $307 million and $301 million for amortization of capitalized software for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.1], ["We review flight equipment, ROU assets and other long-lived assets used in operations for impairment losses when events and circumstances indicate the assets may be impaired.", -0.5], ["Factors which could be indicators of impairment include, but are not limited to (1) a decision to permanently remove flight equipment or other long-lived assets from operations, (2) significant changes in the estimated useful life, (3) significant changes in projected cash flows, (4) permanent and significant declines in fleet fair values and (5) changes to the regulatory environment.", -0.7], ["For long-lived assets held for sale, we discontinue depreciation and record impairment losses when the carrying amount of these assets is greater than the fair value less the cost to sell.", -0.6], ["To determine whether impairments exist for aircraft used in operations, we group assets at the fleet type level or at the contract level for aircraft operated by third-party regional carriers (i.e., the lowest level for which there are identifiable cash flows) and then estimate future cash flows based on projections of capacity, passenger mile yield, fuel and labor costs and other relevant factors.", -0.4], ["If an asset group is impaired, the impairment loss recognized is the amount by which the asset group's carrying amount exceeds its estimated fair value.", -0.5], ["We establish valuation allowances if it is more likely than not that we will be unable to realize our deferred income tax assets.", -0.3], ["At both December 31, 2023 and 2022, we had $1.1 billion outstanding on this purchasing card and the activity was classified as a financing activity in our cash flows statement.", 0.0], ["We periodically receive credits in connection with the acquisition of aircraft and engines.", 0.2], ["These credits are deferred until the aircraft and engines are delivered, and then applied as a reduction to the cost of the related equipment.", 0.1], ["We recognized approximately $7.4 billion, $4.2 billion and $2.2 billion in passenger revenue during the years ended December 31, 2023, 2022 and 2021, respectively, that had been recorded in our air traffic liability balance at the beginning of those periods.", 0.5], ["A change in assumptions regarding the redemption activity for miles or the estimated fair value of miles expected to be redeemed could have a material impact on our revenue in the year in which the change occurs and in future years.", -0.5], ["During the years ended December 31, 2023, 2022 and 2021, total cash sales from marketing agreements related to our loyalty program were $6.9 billion,", 0.8], ["$5.7 billion and $4.1 billion, respectively, which are allocated to travel and other performance obligations, as discussed below.", 0.8], ["As of December 31, 2023, the estimated fair value of our short-term investments was $1.1 billion.", 0.7], ["During the year ended December 31, 2023 there were no material gains or losses related to investments classified as Level 3 as a result of fair value adjustments.", 0.0], ["We recognized losses of $6 million, $394 million and $146 million on our fuel hedge contracts in aircraft fuel and related taxes on our income statement for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.8], ["The losses recognized during 2023 were composed of $58 million of settlements on contracts and $52 million of mark-to-market adjustments.", -0.7], ["Expense from the settlement of closed contracts is offset by higher operating profits at Monroe from higher pricing.", 0.2], ["Changes in the valuation of investments accounted for at fair value are recorded in gain/(loss) on investments, net in our income statement within non-operating expense and are driven by changes in stock prices, foreign currency fluctuations and other valuation techniques for investments in companies without publicly-traded shares.", 0.0], ["During 2023, we recorded a $786 million mark-to-market gain on our investment in Wheels Up based on the closing price of its shares as traded on the New York Stock Exchange.", 0.9], ["As of December 31, 2023, Wheels Up's public float was under 5% of the total outstanding shares which contributed to significant volatility in the value of our Wheels Up equity investment since the announcement of Wheels Up's credit facility in September 2023.", -0.5], ["The carrying value of our investment in Virgin Atlantic remains zero as of December 31, 2023.", -0.8], ["We maintain our 49% equity interest and continue to track our share of Virgin Atlantic's losses under the equity method of accounting.", -0.3], ["These previously unrecognized losses are only recorded to the extent we make additional investments in Virgin Atlantic (i.e., additional shareholder support).", -0.4], ["As of December 31, 2023, we have approximately $400 million of unrecognized equity method losses related to our 49% interest in Virgin Atlantic.", -0.7], ["We recognize an impairment charge if the asset's carrying value exceeds its estimated fair value.", -0.6], ["Factors which could cause impairment include, but are not limited to (1) negative trends in our market capitalization, (2) reduced profitability resulting from lower passenger mile yields or higher input costs (primarily related to fuel and employees), (3) lower passenger demand as a result of weakened U.S. and global economies or other factors, (4) interruption to our operations due to a prolonged employee strike, terrorist attack or other reasons, (5) changes to the regulatory environment (e.g., changes in slot access and/or availability, additional Open Skies agreements or changes to antitrust approvals), (6) competitive changes by other airlines and (7) strategic changes to our operations leading to diminished utilization of the intangible assets.", -0.9], ["These quantitative impairment tests of goodwill and intangibles concluded that there was no indication of impairment as the fair values exceeded our carrying values.", 0.2], ["During 2023, we repurchased a principal amount of $1.4 billion of various secured and unsecured notes and a portion of the SkyMiles Term Loan on the open market and made early principal repayments of $585 million on various notes secured by aircraft.", 0.3], ["Collectively, these payments resulted in a $63 million loss on extinguishment of debt, which is recorded in non-operating expense in our income statement.", -0.4], ["Market risk associated with our fixed- and variable-rate debt relates to the potential reduction in fair value and negative impact to future earnings, respectively, from an increase in interest rates.", -0.7], ["We were in compliance with the covenants in our debt agreements at December 31, 2023.", 0.5], ["During 2023, the revolving credit facility agreement was amended and the revolver capacity was reduced to $626 million.", -0.3], ["Costs incurred in excess of the $1.8 billion maximum will not be reimbursed by the City.", -0.8], ["In 2020, we enhanced the project’s scope to include a more customer-friendly design of Terminal 3, an expanded Delta Sky Club and baggage system upgrades designed to increase the terminals’ operational efficiency going forward.", 0.7], ["Pursuant to the lease agreement, as amended to date, we (1) are funding (through debt issuance and existing cash) and undertaking the design, management and construction of the terminal and certain off-premises supporting facilities, (2) are receiving a Port Authority contribution of approximately $500 million to facilitate construction of the terminal and other supporting infrastructure, (3) will be responsible for all operations and maintenance during the term of the lease and (4) will have preferential rights to all gates in the terminal subject to Port Authority requirements with respect to accommodation of designated carriers.", 0.2], ["The project is expected to cost $4.3 billion and the total amount spent to date is approximately $3.7 billion.", -0.2], ["We currently expect our net project cost to be approximately $3.8 billion and we bear the risks of project construction, including any potential cost over-runs.", -0.5], ["We entered into loan agreements to fund a portion of the construction, which are recorded on our balance sheets as debt with the proceeds reflected as restricted cash.", 0.1], ["The participants’ benefit is the sum of the contributions made on their behalf plus any positive return on the invested contributions.", 0.6], ["$1.2 billion, $1.0 billion and $875 million for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.1], ["During 2023, net actuarial losses increased our benefit obligation primarily due to the decrease in discount rates while net actuarial gains decreased our benefit obligation primarily due to the increase in discount rates during 2022.", -0.5], ["Certain pension plans have benefit obligations in excess of plan assets.", -0.7], ["Our weighted average expected long-term rate of return on assets for net periodic cost/(benefit) for the year ended December 31, 2023 was 7.00%.", 0.2], ["Changes in life expectancy may significantly impact our benefit obligations and future net periodic cost/(benefit).", -0.3], ["(4) Unfunded commitments were $1.3 billion for commingled funds, private equity and private equity-related instruments, $296 million for fixed income and fixed income-related instruments and $584 million for real assets at December 31, 2023.", -0.2], ["Our broad-based employee profit sharing program provides that, for each year in which we have an annual pre-tax profit, as defined by the terms of the program, we will pay a specified portion of that profit to employees.", 0.8], ["For the years ended December 31, 2023 and 2022, we recorded profit sharing expense of $1.4 billion and $563 million under the program, respectively.", 0.7], ["For the year ended December 31, 2021, we recorded a special profit sharing expense of $108 million, based on the adjusted pre-tax profit earned during the second half of the year, to recognize the extraordinary efforts of our employees through the pandemic.", 0.6], ["We record liabilities for losses from legal proceedings when we determine that it is probable that the outcome in a legal proceeding will be unfavorable and the amount of loss can be reasonably estimated.", -0.6], ["Delta pilots ratified a new four-year Pilot Working Agreement effective January 1, 2023.", 0.5], ["The agreement includes numerous work rule changes and pay rate increases during the four-year term, including an initial pay rate increase of 18%.", 0.7], ["The agreement also includes a provision for a one-time payment made upon ratification in the March 2023 quarter of $735 million.", 0.6], ["Additionally, we recorded adjustments to other benefit-related items of approximately $130 million.", 0.2], ["We establish valuation allowances if it is more likely than not that we will be unable to realize our deferred income tax assets.", -0.3], ["At December 31, 2023 our net deferred tax liability balance was $665 million, including an $877 million valuation allowance primarily related to certain net realized and unrealized capital losses and certain state net operating losses.", -0.5], ["As of December 31, 2023, we had approximately $4.5 billion of U.S. federal pre-tax net operating loss carryforwards which we are expecting to utilize by the end of 2025.", 0.4], ["The number of warrants outstanding slightly increased and the exercise price of the warrants slightly decreased since December 31, 2022 due to dividend payments during 2023.", 0.1], ["Under the initial payroll support program under the CARES Act and PSP extensions we received support payments of grants, which included $4.5 billion of grants during the year ended December 31, 2021.", 0.3], ["The grants received from PSP2 and PSP3 were recognized in government grant recognition in our income statement during 2021 over the period that the funds were intended to compensate.", 0.3], ["Equity compensation expense, including awards payable in common stock or cash, is recognized in salaries and related costs over the employee's requisite service period (generally, the vesting period of the award) and totaled $180 million, $150 million and $149 million for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.1], ["Potential performance award payments range from 0%-200% of a target level and are contingent upon our achieving certain financial and operational goals over a three-year performance period.", 0.2], ["Based on the closing stock price at each respective year end and contingent on achieving the specified performance conditions, the maximum shares that could be issued were 0.7 million and 1.5 million for the years ended December 31, 2022 and 2021, respectively.", 0.1], ["Based on the closing stock price at year end and contingent on achieving the specified performance conditions, the maximum shares that could be issued were 3.3 million and 1.3 million for the years ended December 31, 2023 and 2022, respectively.", 0.2], ["(2) Includes approximately $755 million of deferred income tax expense as a result of tax law changes and prior valuation allowance releases through continuing operations, that will not be recognized in net income until pension and other benefit obligations are fully extinguished.", -0.5], ["During 2023, we retired approximately $700 million of our 2021 and 2022 RINs assets to settle our 2021 and 2022 obligations prior to the compliance deadlines.", 0.1], ["Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.", -0.8], ["Equity compensation plans approved by securities holders             9,506,385 $     32.72       13,238,608", 0.0], ["The weighted average exercise price of outstanding options at December 31, 2023 was $50.42.", 0.0], ["Because 4,166,569 shares of restricted stock remained unvested and subject to forfeiture as of December 31, 2023, these shares could again be available for issuance.", 0.0]], "ehc22_sentences.json": [["The aggregate market value of common stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $5.5 billion.", -0.1], ["Actual events or results may differ materially from the results anticipated in these forwardlooking statements as a result of a variety of factors.", -0.5], ["•       If the Spin Off were to fail to qualify as tax-free, including as a result of subsequent acquisitions of our stock or the stock of Enhabit, Inc., we could be subject to significant tax liabilities.", -0.8], ["•                  Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.", -0.9], ["•       Restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare could decrease our revenues and adversely affect other operating results.", -0.8], ["•       New or changing Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.", -0.7], ["•       Reimbursement claims are subject to various audits from time to time and such audits may lead to assertions that we have been overpaid or have submitted improper claims, and such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid.", -0.8], ["•       Delays and other substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, could delay or reduce our reimbursement for services previously provided, including through recoupment from other claims due to us from Medicare.", -0.8], ["•       Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues or profitability.", -0.9], ["•       Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.", -0.8], ["•       Changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations.", -0.8], ["•       The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, could decrease our reimbursement rate or increase costs associated with our operations.", -0.7], ["•       Compliance with the extensive and frequently changing laws and regulations applicable to healthcare providers, including those related to data privacy and security, anti-trust, and employment practices, requires substantial time, effort and expense, and if we fail to comply, we could incur penalties and significant costs of investigating and defending asserted claims, whether meritorious or not, or be required to make significant changes to our operations.", -0.9], ["•       Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, such as the CMS vaccine mandate, could decrease our revenues.", -0.8], ["•       Incidents affecting the proper operation, availability, or security of our or our vendors’ or partners’ information systems, including the patient information stored there, or business continuity could cause substantial losses and adversely affect our operations, and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.", -0.8], ["•       Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed qui tam suits could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.", -0.9], ["•       Our inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.", -0.8], ["•       Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results.", -0.8], ["•       Competitive pressures in the healthcare industry, including from other providers that may be participating in integrated delivery payment arrangements in which we do not participate, and our response to those pressures could adversely affect our revenues or other financial results.", -0.7], ["•       Our inability to provide a consistently high quality of care, including as represented in metrics published by Medicare, could decrease our revenues.", -0.8], ["•       Our inability to maintain or develop relationships with patient referral sources could decrease our revenues.", -1], ["•       A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.", -1], ["•       Governmental actions in response to infectious disease outbreaks, such as limitations on elective procedures, vaccine mandates, shelterin-place orders, new workplace regulations, facility closures and quarantines experienced during the COVID-19 pandemic, could reduce volumes, lead to staffing shortages, increase staffing costs, and otherwise impair our ability to operate and provide care and in many instances already have done so.", -1], ["•       General conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, rising interest rates, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets and interest expense on new or existing debt.", -1], ["•       Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.", -1], ["•       The price of our common stock could adversely affect our willingness and ability to repurchase shares.", -1], ["•       We may be unable or unwilling to continue to declare and pay dividends on our common stock.", -1], ["hospitals in terms of patients treated, revenues, and number of hospitals.", 0], ["Our hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages innovative technologies and advanced therapies and leads to superior outcomes.", 1], ["cost-effectiveness, our financial strength, and our extensive application of technology.", 1], ["We also believe our competitive strengths discussed below give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.", 0.5], ["           ▪      The Patient Protection and Affordable Care Act (the “ACA”) enacted in 2010 instituted several mandatory Medicare payment reforms, including reimbursement reductions for IRFs, and created the Center for Medicare and Medicaid Innovation (“CMMI”) to develop, test, and promote innovative payment and delivery models.", -0.2], ["This program requires IRFs to report quality data, the elements of which are updated annually, and imposes a financial penalty for noncompliance.", -0.5], ["▪      The Budget Control Act of 2011 implemented an automatic 2% reduction, or “sequestration,” of Medicare program payments for all healthcare providers beginning in 2013.", -0.7], ["Joint ventures with market leading acute-care hospitals establish a solid foundation for providing integrated patient care that can improve the quality of outcomes and reduce the total cost of care.", 0.7], ["Care collaboration between our hospitals and the home health agencies selected by our patients offers an excellent means to improve patient experience and outcomes and reduce the total cost of care across a post-acute episode.", 0.8], ["The post-acute innovation tools we have developed, and will continue to develop, support our strategic relationship initiatives by enhancing the effective and efficient management of patients across multiple post-acute care settings and facilitating highquality patient care, improved care coordination, and network provider performance and cost management.", 0.6], ["We believe these clinical best practices and protocols, particularly as leveraged with our well-trained clinicians and industry-leading technology, help ensure the delivery of consistently high-quality healthcare services, reduced inefficiencies, and improved performance across a spectrum of operational areas.", 0.9], ["Our hospitals account for 61% of all stroke rehabilitation accreditations, 97% of hip fracture rehabilitation accreditations, and 78% of all brain injury rehabilitation accreditations.", 0.4], ["Our scale, data-driven business practices, consistent and disciplined operating model, and culture help us provide healthcare services on a cost-effective basis.", 0.6], ["Our de novo and bed addition strategies incorporate pre-fabrication construction technology to create efficiencies by reducing reliance on subcontractors, improving supply chain efficiencies, providing a consistent construction quality and realizing a speed-to-market benefit.", 0.8], ["We have a proven track record of generating strong cash flows from operations that have allowed us to successfully pursue our growth strategy, manage our financial leverage, and make complementary shareholder distributions.", 0.9], ["As of December 31, 2022, we have a strong, well-capitalized balance sheet, including ownership of approximately 76% of our hospital real estate, no significant debt maturities prior to 2025, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our business strategy.", 0.9], ["Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide.", 0.7], ["treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030.", 0.6], ["More specifically, the average age of our Medicare patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026.", 0.6], ["We believe the demand for the services we provide will continue to increase as the U.S. population ages.", 0.7], ["Despite the growing demand for inpatient rehabilitation services, the number of inpatient rehabilitation facilities has remained", -0.2], ["relatively stable — decreasing modestly from 1,182 in 2015 to 1,180 in 2021.", -0.1], ["This supply-demand imbalance is partly responsible for the relatively low conversion rate of inpatient rehabilitation eligible patients.", -0.3], ["Since 2012, we have opened or acquired 53 new hospitals and increased the number of licensed beds we operate by approximately 56%, or 3,700 beds.", 0.8], ["We target the addition of 6 to 10 new inpatient rehabilitation hospitals and 80 to 120 beds to existing hospitals per year.", 0.7], ["In 2021, we opened 8 new hospitals (350 beds total) and added 117 beds to existing hospitals.", 0.7], ["In 2022, we opened 9 new hospitals (410 beds total) and added 87 beds to existing hospitals.", 0.7], ["In 2023, we plan to open 8 hospitals (approximately 395 beds) and add 80 to 100 beds to existing hospitals.", 0.7], ["We also believe we will continue to have organic growth opportunities based on our track record of growth, planned bed additions at a number of existing hospitals, and the maturation of newly opened locations.", 0.9], ["The Medicare Advantage enrollment growth rate is greater than that of traditional Medicare fee-for-service, and our payor mix has shifted accordingly.", 0.6], ["Medicare Advantage payors represented 8.4% of our net operating revenues in 2017 and 15.1% in 2022.", 0.6], ["We believe our outcomes and quality of care data have helped drive a significant improvement in the payments we receive from Medicare Advantage payors.", 0.8], ["For example, reimbursement based on the type of patient/treatment required, commonly referred to as the case mix group basis (“CMG”), is typically greater than reimbursement on a per-diem rate basis, and we increased the percentage of our Medicare Advantage revenue paid based on CMG from approximately 58% in 2017 to approximately 88% in 2022.", 0.8], ["2022, approximately 6% of patients recovering from a stroke in the U.S. were treated at our hospitals, accounting for approximately 19% of our overall patient mix.", -0.1], ["In 2022, we implemented a centralized nurse recruiting model to create recruiting efficiencies, shorten the hiring process, and improve the candidate experience.", 0.3], ["With this new onsite hemodialysis system, we can provide our patients dialysis without interrupting therapy or requiring patient travel, which lowers our cost of treatment and improves patient satisfaction.", 0.7], ["Our strong balance sheet as well as our leverage and liquidity profiles mitigate exposure to interest rate volatility and near-term refinancing risks.", 0.8], ["and other clinical personnel, including therapists, may, from time to time, require us to increase use of more costly temporary personnel, which we refer to as “contract labor,” and other types of premium pay programs.", -0.5], ["•       we base annual increases and incentive compensation on merit, which is communicated to employees through our talent management process as part of our annual review procedures.", 0.2], ["We reimbursed over $1.2 million in tuition and paid over $2.8 million toward employees’ student loan debt in 2022.", 0.6], ["The Medicare reimbursement system for inpatient rehabilitation has changed significantly over the years.", -0.4], ["we have the necessary capabilities — change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities — to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so.", 0.9], ["Revenues and receivables from Medicare are significant to our operations.", 0.0], ["Revenues from Medicare and Medicare Advantage represent approximately 80% of total revenues.", -0.1], ["specific reductions to healthcare providers’ annual market basket updates and other payment policy changes.", -0.5], ["In August 2011, President Obama signed into law the Budget Control Act of 2011 providing for an automatic 2% reduction, or “sequestration,” of Medicare program payments for all healthcare providers.", -0.8], ["Sequestration took effect April 1, 2013 and, as a result of subsequent legislation, will continue through mid-fiscal year 2032 unless Congress and the President take further action.", -0.7], ["In response to the public health emergency associated with the pandemic, Congress and the President suspended sequestration through March 31, 2022.", 0.2], ["The Congressional Budget Office estimated that the American Rescue Plan Act of 2021 would result in budget deficits necessitating a 4% reduction in Medicare program payments under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect.", -0.3], ["Section GG affects patients’ classification into case-mix groupings, relative weights, and length-of-stay values under the IRF-PPS, which in turn affect our reimbursement amounts.", -0.4], ["A facility’s failure to submit the required quality data results in a two percentage point reduction to that facility’s annual market basket increase factor for payments made for discharges in a subsequent Medicare fiscal year.", -0.6], ["All of our inpatient rehabilitation hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.", 0.5], ["Any additional downward adjustment to rates or limitations on reimbursement for the types of facilities we operate and services we provide could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["Although reductions or changes in reimbursement from governmental or third-party payors and regulatory changes affecting our", -0.5], ["business represent one of the most significant challenges to our business, our operations are also affected by other rules and regulations that indirectly affect reimbursement for our services, such as data coding rules and patient coverage rules and determinations.", -0.3], ["For example, Medicare providers like us can be negatively affected by the adoption of coverage policies, either at the national or local level, that determine whether an item or service is covered and under what clinical circumstances it is considered to be reasonable and necessary.", -0.7], ["Medicare contractors processing claims for CMS make coverage determinations regarding medical necessity that can represent novel or restrictive interpretations of the CMS coverage rules.", -0.6], ["However, more restrictive coverage interpretations can limit or delay our reimbursement for services provided to potentially large pools of patients with similar medical conditions.", -0.8], ["Some contractors are paid a percentage of the overpayments recovered.", -0.4], ["Despite our efforts to ensure accurate coding and assessment of patients, audits may lead to assertions that we have been underpaid or overpaid by Medicare or that we have submitted improper claims in some instances.", -0.6], ["Audits may also require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid.", -0.7], ["On March 27, 2020, President Trump signed into law the CARES Act, which authorized the cash distribution of pandemic relief funds from the United States Department of Health and Human Services (“HHS”) to healthcare providers.", 0.5], ["Accordingly, our hospitals benefit from being costeffective providers.", 0.3], ["The 2022 IRF Rule implemented a net 1.9% market basket increase (market basket update of 2.6% reduced by a productivity adjustment of 0.7%) effective for discharges between October 1, 2021 and September 30, 2022.", 0.2], ["The 2022 IRF Rule also included changes that impacted our hospital-by-hospital base rate for Medicare reimbursement.", -0.1], ["The 2023 IRF Rule implements a net 3.9% market basket increase (market basket update of 4.2% reduced by a productivity adjustment of 0.3%) effective for discharges between October 1, 2022 and September 30, 2023.", 0.4], ["that same time frame, and other factors, we believe the 2023 IRF Rule will result in a net increase to our Medicare payment rates of approximately 4.0% effective October 1, 2022.", 0.5], ["HHS-OIG estimated that its recommended change to the policy could reduce total IRF industry reimbursements by approximately 6% based on 2017 and 2018 data.", -0.6], ["Managed care contracts typically have terms between one and three years, although we have a number of managed care contracts that automatically renew each year (with pre-defined rate increases) unless a party elects to terminate the contract.", 0.3], ["In 2022, typical rate increases for our contracts ranged from 2-4%.", 0.2], ["We cannot provide any assurance we will continue to receive increases in the future.", -0.5], ["seen the percentage of our revenue derived from Medicare Advantage payors grow.", 0.1], ["This percentage has steadily increased over time since 2003.", 0.3], ["We expect the percentage of our total revenues attributable to Medicare Advantage plans to continue to grow as well.", -0.1], ["Typically, Medicare Advantage and other managed care plans reimburse us less than traditional Medicare for the same type of care and patient, but that differential has been shrinking in recent years.", -0.2], ["Many states have experienced shortfalls in their Medicaid budgets and are implementing significant cuts in Medicaid reimbursement rates.", -0.8], ["Continuing downward pressure on Medicaid payment rates could cause a decline in that portion of our Net operating revenues.", -0.7], ["In certain states in which we operate, we are experiencing an increase in Medicaid patients, partially the result of expanded coverage consistent with the intent of the ACA and expanded coverage resulting from regulatory actions during the COVID-19 public health emergency.", 0.2], ["adjustments to payments for certain low-income patients after comparing subsequently published statistical data from CMS to the cost report data.", 0.0], ["The 2018 Budget Act continues this emphasis by increasing the criminal and civil penalties that can be imposed for violating federal health care laws.", -0.3], ["Failure to comply with applicable federal and state healthcare regulations can result in a provider’s exclusion from participation in government reimbursement programs and in substantial civil and criminal penalties.", -0.9], ["Failure to comply with applicable certification requirements may make our hospitals ineligible for Medicare or Medicaid reimbursement.", -0.8], ["In addition, Medicare or Medicaid may seek retroactive reimbursement from noncompliant hospitals", -0.7], ["or otherwise impose sanctions for noncompliance.", -0.8], ["Non-governmental payors often have the right to terminate provider contracts if the provider loses its Medicare or Medicaid certification.", -0.6], ["A determination by a regulatory authority that a hospital is not in compliance with applicable requirements could also lead to the assessment of fines or other penalties, loss of licensure, exclusion from participation in Medicare and Medicaid, and the imposition of requirements that the offending hospital must take corrective action.", -0.9], ["We potentially face opposition any time we initiate a project requiring a new or amended CON or seek to acquire an existing CON.", -0.7], ["Opposition to our applications may delay or prevent our future addition of beds or hospitals in given markets or increase our costs in seeking those additions.", -0.7], ["We have generally been successful in obtaining CONs or similar approvals, although there can be no assurance we will achieve similar success in the future, and the likelihood of success varies by locality and state.", 0.2], ["there is a relatively long statute of limitations, a billing error, cost reporting error or disagreement over physician medical judgment could result in significant damages and civil and criminal penalties under the FCA.", -0.8], ["A violation of the FCA by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -0.9], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -0.8], ["These changes and those described above related to the FCA, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally.", -0.7], ["In addition to standard federal criminal and civil sanctions, including imprisonment and penalties of up to $100,000 for each violation plus tripled damages for improper claims, violators of the Anti-Kickback Law may be subject to exclusion from the Medicare and/or Medicaid programs.", -1], ["A violation of the Anti-Kickback Law by us or one or more of our joint ventures could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -1], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -1], ["incorporate a percentage-based management fee.", 0], ["Violators of the Stark law and regulations may be subject to recoupments, civil monetary sanctions (up to $27,750 for each violation and assessments up to three times the amount claimed for each prohibited service) and exclusion from any federal, state, or other governmental healthcare programs.", -1], ["The statute also provides a penalty of up to $185,000 for a circumvention scheme.", -1], ["A violation of the Stark law by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -1], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -1], ["HHS-OIG and other regulators have also increasingly interpreted laws and regulations in a manner as to increase exposure of healthcare providers to allegations of noncompliance.", -1], ["Any actual or perceived violation of privacy-related laws and regulations, including HIPAA and the HITECH Act, could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -1], ["The 2018 Budget Act increased the civil monetary penalties, which vary depending on the offense from $5,000 to $100,000 per violation, plus treble damages for the amount at issue and may include exclusion from federal health care programs such as Medicare and Medicaid.", -0.5], ["HHS may seek to impose monetary penalties under this law for, among other things, offering inducements to beneficiaries for program services and filing false or fraudulent claims.", -0.7], ["Our business, operations, and financial position are subject to various risks.", -0.6], ["If any of the risks below or other risks or uncertainties discussed elsewhere in this annual report are actually realized, our business and financial condition, results of operations, and cash flows could be adversely affected.", -0.8], ["In the event the impact is materially adverse, the trading price of our common stock could decline.", -0.9], ["We may not be able to engage in beneficial capital-raising or strategic transactions.", -0.7], ["If the Spin Off were to fail to qualify as tax-free, including as a result of transactions in our stock or the stock of Enhabit, we could be subject to significant tax liabilities.", -0.8], ["If the IRS were to determine that any post-Spin Off acquisitions of our stock or that of Enhabit, pursuant to such a plan (when aggregated with any pre-Spin Off acquisitions of our stock or that of Enhabit, as applicable, pursuant to such a plan) would represent a 50% or greater ownership interest therein, such determination could result in significant tax liabilities to us.", -0.8], ["Any such tax liabilities imposed on us may adversely affect an investment in our stock.", -0.7], ["The amount of any such taxes for which we would be responsible may be significant, and if we were unable to obtain indemnification payments from Enhabit to which we are entitled under the tax matters agreement or other agreements entered into in connection with the Spin Off, we would incur significant losses.", -0.8], ["Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.", -0.8], ["Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs.", -0.9], ["Many provisions within the ACA have impacted or could in the future impact our business, including Medicare reimbursement reductions and promotion of alternative payment models, such as accountable care organizations (“ACOs”) and bundled payment initiatives.", -0.7], ["For Medicare providers like us, these laws include reductions in CMS’s annual adjustments to Medicare reimbursement rates,", -0.6], ["The ACA required reductions, the last of which ended in 2019, in the annual market basket updates for hospital providers ranging from 10 to 75 basis points.", -0.5], ["In addition, the ACA requires the market basket updates for hospital providers to be reduced by a productivity adjustment on an annual basis.", -0.5], ["To date, the productivity adjustments have typically resulted in decreases to the market basket updates ranging from 30 to 100 basis points.", -0.6], ["signed into law the Budget Control Act of 2011, which provided for an automatic 2% reduction of Medicare program payments.", -0.7], ["This automatic reduction, known as “sequestration,” began affecting payments received after April 1, 2013.", -0.6], ["Under current law, for each year through mid-fiscal year 2032, the reimbursement we receive from Medicare, after first taking into account all annual payment adjustments including the market basket update, will be reduced by sequestration unless it is repealed or modified before then.", -0.7], ["Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (“Statutory PAYGO”).", -0.5], ["If the Office of Management and Budget (the “OMB”) finds there is a deficit in the federal budget, Statutory PAYGO requires OMB to order sequestration of Medicare.", -0.7], ["The Congressional Budget Office estimated that the American Rescue Plan Act would result in budget deficits necessitating a 4% reduction in Medicare program payments for 2022 under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect.", 0.2], ["specifically, including solvency of the Medicare trust fund, could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments.", -0.6], ["Although the IMPACT Act does not specifically call for the implementation of a new post-acute payment system, we believe this act lays the foundation for possible future post-acute payment policies that would be based on patients’ medical conditions and other clinical factors rather than the setting where the care is provided, also referred to as “site neutral” reimbursement.", 0.3], ["CMS has begun changing current post-acute payment systems to improve comparability of patient assessment data and clinical characteristics across settings, which could make it easier to create a unified payment system in the future.", 0.5], ["For example, in a March 2020 report to Congress, MedPAC recommended, among other things, legislative changes to reduce by 5% the base payment rate under IRF-PPS.", -0.4], ["In its March 2022 report, MedPAC again recommended reduction of the base payment rate under the IRF-PPS by 5%.", -0.4], ["MedPAC previously estimated, although we cannot verify the methodology or the accuracy of that estimate, a PAC-PPS would result in a 15% reduction in IRF reimbursements.", -0.6], ["As a precursor to a PAC-PPS, MedPAC discussed in November 2017 a potential recommendation to change the case-mix weights in each postacute setting for 2019 and 2020 to a blend of the current setting specific weight and the proposed PAC-PPS weight, which MedPAC suggested would shift money from for-profit and freestanding IRFs to non-profit and hospital-based IRFs.", -0.3], ["There can be no assurance future governmental action will not result in substantial changes to, or material reductions in, our", -0.8], ["Similarly, we may experience material increases in our operating costs.", -0.7], ["For example, in 2022, our wage and benefit costs increased at a rate in excess of our aggregate Medicare reimbursement rate increases.", -0.6], ["In any given year, the net effect of statutory and regulatory changes may result in a decrease in our reimbursement rate, and that decrease may occur at a time when our expenses are increasing.", -0.9], ["As a result, there could be a material adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["In addition, there are increasing pressures, including as a result of the ACA, from many third-party payors to control healthcare costs", -0.8], ["and to reduce or limit increases in reimbursement rates for medical services.", -0.7], ["Our Net operating revenues and our ability to grow our business with these payors could be adversely affected if we are unable to negotiate and maintain favorable agreements with thirdparty payors.", -0.9], ["Quality reporting requirements could adversely affect the Medicare reimbursement we receive.", -0.8], ["A facility’s failure to submit the required quality data results in a two percentage point reduction to that facility’s annual market basket increase factor for payments made for discharges in the subsequent Medicare fiscal year.", -0.9], ["All of our hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.", -0.1], ["The adoption of additional quality reporting measures to track and report will require additional time and expense and could affect reimbursement in the future.", -0.5], ["may result in one or more of our hospitals seeing a reduction in its Medicare reimbursements.", -0.7], ["Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.", -0.4], ["Reimbursement claims are subject to various audits from time to time and such audits may negatively affect our operations and our cash flows from operations.", -0.8], ["Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect in the aggregate on our financial position, results of operation, cash flows, and liquidity.", -0.9], ["Some MACs have in the past applied and are likely in the future to apply their own unique interpretation of CMS coverage rules or impose otherwise arbitrary conditions not set out in the related rules, which has resulted and may in the future result in payment denials.", -0.6], ["When the government or its contractors reject the medical judgment of physicians or impose documentation and other requirements beyond the language of the statutes and regulations, patient access to inpatient rehabilitation as well as our Medicare reimbursement from the related claims may be adversely affected.", -0.7], ["Some contractors are paid a percentage of the overpayments recovered.", -0.3], ["In December 2017, we received notice of a UPIC audit at one of our hospitals.", -0.2], ["The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3 million in previously paid claims.", -0.5], ["The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of", -0.3], ["Our MAC later reduced the determination of overpayment to", -0.2], ["In October 2022, the ALJ overturned $12.5 million of the overpayment determination.", 0.8], ["We received payment of this amount, plus $3.2 million in interest, in December 2022.", 0.9], ["As a result, we may suffer reduced profitability, and we may have to elect not to accept patients and conditions physicians believe can benefit from inpatient rehabilitation.", -0.8], ["We could be adversely", -0.6], ["affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.", -0.7], ["Because one MAC has jurisdiction over a significant number of our hospitals and our hospitals derive a substantial portion of their revenue from Medicare, the adoption of restrictive or otherwise incorrect interpretations of coverage rules by that MAC could result in a large number of payment denials and materially and adversely affect our financial position, results of operations, and cash flows.", -0.9], ["Delays in the administrative appeals process associated with denied Medicare reimbursement claims could delay or reduce our reimbursement for services previously provided.", -0.7], ["In recent years, this protracted appeals process led to a significant backlog of appeals of denials, which a federal judge ultimately ordered HHS to resolve by the end of 2022.", -0.5], ["By December 31, 2022, we cleared substantially all of our backlog awaiting ALJ hearing.", 0.5], ["Changes implemented by CMS to resolve the appeal backlog may have harmed the ability of providers like us to recover on valid Medicare claims.", -0.7], ["Beginning in March 2020, OMHA increased the frequency of ALJ hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the ALJ appeals process.", -0.6], ["Additionally, the number of new denials frequently exceeds the number of appeals resolved in a given year (CMS suspended payment reviews for several months because of the public health emergency in 2020) as shown in the following summary of our inpatient rehabilitation segment activity:", -0.4], ["We may experience decreases in Net operating revenues and decreases in cash flow as a result of the increasing unresolved denials and the associated increasing accounts receivable, which may in turn force us to change the patients we admit and conditions we treat.", -0.8], ["Any of these impacts could have an adverse effect on our financial position, results of operations, and liquidity.", -0.9], ["Changes in our payor mix or the acuity of our patients could adversely affect our Net operating revenues or our profitability.", -0.8], ["The reimbursement rates we receive from traditional Medicare fee-for-service are generally higher than those received from other payors, although the difference between traditional Medicare and Medicare Advantage payments for inpatient rehabilitation care has decreased in the last several years.", 0.2], ["Over the same period, we have seen a shift in the payor mix from traditional Medicare to Medicare Advantage and other managed care providers.", -0.3], ["Not only do Medicare Advantage and managed care payors generally pay us less, but we would expect bad debt to be slightly higher for patients covered by Medicare Advantage and managed care as patients typically retain more payment responsibility under those arrangements.", -0.8], ["Medicaid reimbursement rates are almost always the lowest among those of our payors, and frequently Medicaid patients come to us with other complicating conditions that make treatment more difficult and costly.", -0.9], ["We could also experience a shift to a lower average patient acuity which typically results in lower reimbursement rates regardless of", -0.7], ["Both a shift in our payor mix away from Medicare fee-for-service and a shift to a lower patient acuity would likely adversely affect reimbursement.", -0.9], ["We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our reimbursement, Net operating revenues, and profitability.", -0.8], ["Delays in collection or non-collection of our accounts receivable could adversely affect our business, financial position, results of operations, cash flows, and liquidity.", -0.9], ["incomplete documentation and billing information could result in non-payment for services rendered.", -0.8], ["Our inability to bill and collect on a timely basis pursuant to these regulations and rules could subject us to payment delays that could have a material adverse effect on our business, financial position, results of operations, cash flows, and liquidity.", -0.9], ["In addition, timing delays in billings and collections may increase our working capital burden.", -0.7], ["including prompt and diligent billing and collection, is an important factor in our financial position and results of operations and in maintaining liquidity.", 0.2], ["It is possible that Medicare, Medicaid, documentation support, system problems or other provider issues or industry trends, particularly with respect to newly acquired entities for which we have limited operational experience, may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.", -0.9], ["In addition, we may experience delays in reimbursement as a result of the failure to receive prompt approvals related to change of ownership applications for acquired or other facilities or from delays caused by our or other third parties’ information system failures.", -0.8], ["Furthermore, the proliferation of Medicare and Medicaid managed care programs could have a material adverse impact on the results of our operations as a result of more complicated authorization, billing and collection requirements implemented by such programs.", -0.9], ["A change in our estimates of collectability or a delay in collection of accounts receivable could adversely affect our results of", -0.8], ["The estimates are based on a variety of factors, including the length of time receivables are past due, significant onetime events, contractual rights, client funding, political pressures, discussions with clients, and historical experience.", -0.2], ["A delay in collecting our accounts receivable, or the non-collection of accounts receivable, including, without limitation, in connection with our transition and integration of acquired companies and the attendant movement of underlying billing and collection operations from legacy systems to future systems, could have a material negative impact on our results of operations and liquidity, and we could be required to record impairment charges on our financial statements.", -0.9], ["Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues and profitability.", -0.8], ["Conveners are not healthcare providers and may suggest a post-acute setting or duration of care that may not be appropriate from a clinical perspective potentially resulting in worse patient outcomes and costly acute-care hospital readmissions.", -0.7], ["result of various alternative payment models, many referral sources are becoming increasingly focused on reducing post-acute costs by eliminating post-acute care referrals or referring patients to perceived low-cost post-acute settings rather than rehabilitation hospitals, sometimes without understanding the potential impact on patient outcomes over an entire episode of care.", -0.8], ["Our ability to attract patients could be adversely affected if any of our hospitals fail to provide or maintain a reputation for providing high-quality care on a cost-effective basis as compared to other providers.", -0.7], ["The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.", -0.2], ["While this is consistent with our goal and proven track record of being a high-quality, cost-effective provider, broadbased implementation of a new payment model would represent a significant evolution or transformation of the healthcare industry, which may have a significant impact on our business and results of operations.", -0.3], ["Providers participating in BPCI Advanced are subject to a semi-annual reconciliation process where CMS compares the aggregate Medicare expenditures for all items and services included in a clinical episode against the target price for that type of episode to determine whether the participant is eligible to receive a portion of the savings, or is required to repay a portion of the payment above target.", 0.0], ["Accordingly, reimbursement may be increased or decreased, compared to what would otherwise be due, based on whether the total Medicare expenditures and patient outcomes meet, exceed or fall short of the targets.", -0.1], ["Each track offers a different degree to which participants share any savings realized or any obligation to repay losses suffered.", 0.0], ["Based on the CMS data below, the MSSP has not experienced growth in recent years.", -0.5], ["However, CMS holds the acute-care hospital where a joint replacement takes place accountable for the quality and costs of care for the entire episode of care — from the time of the original admission through 90 days after discharge.", 0.1], ["Depending on the quality and cost performance during the entire episode, the acute-care hospital may receive an additional payment or be required to repay Medicare a portion of the episode costs.", -0.2], ["beneficiaries who are treated in one of the models increases.", 0.1], ["In an attempt to reduce costs, ACOs may seek to discourage referrals to post-acute care all together.", -0.4], ["To the extent that acute-care hospitals participating in those models do not perceive our quality of care or cost efficiency favorably compared to alternative post-acute providers, we may experience a decrease in volumes and Net operating revenues, which could adversely affect our financial position, results of operations, and cash flows.", -0.8], ["Other legislative and regulatory initiatives and changes affecting the industry could adversely affect our business and results of operations.", -0.7], ["Any such suspension would adversely affect our financial position, results of operations, and cash flows.", -0.9], ["While many of the stated goals of other federal and state reform initiatives are consistent with our own goal to provide care that is highquality and cost-effective, legislation and regulatory proposals may lower reimbursements, increase the cost of compliance, decrease patient volumes, promote frivolous or baseless litigation, and otherwise adversely affect our business.", -0.8], ["In areas where we are not part of a managed care network with significant enrollment, this discharge planning rule may negatively affect the number of patients choosing us.", -0.6], ["We may experience temporary decreases in Net operating revenues and in cash flow, or we may incur costs associated with patient care for which the Medicare claim is subsequently denied, which could have an adverse effect on our financial position, results of operations, and liquidity.", -0.7], ["If enacted, they may be challenging for all providers and have the effect of limiting Medicare beneficiaries’ access to healthcare services and could have a material adverse impact on our Net operating revenues, financial position, results of operations, and cash flows.", -0.8], ["Compliance with the extensive laws and government regulations applicable to healthcare providers requires substantial time, effort and expense, and if we fail to comply with them, we could suffer penalties or be required to make significant changes to our operations.", -0.7], ["Those changes could also affect reimbursements as well as future compliance, training, and staffing costs.", -0.5], ["The HHS-OIG estimated the policy could have reduced total Medicare payments to IRFs in 2017 and 2018 by between 6% and 7%.", -0.6], ["We settled the DOJ investigation, together with the related qui tam or whistleblower lawsuits, in 2019 for a total payment of $48 million.", -0.5], ["training programs as well as internal controls and procedures designed to ensure regulatory compliance, we have in the past been, and could in the future be, required to return portions of reimbursements for discharges alleged after the fact to have not been appropriate under the applicable reimbursement rules and change our patient admissions practices going forward.", -0.7], ["governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us.", -0.8], ["DOJ has pursued and recovered record amounts based on alleged healthcare fraud.", -0.9], ["Settlements of alleged violations or imposed reductions in reimbursements, substantial damages and other remedies assessed against", -0.8], ["us could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation and could cost us significant time and expense to defend.", -0.8], ["The use of sub-regulatory guidance, statistical sampling, and extrapolation by CMS, Medicare contractors, HHS-OIG, and DOJ to deny claims, expand enforcement claims, and advocate for changes in reimbursement policy increases the risk that we could experience reduced revenue, suffer penalties, or be required to make significant changes to our operations.", -0.9], ["governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us.", -0.8], ["CMS’ invocation of its retroactive-rulemaking authority in response to this Supreme Court decision is an unfavorable precedent for providers because it demonstrates a willingness by CMS to revive adverse reimbursement actions after those actions are deemed deficient on administrative procedural grounds.", -0.7], ["Through sampling and extrapolation, the government takes a review of a small number of reimbursement claims and generalizes the results of that review to a much broader universe of claims, which can result in significant increases in the aggregate number and value of claims at issue.", -0.2], ["Any associated loss of revenue or increased legal costs could materially and adversely affect our financial position, results of operations, and cash flows.", -0.9], ["Efforts to comply with regulatory mandates to increase the use of electronic health data and health system interoperability may lead to enforcement and negative publicity which could adversely affect our business.", -0.8], ["There can be no assurance that our efforts to improve the care we deliver and to comply with the law through increasing use of electronic data and system interoperability will not receive negative publicity that may materially and adversely affect our ability to get patient referrals or enter into joint ventures with other providers or may lead to greater regulatory scrutiny.", -0.7], ["If any of our hospitals fail to comply with the Medicare enrollment requirements or conditions of participation, that hospital could be terminated from the Medicare program.", -0.9], ["If any of our hospitals fail to meet any of the Medicare enrollment requirements or conditions of participation, we may receive a notice of deficiency from the applicable survey agency or contractor, as applicable.", -0.8], ["If that hospital then fails to institute an acceptable plan of correction and correct the deficiency within the applicable correction period, it could lose the ability to bill Medicare.", -0.9], ["A hospital could be terminated from the Medicare program if it fails to address the deficiency within the applicable correction period.", -0.9], ["If CMS terminates one hospital, it may increase its scrutiny of others under common control.", -0.8], ["A few provisions of this new rule could significantly increase the complexity of filing enrollment applications for all of our provider entities, including increased burden related to tracking and identifying required reporting data from our joint venture partners.", -0.7], ["If CMS determines an affiliation with a disclosable event poses an undue risk of fraud, waste or abuse, then the provider reporting that affiliation may be subject to exclusion from Medicare.", -0.8], ["Any termination of one or more of our hospitals from the Medicare program for failure to satisfy the enrollment requirements or", -0.9], ["conditions of participation could materially adversely affect our business, financial position, results of operations, and cash flows.", -0.9], ["If we are found to have violated applicable privacy and security laws and regulations or our contractual obligations, we could be subject to sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial position, results of operation and liquidity.", -0.9], ["These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business.", -0.8], ["If we are found to have violated the HIPAA privacy or security regulations or other federal or state laws protecting the confidentiality of patient health or personal information, including but not limited to the HITECH Act, we could be subject to litigation, sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation, and have a material adverse effect on our business, financial position, results of operations and liquidity.", -0.9], ["protections with many of our service providers, any actual or perceived security breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach.", -0.8], ["Any contractual protections we have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections.", -0.8], ["increase over time, require us to change our business practices in a manner adverse to our business, divert resources from other initiatives and projects, and restrict the way products and services involving data are offered, all of which may have a material adverse effect on our business.", -0.8], ["Given the rapid development of cybersecurity and data privacy laws, we expect to encounter inconsistent interpretation and enforcement of these laws and regulations, as well as frequent changes to these laws and regulations which may expose us to significant penalties or liability for noncompliance, the possibility of fines, lawsuits (including class action privacy litigation), regulatory investigations, criminal or civil sanctions, audits, adverse media coverage, public censure, other claims, significant costs for remediation and damage to our reputation, or otherwise have a material adverse effect on our business and operations.", -0.9], ["Any allegations of a failure to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, damage our relationships with patients and have a material adverse effect on our business.", -1.0], ["Any concerns about our data privacy and security practices, even if unfounded, could damage the reputation of our businesses, discourage potential patients from our products and services and have a material adverse effect on our business.", -1.0], ["Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.", -1.0], ["Costs and expenses related to these requirements are a significant operating expense and may increase as laws and regulations change.", -1.0], ["Any failure to comply with these requirements can result in significant penalties or litigation exposure and could have a material adverse effect on our business.", -1.0], ["The Hospital Pricing Transparency Rule could adversely affect our business and results of operations.", -1.0], ["hospital fails to comply with the new requirements and does not complete the prescribed corrective action, CMS may impose a civil monetary penalty of between $300 and $5,500 per day.", -1.0], ["The maximum penalty for violations is more than $2 million per hospital, so our failure to maintain compliance with this rule could adversely affect our financial position, results of operations, and cash flows.", -1.0], [" The proper function, availability, and security of our information systems are critical to our business and failure to maintain proper function, availability, or security of our information systems or protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["We expend significant capital to protect against the threat of security breaches, including cyber attacks, email phishing schemes,", -0.5], ["Substantial additional expenditures may be required to respond to and remediate any problems caused by breaches, including the unauthorized access to or theft of patient data and protected health information stored in our information systems and the introduction of computer malware or ransomware to our systems.", -0.9], ["In recent years, several hospitals have reported being victims of ransomware attacks in which they lost access to their systems, including clinical systems, during the course of the attacks.", -0.8], ["Large, national healthcare systems have reported ransomware attacks that forced their facilities to operate without access to information systems for some time and, to some extent, inhibited their ability to admit patients.", -0.8], ["Accordingly, we may be vulnerable to losses associated with the improper functioning, breach or unavailability of our and our vendors’ information systems, including systems used in acquired operations, and third-party systems we use.", -0.9], ["cyber security threats in the healthcare industry, there can be no assurance we will not experience business interruptions; data loss, ransom, misappropriation or corruption; theft or misuse of proprietary data, patient or other personally identifiable information; or litigation, investigation, or regulatory action related to any of those, any of which could have a material adverse effect on our patient care, ability to admit patients, financial position, and results of operations and harm our business reputation.", -1.0], ["A compromise of our network security measures or other controls, or of those businesses or vendors with whom we interact,", -0.8], ["In the case of a material breach or cyber attack, the associated expenses and losses may exceed our current insurance coverage for such events.", -0.9], ["Failure to maintain proper function, security, or availability of our information systems or protect our data against unauthorized access, or the failure of one or more of our key partners, vendors, or other counterparties to do these things, could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["Our inability, or the inability of our partners or vendors, to continue to maintain and upgrade information systems, software, and hardware could disrupt or reduce the efficiency of our operations, including affecting patient care.", -0.9], ["In addition, costs, unexpected problems, and interruptions associated with the implementation or transition to new systems or technology or with adequate support of those systems or technology across numerous hospitals could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["Given that approximately 91% of our hospitals’ referrals come from acute-care hospitals, that increase in competition could materially and adversely affect our admission referrals in the related markets.", -0.8], ["The other public companies and large health insurance companies expanding into post-acute care have or may obtain significantly greater marketing and financial resources or other advantages of scale than we have or may obtain.", -0.7], ["There can be no assurance this competition, or other competition which we may encounter in the future, will not adversely affect our", -0.9], ["business, financial position, results of operations, or cash flows.", -0.9], ["Conversely, competition and statutory procedural requirements in some CON states may inhibit our ability to expand our operations in those states.", -0.8], ["If we are unable to provide a consistently high quality of care, our business will be adversely impacted.", -0.9], ["Effective October 2012, Medicare began to impose a financial penalty upon acute-care hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge.", -0.8], ["We believe this regulation provides a competitive advantage to post-acute providers who can differentiate themselves based upon quality, particularly by achieving low acute-care hospital readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals.", 0.3], ["If we should fail to attain our goals regarding acute-care hospital readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.", -0.8], ["If we are unable to maintain or develop relationships with patient referral sources, our growth and profitability could be adversely affected.", -0.9], ["Our growth and profitability depend on our ability to establish and maintain close working relationships with patient referral sources", -0.1], ["Our loss of, or failure to maintain, existing relationships or our failure to develop new relationships could adversely affect our ability to grow our business and operate profitably.", -0.8], ["We may have difficulty completing joint ventures, investments and transactions that increase our capacity consistent with our growth strategy.", -0.6], ["In the inpatient rehabilitation industry, the costs of constructing new hospitals are increasing faster than reimbursement rates and the", -0.7], ["Changes in federal laws or regulations may also materially adversely impact our ability to acquire hospitals or open de novo", -0.9], ["Increased DOJ enforcement of antitrust laws will likely increase the time, effort and expense associated with acquisitions and may ultimately make it less likely to consummate acquisitions.", -0.9], ["These factors and others may delay, or increase the cost to us associated with, any acquisition or de novo development or prevent us", -0.7], ["from completing one or more acquisitions or de novo developments.", -0.7], ["We may make investments or complete transactions that could expose us to unforeseen risks and liabilities.", -0.6], ["expenditures, debt incurrence, operating losses, amortization of certain intangible assets of acquired companies, issuances of equity securities, liabilities, and expenses, some of which are unforeseen, that could materially and adversely affect our business, financial position, results of operations and liquidity.", -0.9], ["•       difficulties integrating acquired operations, personnel, and information systems, and in realizing projected revenues, efficiencies and cost savings, or returns on invested capital;", -0.8], ["•       exposure to undisclosed or unforeseen liabilities of acquired operations, including liabilities for failure to comply with healthcare laws and anti-trust considerations as well as risks and liabilities related to previously compromised information systems.", -0.9], ["We may be unable to operate newly constructed hospitals as profitably as expected, and those hospitals may involve significant additional cash expenditures and operating expenses that could, in the aggregate, have an adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["We may not be able to successfully integrate acquisitions or realize the anticipated benefits of any acquisitions.", -0.8], ["The failure to successfully integrate on a timely basis any acquired business with our existing business could have an adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["We anticipate our acquisitions will result in benefits including, among other things, increased revenues.", 0.5], ["businesses may not contribute to our revenues or earnings to the extent anticipated, and any synergies we expect may not be realized after the acquisitions have been completed.", -0.7], ["If the acquired businesses underperform and any underperformance is other than temporary, we may be required to take an impairment charge.", -0.8], ["Failure to achieve the anticipated benefits could result in the diversion of management’s time and energy and could have an adverse effect on our business, financial position, results of operations, and cash flows.", -0.8], ["Competition for staffing, shortages of qualified personnel, union activity or other factors may increase our staffing costs and reduce profitability.", -0.7], ["The operating conditions associated with the COVID-19 pandemic significantly affected the availability and turnover of clinical staff and, in turn, increased staffing costs.", -0.8], ["Availability of clinical staff, elevated turnover and staffing costs continue to be a challenge for us and other healthcare providers.", -0.7], ["Staffing shortages or retention concerns in one or more markets in which we operate have required and may again require us to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel.", -0.7], ["If our staffing costs increase, we may not experience reimbursement rate or pricing increases to offset these additional costs.", -0.9], ["a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased staffing costs is limited.", -0.8], ["In particular, if staffing costs rise at an annual rate greater than our net annual market basket update from Medicare, as occurred in 2022, or we experience a significant shift in our payor mix to lower rate payors such as Medicaid, our results of operations and cash flows will be adversely affected.", -0.9], ["Conversely, decreases in reimbursement revenues, such as with sequestration, may limit our ability to increase compensation or benefits to the extent necessary to retain key employees, in turn increasing our turnover and associated costs.", -0.8], ["We currently have a minimal number of union employees, so an increase in labor union activity could have a significant impact on our staffing costs.", -0.7], ["Our failure to recruit and retain qualified medical personnel, or to control our staffing costs, could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["We are a defendant in various lawsuits, and may be subject to liability under qui tam cases, the outcome of which could have a material adverse effect on us.", -0.9], ["Substantial damages, fines, or other remedies assessed against us or agreed to in settlements could have a material adverse effect on", -1.0], ["our business, financial position, results of operations, and cash flows, including indirectly as a result of the covenant defaults under our credit agreement or debt instruments or other claims such as those in securities actions.", -1.0], ["Additionally, the costs of defending litigation and investigations, even if frivolous or nonmeritorious, could be significant.", -1.0], ["These lawsuits, also known as “whistleblower” or “qui tam” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government.", -1.0], ["In 2019, we settled with DOJ to conclude an investigation that originated in 2013 based on the allegations made by relators.", -0.5], ["We settled the DOJ investigation, together with the related qui tam or “whistleblower” lawsuits, for a payment of $48 million, and we expressly denied any wrongdoing.", -0.5], ["Even when a matter is without merit, as we believe was the case with this investigation, we may still incur significant costs of defense or settlement costs or both.", -1.0], ["We cannot predict the impact any claims arising out of the care being provided (regardless of their ultimate outcomes) could have on our business or reputation or on our ability to attract and retain patients and employees.", -1.0], ["Changes in the number of these liability claims and the cost to resolve them impact the reserves for these risks.", -1.0], ["A variance between our estimated and actual number of claims or average cost per claim could have a material impact, either favorable or unfavorable, on the adequacy of the reserves for these liability risks, which could have an effect on our financial position and results of operations.", -1.0], ["In 2017, the California Supreme Court held that plaintiffs bringing suit under PAGA are generally entitled to request and receive a significant amount of information from the employer early in the litigation, which creates pressure for employers to settle early to avoid substantial litigation costs and which has resulted in a significant increase PAGA claims in recent years.", -0.8], ["The COVID-19 pandemic and actions taken by local, state and federal authorities in response to the pandemic significantly affected our operations, business and financial condition.", -0.7], ["Future outbreaks of contagious diseases and associated governmental actions could adversely affect our operations, business and financial condition, including potentially our liquidity, particularly if the provision of healthcare services and the supplies for those services are disrupted for a lengthy period of time.", -0.9], ["The impact on our operations and financial performance depends on numerous factors, including the rate of spread, duration and geographic coverage of an outbreak; the rate and extent to which the disease mutates and the severity of the symptoms of the disease; the status of testing capabilities; the rates of vaccination and therapeutic remedies for the disease and any variant strains; the legal, regulatory and administrative developments related to the pandemic at federal, state, and local levels, such as vaccine mandates, anti-mandate laws and orders, shelter-in-place orders, facility closures and quarantines; and the infectious disease prevention and control efforts of the Company, governments and third parties.", -0.6], ["For example, if another pandemic were to occur, we could suffer significant losses to our consumer population or a reduction in the availability of our employees and, at a high cost, be required to replace affected workers.", -0.9], ["Accordingly, certain public health catastrophes could have a material adverse effect on our financial condition and results of operations.", -0.9], ["We may incur additional indebtedness in the future, and that debt or the associated increased leverage may have negative consequences for our business.", -0.8], ["The restrictive covenants included in the terms of our indebtedness could affect our ability to execute aspects of our business plan successfully.", -0.7], ["As of December 31, 2022, we have approximately $2.4 billion of long-term debt outstanding (including that portion of long-term", -0.5], ["If new debt is added to our current debt levels, the risks described here could intensify.", -0.8], ["•       limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes;", -0.8], ["•       making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our flexibility in planning for, and making it more difficult for us to react quickly to, changing conditions;", -0.7], ["•       placing us at a competitive disadvantage compared with competing providers that have less debt; and", -0.6], ["•       exposing us to risks inherent in interest rate fluctuations for outstanding amounts under our credit facility, which could result in higher interest expense in the event of increases in interest rates, as discussed in Item 7A, Quantitative and Qualitative Disclosures about Market Risk.", -0.7], ["Although we expect to make scheduled interest payments and principal reductions, we cannot provide assurance that changes in our business or other factors will not occur that may have the effect of preventing us from satisfying obligations under our credit agreement or debt instruments.", -0.9], ["If we are unable to generate sufficient cash flow from operations in the future to service our debt and meet our other needs or have an unanticipated cash payment obligation, we may have to refinance all or a portion of our debt, obtain additional financing or reduce expenditures or sell assets we deem necessary to our business.", -0.9], ["These covenants could also adversely affect our ability to finance our future operations or capital needs and pursue available business opportunities.", -0.8], ["Although we remained in compliance with the financial ratios and financial condition tests as of December 31, 2022, we cannot provide assurance we will continue to do so.", -0.8], ["A severe downturn in earnings, failure to realize anticipated earnings from acquisitions, or, if we have outstanding borrowings under our credit facility at the time, a rapid increase in interest rates could impair our ability to comply with those financial ratios and financial condition tests and we may need to obtain waivers from the required proportion of the lenders to avoid being in default.", -0.9], ["If we try to obtain a waiver or other relief from the required lenders, we may not be able to obtain it or such relief might have a material cost to us or be on terms less favorable than those in our existing debt.", -0.8], ["If a default occurs, the lenders could exercise their rights, including declaring all the funds borrowed (together with accrued and unpaid interest) to be immediately", -0.9], ["due and payable, terminating their commitments or instituting foreclosure proceedings against our assets, which, in turn, could cause the default and acceleration of the maturity of our other indebtedness.", -0.9], ["A breach of any other restrictive covenants contained in our credit agreement or the indentures governing our senior notes would also (after giving effect to applicable grace periods, if any) result in an event of default with the same outcome.", -0.8], ["Uncertainty in the credit markets could adversely affect our financial condition or our growth opportunities.", -0.8], ["Future market shocks, such as the status of deliberations and legislation to increase the debt ceiling in the United States, could result in reductions in the availability of certain types of debt financing, including access to revolving lines of credit.", -0.7], ["Future business needs combined with market conditions at the time may cause us to seek alternative sources of potentially less attractive financing and may require us to adjust our business plan accordingly.", -0.6], ["Tight credit markets, such as might result from further turmoil in the sovereign debt markets, would likely make additional financing more expensive and difficult to obtain.", -0.7], ["Actions by the United States Federal Reserve system, such as increasing the discount rate, may also increase the interest expense associated with our current or future borrowings.", -0.6], ["The inability to obtain additional financing at a reasonable cost could have a material adverse effect on our financial condition or our growth opportunities.", -0.8], ["These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties.", -0.9], ["Some of these matters have been material to us in the past, and others in the future may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity.", -0.8], ["These lawsuits, also known as “qui tam” actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government.", -0.7], ["It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits.", -0.6], ["On February 23, 2023, our board of directors declared a cash dividend of $0.15 per share, payable on April 17, 2023 to stockholders", 0.7], ["The following table summarizes our repurchases of equity securities during the three months ended December 31, 2022:", 0.0], ["(2)          On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock.", 0.5], ["On February 14, 2014, our board approved an increase in this common stock repurchase authorization from $200 million to $250 million.", 0.6], ["On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million.", 0.6], ["We have paid a quarterly cash dividend on our common stock since October 2013.", 0.5], ["The onset of the COVID-19 Pandemic (the “pandemic”) in the United States resulted in significant changes to our operating", -0.5], ["For discussion of the financial and operational impacts we have experienced as a result of the pandemic, see Item 1, Business, Item 1A, Risk Factors, and the “Key Challenges” and “Results of Operations” sections of this Item.", 0.0], ["During 2022, Net operating revenues increased 8.3% over 2021 due primarily to volume growth and increased pricing.", 0.8], ["•       continued our capacity expansions by adding 87 new beds to existing hospitals; and •             announced or continued the development of the following hospitals:", 0.2], ["We remain optimistic regarding the intermediate and long-term prospects of our business.", 0.9], ["aging, should continue to increase long-term demand for the services we provide.", 0.7], ["While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030.", 0.5], ["We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis.", 0.8], ["We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo and bed additions.", 0.9], ["reimbursement for inpatient rehabilitation facilities (“IRFs”) has recently undergone significant changes.", -0.5], ["More specifically, because Medicare comprises a significant portion of our Net operating revenues, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us.", -0.8]], "ehc23_sentences.json": [["The aggregate market value of common stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $6.7 billion.", -0.1], ["relate to, among other things, future events, the spread and impact of an infectious disease outbreak, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy, dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures.", 0.0], ["•       If the Spin Off were to fail to qualify as tax-free, including as a result of subsequent acquisitions of our stock or the stock of Enhabit, Inc., we could be subject to significant tax liabilities.", -0.8], ["•       Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.", -0.9], ["•       Restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare could decrease our revenues and adversely affect other operating results.", -0.8], ["•       Reimbursement claims are subject to various audits and such audits may lead to assertions that we have been overpaid or have submitted improper claims, and these assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and may ultimately require us to refund any amounts determined to have been overpaid.", -0.8], ["•       Substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, could delay or reduce our reimbursement for services previously provided, including through recoupment from other claims due to us from Medicare.", -0.8], ["•       Efforts to reduce payments to healthcare providers undertaken by third-party payors and conveners could adversely affect our revenues or profitability.", -0.9], ["•       Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.", -0.8], ["•       Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.", -0.8], ["•       Changes in the rules and regulations of the healthcare industry at the federal, state or local levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations.", -0.8], ["•       Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, such as the CMS vaccine mandate, could decrease our revenues.", -0.7], ["•       Incidents affecting the proper operation, availability, or security of our or our vendors’ or partners’ information systems, including the patient information stored there, or business continuity could cause substantial losses and adversely affect our operations, and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.", -0.7], ["•       Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed qui tam suits, could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.", -0.8], ["•       Our inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.", -0.7], ["•       Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results.", -0.8], ["•       Competitive pressures in the healthcare industry, including from large acute-care hospitals that would typically serve as a referral source for us, and our response to those pressures could adversely affect our revenues or other financial results.", -0.7], ["•       Our inability to provide a consistently high quality of care, including as represented in metrics published by Medicare, could decrease our revenues.", -0.7], ["•       Our inability to maintain or develop relationships with patient referral sources, including our joint venture hospitals could decrease our revenues.", -0.7], ["•       Acute-care hospitals that participate in joint ventures with us may experience, and in the past some have experienced, operational or financial challenges that, in turn, affect our joint venture inpatient rehabilitation hospitals.", -0.7], ["•       A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis, and governmental responses to those events, could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.", -1.0], ["•       Regulatory and other efforts to promote a transition to a lower-carbon economy may result in significant operational and financial challenges for us.", -0.8], ["•       General conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, rising interest rates, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets and interest expense on new or existing debt.", -1.0], ["•       Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.", -0.9], ["•       The price of our common stock could adversely affect our willingness and ability to repurchase shares.", -0.7], ["•       We may be unable or unwilling to continue to declare and pay dividends on our common stock.", -0.8], ["hospitals in terms of patients treated, revenues, and number of hospitals.", 0.0], ["For 2024, we were again named to Fortune’s list of the World’s Most Admired Companies.", 1.0], ["We believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our", 0.5], ["cost-effectiveness, our financial strength, and our extensive application of technology.", 0.7], ["We also believe our competitive strengths discussed below give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.", -0.1], ["▪      The Patient Protection and Affordable Care Act (the “ACA”) enacted in 2010 instituted several mandatory Medicare payment reforms, including reimbursement reductions for IRFs, and created the Center for Medicare and Medicaid Innovation (“CMMI”) to develop, test, and promote innovative payment and delivery models.", 0.0], ["This program requires IRFs to report quality data, the elements of which are updated annually, and imposes a financial penalty for noncompliance.", -0.5], ["▪      The 2010 CMS reimbursement rule for IRFs implemented new IRF coverage requirements, or specifications as to what conditions must be met to qualify for reimbursement, that were effective for all Medicare discharges on or after January 1, 2010.", 0.0], ["▪      The Budget Control Act of 2011 implemented an automatic 2% reduction, or “sequestration,” of Medicare program payments for all healthcare providers beginning in 2013.", -0.5], ["▪      In October 2022, CMS significantly changed the extensive admission and discharge interdisciplinary data elements required to be collected in connection with Medicare reimbursement claims.", -0.2], ["We believe these clinical best practices and protocols, particularly as leveraged with our well-trained clinicians and industry-leading technology, help ensure the delivery of consistently high-quality healthcare services, reduced inefficiencies, and improved performance across a spectrum of operational areas.", 0.7], ["Our scale, data-driven business practices, consistent and disciplined operating model, and culture help us provide healthcare services on a cost-effective basis.", 0.8], ["We have a proven track record of generating strong cash flows from operations that have allowed us to successfully pursue our growth strategy, manage our financial leverage, and make complementary shareholder distributions.", 0.9], ["As of December 31, 2023, we have a strong, well-capitalized balance sheet, including ownership of approximately 78% of our hospital real estate, no significant debt maturities in 2024, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our business strategy.", 0.9], ["We believe the demand for the services we provide will continue to increase as the U.S. population ages.", -0.1], ["Despite the growing demand for inpatient rehabilitation services, the number of inpatient rehabilitation facilities has remained", -0.3], ["This supply-demand imbalance is partly responsible for the relatively low conversion rate of inpatient rehabilitation eligible patients.", -0.5], ["Since 2012, we have opened or acquired 61 new hospitals and increased the number of licensed beds we operate by approximately 62%, or 4,122 beds.", 0.6], ["We target the addition of 6 to 10 new inpatient rehabilitation hospitals and 80 to 120 beds to existing hospitals per year.", 0.7], ["In 2023, we opened 8 new hospitals (395 beds total) and added 46 beds to existing hospitals.", 0.8], ["We also believe we will continue to have organic growth opportunities based on our track record of growth, planned bed additions at a number of existing hospitals, and the maturation of newly opened locations.", 0.9], ["We will continue to demonstrate our value proposition to Medicare Advantage payors by providing superior patient outcomes, including higher discharge to community rates and lower lengths of stay, compared to alternative sites of care.", 0.7], ["Medicare Advantage payors represented 8.4% of our net operating revenues in 2017 and 16.2% in 2023.", 0.2], ["We believe our outcomes and quality of care data have helped drive a significant improvement in the payments we receive from Medicare Advantage payors.", 0.8], ["For example, reimbursement based on the type of patient/treatment required, commonly referred to as the case mix group basis (“CMG”), is typically greater than reimbursement on a per-diem rate basis, and we increased the percentage of our Medicare Advantage revenue paid based on CMG from approximately 58% in 2017 to approximately 90% in 2023.", -0.1], ["2023, approximately 7% of patients recovering from a stroke in the U.S. were treated at our hospitals, accounting for approximately 18% of our overall patient mix.", 0.0], ["In 2022, we implemented a centralized nurse recruiting model to create recruiting efficiencies, shorten the hiring process, and improve the candidate experience.", 0.3], ["With this new onsite hemodialysis system, we can provide our patients dialysis without interrupting therapy or requiring patient travel, which lowers our cost of treatment and improves patient satisfaction.", 0.5], ["We seek to maintain balance sheet flexibility, consider opportunistic refinancings and augment returns from investments in operations with shareholder distributions via common stock dividends and repurchases of our common stock.", 0.4], ["Our free cash flow is the primary source of funding for the considerable investment in our de novo and bed addition growth plans.", 0.2], ["As an additional source of liquidity, we can access our $1 billion revolving credit facility of which $968 million was available for borrowing as of December 31, 2023.", 0.3], ["Our strong balance sheet as well as our leverage and liquidity profiles mitigate exposure to interest rate volatility and near-term refinancing risks.", 0.4], ["In some markets, the shortage of clinical personnel is a significant operating issue facing healthcare providers.", -0.5], ["Shortages of nurses", -0.7], ["and other clinical personnel, including therapists, may, from time to time, require us to increase use of more costly temporary personnel, which we refer to as “contract labor,” and other types of premium pay programs.", -0.5], ["We believe our outstanding employee engagement scores, discussed below, evidence that our human capital management efforts have been successful.", 0.8], ["•       we base annual increases and incentive compensation on merit, which is communicated to employees through our talent management process as part of our annual review procedures.", 0.2], ["In 2023, the number of people of color in hospital leadership roles increased 11.2%.", 0.7], ["We reimbursed over $1.1 million in tuition and paid over $2.8 million toward employees’ student loan debt in 2023.", 0.9], ["The overall Company engagement score was 83% favorable, representing a 2% increase over 2022.", 0.8], ["We believe we have the necessary capabilities—change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities—to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so.", 0.9], ["Revenues and receivables from Medicare are significant to our operations.", -0.2], ["Revenues from Medicare and Medicare Advantage represent approximately 81% of total revenues.", -0.2], ["specific reductions to healthcare providers’ annual market basket updates and other payment policy changes.", -0.7], ["The Congressional Budget Office estimated that the American Rescue Plan Act of 2021 would result in budget deficits necessitating a 4% reduction in Medicare program payments under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect.", -0.2], ["Section GG affects patients’ classification into case-mix groupings, relative weights, and length-of-stay values under the IRF-PPS, which in turn affect our reimbursement amounts.", -0.1], ["A facility’s failure to submit the required quality data results in a two percentage point reduction to that facility’s annual market basket increase factor for payments made for discharges in a subsequent Medicare fiscal year.", -0.5], ["All of our inpatient rehabilitation hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.", 0.3], ["Any additional downward adjustment to rates or limitations on reimbursement for the types of facilities we operate and services we provide could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.8], ["Although reductions or changes in reimbursement from governmental or third-party payors and regulatory changes affecting our", -0.4], ["For example, Medicare providers like us can be negatively affected by the adoption of coverage policies, either at the national or local level, that determine whether an item or service is covered and under what clinical circumstances it is considered to be reasonable and necessary.", -0.6], ["However, more restrictive coverage interpretations can limit or delay our reimbursement for services provided to potentially large pools of patients with similar medical conditions.", -0.7], ["Some contractors are paid a percentage of the overpayments recovered.", 0.1], ["coding and medical necessity coverage rules.", 0.0], ["Despite our efforts to ensure accurate coding and assessment of patients, audits have in the past led and may in the future lead to assertions that we have been underpaid or overpaid by Medicare or that we have submitted improper claims in some instances.", -0.8], ["Audits also require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid.", -0.7], ["Specifically, at least 60% of a facility’s patients must have a diagnosis or qualifying comorbidity from at least one of these 13 conditions, which requirement is known as the “60% Rule.” If an IRF does not demonstrate compliance with the 60% Rule by either the presumptive method or through a review of medical records, then its classification as an IRF may be terminated by CMS causing the facility to be paid under the acute-care payment system which would result in reduced total reimbursement per patient.", -0.9], ["If some of our hospitals fail to demonstrate compliance with the 60% Rule and CMS re-classifies them as acute-care hospitals, our revenue and profitability may be materially and adversely affected.", -0.9], ["Accordingly, our hospitals benefit from being costeffective providers.", 0.5], ["The 2023 IRF Rule implemented a net 3.9% market basket increase (market basket update of 4.2% reduced by a productivity adjustment of 0.3%) effective for discharges between October 1, 2022 and September 30, 2023.", 0.6], ["The 2023 IRF Rule also included changes that impacted our hospital-by-hospital base rate for Medicare reimbursement.", 0.2], ["The 2024 IRF Rule implements a net 3.4% market basket increase (market basket update of 3.6% reduced by a productivity adjustment of 0.2%) effective for discharges between October 1, 2023 and September 30, 2024.", 0.5], ["The 2024 IRF Rule also includes changes that impact our hospital-byhospital base rate for Medicare reimbursement.", 0.2], ["Based on our analysis, which utilizes, among other things, the acuity of our patients annualized over the twelve-month prior period ended June 30, 2023, our experience with outlier payments over that same time frame, and other factors, we believe the 2024 IRF Rule will result in a net increase to our Medicare payment rates of approximately 3.3% effective October 1, 2023.", 0.7], ["The updates to the fee schedule are not expected to be material to us.", -0.1], ["In 2023, typical rate increases for our contracts ranged from 2-4%.", 0.2], ["We cannot provide any assurance we will continue to receive increases in the future.", -0.5], ["seen the percentage of our revenue derived from Medicare Advantage payors grow.", 0.3], ["We expect the percentage of our total revenues attributable to Medicare Advantage plans to continue to grow as well.", 0.4], ["Typically, Medicare Advantage and other managed care plans reimburse us less than traditional Medicare for the same type of care and patient, but that differential has been shrinking in recent years.", 0.1], ["Historically, states experiencing shortfalls in their Medicaid budgets have implemented cuts in Medicaid reimbursement rates.", -0.6], ["Additionally, certain states control Medicaid expenditures through restricting or eliminating coverage of some services.", -0.4], ["On average, our reimbursement per discharge from Medicaid is lower than that from traditional Medicare, Medicare Advantage and other managed care payors.", -0.3], ["For the year ended December 31, 2023, Medicaid payments represented only 4.0% of our consolidated Net operating revenues, and Medicaid discharges represented 6.3% of our total inpatient discharges.", 0.0], ["Failure to comply with applicable federal and state healthcare regulations can result in a provider’s exclusion from participation in government reimbursement programs and in substantial civil and criminal penalties.", -1.0], ["Given the number of locations in which we operate, increasing state and local regulation, which may be more stringent than federal regulation and may even conflict with federal or other state or local regulation, represents a significant burden and risk to us.", -0.8], ["Failure to comply with applicable certification requirements may make our hospitals ineligible for Medicare or Medicaid", -1.0], ["In addition, Medicare or Medicaid may seek retroactive reimbursement from noncompliant hospitals or otherwise impose sanctions for noncompliance.", -0.9], ["Non-governmental payors often have the right to terminate provider contracts if the provider loses its Medicare or Medicaid certification.", -0.9], ["A determination by a regulatory authority that a hospital is not in compliance with applicable requirements could also lead to the assessment of fines or other penalties, loss of licensure, exclusion from participation in Medicare and Medicaid, and the imposition of requirements that the offending hospital must take corrective action.", -1.0], ["Opposition to our applications may delay or prevent our future addition of beds or hospitals in given markets or increase our costs in seeking those additions.", -0.8], ["We have generally been successful in obtaining CONs or similar approvals, although there can be no assurance we will achieve similar success in the future, and the likelihood of success varies by locality and state.", 0.2], ["In 2019, Florida enacted legislation to repeal CON laws for several provider types, including IRFs.", 0.5], ["Because we have hundreds of thousands of claims a year for which we are reimbursed by Medicare and other federal payors and there is a relatively long statute of limitations, a billing error, cost reporting error or disagreement over physician", -0.7], ["medical judgment could result in significant damages and civil and criminal penalties under the FCA.", -0.9], ["A violation of the FCA by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -0.9], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -0.8], ["These changes and those described above related to the FCA, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally.", -0.7], ["A violation of the Anti-Kickback Law by us or one or more of our joint ventures could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -0.9], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -0.8], ["a violation under the Stark law, nor can there be any assurance our defense against any such assertion would be successful or that new federal or state laws governing physician relationships, or new interpretations of existing laws governing such relationships, might not adversely affect relationships we have established with physicians or result in the imposition of penalties on us.", -0.8], ["A violation of the Stark law by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows.", -0.9], ["Even the assertion of a violation could have an adverse effect upon our stock price or reputation.", -0.8], ["The heightened penalties for noncompliance range from $100 to $50,000 per violation for most violations.", -0.9], ["In the event of violations due to willful neglect that are not corrected within 30 days, penalties start at approximately $64,000 per violation and are not subject to a per violation statutory maximum.", -0.8], ["Pursuant to guidance from HHS-OCR, this enforcement cap ranges from a minimum of $25,000 per year to a maximum of $1,500,000 per year depending on an entity’s level of culpability.", -0.6], ["Any actual or perceived violation of privacy-related laws and regulations, including HIPAA and the HITECH Act, could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["If any of the risks below or other risks or uncertainties discussed elsewhere in this annual report are actually realized, our business and financial condition, results of operations, and cash flows could be adversely affected.", -0.9], ["In the event the impact is materially adverse, the trading price of our common stock could decline.", -0.8], ["We may not be able to engage in beneficial capital-raising or strategic transactions.", -0.7], ["If the Spin Off were to fail to qualify as tax-free, including as a result of transactions in our stock or the stock of Enhabit, we could be subject to significant tax liabilities.", -0.8], ["Although we intend for the Spin Off to be tax-free for U.S. federal income tax purposes, there can be no assurance that the Spin Off will not trigger a tax event.", -0.7], ["If the IRS were to determine that any post-Spin Off acquisitions of our stock or that of Enhabit, pursuant to such a plan (when aggregated with any pre-Spin Off acquisitions of our stock or that of Enhabit, as applicable, pursuant to such a plan) would represent a 50% or greater ownership interest therein, such determination could result in significant tax liabilities to us.", -0.8], ["Any such tax liabilities imposed on us may adversely affect an investment in our stock.", -0.8], ["Additionally, Enhabit is generally required to indemnify us for a specified portion of any taxes we incur (a) arising as a result of the failure of the Spin Off and certain related transactions to qualify as a transaction that is generally tax-free or a failure of the Spin Off that is intended to qualify as a transaction that is generally tax-free to so qualify to the extent such amounts did not result from a disqualifying action by, or acquisition of equity securities of, Enhabit or us or (b) arising from certain audit or other adjustments to tax liabilities incurred with respect to the Spin Off that were not intended to qualify as tax-free.", -0.5], ["The amount of any such taxes for which we would be responsible may be significant, and if we were unable to obtain indemnification payments from Enhabit to which we are entitled under the tax matters agreement or other agreements entered into in connection with the Spin Off, we would incur significant losses.", -0.8], ["Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.", -0.7], ["Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs.", -0.6], ["There can be no assurance that future governmental initiatives will not result in reimbursement freezes and reductions, or reimbursement increases that are less than the increases we experience in our costs of operation.", -0.7], ["Many provisions within the ACA have impacted or could in the future impact our business, including Medicare reimbursement reductions and promotion of alternative payment models, such as accountable care organizations (“ACOs”) and bundled payment initiatives.", -0.6], ["For Medicare providers like us, these laws include reductions in CMS’s annual adjustments to Medicare reimbursement rates,", -0.6], ["To date, the productivity adjustments have typically resulted in decreases to the market basket updates ranging from 30 to 100 basis points.", -0.6], ["signed into law the Budget Control Act of 2011, which provided for an automatic 2% reduction of Medicare program payments.", -0.7], ["This automatic reduction, known as “sequestration,” began affecting payments received after April 1, 2013.", -0.7], ["Under current law, for each year through mid-fiscal year 2032, the reimbursement we receive from Medicare, after first taking into account all annual payment adjustments including the market basket update, will be reduced by sequestration unless it is repealed or modified before then.", -0.8], ["The Congressional Budget Office estimated that the American Rescue Plan Act would result in budget deficits necessitating a 4% reduction in Medicare program payments for 2022 under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect.", -0.2], ["specifically, including solvency of the Medicare trust fund, could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments.", -0.7], ["Although the IMPACT Act does not specifically call for the implementation of a new post-acute payment system, we believe this act lays the foundation for possible future post-acute payment policies that would be based on patients’ medical conditions and other clinical factors rather than the setting where the care is provided, also referred to as “site neutral” reimbursement.", 0.2], ["to payments or reductions to payments.", -0.5], ["For example, in its March 2023 report to Congress, MedPAC recommended, among other things, legislative changes to reduce by 3% the base payment rate under IRF-PPS.", -0.6], ["MedPAC previously estimated, although we cannot verify the methodology or the accuracy of that estimate, a PAC-PPS would result in a 15% reduction in IRF reimbursements.", -0.9], ["As a precursor to a PAC-PPS, MedPAC discussed in November 2017 a potential recommendation to change the case-mix weights in each postacute setting for 2019 and 2020 to a blend of the current setting specific weight and the proposed PAC-PPS weight, which MedPAC suggested would shift money from for-profit and freestanding IRFs to non-profit and hospital-based IRFs.", -0.4], ["Those initiatives or reductions would be in addition to many ordinary course reimbursement rate changes that CMS adopts each year as part of the market basket update rulemaking process for various provider categories.", -0.3], ["While we do not expect the drive toward integrated payment models, value-based purchasing, and post-acute site neutrality in Medicare reimbursement to subside, there will almost certainly be new or alternative healthcare reforms in the future which may change these initiatives and other healthcare laws and regulations.", 0.1], ["There can be no assurance future governmental action will not result in substantial changes to, or material reductions in, our", -0.8], ["Similarly, we may experience material increases in our operating costs.", -0.7], ["For example, in 2022 and 2023, our wage and benefit costs increased at a rate in excess of our aggregate Medicare reimbursement rate increases.", -0.6], ["In any given year, the net effect of statutory and regulatory changes may result in a decrease in our reimbursement rate, and that decrease may occur at a time when our expenses are increasing.", -0.9], ["As a result, there could be a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["healthcare costs and to reduce or limit increases in reimbursement rates for medical services.", -0.7], ["For example, each year, CMS adopts updates to the payments to, and the payment policies for, Medicare Advantage payors, and those updates may result in a net decrease in payments to those payors.", -0.8], ["Our Net operating revenues and our ability to grow our business with these payors could be adversely affected if we are unable to negotiate and maintain favorable agreements with these payors.", -0.8], ["Reimbursement claims are subject to various audits from time to time and such audits may negatively affect our operations and our cash flows from operations.", -0.8], ["If the physicians working with our patients do not adequately document, among other things, their diagnoses and plans of care, our risks related to audits and payment denials in general are greater.", -0.8], ["Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect in the aggregate on our financial position, results of operation, cash flows, and liquidity.", -1.0], ["Some MACs have in the past applied and are likely in the future to apply their own unique interpretation of CMS coverage rules or impose otherwise arbitrary conditions not set out in the related rules, which has resulted and may in the future result in payment denials.", -0.8], ["When the government or its contractors reject the medical judgment of physicians or impose documentation and other requirements beyond the language of the statutes and regulations, patient access to inpatient rehabilitation as well as our Medicare reimbursement from the related claims may be adversely affected.", -0.9], ["claims and challenged the propriety of a subset of the sample representing $1.3 million in previously paid claims.", -0.7], ["The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9 million.", -0.9], ["Our MAC later reduced the determination of overpayment to $30.5 million, which it collected through recoupment of current claims during 2019.", -0.8], ["In October 2022, the ALJ overturned $12.5 million of the overpayment determination.", 0.5], ["We received payment of this amount, plus $3.2 million in interest, in December 2022.", 0.7], ["We have received initial results for the claims under review and, as of December 31, 2023, approximately 87% of these have been approved with approximately $3 million under appeal.", 0.3], ["Such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid.", -0.7], ["As a result, we may suffer reduced profitability, and we may have to elect not to accept patients and conditions physicians believe can benefit from inpatient rehabilitation.", -0.8], ["We could be adversely affected if one or more auditing payors allege substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.", -0.9], ["Because one MAC has jurisdiction over a significant number of our hospitals and our hospitals derive a substantial portion of their revenue from Medicare, the adoption of restrictive or otherwise incorrect interpretations of coverage rules by that MAC could result in a large number of payment denials and materially and adversely affect our financial position, results of operations, and cash flows.", -0.9], ["Substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims could delay and reduce our reimbursement for services previously provided.", -0.8], ["In recent years, this protracted appeals process led to a significant backlog of appeals of denials, which a federal judge ultimately ordered HHS to resolve by the end of 2022.", -0.7], ["By December 31, 2022, substantially all of our backlog awaiting ALJ hearing had been resolved.", 0.5], ["As of December 31, 2023, we have approximately $5 million and $31 million in denied claims awaiting review at the ALJ and DAB levels, respectively.", -0.5], ["In addition, we have approximately $7 million in claims denied by the DAB pending review by United States district courts as of December 31, 2023.", -0.5], ["Changes implemented by CMS to resolve the prior appeal backlog may have harmed the ability of providers like us to recover on", -0.6], ["valid Medicare claims.", -0.7], ["Beginning in March 2020, OMHA increased the frequency of ALJ hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the ALJ appeals process.", -0.5], ["In the fourth quarter of 2023, we recorded an aggregate amount of $21.9 million in additional reserves for estimated uncollectible amounts associated with claims that were part of the prior appeal backlog.", -0.7], ["The increase in reserves was driven principally by an increase in unfavorable adjudication outcomes experienced at the DAB during the second", -0.6], ["We may experience additional decreases in Net operating revenues and decreases in cash flow as a result of greater frequency of unfavorable resolution of denials or increasing unresolved denials and the associated increasing accounts receivable, which may in turn force us to change the patients we admit and conditions we treat.", -0.9], ["Any of these impacts could have an adverse effect on our financial position, results of operations, and liquidity.", -0.8], ["Changes in our payor mix or the acuity of our patients could adversely affect our Net operating revenues or our profitability.", -0.7], ["Many factors affect reimbursement rates for our services and, in turn, our revenues.", -0.4], ["The reimbursement rates we receive from traditional Medicare fee-for-service are generally higher than those received from other payors, although the difference between traditional Medicare and Medicare Advantage payments for inpatient rehabilitation care has decreased in the last several years.", -0.3], ["Over the same period, we have seen a shift in the payor mix from traditional Medicare to Medicare Advantage and other managed care providers.", -0.5], ["Not only do Medicare Advantage and managed care payors generally pay us less, but we would expect bad debt to be higher for patients covered by Medicare Advantage and managed care as patients typically retain more payment responsibility under those arrangements.", -0.6], ["Additionally, the rate at which Medicare Advantage referrals are converted to admissions is lower than the rate for traditional Medicare.", -0.5], ["We have also experienced a shift in recent years to a slightly larger percentage of Medicaid patients, driven in part by the expansion", -0.2], ["Medicaid reimbursement rates are almost always the lowest among those of our payors, and frequently Medicaid patients come to us with other complicating conditions that make treatment more difficult and costly.", -0.7], ["Both a shift in our payor mix away from Medicare fee-for-service and a shift to a lower patient acuity would likely adversely affect reimbursement.", -0.8], ["We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our reimbursement, Net operating revenues, and profitability.", -0.8], ["Delays in collection or non-collection of our accounts receivable could adversely affect our business, financial position, results of operations, cash flows, and liquidity.", -0.9], ["incomplete documentation and billing information could result in non-payment for services rendered.", -0.7], ["Our inability to bill and collect on a timely basis pursuant to these regulations and rules could subject us to payment delays that could have a material adverse effect on our business, financial position, results of operations, cash flows, and liquidity.", -0.9], ["It is possible that Medicare, Medicaid, documentation support, system problems or other provider issues or industry trends, particularly with respect to newly acquired entities for which we have limited operational experience, may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.", -0.8], ["may result in an increased period of time between submission of claims and subsequent payment under specific programs, most notably under the Medicare and Medicaid managed care programs, which in many cases pay claims significantly slower than traditional Medicare or state", -0.7], ["Furthermore, the proliferation of Medicare and Medicaid managed care programs could have a material adverse impact on the", -0.8], ["results of our operations as a result of more complicated authorization, billing and collection requirements implemented by such programs.", -0.7], ["A change in our estimates of collectability or a delay in collection of accounts receivable could adversely affect our results of", -0.8], ["The estimates are based on a variety of factors, including the length of time receivables are past due, significant onetime events, contractual rights, the nature of the underlying payment denials, and historical experience.", -0.3], ["In the fourth quarter of 2023, we recorded aggregate amount of $21.9 million in additional reserves for estimated uncollectible amounts associated with claims denied and appealed prior to 2023.", -0.6], ["A delay in collecting our accounts receivable, or the non-collection of accounts receivable, including, without limitation, in connection with our transition and integration of acquired companies and the attendant movement of underlying billing and collection operations from legacy systems to future systems, could have a material negative impact on our results of operations and liquidity, and we could be required to record impairment charges on our financial statements.", -0.9], ["Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues and profitability.", -0.8], ["result of various alternative payment models, many referral sources are becoming increasingly focused on reducing post-acute costs by eliminating post-acute care referrals or referring patients to perceived low-cost post-acute settings rather than rehabilitation hospitals, sometimes without understanding the potential impact on patient outcomes over an entire episode of care.", -0.7], ["Our ability to attract patients could be adversely affected if any of our hospitals fail to provide or maintain a reputation for providing high-quality care on a cost-effective basis as compared to other providers.", -0.7], ["Quality reporting requirements could adversely affect the Medicare reimbursement we receive.", -0.7], ["A facility’s failure to submit the required quality data results in a two percentage point reduction to that facility’s annual market basket increase factor for payments made for discharges in the subsequent Medicare fiscal year.", -0.8], ["All of our hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.", 0.8], ["adoption of additional quality reporting measures to track and report will require additional time and expense and could affect reimbursement in the future.", -0.5], ["There can be no assurance all of our hospitals will meet quality reporting requirements or quality performance in the future which may result in one or more of our hospitals seeing a reduction in its Medicare reimbursements.", -0.9], ["Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.", -0.6], ["The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.", -0.4], ["While this is consistent with our goal and proven track record of being a high-quality, cost-effective provider, broadbased implementation of a new payment model would represent a significant evolution or transformation of the healthcare industry, which may have a significant impact on our business and results of operations.", -0.3], ["Providers participating in BPCI Advanced are subject to a semi-annual reconciliation process where CMS compares the aggregate Medicare expenditures for all items and services included in a clinical episode against the target price for that type of episode to determine whether the participant is eligible to receive a portion of the savings, or is required to repay a portion of the payment above target.", 0.0], ["Accordingly, reimbursement may be increased or decreased, compared to what would otherwise be due, based on whether the total Medicare expenditures and patient outcomes meet, exceed or fall short of the targets.", 0.0], ["Conceptually, ACOs receive a portion of any savings generated above a certain threshold from care coordination as long as benchmarks for the quality of care are maintained.", 0.5], ["Each track offers a different degree to which participants share any savings realized or any obligation to repay losses suffered.", -0.2], ["Depending on the quality and cost performance during the entire episode, the acute-care hospital may receive an additional payment or be required to repay Medicare a portion of the episode costs.", -0.3], ["CJR has not had a material impact on our hospitals.", 0.0], ["beneficiaries who are treated in one of the models increases.", 0.1], ["Our willingness or inability to participate in integrated payment and other alternative payment models and the referral patterns of other providers participating in those models may limit our access to Medicare patients who would benefit from treatment in inpatient rehabilitation hospitals.", -0.4], ["In an attempt to reduce costs, ACOs may seek to discourage referrals to post-acute care all together.", -0.5], ["To the extent that acute-care hospitals participating in those models do not perceive our quality of care or cost efficiency favorably compared to alternative post-acute providers, we may experience a decrease in volumes and Net operating revenues, which could adversely affect our financial position, results of operations, and cash flows.", -0.6], ["Other legislative and regulatory initiatives and changes affecting the industry could adversely affect our business and results of operations.", -0.7], ["Any such suspension would adversely affect our financial position, results of operations, and cash flows.", -0.8], ["While many of the stated goals of other federal and state reform initiatives are consistent with our own goal to provide care that is highquality and cost-effective, legislation and regulatory proposals may lower reimbursements, increase the cost of compliance, decrease patient volumes, promote frivolous or baseless litigation, and otherwise adversely affect our business.", -0.9], ["In areas where we are not part of a managed care network with significant enrollment, this discharge planning rule may negatively affect the number of patients choosing us.", -0.8], ["As of year end 2023, we cannot be certain our claim validation rate will continue to exceed the required percentage for each review cycle, nor can we predict the impact, if any, it may have on the collectability of our Medicare claims over its five-year term.", -0.7], ["We may ultimately experience decreases in Net operating revenues and in cash flow, or we may incur costs associated with patient care for which the Medicare claim is subsequently denied, any of which could have an adverse effect on our financial position, results of operations, and liquidity.", -0.9], ["The HHS-OIG estimated the policy could have reduced total Medicare payments to IRFs in 2017 and 2018 by between 6% and 7%.", -0.6], ["If enacted, they may be challenging for all providers and have the effect of limiting Medicare beneficiaries’ access to healthcare services and could have a material adverse impact on our Net operating revenues, financial position, results of operations, and cash flows.", -0.9], ["Compliance with the extensive laws and government regulations applicable to healthcare providers requires substantial time, effort and expense, and if we fail to comply with them, we could suffer penalties or be required to make significant changes to our operations.", -0.8], ["If an IRF does not demonstrate compliance with the 60% Rule by either the presumptive method or through a review of medical records, then its classification as an IRF may be terminated by CMS causing the facility to be paid under the acute-care payment system which would result in reduced reimbursement per discharge.", -0.8], ["If one or more of our hospitals fails to demonstrate compliance with the 60% Rule and CMS re-classifies it as an acute-care hospital, our revenue and profitability may be materially and adversely affected.", -0.9], ["Those changes could also affect reimbursements as well as future compliance, training, and staffing costs.", -0.7], ["In September 2018, the HHS-OIG released a report purporting to identify a high error rate (approximately 80% of claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims.", -0.7], ["An HHS-OIG work plan, audit or similar future efforts could result in proposed changes to the payment systems for providers or increased denials of Medicare claims for patients notwithstanding the referring physicians’ judgment that treatment is appropriate.", -0.8], ["We settled the DOJ investigation, together with the related qui tam or whistleblower lawsuits, in 2019 for a total payment of $48 million, and we expressly denied any wrongdoing.", -0.6], ["training programs as well as internal controls and procedures designed to ensure regulatory compliance, we have in the past been, and could in the future be, required to return portions of reimbursements for discharges alleged after the fact to have not been appropriate under the applicable reimbursement rules and change our patient admissions practices going forward.", -0.7], ["We could also be subjected to other liabilities, including (1) criminal penalties, (2) civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3) exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs, which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement or debt instruments.", -0.9], ["governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us.", -0.8], ["DOJ has pursued and recovered record amounts based on alleged healthcare fraud.", -0.7], ["Settlements of alleged violations or imposed reductions in reimbursements, substantial damages and other remedies assessed against", -0.8], ["us could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation and could cost us significant time and expense to defend.", -0.8], ["The use of sub-regulatory guidance, statistical sampling, and extrapolation by CMS, Medicare contractors, HHS-OIG, and DOJ to deny claims, expand enforcement claims, and advocate for changes in reimbursement policy increases the risk that we could experience reduced revenue, suffer penalties, or be required to make significant changes to our operations.", -0.9], ["Because Medicare comprises a significant portion of our Net operating revenues, failure to comply with the laws and regulations", -0.8], ["governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us.", -0.9], ["CMS’ invocation of its retroactive-rulemaking authority in response to this Supreme Court decision is an unfavorable precedent for providers because it demonstrates a willingness by CMS to revive adverse reimbursement actions after those actions are deemed deficient on administrative procedural grounds.", -0.7], ["Through sampling and extrapolation, the government takes a review of a small number of reimbursement claims and generalizes the results of that review to a much broader universe of claims, which can result in significant increases in the aggregate number and value of claims at issue.", -0.6], ["For example, the HHSOIG issued a report in September 2018 purporting to identify a high error rate (approximately 80% of claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims.", -0.7], ["Based on its findings, the HHS-OIG extrapolated the error rate to the universe of inpatient rehabilitation claims and, among other things, recommended reevaluation of the IRF-PPS.", -0.5], ["Notwithstanding the technical statistical flaws that can arise in sampling small groups of claims and the extremely problematic nature of extrapolation in the context of individualized decisions of medical judgment as some courts have noted, sampling and extrapolation pose a growing risk to healthcare providers in the form of more significant claims of overpayments and increased legal costs to defend against these problematic regulatory practices.", -0.8], ["Any associated loss of revenue or increased legal costs could materially and adversely affect our financial position, results of operations, and cash flows.", -0.9], ["Efforts to comply with regulatory mandates to increase the use of electronic health data and health system interoperability may lead to enforcement and negative publicity which could adversely affect our business.", -0.8], ["Enforcement of ONC’s and CMS’ new health information access, exchange, and use standards began in 2021, and noncompliance can result in civil monetary penalties, exclusion from participation in federal health care programs and other appropriate “disincentives,” including reductions in Medicare reimbursements.", -0.9], ["Additionally, interoperability and the sharing of health information have received increasingly negative publicity.", -0.8], ["There is at least one well publicized instance where organizations received significant negative publicity for sharing health data", -0.9], ["There can be no assurance that our efforts to improve the care we deliver and to comply with the law through increasing use of electronic data and system interoperability will not receive negative publicity that may materially and adversely affect our ability to get patient referrals or enter into joint ventures with other providers or may lead to greater regulatory scrutiny.", -0.7], ["If any of our hospitals fail to comply with the Medicare enrollment requirements or conditions of participation, that hospital could be terminated from the Medicare program.", -0.9], ["If any of our hospitals fail to meet any of the Medicare enrollment requirements or conditions of participation, we may receive a notice of deficiency from the applicable survey agency or contractor, as applicable.", -0.8], ["If that hospital then fails to institute an acceptable plan of correction and correct the deficiency within the applicable correction period, it could lose the ability to bill Medicare.", -0.9], ["A hospital could be terminated from the Medicare program if it fails to address the deficiency within the applicable correction period.", -0.9], ["Under this new rule, CMS may revoke a provider’s Medicare enrollment, including all of the provider’s locations, if the provider", -0.8], ["bills for services performed at, or items furnished from, one location that it knew or should have known did not comply with Medicare enrollment requirements, including making the disclosures discussed above.", -0.8], ["CMS has the ability to prevent applicants from enrolling in the program for up to three years if a provider is found to have submitted false or misleading information in its initial enrollment application.", -0.8], ["Additionally, CMS can now block providers and suppliers who are revoked from re-entering the Medicare program for up to 10 years.", -0.5], ["Any termination of one or more of our hospitals from the Medicare program for failure to satisfy the enrollment requirements or", -0.8], ["conditions of participation could materially adversely affect our business, financial position, results of operations, and cash flows.", -0.9], ["If we are found to have violated applicable privacy and security laws and regulations or our contractual obligations, we could be subject to sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial position, results of operation and liquidity.", -0.9], ["These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business.", -0.8], ["It also permits HHS to conduct audits of HIPAA compliance and impose significant civil monetary penalties even if we did not know and could not reasonably have known about a violation.", -0.7], ["If we are found to have violated the HIPAA privacy or security regulations or other federal or state laws protecting the confidentiality of patient health or personal information, including but not limited to the HITECH Act, we could be subject to litigation, sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation, and have a material adverse effect on our business, financial position, results of operations and liquidity.", -0.9], ["These laws in many cases are more restrictive or impose more obligations than, and may not be preempted by, the HIPAA rules, apply to employees and business contacts as well as patients, and may be subject to new and varying interpretations by courts and government agencies, creating complex compliance issues and potentially exposing us to additional expense, adverse publicity and liability.", -0.8], ["These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly.", -0.7], ["Any contractual protections we have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections.", -0.8], ["Complying with these various laws, rules, regulations and standards could cause us to incur substantial costs that are likely to", -0.8], ["increase over time, require us to change our business practices in a manner adverse to our business, divert resources from other initiatives and projects, and restrict the way products and services involving data are offered, all of which may have a material adverse effect on our business.", -0.9], ["Given the rapid development of cybersecurity and data privacy laws, we expect to encounter inconsistent interpretation and enforcement of these laws and regulations, as well as frequent changes to these laws and regulations which may expose us to significant penalties or liability for noncompliance, the possibility of fines, lawsuits (including class action privacy litigation), regulatory investigations, criminal or civil sanctions, audits, adverse media coverage, public censure, other claims, significant costs for remediation and damage to our reputation, or otherwise have a material adverse effect on our business and operations.", -0.9], ["Any allegations of a failure to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, damage our relationships with patients and business partners and have a material adverse effect on our business.", -0.8], ["The publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices.", -0.7], ["Any concerns about our data privacy and security practices, even if unfounded, could damage the reputation of our businesses, discourage potential patients from seeking our services and have a material adverse effect on our business.", -0.8], ["Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.", -0.7], ["Costs and expenses related to these requirements are a significant operating expense and may increase as laws and regulations change.", -0.6], ["Any failure to comply with these employment-related legal requirements can result in significant penalties or litigation exposure and could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.8], ["The pricing transparency and similar consumer protection rules could adversely affect our business and results of operations.", -0.7], ["In the event a hospital fails to comply with the new requirements and does not complete the prescribed corrective action, CMS may impose a civil monetary penalty of between $300 and $5,500 per day.", -0.8], ["Our failure to maintain compliance with these rules could adversely affect our financial position, results of operations, and cash flows.", -0.9], ["The proper function, availability, and security of our information systems are critical to our business and failure to maintain proper function, availability, or security of our information systems or protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["We expend significant capital to protect against the threat of security breaches, including cyber attacks, email phishing schemes,", -0.7], ["Substantial additional expenditures may be required to respond to and remediate any problems caused by breaches, including the unauthorized access to or theft of patient data and protected health information stored in our information systems and the introduction of computer malware or ransomware to our systems.", -0.8], ["Accordingly, we may be vulnerable to losses associated with the improper functioning, breach or unavailability of our and our vendors’ information systems, including systems used in acquired operations, and thirdparty systems we use.", -0.8], ["cybersecurity threats in the healthcare industry, there can be no assurance we will not experience business interruptions; data loss, ransom, misappropriation or corruption, theft, or misuse of proprietary data, patient or other personally identifiable information; or litigation, investigation, or regulatory action related to any of those, any of which could have a material adverse effect on our patient care, ability to admit patients, financial position, and results of operations and harm our business reputation.", -0.9], ["In the case of a material breach or cyber attack, the associated expenses and losses may exceed our current insurance coverage for such events.", -0.8], ["Failure to maintain proper function, security, or availability of our information systems or protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["In addition, costs, unexpected problems, and interruptions associated with the implementation or transition to new systems or technology or with adequate support of those systems or technology across numerous hospitals could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.8], ["The failure of our business partners and vendors to maintain the proper function, availability, or security of their information systems or to protect against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["governmental agencies and their contractors with whom we interact, including our direct and indirect cloud service providers and CMS, which results in confidential information being accessed, obtained, damaged or used by unauthorized persons, or unavailability of systems necessary to the operation of our business, could impact patient care, claims billing and collection, harm our reputation, and expose us to significant remedial costs as well as regulatory actions (fines and penalties) and claims from patients, financial institutions, regulatory and law enforcement agencies, and other persons, any of which could have a material adverse effect on our business, financial position, results of operations and cash flows.", -1.0], ["In the event the Change Healthcare service is not restored in a timely fashion, we may experience payment collection delays as we turn to alternative channels to submit claims.", -0.8], ["A security breach or other system failure involving Oracle Cerner, Change Healthcare, or another third-party with whom we share data or system connectivity could compromise", -0.9], ["our patient data or proprietary information or disrupt our ability to operate, including submitting claims for payment, any of which could have a material adverse effect on our business, financial position, results of operations and cash flows.", -1.0], ["Given that approximately 91% of our hospitals’ admissions come from acute-care hospitals, that increase in competition could materially and adversely affect our admission referrals in the related markets.", -1.0], ["There can be no assurance this competition, or other competition which we may encounter in the future, will not adversely affect our", -0.9], ["Conversely, competition and statutory procedural requirements in some CON states may inhibit our ability to expand our operations in those states.", -0.8], ["If we are unable to provide a consistently high quality of care, our business will be adversely impacted.", -1.0], ["Effective October 2012, Medicare began to impose a financial penalty upon acute-care hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge.", -0.9], ["We believe this regulation provides a competitive advantage to post-acute providers who can differentiate themselves based upon quality, particularly by achieving low acute-care hospital readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals.", -0.1], ["If we should fail to attain our goals regarding acute-care hospital readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations, and cash flows.", -0.8], ["If we are unable to maintain or develop relationships with patient referral sources, our growth and profitability could be adversely affected.", -0.7], ["The establishment of joint ventures or networks between referral sources, such as acute-care hospitals, and other post-acute providers may hinder patient referrals to us.", -0.6], ["Our growth and profitability depend on our ability to establish and maintain close working relationships with patient referral sources", 0.2], ["and to increase awareness and acceptance of the benefits of inpatient rehabilitation care by our referral sources and their patients.", 0.3], ["Our loss of, or failure to maintain, existing relationships, including because of closures of referral sources in concentrated markets, or our failure to develop new relationships could adversely affect our ability to grow our business and operate profitably.", -0.7], ["We may have difficulty completing joint ventures, investments and transactions that increase our capacity consistent with our growth strategy.", -0.5], ["may face limitations on our ability to identify sufficient joint venture, acquisition or other development targets and to complete those transactions to meet goals.", -0.4], ["In the inpatient rehabilitation industry, the costs of constructing new hospitals are increasing faster than reimbursement rates and the", -0.5], ["Increased DOJ enforcement of antitrust laws will likely increase the time, effort and expense associated with acquisitions and may ultimately make it less likely to consummate acquisitions.", -0.8], ["These factors and others may delay, or increase the cost to us associated with, any acquisition or de novo development or prevent us", -0.7], ["from completing one or more acquisitions or de novo developments.", -0.6], ["Acute-care hospitals that participate in joint ventures with us may experience operational or financial challenges that, in turn, affect our joint venture inpatient rehabilitation hospitals.", -0.7], ["substantially all of these joint ventures, our co-owners are nonprofit hospitals or health systems.", -0.3], ["The healthcare provider operating environment has become increasingly challenging in recent years because of inflationary pressures, (particularly labor costs), reimbursement pressures, tight credit markets with increasing interest rates, and other operational challenges such as clinical staffing shortages and shifts of some types of care delivery away from the acute-care setting.", -0.9], ["The continuation of some or all of these conditions together with general weakening economic conditions and increasing federal and state limitations on strategic combinations could subject our joint venture partners to significant operational and financial pressures.", -0.8], ["The financial and operational strength, access to credit, and general liquidity of a joint venture partner may affect the growth or", -0.6], ["performance for the associated inpatient rehabilitation hospital, and in a few instances in the past has done so.", -0.5], ["Our joint venture partners may be, and in the past some have been, unable or unwilling, at the time of our request, to make capital contributions to fund their proportional shares of operating or capital expenditures that we believe are in the best interest of the joint ventures.", -0.7], ["The delay or inability of a joint venture to undertake a funding expenditure could affect the growth or performance of that hospital.", -0.5], ["Should a joint venture partner close its acute-care hospital operating in the market with the joint venture inpatient rehabilitation hospital, we would likely suffer a significant referral disruption or decrease in that market, particularly in smaller markets where the acute-care hospital that is closing is the primary or only hospital.", -0.8], ["We closed that joint venture hospital in February and expect to incur a one-time charge of approximately $2-4 million, net of tax and noncontrolling interest, in the first quarter of 2024.", -0.7], ["Any of these occurrences or similar occurrences affecting a number of our joint ventures could, in the aggregate, have a material adverse impact on our business and consolidated financial condition, results of operations, and cash flows.", -0.9], ["expenditures, debt incurrence, operating losses, amortization of certain intangible assets of acquired companies, issuances of equity securities, liabilities, and expenses, some of which are unforeseen, that could materially and adversely affect our business, financial position, results of operations and liquidity.", -0.9], ["Once built, new hospitals must undergo the state and Medicare certification process, the duration of which may be beyond our control.", -0.6], ["We may be unable to operate newly constructed hospitals as profitably as expected, and those hospitals may involve significant additional cash expenditures and operating expenses that could, in the aggregate, have an adverse effect on our business, financial position, results of operations, and cash flows.", -0.8], ["There may be substantial difficulties, costs and delays involved in the integration of an acquired business with our business.", -0.7], ["Additionally, an acquisition could cause disruption to our business and operations and our relationships with customers, employees and other parties.", -0.6], ["To the extent we are attempting to integrate multiple businesses at the same time, we may not be able to do so as efficiently or effectively as we initially anticipate.", -0.7], ["The failure to successfully integrate on a timely basis any acquired business with our existing business could have an adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["We anticipate our acquisitions will result in benefits including, among other things, increased revenues.", 0.5], ["businesses may not contribute to our revenues or earnings to the extent anticipated, and any synergies we expect may not be realized after the acquisitions have been completed.", -0.5], ["If the acquired businesses underperform and any underperformance is other than temporary, we may be required to take an impairment charge.", -1.0], ["Failure to achieve the anticipated benefits could result in the diversion of management’s time and energy and could have an adverse effect on our business, financial position, results of operations, and cash flows.", -1.0], ["Competition for staffing, shortages of qualified personnel, union activity or other factors may increase our staffing costs and reduce profitability.", -0.5], ["conditions associated with the COVID-19 pandemic significantly affected the availability and turnover of clinical staff and, in turn, increased staffing costs.", -1.0], ["led to prevalent job dissatisfaction among clinicians.", -1.0], ["Availability of clinical staff, elevated turnover and staffing costs continue to be a challenge for us and other healthcare providers.", -0.5], ["Staffing shortages or retention concerns in one or more markets in which we operate have required and may again require us to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel.", -0.5], ["If our staffing costs increase, we may not experience reimbursement rate or pricing increases to offset these additional costs.", -0.8], ["a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased staffing costs is limited.", -0.7], ["In particular, if staffing costs rise at an annual rate greater than our net annual market basket update from Medicare, as occurred in 2022 and 2023, or we experience a significant shift in our payor mix to lower rate payors such as Medicaid, our results of operations and cash flows will be adversely affected.", -0.9], ["Conversely, decreases in reimbursement revenues, such as with sequestration, may limit our ability to increase compensation or benefits to the extent necessary to retain key employees, in turn increasing our turnover and associated costs.", -0.8], ["Union activity is another factor that may contribute to increased staffing costs.", -0.5], ["We currently have a minimal number of union employees, so an increase in labor union activity could have a significant impact on our staffing costs.", -0.6], ["Our failure to recruit and retain qualified clinical personnel, or to control our staffing costs, could have a material adverse effect on our business, financial position, results of operations, and cash flows.", -0.9], ["We are a defendant in various lawsuits, and may be subject to liability under qui tam cases, the outcome of which could have a material adverse effect on us.", -0.8], ["Substantial damages, fines, or other remedies assessed against us or agreed to in settlements could have a material adverse effect on", -0.8], ["our business, financial position, results of operations, and cash flows, including indirectly as a result of the covenant defaults under our credit agreement or debt instruments or other claims such as those in securities actions.", -0.8], ["These lawsuits, also known as “whistleblower” or “qui tam” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government.", -0.8], ["We settled the DOJ investigation, together with the related qui tam or “whistleblower” lawsuits, for a payment of $48 million, and we expressly denied any wrongdoing.", -0.6], ["Even when a matter is without merit, as we believe was the case with this investigation, we may still incur significant costs of defense or settlement costs or both.", -0.7], ["A variance between our estimated and actual number of claims or average cost per claim could have a material impact, either favorable or unfavorable, on the adequacy of the reserves for these liability risks, which could have an effect on our financial position and results of operations.", -0.5], ["Additionally, judges and juries in California have demonstrated a willingness to grant large verdicts to plaintiffs in connection with employment and labor related cases.", -0.4], ["In 2017, the California Supreme Court held that plaintiffs bringing suit under PAGA are generally entitled to request and receive a significant amount of information from the employer early in the litigation, which creates pressure for employers to settle early to avoid substantial litigation burdens and which has resulted in a significant increase in PAGA claims in recent years.", -0.5], ["We may be more vulnerable to the effects of a public health emergency than other businesses due to the nature of our patients, and a regional or global socio-political, weather or other catastrophic event could severely disrupt our business.", -0.9], ["A public health emergency can significantly affect healthcare providers because of the direct impacts on patients, capacity to accept", -0.8], ["The COVID-19 pandemic and actions taken by local, state and federal authorities in response to the pandemic significantly affected our operations, business and financial condition.", -0.9], ["Future outbreaks of contagious diseases and associated governmental actions could adversely affect our operations, business and financial condition, including potentially our liquidity, particularly if the provision of healthcare services and the supplies for those services are disrupted for a lengthy period of time.", -0.9], ["For example, if another pandemic were to occur, we could suffer significant losses to our consumer population or a reduction in the availability of our employees and, at a high cost, be required to replace affected workers.", -1], ["Accordingly, certain public health catastrophes could have a material adverse effect on our financial condition and results of operations.", -1], ["Other unforeseen events, including acts of violence, war, terrorism and other international, regional or local instability or conflicts (including labor issues), embargoes, short-term and long-term weather-related events, natural disasters such as earthquakes and floods, whether occurring in the United States or abroad, could restrict or disrupt our operations and negatively affect our results of operations and cash flows.", -1], ["Regulatory and other efforts to promote a transition to a lower-carbon economy may result in significant operational and financial challenges for us.", -1], ["These climate-related laws and regulations have increased our costs associated with compliance and are likely to continue to do so in the future.", -1], ["Additionally, the costs that other companies incur to comply with these types of laws and regulations are likely to be passed on to us, which would increase the cost of the goods and services that we purchase from vendors and suppliers.", -1], ["These legal requirements, as well as challenges associated with consumer, investor or lender pressure to change business models and practices, may also lead one or more of our vendors or suppliers to alter, disrupt or cease operations, which may adversely affect our operations.", -1], ["Furthermore, we, as well as our vendors and suppliers, may be required to adopt alternative energy sources or technology that may not yet be reliable or cost effective, which may result in disruptions to our operations.", -1], ["In addition to incremental costs and potential disruptions to our energy supply and broader supply chain, subsidies from the federal government to the renewable energy industry and other climate-related costs incurred by the federal government may increase the national deficit and debt, which would increase the reimbursement risks we face.", -1], ["Those organizations, however, may base their ratings on assumptions regarding our business that are not accurate or otherwise lack an understanding of the inpatient rehabilitation business, such as conflating our hospitals with typically much larger and energy intensive acute-care hospitals, and their ratings may result in decreased demand for our stock or advocacy campaigns that divert management attention from our core business or, if successful, impose additional costs and burdens on us.", -1], ["sentiment, regulations, governmental subsidies and deficits, taxes, public mandates or requirements; the increase in climate-related lawsuits and insurance premiums; and the implementation of more robust disaster recovery and business continuity plans are likely to increase the costs to maintain our operations and to divert management attention from our core business, either of which may have an adverse effect on our business, financial position and results of operations.", -1.0], ["We may incur additional indebtedness in the future, and that debt or the associated increased leverage may have negative consequences for our business.", -0.8], ["If new debt is added to our current debt levels, the risks described here could intensify.", -0.7], ["•       limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes;", -0.9], ["•       making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our flexibility in planning for, and making it more difficult for us to react quickly to, changing conditions;", -0.9], ["•       placing us at a competitive disadvantage compared with competing providers that have less debt; and", -0.8], ["•       exposing us to risks inherent in interest rate fluctuations for outstanding amounts under our credit facility, which could result in higher interest expense in the event of increases in interest rates, as discussed in Item 7A, Quantitative and Qualitative Disclosures about Market Risk.", -0.8], ["Although we expect to make scheduled interest payments and principal reductions, we cannot provide assurance that changes in our business or other factors will not occur that may have the effect of preventing us from satisfying obligations under our credit agreement or debt instruments.", -0.9], ["If we are unable to generate sufficient cash flow from operations in the future to service our debt and meet our other needs or have an unanticipated cash payment obligation, we may have to", -0.9], ["refinance all or a portion of our debt, obtain additional financing or reduce expenditures or sell assets we deem necessary to our business.", -0.8]], "f22_sentences.json": [["Based on the New York Stock Exchange Composite Transaction closing price of the Common Stock on that date ($11.13 per share), the aggregate market value of such Common Stock was $43,956,659,969.", 0.0], ["Based on the New York Stock Exchange Composite Transaction closing price of the Common Stock on that date ($12.89 per share), the aggregate market value of such Common Stock was $50,468,600,929.", 0.1], ["In 2022, we sold approximately 4,231,000 vehicles at wholesale throughout the world.", 0.2], ["Our ability to satisfy changing consumer and business preferences with respect to type or size of vehicle, as well as design and performance characteristics, affects our sales and earnings significantly.", -0.1], ["As with other manufacturers, the profitability of our business is affected by many factors, including:", -0.2], ["Margin of profit on each vehicle sold - which, in turn, is affected by many factors, such as:", -0.2], ["Market factors - volume and mix of vehicles and options sold, and net pricing (reflecting, among other factors, incentive programs)", -0.1], ["A high proportion of relatively fixed structural costs, so that small changes in wholesale unit volumes can significantly affect overall profitability", -0.3], ["Although recent supply disruptions have resulted in near-term upward pressure on new vehicle prices, our industry has historically had a very competitive pricing environment, driven in part by excess capacity.", -0.4], ["For the past several decades, manufacturers typically have offered price discounts and other marketing incentives to provide value for customers and maintain market share and production levels, and we are beginning to see indications that some of these actions will resume in 2023 as industry production and inventories improve.", 0.0], ["The decline in value of foreign currencies in the past has also contributed significantly to competitive pressures in many of our markets.", -0.7], ["Historically, we have experienced some seasonal fluctuation in the business, with production in many markets tending to be higher in the first half of the year to meet demand in the spring and summer (typically the strongest sales months of the year).", 0.2], ["In recent years, due to COVID-19, the semiconductor shortage, and other supply constraints, production has been higher in the second half of the year.", -0.3], ["During the past year, gross stock levels at dealers were lower than normal due largely to the semiconductor shortage and other supply constraints, and the amount of time required to fill orders for certain vehicles increased.", -0.6], ["These programs increase Ford Credit’s financing volume and share.", 0.8], ["$500 million.", 0.0], ["Corporate Other primarily includes corporate governance expenses, interest income (excluding interest earned on our extended service contract portfolio that is included in our Automotive segment) and gains and losses from our cash, cash equivalents, and marketable securities (excluding gains and losses on investments in equity securities), and foreign exchange derivatives gains and losses associated with intercompany lending.", 0.1], ["Compliance with emissions standards, OBD requirements, and related regulations can be challenging and can drive increased product development costs, warranty costs, and vehicle recalls.", -0.5], ["These new rules are expected to impose increased challenges and costs on the development of light-duty vehicles and heavy-duty engines.", -0.4], ["Legislative, regulatory, and judicial developments related to fuel quality at both the national and state levels could affect vehicle manufacturers’ warranty costs as well as their ability to comply with vehicle emissions standards.", -0.5], ["California’s light-duty vehicle ZEV regulation, which uses a system based on credits that can be banked and carried forward, mandates annual increases in the production and sale of battery-electric, fuel cell, and plug-in hybrid vehicles.", -0.1], ["These stringent ZEV requirements covering light-, medium-, and heavy-duty vehicles could entail significant costs and compliance challenges, and include complex warranty and recall requirements.", -0.7], ["The costs associated with complying with all of these requirements are significant, and following the EU Commission’s indication of its intent to accelerate emissions rules in its road map publication “EU Green Deal” as well as the EU sustainable mobility action plan, these challenges will continue in European markets, including the United Kingdom.", -0.8], ["Moreover, following the U.K.’s withdrawal from the European Union, we may be subject to diverging requirements in our European markets, which could increase vehicle complexity and duties.", -0.6], ["The speed of implementation of access rules may directly influence customer vehicle residual values and choice of next purchase.", 0.0], ["In an effort to support the Paris Accord, some countries are adopting yearly increases in CO2 taxes, where such a system is in place, and publishing dates by when internal combustion powered vehicles may no longer be registered, e.g., Norway in 2025 and the United Kingdom and the Netherlands in 2030.", 0.2], ["In recent years, EPA and CARB have increased their focus on the use of “defeat devices.” Defeat devices are elements of design (typically embedded in software) that improperly cause the emission control system to function less effectively during normal on-road driving than during an official laboratory emissions test, without justification.", -0.9], ["Regulators around the world continue to scrutinize automakers’ emission testing, which has led to a number of defeat device settlements by various manufacturers.", -0.8], ["In addition, plaintiffs’ attorneys are pursuing consumer class action lawsuits based on alleged excessive emissions from cars and trucks, which could, in turn, prompt further investigations by regulators.", -0.7], ["Manufacturers are subject to substantial civil penalties if they fail to meet the CAFE standard in any model year, after taking into account all available credits for the preceding five model years and expected credits for the three succeeding model years.", -0.5], ["In 2020, EPA introduced significantly less stringent fuel economy and GHG standards applicable to model years 2021-2026.", -0.5], ["These new rules are expected to impose increased challenges and costs on the development of light-duty vehicles.", -0.7], ["If any federal or state agency imposes and enforces fuel economy and GHG standards that are misaligned with market conditions, Ford would likely be forced to take various actions that could have substantial adverse effects on its sales volumes and results of operations.", -0.9], ["Such actions likely would include restricting offerings of selected engines and popular options; increasing market support programs for Ford’s most fuel-efficient vehicles; and ultimately curtailing the production and sale of certain vehicles, such as high-performance cars, utilities, and/or full-size light trucks in order to maintain compliance.", -0.8], ["As the heavy-duty standards increase in stringency, it may become more difficult to comply while continuing to offer a full lineup of heavy-duty trucks.", -0.6], ["Pooling agreements between manufacturers to utilize credits are possible under certain conditions, and we have entered into such pooling agreements in order to comply with fuel economy regulations without paying a penalty and to enable other manufacturers to benefit from our positive CO2 performance.", 0.3], ["The initial target levels get significantly more stringent every five years (2025, 2030, and 2035, after which all new vehicles must be zero emission), requiring significant investments in propulsion technologies and extensive fleet management forcing low CO2 emissions.", -0.4], ["Ford also faces the risk of advance premium payments for both passenger cars and light commercial vehicles in all European markets due to, for example, unexpected market fluctuations and shorter lead times impacting average fleet performance.", -0.7], ["Costs associated with new or incremental testing for WLTP are significant.", -0.6], ["In addition, delayed vehicle launches and supply shortages, as well as an insufficient charging infrastructure and lower demand for ZEV and low CO2 emission vehicles as certain electric vehicle incentives are reduced, can trigger compliance risks in all European markets.", -0.8], ["Risk Factors under “Ford may need to substantially modify its product plans to comply with safety, emissions, fuel economy, autonomous vehicle, and other regulations,” a production disruption, stop ship, lower than planned market acceptance of our vehicles, or other intervening events may cause us to modify our product plans or, in some cases, purchase credits in order to comply with fuel economy standards.", -0.8], ["Meeting or exceeding many safety standards is costly and has continued to evolve as global compliance and public domain (e.g., New Car Assessment Programs (“NCAPs”), Insurance Institute for Highway Safety (“IIHS”)) requirements continue to evolve, are increasing in demands, and lack harmonization globally.", -0.7], ["As we expand our business priorities to include autonomous vehicles and broader mobility products and services, our financial exposure has increased.", -0.6], ["Should we or NHTSA determine that either a safety defect or noncompliance issue exists with respect to any of our vehicles, the cost of such recall campaigns could be substantial.", -0.9], ["Any difference between North American and UN-ECE based regulations can add complexity and costs to the development of global platform vehicles, and we continue to support efforts to harmonize regulations to reduce vehicle design complexity while providing a common level of safety performance; several on-going bilateral negotiations on free trade can potentially contribute to this goal.", -0.5], ["Safety and recall requirements in Brazil, China, India, South Korea, and Gulf Cooperation Council (“GCC”) countries may add substantial costs and complexity to our global recall practice.", -0.7], ["Brazil has set mandatory fleet safety targets and penalties are applied if these levels are not maintained, while a tax reduction may be available for over-performance.", 0.1], ["These protocols impose additional requirements relating to testing, evaluation, and mandatory safety features, and compliance with them (or any subsequent updates to them) may be costly.", -0.6], ["Unfortunately, there were two fatal incidents in 2022 in our China region.", -1.0], ["While our global LTCR remains stable overall, there was an increase to 0.39 in 2022 from 0.35 in 2021.", -0.4], ["The reduction in employees in 2022 is primarily a result of certain divestitures in Europe and in our Mobility segment, and the cessation of operations at certain plants in India.", -0.5], ["Ford and Ford Credit’s financial condition and results of operations have been and may continue to be adversely affected by public health issues, including epidemics or pandemics such as COVID-19.", -0.8], ["For example, in 2020, consistent with the actions taken by governmental authorities, we idled our manufacturing operations in regions around the world before ultimately resuming our manufacturing operations taking a phased approach and after introducing new safety protocols at our plants.", -0.3], ["A future suspension of our manufacturing operations could have a significant adverse effect on our financial condition and results of operations.", -0.9], ["For example, in China, outbreaks of COVID-19 have led the government to impose lockdowns and other restrictions, which have adversely affected our and our supply chain’s production operations, our wholesales, and consumer demand for our products.", -0.7], ["Further, as new strains or variants of COVID-19 or other viruses, diseases, or public health issues develop or sufficient amounts of vaccines or treatments are not available, not widely administered for a significant period of time, or otherwise prove ineffective, the impact of a widespread public health issue on the global economy, and, in turn, our financial condition, liquidity, and results of operations could be material.", -0.8], ["The predominant share of Ford Credit’s business consists of financing Ford and Lincoln vehicles, and the duration or resurgence of public health issues such as COVID-19 may negatively impact the level of originations at Ford Credit.", -0.6], ["For example, Ford’s suspension of manufacturing operations, a significant decline in dealer showroom traffic, and/or a reduction of operations at dealers may lead to a significant decline in Ford Credit’s consumer and non-consumer originations.", -0.7], ["Moreover, economic uncertainty and higher unemployment arising from widespread public health issues or otherwise may result in higher defaults in Ford Credit’s consumer portfolio, and prolonged unemployment may have a negative impact on both new and used vehicle demand.", -0.8], ["As described in more detail below under “Ford and Ford Credit’s access to debt, securitization, or derivative markets around the world at competitive rates or in sufficient amounts could be affected by credit rating downgrades, market volatility, market disruption, regulatory requirements, or other factors,” the volatility created by COVID-19 adversely affected Ford and Ford Credit’s access to the debt and securitization markets and its cost of funding, and any volatility in the capital markets as a result of a public health issue or for any other reason could have an adverse impact on Ford and Ford Credit’s access to those markets and its cost of funding.", -0.7], ["Our Ford Blue, Ford Model e, and Ford Pro operations generally do not realize revenue while our manufacturing operations are suspended, but we continue to incur operating and non-operating expenses, resulting in a deterioration of our cash flow.", -0.8], ["Accordingly, any significant future disruption to our production schedule, regionally or globally, whether as a result of our own or a supplier’s suspension of operations, could have a substantial adverse effect on our financial condition, liquidity, and results of operations.", -0.9], ["Ford is highly dependent on its suppliers to deliver components in accordance with Ford’s production schedule and specifications, and a shortage of or inability to acquire key components, such as semiconductors, or raw materials, such as lithium, cobalt, nickel, graphite, and manganese, can disrupt Ford’s production of vehicles.", -0.7], ["If there is a shortage of a key component in our supply chain or a supplier is unable to deliver a component to us in accordance with our specifications, because of a production issue, limited availability of materials, shipping problems, restrictions on transactions with certain countries or companies, or other reason, and the component cannot be easily sourced from a different supplier, or we are unable to obtain a component on a timely basis, the shortage may disrupt our operations or increase our costs of production.", -0.8], ["For example, the automotive industry continues to face a significant shortage of semiconductors, which has a complex supply chain with long lead times required to increase production and capacity.", -0.7], ["The shortage is due in large part to strong cross-industry demand, which has presented challenges and production disruptions globally, including at our assembly plants, and COVID-19-related work restrictions in various parts of the world have further impacted semiconductor production.", -0.8], ["Accordingly, we and our competitors who need integrated circuits are experiencing various levels of semiconductor impact.", -0.6], ["As we increase our production of electric vehicles, we expect our need for such materials to increase significantly.", 0.1], ["At the same time, other companies are increasing their production of electric vehicles, which will further increase the demand for such raw materials.", -0.2], ["As a result, we may be unable to acquire raw materials needed for electric vehicle production in sufficient amounts that are responsibly sourced or at reasonable prices.", -0.5], ["A shortage of, or our inability to acquire or find adequate suppliers of, key components or raw materials as a result of disruptions in the supply chain, capacity constraints, limited availability, competition for those items within the automotive industry and other sectors, or otherwise can cause a significant disruption to our production schedule and have a substantial adverse effect on our financial condition or results of operations.", -1.0], ["Unlike our historical arrangements with suppliers, which are typically annual commitments, under multi-year offtake agreements and other long-term purchase contracts, the risks associated with lower-than-expected electric vehicle production volumes or changes in battery technology that reduce the need for certain raw materials are borne by Ford rather than our suppliers.", -0.5], ["In the event we do not purchase the materials pursuant to the terms of these agreements, even if the supplier finds another purchaser, we may be obligated to reimburse the supplier for costs it incurs in finding the new purchaser as well as any lost revenue attributable to the replacement purchaser paying a lower price than required under the pricing mechanism in our agreement.", -1.0], ["As a result of the competition for and limited availability of the raw materials needed for our electric vehicle business, the costs of such materials are difficult to accurately forecast as they may fluctuate during the term of the offtake agreements and other long-term purchase contracts based on market conditions.", -0.5], ["Accordingly, we may be subject to increases in the prices we pay for those raw materials, and our ability to recoup such costs through increased pricing to our customers may be limited.", -0.5], ["As a result, our margins, results of operations, financial condition, and reputation may be adversely impacted by commitments we make pursuant to offtake agreements and other long-term purchase contracts.", -1.0], ["If we are unable to optimize our capital allocation among vehicles, services, technology, and other calls on capital, or we are otherwise not successful in executing Ford+ (or are delayed for reasons outside of our control), we may not be able to realize the full benefits of our plan, which could have an adverse effect on our financial condition or results of operations.", -1.0], ["Furthermore, if we fail to make progress on our plan at the pace that shareholders expect, it may lead to an increase in shareholder activism, which may disrupt the conduct of our business and divert management’s attention and resources.", -1.0], ["Ford’s vehicles could be affected by defects that result in delays in new model launches, recall campaigns, or increased warranty costs.", -1.0], ["The cost of recall and customer satisfaction actions to remedy defects in vehicles that have been sold could be substantial, particularly if the actions relate to global platforms or involve defects that are identified years after production.", -1.0], ["Should NHTSA determine that the inflators contain a safety defect, Ford and other manufacturers could potentially face significant incremental recall costs.", -0.8], ["Further, to the extent recall and customer satisfaction actions relate to defective components we receive from suppliers, our ability to recover from the suppliers may be limited by the suppliers’ financial condition.", -0.7], ["If warranty costs are greater than anticipated as a result of increased vehicle and component complexity, the adoption of new technologies, or otherwise, such costs could have an adverse effect on our financial condition or results of operations.", -0.9], ["Furthermore, launch delays, recall actions, and increased warranty costs could adversely affect our reputation or market acceptance of our products as discussed below under “Ford’s new and existing products and digital, software, and physical services are subject to market acceptance and face significant competition from existing and new entrants in the automotive and digital and software services industries, and its reputation may be harmed if it is unable to achieve the initiatives it has announced.”", -0.8], ["Ford may not realize the anticipated benefits of existing or pending strategic alliances, joint ventures, acquisitions, divestitures, restructurings, or new business strategies.", -0.6], ["As a result, we may not be able to complete anticipated transactions, the anticipated benefits of these transactions may not be realized, or the benefits may be delayed.", -0.7], ["For example, we may not successfully integrate an alliance or joint venture with our operations, including the implementation of our controls, systems, procedures, and policies, or unforeseen expenses or liabilities may arise that were not discovered during due diligence prior to an investment or entry into a strategic alliance, or a misalignment of interests may develop between us and the other party.", -0.7], ["In order to secure critical materials for production of electric vehicles, we have entered into and plan to continue to enter into offtake agreements and other long-term purchase contracts with raw materials suppliers and make investments in certain raw material and battery suppliers; however, we may not realize the anticipated benefits of these actions and our efforts to have such suppliers, particularly those in less developed markets, adopt Ford’s sustainability and other standards may be unsuccessful, which could have an adverse impact on our reputation.", -0.8], ["Results of operations from new activities may be lower than our existing activities, and, if a strategy is unsuccessful, we may not recoup our investments, which may be significant, in that strategy.", -0.7], ["Moreover, we may continue to have financial exposure following a strategic divestiture or cessation of operations in a market, and restructuring actions may cause us to incur significant costs, record impairments or other charges, subject us to potential claims from employees, suppliers, dealers, or governmental authorities or harm our reputation.", -0.9], ["Failure to successfully and timely realize the anticipated benefits of the transactions or strategies described herein could have an adverse effect on our financial condition or results of operations.", -0.8], ["Such incidents could materially disrupt operational systems; result in loss of trade secrets or other proprietary or competitively sensitive information; compromise the privacy of personal information of consumers, employees, or others; jeopardize the security of our facilities; affect the performance of in-vehicle systems or services we offer; and/or impact the safety of our vehicles.", -0.9], ["Moreover, a cyber incident could harm our reputation, cause customers to lose trust in our security measures, and/or subject us to regulatory actions or litigation, which may result in fines, penalties, judgments, or injunctions, and a cyber incident involving us or one of our suppliers could impact production, our internal operations, or our ability to deliver products and services to our customers.", -0.9], ["Ford’s production, as well as Ford’s suppliers’ production, and/or the ability to deliver products to consumers could be disrupted by labor issues, natural or man-made disasters, adverse effects of climate change, financial distress, production difficulties, capacity limitations, or other factors.", -0.8], ["A work stoppage or other limitation on production could occur at Ford’s facilities, at a facility in its supply chain, or at one of its logistics providers for any number of reasons, including as a result of labor issues, including shortages of available employees, disputes under existing collective bargaining agreements with labor unions or in connection with negotiation of new collective bargaining agreements, absenteeism, public health issues (e.g., COVID-19), stay-at-home orders, or in response to potential restructuring actions (e.g., plant closures); as a result of supplier financial distress or other production constraints, such as limited quantities of components, including but not limited to semiconductors, or raw materials, quality issues, capacity limitations, or other difficulties; as a result of a natural disaster (including climate-related physical risk); cyber incidents; or for other reasons.", -0.8], ["Further, the limited availability of components, labor shortages, COVID-19, and supplier operating issues has led to an inconsistent production schedule at our facilities.", -0.7], ["This has exacerbated the disruption to our suppliers’ operations, which, in turn, has led to higher costs and production shortfalls.", -0.8], ["Given the worldwide scope of our supply chain and operations, we and our suppliers face a risk of disruption or operating inefficiencies that may increase costs due to the adverse physical effects of climate change, which are predicted to increase the frequency and severity of weather and other natural events, e.g., wildfires, extended droughts, and extreme temperatures.", -0.8], ["In addition, in the event a weather-related event, strike, international conflict, or other occurrence limits the ability of freight carriers to deliver components and other materials from suppliers to us or logistics providers to transport our vehicles for an extended period of time, it may increase our costs and delay or otherwise impact both our production operations and customers’ ability to receive our vehicles.", -0.8], ["Such suppliers also could threaten to disrupt our production as leverage in negotiations.", -0.7], ["Regardless of the cause, our ability to recoup lost production volume may be limited.", -0.8], ["Accordingly, a significant disruption to our production schedule could have a substantial adverse effect on our financial condition or results of operations and may impact our strategy to comply with fuel economy standards as discussed below under “Ford may need to substantially modify its product plans and facilities to comply with safety, emissions, fuel economy, autonomous driving technology, environmental, and other regulations.”", -0.9], ["Ford’s ability to maintain a competitive cost structure could be affected by labor or other constraints.", -0.7], ["Competition for such employees is intense, which has led to an increase in compensation throughout a tight labor market, and, accordingly, may increase costs for employers.", -0.6], ["We have struggled to hire and retain salaried, skilled hourly, and production hourly employees in some of our manufacturing and parts, supplies, and logistics locations.", -0.7], ["Further, if we lose existing employees with needed skills, or we are unable to upskill and develop existing employees, particularly with the introduction of new technologies, it could have a substantial adverse effect on our business.", -0.8], ["Ford’s new and existing products and digital, software, and physical services are subject to market acceptance and face significant competition from existing and new entrants in the automotive and digital and software services industries, and its reputation may be harmed if it is unable to achieve the initiatives it has announced.", -0.7], ["Because customers’ preferences may change quickly, our new and existing products may not generate sales in sufficient quantities and at costs low enough to be profitable and recoup investment costs.", -0.8], ["Offering vehicles and services that customers want and value can mitigate the risks of increasing price competition and declining demand, but products and services that are perceived to be less desirable (whether in terms of price, quality, styling, safety, overall value, fuel efficiency, or other attributes) can exacerbate these risks.", -0.6], ["For example, if we are unable to differentiate our products and services from those of our competitors, develop innovative new products and services, or sufficiently tailor our products and services to customers in other markets, there could be insufficient demand for our products and services, which could have an adverse impact on our financial condition or results of operations.", -0.7], ["With increased consumer interconnectedness through the internet, social media, and other media, mere allegations relating to quality, safety, fuel efficiency, sustainability, corporate social responsibility, or other key attributes can negatively impact our reputation or market acceptance of our products or services, even where such allegations prove to be inaccurate or unfounded.", -0.8], ["This level of competition increases the importance of our ability to anticipate, develop, and deliver products and services that customers desire on a timely basis, in quantities in line with demand, and at costs low enough to be profitable.", 0.2], ["If the market for electrified vehicles does not develop at the rate we expect, even if the regulatory framework encourages a rapid adoption of electrified vehicles, there is a negative perception of our vehicles or about electric vehicles in general, or if consumers prefer our competitors’ vehicles, there could be an adverse impact on our financial condition or results of operations.", -0.9], ["Achievement of these initiatives will require significant investments and the implementation of new processes; however, there is no assurance that the desired outcomes will be achieved.", -0.7], ["To the extent we are unable to achieve these initiatives or our transition to electrification is slower than expected, it may harm our reputation or we may not otherwise receive the expected return on the investment.", -0.8], ["For example, we are exposed to reputational risk if we do not reduce vehicle CO2 emissions in line with our targets or in compliance with applicable regulations.", -0.6], ["Further, our customers and investors evaluate how well we are progressing on our announced climate goals and aspirations, and if we are not on track to achieve those goals and aspirations on a timely basis, or if the expectations of our customers and investors change and we do not adequately address their expectations, our reputation could be impacted, and customers may choose to purchase the products and services of, investors may choose to invest in, and suppliers and vendors may choose to do business with other companies.", -0.7], ["Ford’s results are dependent on sales of larger, more profitable vehicles, particularly in the United States.", 0.3], ["A shift in consumer preferences away from larger, more profitable vehicles with internal combustion engines (including trucks and utilities) to electric or other vehicles in our portfolio that may be less profitable could result in an adverse effect on our financial condition or results of operations.", -0.8], ["If demand for electric vehicles grows at a rate greater than our ability to increase our production capacity for those vehicles, lower market share and revenue, as well as facility and other asset-related charges (e.g., accelerated depreciation) associated with the production of internal combustion vehicles, may result.", -0.9], ["In addition, government regulations aimed at reducing emissions and increasing fuel efficiency (e.g., ZEV mandates and low emission zones) and other factors that accelerate the transition to electric vehicles may increase the cost of vehicles by more than the perceived benefit to consumers and dampen margins.", -0.8], ["With a global footprint, Ford’s results could be adversely affected by economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events.", -0.7], ["Because of the interconnectedness of the global economy, the challenges of a pandemic, a financial crisis, economic downturn or recession, natural disaster, war, geopolitical crises, or other significant events in one area of the world can have an immediate and material adverse impact on markets around the world.", -0.9], ["Changes in international trade policy can also have a substantial adverse effect on our financial condition or results of operations.", -0.8], ["Steps taken by governments to apply or consider applying tariffs on automobiles, parts, and other products and materials have the potential to disrupt existing supply chains, impose additional costs on our business, and may lead to other countries attempting to retaliate by imposing tariffs, which would make our products more expensive for customers, and, in turn, could make our products less competitive.", -0.8], ["This may expose us to heightened risks as a result of economic, geopolitical, or other events, including governmental takeover (i.e., nationalization) of our manufacturing facilities or intellectual property, restrictive exchange or import controls, disruption of operations as a result of systemic political or economic instability, outbreak of war or expansion of hostilities (such as the actions taken by Russia in Ukraine), and acts of terrorism, each of which could impact our supply chain as well as our operations and have a substantial adverse effect on our financial condition or results of operations.", -0.9], ["Industry sales volume can be volatile and could decline if there is a financial crisis, recession, or significant geopolitical event.", -0.7], ["Because we, like other manufacturers, have a higher proportion of fixed structural costs, relatively small changes in industry sales volume can have a substantial effect on our cash flow and results of operations.", -0.7], ["If industry vehicle sales were to decline to levels significantly below our planning assumption, the decline could have a substantial adverse effect on our financial condition, results of operations, and cash flow.", -0.8], ["Ford may face increased price competition or a reduction in demand for its products resulting from industry excess capacity, currency fluctuations, competitive actions, or other factors.", -0.7], ["As a result, we are not necessarily able to set our prices to offset higher marketing incentives, commodity or other cost increases, tariffs, or the impact of adverse currency fluctuations.", -0.8], ["Further, higher inventory levels put downward pressure on pricing, which may have an adverse effect on our financial condition and results of operations.", -0.7], ["This excess capacity may further increase price competition in that segment of the market, which could have a substantial adverse effect on our financial condition or results of operations.", -0.8], ["Inflationary pressure and fluctuations in commodity and energy prices, foreign currency exchange rates, interest rates, and market value of Ford or Ford Credit’s investments, including marketable securities, can have a significant effect on results.", -0.6], ["As a result, significant changes in commodity and energy prices, foreign currency exchange rates, or interest rates as well as increased material, freight, logistics, and similar costs could have a substantial adverse effect on our financial condition or results of operations.", -0.8], ["For example, interest rates have increased significantly as central banks in developed countries attempt to subdue inflation while government deficits and debt remain at high levels in many global markets.", -0.5], ["Accordingly, the eventual implications of higher government deficits and debt, tighter monetary policy, and potentially higher long-term interest rates may drive a higher cost of capital for the business.", -0.6], ["At Ford Credit, rising interest rates may impact Ford Credit’s ability to source funding and offer financing at competitive rates, which could reduce its financing margin.", -0.7], ["In addition, our results are impacted by fluctuations in the market value of our investments, with unrealized gains and losses that could be material in any period.", -0.6], ["Ford and Ford Credit’s access to debt, securitization, or derivative markets around the world at competitive rates or in sufficient amounts could be affected by credit rating downgrades, market volatility, market disruption, regulatory requirements, or other factors.", -0.7], ["Ford and Ford Credit’s ability to obtain unsecured funding at a reasonable cost is dependent on their credit ratings or their perceived creditworthiness.", -0.2], ["Further, Ford Credit’s ability to obtain securitized funding under its committed asset-backed liquidity programs and certain other asset-backed securitization transactions is subject to having a sufficient amount of assets eligible for these programs, as well as Ford Credit’s ability to obtain appropriate credit ratings and, for certain committed programs, derivatives to manage the interest rate risk.", -0.3], ["A significant reduction in the amount of receivables Ford Credit purchases or originates would significantly reduce its ongoing results of operations and could adversely affect its ability to support the sale of Ford vehicles.", -0.7], ["Furthermore, in addition to rising interest rates adversely affecting overall economic activity and the financial condition of our customers, increases in interest rates could cause credit market disruptions, which have historically resulted in higher borrower costs and made it more difficult to access the markets, obtain financing on favorable terms, and fund our operations.", -0.8], ["The impact of government incentives on Ford’s business could be significant, and Ford’s receipt of government incentives could be subject to reduction, termination, or clawback.", -0.6], ["A decrease in, expiration without renewal of, or other cessation or clawback of government incentives for any of our business units, as a result of administrative decision or otherwise, could have a substantial adverse impact on our financial condition or results of operations.", -0.7], ["As a result, the performance of our South American operations had been impacted favorably by government incentives to a substantial extent.", 0.5], ["The IRA’s incentives are having and are expected to have material impacts on the automotive industry and Ford.", 0.3], ["Ford expects that many customers will be able to monetize the commercial clean vehicle credit in light of Ford’s range of electrified product offerings for commercial applications.", 0.7], ["Although we ultimately expect the IRA to benefit Ford and the automotive industry in general, the availability of such benefits will depend on the further development and improvement of the U.S. battery supply, sufficient access to raw materials within the scope of the IRA, and the terms of the regulations and guidance (and the limitations therein) the U.S. government issues to implement the IRA, which will ultimately determine which vehicles qualify for incentives and the amount thereof.", 0.2], ["For example, in late 2022 interim guidance was released on how to apply the MSRP limitations to the retail clean vehicle credit, and subjected a significant number of SUVs to a lower MSRP limitation than the industry expected, thereby excluding vehicles that may otherwise be eligible for the credit.", -0.5], ["Automakers that better optimize eligibility for their vehicles, as compared to their competition, will have a competitive advantage.", 0.5], ["Ford Credit could experience higher-than-expected credit losses, lower-than-anticipated residual values, or higher-than-expected return volumes for leased vehicles.", -0.7], ["Credit risk is the possibility of loss from a customer’s or dealer’s failure to make payments according to contract terms.", -0.6], ["Credit risk (which is heavily dependent upon economic factors including unemployment, consumer debt service burden, personal income growth, dealer profitability, and used car prices) has a significant impact on Ford Credit’s business.", -0.6], ["The level of credit losses Ford Credit may experience could exceed its expectations and adversely affect its financial condition or results of operations.", -0.8], ["Actual proceeds realized by Ford Credit upon the sale of returned leased vehicles at lease termination may be lower than the amount projected, which would reduce Ford Credit’s return on the lease transaction.", -0.7], ["In 2022, Ford Credit experienced lower-than-expected return volumes.", 0.2], ["If auction values decrease significantly in the future, return volumes could exceed Ford Credit’s expectations.", -0.7], ["Each of these factors, alone or in combination, has the potential to adversely affect Ford Credit’s results of operations if actual results were to differ significantly from Ford Credit’s projections.", -0.6], ["Economic and demographic experience for pension and OPEB plans (e.g., discount rates or investment returns) could be worse than Ford has assumed.", -0.8], ["We generally remeasure these estimates at each year end and recognize any gains or losses associated with changes to our plan assets and liabilities in the year incurred.", 0.0], ["recognize a remeasurement loss in our results, which could be substantial.", -0.7], ["Pension and other postretirement liabilities could adversely affect Ford’s liquidity and financial condition.", -0.9], ["These benefit plans impose significant liabilities on us and could require us to make additional cash contributions, which could impair our liquidity.", -0.8], ["If our cash flows and capital resources are insufficient to meet any pension or OPEB obligations, we could be forced to reduce or delay investments and capital expenditures, suspend dividend payments, seek additional capital, or restructure or refinance our indebtedness.", -0.9], ["Government investigations against Ford or Ford Credit could result in fines, penalties, or orders that could have an adverse impact on our financial condition, results of operations, or the operation of our business.", -0.9], ["Litigation also is inherently uncertain, and we could experience significant adverse results, including compensatory and punitive damage awards, a disgorgement of profits or revenue, or injunctive relief, any of which could have an adverse effect on our financial condition, results of operations, or our business in general.", -0.9], ["In addition, adverse publicity surrounding an allegation may cause significant reputational harm that could have a significant adverse effect on our sales.", -0.8], ["Similarly, we are making substantial investments in our facilities and revising our processes to not only comply with applicable regulations but also to make our operations more efficient and sustainable.", 0.2], ["As our suppliers make similar investments, those higher costs may be passed on to us.", -0.5], ["If fuel prices are relatively low and market conditions do not drive consumers to purchase electric vehicles and other highly fuel-efficient vehicles in large numbers, it may be difficult to meet applicable environmental standards without compromising results.", -0.7], ["Moreover, a production disruption, stop ship, limited availability of necessary components, e.g., batteries or the raw materials necessary for their production, lower than planned market acceptance of our vehicles, or other intervening events may cause us to modify our product plans, or, in some cases, purchase credits, in order to comply with standards regarding fuel economy and air pollution, which could have an adverse effect on our financial condition or results of operations and/or cause reputational harm.", -0.8], ["The cost to comply with existing government regulations (in addition to the cost of any field service actions that may result from regulatory actions) is substantial and additional regulations, changes in regulatory interpretations, or changes in consumer preferences that affect vehicle mix, as well as a non-compliance with applicable laws and regulations, could have a substantial adverse impact on our financial condition or results of operations.", -0.9], ["The protocols could change, and any negative perception regarding the performance of our vehicles subjected to such tests could reduce future sales.", -0.6], ["The evolution of the regulatory framework for autonomous vehicles, and the pace of the development of such regulatory framework, may subject us to increased costs and uncertainty, and may ultimately impact our ability to deliver autonomous vehicles and related services that customers want.", -0.7], ["Ford and Ford Credit could be affected by the continued development of more stringent privacy, data use, and data protection laws and regulations as well as consumers’ heightened expectations to safeguard their personal information.", -0.6], ["Accordingly, complying with such laws and regulations may lead to a decline in consumer engagement or cause us to incur substantial costs to modify our operations or business practices.", -0.8], ["Moreover, regulatory actions seeking to impose significant financial penalties for noncompliance and/or legal actions (including pursuant to laws providing for private rights of action by consumers) could be brought against us in the event of a data compromise, misuse of consumer information, or perceived or actual non-compliance with data protection or privacy requirements.", -0.9], ["Further, any unauthorized release of personal information could harm our reputation, disrupt our business, cause us to expend significant resources, and lead to a loss of consumer confidence resulting in an adverse impact on our business and/or consumers deciding to withhold or withdraw consent for our collection or use of data.", -0.9], ["As a finance company, Ford Credit is highly regulated by governmental authorities in the locations in which it operates, which can impose significant additional costs and/or restrictions on its business.", -0.5], ["Exercise of these powers by the CFPB may increase the costs of, impose additional restrictions on, or otherwise adversely affect companies in the automotive finance business.", -0.7], ["Failure to comply with applicable laws and regulations could subject Ford Credit to regulatory enforcement actions, including consent orders or similar orders where Ford Credit may be required to revise practices, remunerate customers, or pay fines.", -0.8], ["An enforcement action against Ford Credit could harm Ford Credit’s reputation or lead to further litigation.", -0.9], ["Individual product liability matters that have more than a remote risk of loss and such loss would likely be significant if the matter is resolved unfavorably to us would be described herein.", -0.6], ["During the second trial in August 2022, a jury found that Pep Boys (the party that sold the tires on the vehicle involved in the rollover accident) was responsible for 30% of the damages, and Ford, as a direct result of the sanctions order prohibiting Ford from presenting its defense, was responsible for 70% of the damages, resulting in $16.8 million in damages being apportioned to Ford.", -0.7], ["The jury subsequently awarded punitive damages against Ford in the amount of $1.7 billion.", -0.9], ["The extent of our financial exposure to asbestos litigation remains very difficult to estimate and could include both compensatory and punitive damage awards.", -0.8], ["Annual payout and defense costs may become significant in the future.", -0.7], ["Our accrual for asbestos matters includes probable losses for both asserted and unasserted claims.", -0.6], ["We are a defendant in numerous actions in state and federal courts alleging breach of warranty and claiming damages based on state and federal consumer protection laws.", -0.9], ["We are currently a defendant in a significant number of litigation matters relating to the performance of vehicles, including those equipped with DPS6 transmissions.", -0.8], ["The amount of any such costs or damages for which we may be held responsible could be significant.", -0.7], ["(ii) have more than a remote risk of loss, and such loss would likely be significant if the action is resolved unfavorably to us.", -0.8], ["One Brazilian state (São Paulo) and the Brazilian federal tax authority currently have outstanding substantial tax assessments against Ford Motor Company Brasil Ltda.", -0.9], ["If we are required to post collateral, which could be in excess of $1 billion, we expect it to be in the form of fixed assets, surety bonds, and/or letters of credit, but we may be required to post cash collateral.", -0.8], ["Although the ultimate resolution of these matters may take many years, we consider our overall risk of loss to be remote.", 0.2], ["U.S. Customs and Border Protection (“CBP”) ruled in 2013 that Transit Connects imported as passenger wagons and later converted into cargo vans are subject to the 25% duty applicable to cargo vehicles, rather than the 2.5% duty applicable to passenger vehicles.", -0.5], ["Following the U.S. Supreme Court’s denial of our petition for a writ of certiorari in 2020, we paid the increased duties for certain prior imports, plus interest, and disclosed that CBP might assert a claim for penalties.", -0.7], ["Subsequently, CBP issued a penalty notice to us dated July 22, 2021, and on November 18, 2021, CBP assessed against us a monetary penalty of $1.3 billion and additional duties of $181 million, plus interest.", -0.9], ["In the fourth quarter of 2022, we completed a modest anti-dilutive share repurchase program to offset the dilutive effect of share-based compensation granted during 2022.", -0.1], ["On February 2, 2023, we declared a regular dividend of $0.15 per share and a supplemental dividend of $0.65 per share.", 0.5], ["The impact of COVID-19, including changes in consumer behavior, pandemic fears and market downturns, and restrictions on business and individual activities, has created significant volatility in the global economy.", -0.8], ["Our inconsistent production schedule has been disruptive to our suppliers’ operations, which, in turn, has led to higher costs and production shortfalls.", -0.9], ["Over the last year, prices of both new and used vehicles have increased substantially due to strong demand, supply shortages, and inflationary costs.", -0.7], ["We have already observed some moderation in the rate of price increases as auto production slowly recovers from the semiconductor shortage, but it is unclear whether prices will decline fully to pre- COVID-19 pandemic levels.", -0.3], ["Over the long term, intense competition and excess capacity are likely to put downward pressure on inflation-adjusted prices for similarly-contented vehicles and contribute to a challenging pricing environment for the automotive industry in most major markets.", -0.6], ["In some cases, spot prices for various commodities have recently diverged somewhat, as anticipated weakening in global industrial activity mitigates price increases for base metals such as steel and aluminum, while precious metals (e.g., palladium), and raw materials that are used in batteries for electric vehicles (e.g., lithium, cobalt, nickel, graphite, and manganese, among other materials, for batteries) remain high.", -0.4], ["The net impact on us and our suppliers has been higher material costs overall.", -0.7], ["Our financial results depend on the profitability of the vehicles we sell, which may vary significantly by vehicle line.", -0.5], ["In general, larger vehicles tend to command higher prices and be more profitable than smaller vehicles, both across and within vehicle segments.", 0.5], ["For example, in North America, our larger, more profitable vehicles had an average contribution margin that was 120% of our total average contribution margin across all vehicles, whereas our smaller vehicles had significantly lower contribution margins.", 0.5], ["In addition, government regulations aimed at reducing emissions and increasing fuel efficiency (e.g., ZEV mandates and low emission zones), and other factors that accelerate the transition to electrified vehicles, may increase the cost of vehicles by more than the perceived benefit to consumers and dampen margins.", -0.5], ["To the extent governments in various regions implement or intensify barriers to imports, such as erecting tariff or non-tariff barriers or manipulating their currency, and provide advantages to local exporters selling into the global marketplace, there can be a significant negative impact on manufacturers based in other markets.", -1.0], ["We continue to see near-term impacts on our business due to inflation, including ongoing global price pressures in the wake of Russia’s invasion of Ukraine, driving up energy prices, freight premiums, and other operating costs above normal rates.", -1.0], ["Although headline inflation in the United States and Europe appears to have peaked, as gasoline and natural gas prices recede from the latest spike, core inflation (excluding food and energy prices) remains elevated and is a source of continued cost pressure on businesses and households.", -0.5], ["Interest rates have increased significantly as central banks in developed countries attempt to subdue inflation while government deficits and debt remain at high levels in many global markets.", -0.5], ["Accordingly, the eventual implications of higher government deficits and debt, tighter monetary policy, and potentially higher long-term interest rates may drive a higher cost of capital for the business.", -0.5], ["At Ford Credit, rising interest rates may impact its ability to source funding and offer financing at competitive rates, which could reduce its financing margin.", -0.5], ["Annual production volumes are heavily impacted by external economic factors, including the pace of economic growth and factors such as the availability of consumer credit and cost of fuel.", -0.5], ["As a result, we analyze the profit impact of certain cost changes holding constant present-year volume and mix and currency exchange, in order to evaluate our cost trends absent the impact of varying production and currency exchange levels.", -0.1], ["Contribution Costs – these costs typically vary with production volume.", 0.0], ["On the other hand, while labor costs do not vary directly with production volume, manufacturing labor costs may be impacted by changes in volume, for example when we increase overtime, add a production shift, or add personnel to support volume increases.", -0.1], ["The net loss attributable to Ford Motor Company was $1,981 million in 2022.", -1.0], ["We recorded $12.2 billion of pre-tax special item charges in 2022, driven by a $7.4 billion mark-to-market net loss on our Rivian investment and a $2.7 billion impairment on our Argo investment.", -1.0], ["In 2022, our diluted earnings per share of Common and Class B Stock was a loss of $0.49 and our diluted adjusted earnings per share was $1.88.", -0.8], ["Net income/(loss) margin was negative 1.3% in 2022, down from 13.2% a year ago.", -1.0], ["Company adjusted EBIT margin was 6.6% in 2022, down from 7.3% a year ago.", -0.5], ["The year-over-year decrease of $19.9 billion in net income/(loss) in 2022 includes the effect of special items, including the mark-to-market net loss on our Rivian investment and the impairment on our Argo investment, and lower Ford Credit EBT, partially offset by higher Automotive EBIT.", -1.0], ["The year-over-year increase of $400 million in Company adjusted EBIT primarily reflects higher Automotive EBIT, offset partially by lower Ford Credit EBT.", 0.2], ["In 2022, wholesales in our Automotive segment increased 7% from a year ago, primarily reflecting stronger wholesales in North America.", 0.7], ["Full year 2022 Automotive revenue increased 18%, driven by higher wholesales and net pricing, offset partially by weaker currencies.", 0.6], ["Our full year 2022 Automotive segment EBIT was $9.7 billion, an increase of $2.3 billion from a year ago, with an EBIT margin of 6.5%.", 0.8], ["The EBIT improvement was driven by higher net pricing and higher wholesales, offset partially by inflationary increases on commodity, material, and freight costs, higher structural costs (including growth-related investments), unfavorable mix, weaker currencies, and higher warranty costs.", 0.2], ["In North America, 2022 wholesales increased 16% from a year ago, primarily reflecting an improvement in production- related supply constraints and a full year of Bronco and Maverick production.", 0.7], ["Full year 2022 revenue increased 24%, driven by higher wholesales and net pricing.", 0.7], ["North America’s 2022 EBIT was $9.2 billion, an increase of $1.8 billion from a year ago, with an EBIT margin of 8.4%.", 0.8], ["The EBIT improvement was driven by higher net pricing and higher wholesales, offset partially by inflationary increases on commodity, material, and freight costs, higher structural costs, unfavorable mix, and higher warranty costs.", 0.2], ["In South America, 2022 wholesales increased 3% from a year ago.", 0.5], ["Full year 2022 revenue increased 29%, driven by higher net pricing, offset partially by weaker currencies.", 0.6], ["South America’s 2022 EBIT was $413 million, an increase of $534 million from a year ago, with an EBIT margin of 13.4%.", -1.0], ["The EBIT improvement was driven by higher net pricing, offset partially by inflationary increases on material, commodity, and freight costs.", 0.5], ["The strong results in South America reflect our restructuring efforts and pricing and were further aided by a balance sheet revaluation in Argentina, the effect of which is not expected to be sustained.", 0.0], ["In Europe, 2022 wholesales increased 14% from a year ago, primarily reflecting an improvement in production-related supply constraints.", 0.5], ["Full year 2022 revenue improved 5%, driven by higher wholesales and net pricing, offset partially by weaker currencies.", 0.5], ["Europe’s 2022 EBIT was $47 million, an improvement of $201 million from a year ago, with an EBIT margin of 0.2%.", 0.5], ["The EBIT improvement was driven by higher net pricing and higher wholesales, offset partially by inflationary increases on commodity, material, and freight costs, higher structural costs, and weaker currencies.", 0.0], ["In China, 2022 wholesales decreased 24% from a year ago, driven by COVID-related restrictions and a weaker", -0.5], ["Full year 2022 revenue at our consolidated operations decreased 31%, primarily driven by lower component sales to our joint ventures in China and lower wholesales.", -0.5], ["China’s 2022 EBIT loss was $572 million, a $245 million higher loss than a year ago, with an EBIT margin of negative 32.3%.", -1.0], ["The EBIT decrease was driven by lower volume and weaker currency, offset partially by lower costs and higher profits at our joint ventures.", -0.5], ["In our International Markets Group, 2022 wholesales decreased 3% from a year ago, primarily reflecting our India restructuring and suspension of our joint venture in Russia, offset partially by the positive impact of the next-generation Ranger and Everest launches.", -0.2], ["Full year 2022 revenue increased 10%, driven by market mix and higher net pricing, offset partially by weaker currencies.", 0.5], ["Our International Market Group’s 2022 EBIT was $628 million, an increase of $6 million from a year ago, with an EBIT margin of 6.4%.", 0.2], ["The EBIT increase was driven by higher net pricing and higher wholesales, offset partially by inflationary increases on commodity, material, and freight costs, weaker currencies, and lower joint venture profits and royalties.", 0.1], ["In our Mobility segment, our 2022 EBIT loss improved $104 million from a year ago.", 0.3], ["The $926 million EBIT loss reflects our strategic investments in our autonomous vehicle capabilities and support of our mobility initiatives.", -0.4], ["In the third quarter of 2022, we made the strategic decision to shift our capital spending from L4 technology being developed by Argo AI to advanced L2/L3 systems, which we believe will ultimately be essential to achieve profitable commercialization of L4 autonomy at scale in the future.", 0.4], ["Additionally, because of the significant additional capital and time required to achieve commercialization of L4, as well as other macroeconomic factors, Argo AI has been unable to attract new investors.", -0.7], ["After performing external outreach in the third quarter to assess market interest in acquiring either Argo AI or its technology components and conducting internal reviews to evaluate opportunities to leverage Argo AI’s technology, Ford determined that Argo AI no longer has value as a going concern.", -0.8], ["As a result, we reassessed the carrying value of our investment in Argo AI starting from September 30, 2022, and in October, Ford and VW initiated the process of exiting the joint development of L4 technology through Argo AI.", -0.5], ["Accordingly, in the second half of 2022, we recorded as a special item a", -0.8], ["$2.7 billion pre-tax impairment on our Argo AI investment, and on October 26, 2022, we announced that Argo AI plans to wind down operations, which is in progress.", -0.9], ["Total net receivables at December 31, 2022 were $5 billion higher than a year ago, primarily reflecting higher non- consumer financing, offset partially by fewer operating leases, lower consumer financing, and currency exchange rates.", 0.2], ["Ford Credit’s loss metrics reflected healthy and stable consumer credit conditions and strong auction values.", 0.7], ["36-month auction values for off-lease vehicles were up 8% from a year ago, reflecting strong demand for used vehicles, including the impact of lower new vehicle production due to the semiconductor shortage.", 0.6], ["We are planning for full year 2023 auction values to decrease as supply constraints improve.", -0.2], ["Ford Credit’s 2022 EBT of $2,657 million was $2,060 million lower than a year ago, reflecting lower credit loss and lease residual reserve releases, lower financing margin, and lower lease return rates.", -0.7], ["Financing margin changes are driven by changes in revenue and interest expense.", 0.0], ["Net charge-off changes are primarily driven by the number of repossessions, severity per repossession, and recoveries.", -0.3], ["Changes in the allowance for credit losses are primarily driven by changes in historical trends in credit losses and recoveries, changes in the composition and size of Ford Credit’s present portfolio, changes in trends in historical used vehicle values, and changes in forward looking macroeconomic conditions.", -0.1], ["Residual gain and loss changes are primarily driven by the number of vehicles returned to Ford Credit and sold, and the difference between the auction value and the depreciated value (which includes both base and accumulated supplemental depreciation) of the vehicles sold.", -0.1], ["Depreciation on vehicles subject to operating leases includes early termination losses on operating leases due to customer default events.", -0.3], ["Reflects changes in EBT driven by the effects of converting functional currency income to U.S. dollars", 0.0], ["In general, other income/(loss) changes are primarily driven by changes in earnings related to market valuation adjustments to derivatives (primarily related to movements in interest rates) and other miscellaneous items", -0.1], ["Ford Credit holds the right to receive the excess cash flows not needed to pay the debt issued by, and other obligations of, the securitization entities that are parties to those securitization transactions", 0.1], ["Earnings Before Taxes (“EBT”) – Reflects Ford Credit’s income before income taxes", 0.2], ["Loss-to-Receivables (“LTR”) Ratio – LTR ratio is calculated using net charge-offs divided by average finance receivables, excluding unearned interest supplements and the allowance for credit losses", -0.2], ["Return on Equity (“ROE”) (as shown in the Key Metrics table) – Reflects return on equity calculated by annualizing net income for the period and dividing by monthly average equity for the period", 0.2], ["Corporate Other primarily includes corporate governance expenses, interest income (excluding interest earned on our extended service contract portfolio that is included in our Automotive segment) and gains and losses from our cash, cash equivalents, and marketable securities (excluding gains and losses on investments in equity securities), and foreign exchange derivatives gains and losses associated with intercompany lending.", 0.0], ["For full year 2022, Corporate Other had a $1,008 million loss, compared with a $1,084 million loss in 2021.", -0.1], ["The improvement was driven by higher Automotive interest income due to higher interest rates (primarily Fed Funds).", 0.5], ["Our full year 2022 interest expense on Company debt excluding Ford Credit was $1,259 million, $544 million lower than in 2021, primarily explained by", 0.3], ["Our Provision for/(Benefit from) income taxes for full year 2022 was a $864 million benefit, resulting in an effective tax rate of 28.6%.", 0.2], ["Any future changes to our structure, as well as any changes in income tax laws in the countries that we operate, could cause increases or decreases to our deferred tax balances and related valuation allowances.", -0.3], ["The net income attributable to Ford Motor Company was $17,937 million in 2021.", 0.8], ["For full year 2021, we recorded $9.6 billion of pre-tax special items, primarily reflecting gains on our equity investment in Rivian in connection with Rivian’s initial public offering and mark-to-market valuation adjustments during the year, as well as a remeasurement gain associated with our global pension and OPEB plans.", 0.6], ["The gains were partially offset by costs associated with our Global Redesign actions and a debt extinguishment premium associated with the repurchase and redemption of $7.6 billion of our higher-coupon debt.", -0.2], ["In 2021, our diluted earnings per share of Common and Class B Stock was $4.45 and our diluted adjusted earnings per share was $1.59.", 0.7], ["Net income/(loss) margin was 13.2% in 2021, up from negative 1.0% in 2020.", 0.7], ["Company adjusted EBIT margin was 7.3% in 2021, up from 2.0% in 2020.", 0.8], ["The year-over-year increase of $19.2 billion in net income/(loss) in 2021 includes the effect of special items, including the Rivian IPO and mark-to-market gain, as well as higher Automotive EBIT and Ford Credit EBT.", 0.6], ["The year-over-year increase of $7.5 billion in Company adjusted EBIT was driven by higher Automotive EBIT and Ford Credit EBT.", 0.7], ["In 2021, wholesales in our Automotive segment declined 6% from 2020, reflecting semiconductor-related production constraints and the shift to a new business model in South America.", -0.3], ["Full year 2021 Automotive revenue increased 9% from 2020, driven by higher net pricing, favorable mix, and stronger currencies, partially offset by lower wholesales.", 0.7], ["Our full year 2021 Automotive segment EBIT increased $5.7 billion from 2020 with an EBIT margin of 5.9 percent.", 0.7], ["The EBIT improvement was driven by higher net pricing (reflecting the strength of our product portfolio and lower incentives in response to reduced dealer stock levels), lower warranty expense, favorable mix, higher profits from our Ford Customer Service Division business, and stronger currencies, partially offset by lower wholesales and increased commodity costs.", 0.6], ["In North America, 2021 wholesales declined 4% from 2020, primarily reflecting the impact of semiconductor-related production constraints.", -0.4], ["Full year 2021 revenue increased 10% from 2020, driven by higher net pricing, favorable mix, and stronger currencies, partially offset by lower wholesales.", 0.7], ["North America’s 2021 EBIT increased $3.7 billion from 2020 with an EBIT margin of 8.4%.", 0.8], ["The EBIT improvement was driven by higher net pricing, lower warranty expense, and favorable mix, partially offset by increased commodity prices, lower volume, and higher structural costs.", 0.2], ["In South America, 2021 wholesales declined 56% from 2020, primarily reflecting the shift to the region’s new business model and the impact of semiconductor-related production constraints.", -0.6], ["Full year 2021 revenue declined 3% from 2020, driven by lower volume and weaker currencies, partially offset by higher net pricing and favorable mix.", -0.2], ["South America’s 2021 EBIT loss improved $369 million from 2020 with an EBIT margin of negative 5.1%.", -0.3], ["The EBIT improvement was driven by higher net pricing, partially offset by lower volume.", 0.1], ["In Europe, 2021 wholesales declined 13% from 2020, primarily reflecting the impact of semiconductor-related production constraints.", -0.4], ["Full year 2021 revenue improved 8% from 2020, driven by favorable mix, stronger currencies, and higher net pricing, partially offset by lower volume.", 0.3], ["Europe’s 2021 EBIT loss improved $697 million from 2020 with an EBIT margin of negative 0.6%.", -0.1], ["The EBIT improvement was driven by higher net pricing, lower material and warranty expenses, and lower structural costs, partially offset by lower volume and increased commodity prices.", 0.2], ["In China, 2021 wholesales increased 5% from 2020, driven by higher joint venture volumes.", 0.5], ["Full year 2021 consolidated revenue declined 20% from 2020, driven by product localization and the de-consolidation of our operations in Taiwan, partially offset by favorable import mix, higher component sales to our joint ventures in China, and stronger currencies.", -0.5], ["China’s 2021 EBIT loss improved $172 million from 2020 with an EBIT margin of negative 12.8%.", -0.2], ["The EBIT improvement was driven by favorable mix of imported vehicles, higher joint venture profits and royalties, and higher net pricing, partially offset by lower volume at our consolidated operations.", 0.3], ["In our International Markets Group, 2021 wholesales increased 11% from 2020, reflecting the non-recurrence of the COVID-related production suspension and higher industry volumes, partially offset by the impact of semiconductor-related supply constraints.", 0.2], ["Full year 2021 revenue increased 19% from 2020, driven by higher volume and mix, higher net pricing, and stronger currencies.", 0.8], ["Our International Markets Group’s 2021 EBIT improved $786 million from 2020 with an EBIT margin of 6.9%.", 0.9], ["The EBIT improvement was driven by stronger currencies, higher net pricing and volume, and lower warranty expense.", 0.7], ["In our Mobility segment, our 2021 EBIT loss improved $22 million from 2020.", 0.1], ["The $1 billion EBIT loss reflected our strategic investments in 2021 as we continued to expand our capabilities in autonomous vehicles and mobility businesses.", -0.3], ["Total net receivables at December 31, 2021 were $14 billion lower than at December 31, 2020, primarily reflecting lower wholesale receivables as a result of lower dealer inventories due to the semiconductor shortage.", -0.4], ["Ford Credit’s loss metrics reflected healthy and stable consumer credit conditions and strong auction values.", 0.8], ["Ford Credit’s U.S. 36-month auction values for off-lease vehicles were up 26% from 2020, reflecting strong demand for used vehicles, including the impact of lower new vehicle production due to the semiconductor shortage.", 0.7], ["Ford Credit’s 2021 EBT increased $2,109 million from 2020, explained primarily by favorable operating lease residual performance, the non-recurrence of the 2020 increase to the credit loss reserve due to deterioration in macroeconomic conditions related to COVID-19, and reductions in the credit loss reserve in 2021, partially offset by lower volume driven by the impact of the global semiconductor shortage and lower financing margin.", 0.5], ["For full year 2021, Corporate Other had a $1,084 million loss, compared with a $726 million loss in 2020.", -0.6], ["The higher loss was driven by lower interest income and higher administrative and IT-related expenses.", -0.7], ["Our full year 2021 interest expense on Company debt excluding Ford Credit was $1,803 million, $154 million higher than in 2020, primarily explained by higher U.S. unsecured debt interest expense.", -0.5], ["Our Provision for/(Benefit from) income taxes for full year 2021 was a $130 million benefit, resulting in an effective tax rate of negative 0.7%.", 0.2], ["This includes a benefit of $2.9 billion to recognize deferred tax assets resulting from changes in our global tax structure and a $918 million benefit from the reversal of U.S. valuation allowances.", 0.4], ["In 2022, we sold approximately 91 million of our Rivian shares resulting in proceeds of about $3 billion.", 0.6], ["As marketable securities increase or decrease in value, Company cash and liquidity will likewise increase or decrease.", 0.0], ["Subject to approval by our Board of Directors, shareholder distributions in the form of dividend payments and/or a share repurchase program (including share repurchases to offset the anti-dilutive effect of increased shared-based compensation) may require the expenditure of a material amount of cash.", -0.2], ["We are party to many contractual obligations involving commitments to make payments to third parties, and, as noted above, such commitments require a material amount of cash.", -0.3], ["As of December 31, 2022, our forecasted expenditures for the maximum quantity that may be purchased under these offtake agreements, which are subject to satisfaction of the conditions in the agreements, total about $2.4 billion through 2029 based on our present pricing forecast; however, our forecasted prices could fluctuate significantly from period to period, which would result in volatility in the estimate of our overall obligation.", -0.4], ["In addition, we plan to continue to enter into offtake agreements with raw material suppliers, the costs under which we expect to be significant.", -0.5], ["As a result, our cash flow deteriorates if wholesale volumes (and the corresponding revenue) decrease while trade payables continue to become due.", -0.7], ["Conversely, our cash flow improves if wholesale volumes (and the corresponding revenue) increase while new trade payables are generally not due for about 45 days.", 0.3], ["For example, the suspension of production at most of our assembly plants and lower industry volumes due to COVID-19 in early 2020 resulted in an initial deterioration of our cash flow, while the subsequent resumption of manufacturing operations and return to pre-COVID-19 production levels at most of our assembly plants resulted in a subsequent improvement of our cash flow.", 0.2], ["For example, we typically experience cash flow timing differences associated with inventories and payables due to our annual summer and December shutdown periods when production, and therefore inventories and wholesale volumes, are usually at their lowest levels, while payables continue to come due and be paid.", -0.4], ["The net impact of this typically results in cash outflows from changes in our working capital balances during these shutdown periods.", -0.6], ["Our finished product inventory at December 31, 2022 was higher year over year due to production and release scheduling, which resulted in higher sales inventory, in-transit inventory, and units awaiting upfit.", 0.1], ["Such actions could have a short-term adverse impact on our cash and increase our inventory.", -0.5], ["Moreover, in order to secure critical materials for production of electric vehicles, we have entered into and plan to continue to enter into offtake agreements with raw material suppliers and make investments in certain raw material and battery suppliers, including contributing up to $6.6 billion in capital to BlueOval SK, LLC over a five-year period ending in 2026.", 0.7], ["Such investments, which are part of our plan to invest over $50 billion in electric vehicles through 2026, could have an additional adverse impact on our cash in the near-term.", -0.4], ["Financial institutions participate in a supply chain finance (“SCF”) program that enables our suppliers, at their sole discretion, to sell their Ford receivables (i.e., our payment obligations to the suppliers) to the financial institutions on a non- recourse basis in order to be paid earlier than our payment terms provide.", 0.2], ["2021 includes our investment in Rivian of $10.6 billion and cash premium paid of $(1.6) billion associated with repurchasing and redeeming $7.6 billion of higher-coupon debt.", -0.3], ["2022 includes a $7.4 billion loss on our Rivian investment.", -0.7], ["Our full year 2022 Net cash provided by/(used in) operating activities was positive $6.9 billion, a decrease of $8.9 billion from a year ago (see page 79 for additional information).", 0.3], ["The year-over-year decrease was driven by a decrease in Ford Credit operating cash flow partially offset by favorable timing differences.", -0.1], ["Company adjusted free cash flow was $9.1 billion,", 0.5], ["$4.5 billion higher than a year ago, driven by higher Company adjusted EBIT excluding Ford Credit, timing benefits, improvement in working capital, and lower interest expense, offset partially by lower Ford Credit distributions.", 0.6], ["The full year 2022 working capital impact was $0.2 billion positive, driven by higher payables.", 0.5], ["All other and timing differences were positive $1.9 billion.", 0.5], ["The cash effect related to our global redesign activities was $3.9 billion through December 31, 2022.", 0.0], ["Ford outperformed the 2021 targets for all three of the sustainability-linked metrics, which impacted pricing beginning in the fourth quarter of 2022.", 0.7], ["As shown in Note 19 of the Notes to the Financial Statements, at December 31, 2022, Company debt excluding Ford Credit was $19.9 billion.", -0.2], ["This balance is $400 million lower than at December 31, 2021, primarily reflecting the repayment in full of our $1.5 billion delayed draw term loan facility, repayment of the remaining $953 million under our Loan Arrangement and Reimbursement Agreement with the U.S. Department of Energy, a $1.1 billion redemption of higher coupon debt, and scheduled maturities, partially offset by the £750 million ($903 million as of December 31, 2022) draw on our U.K.", 0.3], ["Ford Credit ended 2022 with $21 billion of liquidity.", 0.5], ["During the year, Ford Credit completed $16 billion of public term funding.", 0.5], ["Net receivables of $122.3 billion at December 31, 2022 were funded primarily with term debt and term asset-backed securities.", 0.2], ["In 2022, Ford Credit completed $16 billion of public term funding.", 0.5], ["For 2023, Ford Credit projects full year public term funding in the range of $20 billion to $26 billion.", -0.1], ["Through February 1, 2023, Ford Credit has completed $5 billion of public term issuances.", 0.2], ["At December 31, 2022, Ford Credit’s net liquidity available for use was $21 billion, $11 billion lower than year-end 2021.", -0.5], ["At December 31, 2022, Ford Credit’s liquidity sources totaled $50.9 billion, down $1.3 billion from year-end 2021.", -0.3], ["This positive maturity profile is intended to provide Ford Credit with additional liquidity after all of its assets have been funded and is in addition to liquidity available to protect for stress scenarios.", 0.5], ["As of December 31, 2022, Ford Credit had $137 billion of assets, $60 billion of which were unencumbered.", 0.3], ["Prolonged disruption of the debt and securitization markets;", -0.8], ["Ford Credit’s ability to continue funding through asset-backed financing structures;", -0.6], ["Performance of the underlying assets within Ford Credit’s asset-backed financing structures;", -0.4], ["Ford Credit’s ability to maintain credit facilities and committed asset-backed facilities.", -0.7], ["Ford Credit regularly conducts stress testing on its funding and liquidity sources to ensure it can continue to meet financial obligations and support the sale of Ford and Lincoln vehicles during firm-specific and market-wide stress events.", -0.1], ["Stress tests are intended to quantify the potential impact of various adverse scenarios on the balance sheet and liquidity.", -0.2], ["At December 31, 2022, Ford Credit’s financial statement leverage was 10:1.", 0.0], ["Evaluate strategic actions to reduce pension liabilities, such as plan design changes, curtailments, or settlements", -0.3], ["Worldwide, our defined benefit pension plans were underfunded by $0.2 billion at December 31, 2022, an improvement of $0.1 billion from December 31, 2021, primarily reflecting the impact of higher discount rates mostly offset by negative asset performance.", 0.1], ["Of the $0.2 billion underfunded status at year-end 2022, our funded plans were $4.1 billion overfunded and our unfunded plans were $4.3 billion underfunded.", -0.2], ["In 2022, we contributed $567 million to our global funded pension plans, a decrease of $206 million compared with 2021.", -0.1], ["Our global funded plans remain fully funded in aggregate, demonstrating the effectiveness of our de-risking strategy and our commitment to a strong balance sheet.", 0.5], ["Adjusted Free Cash Flow (a)                                                 About $6 billion", 0.3], ["For full-year 2023, we expect adjusted EBIT of $9 billion to $11 billion, which assumes a seasonally adjusted annual rate (“SAAR”) of about 15 million in the United States and about 13 million in Europe.", 0.7], ["We also expect adjusted free cash flow of about $6 billion, which assumes no distributions from Ford Credit.", -0.1], ["An expected mild U.S. recession and a moderate recession in Europe", -0.7], ["Higher incentives across the industry as supply and demand come back into balance", 0.0], ["Ford Credit EBT of about $1.3 billion, down about $1.4 billion, reflecting unfavorable lease residuals and credit losses and the non-recurrence of derivative gains", -0.8], ["About $2 billion lower past service pension income", -0.5], ["Improvement in the supply chain and industry volume", 0.5], ["Lower cost of goods sold, including efficiencies in materials, commodities, logistics, and other parts of our industrial platform", 0.6], ["Ford and Ford Credit’s financial condition and results of operations have been and may continue to be adversely affected by public health issues, including epidemics or pandemics such as COVID-19;", -0.9], ["Ford is highly dependent on its suppliers to deliver components in accordance with Ford’s production schedule and specifications, and a shortage of or inability to acquire key components, such as semiconductors, or raw materials, such as lithium, cobalt, nickel, graphite, and manganese, can disrupt Ford’s production of vehicles;", -0.8], ["To facilitate access to the raw materials necessary for the production of electric vehicles, Ford has entered into, and expects to continue to enter into, multi-year commitments to raw material suppliers that subject Ford to risks associated with lower future demand for such materials as well as costs that fluctuate and are difficult to accurately forecast;", -0.4]], "f23_sentences.json": [["Based on the New York Stock Exchange Composite Transaction closing price of the Common Stock on that date ($15.13 per share), the aggregate market value of such Common Stock was $59,478,802,149.", -0.1], ["Based on the New York Stock Exchange Composite Transaction closing price of the Common Stock on that date ($12.14 per share), the aggregate market value of such Common Stock was $47,379,761,728.", -0.2], ["In 2023, we sold approximately 4,413,000 vehicles at wholesale throughout the world.", 0.5], ["As a result, the number of cars, trucks, and utility vehicles sold may vary substantially from year to year.", -0.5], ["Our wholesale unit volumes vary with the level of total industry demand and our share of that industry demand.", -0.3], ["Our wholesale unit volumes also are influenced by the level of dealer inventory, and our ability to maintain sufficient production levels to support desired dealer inventory in the event of supplier disruptions or other types of disruptions affecting our production.", -0.4], ["Our ability to satisfy changing consumer and business preferences with respect to type or size of vehicle, as well as design and performance characteristics and the services our vehicles offer, affects our sales and earnings significantly.", 0.2], ["Market factors - volume and mix of vehicles and options sold, and net pricing (reflecting, among other factors, incentive programs)", 0.0], ["Costs of components and raw materials necessary for production of vehicles", -0.3], ["Costs for customer warranty claims and additional service actions", -0.4], ["Costs for safety, emissions, and fuel economy technology and equipment", -0.5], ["A high proportion of relatively fixed structural costs, so that small changes in wholesale unit volumes can significantly affect overall profitability", -0.7], ["Although supply disruptions have resulted in near-term upward pressure on new vehicle prices, our industry has historically had a very competitive pricing environment, driven in part by excess capacity.", -0.3], ["For the past several decades, manufacturers typically have offered price discounts and other marketing incentives to provide value for customers and maintain market share and production levels, and we saw some of these actions resume in 2023 with more expected in 2024 as industry production and inventories improve.", 0.2], ["The decline in value of foreign currencies can also contribute significantly to competitive pressures in many of our markets.", -0.6], ["Historically, we have experienced some seasonal fluctuation in the business, with production in many markets tending to be higher in the first half of the year to meet demand in the spring and summer (typically the strongest sales months of the year).", 0.1], ["In addition to the costs associated with this warranty coverage provided on our vehicles, we also incur costs as a result of field service actions (i.e., safety recalls, emission recalls, and other product campaigns) and for customer satisfaction actions.", -0.4], ["These programs increase Ford Credit’s financing volume and share.", 0.5], ["Corporate Other primarily includes corporate governance expenses, past service pension and other postretirement employee benefits (“OPEB”) income and expense, interest income (excluding Ford Credit interest income and interest earned on our extended service contract portfolio) and gains and losses from our cash, cash equivalents, and marketable securities (excluding gains and losses on investments in equity securities), and foreign exchange derivatives gains and losses associated with intercompany lending.", 0.0], ["Compliance with emissions standards, OBD requirements, and related regulations can be challenging and can drive increased product development costs, higher retail prices, warranty costs, and vehicle recalls.", -0.5], ["The EPA rules are therefore expected to impose increased challenges and costs for light-duty vehicle manufacturers, including Ford.", -0.8], ["As the heavy-duty standards increase in stringency, it may become more difficult to comply while continuing to offer a full lineup of heavy-duty trucks.", -0.7], ["The new rules promulgated by EPA and CARB are expected to impose increased challenges and costs on Ford and other manufacturers of light-, medium-, and heavy-duty vehicles and engines.", -0.8], ["Stringent federal or state agency fuel economy and GHG standards that are misaligned with market conditions could also force Ford to take various actions that could have substantial adverse effects on its sales volumes and operations.", -0.9], ["Such actions could include restricting offerings of selected engines and popular options; taking actions to increase sales of Ford’s most fuel-efficient vehicles; and ultimately curtailing the production and sale of certain internal combustion vehicles, such as high-performance cars, utility vehicles, and/or full- size light trucks in order to maintain compliance.", -0.7], ["The ongoing litigation challenging EPA and CARB standards and potential future federal reversals and rollbacks create risks for Ford’s planning and investing for compliance, or could also potentially relieve the burdens of misalignment of the standards with market conditions.", -0.6], ["Legislative, regulatory, and judicial developments related to fuel quality at both the national and state levels could affect vehicle manufacturers’ warranty costs as well as their ability to comply with vehicle emissions standards.", -0.7], ["California’s light-duty vehicle ZEV regulation, which uses a system based on credits that can be banked and carried forward, mandates annual increases in the production and sale of battery-electric, fuel cell, and plug-in hybrid vehicles.", 0.2], ["In ACC II, California has revised the ZEV regulation in a way that will continue to increase ZEV sales.", 0.3], ["These stringent ZEV requirements covering light-, medium-, and heavy-duty vehicles could yield significant costs and compliance challenges, and include complex warranty and recall requirements.", -0.7], ["Different standards pose additional compliance burdens, including complexity and costs.", -0.5], ["The costs associated with complying with all of these requirements are significant, and following the EU Commission’s indication of its intent to accelerate emissions rules in its road map publication “EU Green Deal” as well as the EU sustainable mobility action plan, these challenges will continue in European markets, including the United Kingdom.", -0.7], ["CARB has also been conducting extensive non-standard emission tests, which in some cases have resulted in certification delays for diesel vehicles.", -0.6], ["In addition, plaintiffs’ attorneys are pursuing consumer class action lawsuits based on alleged excessive emissions from cars and trucks, which could, in turn, prompt further investigations by regulators.", -0.8], ["Pooling agreements between manufacturers to utilize credits are possible under certain conditions, and we have entered into such pooling agreements in order to comply with fuel economy regulations without paying a penalty and to enable other manufacturers to benefit from our positive CO2 performance.", 0.3], ["The initial target levels get significantly more stringent every five years (2025, 2030, and 2035, after which all new light-duty vehicles must be zero emission), requiring significant investments in propulsion technologies and extensive fleet management to enable low CO2 emissions for our fleet.", -0.4], ["Ford also faces the risk of advance premium payments for both passenger cars and light commercial vehicles in all European markets due to, for example, unexpected market fluctuations and shorter lead times impacting average fleet performance.", -0.6], ["Costs associated with new or incremental testing for WLTP are significant.", -0.5], ["In addition, delayed vehicle launches and supply shortages, as well as an insufficient charging infrastructure and lower demand for ZEV and low", -0.6], ["While these regulations are applicable in European jurisdictions, they often apply to global corporations and require adjustments in corporate processes, policies, and strategies, which may be costly.", -0.5], ["Companies that fail to comply with these requirements could face significant monetary penalties and suffer reputational harm.", -0.8], ["The CBAM could increase our costs of importing such materials and/or limit our ability to import lower cost materials from non-EU countries.", -0.6], ["Demand for EVs continues to grow, at fluctuating rates.", 0.2], ["Risk Factors under “Ford may need to substantially modify its product plans and facilities to comply with safety, emissions, fuel economy, autonomous driving technology, environmental, and other regulations,” in addition to the rates of EV growth, production disruptions, stop ships, supply chain limitations, lower-than-planned market acceptance of our vehicles, and/or other circumstances may cause us to modify product plans or, in some cases, purchase credits in order to comply with emissions standards, fuel economy standards, or ZEV requirements.", -0.7], ["In the fourth quarter of 2023, for example, we entered into an agreement to purchase about $700 million of regulatory compliance credits for future use in the United States, the ultimate number of which is dependent on the seller’s ability to deliver the credits.", -0.3], ["As we expand our business priorities to include autonomous vehicle technologies and broader mobility products and services, our financial exposure has increased.", -0.5], ["Should we or NHTSA determine that either a safety defect or noncompliance issue exists with respect to any of our vehicles, the cost of such recall campaigns could be substantial.", -0.9], ["Any difference between North American and UN-ECE based regulations can add complexity and costs to the development of global platform vehicles, and we continue to support efforts to harmonize regulations to reduce vehicle design complexity while providing a common level of safety performance; we are seeking new opportunities in bilateral negotiations that can potentially contribute to this goal.", 0.1], ["Safety and recall requirements in Brazil, China, India, South Korea, and Gulf Cooperation Council (“GCC”) countries may add substantial costs and complexity to our global recall practice.", -0.7], ["Brazil has set mandatory fleet safety targets and penalties are applied if these levels are not maintained, while a tax reduction may be available for over-performance.", -0.2], ["Achieving high NCAP ratings, which may vary by country or region, can add complexity and cost to vehicles.", -0.2], ["These protocols impose additional requirements relating to testing, evaluation, and mandatory safety features, and compliance with them (or any subsequent updates to them) may be costly.", -0.3], ["Unfortunately, there was one employee fatality incident in 2023.", -1.0], ["Ford is highly dependent on its suppliers to deliver components in accordance with Ford’s production schedule and specifications, and a shortage of or inability to acquire key components or raw materials, such as lithium, cobalt, nickel, graphite, and manganese, can disrupt Ford’s production of vehicles.", -0.7], ["If there is a shortage of a key component in our supply chain or a supplier is unable to deliver a component to us in accordance with our specifications, because of a production issue, limited availability of materials, shipping problems, restrictions on transactions with certain countries or companies, or other reason, and the component cannot be easily sourced from a different supplier, or we are unable to obtain a component on a timely basis, the shortage may disrupt our operations or increase our costs of production.", -0.8], ["For the production of our electric vehicles, we are dependent on the supply of batteries and the raw materials (e.g., lithium, cobalt, nickel, graphite, and manganese) used by our suppliers to produce those batteries.", -0.5], ["As we increase our production of electric vehicles, we expect our need for such materials to increase significantly.", 0.1], ["In the event the supplier under those agreements or any of our or our suppliers’ raw material supply contracts is unable to deliver sufficient quantities of raw materials needed for our or our suppliers’ production operations, e.g., if a mine does not produce at expected levels, or the raw materials do not otherwise satisfy our requirements, and we or our suppliers are unable to find an alternative resource with sufficient quantities, at reasonable prices, responsibly sourced (e.g., in compliance with the Uyghur Forced Labor Prevention Act and similar regulations and standards), and in a timely manner, it could impact our ability to produce electric vehicles.", -0.6], ["A shortage of, or our inability to acquire or find adequate suppliers of, key components or raw materials as a result of disruptions in the supply chain, capacity constraints, limited availability, competition for those items within the automotive industry and other sectors, or otherwise can cause a significant disruption to our production schedule and have a substantial adverse effect on our financial condition or results of operations.", -0.9], ["Further, as a result of lower-than-anticipated industrywide electric vehicle adoption rates or otherwise, suppliers of such raw materials or components may become distressed.", -0.4], ["We have incurred and we may continue to incur such charges.", -0.5], ["As a result of the competition for and limited availability of the raw materials needed for our electric vehicle business, the costs of such materials are difficult to accurately forecast as they may fluctuate during the term of the offtake agreements and other long-term purchase contracts based on market conditions.", -0.3], ["Accordingly, we may be subject to increases in the prices we pay for those raw materials, and our ability to recoup such costs through increased pricing to our customers may be limited.", -0.4], ["As a result, our margins, results of operations, financial condition, and reputation may be adversely impacted by commitments we make pursuant to offtake agreements and other long-term purchase contracts.", -0.6], ["If we are unable to optimize our capital allocation among vehicles, services, technology, and other calls on capital, make sufficient progress to become competitive on cost and quality, or we are otherwise not successful in executing Ford+ (or are delayed for reasons outside of our control), we may not be able to realize the full benefits of our plan, which could have an adverse effect on our financial condition or results of operations.", -0.7], ["Furthermore, if we fail to make progress on our plan at the pace that shareholders expect, it may lead to an increase in shareholder activism, which may disrupt the conduct of our business and divert management’s attention and resources.", -0.6], ["Ford’s vehicles could be affected by defects that result in recall campaigns, increased warranty costs, or delays in new model launches, and the time it takes to improve the quality of our vehicles and services could continue to have an adverse effect on our business.", -0.7], ["NHTSA’s enforcement strategy has resulted in significant civil penalties being levied and the use of consent orders requiring direct oversight by NHTSA of certain manufacturers’ safety processes, a trend that could continue.", -0.5], ["Should we or government safety regulators determine that a safety or other defect or a noncompliance exists with respect to certain of our vehicles prior to the start of production, the launch of such vehicle could be delayed until such defect is remedied.", -0.4], ["The cost of recall and customer satisfaction actions to remedy defects in vehicles that have been sold could be substantial, particularly if the actions relate to global platforms or involve defects that are identified years after production.", -0.6], ["Should NHTSA determine that these inflators contain a safety defect, Ford and other manufacturers could potentially face significant incremental recall costs.", -0.8], ["Further, to the extent recall and customer satisfaction actions relate to defective components we receive from suppliers, our ability to recover from the suppliers may be limited by the suppliers’ financial condition.", -0.7], ["unsuccessful), or otherwise (including as a result of higher repair costs driven by inflation or other economic factors), such costs could continue to have an adverse effect on our financial condition or results of operations.", -0.9], ["increased warranty costs have adversely affected and could continue to adversely affect our reputation or the public perception and market acceptance of our products and services as discussed below under “Ford’s new and existing products and digital, software, and physical services are subject to market acceptance and face significant competition from existing and new entrants in the automotive and digital and software services industries, and its reputation may be harmed if it is unable to achieve the initiatives it has announced.” In an effort to improve quality, we have slowed down and may continue to slow down launches, which may result in lost sales, revenue, and profits and could have an adverse effect on our financial condition or results of operations.", -0.9], ["Ford may not realize the anticipated benefits of existing or pending strategic alliances, joint ventures, acquisitions, divestitures, or business strategies.", -0.7], ["As a result, we may not be able to complete anticipated transactions, the anticipated benefits of these transactions may not be realized, or the benefits may be delayed.", -0.8], ["For example, we may not successfully integrate an alliance or joint venture with our operations, including the implementation of our controls, systems, procedures, and policies, or unforeseen expenses or liabilities may arise that were not discovered during due diligence prior to an investment or entry into a strategic alliance, or a misalignment of interests may develop between us and the other party.", -0.8], ["In order to secure critical materials for production of electric vehicles, we have entered into and may, in the future, enter into offtake agreements and other long-term purchase contracts with raw materials suppliers and make investments in certain raw material and battery suppliers; however, we may not realize the anticipated benefits of these actions and our efforts to have such suppliers, particularly those in less developed markets, adopt Ford’s sustainability and other standards may be unsuccessful, which could have an adverse impact on our reputation.", -0.8], ["For example, our efforts to evaluate and implement alternative distribution models and channels for our products and services from those we have traditionally used may be challenged or may not succeed or be as successful as our historical arrangements.", -0.7], ["For example, our business and strategy are susceptible to tensions in U.S.-China relations and the rapid development of the Chinese electric vehicle industry, with domestic Chinese producers exporting to some key markets in which we operate.", -0.7], ["In addition, as we transition to producing a higher percentage of electric vehicles, if industrywide adoption rates continue to be lower than anticipated, we may take actions to better match the pace of electric vehicle adoption, such as not fully utilizing or reducing the capacity of our existing or future plants, reducing production hours or shifts, and we may become subject to claims by suppliers as a result.", -0.8], ["Results of operations from new activities may be lower than our existing activities, and, if a strategy is unsuccessful, we may not recoup our investments, which may be significant, in that strategy.", -0.7], ["Failure to successfully and timely realize the anticipated benefits of the transactions or strategies described herein could have an adverse effect on our financial condition or results of operations.", -0.9], ["Ford may not realize the anticipated benefits of restructuring actions and such actions may cause Ford to incur significant charges, disrupt our operations, or harm our reputation.", -0.8], ["In doing so, we have taken and may in the future take restructuring actions, such as strategic divestitures or ceasing of operations in a market, particularly for those businesses where a path to sustained profitability is not feasible in light of the capital allocation requirements or for other reasons.", -0.6], ["These actions may include employee separations, a reduced footprint (e.g., plant closures or smaller operations at existing plants or plants that are not yet on-line), or operating our plants at less than full capacity (e.g., reducing shifts).", -0.7], ["Such restructuring actions have caused us and may in the future cause us to incur significant costs; record impairments or other charges; subject us to potential claims from employees, suppliers, dealers, other counterparties, or governmental authorities (including a reduction or clawback of incentives); disrupt our operations; distract management from current operations; or harm our reputation.", -0.9], ["Further, we may not realize the expected benefits of such restructuring actions (e.g., anticipated cost savings), such benefits may be delayed, or market dynamics or other factors may have evolved such that we cannot obtain the original intended results of an action.", -0.8], ["Such incidents could materially disrupt operational information systems; result in loss or unwilling publication of trade secrets or other proprietary or competitively sensitive information; compromise the privacy of personal information of consumers, employees, or others; jeopardize the security of our facilities; affect the performance of in-vehicle systems or services we offer; and/or impact the safety of our vehicles.", -0.9], ["Moreover, a cybersecurity incident could harm our reputation, cause customers to lose trust in our security measures, and/or subject us to regulatory actions or litigation, which may result in fines, penalties, judgments, or injunctions, and a cybersecurity incident involving us or one of our suppliers could impact our production, internal operations, business strategy, results of operations, financial condition, or our ability to deliver products and services to our customers.", -0.9], ["Ford’s production, as well as Ford’s suppliers’ production, and/or the ability to deliver products to consumers could be disrupted by labor issues, public health issues, natural or man-made disasters, adverse effects of climate change, financial distress, production difficulties, capacity limitations, or other factors.", -0.8], ["A suspension or substantial curtailment of our manufacturing operations could have a significant adverse effect on our financial condition and results of operations, as was the case in 2020, when, consistent with actions taken by governmental authorities, we idled our plants in regions around the world.", -0.9], ["Our Ford Blue, Ford Model e, and Ford Pro operations generally do not realize revenue while our manufacturing operations are suspended, but we continue to incur operating and non-operating expenses, resulting in a deterioration of our cash flow.", -0.9], ["Accordingly, any significant future disruption to our production schedule, regionally or globally, whether as a result of our own or a supplier’s suspension of operations, could have a substantial adverse effect on our financial condition, liquidity, and results of operations.", -0.9], ["Moreover, our supply and distribution chains may be disrupted by supplier or dealer bankruptcies or their permanent discontinuation of operations triggered by a shutdown of operations.", -0.8], ["The limited availability of components, labor shortages, public health emergencies, and supplier operating issues has led to intermittent interruptions in our supply chain and an inconsistent production schedule at our facilities.", -0.8], ["This has exacerbated the disruption to our suppliers’ operations, which, in turn, has led to higher costs and production shortfalls.", -0.8], ["As a result of this disrupted production schedule, we have received and continue to receive claims from our supply base for reimbursement of costs beyond our original agreed terms.", -0.8], ["Upon receipt, we evaluate those claims, and, in certain circumstances, we have made payments to our suppliers, and this trend may continue.", -0.7], ["Given the worldwide scope of our supply chain and operations, we and our suppliers face a risk of disruption or operating inefficiencies that may increase costs due to the adverse physical effects of climate change, which are predicted to increase the frequency and severity of weather and other natural events, e.g., wildfires, extended droughts, and extreme temperatures.", -0.8], ["In addition, in the event a weather-related event, strike, international conflict, or other occurrence limits the ability of freight carriers to deliver components and other materials from suppliers to us or logistics providers to transport our vehicles for an extended period of time, it may increase our costs and delay or otherwise impact both our production operations and customers’ ability to receive our vehicles.", -0.8], ["Such suppliers also could threaten to disrupt our production as leverage in negotiations.", -0.7], ["In addition, when we undertake a model changeover, significant downtime at one or more of our production facilities may be required, and our ability to return to full production may be delayed if we experience production difficulties at one of our facilities or a supplier’s facility.", -0.6], ["Moreover, as vehicles, components, and their integration become more complex, we may face an increased risk of a delay in production of new vehicles.", -0.7], ["Regardless of the cause, our ability to recoup lost production volume may be limited.", -0.9], ["Accordingly, a significant disruption to our production schedule could have a substantial adverse effect on our financial condition or results of operations and may impact our strategy to comply with fuel economy standards as discussed below under “Ford may need to substantially modify its product plans and facilities to comply with safety, emissions, fuel economy, autonomous driving technology, environmental, and other regulations.”", -1.0], ["Failure to develop and deploy secure digital services that appeal to customers could have a negative impact on", -0.9], ["Ford’s business.", -0.8], ["If we fail to generate sufficient demand for our integrated software and digital services or if customers do not opt to activate the modems in our vehicles, which would hinder our ability to offer and sell such services, we may not grow revenue in line with the costs we are investing or achieve profitability on our increasingly digitally-connected products.", -0.8], ["If we are unable to offer integrated software applications and digital services on competitive terms, it may reduce customer demand or increase our costs to provide such applications and services, which we may be unable to pass on to customers.", -0.8], ["Alternatively, we may have to develop or license new content or technology to provide digital services, and there can be no assurance we would be able to develop or license such content or technology at a reasonable cost or in a timely manner, either of which could have a negative impact on our financial condition, results of operations, or reputation.", -0.8], ["Failure to do so on a timely basis could result in widespread technical and performance issues affecting our products and services.", -0.9], ["For additional discussion on the risks associated with defects and quality issues, see above under “Ford’s vehicles could be affected by defects that result in recall campaigns, increased warranty costs, or delays in new model launches, and the time it takes to improve the quality of our vehicles and services could continue to have an adverse effect on our business.”", -0.85], ["If our efforts to detect such violations or our actions to control these types of fraud and abuse are not effective or timely, it may have an adverse effect on our financial condition, results of operations, or reputation.", -0.85], ["Ford’s ability to maintain a competitive cost structure could be affected by labor or other constraints.", -0.7], ["With the ratification of our new contracts with the International Union, United Automobile, Aerospace and Agricultural Implement Workers of America (“UAW”) in the United States and Unifor in Canada in 2023, we expect to have a significant increase in labor costs through the life of the contracts, and if we are unable to offset those costs, it could have a significant adverse effect on our business.", -0.9], ["Competition for such talent is intense, which has led to an increase in compensation throughout a tight labor market, and, accordingly, may increase costs for companies.", -0.75], ["Further, if we lose existing employees with needed skills or we are unable to develop existing employees, particularly with the introduction of new technologies and our focus on operational efficiency and quality, it could have a substantial adverse effect on our business.", -0.8], ["Because customers’ preferences may change quickly, our new and existing products may not generate sales in sufficient quantities and at costs low enough to be profitable and recoup investment costs.", -0.8], ["Offering vehicles and services that customers want and value can mitigate the risks of increasing price competition and declining demand, but products and services that are perceived to be less desirable (whether in terms of price, quality, styling, safety, overall value, fuel efficiency, or other attributes) can exacerbate these risks.", -0.7], ["For example, if we are unable to differentiate our products and services from those of our competitors, develop innovative new products and services, or sufficiently tailor our products and services to customers in other markets, there could be insufficient demand for our products and services, which could have an adverse impact on our financial condition or results of operations.", -0.8], ["With increased consumer interconnectedness through the internet, social media, and other media, mere allegations relating to quality, safety, fuel efficiency, sustainability, corporate social responsibility, or other key attributes can negatively impact our reputation or market acceptance of our products or services, even where such allegations prove to be inaccurate or unfounded.", -0.9], ["This level of competition necessitates that we invest in and integrate emerging technologies into our business and increases the importance of our ability to anticipate, develop, and deliver products and services that customers desire on a timely basis, in quantities in line with demand, with the quality they expect, and at costs low enough to be profitable.", 0.2], ["Moreover, if we do not meet customer expectations for quickly and effectively addressing and remedying issues that may develop with or that improve our products and services, e.g., successfully delivering OTA updates, it would have an adverse effect on our business.", -0.7], ["If the market for electrified vehicles does not develop at the rate we expect, even if the regulatory framework encourages a rapid adoption of electrified vehicles, there is a negative perception of our vehicles or about electric vehicles in general, we are unable to or are delayed in developing or embracing new technologies or processes, or if consumers prefer our competitors’ vehicles, there could be an adverse impact on our financial condition or results of operations.", -0.8], ["We have announced interim emissions targets approved by the Science Based Targets initiative (SBTi) and made other statements about similar initiatives, e.g., our expected electric vehicle volumes in future years.", 0.3], ["Achievement of these initiatives will require significant investments and the implementation of new processes; however, there is no assurance that the desired outcomes will be achieved.", -0.5], ["To the extent we are unable to achieve these initiatives or our transition to electrification is slower than expected, it may harm our reputation or we may not otherwise receive the expected return on the investment.", -0.6], ["Further, our customers, investors, and other stakeholders evaluate how well we are progressing on our announced climate goals and aspirations, and if we are not on track to achieve those goals and aspirations on a timely basis, or if the expectations of our customers and investors change and we do not adequately address their expectations, our reputation could be impacted, and customers may choose to purchase the products and services of, investors may choose to invest in, and suppliers and vendors may choose to do business with other companies.", -0.7], ["Other parties may object to the positions we have taken and may, in the future, take on environmental, social, or other issues, or in the event we change our position on such issues, which may result in a loss of customers, a boycott of our products or services, or other actions that may impact not only our brand and reputation but also our results of operations, financial condition, and the price of our Common Stock.", -0.8], ["Moreover, new offerings, including those related to electric vehicles and autonomous driving technologies, may present technological challenges that could be costly to implement and overcome and may subject us to customer claims if they do not operate as anticipated.", -0.8], ["In addition, since new technologies are subject to market acceptance, a malfunction involving any manufacturer’s autonomous vehicle may negatively impact the perception of autonomous vehicles and autonomous vehicle technologies and erode customer trust.", -0.7], ["A shift in consumer preferences away from larger, more profitable vehicles with internal combustion engines (including trucks and utilities) to electric or other vehicles in our portfolio that may be less profitable could result in an adverse effect on our financial condition or results of operations.", -0.9], ["If demand for electric vehicles grows at a rate greater than our ability to increase our production capacity for those vehicles, lower market share and revenue, as well as facility and other asset-related charges (e.g., accelerated depreciation) associated with the production of internal combustion vehicles, may result.", -0.8], ["In addition, government regulations aimed at reducing emissions and increasing fuel efficiency (e.g., ZEV mandates and low emission zones) and other factors that accelerate the transition to electric vehicles may increase the cost of vehicles by more than the perceived benefit to consumers and dampen margins.", -0.7], ["With a global footprint and supply chain, Ford’s results and operations could be adversely affected by economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events.", -0.9], ["Because of the interconnectedness of the global economy, the challenges of a pandemic, a financial crisis, economic downturn or recession, natural disaster, war, geopolitical crises, or other significant events in one area of the world can have an immediate and material adverse impact on markets around the world.", -0.9], ["Changes in international trade policy can also have a substantial adverse effect on our financial condition, results of operations, or our business in general.", -0.8], ["Steps taken by governments to apply or consider applying tariffs on automobiles, parts, and other products and materials have the potential to disrupt existing supply chains, impose additional costs on our business, and could lead to other countries attempting to retaliate by imposing tariffs, which would make our products more expensive for customers, and, in turn, could make our products less competitive.", -0.8], ["This could include governmental takeover (i.e., nationalization) of our manufacturing facilities or intellectual property, restrictive exchange or import controls, disruption of operations as a result of systemic political or economic instability, outbreak of war or expansion of hostilities (such as the ongoing conflicts between Russia and Ukraine and between Israel and Hamas, heightened tensions in the Red Sea, and potential tensions in the South China Sea), and acts of terrorism, each of which could impact our supply chain as well as our operations and have a substantial adverse effect on our financial condition or results of operations.", -0.9], ["Industry sales volume can be volatile and could decline if there is a financial crisis, recession, public health emergency, or significant geopolitical event.", -0.8], ["Because we, like other manufacturers, have a higher proportion of fixed structural costs, relatively small changes in industry sales volume can have a substantial effect on our cash flow and results of operations.", -0.6], ["If industry vehicle sales were to decline to levels significantly below our planning assumption, the decline could have a substantial adverse effect on our financial condition, results of operations, and cash flow.", -0.9], ["Ford may face increased price competition or a reduction in demand for its products resulting from industry excess capacity, currency fluctuations, competitive actions, or other factors, particularly for electric vehicles.", -0.7], ["The global automotive industry is intensely competitive, with installed manufacturing capacity generally exceeding current demand.", -0.6], ["Historically, industry overcapacity has resulted in many manufacturers offering marketing incentives on vehicles in an attempt to maintain and grow market share; these incentives historically have included a combination of subsidized financing or leasing programs, price rebates, and other incentives.", -0.5], ["Further, higher inventory levels put downward pressure on pricing, which may have an adverse effect on our financial condition and results of operations.", -0.7], ["Although we continue to invest in our electric vehicle strategy, we have observed lower-than-anticipated industrywide electric vehicle adoption rates and near-term pricing pressures, which has led us and may in the future lead us to adjust our spending, production, and/or product launches to better match the pace of electric vehicle adoption.", -0.8], ["As a result of the lower- than-anticipated adoption rates, near-term pricing pressures, and other factors, we have accrued and may continue to incur charges, which could be substantial, related to payments to our electric vehicle-related suppliers (battery, raw material, or otherwise), inventory adjustments, or other matters.", -0.9], ["Furthermore, as we invest in battery production, including the construction of battery plants, if we are unable to operate those plants at their expected capacity because electric vehicle adoption rates remain lower-than-anticipated or otherwise, we may be unable to recoup the investments we have made.", -0.8], ["This excess capacity may further increase price competition in that segment of the market, which could have a substantial adverse effect on our financial condition or results of operations.", -0.9], ["Inflationary pressure and fluctuations in commodity and energy prices, foreign currency exchange rates, interest rates, and market value of Ford or Ford Credit’s investments, including marketable securities, can have a significant effect on results.", -0.7], ["As a result, significant changes in commodity and energy prices, foreign currency exchange rates, or interest rates as well as increased material, freight, logistics, and similar costs could have a substantial adverse effect on our financial condition or results of operations.", -0.9], ["These market forces have caused us to incur higher material costs, which may continue, and our warranty costs have increased, in part, due to inflationary cost pressures at our dealers.", -0.8], ["Moreover, due to inflationary pressure, some of our suppliers have submitted claims to us for reimbursement of costs beyond our original agreed terms.", -0.8], ["Further, interest rates have increased significantly as central banks in developed countries attempt to subdue inflation while government deficits and debt remain at high levels in many global markets.", -0.7], ["Accordingly, the eventual implications of higher government deficits and debt, tighter monetary policy, and potentially higher long-term interest rates may drive a higher cost of capital for the business.", -0.7], ["At Ford Credit, rising interest rates may impact Ford Credit’s ability to source funding and offer financing at competitive rates, which could reduce its financing margin.", -0.8], ["In addition, our results are impacted by fluctuations in the market value of our investments, with unrealized gains and losses that could be material in any period.", -0.6], ["Over time, and particularly in the event of credit rating downgrades, market volatility, market disruption, or other factors, Ford Credit may reduce the amount of receivables it purchases or originates because of funding constraints.", -0.8], ["In addition, Ford Credit may reduce the amount of receivables it purchases or originates if there is a significant decline in the demand for the types of securities it offers or Ford Credit is unable to obtain derivatives to manage the interest rate risk associated with its securitization transactions.", -0.5], ["A significant reduction in the amount of receivables Ford Credit purchases or originates would significantly reduce its ongoing results of operations and could adversely affect its ability to support the sale of Ford vehicles.", -0.8], ["To the extent interest rates remain relatively high, they may have an adverse effect on borrowing costs for Ford Credit, making it more expensive to fund our operations or leading to higher rates charged to our customers if these costs are", -0.7], ["The impact of government incentives on Ford’s business could be significant, and Ford’s receipt of government incentives could be subject to reduction, termination, or clawback.", -0.6], ["A decrease in, expiration without renewal of, or other cessation or clawback of government incentives for any of our operations, as a result of administrative decision or otherwise, could have a substantial adverse impact on our financial condition or results of operations.", -0.9], ["As a result, the performance of our South American operations had been impacted favorably by government incentives to a substantial extent.", 0.5], ["The federal government in Brazil has levied assessments against us concerning the federal incentives we previously received, and the State of São Paulo has challenged the grant to us of tax incentives by the State of Bahia.", -0.7], ["The IRA’s incentives are having and are expected to have material impacts on the automotive industry and Ford.", 0.3], ["The IRA authorizes tax credits to manufacturers for the domestic production of batteries and battery components for EVs and PHEVs, and this credit is expected to improve the financial performance of domestic battery manufacturers, including the new operations at our upcoming facility in Michigan and BlueOval SK’s facilities in Kentucky and Tennessee.", 0.7], ["Further, the degree of success of some of our investment strategies depends upon IRA tax credit eligibility and for those credits to continue to remain available through the currently contemplated expiration.", 0.2], ["Ford expects that most commercial customers that purchase an EV or PHEV will be eligible for the commercial clean vehicle credit, although it is unclear at this time how many commercial vehicle purchasers will have the underlying federal tax liability that is necessary to actually monetize this credit.", -0.2], ["When paired with the IRA’s tax credit for the construction of certain electric vehicle charging infrastructure, Ford expects the commercial clean vehicle credit will influence commercial fleets, governmental fleets, and other vehicle purchasers in their evaluation of a transition from internal combustion engine vehicles to EVs and PHEVs.", 0.3], ["Ford Credit could experience higher-than-expected credit losses, lower-than-anticipated residual values, or higher-than-expected return volumes for leased vehicles.", -0.7], ["Credit risk (which is heavily dependent upon economic factors including unemployment, consumer debt service burden, personal income growth, dealer profitability, and used car prices) has a significant impact on Ford Credit’s business.", -0.5], ["The level of credit losses Ford Credit may experience could exceed its expectations and adversely affect its financial condition or results of operations.", -0.8], ["Actual proceeds realized by Ford Credit upon the sale of returned leased vehicles at lease termination may be lower than the amount projected, which would reduce Ford Credit’s return on the lease transaction.", -0.6], ["If auction values decrease significantly in the future, return volumes could exceed Ford Credit’s expectations.", -0.7], ["Each of these factors, alone or in combination, has the potential to adversely affect Ford Credit’s results of operations if actual results were to differ significantly from Ford Credit’s projections.", -0.6], ["Economic and demographic experience for pension and OPEB plans (e.g., discount rates or investment returns) could be worse than Ford has assumed.", -0.5], ["To the extent actual results are less favorable than our assumptions, we may recognize a remeasurement loss in our results, which could be substantial.", -0.7], ["Pension and other postretirement liabilities could adversely affect Ford’s liquidity and financial condition.", -1.0], ["These benefit plans impose significant liabilities on us and could require us to make additional cash contributions, which could impair our liquidity.", -1.0], ["If our cash flows and capital resources are insufficient to meet any pension or OPEB obligations, we could be forced to reduce or delay investments and capital expenditures, suspend dividend payments, seek additional capital, or restructure or refinance our indebtedness.", -1.0], ["Ford and Ford Credit could experience unusual or significant litigation, governmental investigations, or adverse publicity arising out of alleged defects in products, services, perceived environmental impacts, or otherwise.", -1.0], ["Government investigations against Ford or Ford Credit could result in fines, penalties, orders, or other resolutions that could have an adverse impact on our financial condition, results of operations, or the operation of our business.", -1.0], ["Litigation also is inherently uncertain, and we have in the past experienced and could in the future experience significant adverse results, including compensatory and punitive damage awards, a disgorgement of profits or revenue, or injunctive relief, any of which could have an adverse effect on our financial condition, results of operations, or our business in general, particularly with larger jury verdicts becoming more prevalent.", -1.0], ["In addition, adverse publicity surrounding an allegation, litigation, or investigation, even if there is no merit to the matter, may cause significant reputational harm or create a negative public perception of our products and services, which could have a significant adverse effect on our sales.", -1.0], ["As our suppliers make similar investments, any higher costs may be passed on to us.", -0.5], ["of our vehicles do not lead consumers to purchase electric vehicles and other highly fuel-efficient vehicles in sufficient numbers, it may be difficult to meet applicable environmental standards.", -0.5], ["Moreover, the rates of EV growth, production disruptions, stop ships, supply chain limitations, lower-than-planned market acceptance of our vehicles, and/or other circumstances may cause us to modify product plans, or, in some cases, purchase credits, which we have done, in order to comply with emissions standards, fuel economy standards, or ZEV requirements, which could have an adverse effect on our financial condition and results of operations and cause reputational harm.", -1.0], ["The cost to comply with government regulations concerning new vehicle standards and in-use vehicle requirements, including field service actions, is substantial.", -0.8], ["Additional regulations, changes in regulatory interpretations, or changes in consumer preferences that affect vehicle mix, as well as any non-compliance with applicable laws and regulations, could have a substantial adverse impact on our financial condition or results of operations.", -0.9], ["Any negative perception regarding the performance of our vehicles subjected to such tests could reduce future sales.", -0.7], ["This patchwork approach without federal guidance may subject Ford to additional compliance costs.", -0.6], ["In addition, the demand for these services by consumers is fluctuating as the technology is rolled out in various stages and with mixed industry results.", -0.5], ["Accordingly, complying with such laws and regulations may lead to a decline in consumer engagement or cause us to incur substantial costs to modify our operations or business practices.", -0.7], ["Moreover, regulatory actions seeking to impose significant financial penalties for noncompliance and/or legal actions (including pursuant to laws providing for private rights of action by consumers) could be brought against us in the event of a data compromise, misuse of consumer information, or perceived or actual non-compliance with data protection, privacy, or artificial intelligence requirements.", -0.8], ["Further, any unauthorized release of personal information could harm our reputation, disrupt our business, cause us to expend significant resources, and lead to a loss of consumer confidence resulting in an adverse impact on our business and/or consumers deciding to withhold or withdraw consent for our collection or use of data.", -0.9], ["As a finance company, Ford Credit is highly regulated by governmental authorities in the locations in which it operates, which can impose significant additional costs and/or restrictions on its business.", -0.7], ["Exercise of these powers by the CFPB may increase the costs of, impose additional restrictions on, or otherwise adversely affect companies in the automotive finance business.", -0.8], ["Failure to comply with applicable laws and regulations could subject Ford Credit to regulatory enforcement actions, including consent orders or similar orders where Ford Credit may be required to revise practices, remunerate customers, or pay fines.", -0.8], ["An enforcement action against Ford Credit could harm Ford Credit’s reputation or lead to further litigation.", -0.7], ["In 2023, we did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition.", 0.5], ["A cybersecurity incident could harm our reputation, cause customers to lose trust in our security measures, and/or subject us to regulatory actions or litigation, which may result in fines, penalties, judgments, or injunctions, and a cybersecurity incident involving us or one of our suppliers could impact our business strategy, results of operations, financial condition, or our reputation.", -0.9], ["See Note 25 of the Notes to the Financial Statements for a discussion of loss contingencies.", 0.1], ["During the first trial in 2018, the judge declared a mistrial, ruled that Ford’s attorneys had violated pre-trial rulings while presenting evidence, and sanctioned Ford by prohibiting Ford from introducing any evidence at the second trial to show that the roof design of the F-250 was not defective.", -0.6], ["During the second trial in August 2022, a jury found that Pep Boys (the party that sold the tires on the vehicle involved in the rollover accident) was responsible for 30% of the damages, and Ford, as a direct result of the sanctions order prohibiting Ford from presenting its defense, was responsible for 70% of the damages, resulting in $16.8 million in damages being apportioned to Ford.", -0.7], ["The jury subsequently awarded punitive damages against Ford in the amount of $1.7 billion.", -0.9], ["The extent of our financial exposure to asbestos litigation remains very difficult to estimate and could include both compensatory and punitive damage awards.", -0.8], ["Annual payout and defense costs may become significant in the future.", -0.7], ["Our accrual for asbestos matters includes probable losses for both asserted and unasserted claims.", -0.5], ["The amount of any such costs or damages for which we may be held responsible could be significant.", -0.7], ["One Brazilian state (São Paulo) and the Brazilian federal tax authority currently have outstanding substantial tax assessments against Ford Motor Company Brasil Ltda.", -0.8], ["If we are required to post collateral, which could be in excess of $1 billion, we expect it", -0.6], ["We filed a challenge in the U.S. Court of International Trade (“CIT”), and CIT ruled in our favor in 2017.", 0.5], ["Following the U.S. Supreme Court’s denial of our petition for a writ of certiorari in 2020, we paid the increased duties for certain prior imports, plus interest, and disclosed that CBP might assert a claim for penalties.", -0.4], ["Subsequently, CBP issued a penalty notice to us dated July 22, 2021, and on November 18, 2021, CBP assessed against us a monetary penalty of $1.3 billion and additional duties of $181 million, plus interest.", -0.9], ["In the fourth quarter of 2023, we completed a modest anti-dilutive share repurchase program to offset the dilutive effect of share-based compensation granted during 2023.", 0.2], ["As shown in the rightmost column of the table below, we do not intend to make any further purchases under this program because its anti-dilutive purpose was fulfilled after purchasing only 31 million shares.", 0.1], ["we have repurchased 31 million shares and the program was authorized for up to 51 million, we do not intend to make any further purchases under this program because its anti-dilutive purpose has been fulfilled.", 0.1], ["The table below shows the dividends we paid per share of Common and Class B Stock for each quarterly period in 2022 and 2023:", -0.1], ["(a) In the first quarter of 2023, in addition to a regular dividend of $0.15 per share, we paid a supplemental dividend of $0.65 per share.", 0.5], ["On February 6, 2024, we declared a regular dividend of $0.15 per share and a supplemental dividend of $0.18 per share.", 0.3], ["Although we saw improvements in our supply chain throughout 2023, including easing of the semiconductor shortage, we continue to face some production issues due to, among other things, labor shortages at our suppliers.", -0.6], ["Moreover, we have received and continue to receive claims from our supply base related to inflationary pressure and production disruption.", -0.7], ["Upon receipt, we evaluate those claims, and, in certain circumstances, in order to ensure continuity of supply and mitigate the impact on our production, have made payments to our suppliers, sometimes under duress.", -0.8], ["We continue to reevaluate our supply base and sourcing decisions and may in the future incur charges to improve flexibility and cost competitiveness.", -0.4], ["Despite vehicle pricing remaining elevated over the last year due to strong demand, supply shortages, and inflationary costs, we have already observed moderation in the rate of new and used vehicle price increases as auto production recovers from the semiconductor shortage, but it is unclear whether prices will decline fully to pre-COVID-19 pandemic levels.", -0.3], ["Over the long term, intense competition and excess capacity are likely to put downward pressure on inflation-adjusted prices for similarly-contented vehicles and contribute to a challenging pricing environment for the automotive industry in most major markets.", -0.5], ["Although we continue to invest in our electric vehicle strategy, we have observed lower-than- anticipated industrywide electric vehicle adoption rates and near-term pricing pressures, which has led us and may in the future lead us to adjust our spending, production, and/or product launches to better match the pace of electric vehicle", -0.6], ["As a result of the lower-than-anticipated adoption rates, near-term pricing pressures, and other factors, we recorded about $0.7 billion of charges in 2023 and may continue to incur charges, which could be substantial, related to payments to our electric vehicle-related suppliers (battery, raw material, or otherwise), inventory adjustments, or other", -0.8], ["Prices for commodities remain volatile.", -0.2], ["In some cases, spot prices for various commodities have recently diverged somewhat, as anticipated weakening in global industrial activity mitigates price increases for base metals such as steel and aluminum, while precious metals (e.g., palladium), and raw materials that are used in batteries for electric vehicles (e.g., lithium, cobalt, nickel, graphite, and manganese, among other materials, for batteries) remain elevated.", -0.3], ["The net impact on us and our suppliers has been higher material costs overall.", -0.7], ["Similar dynamics are impacting energy markets, with Europe particularly exposed to the risk of both higher prices and constraints on supply of natural gas due to the ongoing conflict in Ukraine.", -0.6], ["Such shortages may impact facilities operated by us or our suppliers, which could have an impact on us in Europe and other regions.", -0.5], ["In the long term, the outcome of de-carbonization and electrification of the vehicle fleet may depress oil demand, but the global energy transition will also contribute to ongoing volatility of oil and other energy prices.", -0.4], ["Our financial results depend on the profitability of the vehicles we sell, which may vary significantly by vehicle line.", 0.0], ["In general, larger vehicles tend to command higher prices and be more profitable than smaller vehicles.", 0.2], ["For example, in Ford Blue, our larger, more profitable vehicles had an average contribution margin that was 139% of our total average contribution margin across all vehicles, whereas our smaller vehicles had significantly lower contribution margins.", 0.5], ["In addition, government regulations aimed at reducing emissions and increasing fuel efficiency (e.g., ZEV mandates and low emission zones), and other factors that accelerate the transition to electrified vehicles, may increase the cost of vehicles by more than the perceived benefit to consumers and dampen margins.", -0.7], ["To the extent governments in various regions implement or intensify barriers to imports, such as erecting tariff or non-tariff barriers or manipulating their currency, and provide advantages to local exporters selling into the global marketplace, there can be a significant negative impact on manufacturers based in other markets.", -0.9], ["We continue to see near-term impacts on our business due to inflation, including ongoing global price pressures in the wake of geopolitical volatility, driving up energy prices, freight premiums, and other operating costs above normal rates.", -0.8], ["Although headline inflation in the United States and Europe appears to have peaked, as gasoline and natural gas prices recede from the latest spike, core inflation (excluding food and energy prices) remains elevated and is a source of continued cost pressure on businesses and households.", -0.6], ["Interest rates have increased significantly as central banks in developed countries attempt to subdue inflation while government deficits and debt remain at high levels in many global markets.", -0.5], ["Accordingly, the eventual implications of higher government deficits and debt, tighter monetary policy, and potentially higher long-term interest rates may drive a higher cost of capital for the business.", -0.6], ["At Ford Credit, rising interest rates may impact its ability to source funding and offer financing at competitive rates, which could reduce its financing margin.", -0.7], ["On the other hand, while labor costs do not vary directly with production volume, manufacturing labor costs may be impacted by changes in volume, for example when we increase overtime, add a production shift, or add personnel to support volume increases.", -0.2], ["For example, structural costs are necessary to grow our business and improve profitability, invest in new products and technologies, respond to increasing industry sales volume, and grow our market share.", 0.2], ["Although material costs are our largest absolute cost, our margins can be affected significantly by changes in any category of costs.", -0.4], ["The net income attributable to Ford Motor Company was $4,347 million in 2023.", 0.8], ["2022 includes $298 million related to restructuring charges in India and $198 million in North America.", -0.2], ["2023 includes $28 million related to restructuring charges in India and $41 million in North America.", -0.2], ["We recorded $5.1 billion of pre-tax special item charges in 2023, driven primarily by pension and OPEB remeasurement, restructuring actions in Europe and China, and the Transit Connect customs matter.", -0.8], ["In 2023, our diluted earnings per share of Common and Class B Stock was $1.08 and our diluted adjusted earnings per share was $2.01.", 0.7], ["Net income/(loss) margin was 2.5% in 2023, up from negative 1.3% a year ago.", 0.5], ["Company adjusted EBIT margin was 5.9% in 2023, down from 6.6% a year ago.", -0.3], ["The year-over-year increase of $6.3 billion in net income/(loss) in 2023 was primarily driven by the non-recurrences of the mark-to-market net loss on our Rivian investment and the impairment on our Argo investment (both of which were included in special items in 2022), partially offset by a pension and OPEB remeasurement loss and higher charges for restructuring actions in Europe and China.", 0.3], ["The flat year-over-year Company adjusted EBIT primarily reflects higher Ford Pro and Ford Blue EBIT and a lower EBIT loss in Ford Next.", 0.1], ["Offsets included higher EBIT losses in Ford Model e, lower past service pension and OPEB income in Corporate Other, and lower Ford Credit EBT.", -0.4], ["In 2023, Ford Blue’s wholesales increased 3% from a year ago, primarily reflecting an improvement in production-related supply constraints, offset partially by ceasing production of EcoSport and Fiesta small vehicles and production losses during the UAW strike.", 0.3], ["Full year 2023 revenue increased 8%, driven by higher wholesales, favorable mix, and higher net pricing, offset partially by weaker currencies.", 0.5], ["Ford Blue’s 2023 full year EBIT was $7.5 billion, an increase of $615 million from a year ago, with an EBIT margin of 7.3%.", 0.7], ["The EBIT improvement was driven primarily by favorable mix, lower commodity costs, higher wholesales and net pricing.", 0.6], ["Partial offsets primarily include higher warranty costs (reflecting inflationary cost pressures and increased field service actions), higher material costs related to new products, higher structural costs and supplemental compensation (including the impact of the new UAW collective bargaining agreement), and weaker currencies.", -0.4], ["In 2023, Ford Model e’s wholesales increased 20% from a year ago, primarily reflecting higher production of F-150 Lightning.", 0.8], ["Full year 2023 revenue increased 12%, driven by higher wholesales, offset partially by lower net pricing.", 0.6], ["Ford Model e’s 2023 full year EBIT loss was $4.7 billion, a $2.6 billion higher loss than a year ago, with an EBIT margin of negative 79.7%.", -0.8], ["The EBIT deterioration was primarily driven by lower net pricing, higher material cost (including volume- related obligations for batteries of about $310 million, inflationary cost increases, and higher launch-related supplier costs), higher volume/capacity-related manufacturing and spending-related costs, higher warranty costs, and higher engineering costs for future programs, offset partially by lower commodity costs and stronger currencies.", -0.7], ["In 2023, Ford Pro’s wholesales increased 6% from a year ago, primarily reflecting an improvement in production-related supply constraints, offset partially by production losses during the UAW strike.", 0.4], ["Full year 2023 revenue increased 19%, driven by higher net pricing and wholesales, offset partially by unfavorable mix.", 0.8], ["Ford Pro’s 2023 full year EBIT was $7.2 billion, an increase of $4.0 billion from a year ago, with an EBIT margin of 12.4%.", 1.0], ["The EBIT improvement was driven by higher net pricing, lower commodity costs, and higher wholesales.", 0.9], ["Partial offsets primarily include higher material costs (related to inflationary cost pressures, new products, and about $80 million of volume-related obligations for batteries), higher warranty costs (reflecting inflationary cost pressures and increased field service actions), and higher structural costs (including volume-related) and supplemental compensation (including the impact of the new UAW collective bargaining agreement).", -0.5], ["In this segment, our 2023 EBIT loss was $138 million, a $788 million improvement from a year ago.", 0.3], ["Total net receivables at December 31, 2023 were 9% higher than a year ago, primarily reflecting higher consumer and non-consumer financing and currency exchange rates, partially offset by fewer operating leases.", 0.2], ["Ford Credit’s U.S. 36-month auction values for off-lease vehicles were down 7% from a year ago.", -0.7], ["We are planning for full year 2024 auction values to decrease as vehicle availability continues to improve.", -0.3], ["Ford Credit’s 2023 EBT of $1,331 million was $1,326 million lower than a year ago, reflecting lower financing margin, non-recurrence of supplemental depreciation and credit loss reserve releases, lower lease residual performance, unfavorable derivative market valuation, and higher credit losses.", -0.9], ["Financing margin changes are driven by changes in revenue and interest expense.", 0.0], ["Changes in revenue are primarily driven by the level of market interest rates, cost assumptions in pricing, mix of business, and competitive environment.", -0.1], ["Changes in interest expense are primarily driven by the level of market interest rates, borrowing spreads, and asset-liability management", -0.1], ["Net charge-off changes are primarily driven by the number of repossessions, severity per repossession, and recoveries.", -0.2], ["For analysis purposes, management splits residual performance primarily into residual gains and losses, and the change in accumulated supplemental depreciation", 0.0], ["Residual gain and loss changes are primarily driven by the number of vehicles returned to Ford Credit and sold, and the difference between the auction value and the depreciated value (which includes both base and accumulated supplemental depreciation) of the vehicles sold.", -0.1], ["Depreciation on vehicles subject to operating leases includes early termination losses on operating leases due to customer default events.", -0.2], ["Corporate Other primarily includes corporate governance expenses, past service pension and OPEB income and expense, interest income (excluding Ford Credit interest income and interest earned on our extended service contract portfolio) and gains and losses from our cash, cash equivalents, and marketable securities (excluding gains and losses on investments in equity securities), and foreign exchange derivatives gains and losses associated with intercompany lending.", 0.0], ["For full year 2023, Corporate Other had a $760 million EBIT loss, compared with $748 million of positive EBIT in 2022.", -0.5], ["The EBIT deterioration was driven by lower past service pension and OPEB income, partially offset by higher Company excluding Ford Credit interest income, reflecting higher interest rates.", -0.3], ["Our full year 2023 interest expense on Company debt excluding Ford Credit was $1,302 million, $43 million higher than in 2022.", -0.4], ["Our Provision for/(Benefit from) income taxes for full year 2023 was a $362 million benefit, resulting in an effective tax rate of negative 9.1%.", -0.2], ["Any future changes to our structure, as well as any changes in income tax laws in the countries that we operate, could cause increases or decreases to our deferred tax balances and related valuation allowances.", 0.0], ["The net loss attributable to Ford Motor Company was $1,981 million in 2022.", -0.8], ["For full year 2022, we recorded $12.2 billion of pre-tax special item charges, driven by a $7.4 billion mark-to-market net loss on our Rivian investment and a $2.7 billion impairment on our Argo investment.", -0.9], ["In 2022, our diluted earnings per share of Common and Class B Stock was a loss of $0.49 and our diluted adjusted earnings per share was $1.88.", -0.7], ["Net income/(loss) margin was negative 1.3% in 2022, down from 13.2% in 2021.", -0.8], ["Company adjusted EBIT margin was 6.6% in 2022, down from 7.3% in 2021.", -0.3], ["The year-over-year decrease of $19.9 billion in net income/(loss) in 2022 includes the effect of special items, including the mark-to-market net loss on our Rivian investment and the impairment on our Argo investment.", -0.9], ["The year-over-year increase of $415 million in Company adjusted EBIT primarily reflects higher Ford Blue and Ford Pro EBIT, offset partially by lower Ford Credit EBT, higher EBIT losses in Ford Model e, and lower past service pension and OPEB income in Corporate Other.", 0.1], ["In 2022, Ford Blue’s wholesales increased 5% from 2021, primarily reflecting an improvement in production-related supply constraints and a full year of Bronco and Maverick production, offset partially by our India restructuring, suspension of our joint venture in Russia, and COVID-related restrictions in China.", 0.3], ["Full year 2022 revenue increased 18%, driven by higher net pricing and wholesales, offset partially by weaker currencies.", 0.5], ["Ford Blue’s full year 2022 EBIT was $6.8 billion, an increase of $3.6 billion from 2021, with an EBIT margin of 7.2%.", 0.8], ["The EBIT improvement was driven by higher net pricing and higher wholesales, offset partially by inflationary increases on commodity, material, and freight costs, higher warranty costs, higher structural costs, and weaker currencies.", 0.2], ["In 2022, Ford Model e’s wholesales increased 58% from 2021, primarily reflecting the launch of the F-150 Lightning and incremental Mach-E production.", 0.7], ["Full year 2022 revenue increased 70%, driven by higher wholesales and net pricing.", 0.9], ["Model e’s full year 2022 EBIT loss was $2.1 billion, a $1.2 billion higher loss than in 2021, with an EBIT margin of negative 40.6%.", -0.8], ["The lower EBIT was primarily driven by inflationary increases on commodity, material, and freight costs, higher structural costs (including higher engineering cost for future programs), and unfavorable mix.", -0.7], ["Partial offsets included higher net pricing and wholesales.", 0.1], ["In 2022, Ford Pro’s wholesales increased 10% from 2021, primarily reflecting an improvement in production-related supply constraints.", 0.6], ["Full year 2022 revenue increased 15%, driven by higher net pricing and wholesales, offset partially by weaker currencies.", 0.5], ["Ford Pro’s full year 2022 EBIT was $3.2 billion, an increase of $557 million from 2021, with an EBIT margin of 6.6%.", 0.7], ["The EBIT improvement was driven by higher net pricing and wholesales, offset partially by inflationary increases on commodity, material, and freight costs, higher structural costs, and unfavorable mix.", -0.2], ["In our Ford Next segment (formerly Mobility), our 2022 EBIT loss improved $104 million from 2021.", 0.3], ["The $926 million EBIT loss reflected our strategic investments in our autonomous vehicle capabilities and support of our mobility initiatives.", -0.5], ["Total net receivables at December 31, 2022 were 3% higher than at December 31, 2021, primarily reflecting higher non- consumer financing, offset partially by fewer operating leases, lower consumer financing, and currency exchange rates.", 0.1], ["Ford Credit’s loss metrics reflected healthy and stable consumer credit conditions and strong auction values.", 0.5], ["36-month auction values for off-lease vehicles were up 5% from 2021, reflecting strong demand for used vehicles, including the impact of lower new vehicle production due to the semiconductor shortage.", 0.4], ["Ford Credit’s 2022 EBT of $2,657 million was $2,060 million lower than 2021, reflecting lower credit loss and lease residual reserve releases, lower financing margin, and lower lease return rates.", -0.6], ["For full year 2022, Corporate Other EBIT was $748 million, compared with EBIT of $1,247 million in 2021.", -0.3], ["The deterioration was driven by lower past service pension and OPEB income.", -0.4], ["Our full year 2022 interest expense on Company debt excluding Ford Credit was $1,259 million, $544 million lower than in 2021, primarily explained by U.S. debt restructuring actions taken in the fourth quarter of 2021 and during 2022.", -0.1], ["However, our forecast could fluctuate from period to period based on market prices, which could result in significant increases or decreases in our estimate.", -0.5], ["Non-operating items include: restructuring costs, changes in Company debt excluding Ford Credit, contributions to funded pension plans, shareholder distributions, and other items (including gains and losses on investments in equity securities, acquisitions and divestitures, equity investments, and other transactions with Ford Credit).", 0.0], ["As a result, our cash flow deteriorates if wholesale volumes (and the corresponding revenue) decrease while trade payables continue to become due.", -0.8], ["Conversely, our cash flow improves if wholesale volumes (and the corresponding revenue) increase while new trade payables are generally not due for about 45 days.", 0.5], ["For example, the suspension of production at most of our assembly plants and lower industry volumes due to COVID-19 in early 2020 resulted in an initial deterioration of our cash flow, while the subsequent resumption of manufacturing operations and return to pre-COVID-19 production levels at most of our assembly plants resulted in a subsequent improvement of our cash flow.", 0.2], ["The net impact of this typically results in cash outflows from changes in our working capital balances during these shutdown periods.", -0.6], ["Such actions could have a short-term adverse impact on our cash and increase our inventory.", -0.7], ["Such investments could have an additional adverse impact on our cash in the near-term.", -0.7], ["Unlike our historical arrangements with suppliers, under multi-year offtake agreements, the risks associated with lower- than-expected electric vehicle production volumes or changes in battery technology that reduce the need for certain raw materials are borne by Ford rather than our suppliers.", -0.9], ["Accordingly, in the event we do not purchase the materials pursuant to the terms of these agreements and we are unable to restructure an agreement or an alternate purchaser is unable to be found, Ford retains its obligation for the cost of those materials.", -0.5], ["As of December 31, 2023, the outstanding amount of Ford receivables that suppliers elected to sell to the SCF financial institutions was $220 million.", 0.0], ["The amount settled through the SCF program during 2023 was $1.8 billion.", 0.0], ["2021 includes our investment in Rivian of $10.6 billion and cash premium paid of $(1.6) billion associated with repurchasing and redeeming $7.6 billion of higher-coupon debt.", -0.3], ["2022 includes a $7.4 billion loss on our Rivian investment.", -0.8], ["Our full year 2023 Net cash provided by/(used in) operating activities was positive $14.9 billion, an increase of", 0.8], ["$8.1 billion from a year ago (see page 78 for additional information).", 0.5], ["The year-over-year increase was primarily driven by higher net income.", 0.7], ["Company adjusted free cash flow was $6.8 billion, $2.3 billion lower than a year ago.", -0.2], ["An improvement in Company adjusted EBIT excluding Ford Credit and timing differences were more than offset by the non-repeat of working capital improvements and Ford Credit distributions, as well as higher capital spending.", 0.1], ["Capital spending was $8.2 billion in 2023, $1.6 billion higher than a year ago, and is expected to be in the range of", -0.1], ["The full year 2023 working capital impact was $2.4 billion negative, driven by an increase in inventory and receivables.", -0.8], ["All other and timing differences were positive $5.2 billion.", 0.5], ["Shareholder distributions (including cash dividends and anti-dilutive share repurchases) were $5.3 billion in 2023.", 0.2], ["Ford outperformed the 2022 targets for all three of the sustainability-linked metrics, which favorably impacted pricing beginning in the third quarter of 2023.", 0.7], ["Ford Credit continues to have robust access to the capital markets, and ended 2023 with $25.7 billion of liquidity, up $4.6 billion from 2022.", 0.8], ["Net receivables of $133.2 billion at December 31, 2023 were funded primarily with term unsecured debt and term asset- backed securities.", 0.3], ["In 2023, Ford Credit completed $28 billion of public term funding.", 0.4], ["At December 31, 2023, Ford Credit’s net liquidity available for use was $25.7 billion, $4.6 billion higher than year-end 2022, reflecting strong access to public funding markets and the addition of $5.5 billion in committed asset-backed capacity.", 0.6], ["At December 31, 2023, Ford Credit’s liquidity sources, including cash, committed asset-backed facilities, and unsecured credit facilities, totaled $56.2 billion, up $5.2 billion from year-end 2022.", 0.7], ["As of December 31, 2023, Ford Credit had $149 billion of assets, $68 billion of which were unencumbered.", -0.1], ["Ford Credit’s funding plan is subject to risks and uncertainties, many of which are beyond its control, including disruption in the capital markets that could impact both unsecured debt and asset-backed securities issuance and the effects of regulatory changes on the financial markets.", -0.8], ["December 31, 2023, Ford Credit’s financial statement leverage was 9.7:1.", 0.0], ["Worldwide, our defined benefit pension plans were underfunded by $2.3 billion at December 31, 2023, a deterioration of", -0.7], ["$2.1 billion from December 31, 2022, primarily reflecting the impact of lower discount rates compared to year-end 2022 and pension benefit enhancements as part of the collective bargaining agreements in the United States and Canada, partially offset by asset gains in excess of our assumptions.", -0.5], ["Of the $2.3 billion underfunded status at year-end 2023, our funded plans were $2.1 billion overfunded and our unfunded plans were $4.4 billion underfunded.", -0.6], ["In 2023, we contributed $592 million to our global funded pension plans, an increase of $25 million compared with 2022.", 0.2], ["During 2024, we expect to contribute about $1 billion of cash to our global funded pension plans.", 0.5], ["We also expect to make about $400 million of benefit payments to participants in unfunded plans.", 0.1], ["Our global funded plans remain fully funded in aggregate, demonstrating the effectiveness of our de-risking strategy and our commitment to a strong balance sheet.", 0.8], ["Calculated as the sum of net operating profit/(loss) after cash tax from the last four quarters, divided by the average invested capital over the last four quarters.", -0.1], ["Calculated as the sum of adjusted net operating profit/(loss) after cash tax from the last four quarters, divided by the average invested capital over the last four quarters.", -0.1], ["On October 30, 2023, S&P upgraded the credit ratings for Ford and Ford Credit to BBB- from BB+ and revised the outlook to stable from positive.", 0.5], ["Adjusted Free Cash Flow (a)                                                 $6 - $7 billion", 0.2], ["For full-year 2024, we expect adjusted EBIT of $10 billion to $12 billion and adjusted free cash flow of $6 billion to", 0.3], ["Ford Pro EBIT of $8 billion to $9 billion driven by continued growth and favorable mix, partially offset by moderated pricing", 0.4], ["Ford Blue EBIT of $7 billion to $7.5 billion, reflecting a balanced market equation, including the impact of our all-new F-150 launch; we also expect costs to be flat as we offset higher labor and product cost with efficiencies", 0.3], ["Ford Model e EBIT loss of $5 billion to $5.5 billion, primarily driven by continued pricing pressure and investments in next generation vehicles", -0.5], ["Full year of all-new Super Duty, which drives positive pricing and mix in Ford Pro", 0.6], ["Lower industry pricing as supply and demand normalize", -0.3], ["$2 billion benefit from cost reduction initiatives, offsetting higher labor and major product refresh actions", -0.1], ["Ford’s vehicles could be affected by defects that result in recall campaigns, increased warranty costs, or delays in new model launches, and the time it takes to improve the quality of our vehicles and services could continue to have an adverse effect on our business;", -0.8], ["Ford may not realize the anticipated benefits of restructuring actions and such actions may cause Ford to incur significant charges, disrupt our operations, or harm our reputation;", -0.7], ["Ford’s production, as well as Ford’s suppliers’ production, and/or the ability to deliver products to consumers could be disrupted by labor issues, public health issues, natural or man-made disasters, adverse effects of climate change, financial distress, production difficulties, capacity limitations, or other factors;", -0.9], ["Failure to develop and deploy secure digital services that appeal to customers could have a negative impact on Ford’s business;", -0.6], ["Ford’s ability to maintain a competitive cost structure could be affected by labor or other constraints;", -0.5], ["Ford’s results are dependent on sales of larger, more profitable vehicles, particularly in the United States;", 0.2], ["With a global footprint and supply chain, Ford’s results and operations could be adversely affected by economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events;", -0.7], ["Industry sales volume can be volatile and could decline if there is a financial crisis, recession, public health emergency, or significant geopolitical event;", -0.8], ["Ford may face increased price competition or a reduction in demand for its products resulting from industry excess capacity, currency fluctuations, competitive actions, or other factors, particularly for electric vehicles;", -0.6], ["Inflationary pressure and fluctuations in commodity and energy prices, foreign currency exchange rates, interest rates, and market value of Ford or Ford Credit’s investments, including marketable securities, can have a significant effect on results;", -0.8], ["Ford and Ford Credit’s access to debt, securitization, or derivative markets around the world at competitive rates or in sufficient amounts could be affected by credit rating downgrades, market volatility, market disruption, regulatory requirements, or other factors;", -0.7], ["The impact of government incentives on Ford’s business could be significant, and Ford’s receipt of government incentives could be subject to reduction, termination, or clawback;", -0.6], ["Ford Credit could experience higher-than-expected credit losses, lower-than-anticipated residual values, or higher- than-expected return volumes for leased vehicles;", -0.7], ["Economic and demographic experience for pension and OPEB plans (e.g., discount rates or investment returns) could be worse than Ford has assumed;", -0.6], ["Pension and other postretirement liabilities could adversely affect Ford’s liquidity and financial condition;", -0.7], ["Ford and Ford Credit could experience unusual or significant litigation, governmental investigations, or adverse publicity arising out of alleged defects in products, services, perceived environmental impacts, or otherwise;", -0.7], ["Company Adjusted EBIT (Most Comparable GAAP Measure: Net Income/(Loss) Attributable to Ford) – Earnings before interest and taxes (EBIT) excludes interest on debt (excl.", 0.0], ["∘ Pension and OPEB remeasurement gains and losses      ∘ No minimum", 0.0], ["∘ Gains and losses on investments in equity securities       ∘ No minimum", 0.0]], "fdx22_sentences.json": [["For each FedEx operating company, we focus on making appropriate investments in the technology and assets necessary to optimize our long-term earnings performance and cash flow.", 0.8], ["We continue to position our companies and team members to facilitate and capitalize on this access and to achieve stronger long-term growth, productivity, and profitability.", 0.9], ["Continuing to increase collaboration across our operating companies to utilize our air and ground networks in a more efficient manner.", 0.5], ["Delivering excellence and value for our customers and stockholders.", 0.9], ["Growing profitably to reinvest in our team members and business.", 0.8], ["In 2021, we provided over", 0.7], ["$17 million in tuition assistance to nearly 11,000 employees to further their education.", 0.6], ["Due to the COVID-19 pandemic, we have reevaluated how and where team members work and, where appropriate, have provided more flexibility to increase effectiveness and optimize our workspaces.", 0.2], ["Globally, FedEx hired nearly 367,000 full- and part-time team members in 2021, largely to keep up with increased shipping volumes.", 0.7], ["Turnover for part-time team members, primarily package handlers at our sorting locations, was 200%, while full-time team member turnover was 32% in 2022.", -0.5], ["These traditionally higher rates have recently been further exacerbated by the highly competitive labor market and the conditions created by the COVID-19 pandemic.", -0.5], ["Our “Practical Sustainability” philosophy and “Reduce, Replace, Revolutionize” approach guide our efforts to mitigate environmental impacts, increase efficiency, reduce costs, and protect against future risks.", 0.8], ["In 2021 we announced our goal to achieve carbon neutrality by calendar 2040 across our global operations’ Scope 1 and Scope 2 emissions and our Scope 3 contracted transportation GHG emissions.", 0.7], ["To help reach this goal, we are investing more than $2.0 billion in vehicle electrification, sustainable energy, and carbon sequestration, including a pledge of $100 million to Yale University to help establish the Yale Center for Natural Carbon Capture.", 0.9], ["In addition, we continue to leverage other approaches to reduce vehicle emissions, such as increased intermodal rail usage at FedEx Ground and FedEx Freight.", 0.6], ["Through 2021, our efforts collectively resulted in a 42% improvement in FedEx Express vehicle fuel efficiency from our 2005 baseline.", 0.9], ["To reduce the cost of fuel use and associated GHG emissions, we have implemented efficiencies in flight operations through our global FedEx Fuel Sense program and are replacing many of our older airplanes with more fuel-efficient models.", 0.8], ["Our team members remain committed to improving our fuel efficiency and reducing our environmental impact, which led to 65 million gallons of jet fuel savings from our FedEx Fuel Sense program in 2021.", 0.9], ["Additionally, we are modernizing our aircraft fleet to reduce costs, enhance reliability and operational adaptability, improve fuel efficiency, and reduce emissions.", 0.8], ["A global increase in shipping volume exacerbated by the COVID-19 pandemic delayed the retirement of certain older aircraft and led us to fall short of our goal to reduce aircraft emissions intensity by 30% from a 2005 baseline by calendar 2020.", -0.3], ["Due to the increased demand for essential deliveries, e-commerce, and other global shipments in 2021, our aircraft emissions increased 12% compared to our 2020 performance.", -0.2], ["However, we have reduced our overall aircraft emissions intensity by 27% since 2005.", 0.5], ["As of July 15, 2022, the money-back guarantee remains suspended for certain FedEx Express services in order to balance our focus on service and safety.", -0.4], ["Our 2016 acquisition of TNT Express accelerated our European and global growth; substantially enhanced our global footprint through TNT Express’s lower-cost road networks in Europe, the Middle East, and Asia; and expanded our capabilities and solutions for our customers.", 0.7], ["The completion of the physical network integration of TNT Express into FedEx Express in 2022 and consolidation of flights into our Paris hub allow us to significantly improve operational efficiency.", 0.6], ["Additionally, we continue to execute initiatives to transform and optimize the FedEx Express international business, particularly in Europe.", 0.4], ["Effective January 3, 2022, FedEx Express implemented a 5.9% average list price increase for U.S. domestic, U.S. export, and U.S. import services.", -0.1], ["In order to manage demand and capacity constraints in connection with the COVID-19 pandemic, between April 2020 and November 2020 FedEx Express implemented temporary surcharges on all international package and airfreight shipments.", -0.3], ["These surcharges continued as peak surcharges beginning in November 2020 and remain in effect.", -0.3], ["Additionally, beginning in June 2020 FedEx Express has implemented a series of peak surcharges generally applying to U.S. domestic shipments that are oversized or require additional handling, and to residential packages for customers meeting a certain volume threshold.", -0.2], ["Specific applicable surcharges have been adjusted periodically since their implementation, and higher surcharges were applied during the 2022 holiday peak season.", -0.2], ["Effective January 17, 2022, the U.S. domestic holiday peak surcharges were no longer in effect, and an additional residential surcharge was applied for customers who met certain volume thresholds.", -0.1], ["These changes reflect incremental costs associated with the challenging operating environment, while enabling FedEx Express to continue investing in service enhancement, fleet maintenance, technology innovations, and other areas to serve customers more effectively and efficiently.", 0.3], ["Effective June 21, 2021, November 1, 2021, and April 4, 2022, the tables used to determine fuel surcharges at FedEx Express were updated.", 0.0], ["The weighted-average U.S. domestic and outbound fuel surcharges for the past three years were: 2022 — 13.1%; 2021 — 4.9%; and 2020 — 6.3%.", 0.1], ["We are making investments over multiple years in our facilities to expand and modernize our Indianapolis hub and Memphis World Hub.", 0.5], ["The following table sets forth FedEx Express’s costs for jet fuel and its percentage of FedEx Corporation consolidated revenues for the last five fiscal years:", 0.0], ["Risk Factors” of this Annual Report, the express package and freight markets are both highly competitive and sensitive to price and service, especially in periods of little or no macroeconomic growth.", -0.4], ["Many of FedEx Express’s international competitors are government-owned, -controlled, or    - subsidized carriers, which may have greater resources, lower costs, less profit sensitivity, and more favorable operating conditions than FedEx Express.", -0.5], ["As of July 15, 2022, the money-back guarantee for all FedEx Ground services remains temporarily suspended in order to balance our focus on service and safety.", -0.3], ["Effective January 3, 2022, FedEx Ground and FedEx Home Delivery implemented a 5.9% average list price increase.", -0.2], ["FedEx Ground Economy average list prices also increased.", -0.1], ["In recent years, FedEx Ground’s network expansion has substantially increased the company’s daily capacity through the addition of new facilities featuring the latest automated sorting technology as well as the expansion or relocation of existing hubs and other facilities.", 0.5], ["FedEx Ground continues to leverage opportunities to maximize utilization of existing facilities and deploy new technologies to enhance operational efficiency.", 0.6], ["FedEx Ground is defending lawsuits in which it is alleged that FedEx Ground should be treated as an employer or joint employer of drivers employed by service providers engaged by FedEx Ground.", -0.8], ["FedEx Freight continues to expand its use of DIM technology to more accurately capture freight profile, which improves the company’s ability to cost and price shipments.", 0.4], ["On January 3, 2022, FedEx Freight implemented a 5.9% average list price increase for customers who use FXF PZONE and FXF EZONE rates and a 7.9% average list price increase for customers who use FXF 1000 and FXF 501.", -0.2], ["These increases apply for shipments within the U.S. and between the contiguous U.S. and Canada.", 0.0], ["In order to manage demand and capacity constraints, beginning in July 2021 FedEx Freight implemented a peak surcharge applying to specific delivery points within the U.S.", -0.3], ["Effective November 15, 2021, FedEx Freight increased applicable length surcharges.", -0.1], ["Effective January 17, 2022, FedEx Freight added a surcharge that applies when a pickup is performed and no shipment is tendered to the carrier.", -0.5], ["Effective November 1, 2021 and April 4, 2022, the tables used to determine fuel surcharges at FedEx Freight were updated.", 0.0], ["During 2022 we continued to advance a major information technology transition from traditional mainframe computing to cloud-based systems, which is delivering significant benefits in terms of flexibility, security, speed to market, and resiliency.", 0.8], ["The network provides an adaptable cost model helping to save time, labor, and overhead by freeing up resources and avoiding fixed costs associated with large-scale printing and e-commerce parcel volumes.", 0.7], ["FedEx Office has prioritized our e-commerce and digital offerings as a growth opportunity for the enterprise/large, medium, and small business customers we serve.", 0.6], ["FedEx Office has also made investments in new machines and technology, enhancing capabilities in narrow format color, grand format, large format, color management, enhanced finishing, and other technologies.", 0.7], ["As trade throughout the world grows, so does the FedEx Trade Networks Transport & Brokerage solutions portfolio.", 0.5], ["With approximately 15,000 employees at approximately 100 facilities as of May 31, 2022, FedEx Supply Chain provides a comprehensive range of integrated logistics services to enable growth, minimize cost, mitigate supply chain risk, and improve customer services.", 0.7], ["In 2022, we enhanced tracking capabilities on fedex.com based on an advanced machine learning and artificial intelligence model developed by FedEx Dataworks.", 0.8], ["This new experience delivers greater estimated delivery date accuracy, including updates for early or delayed shipments.", 0.9], ["These requirements are not static, but change periodically as the result of regulatory and legislative requirements, imposing additional security costs and creating a level of uncertainty for our operations.", -0.7], ["It is reasonably possible that these rules or other future security requirements could impose material costs on us.", -0.6], ["FedEx Express is compensated for the operation of any aircraft requisitioned under the CRAF program at standard contract rates established each year in the normal course of awarding contracts.", 0.3], ["Accordingly, it is possible that the FAA may take additional action to address aviation safety concerns related to 5G implementation, which could adversely affect FedEx Express’s U.S. domestic air operations.", -0.8], ["We expect compliance with CORSIA to increase FedEx operating expenses.", -0.5], ["Additionally, the extent to which other countries implement that agreement could have an adverse direct or indirect effect on our business.", -0.6], ["In September 2020 the court granted the DOC’s motion to dismiss the lawsuit.", 0.2], ["On July 8, 2022, the U.S. Court of Appeals for the District of Columbia Circuit affirmed the dismissal of the lawsuit.", 0.2], ["For example, there is always a possibility that Congress could remove most FedEx Express employees from the jurisdiction of the RLA, thereby exposing the FedEx Express network to sporadic labor disputes and the risk that small groups of employees could disrupt the entire air/ground network.", -0.7], ["In addition to the other information set forth in this Annual Report, you should carefully consider the following factors, which could materially affect our business, results of operations, financial condition, and the price of our common stock.", -0.6], ["Moreover, given the nature of our business and our global operations, political, economic, and other conditions in foreign countries and regions, including international taxes, government-to-government relations, the typically more volatile economies of emerging markets, and geopolitical risks such as the current conflict between Russia and Ukraine, may adversely affect our business and results of operations.", -0.8], ["To the extent the current conflict between Russia and Ukraine adversely affects our business, it may also have the effect of heightening many other risks disclosed in this Annual Report, any of which could materially and adversely affect our business and results of operations.", -0.9], ["Such risks include, but are not limited to, disruptions to our global technology infrastructure, including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies; our ability to maintain or increase our prices, including our fuel surcharges in response to rising fuel costs; our ability to implement and execute our business strategy, particularly with regard to our FedEx Express international business; disruptions in global supply chains, which can limit the access of FedEx and our service providers to vehicles and other key capital resources and increase our costs and could affect our ability to achieve our goal of carbon neutrality for our global operations by calendar 2040; our ability to maintain our strong reputation and the value of the FedEx brand; terrorist activities targeting transportation infrastructure; our exposure to foreign currency fluctuations; and constraints, volatility, or disruption in the capital markets.", -0.7], ["Geopolitical uncertainty negatively impacted operations at FedEx Express in 2022.", -0.9], ["We expect slowing economic conditions during 2023.", -0.8], ["Additionally, we incurred higher costs due to labor market challenges in 2022, and we expect such conditions to continue to be present in 2023.", -0.8], ["Furthermore, given the nature of our business and our global recognizability, foreign governments may target FedEx by limiting the ability of foreign entities to do business with us in certain instances, imposing monetary or other penalties or taking other retaliatory action, which could have an adverse effect on our business, results of operations, and financial condition, as well as on the price of our common stock.", -0.9], ["Even if we are able to offset the cost of fuel with our surcharges, high fuel surcharges could move our customers away from our higher- yielding express services to our lower-yielding deferred or ground services or even reduce customer demand for our services altogether.", -0.8], ["In addition, disruptions in the supply of fuel could have a negative impact on our ability to operate our transportation networks.", -0.8], ["Several of these factors combined to constrain fuel supply and increase prices in 2022, and we expect such conditions to continue to be present in 2023.", -0.8], ["A disruption to our complex, global technology infrastructure, including those impacting our computer systems and websites, could result in the loss of confidential business or customer information, require substantial repairs or replacements, resulting in significant costs, and lead to the temporary or permanent transfer by customers of some or all of their business to our competitors.", -0.9], ["The foregoing could harm our reputation and adversely impact our operations, customer service, and results of operations.", -0.8], ["These types of adverse impacts could also occur in the event the confidentiality, integrity, or availability of company and customer information was compromised due to a data loss by FedEx or a trusted third party.", -0.7], ["Despite our efforts, we are not fully insulated from data breaches, technology disruptions, data loss, and cyber-fraud, which could adversely impact our competitiveness and results of operations.", -0.8], ["Additionally, we have experienced continual attempts by cyber criminals, some of which have been successful, to gain access to customer accounts for the purposes of fraudulently diverting and misappropriating items being transported in our network.", -0.9], ["The COVID-19 pandemic negatively impacted our operating results in 2022.", -0.9], ["Global recovery from the impacts of the COVID-19 pandemic slowed with the onset of new variants, which resulted in reduced shipping demand and caused network disruptions, particularly at FedEx Express.", -0.8], ["Our business is labor and capital intensive in nature, which has required us to incur higher costs to operate our networks during the pandemic.", -0.7], ["If we are unable to remain agile and continue to flex our networks to align with shipping volumes, customer needs, disrupted global supply chains and other network inefficiencies, market demands, and operating conditions, or are unable to continuously respond to evolving governmental policies for the duration of a prolonged period of economic recovery, our business operations could be negatively impacted, which could have a further adverse effect on our results of operations.", -0.8], ["We have also incurred increased operating expenses related to personal protective equipment and medical/safety supplies, as well as additional security and cleaning services, in order to protect our team members and customers.", -0.7], ["Our business operations may be disrupted, and we may experience increased risk of adverse effects on our business, if a significant portion of our workforce or certain business operations are negatively impacted as a result of remote work arrangements, including due to cyber risks or other disruption to our technology infrastructure.", -0.8], ["To the extent the COVID-19 pandemic continues to adversely affect our business and financial results, it may also have the effect of heightening many other risks described in this section, any of which could materially and adversely affect our business, results of operations, and financial condition.", -0.9], ["Although we believe our aggregate insurance limits should be sufficient to cover our historic claims amounts, the commercial trucking industry has experienced a wave of blockbuster or so-called “nuclear” verdicts, including some instances in which juries have awarded hundreds of millions of dollars to those injured in accidents and their families (such as the recently affirmed award by a New Mexico state court jury in a personal injury and wrongful death lawsuit against FedEx Ground discussed below).", -0.6], ["Given this recent trend, it is possible that additional claims could exceed our aggregate coverage limits.", -0.7], ["If any other claim were to exceed our aggregate insurance coverage, we would bear the excess in addition to our other self-insured amounts.", -0.8], ["Given the current claims environment, the amount of coverage available from excess insurance carriers is decreasing, the premiums for this excess coverage are increasing significantly, and excess insurance carriers are challenging insurance claims more frequently.", -0.8], ["Accordingly, our excess insurance and claims expenses may continue to increase, or we could further increase our self-insured retention as policies are renewed or replaced.", -0.7], ["In 2015, a jury awarded compensatory damages of approximately $160 million to plaintiffs in connection with a personal injury and wrongful death lawsuit filed against FedEx Ground in New Mexico state court.", -0.7], ["Our results of operations and financial condition could continue to be adversely affected if our costs or losses significantly exceed our aggregate coverage limits, we are unable to obtain excess insurance coverage in amounts we deem sufficient, our insurance carriers fail to pay on our insurance claims, or we experience a claim for which coverage is not provided.", -0.9], ["Such initiatives and enhancements may require us to make significant capital expenditures or incur significant expenses.", -0.6], ["We have also incurred, and may continue to incur, increased operating expenses in connection with certain changes to our business strategy.", -0.5], ["We may not be able to derive the expected operational efficiencies, cost savings, and other benefits from our strategic investments and other decisions.", -0.7], ["For example, in 2021 we announced a workforce reduction plan in Europe.", -0.2], ["If we are not able to successfully implement this plan, our future financial results may suffer.", -0.8], ["If we are not able to successfully implement our business strategy and effectively respond to changes in market dynamics and customer preferences, our future financial results will suffer.", -0.9], ["The COVID-19 pandemic has negatively impacted the USPS.", -0.9], ["The USPS is currently implementing strategic changes to its operations to reduce its reliance on the air networks of FedEx Express and other transportation providers, which negatively impacted our results of operations in 2022.", -0.8], ["The difficulties discussed above or additional changes in the USPS’s business, including its ability to access capital or any structural changes to its operations, network, volume levels, service offerings, service commitments, or pricing, could have additional negative impacts on our revenue, results of operations, and financial condition.", -0.9], ["Further, a decision by the USPS to terminate early or not renew its contract with FedEx Express for domestic services, which expires in September 2024, would negatively impact our profitability.", -0.9], ["However, the existence of an irrational pricing environment could limit our ability not only to maintain or increase our prices (including our fuel surcharges in response to rising fuel costs), but also to maintain or grow our revenues and market share.", -0.7], ["While we believe we compete effectively through our current and planned service offerings, if our current competitors or potential future competitors offer a broader range of services or better service levels, more effectively bundle their services, or offer services at lower prices, it could impede our ability to maintain or grow our market share.", -0.5], ["Moreover, if high-volume package shippers further develop or expand internal capabilities for the services we provide, it may reduce our revenue and could negatively impact our financial condition and results of operations.", -0.8], ["News regarding such developments or expansions could also negatively impact the price of our common stock.", -0.7], ["Additionally, advancements in technology, such as advanced safety systems; automated package sorting, handling, and delivery; autonomous delivery; third-party supply chain insight and management; vehicle platooning; alternative fuel vehicles; and digitization of freight services, may necessitate that we increase investments in order to remain competitive, and our customers may not be willing to accept higher rates to cover the cost of these investments.", -0.6], ["Additionally, we may be required to make significant capital expenditures and/or incur certain operating expenses following the completion of certain transactions, which may be higher than initially expected.", -0.6], ["While we expect our past and future acquisitions and strategic transactions to enhance our value proposition to customers and improve our business and long-term profitability, there can be no assurance that we will realize our expectations within the time frame we have established, if at all, or that we can continue to support the value we allocate to acquired businesses, including their goodwill or other intangible assets.", 0.1], ["We have previously incurred goodwill impairment charges related to certain of our acquisitions, some of which have been material, and may incur additional goodwill impairment charges in the future.", -0.7], ["Any of the foregoing could adversely impact our results of operations, financial condition, and growth prospects.", -0.9], ["Labor market challenges contributed to global supply chain disruptions and affected the availability and cost of labor resulting in network inefficiencies, higher purchased transportation costs, and higher wage rates in 2022.", -0.8], ["We expect such conditions to continue to be present in 2023.", -0.7], ["Our inability to effectively meet our labor and purchased transportation needs can hinder our ability to execute our business strategy, negatively impact service levels, and adversely affect our business and results of operations.", -1.0], ["While collective bargaining agreements under the RLA, which covers the pilots at FedEx Express, do not expire, we may be unable to maintain certain favorable terms included in the current collective bargaining agreement following negotiations with the ALPA.", -0.5], ["Our inability to successfully reach new collective bargaining agreements with the ALPA and other unions representing FedEx employees could adversely affect our business and results of operations.", -1.0], ["Such disruptions could threaten our ability to provide competitively priced shipping options and ready access to global markets.", -0.5], ["There is also the possibility that Congress could pass other labor legislation that could adversely affect our companies, such as FedEx Ground and FedEx Freight, whose employees are governed by the NLRA.", -1.0], ["In addition, federal and state governmental agencies, such as the National Mediation Board and the NLRB, have and may continue to take actions that could make it easier for our employees, as well as our vendor and supplier workforces, to organize under the RLA or NLRA.", -0.5], ["Finally, changes to federal or state laws, regulations, rules, judicial or administrative precedent, or guidance governing employee classification could impact the status of FedEx Ground’s service providers as independent employers of drivers.", -0.5], ["If FedEx Ground is deemed to be an employer or joint employer of the drivers of these service providers, labor organizations could more easily organize these individuals, our operating costs could increase materially, and we could incur significant capital outlays and experience adverse impacts to service levels.", -1.0], ["Moreover, even without such regulation, increased awareness and any adverse publicity in the global marketplace about the GHGs emitted by companies in the airline and transportation industries could harm our reputation and reduce customer demand for our services, especially our air express services.", -0.5], ["Failure to achieve our calendar 2040 goal could damage our reputation and customer and other stakeholder relationships.", -0.5], ["Further, given investors’ increased focus related to environmental, social, and governance matters, such a failure could cause large stockholders to reduce their ownership of FedEx common stock and limit our access to financing.", -0.8], ["Such conditions could have an adverse effect on our business, results of operations, and financial condition, as well as on the price of our common stock.", -0.9], ["Standard-setting bodies could interpret or issue guidance on how provisions of certain tax laws and regulations will be applied or otherwise administered that is different from our interpretation, and we may be required to make adjustments to amounts that we have recorded that may adversely impact our results of operations and financial condition.", -0.8], ["Further, our business may be adversely impacted when government agencies cease to operate as expected, including due to partial shutdowns, sequestrations, or similar events, which may result in, among other things, disruption in the ability of government agencies to grant required regulatory approvals.", -0.8], ["the increasing costs of compliance with federal, state, and foreign governmental agency mandates (including the Foreign Corrupt Practices Act and the U.K.", -0.7], ["any liability resulting from and the costs of defending against class-action, derivative, and other litigation, such as wage-and- hour, joint employment, securities, vehicle accident, and discrimination and retaliation claims, claims related to our mandatory and voluntary reporting and disclosure of climate change and other ESG topics, and any other legal or governmental proceedings, including the matters discussed in Note 19 of the consolidated financial statements included in “Item 8.", -0.8], ["disruptions in global supply chains, which can limit the access of FedEx and our service providers to vehicles and other key capital resources and increase our costs;", -0.7], ["governmental underinvestment in transportation infrastructure, which could increase our costs and adversely impact our service levels due to traffic congestion, prolonged closure of key thoroughfares, or sub-optimal routing of our vehicles and aircraft;", -0.8], ["stockholder activism, which could divert the attention of management and our board of directors from our business, hinder execution of our business strategy, give rise to perceived uncertainties as to our future, and cause the price of our common stock to fluctuate significantly; and", -0.8], ["constraints, volatility, or disruption in the capital markets, our ability to maintain our current credit ratings, commercial paper ratings, and senior unsecured debt and pass-through certificate credit ratings, and our ability to meet credit agreement financial covenants.", -0.8], ["As of May 31, 2022, we had $1.3 billion in deposits and progress payments on aircraft purchases and other planned aircraft-related transactions.", -0.1], ["On December 16, 2021, we announced a stock repurchase program approved by our Board of Directors, through which we are authorized to purchase, in the open market or in privately negotiated transactions, up to $5 billion of FedEx common stock.", 0.5], ["Many of our operating expenses are directly impacted by revenue and volume levels, and we expect these operating expenses to fluctuate on a year-over-year basis consistent with changes in revenue and volumes.", 0.0], ["(1)  The following is a summary of the effects of the (costs) benefits of certain items affecting our financial results for the years ended May 31 (in millions):", -0.5], ["Business realignment costs                                   $     (278 )   $     (116 )", -0.7], ["TNT Express integration expenses  (132 )    (210 )", -0.6], ["We experienced revenue and operating income growth in 2022 resulting from yield management actions, including the favorable net impact of fuel at all of our transportation segments.", 0.7], ["In addition, our results were positively affected by a mix shift to our higher yielding services due to strategic actions to improve revenue quality.", 0.6], ["Lower variable incentive compensation expense, as well as severe winter weather experienced in the prior year, also benefited year-over-year operating income in 2022.", 0.4], ["Our operating results for 2022 were negatively affected by the coronavirus (“COVID-19”) pandemic, labor market challenges, and inflationary cost pressures.", -0.8], ["Labor market challenges contributed to global supply chain disruptions and affected the availability and cost of labor resulting in network inefficiencies, higher purchased transportation costs, and higher wage rates.", -0.8], ["In addition, global recovery from the impacts of the COVID-19 pandemic slowed with the onset of new variants, which resulted in reduced shipping demand and caused network disruptions, particularly at FedEx Express during 2022.", -0.7], ["Our 2022 results include business realignment costs of $278 million ($214 million, net of tax, or $0.80 per diluted share) associated with our workforce reduction plan in Europe announced in 2021.", -0.6], ["Our 2022 results also include a $210 million charge ($160 million, net of tax, of $0.60 per diluted share) recognized in the fourth quarter related to pre- and post-judgment interest in connection with a FedEx Ground legal matter.", -0.5], ["We incurred TNT Express integration expenses totaling $132 million ($103 million, net of tax, or $0.39 per diluted share) in 2022, a decrease of $78 million from 2021.", -0.3], ["Consolidated net income includes a pre-tax, noncash loss of $1.6 billion in 2022 ($1.2 billion, net of tax, or $4.49 per diluted share) and a gain of $1.2 billion in 2021 ($895 million, net of tax, or $3.33 per diluted share) associated with our MTM retirement plans accounting adjustments.", -0.4], ["Consolidated net income in 2021 also includes a loss on debt extinguishment of $393 million ($297 million, net of tax, or $1.11 per diluted share) associated with our capital allocation strategy, which includes reducing outstanding debt.", -0.5], ["Net income for 2022 includes a $142 million ($0.53 per diluted share) tax benefit related to revisions of prior year estimates identified during the preparation of U.S. and foreign tax returns.", 0.2], ["In 2021, we recognized a tax benefit of $279 million ($1.04 per diluted share) related to the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), which allows tax losses to be offset against income from prior years that was taxed at higher rates, and a tax benefit of $66 million ($0.25 per diluted share) from a tax rate increase in the Netherlands applied to our deferred tax asset balances.", 0.3], ["In December 2021, our Board of Directors authorized a new stock repurchase program of up to $5 billion of FedEx common stock (in addition to a 25 million share repurchase program authorized in 2016), and we entered into an accelerated share repurchase (“ASR”) agreement with a bank to repurchase an aggregate of $1.5 billion of our common stock.", 0.7], ["Share repurchases had a benefit of $0.13 per diluted share in 2022.", 0.3], ["Revenue increased 11% in 2022 primarily due to yield management actions, including higher fuel surcharges, as well as commercial and home delivery volume growth at FedEx Ground and volume growth at FedEx Freight.", 0.8], ["In addition, we experienced severe winter weather in the prior year which positively affected the year-over-year comparisons in 2022.", 0.2], ["Revenue at FedEx Express increased 9% in 2022 due to global package and international priority freight yield improvement, partially offset by decreased international and U.S. domestic package volume, as well as lower U.S. average daily freight pounds.", 0.1], ["At FedEx Ground, revenue increased 9% in 2022 primarily due to yield improvement, two additional ground commercial operating days, a mix shift to higher-yielding services, and growth in our commercial services.", 0.7], ["FedEx Freight revenue increased 22% in 2022 primarily due to higher revenue per shipment and increased average daily shipments.", 0.9], ["Revenue at Corporate, other, and eliminations increased 33% in 2022 primarily due to higher yields at FedEx Logistics, Inc. (“FedEx Logistics”) as a result of market capacity constraints related to the COVID-19 pandemic.", 0.6], ["In 2021, FedEx Express announced a workforce reduction plan in Europe related to the network integration of TNT Express.", -0.5], ["The plan will affect approximately 5,000 employees in Europe across operational teams and back-office functions.", -0.7], ["We incurred costs of $278 million ($214 million, net of tax, or $0.80 per diluted share) in 2022 and $116 million ($90 million, net of tax, or $0.33 per diluted share) in 2021 associated with our business realignment activities.", -0.6], ["Payments under this program totaled approximately $225 million in 2022 and approximately $15 million in 2021.", -0.1], ["We expect savings from our business realignment activities to be between $275 million and $350 million on an annualized basis beginning in 2024.", 0.5], ["(3)  Includes a $210 million charge in 2022 related to pre- and post-judgment interest in connection with a FedEx Ground legal matter.", -0.7], ["The challenging labor market and inflationary pressures contributed to increases in purchased transportation, salaries and employee benefits, and other operating expenses in 2022.", -0.8], ["Higher fuel surcharges also contributed to increased purchased transportation costs.", -0.3], ["Salaries and employee benefits expense also increased in 2022 due to merit increases, partially offset by lower variable incentive compensation expense.", -0.2], ["Higher self-insurance accruals, increased costs related to information technology expenses, a charge related to pre- and post-judgment interest in connection with a FedEx Ground legal matter, and additional volume-related expenses also contributed to an increase in other operating expense in 2022.", -0.6], ["Rentals and landing fees increased in 2022 primarily driven by increased vehicle and aircraft leases at FedEx Express, as well as network expansion at FedEx Ground.", -0.4], ["Fuel expense increased 77% during 2022 due to higher fuel prices.", -0.9], ["Because of the factors described above, our operating results may be affected should the market price of fuel suddenly change by a significant amount or change by amounts that do not result in an adjustment in our fuel surcharges, which can significantly affect our earnings either positively or negatively in the short-term.", -0.5], ["The net impact of fuel had a significant benefit to operating income in 2022 as higher fuel surcharges outpaced increased fuel prices.", 0.5], ["Interest expense decreased $104 million in 2022 primarily due to the 2021 debt extinguishment transactions further discussed in the “Liquidity” section of this MD&A and Note 7 of the accompanying consolidated financial statements.", 0.3], ["In connection with our debt restructuring, we recognized a loss on debt extinguishment of $393 million ($297 million, net of tax, or $1.11 per diluted share) in 2021.", -0.7], ["In 2022, we incurred a pre-tax, noncash MTM loss of $1.6 billion ($1.2 billion, net of tax, or $4.49 per diluted share), which includes a net loss of $1.3 billion ($1.0 billion, net of tax, or $3.76 per diluted share) related to the year-end actuarial adjustments of pension and postretirement healthcare plans’ assets and liabilities.", -0.9], ["In addition, we incurred a pre-tax, noncash MTM net loss of $260 million ($195 million, net of tax, or $0.73 per diluted share) in the second quarter of 2022, of which $224 million was related to the termination of the TNT Express Netherlands Pension Plan.", -0.8], ["The remaining $36 million net loss was related to the U.S. FedEx Freight Pension Plan and consisted of a $75 million MTM loss due to a lower discount rate in the second quarter of 2022, partially offset by a $39 million curtailment gain.", -0.4], ["In 2021, we incurred a pre-tax, noncash MTM gain of $1.2 billion ($936 million, net of tax, or $3.48 per diluted share) related to the year-end actuarial adjustments of pension and postretirement healthcare plans’ assets and liabilities.", 0.7], ["Additionally, in 2021, we incurred a pre-tax, noncash MTM net loss of $52 million ($41 million, net of tax, or $0.15 per diluted share) related to amendments to the TNT Express Netherlands Pension Plan.", -0.5], ["This $52 million net loss consisted of a $106 million MTM loss due to a lower discount rate and a $54 million curtailment gain.", -0.3], ["The 2022 tax provision was favorably impacted by a benefit of $142 million related to revisions of prior year tax estimates identified during the preparation of U.S. and foreign tax returns.", 0.6], ["The 2021 tax provision includes a benefit of $279 million from an increase in our 2020 tax loss that the CARES Act allowed to be carried back to 2015, when the U.S. federal income tax rate was 35%.", -0.1], ["The 2021 tax provision also includes a benefit of $66 million from a tax rate increase in the Netherlands applied to our deferred tax asset balances and was unfavorably impacted by an increase in uncertain tax positions for matters in multiple jurisdictions.", -0.3], ["We have recorded a cumulative benefit of $215 million through 2022 attributable to our interpretation of the TCJA and the Internal Revenue Code.", 0.2], ["We continue to pursue this lawsuit; however, if we are ultimately unsuccessful in defending our position, we may be required to reverse the benefit previously recorded.", -0.7], ["As part of the collaboration, FedEx Express made a $100 million equity investment in Delhivery, FedEx Express sold certain assets pertaining to its domestic business in India to Delhivery, and the companies entered into a long-term commercial agreement.", 0.5], ["During 2023, we anticipate revenue and operating income growth will be driven by improved yields and cost control actions, as we continue to focus on yield management and revenue quality to help mitigate the impact of slowing economic conditions on our volumes and inflationary pressures on our costs.", 0.3], ["We will also continue executing targeted actions to improve productivity and lower costs both through advanced technology and optimization of operations.", 0.4], ["These actions are focused on reducing the complexity and fragmentation of our international business, improving efficiency to meet changing customer expectations and business dynamics, lowering costs, increasing profitability, and improving service levels.", 0.6], ["As part of this strategy, in 2021 we announced a workforce reduction plan in Europe, which we expect to be substantially complete in 2023, with aggregate spend through the completion of the program anticipated to be approximately $420 million in cash expenditures.", -0.2], ["We expect savings from our business realignment activities to be between $275 million and $350 million on an annualized basis beginning in 2024.", 0.4], ["The uncertainty of a slowing global economy, geopolitical challenges including the ongoing conflict between Russia and Ukraine, and the continuing effect of the COVID-19 pandemic, and the impact these factors will have on the rate of growth of global trade, supply chains, fuel prices, and our business in particular, make any expectations for 2023 inherently less certain.", -0.8], ["Historically, the U.S. express package business experiences an increase in volumes in late November and December.", 0.2], ["International business, particularly in the Asia- to-U.S. market, peaks in October and November in advance of the U.S. holiday sales season.", 0.3], ["Our first and third fiscal quarters, because they are summer vacation and post winter-holiday seasons, have historically experienced lower volumes relative to other periods.", -0.1], ["Shipment levels, operating costs, and earnings for each of our companies can also be adversely affected by inclement weather, particularly the impact of severe winter weather in our third fiscal quarter.", -0.7], ["In 2022, the increase in operating results in Corporate, other, and eliminations was primarily due to improved operating income at FedEx Logistics.", 0.5], ["Market capacity constraints related to the COVID-19 pandemic drove higher revenue due to increased yields, partially offset by higher purchased transportation costs.", 0.1], ["In addition, 2022 operating results in Corporate, other, and eliminations include a $210 million charge recognized in the fourth quarter of 2022 related to pre- and post-judgment interest in connection with a FedEx Ground legal matter.", -0.4], ["FedEx Express segment revenue increased 9% in 2022 primarily due to global package and international priority freight yield management actions, including higher fuel surcharges.", 0.7], ["These factors were partially offset by decreased international domestic package volume driven by yield management actions.", -0.2], ["Additionally, we experienced lower U.S. average daily freight pounds primarily due to decreased demand and a reduction in charter flights, as well as decreased U.S. domestic package volume due to a decline in our deferred service offerings, reflecting year-over-year impacts of the COVID-19 pandemic on consumer behavior in 2022.", -0.8], ["Yield improvement, including higher fuel surcharges, drove increases in international export package yield of 13%, U.S. domestic package yield of 13%, composite freight yield of 12%, and international domestic package yield of 13% in 2022. International export average daily volumes increased 3% primarily due to growth in our international priority service offering, as industry-wide capacity constraints and actions to prioritize premium-yielding products drove a mix shift from international economy to international priority services.", 0.7], ["Total average daily freight pounds decreased 5% primarily due to decreased demand and a reduction in charter flights.", -0.6], ["This decrease was partially offset by higher international priority freight pounds resulting from increased demand for international freight capacity in 2022.", 0.2], ["FedEx Express segment operating income increased 4% in 2022 primarily due to yield management actions, including the favorable net impact of fuel, lower variable incentive compensation expense, and less severe weather experienced in 2022, partially offset by higher operating expenses related to labor market challenges and inflationary pressures.", 0.4], ["The COVID-19 pandemic and geopolitical uncertainty negatively impacted our operations in 2022 as we experienced reduced shipping demand and network disruptions, particularly in the second half of the year.", -0.9], ["In addition, we experienced lower U.S. average daily freight pounds due to decreased demand and a reduction in charter flights in 2022.", -0.7], ["FedEx Express prior year operating results included a pre-tax benefit of approximately $165 million from a reduction in aviation excise taxes provided by the CARES Act, which expired on December 31, 2020 and negatively affected year-over-year comparisons in 2022.", -0.8], ["FedEx Express segment results include business realignment costs of $278 million in 2022 associated with our workforce reduction plan in Europe.", -0.7], ["FedEx Express segments results also include approximately $115 million of TNT Express integration expenses in 2022, a decrease of $61 million from 2021.", -0.5], ["Purchased transportation expense increased 10% in 2022 primarily due to higher utilization of third-party transportation providers and increased rates.", -0.2], ["Other operating expense increased 8% in 2022 primarily due to higher outside service contract expense, which includes variable costs driven by the constrained labor market, as well as additional volume-related expenses.", -0.3], ["Rentals and landing fees expense increased 12% in 2022 primarily due to increased vehicle and aircraft leases.", -0.2], ["Salaries and employee benefits expense increased 1% in 2022 primarily due to higher labor costs related to the constrained labor market and wage pressures, partially offset by lower variable incentive compensation expense.", -0.1], ["Fuel expense increased 80% in 2022 due to increased fuel prices.", -0.5], ["The net impact of fuel had a significant benefit to operating income in 2022 as higher fuel surcharges outpaced increased fuel prices.", 0.3], ["In 2023, we will focus on actions to improve global network efficiencies and lower our cost to serve as we expect rising uncertainty from the slowing economic environment, including inflationary pressures and geopolitical conditions, to impact our business.", -0.4], ["In addition, we will execute our disciplined revenue management strategy and implement cost control actions to drive improved revenue and operating income.", 0.2], ["Capital expenditures at FedEx Express are expected to be relatively flat in 2023, with an increase in capital spend primarily related to vehicle purchases including our vehicle electrification initiative, investments in information technology, and package handling equipment, offset by a decrease in aircraft spend.", 0.1], ["FedEx Ground segment revenue increased 9% in 2022 due to yield management actions, including higher fuel surcharges, as well as two additional ground commercial operating weekdays.", 0.4], ["In addition, a mix shift to higher yielding services due to strategic actions to improve revenue quality and growth in our commercial services as business returned to pre-pandemic levels contributed to the increase in revenue in 2022.", 0.8], ["FedEx Ground yield increased 10% in 2022 primarily due to higher fuel surcharges, product mix, and revenue management actions.", 0.7], ["Average daily volume decreased 1% in 2022 driven by lower economy volume, partially offset by growth in ground commercial and home delivery services.", -0.1], ["Strategic actions to improve revenue quality and prioritize capacity for higher yielding business-to-consumer volume drove a mix shift from economy to home delivery services in 2022.", 0.5], ["Commercial services experienced growth in 2022 as business returned to pre-pandemic levels.", 0.6], ["FedEx Ground segment operating income decreased 17% in 2022 primarily due to higher operating expenses related to labor market challenges and inflationary pressures, as well as incremental costs associated with changes to our product mix.", -0.7], ["The constrained labor market affected the availability and cost of labor resulting in higher purchased transportation costs, network inefficiencies, and higher wage rates.", -0.8], ["In addition, higher self-insurance accruals and increased costs resulting from network expansion negatively impacted operating income in 2022.", -0.9], ["These factors were partially offset by yield management actions, including the favorable net impact of fuel, a favorable mix shift to higher yielding services, growth in commercial services, and two additional ground commercial operating weekdays in 2022.", 0.2], ["Purchased transportation expense increased 8% in 2022 due to higher fuel surcharges, as well as the challenging labor market resulting in increased rates, higher utilization of third-party service providers, and network inefficiencies.", -0.6], ["Salaries and employee benefits expense increased 17% in 2022 due to inflationary pressures and network inefficiencies related to the constrained labor market.", -0.5], ["Other operating expense increased 23% in 2022 primarily due to higher self-insurance accruals, higher variable costs associated with the constrained labor market, and additional volume-related expenses.", -0.6], ["Rentals expense increased 21% in 2022 due to network expansion.", -0.3], ["The net impact of fuel had a significant benefit to operating income in 2022 as higher fuel surcharges outpaced increased fuel prices.", 0.4], ["We anticipate these actions, as well as cost control measures, will result in improved revenue and operating income in 2023.", 0.7], ["Capital expenditures at FedEx Ground are expected to decrease in 2023 primarily related to lower spending on trailers and investments in information technology.", 0.2], ["Revenue                            $    9,532  $    7,833      22     100.0 %  100.0 %", 0.0], ["Salaries and employee benefits                   4,140      3,666      13      43.4    46.8", 0.0], ["Depreciation and amortization                     406       417      (3 )      4.3     5.3", 0.0], ["Maintenance and repairs                        274       227      21       2.9     2.9", 0.0], ["Operating margin                            17.4 %     12.8 %    460 bp", -0.1], ["FedEx Freight segment revenue increased 22% in 2022 primarily due to yield management actions, including higher fuel surcharges, as well as increased average daily shipments.", 0.8], ["Revenue per shipment increased 18% in 2022 primarily due to revenue quality initiatives, including higher fuel surcharges, which more than offset the effect of slightly lower weight per shipment.", 0.7], ["Average daily shipments increased 3% in 2022 due to higher demand for our service offerings.", 0.6], ["FedEx Freight segment operating income increased significantly in 2022 driven by continued focus on revenue quality and profitable growth.", 0.9], ["Severe winter weather experienced in the prior year, as well as one additional operating day, benefited our year-over-year operating income comparisons in 2022.", 0.2], ["Higher purchased transportation costs and wage rates as a result of constrained labor market conditions negatively affected results in 2022.", -0.7], ["Salaries and employee benefits increased 13% in 2022 primarily due to merit increases, higher volumes, and higher labor costs in the constrained labor market.", -0.4], ["Purchased transportation increased 18% in 2022 primarily due to the challenging labor market resulting in higher utilization of third-party service providers and increased rates, as well as higher fuel surcharges.", -0.5], ["Fuel expense increased 66% in 2022 primarily due to increased fuel prices.", -0.8], ["The net impact of fuel had a significant benefit to operating income in 2022 as higher fuel surcharges outpaced increased fuel prices.", 0.5], ["We expect higher revenue and operating income for 2023 as we continue to utilize technology to improve the customer experience and deliver profitable growth.", 0.8], ["We will continue to invest in FedEx Freight Direct, a service to meet the needs of the growing e-commerce market for delivery of heavy, bulky products to or through the door for residences and businesses, and expect profitable growth in 2023.", 0.7], ["Capital expenditures at FedEx Freight are expected to increase in 2023 primarily due to fleet modernization and strategic investments in our network to support our focus on the security of our people, assets, and customers’ freight.", 0.3], ["Cash and cash equivalents totaled $6.9 billion at May 31, 2022, compared to $7.1 billion at May 31, 2021.", 0.0], ["Net (decrease) increase in cash and cash equivalents", -0.5], ["Cash flows from operating activities decreased $0.3 billion in 2022 primarily due to timing of variable incentive compensation payments and a decrease in other tax liabilities, including prior year relief from certain taxes in the", -0.6], ["U.S. pursuant to the CARES Act, partially offset by lower accounts receivable due to the prior year effects of the COVID-19 pandemic, as well as higher net income (net of noncash items).", 0.1], ["Capital expenditures were 15% higher in 2022 primarily due to increased spending on package handling equipment, vehicles and trailers, facilities, and information technology, partially offset by decreased aircraft spending.", -0.2], ["As part of the repurchase programs, we entered into an ASR agreement with a bank in December 2021 to repurchase an aggregate of", 0.0], ["$1.5 billion of our common stock.", 0.5], ["During 2022, the ASR transaction was completed, and 6.1 million shares were delivered under the ASR agreement.", 0.2], ["We repurchased 2.8 million additional shares of our common stock during 2022.", 0.3], ["During 2021, we issued $3.25 billion of senior unsecured debt under our shelf registration statement and used the net proceeds to redeem $5.8 billion of outstanding debt and pay associated redemption premiums of $393 million, eliminating all debt maturities through 2025 and one maturity in 2027.", 0.1], ["Capital expenditures increased $0.9 billion during 2022 primarily due to increased spending on package handling equipment at all transportation segments, higher spending on vehicles and trailers, as well as facilities at FedEx Ground and FedEx Express, and higher information technology spending at FedEx Services, partially offset by decreased aircraft spending at FedEx Express.", 0.0], ["In response to current business and economic conditions as referenced above in the “Outlook” section of this MD&A, we are continuing to actively manage and optimize our capital allocation in a challenging macroeconomic environment due to the ongoing COVID-19 pandemic, labor availability and supply chain constraints, inflationary pressures, rising fuel prices, and geopolitical conflicts.", -0.5], ["We expect to repurchase $1.5 billion of our common stock in 2023.", 0.6], ["We expect increased investment in replacement vehicles including our vehicle electrification initiative, information technology, and strategic investments aimed to optimize operations across our networks to be offset with lower aircraft fleet modernization spend.", 0.4], ["These aircraft are significantly more fuel-efficient per unit than the aircraft types previously utilized, and", 0.2], ["these expenditures are necessary to achieve significant long-term operating savings and to replace older aircraft.", 0.3], ["Our ability to delay the timing of these aircraft-related expenditures is limited without incurring significant costs to modify existing purchase agreements.", -0.8], ["We made a voluntary contribution of $400 million to our tax qualified U.S. domestic pension plans (“U.S.", 0.2], ["Pension Plans”) in June 2023 and anticipate making $400 million of additional voluntary contributions during the remainder of 2023.", 0.3], ["On June 14, 2022, our Board of Directors declared a quarterly cash dividend of $1.15 per share of common stock.", 0.5], ["The dividend was paid on July 11, 2022 to stockholders of record as of the close of business on June 27, 2022.", 0.4], ["Standard & Poor’s has assigned us a senior unsecured debt credit rating of BBB, a Certificates rating of AA-, a commercial paper rating of A-2, and a ratings outlook of “stable.” Moody’s Investors Service has assigned us an unsecured debt credit rating of Baa2, a Certificates rating of Aa3, a commercial paper rating of P-2, and a ratings outlook of “stable.” If our credit ratings drop, our interest expense may increase.", -0.7], ["If our commercial paper ratings drop below current levels, we may have difficulty utilizing the commercial paper market.", -0.6], ["If our senior unsecured debt credit ratings drop below investment grade, our access to financing may become limited.", -0.7], ["The rules for pension accounting are complex and can produce volatility in our earnings, financial condition, and liquidity.", -0.5], ["Our defined benefit pension and postretirement benefit plans are measured using actuarial techniques that reflect management’s assumptions for expected returns on assets (“EROA”), discount rate, and demographic experience such as salary increases, expected retirement, mortality, employee turnover, and future increases in healthcare costs.", -0.4], ["Differences between these assumptions and actual experience are recognized in our earnings through MTM accounting.", -0.2], ["The components of the MTM adjustments for the period ended May 31 are as follows (presented as loss (gain) in millions):", -0.1], ["The following sensitivity analysis shows the impact of a 50-basis-point change in the EROA and discount rate assumptions for our largest pension plan and the resulting increase (decrease) in our projected benefit obligation (“PBO”) as of May 31, 2022 and expense for the year ended May 31, 2022 (in millions):", -0.1], ["To the extent we do not consider it more likely than not that a deferred tax asset will be recovered, a valuation allowance is established.", -0.3], ["We believe we will generate sufficient future taxable income to realize the tax benefits related to the remaining net deferred tax assets in our consolidated balance sheets that are not subject to valuation allowances.", 0.5], ["Nevertheless, changes in accident frequency and severity, healthcare costs, insurance retention levels, and other factors can materially affect the estimates for these liabilities and affect our results of operations.", -0.4], ["A five-percent reduction or improvement in the assumed claim severity used to estimate our self-insurance accruals would result in an increase or decrease of approximately $230 million in our reserves and expenses as of and for the year ended May 31, 2022.", -0.3], ["This evaluation may result in changes in the estimated lives and residual values used to depreciate our aircraft and other equipment.", -0.2], ["These estimates affect the amount of depreciation expense recognized in a period and, ultimately, the gain or loss on the disposal of the asset.", -0.2], ["Changes in the estimated lives of assets will result in an increase or decrease in the amount of depreciation recognized in future periods and could have a material impact on our results of operations (as described below).", -0.3], ["However, such amounts may differ materially in the future due to changes in business levels, technological obsolescence, accident frequency, regulatory changes, and other factors beyond our control.", -0.8], ["Furthermore, the timing and availability of certain used aircraft types (particularly those with better fuel efficiency) may create limited opportunities to acquire these aircraft at favorable prices in advance of our capacity needs.", 0.2], ["We make decisions to remove certain long-lived assets from service based on projections of reduced capacity needs or lower operating costs of newer aircraft types, and those decisions may result in an impairment charge.", -0.6], ["These aircraft have been idled for an average of 24 months and are expected to return to revenue service in order to meet expected demand.", 0.5], ["We evaluated these reporting units during the fourth quarters of 2022 and 2021 and the estimated fair value of each of these reporting units exceeded their carrying values as of the end of 2022 and 2021; therefore, we do not believe that any of these reporting units were impaired as of the balance sheet dates.", 0.7], ["In the opinion of management, the aggregate liability, if any, of individual matters or groups of related matters not specifically described in Note 19 is not expected to be material to our financial position, results of operations, or cash flows.", 0.3], ["A loss is recognized for all contingencies deemed probable and estimable, regardless of amount.", -0.9], ["For unresolved contingencies with potentially material exposure that are deemed reasonably possible, we evaluate whether a potential loss or range of loss can be reasonably estimated.", -0.4], ["Our evaluation of these matters is the result of a comprehensive process designed to ensure that accounting recognition of a loss or disclosure of these contingencies is made in a timely manner and involves our legal and accounting personnel, as well as external counsel where applicable.", 0.1], ["In reaching our conclusions with respect to accrual of a loss or loss contingency disclosure, we take a holistic view of each matter based on these factors and the information available prior to the issuance of our financial statements.", 0.0], ["Uncertainty with respect to an individual factor or combination of these factors may impact our decisions related to accrual or disclosure of a loss contingency, including a conclusion that we are unable to establish an estimate of possible loss or a meaningful range of possible loss.", -0.8], ["However, events may arise that were not anticipated and the outcome of a contingency may result in a loss to us that differs materially from our previously estimated liability or range of possible loss.", -0.7], ["As disclosed in Note 7 to the accompanying consolidated financial statements, we had outstanding fixed-rate long-term debt (exclusive of finance leases) with an estimated fair value of $18.8 billion at May 31, 2022 and outstanding fixed- and floating-rate long-term debt (exclusive of finance leases) with an estimated fair value of $23.1 billion at May 31, 2021.", 0.2], ["Market risk for long-term debt is estimated as the potential decrease in fair value resulting from a hypothetical 10% increase in interest rates and amounts to approximately $518 million as of May 31, 2022 and approximately $507 million as of May 31, 2021.", 0.1], ["Changes in interest rates impact our liabilities associated with these retirement plans, as well as the amount of pension and postretirement benefit expense recognized.", -0.3], ["Declines in the value of plan assets could diminish the funded status of our pension plans and potentially increase our requirement to make contributions to the plans.", -0.6], ["Substantial investment losses on plan assets would also increase net pension expense.", -0.7], ["Foreign currency fluctuations had a slightly positive impact on operating income in 2022 and a slightly negative impact on operating income in 2021.", 0.1], ["At May 31, 2022, the result of a uniform 10% strengthening in the value of the dollar relative to the currencies in which our transactions are denominated would result in a decrease in expected operating income of approximately $50 million for 2023.", -0.4], ["While we have market risk for changes in the price of jet and vehicle fuel, this risk is largely mitigated by our indexed fuel surcharges.", 0.3], ["Based on this assessment, management has concluded that our internal control over financial reporting was effective as of May 31, 2022.", 0.8], ["In our opinion, FedEx Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of May 31, 2022, based on the COSO criteria.", 0.8], ["We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of May 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, cash flows and changes in common stockholders’ investment for each of the three years in the period ended May 31, 2022, and the related notes and our report dated July 18, 2022 expressed an unqualified opinion thereon.", 0.7], ["At May 31, 2022, the Company’s aggregated projected benefit obligation for U.S. pension plans was $28.7 billion and exceeded the $26.0 billion fair value of U.S. pension plan assets, resulting in an unfunded U.S. pension obligation of $2.7 billion.", -0.5], ["The net periodic benefit cost for the year ended May 31, 2022 for the U.S. pension plans was $1.6 billion.", -0.3], ["U.S. pension plans from the prior year due to the change in service cost, interest cost, actuarial gains and losses, benefit payments, contributions and other activities.", 0.0], ["Current portion of long-term debt                              $        82  $       146", -0.2], ["LONG-TERM DEBT, LESS CURRENT PORTION                           20,182        20,733 OTHER LONG-TERM LIABILITIES", -0.2], ["Pension, postretirement healthcare, and other benefit obligations                    4,448         3,501", -0.3], ["Accumulated other comprehensive loss                                 (1,103 )         (732 ) Treasury stock, at cost  (10,484 )      (8,430 )", -0.4], ["Total common stockholders’ investment                               24,939        24,168 TOTAL LIABILITIES AND COMMON STOCKHOLDERS’ INVESTMENT        $      85,994  $      82,777", -0.1], ["NET INCOME                                  $     3,826  $     5,231  $     1,286", 0.5], ["Net income                                  $     3,826  $     5,231  $     1,286", 0.5], ["Loss on extinguishment of debt                             —        393         —", -0.7], ["Retirement plans mark-to-market adjustments                    1,578       (1,176 )        794", 0.2], ["Goodwill and other asset impairment charges                      —         —        435", -0.5], ["Pension and postretirement healthcare assets and liabilities, net           (697 )       (317 )       (908 )", -0.6], ["Other current assets                                 (158 )        (40 )        (59 )", -0.3], ["Other, net      (93 )       (197 )       (7 )", -0.2], ["Accounts payable and other liabilities                       (1,861 )        71       (1,787 )", -0.4], ["Cash provided by operating activities                           9,832       10,135       5,097", -0.1], ["Business acquisitions, net of cash acquired                         —        (228 )        —", -0.5], ["Capital expenditures                                  (6,763 )      (5,884 )      (5,868 )", -0.7], ["Proceeds from asset dispositions and other     94     102      22", 0.1], ["Cash used in investing activities                             (6,816 )      (6,010 )      (5,846 )", -0.6], ["Principal payments on debt                                (161 )      (6,318 )      (2,548 )", -0.8], ["Dividends paid                                      (793 )       (686 )       (679 )", -0.5], ["Purchase of treasury stock                               (2,248 )        —         (3 )", -0.7], ["Cash (used in) provided by financing activities                      (3,019 )      (2,090 )       3,381", -0.3], ["Net (decrease) increase in cash and cash equivalents                    (190 )       2,206       2,562", 0.2], ["Net income                           —       —    1,286       —      —    1,286 Other comprehensive loss, net of tax of $43           —       —      —      (333 )     —     (333 ) Purchase of treasury stock (0.02 million shares)         —       —      —       —      (3 )     (3 ) Cash dividends declared ($2.60 per share)           —       —     (679 )       —      —     (679 )", -0.5], ["(1.0 million shares issued)                  —      125     (35 )       —     130     220", 0.2], ["—      —      (4 )      —      —      (4 )", -0.1], ["Net income                           —      —    5,231       —      —    5,231", 1.0], ["Other comprehensive gain, net of tax of ($10)         —      —      —      415      —     415", 0.8], ["Cash dividends declared ($2.60 per share)           —      —     (686 )       —      —    (686 )", -0.6], ["Balance at May 31, 2021                   32     3,481    29,817      (732 )   (8,430 )   24,168", 0.3], ["Net income                           —       —    3,826       —      —    3,826 Other comprehensive loss, net of tax of $19           —       —      —      (371 )     —     (371 ) Purchase of treasury stock (8.9 million shares)         —       (9 )     —       —    (2,239 )   (2,248 ) Cash dividends declared ($3.00 per share)           —       —     (793 )       —      —     (793 )", -0.8], ["Revenue, including ancillary or accessorial fees and reductions for estimated customer incentives, is recorded proportionally as costs are incurred.", 0.0], ["Certain contracts contain customer incentives, guaranteed service refunds, and other provisions that can either increase or decrease the transaction price.", 0.0], ["We include estimated amounts of revenue, which may be reduced by incentives or other contract provisions, in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.", -0.2], ["Gross contract assets related to in-transit shipments totaled $861 million and $715 million at May 31, 2022 and May 31, 2021, respectively.", 0.1], ["Advertising and promotion expenses were $470 million in 2022, $428 million in 2021, and $427 million in 2020.", 0.1], ["Gains and losses on sales of property used in operations are classified within operating expenses and historically have been nominal.", 0.0], ["Depreciation and amortization expense, excluding gains and losses on sales of property and equipment used in operations, was $4.0 billion in 2022, $3.8 billion in 2021, and $3.6 billion in 2020.", 0.1], ["Capitalized interest was $62 million in 2022, $68 million in 2021, and $54 million in 2020.", 0.1], ["For assets that are to be held and used, an impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value.", -0.5], ["If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.", -0.5], ["As a consequence of this decision, we recognized noncash impairment charges of $66 million ($50 million, net of tax, or $0.19 per diluted share) in the FedEx Express segment in 2020.", -0.7], ["Such a change in recognition or measurement could result in the recognition of a tax benefit or an increase to the related provision.", 0.0], ["Any portion of a change in the fair value of a derivative that is considered to be ineffective, along with the change in fair value of any derivatives not designated in a hedging relationship, is immediately recognized in the income statement.", -0.2], ["Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the local currency are included in the caption “Other, net” in the accompanying consolidated statements of income and were immaterial for each period presented.", 0.0], ["As part of the collaboration, FedEx Express made a $100 million equity investment in Delhivery, FedEx Express sold certain assets pertaining to its domestic business in India to Delhivery, and the companies entered into a long-term commercial agreement.", 0.5], ["As part of the repurchase programs, we entered into an accelerated share repurchase (“ASR”) agreement with a bank in December 2021 to repurchase an aggregate of $1.5 billion of our common stock.", 0.3], ["During the third quarter of 2022, the ASR transaction was completed, and 6.1 million shares were delivered under the ASR agreement.", 0.2], ["The repurchased shares were accounted for as a reduction to common stockholders’ investment in the accompanying consolidated balance sheets and resulted in a reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted earnings per share.", 0.0], ["In 2022, including the ASR transaction, we repurchased 8.9 million shares of FedEx common stock at an average price of $253.85 per share for a total of $2.2 billion.", 0.4], ["In 2020, we repurchased 0.02 million shares of FedEx common stock at an average price of $156.90 per share for a total of $3 million.", 0.1], ["On June 14, 2022, our Board of Directors declared a quarterly cash dividend of", 0.1], ["In January 2021, FedEx Express announced a workforce reduction plan in Europe related to the network integration of TNT Express.", -0.5], ["The plan will impact approximately 5,000 employees in Europe across operational teams and back-office functions.", -0.5], ["We incurred costs associated with our business realignment activities of $278 million ($214 million, net of tax, or $0.80 per diluted share) in 2022.", -0.7], ["We incurred costs during 2021 of $116 million ($90 million, net of tax, or $0.33 per diluted share) associated with our business realignment activities.", -0.6], ["We expect the pre-tax cost of our business realignment activities to be approximately $420 million through fiscal 2023.", -0.8], ["The actual amount and timing of business realignment costs and related cost savings resulting from the workforce reduction plan are dependent on local country consultation processes and regulations and negotiated social plans and may differ from our current expectation and estimates.", -0.9], ["While there has been no material effect to our financial condition, results of operations, or cash flows from reference rate reform as of May 31, 2022, we continue to monitor our contracts and transactions for potential application of this ASU.", 0.0], ["This standard will not have a material impact on our consolidated financial statements and related disclosures.", 0.0], ["We are exposed to credit losses primarily through our trade receivables.", -0.4], ["Credit losses were $403 million in 2022, $577 million in 2021, and $442 million in 2020.", -0.6], ["On December 23, 2020, we acquired ShopRunner, Inc. (“ShopRunner”), an e-commerce platform that directly connects brands and merchants with online shoppers, for $228 million in cash from operations.", 0.3]], "fdx23_sentences.json": [["The aggregate market value of the common stock held by non-affiliates of the Registrant, computed by reference to the closing price as of the last business day of the Registrant’s most recently completed second fiscal quarter, November 30, 2022, was approximately $42.4 billion.", 0.5], ["Financial Statements and Supplementary Data” are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations, cash flows, plans, objectives, future performance, and business.", 0.0], ["Actual results may differ materially from those contemplated (expressed or implied) by such forward-looking statements, because of, among other things, the risk factors identified above and the other risks and uncertainties you can find in our press releases and other Securities and Exchange Commission (“SEC”) filings.", -0.5], ["As a result of these and other factors, no assurance can be given as to our future results and achievements.", -0.8], ["One FedEx will help facilitate our DRIVE transformation program to improve long-term profitability, including Network 2.0, the multi-year effort to improve the efficiency with which FedEx picks up, transports, and delivers packages in the U.S. and Canada.", 0.7], ["We made significant investments in our service network in recent years to build out our infrastructure and services to meet increased e-commerce demand.", 0.6], ["We continue to position our company and team members to facilitate and capitalize on this access and to achieve stronger long-term growth, productivity, and profitability.", 0.8], ["Launching DRIVE, a comprehensive program to improve our long-term profitability, including Network 2.0, the multi-year effort to improve the efficiency with which FedEx picks up, transports, and delivers packages in the U.S. and Canada.", 0.7], ["Growing profitably to reinvest in our team members and business.", 0.9], ["DEI fosters collaboration, enables us to recruit, retain, and develop a talented workforce, and underpins our business performance and sustainability.", 0.8], ["The continued integration of DEI into our business strategies and progress towards our DEI objectives supported our ability to respond to the challenging labor market our industry faced in recent years.", 0.5], ["Turnover for part-time team members, primarily package handlers at our sorting locations, was 205%, while full-time team member turnover was 32% in 2023.", -0.5], ["These traditionally higher rates have recently been further exacerbated by the highly competitive labor market.", -0.7], ["In May 2023, FedEx Express reached a tentative successor agreement with ALPA.", 0.2], ["In 2023 we exceeded our FedEx Cares 50 by 50 goal of positively impacting 50 million people around the world by our 50th anniversary in April 2023.", 0.8], ["While climate change poses a strategic risk to our business and stakeholders, we recognize the opportunities it simultaneously creates around sustainable products and services that advance our customers’ environmental goals.", 0.3], ["Fleet efficiency enables ongoing fuel, emissions, and cost reductions as the industry works to address these challenges.", 0.4], ["Through 2022, our efforts collectively resulted in a 40% improvement in FedEx Express vehicle fleet efficiency from our 2005 baseline.", 0.6], ["Since 2005, we reduced our overall aircraft emissions intensity by 28%, primarily due to our ongoing FedEx Fuel Sense and aircraft modernization initiatives.", 0.7], ["Our global FedEx Fuel Sense program, which accounted for 13 million gallons of jet fuel savings in 2022, enables us to reduce the cost of fuel use and associated GHG emissions.", 0.9], ["Additionally, our commitment to modernizing our aircraft fleet lowers costs, enhances reliability and operational adaptability, improves fuel efficiency, and reduces emissions intensity.", 0.8], ["During 2023, we retired our MD-10-30 fleet and accelerated the retirement of our MD- 11 fleet to the end of 2028.", -0.2], ["Over the years, FedEx Express has added capabilities in important international markets that have given us more robust transportation networks.", 0.7], ["Our 2016 acquisition of TNT Express accelerated our European and global growth; substantially enhanced our global footprint through TNT Express’s lower-cost road networks in Europe, the Middle East, and Asia; and expanded our capabilities and solutions for our customers.", 0.9], ["The completion of the physical network integration of TNT Express into FedEx Express in 2022 and consolidation of flights into our Paris hub allow us to significantly improve operational efficiency, and the reopening and completion of central European road hubs in Duiven, The Netherlands and Novara, Italy in 2023 have improved our intra-European service.", 0.8], ["We also have expanded our capabilities in the Asia-Pacific markets, including through the establishment of our Asia-Pacific hub at the Guangzhou Baiyun International Airport in southern China; our North Pacific regional hub at the Kansai International Airport in Osaka, Japan, which serves as a consolidation point for shipments from northern Asia to the U.S.; and our International Express and Cargo Hub in Shanghai at Shanghai’s Pudong International Airport.", 0.7], ["Effective January 2, 2023, FedEx Express implemented a 6.9% average list price increase for U.S. domestic, U.S. export, and U.S. import services.", -0.1], ["Specific applicable surcharges have been adjusted periodically since their implementation, and higher surcharges were applied during the 2023 holiday peak season.", -0.3], ["Effective January 16, 2023, the U.S. domestic holiday peak surcharges were no longer in effect for residential shipments, and peak surcharges for shipments that are oversized or require additional handling were adjusted downward.", 0.2], ["Many of FedEx Express’s international competitors are government-owned, -controlled, or - subsidized carriers, which may have greater resources, lower costs, less profit sensitivity, and more favorable operating conditions than FedEx Express.", -0.7], ["In May 2023, FedEx Express reached a tentative successor agreement with ALPA.", -0.1], ["By leveraging the FedEx brand, maintaining a low-cost structure, and efficiently using information technology and advanced automation systems, FedEx Ground continues to enhance its competitive position as a leading provider of business and residential ground package delivery services.", 0.8], ["Effective January 2, 2023, FedEx Ground and FedEx Home Delivery implemented a 6.9% average list price increase.", 0.2], ["FedEx Ground Economy average list prices also increased.", 0.1], ["To manage demand and capacity constraints in connection with the COVID-19 pandemic, beginning in June 2020 FedEx Ground implemented a series of surcharges generally applying to shipments that are oversized, unauthorized, or require additional handling; to residential packages for customers meeting a certain volume threshold; and to FedEx Ground Economy shipments.", -0.3], ["Specific applicable surcharges have been adjusted periodically since their implementation, and higher surcharges were applied during the 2023 holiday peak season.", -0.2], ["Effective January 16, 2023, the holiday peak surcharges were no longer in effect for residential shipments, and peak surcharges for shipments that are oversized or require additional handling were adjusted downward.", 0.3], ["Following a network expansion in recent years that substantially increased FedEx Ground’s daily capacity through the addition of new facilities featuring the latest automated sorting technology as well as the expansion or relocation of existing hubs and other facilities, in 2023 the company rationalized its operations in response to lower volumes by consolidating sorts and cancelling several planned network capacity projects, continuing to manage staffing levels effectively, and reducing Sunday delivery operations.", 0.0], ["Additionally, FedEx Ground has made significant operational enhancements to ensure safe and reliable handling of large and heavy items.", 0.5], ["FedEx Ground is defending lawsuits in which it is alleged that FedEx Ground should be treated as an employer or joint employer of drivers employed by service providers engaged by FedEx Ground.", -0.5], ["The status of the drivers employed by these service providers could be further challenged in connection with our one FedEx consolidation plan.", -0.5], ["The company plans to close and consolidate approximately 30 locations in the first quarter of 2024, and conducted several rounds of furloughs to match staffing with volume levels in 2023.", -0.7], ["On January 2, 2023, FedEx Freight implemented a 6.9% average list price increase for customers who use FXF PZONE and FXF EZONE rates and a 7.9% average list price increase for customers who use FXF 1000 and FXF 501.", 0.2], ["Effective November 15, 2021, FedEx Freight increased applicable length surcharges.", -0.3], ["Effective January 17, 2022, FedEx Freight added a surcharge that applies when a pickup is performed and no shipment is tendered to the carrier.", -0.4], ["During 2023 we continued to advance a major information technology transition from traditional mainframe computing to cloud-based systems, which is delivering significant benefits in terms of flexibility, security, speed to market, and resiliency.", 0.8], ["The advanced tracking capability within FedEx Tracking provides customers with a consolidated view of inbound and outbound shipments.", 0.6], ["Additionally, an advanced machine learning and artificial intelligence model developed by FedEx Dataworks has enhanced tracking capabilities on fedex.com, delivering greater estimated delivery date accuracy, including updates for early or delayed shipments.", 0.7], ["In 2023, FedEx ended the research and development program for Roxo, the FedEx SameDay Bot, to prioritize these other nearer-term opportunities.", -0.2], ["FedEx Dataworks is also helping to build out a dynamic pricing infrastructure, which enabled 2023 holiday peak residential surcharges to adjust dynamically based on an individual customer’s weekly peaking factor, and exploring and implementing ways for predictive anomaly detection to improve revenue quality.", 0.5], ["For information regarding FedEx Consolidated Returns, see “FedEx Services Segment — Customer-Driven Technology — E- Commerce Solutions.” We discontinued FedEx SameDay City operations during 2023.", -0.2], ["As trade throughout the world grows, so does the FedEx Trade Networks Transport & Brokerage solutions portfolio.", 0.5], ["It is reasonably possible that these rules or other future security requirements could impose material costs on us.", -0.7], ["FedEx Express’s U.S. air operations continued to operate with minimal interruption due to the FAA’s issuance of alternative means of compliance while the company modified its fleet to comply with the directives.", 0.1], ["As of July 1, 2023, FedEx Express’s U.S. air operations are in compliance with the airworthiness directives, and we do not expect any subsequent operational disruptions from “5G” cellular network implementation.", 0.3], ["Beginning in calendar 2012, airlines including FedEx were required to purchase emissions allowances or, alternatively, purchase qualifying sustainable aviation fuel if they exceeded the number of free allowances allocated under the ETS.", -0.1], ["We expect compliance with CORSIA and the ETS to increase FedEx operating expenses.", -0.6], ["The amount of such increase will ultimately depend on a number of factors, including the number of our flights subject to CORSIA and the ETS, the fuel efficiency of our fleet, the average growth of the aviation sector, our ability to utilize sustainable aviation fuels in the future and the price of such fuels, and the price of eligible emission units, offsets, or allowances required to be purchased by FedEx.", -0.4], ["Additionally, the extent to which other countries implement that agreement could have an adverse direct or indirect effect on our business.", -0.8], ["Violations of these regulations can result in significant monetary and other penalties.", -0.9], ["Violations of the ECRA can result in criminal penalties of up to $1 million and civil penalties of $305,000 (or twice the value of the transaction) per individual violation.", -0.8], ["However, the heightened focus on export controls by the U.S. government increases FedEx’s exposure to potential regulatory penalties and could result in higher compliance costs.", -0.6], ["In addition to the other information set forth in this Annual Report, you should carefully consider the following factors, which could materially affect our business, results of operations, financial condition, and the price of our common stock.", -0.5], ["When individuals and companies purchase and produce fewer goods, we transport fewer goods, and as companies move manufacturing closer to consumer markets and expand the number of distribution centers, we transport goods shorter distances, which adversely affects our yields and profitability.", -0.7], ["Additionally, consumer spending has shifted from goods to services, and in 2023 we saw a customer preference for slower, less costly shipping services.", -0.6], ["Further, the scale of our operations and our relatively high fixed-cost structure, particularly at FedEx Express, make it difficult to quickly adjust to match shifting volume levels, which negatively affected our results of operations in 2023.", -0.7], ["Our results in 2023 were adversely impacted by lower global volumes due to weak economic conditions.", -0.8], ["We are experiencing a decline in demand for our transportation services as inflation and interest rate increases are negatively affecting consumer and business spending.", -0.9], ["Additionally, we are experiencing higher costs to serve through higher fuel prices, wage rates, purchased transportation costs, and other direct operating expenses such as operational supplies.", -0.8], ["During 2024, we expect macroeconomic conditions to continue to negatively affect customer demand for our services.", -0.9], ["Moreover, given the nature of our business and our global operations, political, economic, and other conditions in foreign countries and regions, including international taxes, government-to-government relations, the typically more volatile economies of emerging markets, and geopolitical risks such as the ongoing conflict between Russia and Ukraine, may adversely affect our business and results of operations.", -0.8], ["To the extent the current conflict between Russia and Ukraine, or subsequent similar conflicts between or among other nations, adversely affects our business, it may also have the effect of heightening many other risks disclosed in this Annual Report, any of which could materially and adversely affect our business and results of operations.", -0.9], ["Geopolitical uncertainty negatively affected operations at FedEx Express in recent years.", -0.7], ["Additional changes in international trade policies and relations could significantly reduce the volume of goods transported globally and adversely affect our business and results of operations.", -0.8], ["The U.S. government has taken certain actions that have negatively affected U.S. trade, including imposing tariffs on certain goods imported into the U.S. Additionally, several foreign governments have imposed tariffs on certain goods imported from the U.S.", -0.7], ["These actions contributed to weakness in the global economy that adversely affected our results of operations in recent years.", -0.8], ["Any further changes in U.S. or international trade policy, including tariffs, export controls, quotas, embargoes, or sanctions, could trigger additional retaliatory actions by affected countries, resulting in “trade wars” and further increased costs for goods transported globally, which may reduce customer demand for these products if the parties having to pay tariffs or other anti-trade measures increase their prices, or in trading partners limiting their trade with countries that impose such measures.", -0.9], ["Political uncertainty surrounding international trade and other disputes could also have a negative effect on business and consumer confidence and spending.", -0.8], ["Such conditions could have an adverse effect on our business, results of operations, and financial condition, as well as on the price of our common stock.", -0.8], ["Furthermore, given the nature of our business and our global recognizability, foreign governments may target FedEx by limiting the ability of foreign entities to do business with us in certain instances, imposing monetary or other penalties or taking other retaliatory action, which could have an adverse effect on our business, results of operations, and financial condition, as well as on the price of our common stock.", -0.8], ["To date, we have been mostly successful in mitigating over time the expense effect of higher fuel costs through our indexed fuel surcharges, as the amount of the surcharges is closely linked to the market prices for fuel.", -0.1], ["If we are unable to maintain or increase our fuel surcharges because of competitive pricing pressures or some other reason, fuel costs could adversely affect our operating results.", -0.7], ["Even if we are able to offset the cost of fuel with our surcharges, high fuel surcharges could move our customers away from our higher- yielding express services to our lower-yielding deferred or ground services or even reduce customer demand for our services altogether.", -0.8], ["In addition, disruptions in the supply of fuel could have a negative effect on our ability to operate our transportation networks.", -0.9], ["The failure to successfully execute our DRIVE transformation program, including Network 2.0, and our one FedEx consolidation plan in the expected time frame and at the expected cost may adversely affect our future results.", -0.8], ["In the first quarter of fiscal 2023, FedEx announced our DRIVE transformation program to improve long-term profitability, including Network 2.0, the multi-year effort to improve the efficiency with which FedEx picks up, transports, and delivers packages in the U.S. and Canada.", 0.5], ["There can be no assurances that these businesses and networks can successfully be consolidated and fully integrated as planned.", -0.6], ["It is possible that the consolidation and integration process could result in higher than currently expected costs, less-than-expected savings, the loss of customers, the disruption of ongoing businesses, union organizing, litigation, the loss of key FedEx employees or service providers, or other unexpected issues.", -0.7], ["our ability to maintain coverage of U.S. employees at FedEx Express under the RLA and manage challenges to the employment status of drivers employed by service providers engaged by FedEx Ground, in addition to other labor-related risks;", -0.5], ["managing unforeseen increased expenses or delays associated with the consolidation and integration process.", -0.6], ["We may not be able to achieve the expected operational efficiencies and network flexibility, alignment of our cost base with demand, cost savings and reductions to our permanent cost structure, and other benefits from our DRIVE transformation and one FedEx consolidation plan.", -0.8], ["The actual amount and timing of costs to be incurred and related cost savings and reductions to our permanent cost structure resulting from these initiatives and enhancements may differ from our current expectations and estimates.", -0.6], ["These initiatives and enhancements could also result in asset impairment charges and changes to our tax liabilities and deferred tax balances.", -0.7], ["If we are not able to successfully implement our DRIVE transformation and one FedEx consolidation plan, our future financial results will suffer and we may not be able to achieve our financial performance goals.", -0.9], ["All of these factors could adversely affect FedEx’s results of operations and negatively affect the price of our common stock.", -1.0], ["A significant data breach or other disruption to our technology infrastructure could disrupt our operations and result in the loss of critical confidential information, adversely affecting our reputation, business, or results of operations.", -0.9], ["A disruption to our complex, global technology infrastructure, including those affecting our computer systems and websites, could result in the loss of confidential business or customer information, require substantial repairs or replacements, resulting in significant costs, and lead to the temporary or permanent transfer by customers of some or all of their business to our competitors.", -0.9], ["The foregoing could harm our reputation and adversely affect our operations, customer service, and results of operations.", -0.8], ["These types of adverse effects could also occur in the event the confidentiality, integrity, or availability of company and customer information was compromised due to a data loss by FedEx or a trusted third party.", -0.8], ["Despite our efforts, we are not fully insulated from data breaches, technology disruptions, data loss, and cyber-fraud, which could adversely affect our competitiveness and results of operations.", -0.9], ["We are self-insured for certain costs associated with our operations, and insurance and claims expenses could have a material adverse effect on us.", -0.8], ["Material increases in the magnitude of claims, changes to healthcare costs, accident frequency and severity, insurance retention levels, judgment and settlement amounts, associated legal expenses, and other factors could result in unfavorable differences between actual self-insurance costs and our reserve estimates.", -0.7], ["As a result, our insurance and claims costs could continue to increase materially which could adversely affect our results of operations and financial condition.", -0.9], ["During 2023, higher self-insurance accruals negatively affected our results of operations.", -0.8], ["Financial Statements” of our Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2022 for information regarding the 2015 jury award of approximately $160 million in compensatory damages in a lawsuit related to a vehicle accident involving a driver employed by a service provider engaged by FedEx Ground, subsequent court affirmation of the award in 2018 and 2022, and our pursuit of reimbursement from insurers of our payment of approximately $210 million of pre- and post-judgment interest.", -0.6], ["Given the current claims environment, the amount of coverage available from excess insurance carriers is decreasing, the premiums for this excess coverage are increasing significantly, and excess insurance carriers are challenging insurance claims more frequently.", -0.7], ["Accordingly, our excess insurance and claims expenses may continue to increase, or we could further increase our self-insured retention as policies are renewed or replaced.", -0.7], ["Our results of operations and financial condition could continue to be adversely affected if our costs or losses significantly exceed our aggregate coverage limits, we are unable to obtain excess insurance coverage in amounts we deem sufficient, our insurance carriers fail to pay on our insurance claims, or we experience a claim for which coverage is not provided.", -0.9], ["We have now shifted to operating in a more stable post-COVID-19 environment with less restrictions, which resulted in consumers returning to near pre-pandemic shopping patterns during 2023.", 0.5], ["If we are unable to remain agile and flex our networks to align with shipping volumes, customer needs, disrupted global supply chains and other network inefficiencies, market demands, and operating conditions, or are unable to continuously respond to evolving governmental policies, our business operations could be negatively affected, which could have a further adverse effect on our results of operations.", -0.8], ["To the extent a widespread outbreak of an illness or any other communicable disease or public health crisis adversely affects our business and financial results, it may also have the effect of heightening many other risks described in this section, any of which could materially and adversely affect our business, results of operations, and financial condition.", -1.0], ["Management’s Discussion and Analysis of Results of Operations and Financial Condition” of our Annual Reports on Form 10-K for the years ended May 31, 2020, May 31, 2021, and May 31, 2022, for information regarding the COVID-19 pandemic and its effects on our business, results of operations, and financial condition.", -0.5], ["Because transportation assets continue to be a target of terrorist activities, governments around the world are adopting or are considering adopting stricter security requirements that will increase operating costs and potentially slow service for businesses, including those in the transportation industry.", -0.8], ["It is reasonably possible that these rules or other future security requirements could impose material costs on us or slow our service to our customers.", -0.7], ["The effects on our operations of avoiding areas of the world, including airspace, in which there are geopolitical conflicts and the targeting of aircraft by parties to those conflicts can also be significant.", -0.9], ["Moreover, a terrorist attack directed at FedEx or other aspects of the transportation infrastructure could disrupt our operations and adversely affect demand for our services.", -1.0], ["Failure to successfully implement our business strategy and effectively respond to changes in market dynamics and customer preferences will cause our future financial results to suffer.", -0.9], ["See “The failure to successfully execute our DRIVE transformation, including Network 2.0, and one FedEx consolidation plan in the expected time frame and at the expected cost may adversely affect our future results.” above and “Item 1.", -0.8], ["Such initiatives and enhancements may require us to make significant capital expenditures or incur significant expenses.", -0.6], ["We have also incurred, and may continue to incur, increased operating expenses in connection with certain changes to our business strategy.", -0.7], ["We may not be able to derive the expected operational efficiencies and network flexibility, alignment of our cost base with demand, cost savings and reductions to our permanent cost structure, and other benefits from our strategic investments and other decisions.", -0.8], ["If we are not able to successfully implement our business strategy and effectively respond to changes in market dynamics and customer preferences, our future financial results will suffer.", -0.9], ["Missing our projections could result in too much or too little capacity relative to our shipping volumes.", -0.7], ["Overcapacity could lead to below- market asset dispositions or write-downs, as well as negatively affect operating margins, and undercapacity could negatively affect service levels.", -0.8], ["Difficulties in quickly adjusting our operations and fixed-cost structure to match shifting volume levels, particularly at FedEx Express, negatively affected our results of operations in 2023.", -0.9], ["Management’s Discussion and Analysis of Results of Operations and Financial Condition — Results of Operations and Outlook — Consolidated Results — Goodwill and Other Asset Impairment Charges” of this Annual Report for information regarding a noncash impairment charge recorded in the fourth quarter of 2023 in connection with our decision to permanently retire certain aircraft and related engines from service.", -0.6], ["Adverse publicity (whether or not justified) relating to activities by our team members or others with whom we do business, such as customer service mishaps, accidents, catastrophes, or incidents involving aircraft, vehicles, or facilities operated by us or our service providers; low safety or service levels; data breaches or technology infrastructure disruptions; noncompliance with laws and allegations or claims that result in litigation; the shipment of certain items pursuant to our obligation as a common carrier operating under federal law; labor relations and workforce reductions; our advertising campaigns, sponsorship arrangements, or marketing programs; our political activities and expenditures; our executive compensation practices; or use of artificial intelligence could tarnish our reputation and reduce the value of our brand.", -0.9], ["Damage to our reputation and loss of brand equity could reduce demand for our services and/or create difficulties in retaining and recruiting employee talent, and thus have an adverse effect on our financial condition, liquidity, and results of operations, as well as require additional resources to rebuild our reputation and restore the value of our brand.", -0.9], ["Changes in the business or financial soundness of the USPS, including strategic changes to its operations to reduce its reliance on the air network of FedEx Express, are likely to have an adverse effect on our results of operations and financial condition.", -0.8], ["Pursuant to previously announced plans to restructure its operations, the USPS continues to implement strategic changes to its operations to reduce its reliance on the air network of FedEx Express, which negatively affected our results of operations in 2023.", -0.8], ["FedEx Express expects lower volumes from the USPS in 2024.", -0.5], ["Additional changes in the USPS’s business, including further structural changes to its operations, network, volume levels, service offerings, service commitments, or pricing, could have additional negative effects on our revenue, results of operations, and financial condition.", -1.0], ["Additionally, a decision by the USPS to terminate the contract early could negatively affect our profitability.", -0.8], ["Some of our competitors have more financial resources and competitive advantages than we do, appear willing to operate at little or no margin to gain market share, or they are owned, controlled, or subsidized by foreign governments, which enables them to raise capital more easily.", -0.7], ["In addition, some high-volume package shippers are developing and implementing in-house delivery capabilities and utilizing independent contractors for deliveries, which could in turn reduce our revenues and market share.", -0.6], ["For example, Amazon.com has established a network of hubs, aircraft, and vehicles and has expressed an intention to offer its internal delivery capabilities broadly to third parties.", -0.4], ["However, the existence of an irrational pricing environment could limit our ability not only to maintain or increase our prices (including our fuel surcharges in response to rising fuel costs), but also to maintain or grow our revenues and market share.", -0.7], ["While we believe we compete effectively through our current and planned service offerings, if our current competitors or potential future competitors offer a broader range of services or better service levels, more effectively bundle their services, or offer services at lower prices, it could impede our ability to maintain or grow our market share.", -0.6], ["Moreover, if high-volume package shippers further develop or expand internal capabilities for the services we provide, it may reduce our revenue and could negatively affect our financial condition and results of operations.", -0.8], ["News regarding such developments or expansions could also negatively affect the price of our common stock.", -0.9], ["Additionally, advancements in technology, such as advanced safety systems; automated package sorting, handling, and delivery; autonomous delivery; third-party supply chain insight and management; artificial intelligence; vehicle platooning; alternative fuel vehicles; and digitization of freight services, may necessitate that we increase investments in order to remain competitive, and our customers may not be willing to accept higher rates to cover the cost of these investments.", -0.2], ["Our inability to execute and effectively operate, integrate, leverage, and grow acquired businesses and realize the anticipated benefits of acquisitions, joint ventures, and strategic alliances and investments could materially adversely affect us.", -0.8], ["Additionally, we may be required to make significant capital expenditures and/or incur certain operating expenses following the completion of certain transactions, which may be higher than initially expected.", -0.6], ["For example, existing and future customer data in the systems and business of FedEx and ShopRunner may not be ultimately interoperable, or may not be interoperable without significant added expense.", -0.7], ["While we expect our past and future acquisitions and strategic transactions to enhance our value proposition to customers and improve our business and long-term profitability, there can be no assurance that we will realize our expectations within the time frame we have established, if at all, or that we can continue to support the value we allocate to acquired businesses, including their goodwill or other intangible assets.", -0.5], ["We have previously incurred goodwill impairment charges related to certain of our acquisitions, some of which have been material, and may incur additional goodwill impairment charges in the future.", -0.7], ["Management’s Discussion and Analysis of Results of Operations and Financial Condition — Results of Operations and Outlook — Consolidated Results — Goodwill and Other Asset Impairment Charges” of this Annual Report for information regarding a noncash impairment charge recorded in the fourth quarter of 2023 related to the ShopRunner acquisition.", -0.4], ["Our failure to attract and retain employee talent, meet our purchased transportation needs, or maintain our company culture, as well as increases in labor and purchased transportation costs, could adversely affect our business and results of operations.", -0.9], ["Difficulties in motivating, rewarding, recruiting, and retaining employee talent, including successors to members of senior management; the unexpected loss of such individuals resulting in the depletion of our institutional knowledge base; and/or our inability to successfully transition key roles could have an adverse effect on our business, results of operations, reputation, and the price of our common stock.", -0.9], ["Certain positions at FedEx have historically experienced high turnover rates, which can lead to increased recruiting, training, and retention costs.", -0.8], ["If we fail to maintain the strength of our company culture, our competitive ability and our business may be harmed.", -0.8], ["Our business is labor intensive in nature, and our ability to meet our labor and purchased transportation needs while controlling related costs is generally subject to numerous external factors, including the availability of qualified service providers and persons in the markets where we and our contracted service providers operate and unemployment levels within these markets, prevailing and competitive wage rates and other benefits, health and other insurance costs, inflation, fuel and energy prices and availability, behavioral changes, adoption of new or revised employment and labor laws and regulations (including increased minimum wage requirements) or government programs, safety levels of our operations, our reputation within the labor and transportation markets, changes in the business or financial soundness of service providers, interest in contracting with FedEx, the effect of a widespread public health crisis, the availability of child care, and vaccine mandates that may be announced in jurisdictions in which our businesses and service providers operate.", -0.7], ["Additionally, certain service providers (acting collectively or in coordination in some instances) may seek to increase financial rates or modify contract terms and may refuse to provide service to FedEx in connection with such initiatives.", -0.6], ["Our inability to effectively meet our labor and purchased transportation needs can increase our costs, hinder our ability to execute our business strategy, negatively affect service levels, and adversely affect our business and results of operations.", -0.9], ["If we are unable to maintain positive relationships with our employees and to avoid having labor organizations organize groups of our employees, our operating costs could significantly increase and our operational flexibility could be significantly reduced.", -0.8], ["Such disruptions could threaten our ability to provide competitively priced shipping options and ready access to global markets.", -0.7], ["There is also the possibility that Congress could pass other labor legislation that could adversely affect our companies, such as FedEx Ground and FedEx Freight, whose employees are governed by the NLRA.", -0.7], ["In addition, federal and state governmental agencies, such as the NMB and the NLRB, have and may continue to take actions that could make it easier for our employees, as well as our vendor and supplier workforces, to organize under the RLA or NLRA.", -0.6], ["Finally, changes to federal or state laws, regulations, rules, judicial or administrative precedent, or guidance governing employee classification could affect the status of FedEx Ground’s service providers as independent employers of drivers.", -0.6], ["If FedEx Ground is deemed to be an employer or joint employer of the drivers of these service providers, labor organizations could more easily organize these individuals, our operating costs could increase materially, and we could incur significant capital outlays and experience adverse effects to service levels.", -0.9], ["However, adverse determinations in these matters or regulatory developments could, among other things, entitle service providers’ drivers to certain wage payments and penalties from the service providers and FedEx Ground, and result in employment and withholding tax and benefit liability for FedEx Ground.", -0.8], ["Proposed pilot flight and duty time regulations could impair our operations and impose substantial costs on us.", -0.7], ["Required compliance with the 2011 regulations would make it more difficult to avoid pilot fatigue and could impose substantial costs on us in order to maintain operational reliability.", -0.7], ["Increasing costs, the volatility of costs and funding requirements, and other legal mandates for employee benefits, especially pension and healthcare benefits, could adversely affect our results of operations, financial condition, and liquidity.", -0.9], ["Changes in actuarial assumptions and differences between the assumptions and actual values, as well as significant declines in the value of investments that fund our pension and other postretirement plans, if not offset or mitigated by a decline in plan liabilities, could increase pension and other postretirement expense, and we could be required from time to time to fund the pension plans with significant amounts of cash.", -0.8], ["Such cash funding obligations could adversely affect our results of operations and liquidity.", -0.8], ["Additionally, the rules for pension and retirement benefit plan accounting are complex, involve numerous assumptions, and can produce volatility in our results of operations, financial condition, and liquidity.", -0.8], ["For example, our fourth quarter mark-to-market (“MTM”) retirement plans accounting adjustment resulted in a pre-tax, noncash gain of $650 million in 2023 ($493 million, net of tax, or $1.92 per diluted share) and a loss of $1.6 billion in 2022 ($1.2 billion, net of tax, or $4.49 per diluted share).", 0.2], ["Increased regulation regarding GHG emissions, especially aircraft or vehicle engine emissions, could impose substantial costs on us, especially at FedEx Express.", -0.7], ["These costs include an increase in the cost of the fuel and other energy we purchase and capital and impairment costs associated with updating or replacing our aircraft or vehicles prematurely.", -0.8], ["It is reasonably possible, however, that it could materially increase our operating expenses and have an adverse direct or indirect effect on our business, if instituted.", -0.8], ["Business” of this Annual Report under the caption “Regulation.” We may also incur additional expenses as a result of U.S. and international regulators requiring additional disclosures regarding GHG emissions.", -0.6], ["Moreover, even without such regulation, increased awareness and any adverse publicity in the global marketplace about the GHGs emitted by companies in the airline and transportation industries could harm our reputation and reduce customer demand for our services, especially our air express services.", -0.7], ["We may be unable to achieve or demonstrate progress on our goal of carbon neutrality for our global operations by calendar 2040.", -0.7], ["Further, given investors’ and banks’ increased focus related to ESG matters, such a failure could cause large stockholders to reduce their ownership of FedEx common stock and limit our access to financing.", -0.8], ["Such conditions could have an adverse effect on our business, results of operations, and financial condition, as well as on the price of our common stock.", -0.8], ["Our inability to quickly and effectively restore operations following adverse weather or a localized disaster or disturbance in a key geography could adversely affect our business and results of operations.", -0.7], ["Prolonged interruptions or disruptions at a key location such as our FedEx Express Memphis World Hub or one of our information-technology centers could adversely affect our business and results of operations.", -0.7], ["We also may incur significant costs to reestablish or relocate these functions.", -0.6], ["Moreover, resulting economic dislocations, including supply chain and fuel disruptions, could adversely affect demand for our services resulting in an adverse effect on our business and results of operations.", -0.7], ["Government regulation and enforcement are evolving and unfavorable changes could harm our business.", -0.8], ["There can be no assurance that such regulations, laws, policies, and actions will not be changed in ways that will decrease the demand for our services, subject us to escalating costs, or require us to modify our business models and objectives (such as our DRIVE transformation program, including Network 2.0, and one FedEx consolidation plan), harming our financial results.", -0.9], ["In particular, legislative, regulatory, or other actions that U.S. and non-U.S. governments have undertaken or could take in areas such as data privacy and sovereignty, the use of new technology, taxes, foreign exchange intervention in response to currency volatility, currency controls that could restrict the movement of liquidity from particular jurisdictions, trade controls, tariffs, quotas, embargoes, or sanctions in the U.S. or other countries, complex economic sanctions, import and export controls, customs standards, additional security or workplace and transportation health and safety requirements, labor and employment standards (including with respect to our pilots), worker classification, joint employment and benefits, government contracting, regulated commodities, environmental or emission standards, and accounting may have an adverse effect on our results of operations, financial condition, capital requirements, effective tax rate, and service levels.", -0.9], ["Business” of this Annual Report under the caption “Regulation.” Additionally, the current U.S. presidential administration and various U.S. federal and state regulatory bodies have indicated a desire to reform various aspects of existing laws, regulations, and enforcement priorities and strategies that could, among other things, lead to comprehensive tax reform, broadly increase the U.S. minimum wage, make it easier for unions to organize our U.S. employees or the employees of our service providers, and alter the employment relationship between service providers engaged by FedEx Ground and the drivers employed by those service providers.", -0.7], ["We could be subject to adverse changes in regulations and interpretations or challenges to our tax positions.", -0.8], ["From time to time, changes in tax laws or regulations may be enacted that could significantly affect our overall tax liabilities and our effective tax rate.", -0.7], ["Standard-setting bodies could interpret or issue guidance on how provisions of certain tax laws and regulations will be applied or otherwise administered that is different from our interpretation, and we may be required to make adjustments to amounts that we have recorded that may adversely affect our results of operations and financial condition.", -0.8], ["An actual or alleged failure to comply with applicable U.S. or foreign data protection laws, regulations, or other data protection standards may expose us to litigation (including, in some instances, class action litigation), fines, sanctions, or other penalties, which could harm our reputation and adversely affect our business, results of operations, and financial condition.", -0.9], ["Consequently, compliance with all applicable regulations in the various jurisdictions in which we do business may present material obligations and risks to our business, including significantly expanded compliance burdens, costs, and enforcement risks; require us to make extensive system or operational changes; or adversely affect the cost or attractiveness of the services we offer.", -0.8], ["All of these evolving compliance and operational requirements, as well as the uncertain interpretation and enforcement of laws, impose significant costs and regulatory risks that are likely to increase over time.", -0.8], ["The regulatory environment for global aviation or other transportation rights may affect our operations and increase our operating costs.", -0.7], ["Our operations outside of the U.S., such as FedEx Express’s international domestic operations, are also subject to current and potential regulations, including certain postal regulations and licensing requirements, that restrict, make difficult, and sometimes prohibit, the ability of foreign-owned companies such as FedEx Express to compete effectively in parts of the international domestic transportation and logistics market.", -0.8], ["Further, our ability to obtain or maintain aviation or other transportation rights internationally may be adversely affected by changes in international trade policies and relations.", -0.6], ["For instance, the FAA from time to time issues directives and other regulations relating to the maintenance and operation of aircraft that require significant expenditures in order to comply.", -0.5], ["These requirements can be issued with little or no notice, or can otherwise affect our ability to efficiently or fully utilize our aircraft, and in some instances have resulted in the temporary grounding of aircraft types altogether.", -0.7], ["Further, our business may be adversely affected when government agencies and air traffic control and other systems they oversee cease to operate as expected, including due to partial shutdowns, sequestrations, or similar events.", -0.8], ["Lapses in government operations may result in, among other things, disruptions in the ability of government agencies to grant required regulatory approvals.", -0.7], ["changes in foreign currency exchange rates, especially in the euro, Chinese yuan, British pound, Canadian dollar, Hong Kong dollar, Australian dollar, Japanese yen, and Mexican peso, which can affect our sales levels and foreign currency sales prices;", -0.6], ["loss or delay in the collection of accounts receivable;", -0.5], ["any liability resulting from and the costs of defending against class-action, derivative, and other litigation, such as wage-and- hour, joint employment, securities, vehicle accident, and discrimination and retaliation claims, claims related to our reporting and disclosure of climate change and other ESG topics, and any other legal or governmental proceedings, including the matters discussed in Note 18 of the consolidated financial statements included in “Item 8.", -0.8], ["disruptions in global supply chains, which can limit the access of FedEx and our service providers to vehicles and other key capital resources and increase our costs;", -0.8], ["difficulties experienced by the companies with which we contract to fly smaller regional “feeder” aircraft in attracting and retaining pilots, which could cause a reduction of service offered to certain locations, service disruptions, increased costs of operations, and other difficulties;", -0.9], ["governmental underinvestment in transportation infrastructure, which could increase our costs and adversely affect our service levels due to traffic congestion, prolonged closure of key thoroughfares, or sub-optimal routing of our vehicles and aircraft;", -0.8], ["stockholder activism, which could divert the attention of management and our board of directors from our business, hinder execution of our business strategy, give rise to perceived uncertainties as to our future, and cause the price of our common stock to fluctuate significantly;", -0.9], ["constraints, volatility, or disruption in the capital markets, our ability to maintain our current credit ratings, commercial paper ratings, and senior unsecured debt and pass-through certificate credit ratings, and our ability to meet credit agreement financial covenants.", -0.8], ["During 2023, we retired our MD-10-30 fleet and accelerated the retirement of our MD-11 fleet to the end of 2028.", 0.2], ["As of May 31, 2023, we had $1.0 billion in deposits and progress payments on aircraft purchases and other planned aircraft-related transactions.", 0.3], ["FedEx Freight plans to close and consolidate approximately 30 locations in the first quarter of 2024.", -0.7], ["During 2023 approximately 150 FedEx Office stores were closed.", -0.7], ["On December 16, 2021, we announced a stock repurchase program approved by our Board of Directors, through which we are authorized to purchase, in the open market or in privately negotiated transactions, up to $5 billion of FedEx common stock.", 0.5], ["We did not repurchase any shares of FedEx common stock during the fourth quarter of 2023.", -0.5], ["Our results in 2023 were adversely impacted by lower global volumes due to weak economic conditions.", -0.8], ["During the first half of 2023, we continued to be affected by COVID-19 lockdowns in Asia, which impacted both manufacturing and supply chains.", -0.7], ["environment with less restrictions, which resulted in consumers returning to near pre-pandemic shopping patterns during 2023.", 0.2], ["As global supply chains stabilized during 2023, we experienced improvements in the availability of labor and vehicles, trailers, and other package handling equipment.", 0.5], ["Global inflation is well above historical levels, impacting all areas of our business.", -0.9], ["We are experiencing a decline in demand for our transportation services as inflation and interest rate increases are negatively affecting consumer and business spending.", -0.8], ["Additionally, we are experiencing higher costs to serve through higher fuel prices, wage rates, purchased transportation costs, and other direct operating expenses such as operational supplies.", -0.7], ["We expect inflation and high interest rates to continue to negatively affect our results in 2024.", -0.9], ["The timing and amount of fluctuations in fuel prices and our ability to recover incremental fuel costs through our fuel surcharges can significantly affect our operating results either positively or negatively in the short-term.", 0.0], ["Higher fuel prices drove an increase in yields through higher fuel surcharges and an increase in fuel expense during 2023 at all of our transportation segments.", -0.2], ["As a result, we incurred an immaterial amount of severance and other related expenses in 2023, which is included in business optimization expenses at FedEx Express.", -0.1], ["While we do not expect this conflict to have a direct material impact on our business or results of operations, the broader consequences are adversely affecting the global economy and fuel prices generally and may also have the effect of heightening other risks disclosed under Part I, Item 1A.", -0.7], ["Many of our operating expenses are directly affected by revenue and volume levels, and we expect these operating expenses to fluctuate on a year-over-year basis consistent with changes in revenue and volumes.", 0.0], ["(1)  The following is a summary of the effects of the (costs) benefits of certain items affecting our financial results for the years ended May 31 (in millions):", 0.0], ["Our operating results for 2023 were negatively affected by macroeconomic conditions, including inflation well above historical levels, and elevated global interest rates.", -0.8], ["In response to market conditions, we implemented cost reductions and focused on yield improvement to partially mitigate the effect of volume declines.", 0.1], ["Cost reductions included reducing flight hours, temporarily parking and retiring aircraft, improving productivity, delaying and reducing certain peak wage programs, consolidating and closing sorts, canceling network capacity projects, and reducing select Sunday operations.", 0.2], ["The impact of cost actions lagged volume declines, particularly in the first half of 2023 and at FedEx Express, resulting in elevated operating expenses relative to demand.", -0.5], ["Additionally, our results in the first half of 2023 were negatively impacted by service challenges at FedEx Express.", -0.6], ["Operating income in 2023 includes $70 million ($54 million, net of tax, or $0.21 per diluted share) of asset impairment charges associated with the decision to permanently retire certain aircraft and related engines at FedEx Express, and also includes $47 million ($44 million, net of tax, or $0.17 per diluted share) of goodwill and other asset impairment charges associated with the ShopRunner, Inc. (“ShopRunner”) acquisition at FedEx Dataworks, Inc. (“FedEx Dataworks”).", -0.5], ["Operating income in 2023 includes $273 million ($209 million, net of tax, or $0.81 per diluted share) of expenses associated with our DRIVE business optimization strategy announced in the first quarter of 2023, and also includes business realignment costs of $36 million ($27 million, net of tax, or $0.11 per diluted share) associated with our workforce reduction plan in Europe announced in 2021.", -0.6], ["Operating income in 2022 includes $278 million ($214 million, net of tax, or $0.80 per diluted share) of costs under this program.", -0.4], ["Operating income includes a $35 million charge ($26 million, net of tax, or $0.10 per diluted share) in 2023 related to a FedEx Ground legal matter and a $210 million charge ($160 million, net of tax, or $0.60 per diluted share) in 2022 related to pre- and post-judgment interest in connection with a separate FedEx Ground legal matter.", -0.7], ["Operating expenses in 2022 include $132 million ($103 million, net of tax, or $0.39 per diluted share) of TNT Express integration expenses.", -0.5], ["Net income includes a pre-tax, noncash gain of $650 million in 2023 ($493 million, net of tax, or $1.92 per diluted share) and a loss of", 0.3], ["$1.6 billion in 2022 ($1.2 billion, net of tax, or $4.49 per diluted share) associated with our MTM retirement plans accounting adjustments.", -0.9], ["Net income in 2023 includes a $46 million ($0.18 per diluted share) tax expense from a revaluation of certain foreign tax assets.", -0.4], ["In 2022, we recognized a $142 million ($0.53 per diluted share) tax benefit related to revisions of prior-year tax estimates for actual tax return results.", 0.2], ["Revenue decreased 4% in 2023 primarily due to global volume declines at all of our transportation segments, partially offset by yield improvement, including higher fuel surcharges.", -0.8], ["FedEx Express revenue decreased 7% in 2023 due to lower global volume and unfavorable foreign currency, partially offset by yield improvement, including higher fuel surcharges.", -0.5], ["Revenue at Corporate, other, and eliminations decreased due to lower yields and volumes at FedEx Trade Networks Transport & Brokerage, Inc. FedEx Ground revenue and FedEx Freight revenue each increased 1% in 2023, primarily due to yield improvement, including higher fuel surcharges, partially offset by lower volume.", 0.1], ["As a consequence of this decision, a noncash impairment charge of $70 million ($54 million, net of tax, or $0.21 per diluted share) was recorded in the fourth quarter.", -0.7], ["In the fourth quarter of 2023, we also recorded a noncash impairment charge of $36 million ($36 million, net of tax, or $0.14 per diluted share) for all of the goodwill attributable to FedEx Dataworks.", -0.6], ["The key factors contributing to the goodwill impairment were underperformance of the ShopRunner business during 2023, including base business erosion, and the failure to attain the level of operating synergies and revenue and profit growth anticipated at the time of acquisition.", -0.8], ["We also recorded an $11 million ($8 million, net of tax, or $0.03 per diluted share) noncash intangible asset impairment charge related to the ShopRunner acquisition at FedEx Dataworks.", -0.6], ["In the second quarter of 2023, FedEx announced DRIVE, a comprehensive program to improve the company’s long-term profitability.", 0.5], ["This program includes a business optimization plan to drive efficiency among our transportation segments and lower our overhead and support costs.", 0.4], ["One FedEx will help facilitate our DRIVE transformation program to improve long-term profitability.", 0.4], ["We incurred costs associated with our business optimization activities of $273 million ($209 million, net of tax, or $0.81 per diluted share) in 2023.", -0.3], ["These costs were primarily related to consulting services, severance, professional fees, and idling our operations in Russia.", -0.5], ["We expect the pre-tax cost of our business optimization activities to be approximately $500 million in 2024 and approximately $2.0 billion through 2025.", -0.3], ["In 2021, FedEx Express announced a workforce reduction plan in Europe related to the network integration of TNT Express.", -0.4], ["The plan affected approximately 5,000 employees in Europe across operational teams and back-office functions and was completed during 2023.", -0.4], ["We incurred costs of $36 million ($27 million, net of tax, or $0.11 per diluted share) in 2023 and $278 million ($214 million, net of tax, or $0.80 per diluted share) in 2022 associated with our business realignment activities.", -0.5], ["Payments under this program totaled approximately $118 million in 2023 and approximately $225 million in 2022.", -0.4], ["The pre-tax cost of our business realignment activities was approximately $430 million through 2023.", -0.5], ["We expect savings from our business realignment activities to be approximately $275 million on an annualized basis beginning in 2024.", 0.2], ["(1)  Includes TNT Express integration expenses of $132 million in 2022.", -0.3], ["(2)  Includes goodwill and other asset impairment charges in 2023 associated with the FedEx Express and FedEx Dataworks operating segments.", -0.4], ["(3)  Includes costs associated with our DRIVE program in 2023 and the workforce reduction plan in Europe in 2023 and 2022.", -0.5], ["(4)  Includes a $35 million charge in 2023 related to a FedEx Ground legal matter and a $210 million charge in 2022 related to pre- and post-judgment interest in connection with a separate FedEx Ground legal matter.", -0.7], ["Operating income declined in 2023 primarily due to lower volumes at each of our transportation segments, partially offset by yield improvement, including higher fuel surcharges.", -0.6], ["Cost reduction efforts such as reducing flight hours, temporarily parking and retiring aircraft, improving productivity, delaying and reducing certain peak wage programs, consolidating and closing sorts, canceling network capacity projects, and reducing select Sunday operations partially mitigated the effects of volume declines on our results.", -0.2], ["Global inflation drove higher operating expenses related to salaries and employee benefits and other operating expenses in 2023.", -0.4], ["In addition, higher self-insurance and bad debt accruals contributed to an increase in other operating expense in 2023.", -0.3], ["We recognized $70 million of asset impairment charges associated with the decision to permanently retire certain aircraft and related engines at FedEx Express.", -0.8], ["Our 2023 results also include $47 million of goodwill and other asset impairment charges in the fourth quarter of 2023 associated with the ShopRunner acquisition at FedEx Dataworks.", -0.7], ["Fuel expense increased 16% during 2023 due to higher fuel prices, partially offset by a decline in fuel usage.", -0.5], ["Because of the factors described above, our operating results may be affected should the market price of fuel suddenly change by a significant amount or change by amounts that do not result in an adjustment in our fuel surcharges, which can significantly affect our earnings either positively or negatively in the short-term.", -0.6], ["Other retirement plans income (expense) increased primarily due to a noncash MTM gain of $650 million in 2023 compared to a $1.6 billion loss in 2022 (described below).", -0.2], ["In addition, interest income increased $145 million in 2023 primarily due to an increase in interest rates, partially offset by a decrease in other income of $120 million related to changes in the value of equity investments.", 0.1], ["In 2023, we incurred a pre-tax, noncash MTM gain of $650 million ($493 million, net of tax, or $1.92 per diluted share), related to the year-end actuarial adjustments of pension and postretirement healthcare plans’ assets and liabilities.", 0.5], ["In 2022, we incurred a pre-tax, noncash MTM loss of $1.6 billion ($1.2 billion, net of tax, or $4.49 per diluted share), which includes a net loss of $1.3 billion ($1.0 billion, net of tax, or $3.76 per diluted share) related to the year-end actuarial adjustments of pension and postretirement healthcare plans’ assets and liabilities.", -0.8], ["Additionally, in 2022, we incurred a pre-tax, noncash MTM net loss of $260 million ($195 million, net of tax, or $0.73 per diluted share) in the second quarter of 2022, of which $224 million was related to the termination of the TNT Express Netherlands Pension Plan.", -0.7], ["The remaining $36 million net loss was related to the U.S. FedEx Freight Pension Plan and consisted of a $75 million MTM loss due to a lower discount rate in the second quarter of 2022, partially offset by a $39 million curtailment gain.", -0.3], ["Our effective tax rate was 25.9% for 2023, compared to 21.9% for 2022.", -0.1], ["The 2023 tax provision was negatively impacted by an expense of $46 million related to a write-down and valuation allowance on certain foreign tax credit carryforwards due to operational changes which impacted the determination of the realizability of the deferred tax asset.", -0.6], ["The 2023 tax provision was also negatively impacted by lower earnings in certain non-U.S. jurisdictions.", -0.4], ["The 2022 tax provision includes a benefit of $142 million related to revisions of prior year tax estimates for actual tax return results.", 0.2], ["The 2022 tax provision was also favorably impacted by changes in our corporate legal entity structure.", -0.1], ["We have recorded a cumulative benefit of $223 million through 2023 attributable to our interpretation of the TCJA and the Internal Revenue Code.", 0.3], ["If we are ultimately unsuccessful in defending our position, we may be required to reverse the benefit previously recorded.", -0.7], ["During 2024, we expect macroeconomic conditions to continue to negatively impact customer demand for our services.", -0.8], ["However, we expect operating income improvement in 2024 as a result of our DRIVE program initiatives focused on aligning our cost base with demand, reducing our permanent cost structure, and increasing the flexibility of our network.", 0.5], ["We expect international export yield declines and reduced customer demand for our U.S. freight product at FedEx Express to negatively impact revenue and operating income in 2024.", -0.6], ["In addition, we expect expense headwinds in 2024 related to higher global inflation and variable incentive compensation.", -0.5], ["Our capital expenditures for 2024 are expected to be approximately $5.7 billion, a decrease of $0.5 billion from 2023, as we continue to reduce our capital intensity relative to revenue.", 0.2], ["Our businesses are cyclical in nature, as seasonal fluctuations affect volumes, revenue, and earnings.", 0.0], ["Historically, the U.S. express package business experiences an increase in volumes in late November and December.", 0.1], ["International business, particularly in the Asia- to-U.S. market, peaks in October and November in advance of the U.S. holiday sales season.", -0.1], ["Shipment levels, operating costs, and earnings for each of our companies can also be adversely affected by inclement weather, particularly the impact of severe winter weather in our third fiscal quarter.", -0.7], ["In 2023, the decrease in operating results in Corporate, other, and eliminations was primarily due to lower operating income at FedEx Logistics due to decreased revenue and an increase in bad debt, partially offset by decreased purchased transportation expense.", -0.8], ["Additionally, operating results in Corporate, other, and eliminations were negatively impacted by higher professional fees and outside service contract spend at FedEx Dataworks.", -0.9], ["The comparison of operating loss between 2023 and 2022 at Corporate, other, and eliminations is affected by goodwill and other asset impairment charges of $47 million associated with the ShopRunner acquisition at FedEx Dataworks in 2023.", -0.8], ["FedEx Express segment revenue decreased 7% in 2023 primarily due to decreased global volume and unfavorable exchange rates, partially offset by yield improvement.", -0.7], ["Total average daily package volume decreased 10% in 2023, and total average daily freight pounds decreased 14% in 2023, due to reduced demand for our services, primarily resulting from macroeconomic conditions.", -0.9], ["Volume declines were partially offset by yield improvement, including increases in composite package yield of 6% and composite freight yield of 2% in 2023.", -0.3], ["The 6% increase in composite package yield was primarily due to a U.S. domestic package yield increase of 12%, driven by higher base yields and fuel surcharges.", 0.2], ["Unfavorable exchange rates negatively impacted all international package and freight product yields in 2023.", -0.6], ["FedEx Express segment operating income decreased 64% in 2023 primarily due to global volume declines, partially offset by yield improvement and lower operating expenses.", -0.8], ["During 2023, we implemented cost reductions to mitigate the impact of volume declines, including reducing flight hours, temporarily parking and retiring aircraft, improving productivity, and consolidating routes and closing sorts.", -0.5], ["The impact of these reductions, while improving throughout the year, lagged volume declines, and operating expenses remained high relative to demand.", -0.7], ["Currency exchange rates had a negative effect on revenue and a positive effect on expenses, resulting in a slightly negative effect on operating income in 2023.", -0.6], ["Fuel expense increased 16% in 2023 due to a 27% increase in fuel prices, partially offset by a 9% decline in total fuel gallons.", -0.4], ["Purchased transportation expense decreased 11% in 2023 primarily due to favorable exchange rates and lower utilization, partially offset by higher rates charged by third-party providers.", 0.1], ["Salaries and employee benefits expense decreased 3% in 2023 primarily due to decreased staffing to align with lower volume, favorable currency exchange rates, and lower variable incentive compensation, partially offset by increased wage rates.", 0.2], ["Rentals and landing fees expense decreased 10% in 2023 primarily due to decreased aircraft leases and favorable currency exchange rates.", 0.3], ["Other operating expense decreased 2% in 2023 primarily due to favorable currency exchange rates and lower outside service contract expense, partially offset by higher bad debt expense.", 0.1], ["Maintenance and repairs expense decreased 6% in 2023 primarily due to lower aircraft maintenance resulting from an increase in aircraft temporarily parked.", 0.2], ["During 2023, we recorded asset impairment charges of $70 million associated with the decision to permanently retire certain aircraft and related engines.", -0.7], ["Additionally, FedEx Express segment results include business realignment costs of $36 million in 2023 associated with our workforce reduction plan in Europe.", -0.5], ["FedEx Express segment results also include business optimization costs of $11 million in 2023, which includes costs associated with idling our business in Russia.", -0.6], ["FedEx Express segments results include $115 million of TNT Express integration expenses in 2022.", -0.4], ["FedEx Ground segment revenue increased 1% in 2023 primarily due to yield improvement, partially offset by lower volumes.", 0.2], ["FedEx Ground yield increased 10% in 2023 primarily due to higher fuel and other surcharges, and a mix shift towards higher-yielding business-to-consumer products.", 0.3], ["Total average daily volume decreased 7% in 2023 due to reduced demand for our services, primarily resulting from macroeconomic conditions.", -0.8], ["FedEx Ground segment operating income increased 19% in 2023 primarily due to yield improvement, including higher fuel surcharges, partially offset by lower volume and higher other operating and rentals expense.", 0.4], ["The 2023 results benefited from certain cost reductions to mitigate the effect of volume declines, primarily a delay and reduction in peak wage programs, the consolidation and closing of certain sort and linehaul operations, cancellation of network capacity projects, and reduced Sunday delivery coverage.", 0.1], ["Purchased transportation expense decreased 4% in 2023 primarily due to lower volumes, partially offset by lower productivity and higher fuel prices.", -0.3], ["Salaries and employee benefits decreased 5% in 2023 primarily due to decreased staffing to align with lower volume and lower variable incentive compensation, partially offset by higher wage rates.", -0.5], ["Other operating expense increased 11% in 2023 primarily due to higher self-insurance accruals and higher outside service contracts expense.", -0.5], ["Rentals and depreciation expense increased 18% and 11%, respectively, in 2023 due to the completion of previously committed multi-year expansion projects.", -0.5], ["Salaries and employee benefits                    4,002      4,140      (3 )     41.5    43.4", -0.2], ["Purchased transportation                        731       976      (25 )     7.6    10.2", -0.3], ["Depreciation and amortization                     387       406      (5 )     4.0     4.3", -0.2], ["Total operating expenses                      7,707      7,869      (2 )     80.0 %   82.6 %", -0.3], ["Operating margin                             20.0 %      17.4 %    260 bp", 0.2], ["FedEx Freight segment revenue increased 1% in 2023 primarily due to yield improvement, partially offset by lower volumes.", 0.1], ["Revenue per shipment increased 14% in 2023 primarily due to continued focus on revenue quality, including higher fuel surcharges, partially offset by lower weight per shipment.", 0.3], ["Average daily shipments decreased 11% in 2023 due to reduced demand for our services, primarily resulting from macroeconomic conditions.", -0.8], ["FedEx Freight segment operating income increased 16% in 2023 driven by yield improvement, including higher fuel surcharges, partially offset by lower volumes.", 0.6], ["Additionally, FedEx Freight results were positively affected by initiatives to align costs to volumes and a gain on the sale of a facility during the third quarter of 2023.", 0.7], ["Purchased transportation expense decreased 25% in 2023 primarily due to lower volumes and reduced utilization due to the shift to company linehaul.", 0.2], ["Salaries and employee benefits expense decreased 3% in 2023 primarily due to decreased staffing to align with lower volume and lower variable incentive compensation, partially offset by higher wage rates and increased company linehaul utilization.", 0.1], ["Fuel expense increased 13% in 2023 primarily due to increased fuel prices, partially offset by lower volume.", -0.3], ["Other operating expense increased 12% in 2023 primarily due to higher self- insurance accruals and bad debt expense.", -0.4], ["Maintenance and repairs expense increased 16% in 2023 primarily due to higher costs associated with vehicle parts, outside vendor labor, and facility maintenance.", -0.5], ["Cash flows from operating activities decreased $1.0 billion in 2023 primarily due to lower net income (net of noncash items), as well as a decrease in accounts payable and legal settlements, partially offset by a decrease in accounts receivable.", -0.7], ["Capital expenditures were 9% lower in 2023 primarily due to decreased spending on aircraft.", 0.1], ["In December 2021, our Board of Directors authorized a stock repurchase program of up to $5 billion of FedEx common stock.", -0.1], ["repurchase an aggregate of $1.5 billion of our common stock.", 0.0], ["During 2022, as part of the repurchase program, we completed an ASR agreement with a bank to repurchase an aggregate of $1.5 billion of our common stock, and 6.1 million shares were delivered.", 0.1], ["Capital expenditures decreased $0.6 billion during 2023 primarily due to decreased spending on aircraft and related equipment at FedEx Express.", -0.2], ["In response to current business and economic conditions as referenced above in the “Outlook” section of this MD&A, we are continuing to actively manage and optimize our capital allocation to mitigate the impact of the slowing economy, inflationary pressures, and geopolitical conflicts.", -0.3], ["Credit Agreement” and together with the Five-Year Credit Agreement, the “Credit Agreements”), and we believe that our cash and cash equivalents, cash flow from operations, and available financing sources are adequate to meet our liquidity needs, which include operational requirements, expected capital expenditures, voluntary pension contributions, dividend payments, and stock repurchases.", 0.2], ["As announced on June 20, 2023, we expect to repurchase $2.0 billion of our common stock in 2024.", 0.3], ["We executed an ASR agreement with a bank in June 2023 to repurchase an aggregate of $500 million of our common stock with a completion date no later than August 2023.", 0.1], ["Our capital expenditures for 2024 are expected to be approximately $5.7 billion, a decrease of $0.5 billion from 2023, as we continue to reduce our capital intensity relative to revenue.", 0.0], ["These aircraft are significantly more fuel-efficient per unit than the aircraft types previously utilized, and these expenditures are necessary to achieve significant long-term operating savings and to replace older aircraft.", 0.2], ["We made a voluntary contribution of $200 million to our tax-qualified U.S. domestic pension plans (“U.S.", -0.1], ["Pension Plans”) in June 2023 and anticipate making $600 million of additional voluntary contributions during the remainder of 2024.", 0.5], ["On April 5, 2023, our Board of Directors declared a quarterly cash dividend of $1.26 per share of common stock.", 0.2], ["Standard & Poor’s has assigned us a senior unsecured debt credit rating of BBB, a Certificates rating of AA-, a commercial paper rating of A-2, and a ratings outlook of “stable.” Moody’s Investors Service has assigned us an unsecured debt credit rating of Baa2, a Certificates rating of Aa3, a commercial paper rating of P-2, and a ratings outlook of “stable.” If our credit ratings drop, our interest expense may increase.", -0.5], ["If our commercial paper ratings drop below current levels, we may have difficulty utilizing the commercial paper market.", -0.7], ["If our senior unsecured debt credit ratings drop below investment grade, our access to financing may become limited.", -0.8], ["The estimates discussed below include the financial statement elements that are either the most judgmental or involve the selection or application of alternative accounting policies and are material to our results of operations and financial condition.", -0.3], ["The rules for pension accounting are complex and can produce volatility in our earnings, financial condition, and liquidity.", -0.6], ["Differences between these assumptions and actual experience are recognized in our earnings through MTM accounting.", -0.4], ["The components of the MTM adjustments for the period ended May 31 are as follows (presented as (gain) loss in millions):", -0.2], ["The following sensitivity analysis shows the impact of a 50-basis-point change in the EROA and discount rate assumptions for our largest pension plan and the resulting increase (decrease) in our projected benefit obligation (“PBO”) as of May 31, 2023 and expense for the year ended May 31, 2023 (in millions):", -0.1], ["We believe we will generate sufficient future taxable income to realize the tax benefits related to the remaining net deferred tax assets in our consolidated balance sheets that are not subject to valuation allowances.", 0.5], ["Nevertheless, changes in accident frequency and severity, healthcare costs, insurance retention levels, and other factors can materially affect the estimates for these liabilities and affect our results of operations.", -0.5], ["A five-percent reduction or improvement in the assumed claim severity used to estimate our self-insurance accruals would result in an increase or decrease of approximately $250 million in our reserves and expenses as of and for the year ended May 31, 2023.", -0.2], ["These estimates affect the amount of depreciation expense recognized in a period and, ultimately, the gain or loss on the disposal of the asset.", -0.3], ["Changes in the estimated lives of assets will result in an increase or decrease in the amount of depreciation recognized in future periods and could have a material impact on our results of operations (as described below).", -0.4], ["However, such amounts may differ materially in the future due to changes in business levels, technological obsolescence, accident frequency, regulatory changes, and other factors beyond our control.", -0.6], ["We make decisions to remove certain long-lived assets from service based on projections of reduced capacity needs or lower operating costs of newer aircraft types, and those decisions may result in an impairment charge.", -0.7], ["In the fourth quarter of 2023, we made the decision to permanently retire from service 12 Boeing MD-11F aircraft and 25 related engines, four Boeing 757-200 aircraft and one related engine, and two Airbus A300-600 aircraft and eight related engines, to align with the plans of FedEx Express to modernize its aircraft fleet, improve its global network, and better align air network capacity to match current and anticipated shipment volumes.", 0.2], ["As a consequence of this decision, a noncash impairment charge of $70 million ($54 million, net of tax, or $0.21 per diluted share) was recorded in the fourth quarter.", -0.8], ["In addition, in the fourth quarter of 2023, FedEx Express made the decision to accelerate the retirement of 46 MD-11F aircraft and related engines to aid in our fleet modernization, improve our global network, and better align air network capacity of FedEx Express to", -0.1], ["As a result of this decision, we expect a net increase of approximately $12 million in depreciation expense in 2024 with the expense impact in 2025 being immaterial.", -0.2], ["Based on our reviews, we recognized an $11 million ($8 million, net of tax, or $0.03 per diluted share) asset impairment charge related to an intangible asset from the ShopRunner acquisition.", -0.5], ["In connection with our annual impairment testing of goodwill conducted in the fourth quarter of 2023, we recorded an impairment charge of $36 million ($36 million, net of tax, or $0.14 per diluted share) for all of the goodwill attributable to our FedEx Dataworks reporting unit.", -0.7], ["The key factors contributing to the goodwill impairment were underperformance of the ShopRunner business during 2023, including base business erosion, and the failure to attain the level of operating synergies and revenue and profit growth anticipated at the time of acquisition.", -0.8], ["We evaluated these reporting units during the fourth quarters of 2023 and 2022 and the estimated fair value of each of these reporting units exceeded their carrying values as of the end of 2023 and 2022; therefore, we do not believe that any of these reporting units were impaired as of the balance sheet dates.", 0.2], ["In the opinion of management, the aggregate liability, if any, of individual matters or groups of related matters not specifically described in Note 18 is not expected to be material to our financial position, results of operations, or cash flows.", 0.3], ["Accounting guidance for contingencies requires an accrual of estimated loss from a contingency, such as a non-income tax or other legal proceeding or claim, when it is probable (i.e., the future event or events are likely to occur) that a loss has been incurred and the amount of the loss can be reasonably estimated.", 0.0], ["A loss is recognized for all contingencies deemed probable and estimable, regardless of amount.", -0.3], ["For unresolved contingencies with potentially material exposure that are deemed reasonably possible, we evaluate whether a potential loss or range of loss can be reasonably estimated.", 0.0], ["However, events may arise that were not anticipated and the outcome of a contingency may result in a loss to us that differs materially from our previously estimated liability or range of possible loss.", -0.8], ["Declines in the value of plan assets could diminish the funded status of our pension plans and potentially increase our requirement to make contributions to the plans.", -0.7], ["Substantial investment losses on plan assets would also increase net pension expense.", -0.9], ["Foreign currency fluctuations had a slightly negative impact on operating income in 2023 and a slightly positive impact on operating income in 2022.", -0.1], ["At May 31, 2023, the result of a uniform 10% strengthening in the value of the dollar relative to the currencies in which our transactions are denominated would result in a decrease in expected operating income of approximately $236 million for 2024.", -0.5], ["These derivatives are not designated as hedges and are accounted for at fair value with any profit or loss recorded in income, which was immaterial for 2023 and 2022.", 0.0], ["While we have market risk for changes in the price of jet and vehicle fuel, this risk is largely mitigated by our indexed fuel surcharges.", 0.2], ["Based on this assessment, management has concluded that our internal control over financial reporting was effective as of May 31, 2023.", 0.8], ["In our opinion, FedEx Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of May 31, 2023, based on the COSO criteria.", 0.9], ["We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of May 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, cash flows and changes in common stockholders’ investment for each of the three years in the period ended May 31, 2023, and the related notes and our report dated July 17, 2023 expressed an unqualified opinion thereon.", 1.0]], "holx22_sentences.json": [["$18,757,846,271 based on the price of the last reported sale on NASDAQ Global Select Market on that date.", -0.1], ["These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.", -0.8], ["the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on our customers and suppliers and on our business, financial condition, results of operations and cash flows and our ability to draw down our revolver;", -0.9], ["the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of our products in certain countries, or increase the costs we may incur to purchase materials, parts and equipment from our suppliers;", -0.8], ["the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation;", -0.7], ["the possibility of interruptions or delays at our manufacturing facilities, or the failure to secure alternative suppliers if any of our sole source third-party manufacturers fail to supply us;", -0.7], ["anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations;", -0.5], ["the impact and costs and expenses of any litigation we may be subject to now or in the future;", -0.6], ["We completed the sale of our Medical Aesthetics segment on December 30, 2019 (the first day of the second quarter of fiscal 2020).", 0.2], ["Both of these assays have been granted Emergency Use Authorization by the FDA and are also CE-marked.", 0.5], ["With our HPA technology, we have simplified testing, further increased test sensitivity and specificity, and increased convenience.", 0.8], ["Our DKA technology uses two types of AE molecules that can be differentiated from each other — one that “flashes” and another one that “glows.” By using DKA technology, we have created nucleic acid test, or NAT, assays that can detect two separate targets simultaneously.", 0.9], ["In addition, in response to the COVID-19 pandemic, in fiscal 2020 we developed and launched the Panther Fusion SARS-CoV-2 assay for the detection of SARS-CoV-2.", 0.7], ["In February 2021, we completed the acquisition of Biotheranostics, Inc., or Biotheranostics, and now offer two proprietary laboratory developed tests, or LDTs, that support physicians in the treatment of cancer: the Breast Cancer Index test and the CancerTYPE ID test.", 0.8], ["In June 2021, we completed the acquisition of Mobidiag Oy, or Mobidiag, a developer of innovative molecular diagnostic tests and instrumentation, headquartered in Espoo, Finland.", 0.8], ["Although Mobidiag currently does not offer any of its products in the U.S., we intend to invest in assay development to drive growth of the Novodiag instrument, including seeking clearance for the Novodiag instrument and related assays in the U.S.", 0.5], ["These technologies provide reviewers with the potential to focus on key patients that might otherwise be overlooked during the review process, thus potentially increasing cancer detection.", 0.9], ["The Affirm tomosynthesis option provides faster lesion targeting and reduced patient procedure time compared to traditional stereotactic biopsy procedures.", 0.8], ["In fiscal 2020, revenues from two customers accounted for 12.5% and 10.9%, respectively, of our Diagnostics segment revenue.", 0.2], ["Our Breast Health business generates a majority of our service revenue, primarily relating to service contracts for our digital mammography and related products.", 0.6], ["Many of these competitors offer a broader product portfolio and have greater brand recognition than we do, which may make these competitors more attractive to hospitals, radiology clients, group purchasing organizations, laboratories, physicians and other potential customers.", -0.8], ["Competitors may develop superior products or products of similar quality for sale at the same or lower prices.", -0.7], ["Moreover, our products could be rendered obsolete by changes to industry standards or guidelines or advances in technology.", -0.9], ["We can give no assurance that we will be able to compete successfully with existing or new competitors.", -0.8], ["In the current environment of managed care, economically motivated buyers, consolidation among healthcare providers, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price, value, reliability and efficiency.", -0.6], ["We believe the current global economic conditions and healthcare reform measures are putting additional competitive pressure on us, including on our average selling prices, overall procedure rates and market sizes.", -0.7], ["Internationally, our ThinPrep product competes with a variety of companies and other non- FDA approved tests, since the devices often have lower risk classification with fewer regulatory barriers in many international markets as compared to the U.S. Additionally, testing volume in this category is also under pressure due to clinical guideline changes, which lengthen the interval between screenings and increasingly afford the option of HPV testing as the primary means of detection.", -0.7], ["In addition, the COVID-19 pandemic and associated economic disruptions have had an adverse impact on our supply chains.", -0.9], ["In the event we are unable to obtain sufficient quantities of raw materials or components or subassemblies on commercially reasonable terms or in a timely manner, our ability to manufacture our products on a timely and cost-competitive basis may be compromised, which may have a material adverse effect on our business, financial condition and results of operations.", -0.8], ["We are dependent on these sole source third-party manufacturers, and this dependence exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.", -0.8], ["If KMC Systems, Stratec, Flextronics or any of our other third-party manufacturers experiences delays, disruptions, capacity constraints or quality control problems in its development or manufacturing operations, curtails operations or otherwise fails to supply us with products in sufficient quantities, instrument and equipment shipments to our customers could be delayed or cancelled, which would decrease our revenues and may harm our competitive position and reputation.", -1.0], ["Further, because we place orders with our manufacturers based on forecasts of expected demand for our instruments and Skeletal Health products, if we inaccurately forecast demand, we may be unable to obtain adequate manufacturing capacity or adequate quantities of components to meet our customers' delivery requirements.", -0.8], ["An interruption in manufacturing capabilities at any of these facilities, as a result of equipment failure or other reasons, could reduce, delay or prevent the production of our products.", -0.9], ["In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities.", -0.7], ["Since our supply chain is complex, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation.", -0.8], ["In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.", -0.8], ["These redesigns or alternative materials may detrimentally impact the performance of our products, add greater testing lead-times for product introductions, result in additional costs or have other similar negative effects.", -0.9], ["There is a risk that our patent applications will not result in granted patents or that granted patents will not provide significant protection for our products and technology.", -0.8], ["Our competitors may independently develop similar or superior technology that our patents do not cover.", -0.8], ["In the absence of significant patent protection, we may be vulnerable to competitors who attempt to copy our products, processes or technology.", -0.9], ["A successful claim against us may require us to remove the alleged infringing product from the market or to design around the third party's patent, potentially resulting in less market demand for the product.", -0.8], ["FDA product approvals may be withdrawn or suspended if compliance with regulatory standards is not maintained or if problems occur following initial marketing.", -0.7], ["In March 2020, the FDA granted EUA for our Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus.", 0.8], ["In May 2020, the FDA granted EUA for our Aptima SARS-CoV-2 assay for use on our standard Panther instrument.", 0.8], ["Adverse interpretations of current CLIA regulations or future changes in CLIA regulations could have an adverse effect on sales of any affected products or services.", -0.6], ["If a laboratory is out of compliance with CLIA or with state laws or regulations governing licensed laboratories, penalties may include suspension, limitation or revocation of the license or CLIA certificate, assessment of financial penalties or fines, or imprisonment.", -0.9], ["Loss of a laboratory's CLIA certificate or state license may also result in the inability to receive payments from state and federal health care programs as well as private third party payors.", -0.9], ["We may be required to incur significant costs to comply with these laws and regulations in the future and complying with these laws may result in a material adverse effect upon our business, financial condition and results of operations.", -0.8], ["Complying with the requirements of these regulations has required us to, and may continue to require us to, incur significant expenditures.", -0.7], ["Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.", -0.8], ["If this continues, this could favorably affect our ability to introduce new products in the Chinese market.", -0.1], ["It is possible that the Chinese government's current or future interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory investigations or lead to fines or penalties.", -0.8], ["We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in laws, regulations or policies by governmental authorities may cause increases in uncertainties and compliance costs, exposure to litigation and other adverse effects to our business and operations.", -0.7], ["Delays in receipt of, or failure to obtain, clearances or approvals for future products could delay or preclude realization of product revenues from new products or result in substantial additional costs which could decrease our profitability.", -0.9], ["The ability of our customers to obtain adequate reimbursement for our products and services from private and governmental third-party payors is critical to the success of medical technology companies because it may affect which products customers purchase and the prices they are willing to pay.", 0.2], ["Reimbursement and coverage vary by country and can significantly impact acceptance of new products and technologies.", -0.3], ["These trends could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["our employees, and their commitment to each other fortifies our leaders and teams and improves their business performance.", 0.7], ["For our front-line employees who came to our facilities throughout the COVID-19 pandemic to develop and manufacture our COVID-19 tests, or who installed Panther instruments in locked-down hospitals during the most uncertain times of the COVID-19 pandemic, we were able to provide extraordinary financial awards.", 0.5], ["Our respiratory infectious disease product line (including our assays for the detection of SARS-CoV-2) within our Diagnostics segment is also subject to significant seasonal and year-over-year fluctuations.", -0.2], ["Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business.", -0.8], ["The occurrence of any of these events or circumstances could individually or in the aggregate have a material adverse effect on our business, financial condition, cash flow or results of operations.", -0.9], ["The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects, both domestically and internationally.", -0.8], ["Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues, including the war in Ukraine, have contributed to increased market volatility and diminished expectations for economic growth in the world.", -0.9], ["Our business and results of operations have been and may continue to be adversely impacted by changes in macroeconomic conditions, including inflation, rising interest rates and availability of capital markets.", -0.8], ["Uncertainty about global economic conditions, particularly in emerging markets and countries with government-sponsored healthcare systems, may also cause decreased demand for our products and services and increased competition, which could result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies.", -0.8], ["A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply.", -0.7], ["Economic uncertainty, an increase in unemployment rates, as well as increasing health insurance premiums, co-payments and deductibles may continue to result in cost-conscious consumers making fewer trips to their physicians and specialists, which in turn would adversely affect demand for our products and procedures.", -0.8], ["Furthermore, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could adversely affect sales of our products.", -0.8], ["Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of our revenues outside the U.S. and associated cash flows and our ability to compete effectively in foreign markets.", -0.7], ["In addition, such fluctuations can also result in foreign currency exchange losses.", -0.8], ["We currently have limited hedging arrangements in place to mitigate some of the impact of negative exchange rates.", -0.6], ["In fiscal 2022, 28.7% of our revenue came from outside of the U.S. As we grow internationally, our future and existing international operations may subject us to a number of additional risks and expenses, any of which could harm our operating results.", -0.7], ["lower margins on a number of our products sold outside of the U.S.", -0.7], ["The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results of operations and financial condition.", -0.9], ["For example, a government's adoption of \"buy national\" policies or retaliation by another government against such policies could have a negative impact on our results of operations.", -0.8], ["It is possible that the Chinese government's current or future interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory investigations or lead to fines or penalties.", -0.9], ["Supply chain disruptions and constraints and inflationary pressures have had, and may continue to have, a material adverse effect on our ability to procure raw materials and components, including semiconductor chips, and are adversely affecting our ability to meet customer demand for, and increasing our costs to manufacture, warehouse, and transport, certain of our products.", -0.9], ["Global supply constraints and cost impacts as a result of worldwide economic disruptions, electronic component shortages, fear of future or ongoing pandemics, inflation, recessionary conditions and geopolitical events, including the war in Ukraine, are impacting our ability to procure critical raw materials and components, including semiconductor chips, and are adversely affecting our ability to meet customer demand for, and increasing our costs to manufacture, transport and warehouse a certain subset of our products.", -0.9], ["If we remain unable to obtain sufficient quantities of raw materials and components on commercially reasonable terms or in a timely manner, our ability to manufacture our capital equipment products, in particular, our Breast Health products, on a timely and cost-competitive basis could materially adversely affect our revenues and results of operations and harm our competitive position and reputation.", -0.9], ["Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some key raw materials, components and subassemblies for our products exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.", -0.8], ["If any of our sole source manufacturers or suppliers, or other third-party manufacturers or suppliers, experiences delays, disruptions, capacity constraints or quality control problems in its development or manufacturing operations or becomes insolvent or otherwise fails to supply us with goods in sufficient quantities, including as a result of disruptions caused by the continued impact of COVID-19, other epidemics or pandemics, natural disasters, supplier facility shutdowns, or otherwise, then shipments to our customers could be delayed, which would decrease our revenues and harm our competitive position and reputation.", -0.9], ["Moreover, the failure of a supplier to provide sufficient quantities, acceptable quality and timely delivery of goods at an acceptable price, or an interruption in the delivery of goods from such a supplier could adversely affect our business and results of operations.", -0.8], ["As a result, we may lose revenues and our customer relationships may suffer.", -0.7], ["Interruptions, delays, shutdowns or damage at our manufacturing or laboratory facilities could harm our business.", -0.8], ["An interruption in manufacturing, testing capabilities or warehousing at any of these facilities, as a result of equipment failure, transportation interruptions, disruptions caused by the continued impact of COVID-19, other epidemics or pandemics, natural disaster, environmental factors or property damage could reduce, delay or prevent the production and distribution of our products.", -0.8], ["Our facilities may experience plant shutdowns, strikes or other labor disruptions, or periods of reduced production as a result of equipment failures, loss of power, gray outs, delays in deliveries or extensive damage, which could harm our business and prospects.", -0.8], ["We also developed assays to detect COVID-19.", 0.2], ["While we have seen significant demand for our COVID-19 assays, other companies are working to produce or have produced tests for COVID-19 (including so-called high throughput nucleic acid tests, rapid antigen tests and at- home testing solutions) which may lead to the diversion of customers away from us and toward other companies.", -0.5], ["Moreover, considerable uncertainty remains as to the demand for ongoing COVID-19 testing, and thus, for our COVID-19 assays.", -0.6], ["There is no guarantee that current or anticipated demand will continue, or if demand does continue or increases, that we will be able to produce in quantities to meet the demand.", -0.8], ["As COVID-19 testing declines, customers may also consolidate their molecular testing menu to high throughput, high automation platforms which may further increase the competition our Panther and Panther Fusion instruments face.", -0.6], ["A significant decline in demand for our COVID- 19 assays or a reduction in the reimbursement rates for our COVID-19 assays without a corresponding increase in our other businesses could have a material, adverse effect on our results of operations, cash flow and financial position.", -0.9], ["Challenges in the development of our products could materially impact our long-term success.", -0.7], ["Our growth depends in large part on our ability to identify and develop new products or new indications for or enhancements of existing products.", 0.3], ["If we are not able to successfully enhance existing products or develop new products, our products may be rendered obsolete or uncompetitive by changing technology or new industry standards.", -0.8], ["We cannot assure that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance, and we may be unable to recover all or a meaningful part of our investment in such products and technologies.", -0.7], ["The markets for our newly developed products and newly introduced enhancements to our existing products may not develop as expected.", -0.6], ["If we are unable to successfully commercialize and create a significant market for our newly developed products and newly introduced enhancements to our existing products our business and prospects could be harmed.", -0.7], ["If we cannot maintain our current corporate collaborations and enter into new corporate collaborations, our product development could be delayed and our revenue could be adversely impacted.", -0.8], ["If any of our corporate collaborators were to breach, terminate, fail to renew our agreements or otherwise fail to properly conduct its obligations in a timely manner, the development or commercialization and subsequent marketing of the products contemplated by the collaboration could be delayed or terminated.", -0.9], ["Any of the foregoing risks could harm our business and prospects.", -0.8], ["If we are successful in pursuing future acquisitions, we may face significant competition, be required to expend significant funds, incur additional debt or other obligations, or issue", -0.5], ["additional securities, which may negatively affect our operating results and financial condition.", -0.7], ["If we spend significant funds or incur additional debt or obligations, our ability to obtain financing for working capital or other purposes could be adversely affected, and we may be more vulnerable to economic downturns and competitive pressures.", -0.8], ["During fiscal 2021, we made a number of tactical acquisitions which complemented our existing businesses.", 0.3], ["Any inability to successfully integrate new businesses, including our recent acquisitions, decreases in customer loyalty or product orders, failure to retain or develop the acquired workforce, failure to realize anticipated economic, operational and other benefits and synergies in a timely manner, failure to establish and maintain appropriate controls or unknown or contingent liabilities could adversely affect our ability to realize the anticipated benefits of any new product or acquisition.", -0.7], ["Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.", -0.9], ["Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created and may continue to create significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate in, primarily the U.S., Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally.", -0.9], ["In particular, elective procedures and exams were delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated services.", -0.8], ["While elective procedures and exams and capital purchases have increased from initially depressed levels, the reduction in elective procedures, exams and capital purchases has had, and we believe may continue to have, a negative impact on the sales of most of our products (other than our COVID-19 assays and related systems and ancillaries).", -0.8], ["Additionally, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could further adversely affect sales of our products.", -0.9], ["Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, and the loss of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly reduce revenues in our Diagnostics segment.", -0.7], ["The loss of any of these key customers, or a significant reduction in sales volume or pricing to these customers, could significantly reduce our Diagnostics segment revenues or profitability.", -0.7], ["We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these distributors.", -0.6], ["If any of our strategic relationships terminate without replacement or if our strategic partners fail to perform their contractual obligations, our revenues and/or ability to service our products in the territories serviced by these distributors could be adversely affected.", -0.7], ["If we elect to distribute new products directly, we will have to invest in additional sales and marketing resources, including additional field sales personnel, which would significantly increase future selling, general and administrative expenses.", -0.5], ["If we fail to successfully market our products, our product sales will decrease.", -0.8], ["We may also be exposed to risks as a result of transitioning a territory from a distributor sales model to a direct sales model, such as difficulties maintaining relationships with specific customers, hiring appropriately trained personnel or ensuring compliance with local product registration requirements, any of which could result in lower revenues than previously received from the distributor in that territory.", -0.7], ["The loss of any of our key personnel, particularly executive management or key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operational or strategic objectives.", -0.8], ["We also continue to face the challenges of maintaining employee well-being, recognizing that the continued additional financial, family and health burdens that many employees may be experiencing due to the ongoing impacts of COVID-19, macroeconomic uncertainties, including inflation, and other factors, may adversely impact job performance and employee retention.", -0.8], ["If our succession planning efforts are not effective, it could adversely impact our business.", -0.7], ["Future organizational changes could also cause our employee attrition rate to increase.", -0.6], ["If we fail to effectively manage any organizational and/or strategic changes, our financial condition, results of operations, and reputation, as well as our ability to successfully attract, motivate and retain key employees, could be harmed.", -0.8], ["Despite our implementation of controls to protect our systems and sensitive, confidential or personal data or information, we may be vulnerable to material security breaches, theft, misplaced, lost or corrupted data, employee errors and/or malfeasance (including misappropriation by departing employees) that could potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems, software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products, production downtimes and operational disruptions.", -0.9], ["In addition, a cyber-related attack could result in other negative consequences, including damage to our reputation or competitiveness, remediation or increased protection costs, litigation or regulatory action.", -0.8], ["Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or other liabilities.", -0.7], ["Evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional costs to re-design our products in a timely manner, either of which could have an adverse impact on our results of operations.", -0.7], ["More privacy and security laws and regulations are being adopted, and more are being enforced, with potential for significant financial penalties.", -0.6], ["Failure to maintain the confidentiality of sensitive personal information in accordance with the applicable regulatory requirements, or to abide by electronic health data transmission standards, could expose us to breach of contract claims, fines and penalties, costs for remediation and harm to our reputation.", -0.7], ["Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.", -0.8], ["Sales and market acceptance of our diagnostics, breast and skeletal health and surgical products and the treatments facilitated by these products are dependent upon the coverage decisions and reimbursement policies established by government healthcare programs and private health insurers.", -0.2], ["Reimbursement varies by country and can significantly impact the acceptance of new products and technologies.", -0.4], ["Even if we develop a promising new product, we may find limited demand for the product unless appropriate reimbursement approval is obtained from private and governmental third-party payors.", -0.6], ["Further legislative or administrative reforms to the reimbursement systems in the U.S. and other countries in a manner that significantly reduces reimbursement for procedures using our diagnostics, breast and skeletal health and surgical products or denies coverage for those procedures facilitated by our products, including price regulation, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["If followed by healthcare providers and insurers, such publications could result in decreased use of our products.", -0.7], ["We believe that these recommendations and guidelines may have contributed to increased screening intervals for cervical cancer, which we believe has and may continue to adversely affect our ThinPrep revenues.", -0.8], ["Our ThinPrep revenues may also be adversely affected by the July 2020 American Cancer Society cervical cancer screening recommendation for a primary human papillomavirus (HPV) test rather than a Pap test.", -0.8], ["We believe that this recommendation could result in a decrease in use and purchases of our mammography systems.", -0.7], ["We operate in a highly regulated industry, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products and services or product or service enhancements, could adversely affect our business and prospects.", -0.9], ["As a result, governmental actions may adversely affect our business, operations or financial condition, including:", -1.0], ["changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;", -0.8], ["changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products; and", -0.9], ["In addition, there is a risk that any approvals or clearances, once obtained, may be withdrawn.", -1.0], ["If the FDA requires us to seek one or more pre-market approval supplements or new pre-market approvals for any modification to a previously approved device, we may be required to cease marketing or to recall the modified device until we obtain approval, and we may be subject to significant criminal and/or civil sanctions, including, but not limited to, regulatory fines or penalties.", -1.0], ["Implementation of the compliance requirements of these regulations requires us to incur significant expenditures and utilize resources.", -0.9], ["Failure to continue to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.", -1.0], ["We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in laws, regulations or policies by governmental authorities may cause increased uncertainties and compliance costs, exposure to litigation and other adverse effects to our business and operations.", -1.0], ["Delays in receipt of, or failure to obtain or maintain, clearances or approvals for future products could delay or preclude realization of product revenues from new or existing products or result in substantial additional costs which could decrease our profitability.", -1.0], ["In addition, maintaining compliance with multiple regulators, and multiple centers within the FDA, adds complexity and cost to our manufacturing processes.", -0.9], ["We or our contractors may fail to satisfy these regulatory requirements in the future, and any failure to do so may prevent us from selling our products.", -0.8], ["Anti-kickback and false claims laws and the Physician Payment Sunshine Act prescribe civil and criminal penalties (including fines) for noncompliance that can be substantial.", -0.9], ["Violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction and have a material adverse effect on our business, financial condition and results of operations.", -0.9], ["Moreover, our failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures, and withdrawal of an approved product from the market.", -0.9], ["We are subject to the risk of product liability claims relating to our products for which we may not have adequate insurance.", -0.8], ["If even one of our products is found to have caused or contributed to injuries or deaths, we could be held liable for substantial damages.", -0.9], ["An under-insured or uninsured claim could harm our business and prospects.", -0.8], ["In addition, claims could adversely affect the reputation of the related product, which could damage that product’s competitive position in the market.", -0.8], ["Any product liability claim brought against us, with or without merit, could result in an increase in our product liability insurance rates or the inability to secure additional coverage in the future.", -0.8], ["This could result in a diversion of management’s attention from our business and adversely affect the perceived safety and efficacy of our products, which could harm our business and prospects.", -0.8], ["In such event, we could be held liable for any resulting damages, and any such liability could be extensive.", -1], ["These redesigns or the use of alternative materials may detrimentally impact the performance of our products, add greater testing lead times for product introductions, result in additional costs or have other similar effects.", -1], ["In addition, changes in environmental laws and regulations, in particular relating to climate change and greenhouse gas (“GHG”) emissions, could require us, or our contract manufacturers or suppliers, to install additional equipment, or alter operations to incorporate new technologies or processes, which may result in additional expenses and adversely affect our operating results.", -1], ["We may also incur significant costs and utilize additional resources to comply with future regulations related to climate-related disclosures.", -1], ["We may also be required to incur significant costs to comply with these and future regulations, which may result in a material adverse effect upon our business, financial condition and results of operation.", -1], ["Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.", -1], ["We are subject to income taxes, as well as taxes that are not income-based, in both the U.S. and jurisdictions outside of the U.S. Our future effective tax rate could be unfavorably affected by numerous factors including a change in, or the interpretation of, tax rules and regulations in the jurisdictions in which we operate (including changes in legislation currently being considered), a change in our geographic earnings mix, and/or to the jurisdictions in which we operate, or a change in the measurement of our deferred taxes.", -1], ["If we are unable to access new technologies or the rights to particular sequences or markers necessary for additional diagnostic products on commercially reasonable terms, we may be limited in our ability to develop new diagnostic products.", -1], ["Our business could be adversely affected if we are unable to obtain the additional intellectual property rights necessary to commercialize our products.", -1], ["Our business could be harmed if we are unable to protect our proprietary technology.", -1], ["As a result, any infringement claims by third parties or claims for indemnification by customers resulting from infringement claims, whether or not proven to be true, may harm our business and prospects.", -0.8], ["We have a significant amount of indebtedness outstanding, which limits our operating flexibility, and could adversely affect our operations and financial results and prevent us from fulfilling our obligations.", -0.9], ["make it more difficult for us to satisfy our obligations with respect to our outstanding indebtedness;", -0.7], ["increase our vulnerability to general adverse economic and industry conditions, including increases in interest rates;", -0.7], ["require us to dedicate a substantial portion of our cash flow from operations to interest and principal payments on our indebtedness, which would reduce the availability of our cash flow to fund working capital, capital expenditures, expansion efforts, strategic transactions and other general corporate purposes;", -0.8], ["limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we participate;", -0.7], ["place us at a competitive disadvantage compared to our competitors that have less debt; and", -0.6], ["limit our ability to borrow additional funds for working capital, capital expenditures, expansion efforts, strategic transactions or other general corporate purposes.", -0.8], ["pay dividends, repurchase our common stock, or make other distributions or restricted payments;", -0.7], ["Our failure to comply with the covenants contained in our credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.", -0.9], ["If there were an event of default under one of our debt instruments or a change of control, the holders of the defaulted debt could cause all amounts outstanding with respect to that debt to be due and payable immediately and may be cross-defaulted to other debt, including our outstanding notes.", -1], ["Our assets or cash flow may not be sufficient to fully repay borrowings under our outstanding debt instruments if accelerated upon an event of default or a change of control, and there is no guarantee that we would be able to repay, refinance or restructure the payments on such debt.", -1], ["We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.", -1], ["Our business may not be able to generate sufficient cash flow from operations, and we cannot assure that future borrowings will be available to us in amounts sufficient to enable us to pay our indebtedness as such indebtedness matures and to fund our other liquidity needs.", -1], ["If this occurs, we will need to refinance all or a portion of our indebtedness on or before maturity, and there can be no assurance that we will be able to refinance any of our indebtedness on commercially reasonable terms, or at all.", -1], ["We may need to adopt one or more alternatives, such as reducing or delaying planned expenses and capital expenditures, selling assets, restructuring debt, or obtaining additional equity or debt financing.", -1], ["If we do not generate sufficient cash flow from operations, and additional borrowings, refinancings or proceeds from asset sales are not available to us, we may not have sufficient cash to enable us to meet all of our obligations.", -1], ["A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest payments.", -1], ["A significant portion of our indebtedness is subject to floating interest rates, which makes us more vulnerable in the event of adverse economic conditions, increases in prevailing interest rates, or a downturn in our business.", -1], ["Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our business or common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.", -1], ["Our indebtedness also contains provisions which either accelerate or require us to offer to repurchase the indebtedness at a premium upon a change of control.", -0.8], ["These provisions could limit the price that our stockholders might receive in the future for shares of our common stock.", -0.7], ["quarterly fluctuations in our actual or anticipated operating results and order levels;", -0.5], ["the success or lack of success of integrating our acquisitions.", -0.4], ["In addition, the stock market in general and the markets for shares of “high-tech” and life sciences companies, have historically experienced extreme price fluctuations which have often been unrelated to the operating performance of affected companies.", -0.6], ["Any such fluctuations in the future could adversely affect the market price of our common stock, and the market price of our common stock may decline.", -0.9], ["We have never declared or paid cash dividends on our capital stock, and we currently have no plans to do so.", -0.7], ["The current worldwide supply chain shortages and constraints are impacting our ability to obtain certain critical raw materials and components used primarily in our Breast Health capital equipment products.", -0.8], ["The supply chain shortages and disruptions primarily affecting our Breast Health manufacturing lines are related to electronic components, primarily semiconductor chips.", -0.6], ["Based on our current understanding of their allocation of chips to us we expect we will be able to increase production on a sequential quarterly basis throughout fiscal 2023.", 0.2], ["If such allocation does not meet our expectations or we are not able to obtain alternative sources of chips, we believe we will not be able to manufacture sufficient quantities of our capital equipment products, primarily 3D Dimension systems, Trident specimen radiography systems, Affirm Prone biopsy systems and Brevera systems to meet customer demand.", -0.8], ["As a result, if we are unable to obtain sufficient quantities of chips, sales of these products may decline or will not increase in fiscal 2023 compared to fiscal 2022 levels.", -0.7], ["In addition, the prices of raw materials and components, as well as freight, have been rising and continued supply chain shortages could increase the costs further.", -0.6], ["These factors may result in a lower gross margin for Breast Health in fiscal 2023 for our affected products.", -0.7], ["We also acquired $66.1 million of debt, which was paid off in fiscal 2022.", 0.2], ["This acquisition expands our molecular diagnostics portfolio into the near-patient testing market.", 0.8], ["Based on our valuation, we allocated $162.4 million of the purchase price to the value of intangible assets and $80.9 million to goodwill.", 0.5], ["On March 1, 2021, we completed the acquisition of Diagenode SA, or Diagenode, for a purchase price of $155.1 million.", 0.5], ["Based on our valuation, we allocated $79.0 million of the purchase price to the value of intangible assets and $83.5 million to goodwill.", 0.5], ["On December 30, 2020, we completed the acquisition of Somatex Medical Technologies GmbH, or Somatex, for a purchase price of", 0.4], ["We had a decrease in product revenue of 15.6% in fiscal 2022 compared to fiscal 2021.", -0.8], ["This decrease was primarily due to the decline in revenues in the Diagnostics business as a result of lower COVID-19 assay sales, a decrease in Breast Health revenue, which we primarily attribute to supply chain constraints, and to a lesser extent the negative effect from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.7], ["The decrease in product revenues in fiscal 2022 compared to fiscal 2021 was partially offset by an increase in GYN Surgical product revenue due to an increase in sales volume of these products which we attribute to a recovery of elective procedures as COVID-19 restrictions eased, as well as an increase from our recent acquisitions.", 0.2], ["Diagnostics product revenues decreased 18.7% in fiscal 2022 compared to fiscal 2021 primarily due to decreases in Molecular Diagnostics of $656.4 million and a decrease in blood-screening of $15.8 million, partially offset by an increase in Cytology and Perinatal revenue of $0.7 million.", -0.9], ["$2,427.5 million in fiscal 2022 compared to $3,083.9 million in fiscal 2021.", -0.9], ["The decrease was primarily attributable to a reduction of $729.0 million in sales our two SARS-CoV-2 assays (primarily the Aptima SARS-CoV-2 assay and to a lesser extent the Panther Fusion SARS-CoV-2 assay) to $1,430.5 million in fiscal 2022 compared to $2,159.5 million in fiscal 2021 primarily due to lower demand from an improvement in the COVID-19 pandemic and, to a lesser extent, the impact of at-home testing alternatives and lower average selling prices on a worldwide basis .", -0.8], ["We also had a decrease in Panther and Panther Fusion instrument sales in fiscal 2022 compared to fiscal 2021 as sales in fiscal 2021 were higher primarily due to the COVID-19 pandemic as customers expanded their Covid assay testing capacity.", -0.8], ["These decreases were partially offset by an increase of $53.6 million in our Aptima assays and STD collection kits (exclusive of our SARS-CoV-2 assay), which primarily consist of our CTGC, Bacterial Vaginosis, and CV Candida assays, on a worldwide basis as volumes increased, partially offset by lower HPV assay volumes and a decrease in average selling prices.", 0.1], ["In addition, we had an increase of $32.6 million in worldwide sales of our Quant Viral assays and Fusion respiratory products in the current fiscal year.", 0.3], ["$13.3 million of incremental product revenue in the current fiscal year.", 0.1], ["We also experienced a decrease in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.8], ["We expect that sales of our COVID-19 assays will continue to decline in fiscal 2023 compared to the current fiscal year as the pandemic recedes and given the continued distribution of vaccines and boosters.", -0.7], ["Breast Health product revenues decreased 16.5% in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in volumes of our digital mammography systems, primarily 3D Dimensions systems, related software and workflow products, Affirm biopsy systems and Brevera biopsy systems.", -0.9], ["The decrease in volume was primarily driven by supply chain constraints related to electronic components, primarily semiconductor chips, that impacted our ability to manufacture sufficient quantities to meet customer demand.", -0.8], ["These decreases were partially offset by an increase in average selling prices, as well as an increase in sales of our interventional breast solutions products, primarily driven by ATEC and Brevera disposables.", 0.2], ["We also experienced a decrease in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.8], ["GYN Surgical product revenues increased 7.1% in fiscal 2022 compared to fiscal 2021, primarily due to increases in the sales volume of our Fluent Fluid Management products, Bolder products (comprised of CoolSeal vessel sealing devices and JustRight surgical staplers), MyoSure system sales and Acessa ProVu systems.", 0.6], ["These increases were partially offset by decreases in NovaSure system sales.", -0.2], ["We also experienced a decrease in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.8], ["Skeletal Health product revenues decreased 6.6% in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in sales volume of our Horizon DXA systems and Insight FD Fluoroscan systems.", -0.7], ["We also experienced a decrease in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.8], ["The percentage of product revenue derived from the U.S. and Asia-Pacific increased while Europe decreased, which we primarily attribute to a steeper decline in SARS-CoV-2 assay sales in Europe compared to the U.S., partially offset by an increase in HIV assay sales in Africa, and an increase in SARS-CoV-2 assay sales in Australia and New Zealand.", 0.1], ["The percentage of product revenue increased in Asia- Pacific is primarily due to an increase in volume of ThinPrep and HPV assays in China.", 0.5], ["In addition, the strengthening of the U.S. dollar against a number of currencies contributed to the increase in the percentage of revenue derived from the U.S. compared to revenue derived from the other geographic regions.", 0.2], ["Service and other revenues increased 1.0% in fiscal 2022 compared to fiscal 2021 primarily due to an increase in Breast Health service contract revenue as the Breast Health business continued to convert a high percentage of our installed base of digital mammography systems to service contracts upon expiration of the warranty period, as well as additions from our distributor acquisitions.", 0.7], ["This increase was partially offset by a decrease in installation and training services that are provided with capital product sales as a result of lower unit sales in the current fiscal year.", -0.3], ["In our Diagnostics business, lab testing revenue from the inclusion of our Biotheranostics acquisition in the second quarter of fiscal 2021, increased", 0.6], ["$35.9 million in the current year.", -0.4], ["This was offset by a decrease in royalty revenue of $46.2 million from Grifols, S.A., or Grifols, related to licensing our intellectual property to our COVID-19 assays for their sale in Spain, as the contract expired in December 2021.", -0.5], ["Intangible Assets              295.7       7.1 %      276.7        5.5 %      19.0       6.9 %", -0.1], ["Product gross margin was 64.7% in fiscal 2022 compared to 70.2% in fiscal 2021.", -0.5], ["The cost of product revenues as a percentage of product revenues was 27.8% in the current year compared to 24.3% in the prior year.", -0.4], ["Cost of product revenues as a percentage of revenue increased in fiscal 2022 primarily due to a decrease in sales of our SARS-CoV-2 assays, which have higher gross margins compared to our other Diagnostic products, and comprised 34.1% and 43.5% of total product revenue in fiscal 2022 and fiscal 2021, respectively.", -0.6], ["Diagnostics' product costs as a percentage of revenue increased in fiscal 2022 compared to fiscal 2021 primarily due to lower sales of our SARS-CoV-2 assays, a slight decline in average selling prices of certain assays, an increase in inventory reserves, higher field service costs for our expanded instrument installed base and higher freight charges internationally, partially offset by lower sales of instruments, which carry low margins, and an increase in sales of our Aptima and Quant Viral assays.", -0.7], ["Breast Health’s product costs as a percentage of revenue increased in fiscal 2022 compared to fiscal 2021 primarily due to the impact of the COVID-19 pandemic on the supply chain resulting in lower sales volumes of our higher margin products, reduced manufacturing utilization and higher prices of raw materials and components, partially offset by a slight increase in average selling prices of our 3Dimensions systems and related workflow products.", -0.6], ["GYN Surgical’s product costs as a percentage of revenue increased in fiscal 2022 compared to fiscal 2021 primarily due to product mix of higher volumes of lower margin products, mostly attributable to sales of our Fluent Fluid Management systems, Bolder products (comprised of CoolSeal vessel sealing devices and JustRight surgical staplers) and Acessa ProVu systems.", -0.6], ["Skeletal Health’s product costs as a percentage of revenue increased in fiscal 2022 compared to fiscal 2021 primarily due to increased costs for our Horizon DXA systems workstation upgrades and lower sales volumes of our Horizon DXA and Insight FD systems primarily due to supply chain constraints, partially offset by a slight increase in average selling prices of our Horizon DXA and Insight FD systems.", -0.6], ["Amortization expense increased in fiscal 2022 compared to fiscal 2021 primarily due to intangible assets acquired in the Mobidiag, Biotheranostics, Diagenode and Bolder acquisitions as well as accelerated amortization related to shortening the life of certain intangible assets acquired in the acquisitions of SuperSonic Imagine SA, or SSI and Faxitron.", -0.5], ["As discussed in Note 2 to the consolidated financial statements, we determined that certain developed technology assets acquired in the Focal and Faxitron acquisitions were impaired as a result of decisions to no longer sell certain low-volume products.", -0.8], ["As a result, we recorded an impairment charge of $17.4 million to write-off these developed technology assets in fiscal 2022.", -0.8], ["Service and other revenues gross margin was 42.5% in fiscal 2022 compared to 46.7% in fiscal 2021.", -0.3], ["The decrease in gross margin was primarily due to a decrease in royalty revenue from Grifols related to licensing our intellectual property related to our COVID-19 assays for their sale in Spain, which had a high margin.", -0.6], ["This decrease is partially offset by the inclusion of lab testing revenue from Biotheranostics, which has higher margins than our legacy service business and an increase in Breast Health service contract revenue which benefited gross margin as service contract revenue has higher margins compared to revenue from spare parts, installation and training.", 0.2], ["General and administrative        407.7       8.4 %      433.2       7.7 %      (25.5)      (5.9)%", -0.2], ["charges                   2.4       — %       9.3       0.2 %      (6.9)      (74.2)%", -0.5], ["Research and development expenses increased 2.6% in fiscal 2022 compared to fiscal 2021 primarily due to the inclusion of incremental expenses from the Mobidiag, Biotheranostics, Diagenode and Bolder acquisitions aggregating", 0.1], ["Partially offsetting this increase was the prior year period inclusion of a $7.0 million charge related to the purchase of intellectual property in Breast Health that has no future alternative use, the reversal of a $5.2 million research and development tax credit reserve related to the SSI acquisition in fiscal 2022, a higher credit of $3.2 million recorded to research and development expenses in fiscal 2022 from the Biomedical Advanced Research and Development Authority (BARDA) in connection with a grant to obtain FDA approval of our SARS-CoV-2 assays and develop sampling pooling capability and other enhancements to our SARS-CoV-2 assays, a reduction in spend to implement the European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) requirements, and lower bonus and expense under our deferred compensation plan.", 0.3], ["Selling and marketing expenses increased 12.3% in fiscal 2022 compared to fiscal 2021 primarily due to increased spend on marketing initiatives including our sponsorship of the Women's Tennis Association and our Super Bowl commercial, the inclusion of expenses from the Mobidiag, Biotheranostics, Diagenode and Bolder acquisitions aggregating $28.9 million and an increase in travel, meetings and trade shows that were lower in the prior year primarily due to canceled or curtailed events as a result of the COVID-19 pandemic.", 0.1], ["Partially offsetting these increases in the current year is a decrease in Breast Health commissions due to lower revenue, a decrease in consulting spend and lower bonus.", 0.0], ["General and administrative expenses decreased 5.9% in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in acquisition transactions costs of $19.7 million, lower bonus and expense from our deferred compensation plan, a decrease in bad debt expense of $10.1 million, lower litigation and settlement costs, lower", -0.2], ["Partially offsetting these decreases was the inclusion of incremental expenses from the Mobidiag, Biotheranostics, Diagenode and Bolder acquisitions aggregating $13.1 million, an increase in charitable donations of $9.0 million, an increase in non-income tax charges, higher information systems infrastructure project spend, an increase in tax and accounting projects and increased travel.", -0.3], ["In addition, in fiscal 2021 we recorded a $3.5 million credit related to services provided under the transition services agreement for the Cynosure medical aesthetics business we sold in fiscal 2020.", 0.1], ["Amortization expense increased 7.1% in fiscal 2022 compared to fiscal 2021 primarily due to increases from recent acquisitions, partially offset by assets from older acquisitions becoming fully amortized.", -0.1], ["As discussed in Note 2 to the consolidated financial statements, we recorded an impairment charge of $27.7 million during fiscal 2022 to record our only IPR&D asset to fair value.", -0.5], ["The reduction in fair value was due to an increase in the discount rate from higher interest rates, a reduction in forecasted revenues and timing of completing the project.", -0.4], ["In the current year, we recorded a gain of $39.5 million to decrease the liability to its fair value.", 0.4], ["The reduction in fair value was primarily due to a decrease in forecasted revenues over the measurement period and to a lesser extent an increase in interest rates.", -0.3], ["In 2021, we recorded a gain of $6.7 million primarily due to a decrease in forecasted revenues over the measurement period.", 0.2], ["These actions have primarily resulted in the termination of employees.", -0.6], ["As a result, we recorded charges of $2.4 million in fiscal 2022 and $9.3 million in fiscal 2021, primarily related to severance benefits.", -0.8], ["Interest expense in fiscal 2022 increased compared to fiscal 2021 primarily due to an increase in the variable interest rate under our 2021 Credit Agreement partially offset by lower interest rate swap expense as our hedged benchmark interest rate increased throughout the year, lower debt refinancing costs of $4.0 million, and lower interest on our Senior Notes due to issuing our 2029 Senior Notes and paying off our 2025 Senior Notes in the prior year, which had a higher fixed rate.", -0.2], ["In connection with this transaction we recorded a debt extinguishment charge of $0.7 million.", -0.7], ["In the first quarter of fiscal 2021, we completed a private placement of $950 million aggregate principal amount of our 2029 Senior Notes.", 0.3], ["In connection with this transaction, we recorded a debt extinguishment loss of $21.6 million in the first quarter of fiscal 2021.", -0.9], ["In fiscal 2022, this account primarily consisted of net foreign currency exchange gains of $48.5 million, primarily from settling forward foreign currency hedging transactions and mark-to-market of outstanding foreign currency contracts, and a $2.4 million gain on life insurance proceeds as a result of the death of a former employee, partially offset by a loss of $12.2 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan primarily driven by stock market losses, a $4.0 million impairment charge of an equity investment and a charge of $4.3 million to write-off an equity method investment acquired in the Mobidiag acquisition.", 0.1], ["In fiscal 2021, this account primarily consisted of a net foreign currency exchange loss of $17.1 million, partially driven by the mark- to-market and settling of outstanding foreign currency contracts, and a charge of $1.8 million for the write-off of an equity investment, partially offset by a gain of $13.4 million on the cash surrender value of life insurance contracts related to our deferred compensation plan driven by prior year stock market gains.", -0.3], ["Diagnostics revenues, as discussed above, decreased in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in sales of our SARS-CoV-2 assays and a decrease in royalty revenue from Grifols related to licensing our intellectual property of our COVID-19 assays for their sale in Spain, partially offset by revenue from recent acquisitions and an increase in sales of our Aptima and Quant Viral assays.", -0.5], ["Operating income for this business segment decreased in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in gross profit from lower revenues and an increase in operating expenses.", -0.6], ["Gross margin was 67.1% in the current year compared to 73.2% in the prior year.", -0.4], ["The decrease in gross margin was primarily due to decreased sales of our SARS-CoV-2 assays which have a higher margin, an increase in intangible asset amortization expense from recent acquisitions, lower Grifols license revenue, an increase in inventory reserves, higher field service costs for our expanded install bases and an increase in freight internationally, partially offset by the inclusion of Biotheranostics lab testing revenue which has a higher gross margin than our legacy businesses.", -0.8], ["Operating expenses increased in fiscal 2022 compared to fiscal 2021 primarily due to the IPR&D charge of $27.7 million, the inclusion of operating expenses from the Biotheranostics, Mobidiag, and Diagenode acquisitions in the amount of $67.6 million, an increase in allocated advertising and charitable contributions, an increase in marketing initiatives, trade shows, meetings and travel expenses.", -0.7], ["These increases were partially offset by lower acquisition transaction costs, lower bonus and expense from our deferred compensation plan, lower integration costs, lower bad debt expense, lower MDR/IVDR implementation costs, and a higher BARDA credit of $3.2 million in the current year.", 0.2], ["Breast Health revenues decreased in fiscal 2022 compared to fiscal 2021 primarily due to a decrease of $134.6 million in product revenue as discussed above, partially offset by an increase of $10.1 million in service and other revenue.", -0.6], ["The increase in service revenue is primarily due to an increase in service contract revenue as the Breast Health business continued to convert a high percentage of our installed base of digital mammography systems to service contracts upon expiration of the warranty period.", 0.5], ["Operating income for this business segment decreased in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in product sales and service gross profit, partially offset by a decrease in operating expenses.", -0.5], ["Gross margin was 51.9% in the current year compared to 56.4% in the prior year.", -0.7], ["The decrease in gross margin is primarily due to lower volumes of capital equipment sales, the reduced manufacturing utilization from supply chain shortages, higher costs for raw materials and components, an intangible asset charge of $17.4 million related to certain developed technology assets our Faxitron and Focal acquisitions and an increase in intangible asset amortization expense.", -0.8], ["Operating expenses decreased in fiscal 2022 compared to fiscal 2021 primarily due to the reversal of a research and development credit reserve related to the SSI acquisition, a decrease in compensation and commissions from lower sales and sales force headcount, lower bad debt expense, lower bonus and expense from our deferred compensation plan, lower MDR/IVDR implementation costs, lower legal expenses, and a reduction of restructuring charges.", 0.4], ["GYN Surgical revenues increased in fiscal 2022 compared to fiscal 2021 due to the increase in product revenues discussed above.", 0.6], ["Operating income for this business segment increased in fiscal 2022 compared to fiscal 2021 primarily due to an increase in gross profit from higher revenues and a decrease in operating expenses.", -0.1], ["Gross margin was 59.2% in the current year, compared to 61.0% in the prior year.", -0.2], ["The decrease in gross margin was primarily due to product mix as we sold more lower margin products, including our Fluent Fluid Management systems, Bolder products (comprised of CoolSeal vessel sealing devices and JustRight surgical staplers) and Acessa ProVu systems in the current fiscal year.", -0.5], ["Operating expenses decreased in fiscal 2022 compared to fiscal 2021 primarily due to a gain of $39.5 million related to the fair value adjustments to the contingent consideration liability related to the Acessa acquisitions compared to a gain of $6.7 million in the prior year.", 0.2], ["Skeletal Health revenues decreased in fiscal 2022 compared to fiscal 2021 primarily due to the decrease in product revenues discussed above, partially offset by an increase in service revenue.", -0.4], ["Operating loss increased in fiscal 2022 compared to fiscal 2021 primarily due to a decrease in gross profit from lower revenues and an increase in product cost.", -0.7], ["Gross margin decreased to 28.2% in the current year compared to 31.4% in the prior year primarily due to increased costs for our Horizon DXA systems workstation upgrades and lower sales volume of our Horizon DXA and Insight FD systems primarily due to supply chain constraints, partially offset by a slight increase in average selling prices of our Horizon DXA and Insight FD systems.", -0.6], ["Our cash and cash equivalents balance increased by $1,169.2 million during fiscal 2022 principally due to cash generated from operating activities partially offset by cash used in financing and investing activities related to a business acquisition, repurchases of our common stock and the pay-off of amounts outstanding under the accounts receivable securitization program (the \"Securitization Program\").", 0.5], ["In fiscal 2022, our operating activities provided cash of $2,125.7 million, primarily due to net income of $1,302.0 million, non-cash charges for depreciation and amortization aggregating $430.1 million, stock-based compensation expense of $66.7 million and acquired intangible asset impairment charges of $45.1 million.", 0.7], ["offset by a decrease in net deferred taxes of $166.2 million primarily due to recording a deferred tax asset in connection with an internal restructuring and intangible asset impairments, and a $39.5 million non-cash adjustment to decrease the contingent consideration liability to the former shareholder of Acessa.", -0.3], ["The net cash inflow was primarily driven by a $384.3 million dollar decrease in prepaid expenses and other assets primarily due to tax refunds received in the second quarter related to federal and state loss carryback claims partially offset by a payment for our Women's Tennis Association sponsorship, and a decrease in accounts receivable of $272.3 million due to strong collections in the current year and lower revenues in fiscal 2022 compared to fiscal 2021.", 0.3], ["These cash inflows were partially offset by an increase in inventory of $136.6 million primarily due to a strategic buildup of emergency sourced components for our Breast Health business to hedge against the continuing worldwide supply constraints, a $15.8 million decrease in accrued expenses and other liabilities related to a decrease in accrued compensation and benefits and payments of value-add taxes partially offset by accrued federal and state income taxes due to timing of payments, a $23.3 million increase in prepaid income taxes, and a $14.4 million decrease in accounts payable due to the timing of payments.", -0.2], ["In fiscal 2022, our investing activities used cash of $206.3 million primarily due to net cash paid for our acquisitions (primarily Bolder) of $158.6 million and capital expenditures of $127.2 million, which consisted of the purchases of property and equipment of $70.6 million and", -0.5], ["These uses of cash in investing activities were partially offset by $75.0 million of proceeds received from the Department of Defense under a grant to increase production capacity of our two SARS-CoV-2 assays.", 0.1], ["In fiscal 2022, our financing activities used cash of $756.0 million, primarily due to $542.1 million for repurchases of our common stock, $248.5 million for the repayment under the Securitization Program, $63.7 million for the repayment of debt acquired in the Mobidiag acquisition, $22.9 million for the payment of employee taxes withheld for the net share settlement of vested stock units, and a $12.2 million contingent consideration payment as a result of the completion of the first annual earn-out period related to the Acessa acquisition.", -0.7], ["Partially offsetting these uses of cash were net proceeds of $103.7 million from the refinancing of the 2021 Credit Agreement and $33.5 million from our equity plans, primarily from the exercise of stock options.", 0.2], ["As of September 24, 2022, we were in compliance with these covenants.", 0.4], ["On June 11, 2021, we amended and restated the Credit and Security agreement to restart the Securitization Program (the \"Securitization Program\") and increased the maximum borrowing amount to $320.0 million.", 0.1], ["During fiscal 2022, we repaid the outstanding balance of $248.5 million under the Securitization Program.", -0.3], ["On June 10, 2022, we amended the Credit and Security agreement and temporarily suspended the ability to borrow and the need to comply with covenants for up to a year.", 0.0], ["Our obligation to make contingent payments may also result in significant operating expenses.", -0.8], ["This liability is re-measured each reporting period with the change in fair value recorded through a separate line item within our Consolidated Statements of Income.", 0.0], ["Increases or decreases in the fair value of contingent consideration liabilities can result from changes in discount rates, changes in the timing, probabilities and amount of revenue estimates, and accretion of the liability for the passage of time.", -0.5], ["The first earn-out period was completed in December 2021, and we paid $12.2 million to the former shareholders in the second quarter of fiscal 2022.", 0.2], ["During fiscal 2022, we repurchased 7.7 million shares of our common stock for a total consideration of $542.1 million.", 0.5], ["Subsequent to September 24, 2022, we repurchased 1.5 million shares of our common stock for total consideration of $100.0 million.", 0.3], ["Subject to the \"Risk Factors\" set forth in Part I, Item 1A of this Annual Report and the general disclaimers set forth in our Special Note Regarding Forward-Looking Statements at the outset of this Annual Report, we believe that our cash and cash equivalents, cash flows from operations, the cash available under our 2021 Revolver will provide us with sufficient funds in order to fund our expected normal operations and debt payments over the next twelve months.", 0.7], ["These risks, trends and uncertainties may also adversely affect our long-term liquidity.", -0.7], ["In accordance with ASC 450, Contingencies, loss contingencies are accrued if, in the opinion of management, an adverse outcome is probable and such financial outcome can be reasonably estimated.", -0.6], ["It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings.", -0.4], ["Any differences may have a material impact on our financial condition and results of operations.", -0.5], ["Although considerable effort is made to ensure the accuracy of our forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of our inventory and our operating results.", -0.8], ["Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator.", -0.9], ["As a result of this simplified approach the goodwill impairment is calculated as the amount by which the carrying value of the reporting unit exceeds its fair value to the extent of the goodwill balance.", -0.7], ["As a result of completing this analysis, all of our reporting units had fair values exceeding their carrying values.", 0.5], ["In the DCF as the WACC increases, the fair value decreases.", -0.6], ["The other significant factor in the DCF is our projected financial information (i.e., amount and timing of expected future cash flows and growth rates) and if these assumptions were to be adversely impacted, this could result in a reduction of the fair value of a reporting unit.", -0.7], ["These estimates require significant judgment and adverse changes in assumptions could result in a lower fair value.", -0.6], ["We have recognized $74.6 million in net deferred tax liabilities at September 24, 2022 and $228.6 million at September 25, 2021.", 0.2], ["The decrease was primarily due to recording a deferred tax asset in connection with an internal restructuring and intangible asset impairments in fiscal 2022.", -0.3], ["As of September 24, 2022, we had $247.6 million in gross unrecognized tax benefits excluding interest, of which $231.6 million, if recognized, would reduce our effective tax rate.", -0.1], ["As of September 25, 2021, we had $212.8 million in gross unrecognized tax benefits excluding interest, of which $197.0 million, if recognized, would have reduced our effective tax rate.", -0.1], ["If our assumptions are incorrect, the differences could have a material impact on our income tax provision and operating results in the period in which such determination is made.", -0.7], ["We incur interest expense on borrowings outstanding under our 2028 and 2029 Senior Notes, and 2021 Credit Agreement.", -0.5], ["A hypothetical 10% adverse movement (increase in the SOFR rate) would increase annual interest expense by approximately $1.6 million, which is net of the impact of our interest rate swap hedge.", -0.4], ["Accordingly, our future results could be materially adversely impacted by changes in these or other factors.", -0.8], ["Fluctuations in the foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses.", -0.6], ["In addition, currency devaluations can result in a loss if we hold deposits of that currency.", -0.7], ["As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of unrealized gains and losses reported in other income, net on the mark-to-market of outstanding contracts and (ii) realized gains and losses recognized in other income, net, whereas the offsetting economic gains and losses are reported in the line item of the underlying cash flow, for example, revenue.", -0.6], ["Our expenses, denominated in foreign currencies, are positively affected when the U.S. dollar strengthens against those currencies and adversely affected when the U.S. dollar weakens.", -0.5], ["During fiscal 2022, we incurred net foreign exchange gains of $48.5 million, net foreign exchange losses of $15.1 million in fiscal 2021 and net foreign exchange gains of $3.4 million in fiscal 2020.", 0.3], ["Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.", 0.8], ["Management has excluded from our assessment of and conclusion on the effectiveness of internal control over financial reporting the internal controls of Bolder Surgical Holdings, Inc., which is included in the consolidated financial statements of Hologic, Inc. as of and for the year ended September 24, 2022 and constituted $168.2 million and $142.4 million of our total assets and net assets, respectively, as of September 24, 2022 and $9.9 million and $18.0 million of revenues and pre-tax losses, respectively, for the year then ended.", -0.2], ["As indicated in the accompanying Report of Management on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Bolder Surgical Holdings, Inc., which is included in the 2022 consolidated financial statements of the Company and constituted $168.2 million and $142.4 million of total and net assets, respectively, as of September 24, 2022 and $9.9 million and $18.0 million of revenues and pre-tax losses, respectively, for the year then ended.", -0.2], ["During the quarter ended September 24, 2022, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", 0.0], ["In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 24, 2022 and September 25, 2021, and the results of its operations and its cash flows for each of the three years in the period ended September 24, 2022, in conformity with U.S. generally accepted accounting principles.", 0.7], ["As described in Note 5 to the consolidated financial statements, during 2022, the Company completed one busi combination for total consideration of $160.1 million.", 0.2], ["The business combination resulted in the recognitio intangible assets of $96.7 million.", 0.2], ["Net income per common share attributable to Hologic:", 0.0], ["Gain (loss) recognized, net of tax of $13.7 in 2022, $2.5 in 2021, and $(8.3) in 2020 for interest rate swaps", 0.1], ["Loss reclassified from accumulated other comprehensive loss to the statement of operations, net", -0.8], ["expense              —    —     83.3       —        —      —     —        —       83.3", -0.5], ["translation adjustment       —    —      —       —        18.5      —     —        —       18.5", 0.1], ["cap reclassified to income      —    —      —       —        2.3      —     —        —        2.3", 0.2], ["Exercise of stock options      857    —     32.9       —        —      —     —        —       32.9", 0.7], ["2020            295,107  $  2.9  $  5,904.8  $   (1,573.2)  $     (49.7)    37,609  $ (1,579.6)  $      2.1  $    2,707.3", 0.3], ["taxes              980   0.1     (47.6)       —        —      —     —        —       (47.5)", -0.6], ["Net income (loss)         —    —      —     1,871.5        —      —     —       (1.8)     1,869.7", 0.9], ["expense              —    —     65.0       —        —      —     —        —       65.0", -0.5], ["translation adjustment       —    —      —       —       (20.2)      —     —        —       (20.2)", -0.7], ["stock               —    —      —       —        —     6,044    (409.8)        —      (409.8)", -0.5], ["rate swap             —    —      —       —        9.4      —     —        —        9.4", 0.2], ["controlling interest         —    —     (8.2)       —        —      —     —       (0.3)       (8.5)", -0.7], ["Exercise of stock options      336    —     13.8       —        —      —     —        —       13.8", 0.5], ["purchase plan           330    —     19.2       —        —      —     —        —       19.2", 0.6], ["Net income            —    —      —     1,302.0        —      —     —        —      1,302.0", 1.0], ["pension liability, net        —    —      —       —        1.0      —     —        —        1.0", 0.1], ["Net income                                     $     1,302.0  $     1,869.7  $     1,110.5", 1.0], ["Deferred income taxes and other non-cash taxes                        (166.2)       (70.1)       (94.4)", -0.8], ["Intangible asset and equipment impairment charges                       45.1         —        30.2", -0.2], ["Contingent consideration fair value adjustments                        (39.5)        (6.7)         0.3", -0.5], ["Prepaid expenses and other assets                             384.3        (56.3)       (286.2)", -0.7], ["Accrued expenses and other liabilities                           (15.8)        (4.9)        96.0", 0.1], ["Net cash provided by operating activities                       2,125.7       2,330.4        896.6", 0.8], ["The Company completed the sale of its Medical Aesthetics segment on December 30, 2019 (the first day of the second quarter of fiscal 2020).", 0.2], ["A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations.", -0.9], ["Cash paid for income taxes presented above is net of tax refunds of $430.4 million, $13.7 million and $15.5 million for fiscal years 2022, 2021 and 2020, respectively, driven primarily by federal and state loss carryback claims.", 0.3], ["A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future.", -0.8], ["Less - accumulated depreciation and amortization                            (705.6)          (695.9)", -0.4], ["In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force (\"DOD\") to expand production capacity for the Company's two SARS-CoV-2 assays.", 0.7], ["As of September 24, 2022, the Company had $20.5 million of capital equipment that was awaiting approval from the DOD pending completion of the defined milestones.", -0.1], ["In fiscal 2022 and 2021, the Company received $75.0 million and $21.5 million, respectively, from the DOD for reimbursement of capital equipment, which has been recorded as a reduction of the cost basis of the purchased equipment.", 0.5], ["In addition, a portion of the DOD grant funds expenditures in connection with the project that don't qualify for capitalization and are recorded as a reduction to expenses, which was", 0.0], ["$7.6 million and $1.3 million in fiscal 2022 and 2021, respectively.", 0.0], ["The Company evaluates the recoverability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group.", -0.3], ["If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of after-tax cash flows to be generated by the assets using a risk-adjusted discount rate.", -0.4], ["The Company determined the fair value of the asset utilizing a DCF model and recorded a", -0.5], ["$27.7 million impairment charge.", -0.7], ["The reduction in fair value was due to an increase in the discount rate from higher interest rates, a reduction in forecasted revenues and timing of completing the project.", -0.6]], "holx23_sentences.json": [["These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.", -0.5], ["the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, such as inflation, bank failures, rising interest rates and availability of capital markets, the Israel-Hamas and Ukraine-Russia wars, other economic disruptions and U.S. and global recession concerns, on our customers and suppliers and on our business, financial condition, results of operations and cash flows and our ability to draw down our revolver;", -0.8], ["the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulations and tariffs, that may adversely impact the cost and sale of our products in certain countries, or increase the costs we may incur to purchase materials, parts and equipment from our suppliers;", -0.7], ["the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation;", -0.6], ["the ability to consolidate certain of our manufacturing and other operations on a timely basis and within budget, without disrupting our business and to achieve anticipated cost synergies related to such actions;", 0.2], ["the anticipated development of markets we sell our products into and the success of our products in these markets;", 0.5], ["the anticipated performance and benefits of our products;", 0.6], ["anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations;", 0.3], ["With our HPA technology, we have simplified testing, further increased test sensitivity and specificity, and increased convenience.", 0.9], ["Our DKA technology uses two types of AE molecules that can be differentiated from each other — one that “flashes” and another one that “glows.” By using DKA technology, we have created nucleic acid test, or NAT, assays that can detect two separate targets simultaneously.", 0.8], ["By directing the cytotechnologist to areas of interest on a slide, these systems may increase a cytology laboratory’s screening productivity and diagnostic accuracy.", -0.1], ["In January 2021, the National Comprehensive Cancer Network revised its clinical practice guidelines to include BCI as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage HR+ breast cancer.", 0.8], ["Although Mobidiag currently does not offer any of its products in the U.S., we intend to invest in assay development to drive growth of the Novodiag instrument, including seeking clearance for the Novodiag instrument and related assays in the U.S.", 0.2], ["Our clinical results for FDA approval demonstrate that conventional 2D digital mammography with the addition of our Genius 3D Mammography is superior to 2D digital mammography alone for both screening and diagnostics.", 0.9], ["We can give no assurance that we will be able to compete successfully with existing or new competitors.", -0.8], ["In the current environment of managed care, economically motivated buyers, consolidation among healthcare providers, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price, value, reliability and efficiency.", -0.6], ["We believe the current global economic conditions and healthcare reform measures are putting additional competitive pressure on us, including on our average selling prices, overall procedure rates and market sizes.", -0.7], ["We believe our continued success depends in large part upon our ability to invest in product enhancements and technologies that will help us distinguish ourselves from our competitors.", 0.5], ["Internationally, our ThinPrep product competes with a variety of companies and other non- FDA approved tests, since the devices often have lower risk classification with fewer regulatory barriers in many international markets as compared to the U.S. Additionally, testing volume in this category is also under pressure due to clinical guideline changes, which lengthen the interval between screenings and increasingly afford the option of HPV testing as the primary means of detection.", -0.4], ["In addition, the COVID-19 pandemic and associated economic disruptions have had an adverse impact on our supply chains.", -0.9], ["Moreover, we use certain components in our products, including semiconductor chips, which have been the subject of recent global supply chain shortages and disruptions.", -0.5], ["In the event we are unable to obtain sufficient quantities of raw materials or components or subassemblies on commercially reasonable terms or in a timely manner, our ability to manufacture our products on a timely and cost-competitive basis may be compromised, which may have a material adverse effect on our business, financial condition and results of operations.", -1.0], ["If Stratec, Flextronics or any of our other third-party manufacturers experiences delays, disruptions, capacity constraints or quality control problems in its development or manufacturing operations, curtails operations or otherwise fails to supply us with products in sufficient quantities, instrument and equipment shipments to our customers could be delayed or cancelled, which would decrease our revenues and may harm our competitive position and reputation.", -1.0], ["An interruption in manufacturing capabilities at any of these facilities, as a result of equipment failure or other reasons, could reduce, delay or prevent the production of our products.", -0.8], ["The number of suppliers who provide conflict-free minerals may be limited.", -0.6], ["In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities.", -0.7], ["Since our supply chain is complex, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation.", -0.9], ["In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.", -0.8], ["These redesigns or alternative materials may detrimentally impact the performance of our products, add greater testing lead-times for product introductions, result in additional costs or have other similar negative effects.", -0.9], ["Over the coming years, certain patents relating to current products will expire in the U.S. and abroad which may allow third parties to exploit those technologies.", -0.7], ["In the absence of significant patent protection, we may be vulnerable to competitors who attempt to copy our products, processes or technology.", -0.8], ["A successful claim against us may require us to remove the alleged infringing product from the market or to design around the third party's patent, potentially resulting in less market demand for the product.", -0.7], ["In March 2020, the FDA granted EUA for our Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus.", 0.7], ["In May 2020, the FDA granted EUA for our Aptima SARS-CoV-2 assay for use on our standard Panther instrument.", 0.7], ["Adverse interpretations of current CLIA regulations or future changes in CLIA regulations could have an adverse effect on sales of any affected products or services.", -0.6], ["If a laboratory is out of compliance with CLIA or with state laws or regulations governing", -0.5], ["licensed laboratories, penalties may include suspension, limitation or revocation of the license or CLIA certificate, assessment of financial penalties or fines, or imprisonment.", -0.9], ["Loss of a laboratory's CLIA certificate or state license may also result in the inability to receive payments from state and federal health care programs as well as private third-party payors.", -0.8], ["We may be required to incur significant costs to comply with these laws and regulations in the future and complying with these laws may result in a material adverse effect upon our business, financial condition and results of operations.", -0.7], ["Complying with the requirements of these regulations has required us to, and may continue to require us to, incur significant expenditures.", -0.6], ["Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.", -0.8], ["If this continues, this could favorably affect our ability to introduce new products in the Chinese market.", 0.6], ["It is possible that the Chinese government's current or future interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory investigations or lead to fines or penalties.", -0.9], ["We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in laws, regulations or policies by governmental authorities may cause increases in uncertainties and compliance costs, exposure to litigation and other adverse effects to our business and operations.", -0.7], ["Delays in receipt of, or failure to obtain, clearances or approvals for future products could delay or preclude realization of product revenues from new products or result in substantial additional costs which could decrease our profitability.", -0.8], ["Reimbursement and coverage vary by country and can significantly impact acceptance of new products and technologies.", -0.3], ["Even if we develop a promising new product, we may find limited demand for the product unless reimbursement approval and coverage is obtained from private and governmental third-party payors.", -0.5], ["Further, ongoing legislative or administrative reform to the reimbursement system in the U.S. and other countries may impact reimbursement for procedures using our medical products and/or limit coverage for those procedures facilitated by our products.", -0.6], ["These trends could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["Worldwide sales, including U.S. sales, do not reflect any significant degree of seasonality; however, customer purchases of our GYN Surgical products have been historically lower in our second fiscal quarter compared to our other fiscal quarters.", -0.2], ["Our respiratory infectious disease product line (including our assays for the detection of SARS-CoV-2) within our Diagnostics segment is also subject to significant seasonal and year-over-year fluctuations.", -0.2], ["In addition, the summer months, which occur during our fourth fiscal quarter, typically have had lower order rates internationally for most of our products.", -0.3], ["The occurrence of any of these events or circumstances could individually or in the aggregate have a material adverse effect on our business, financial condition, cash flow or results of operations.", -0.8], ["The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects, both domestically and internationally.", -0.9], ["Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues, including wars and terrorism, have contributed to increased market volatility and diminished expectations for economic growth in the world.", -0.9], ["Our business and results of operations have been and may continue to be adversely impacted by changes in macroeconomic conditions, including inflation, bank failures, rising interest rates and availability of capital markets.", -0.8], ["Uncertainty about global economic conditions, particularly in emerging markets and countries with government-sponsored healthcare systems, may also cause decreased demand for our products and services and increased competition, which could result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies.", -0.7], ["A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply.", -0.6], ["In addition, continuing social concerns and divisions in the U.S. and throughout the world, could have a material, adverse effect on the economic conditions in markets we serve, and our results of operations, cash flow and financial position.", -0.7], ["The continuing uncertainty surrounding global economic conditions and financial markets may cause the purchasers of medical equipment to decrease their medical health insurance premiums and procurement activities.", -0.8], ["Economic uncertainty, an increase in unemployment rates, as well as an increase in health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer trips to their physicians and specialists, which in turn would adversely affect demand for our products and procedures.", -0.9], ["Furthermore, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could adversely affect sales of our products.", -0.8], ["Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of our revenues outside the U.S. and associated cash flows and our ability to compete effectively in foreign markets.", -0.7], ["In addition, such fluctuations can also result in foreign currency exchange losses.", -0.6], ["lower margins on a number of our products sold outside of the U.S.", -0.7], ["The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results of operations and financial condition.", -0.8], ["For example, a government's adoption of “buy national” policies or retaliation by another government against such policies could have a negative impact on our results of operations.", -0.7], ["It is possible that the Chinese government’s current or future interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory investigations or lead to fines or penalties.", -0.8], ["If we are successful in pursuing future acquisitions, we may face significant competition, be required to expend significant funds, incur additional debt or other obligations, or issue", 0.2], ["additional securities, which may negatively affect our operating results and financial condition.", -0.6], ["If we spend significant funds or incur additional debt or obligations, our ability to obtain financing for working capital or other purposes could be adversely affected, and we may be more vulnerable to economic downturns and competitive pressures.", -1.0], ["During fiscal 2021, we made a number of tactical acquisitions which complemented our existing businesses.", 0.5], ["Any inability to successfully integrate new businesses, including our more recent acquisitions, decreases in customer loyalty or product orders, failure to retain or develop the acquired workforce, failure to realize anticipated economic, operational and other benefits and synergies in a timely manner, failure to establish and maintain appropriate controls or unknown or contingent liabilities could adversely affect our ability to realize the anticipated benefits of any new product or acquisition.", -1.0], ["For example, in the third quarter of fiscal 2023, we reassessed our short-term and long-term commercial plans for the Mobidiag business, which we acquired in fiscal 2021, and recorded aggregate impairment charges of $197.4 million.", -1.0], ["The integration of an acquired business, whether or not successful, requires significant efforts which may result in additional expenses and divert the attention of our management and technical personnel from other projects.", -0.5], ["Acquisitions, in particular, are inherently risky, and we cannot guarantee that any past or future transaction will be successful.", -1.0], ["We face intense competition from other companies and may not be able to compete successfully.", -1.0], ["The markets in which we sell our products are intensely competitive, subject to rapid technological change and may be significantly affected by new product introductions and other market activities of industry participants, and these competitive pressures may reduce the demand and prices for our products.", -1.0], ["Other companies may develop products that are superior to and/or less expensive than our products.", -1.0], ["Improvements in existing competitive products or the introduction of new competitive products may reduce our ability to compete for sales, particularly if those competitive products demonstrate better safety or effectiveness, clinical results, ease of use or lower costs.", -1.0], ["Organizational changes we have made or may make to streamline and improve customer experience may not have the intended effect and may instead harm our competitive position and reputation.", -0.8], ["In addition, some companies may have significant competitive advantages over us, which may make them more attractive to hospitals, clinics, radiology clients, group purchasing organizations, laboratories, and physicians, including:", -0.6], ["In addition, other companies have produced tests for COVID-19 (including so-called high throughput nucleic acid tests, rapid antigen tests and at-home testing solutions) which may lead to the diversion of customers away from us and toward other companies.", -0.7], ["As COVID-19 testing declines, customers may also consolidate their molecular testing menu to high throughput, high automation platforms which may further increase the competition our Panther and Panther Fusion instruments face.", -0.7], ["Continued decline in demand for our COVID-19 assays or a reduction in the reimbursement rates for our COVID-19 assays without a corresponding increase in our other businesses could have a material, adverse effect on our results of operations, cash flow and financial position.", -0.9], ["Challenges in the development of our products could materially impact our long-term success.", -0.8], ["Our growth depends in large part on our ability to identify and develop new products or new indications for or enhancements of existing products.", 0.2], ["If we are not able to successfully enhance existing products or develop new products, our products may be rendered obsolete or uncompetitive by changing technology or new industry standards.", -0.8], ["We cannot assure that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance, and we may be unable to recover all or a meaningful part of our investment in such products and technologies.", -0.8], ["The markets for our newly developed products and newly introduced enhancements to our existing products may not develop as expected.", -0.7], ["If we are unable to successfully commercialize and create a significant market for our newly developed products and newly introduced enhancements to our existing products our business and prospects could be harmed.", -1], ["If we cannot maintain our current corporate collaborations and enter into new corporate collaborations, our product development could be delayed and our revenue could be adversely impacted.", -1], ["If any of our corporate collaborators were to breach, terminate, fail to renew our agreements or otherwise fail to properly conduct its obligations in a timely manner, the development or commercialization and subsequent marketing of the products contemplated by the collaboration could be delayed or terminated.", -1], ["Any of the foregoing risks could harm our business and prospects.", -1], ["Additionally, we have incurred and expect to continue to incur significant costs implementing additional security measures to protect against existing and emerging cybersecurity threats.", -1], ["Despite our implementation of certain controls to protect our systems and sensitive, confidential or personal data or information, we may be vulnerable to material security breaches, theft, misplaced, lost or corrupted data, employee errors and/or malfeasance (including misappropriation by departing employees) that could potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems, software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products, production downtimes and operational disruptions.", -1], ["In addition, a cyber-related attack could result in other negative consequences, including damage to our reputation or competitiveness, remediation or increased protection costs, litigation or regulatory action.", -1], ["Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or other liabilities.", -1], ["Evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional costs to re-design our products in a timely manner, either of which could have an adverse impact on our results of operations.", -1], ["We have incurred and expect that we will continue to incur significant costs implementing additional security measures to protect against new or enhanced data security or privacy threats, or to comply with current and new federal, state and international laws governing the unauthorized disclosure or exfiltration of confidential and personal information which are continuously being enacted and proposed.", -1], ["More privacy and security laws and regulations are being adopted, and more are being enforced, with potential for significant financial penalties.", -0.5], ["Failure to maintain the confidentiality of sensitive personal information in accordance with the applicable regulatory requirements, or to abide by electronic health data transmission standards, could expose us to breach of contract claims, fines and penalties, costs for remediation and harm to our reputation.", -0.8], ["Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.", -0.7], ["Reimbursement varies by country and can significantly impact the acceptance of new products and technologies.", -0.6], ["Further legislative or administrative reforms to the reimbursement systems in the U.S. and other countries in a manner that significantly reduces reimbursement for procedures using our diagnostics, breast and skeletal health and surgical products or denies coverage for those procedures facilitated by our products, including price regulation, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["Guidelines, recommendations and studies published by various organizations may reduce the use of our products.", -0.6], ["If followed by healthcare providers and insurers, such publications could result in decreased use of our products.", -0.7], ["We believe that these recommendations and guidelines may have contributed to increased screening intervals for cervical cancer, which we believe has and may continue to adversely affect our ThinPrep revenues.", -0.8], ["Our cervical cancer screening revenues, primarily from ThinPrep sales, may also be adversely affected by the July 2020 American Cancer Society cervical cancer screening guidelines, which recommended the use of a human papillomavirus (HPV) test for primary screening rather than co-testing (the use of an HPV test with a Pap test) or a standalone Pap test.", -0.8], ["We believe that this recommendation may have resulted in a decrease in the use of mammography systems.", -0.7], ["Supply chain constraints and inflationary pressures have had, and may continue to have, a material adverse effect on our ability to procure raw materials and components, including semiconductor chips, and to meet customer demand for, and increase our costs to manufacture, warehouse, and transport, certain of our products.", -1], ["Global supply constraints have and may continue to adversely affect our ability to meet customer demand, and increase our costs to manufacture, transport and warehouse a certain subset of our products.", -1], ["In addition, global supply constraints have resulted in increases to the costs of production of certain of our products that we may not be able to pass on to our customers.", -1], ["If we are unable to obtain sufficient quantities of raw materials and components on commercially reasonable terms or in a timely manner, our ability to manufacture our capital equipment products, in particular, our Breast Health products, on a timely and cost-competitive basis could materially adversely affect our revenues and results of operations and harm our competitive position and reputation.", -1], ["Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some key raw materials, components and subassemblies for our products exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.", -1], ["If any of our sole source manufacturers or suppliers, or other third-party manufacturers or suppliers, experiences delays, disruptions, capacity constraints or quality control problems in its development or manufacturing operations or becomes insolvent or otherwise fails to supply us with goods in sufficient quantities, including as a result of disruptions caused by epidemics or pandemics, natural disasters, supplier facility shutdowns, or otherwise, then shipments to our customers could be delayed, which would decrease our revenues and harm our competitive position and reputation.", -1], ["Moreover, the failure of a supplier to provide sufficient quantities, acceptable quality and timely delivery of goods at an acceptable price, or an interruption in the delivery of goods from such a supplier could adversely affect our business and results of operations.", -1], ["Obtaining alternative sources of supply of products, components, subassemblies or raw materials could involve significant delays and other costs and regulatory challenges and may not be available to us on reasonable terms, if at all.", -1], ["As a result, we may lose revenues and our customer relationships may suffer.", -1], ["Interruptions, delays, shutdowns or damage at our manufacturing or laboratory facilities, or the facilities of third parties on which we depend, could harm our business.", -1], ["environmental factors or property damage could reduce, delay or prevent the production and distribution of our products.", -0.8], ["Our facilities may experience plant shutdowns, strikes or other labor disruptions, or periods of reduced production as a result of equipment failures, loss of power, gray outs, delays in deliveries or extensive damage, which could harm our business and prospects.", -0.9], ["Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, and the loss of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly reduce revenues in our Diagnostics segment.", -0.8], ["The loss of any of these key customers, or a significant reduction in sales volume or pricing to these customers, could significantly reduce our Diagnostics segment revenues or profitability.", -0.8], ["We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these distributors.", -0.7], ["If any of our strategic relationships terminate without replacement or if our strategic partners fail to perform their contractual obligations, our revenues and/or ability to service our products in the territories serviced by these distributors could be adversely affected.", -0.8], ["If we elect to distribute new products directly, we will have to invest in additional sales and marketing resources, including additional field sales personnel, which would significantly increase future selling, general and administrative expenses.", -0.6], ["If we fail to successfully market our products, our product sales will decrease.", -0.9], ["We may also be exposed to risks as a result of transitioning a territory from a distributor sales model to a direct sales model, such as difficulties maintaining relationships with specific customers, hiring appropriately trained personnel or ensuring compliance with local product registration requirements, any of which could result in lower revenues than previously received from the distributor in that territory.", -0.7], ["The loss of any of our key personnel, particularly executive management or key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operational or strategic objectives.", -0.9], ["We also continue to face the challenges of maintaining employee well-being, recognizing that the continued additional financial, family and health burdens that many employees may be experiencing due to macroeconomic uncertainties, including inflation, and other factors, may adversely impact job performance and employee retention.", -0.8], ["If our succession planning efforts are not effective, it could adversely impact our business.", -0.7], ["Future organizational changes could also cause our employee attrition rate to increase.", -0.6], ["If we fail to effectively manage any organizational and/or strategic changes, our financial condition, results of operations, and reputation, as well as our ability to successfully attract, motivate and retain key employees, could be harmed.", -0.9], ["We operate in a highly regulated industry, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products and services or product or service enhancements, could adversely affect our business and prospects.", -0.8], ["As a result, governmental actions may adversely affect our business, operations or financial condition, including:", -0.7], ["changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;", -0.7], ["changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products; and", -0.7], ["new laws, regulations and judicial decisions affecting pricing or marketing practices.", -0.6], ["If the FDA requires us to seek one or more pre-market approval supplements or new pre-market approvals for any modification to a previously approved device, we may be required to cease marketing or to recall the modified device until we obtain approval, and we may be subject to significant criminal and/or civil sanctions, including, but not limited to, regulatory fines or penalties.", -0.9], ["Implementation of the compliance requirements of these regulations requires us to incur significant expenditures and utilize resources.", -0.5], ["Failure to continue to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.", -0.8], ["We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in laws, regulations or policies by governmental authorities may cause increased uncertainties and compliance costs, exposure to litigation and other adverse effects to our business and operations.", -0.7], ["Delays in receipt of, or failure to obtain or maintain, clearances or approvals for future products could delay or preclude realization of product revenues from new or existing products or result in substantial additional costs which could decrease our profitability.", -0.9], ["Violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction and have a material adverse effect on our business, financial condition and results of operations.", -0.9], ["We also could be subject to adverse publicity, severe penalties, including criminal and civil penalties, disgorgement, further changes or enhancements to our procedures, policies and controls, personnel changes and other remedial actions.", -0.8], ["Moreover, our failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures, and withdrawal of an approved product from the market.", -0.8], ["If even one of our products is found to have caused or contributed to injuries or deaths, we could be held liable for substantial damages.", -0.9], ["There is a risk that the insurance coverage will not be sufficient to protect us from product and other liability claims, or that product liability insurance will not be available to us at a reasonable cost, if at all.", -0.7], ["An under-insured or uninsured claim could harm our business and prospects.", -0.8], ["In addition, claims could adversely affect the reputation of the related product, which could damage that product’s competitive position in the market.", -0.8], ["The sale and use of our diagnostic products could also lead to product liability claims if someone were to allege that one of our products contained a design or manufacturing defect that resulted in inaccurate test results or the failure to detect a disorder for which it was being used to screen, or caused injuries to a patient.", -0.9], ["Any product liability claim brought against us, with or without merit, could result in an increase in our product liability insurance rates or the inability to secure additional coverage in the future.", -0.8], ["This could result in a diversion of management’s attention from our business and adversely affect the perceived safety and efficacy of our products, which could harm our business and prospects.", -0.9], ["In such event, we could be held liable for any resulting damages, and any such liability could be extensive.", -0.8], ["These redesigns or the use of alternative materials may detrimentally impact the performance of our products, add greater testing lead times for product introductions, result in additional costs or have other similar effects.", -0.8], ["In addition, changes in environmental laws and regulations, in particular relating to climate change and greenhouse gas (“GHG”) emissions, could require us, or our contract manufacturers or suppliers, to install additional equipment, or alter operations to incorporate new technologies or processes, which may result in additional expenses and adversely affect our operating results.", -0.7], ["We may also incur significant costs and utilize additional resources to comply with future regulations related to climate-related disclosures.", -0.7], ["The failure to comply with such regulations could subject us to, among other things, fines and criminal liability.", -0.8], ["be required to incur significant costs to comply with these and future regulations, which may result in a material adverse effect upon our business, financial condition and results of operations.", -0.8], ["Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.", -0.8], ["We are subject to income taxes, as well as taxes that are not income-based, in both the U.S. and jurisdictions outside of the U.S. Our future effective tax rate could be unfavorably affected by numerous factors including a change in, or the interpretation of, tax rules and regulations in the jurisdictions in which we operate (including changes in legislation currently being considered), a change in our geographic earnings mix, and/or to the jurisdictions in which we operate, or a change in the measurement of our deferred taxes.", -0.7], ["Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.", -0.9], ["Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created and may continue to create significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate in, primarily the U.S., Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally.", -0.9], ["In particular, elective procedures and exams were delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated services.", -0.8], ["While elective procedures and exams and capital purchases have increased from initially depressed levels, a reduction in elective procedures, exams and capital purchases has had, and we believe may continue to have, a negative impact on the sales of most of our products (other than our COVID-19 assays and related systems and ancillaries).", -0.8], ["Additionally, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could further adversely affect sales of our products.", -0.8], ["If our license with respect to any of these technologies or markers is terminated for any reason, we may not be able to sell products that incorporate that technology.", -0.7], ["Similarly, we may lose competitive advantages if we fail to maintain exclusivity under an exclusive license.", -0.7], ["If we are unable to access new technologies or the rights to particular sequences or markers necessary for additional diagnostic products on commercially reasonable terms, we may be limited in our ability to develop new diagnostic products.", -0.7], ["Our business could be adversely affected if we are unable to obtain the additional intellectual property rights necessary to commercialize our products.", -0.8], ["The patents that we own or license could also be subjected to invalidation proceedings or similar disputes, and an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to the technology from the prevailing party.", -0.9], ["In the absence of significant patent protection, we may be vulnerable to competitors who attempt to copy our products, processes or technology.", -0.7], ["Our business could be harmed if we infringe upon the intellectual property rights of others.", -0.8], ["These actions could be costly and would divert the efforts and attention of our management and technical personnel.", -0.6], ["As a result, any infringement claims by third parties or claims for indemnification by customers resulting from infringement claims, whether or not proven to be true, may harm our business and prospects.", -0.8], ["We have a significant amount of indebtedness outstanding, which limits our operating flexibility, and could adversely affect our operations and financial results and prevent us from fulfilling our obligations.", -0.9], ["make it more difficult for us to satisfy our obligations with respect to our outstanding indebtedness;", -0.7], ["increase our vulnerability to general adverse economic and industry conditions, including increases in interest rates;", -0.7], ["require us to dedicate a substantial portion of our cash flow from operations to interest and principal payments on our indebtedness, which would reduce the availability of our cash flow to fund working capital, capital expenditures, expansion efforts, strategic transactions and other general corporate purposes;", -0.8], ["place us at a competitive disadvantage compared to our competitors that have less debt; and", -0.8], ["limit our ability to borrow additional funds for working capital, capital expenditures, expansion efforts, strategic transactions or other general corporate purposes.", -0.7], ["In addition, the terms of our financing obligations contain certain covenants that restrict our ability, and that of our subsidiaries, to engage in certain transactions and may impair our ability to respond to changing business and economic conditions, including, among other things, limitations on our ability to:", -0.6], ["Our failure to comply with the covenants contained in our credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.", -0.9], ["If there were an event of default under one of our debt instruments or a change of control, the holders of the defaulted debt could cause all amounts outstanding with respect to that debt to be due and payable immediately and may be cross-defaulted to other debt, including our outstanding notes.", -0.9], ["Our assets or cash flow may not be sufficient to fully repay borrowings under our outstanding debt instruments if accelerated upon an event of default or a change of control, and there is no guarantee that we would be able to repay, refinance or restructure the payments on such debt.", -0.8], ["We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.", -0.8], ["Our ability to make payments on and to refinance our indebtedness and to fund planned capital expenditures, strategic transactions and expansion efforts will depend on our ability to generate cash in the future.", -0.7], ["Our business may not be able to generate sufficient cash flow from operations, and we cannot assure that future borrowings will be available to us in amounts sufficient to enable us to pay our indebtedness as such indebtedness matures and to fund our other liquidity needs.", -0.8], ["If this occurs, we will need to refinance all or a portion of our indebtedness on or before maturity, and there can be no assurance that we will be able to refinance any of our indebtedness on commercially reasonable terms, or at all.", -0.8], ["We may need to adopt one or more alternatives, such as reducing or delaying planned expenses and capital expenditures, selling assets, restructuring debt, or obtaining additional equity or debt financing.", -0.8], ["If we do not generate sufficient cash flow from operations, and additional borrowings, refinancings or proceeds from asset sales are not available to us, we may not have sufficient cash to enable us to meet all of our obligations.", -0.9], ["A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest payments.", -0.7], ["A significant portion of our indebtedness is subject to floating interest rates, which makes us more vulnerable in the event of adverse economic conditions, increases in prevailing interest rates, or a downturn in our business.", -0.8], ["The new interest rate swaps are at higher interest rates than the current swaps.", -0.6], ["As a result of the lower notional amount and higher interest rates, we expect that we will continue to have exposure to increased interest rates and incur charges for interest at a higher rate, following the expiration of our current interest rate swap on December 17, 2023.", -0.7], ["Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our business or common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.", -0.6], ["quarterly fluctuations in our actual or anticipated operating results and order levels;", -0.5], ["Any such fluctuations in the future could adversely affect the market price of our common stock, and the market price of our common stock may decline.", -0.7], ["We have never declared or paid cash dividends on our capital stock, and we currently have no plans to do so.", -0.6], ["Our current policy is to retain all of our earnings to finance future growth (including acquisitions), pay down our existing indebtedness and repurchase our common stock.", -0.1], ["(1) On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading on September 23, 2022.", 0.5], ["The following graph compares cumulative total shareholder return on our common stock since September 29, 2018 with the cumulative total return of the Standard & Poor’s 500 Index and the S&P Health Care Supplies Index.", 0.3], ["The current worldwide supply chain shortages and constraints continue to impact, although to a lesser extent compared to fiscal 2022, our ability to obtain certain critical raw materials and components used primarily in our Breast Health capital equipment products.", -0.5], ["Based on our recent experience and current understanding of their allocation of chips to us, we have been able to and expect that we will continue to be able to increase production to normalized levels.", 0.4], ["If such allocation does not meet our expectations or we are not able to obtain alternative sources of chips, we believe we will not be able to manufacture sufficient quantities of our capital equipment products, primarily Selenia Dimensions and 3Dimension systems, Trident specimen radiography systems and Affirm Prone biopsy systems to meet customer demand and our results of operations would be adversely affected.", -0.7], ["In addition, the prices of certain raw materials and components have been rising due to certain supply chain shortages and inflation and could increase our costs further.", -0.6], ["On September 28, 2023, we entered into a definitive agreement to sell our SSI ultrasound imaging business to SSH Holdings Limited for a sales price of $1.9 million in cash.", 0.2], ["As a result, we recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group at its fair value less costs to sell pursuant to ASC 360, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets.", -0.8], ["On July 3, 2023, we completed the acquisition of assets from JW Medical Corporation (“JW Medical”) for a purchase price of $6.7 million.", 0.3], ["On April 3, 2023, we completed the acquisition of Normedi Nordic AS (“Normedi”) for a purchase price of $7.7 million, which includes $1.1 million for contingent consideration.", -0.1], ["On November 29, 2021, we completed the acquisition of Bolder Surgical Holdings, Inc. (“Bolder”) for a purchase price of $160.1 million.", 0.1], ["We had a decrease in product revenue of 21.7% in fiscal 2023 compared to fiscal 2022.", -0.8], ["This decrease was primarily due to the decline in revenues in the Diagnostics business as a result of lower COVID-19 assay sales.", -0.7], ["This decrease in product revenue was partially offset by an increase in Breast Health and Skeletal Health revenue as supply chain constraints continued to ease, an increase in GYN Surgical revenues, as well as an extra week of activity in the current fiscal year compared to the prior fiscal year.", 0.2], ["Diagnostics product revenues decreased 39.7% in fiscal 2023 compared to fiscal 2022 primarily due to a decrease in Molecular Diagnostics of $1,173.2 million, partially offset by an increase in Cytology and Perinatal revenue of $6.8 million, and an increase in Blood Screening of $6.2 million.", -0.6], ["Molecular Diagnostics product revenue was $1,254.3 million in fiscal 2023 compared to $2,427.5 million in fiscal 2022.", -0.9], ["The decrease was primarily attributable to a reduction of $1,182.3 million in sales of our two SARS-CoV-2 assays (primarily the Aptima SARS-CoV-2 assay and to a lesser extent the Panther Fusion SARS-CoV-2 assay) to $248.2 million in fiscal 2023 compared to $1,430.5 million in fiscal 2022 primarily due to lower demand from an improvement in the COVID-19 pandemic compared to the prior year, the increasing use of rapid tests and a decrease in average selling prices internationally.", -0.9], ["We also had a decrease in sales of collection devices as a result of lower assay sales, lower Panther instruments sales as demand for those instruments has decreased, which we primarily attribute to our significantly expanded install base and the decline in the COVID-19 pandemic in the current year, and lower Mobidiag product sales.", -0.8], ["These decreases were partially offset by an increase of $86.3 million in our Aptima assays (exclusive of our SARS-CoV-2 assay), primarily driven by an increase in our CV Candida, Bacterial Vaginosis, and CT/NG assay volumes, which we attribute to an increase in wellness visits and expanded adoption by our laboratory customers.", 0.3], ["In addition, we had an increase in worldwide sales of our Fusion respiratory products, which we attribute to a strong flu season, and Quant Viral assays, including our HIV assay sold in Africa, in the current fiscal year.", 0.8], ["Within Cytology & Perinatal, we had an increase in sales of our ThinPrep Pap Test products driven by increased demand which we primarily attribute to the increase in wellness visits following the recovery from the COVID-19 pandemic, partially offset by lower Perinatal volumes in Europe.", 0.5], ["We also experienced a decline in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.7], ["Breast Health product revenues increased 22.9% in fiscal 2023 compared to fiscal 2022 primarily due to a significant increase in volumes of our digital mammography systems, primarily Selenia 3D Dimensions and 3Dimensions systems and related workstation and workflow products including software, and to a lesser extent an increase in Trident systems unit sales and higher Faxitron breast conserving surgery products.", 0.9], ["The increase in volume was primarily driven by the improvement in supply chain constraints related to electronic components, primarily semiconductor chips, which impacted our ability to manufacture sufficient quantities to meet customer demand in the prior year.", 0.6], ["These increases were slightly offset by a reduction in the volume of our ultrasound imaging products.", -0.2], ["In addition, we had an increase in sales of our interventional breast solutions products of $8.7 million in the current fiscal year compared to the prior fiscal year primarily driven by higher Brevera systems sales and related disposables, partially offset by lower volumes of Eviva handpieces.", 0.4], ["We also experienced a decline in revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened", -0.7], ["GYN Surgical product revenues increased 15.1% in fiscal 2023 compared to fiscal 2022, primarily due to increases in the sales volume of our MyoSure devices, Fluent Fluid Management disposables and NovaSure devices as procedure rates continue to recover from the impact of the COVID-19 pandemic and to a lesser extent an increase in sales volume of our CoolSeal vessel sealers from the Bolder acquisition as we expand physician adoption.", 0.7], ["Partially offsetting this increase was the negative effect on revenue from international sales denominated in foreign currencies from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.", -0.5], ["Skeletal Health product revenues increased 21.9% in fiscal 2023 compared to fiscal 2022 primarily due to an increase in sales volume of our Horizon DXA systems and to a lesser extent our InSight FD Fluoroscan systems and system upgrades.", 0.9], ["The sales volume increase was largely attributable to the easing of supply chain constraints.", 0.8], ["The percentage of product revenue derived from the U.S. increased while Europe and Asia-Pacific decreased, which we primarily attribute to the significant increase in the U.S. of Breast Health capital equipment sales and related workflow products including software, and increases in Aptima assay sales (exclusive of our Aptima SARS-CoV-2 assays), Surgical devices and disposables including MyoSure, Fluent, and CoolSeal, as well as a lesser decline in SARS-CoV-2 assay volume in the U.S. compared to Europe and Asia-Pacific.", 0.5], ["Product revenue decreased in China in the current year which we primarily attribute to surges of COVID-19 and related shutdowns in the first six months of the current year, which primarily impacted the sale of our Diagnostics products (excluding SARS-CoV-2 assays) and digital mammography systems.", -0.7], ["The percentage of product revenue increased in Rest of World in the current year primarily due to an increase in Breast Health capital equipment sales and to a lesser extent Surgical sales for Canada, the Middle East, and Latin America, partially offset by a decrease in SARS- CoV-2 assay volumes in the Rest of World.", 0.6], ["Service and other revenues increased 11.7% in fiscal 2023 compared to fiscal 2022 primarily due to the continued conversion of a high percentage of our installed base of digital mammography systems to service contracts upon expiration of the warranty period, and to a lesser extent an increase in spare parts and installation and training revenue related to an increase in sales of our mammography systems.", 0.7], ["In the current year, revenues were also higher from the extra week of service contract activity, resulting in $7.9 million of incremental revenue.", 0.6], ["In our Diagnostics business, service revenue increased as a result of higher lab testing volumes from our Biotheranostics CLIA laboratory, which we primarily attribute to market acceptance from increased marketing efforts and improved customer experience.", 0.7], ["Product gross margin was 52.1% in fiscal 2023 compared to 64.7% in fiscal 2022.", -0.8], ["The cost of product revenues as a percentage of product revenues was 36.1% in the current year compared to 27.8% in the prior year.", -0.7], ["Cost of product revenues as a percentage of revenue increased in fiscal 2023 primarily due to a decrease in sales of our SARS-CoV-2 assays, which have higher gross margins compared to our other Diagnostic products and comprised 7.6% and 34.1% of total product revenue in fiscal 2023 and fiscal 2022, respectively.", -0.5], ["Higher product costs from supply chain constraints and inflation also contributed to the increase in the cost of product revenue.", -0.7], ["This increase was partially offset by higher sales of our digital mammography systems and related software products.", 0.2], ["Diagnostics' product costs as a percentage of revenue increased in fiscal 2023 compared to fiscal 2022 primarily due to lower sales of our SARS-CoV-2 assays, a slight decline in average selling prices of certain assays, a $24.7 million charge recorded in the fourth quarter to write- off inventory related to a certain product line discontinuance, unfavorable manufacturing variances at certain of our manufacturing facilities and higher field service costs for our expanded instrument installed base.", -0.8], ["Partially offsetting this increase was lower sales of instruments, which carry low margins, an increase in sales of our Aptima, Fusion, and Quant Viral assays, and lower freight costs internationally.", 0.1], ["Breast Health’s product costs as a percentage of revenue decreased in fiscal 2023 compared to fiscal 2022 primarily due to higher sales volumes of our higher margin products, primarily 3D Dimensions, and improved manufacturing utilization partially offset by a slight decline in average selling prices of our biopsy disposables due to competitive pressures, and higher prices of raw materials and components from supply chain constraints and inflation.", 0.3], ["Also partially offsetting the decrease in product costs as a percentage of revenue was an increase in inventory reserves and freight.", -0.2], ["GYN Surgical’s product costs as a percentage of revenue increased slightly in fiscal 2023 compared to fiscal 2022 primarily due to product mix of higher volumes of lower margin products, mostly attributable to sales of our Fluent Fluid Management systems, CoolSeal vessel sealers and scopes, partially offset by an increase in volume of higher margin products, primarily MyoSure and NovaSure, as procedure rates continue to recover from the impact of the COVID-19 pandemic and higher average selling prices of our NovaSure V5 device.", -0.1], ["Skeletal Health’s product costs as a percentage of revenue decreased in fiscal 2023 compared to fiscal 2022 primarily due to higher sales volumes of our Horizon DXA systems, upgrades and Insight FD systems as well as an increase in average selling prices of our Horizon DXA systems, partially offset by a decrease in average selling prices of our Insight FD systems and higher component costs from supply chain constraints and inflation.", 0.4], ["Amortization expense decreased in fiscal 2023 compared to fiscal 2022 primarily due to lower amortization of intangible assets acquired in the Cytyc acquisition which became fully amortized in the beginning of the first quarter of fiscal 2023 and to a lesser extent, lower amortization of intangible assets acquired in the Mobidiag and SSI acquisitions due to impairment charges recorded in the third quarter of fiscal 2023, and lower amortization of intangible assets acquired in the Focal and Faxitron acquisitions due to impairments in the prior year.", 0.1], ["We made certain operational and strategic decisions to invest and focus more on the long-term success of this business, which resulted in the significant reduction of forecasted revenues and operating results.", -0.5], ["Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets.", -0.8], ["As a result of this analysis, the fair value of the Mobidiag asset group was below its carrying value.", -0.7], ["To record the asset group to fair value, we recorded an impairment charge of $186.9 million during the third quarter of fiscal 2023.", -0.9], ["The impairment charge was allocated to the long-lived assets on a pro-rata basis and $153.7 million of developed technology assets and $9.1 million of equipment was written off to cost of product revenues.", -0.8], ["Prior to recording this impairment charge, we determined that the in-process research and development asset (“IPR&D”) recorded in connection with the Mobidiag acquisition was impaired and based on its fair value determined utilizing the DCF, we recorded an impairment charge of $10.5 million in the third quarter of fiscal 2023.", -0.9], ["In the event the asset group does not meet its forecasted projections, additional impairment charges could be recorded in the future.", -0.7], ["We determined that the fair value of this asset group was approximately zero and the carrying value of the long-lived assets was fully impaired.", -0.9], ["As a result, we recorded an impairment charge of $26.4 million.", -0.8], ["The impairment charge was allocated to the long-lived assets and $16.7 million of developed technology assets were written off to cost of product revenues.", -0.8], ["In fiscal 2022, we determined that certain developed technology assets acquired in the Focal and Faxitron acquisitions were impaired as a result of the decision to cease selling certain low volume products.", -0.7], ["As a result, we recorded an impairment charge of $17.4 million to write- off these developed technology assets.", -0.8], ["Cost of Service and Other Revenues  $    389.4       51.9 % $    386.2       57.5 % $     3.2       0.8 %", 0.1], ["Service and other revenues gross margin was 48.1% in fiscal 2023 compared to 42.5% in fiscal 2022.", 0.6], ["The increase in gross margin was primarily due to an increase in lab testing revenue from our Biotheranostics business, which has higher margins than our legacy service business, and an increase in the average selling prices and attachment rates of our Breast Health service contracts and time and material billings.", 0.8], ["Research and development expenses increased 3.8% in fiscal 2023 compared to fiscal 2022 primarily due to an increase in compensation and benefits primarily from our deferred compensation plan and an extra week of expenses in the current fiscal year and an increase in Breast Health as the prior year period included a $5.2 million credit for the release of a research and development tax credit reserve related to the SSI acquisition.", 0.2], ["Selling and marketing expenses decreased 5.6% in fiscal 2023 compared to fiscal 2022 primarily due to lower spending on advertising and marketing initiatives as the prior year included a significantly larger sponsorship amount in fiscal 2022 for the Women's Tennis Association, the airing of our Super Bowl commercial, and grants supporting women’s health initiatives.", 0.4], ["General and administrative expenses decreased 3.8% in fiscal 2023 compared to fiscal 2022 primarily due to a decrease in charitable donations of $23.0 million, a $7.4 million settlement awarded to Hologic in the Minerva litigation received in the first quarter of fiscal 2023, and lower tax consulting and legal expenses.", 0.3], ["These decreases were partially offset by an increase in compensation and benefits from higher expense from our deferred compensation plan due to stock market gains and an increase in stock compensation, an $8.9 million charge to settle a business dispute in connection with terminating the Mobidiag joint venture agreement in China, an increase in information systems infrastructure and facilities costs, an increase in reserves for sales and use tax matters, higher travel, and higher compensation and benefits from the extra week in the current fiscal year.", -0.1], ["Amortization expense decreased 37.8% in fiscal 2023 compared to fiscal 2022 primarily due to assets from our Cytyc acquisition becoming fully amortized at the beginning of the first quarter of fiscal 2023.", 0.5], ["As discussed above, we recorded an aggregate impairment charge of $197.4 million in the third quarter of fiscal 2023 related to our Mobidiag acquisition and $26.4 million related to our SSI ultrasound imaging assets.", -0.8], ["The impairment charges were allocated to the long-lived assets and written off to operating expenses as follows: Mobidiag - $10.5 million to IPR&D, $10.4 million to customer relationships, $10.7 million to trade names, and $3.0", -0.7], ["Increases or decreases in the fair value of contingent consideration liabilities can result from the passage of time, changes in discount rates, and changes in the timing, probabilities and amount of revenue estimates.", 0.0], ["In the current year, we recorded a gain of", 0.2], ["$14.9 million based on a decrease in forecasted revenues over the remaining earn-out period.", 0.3], ["In fiscal 2022, we recorded a gain of $39.5 million primarily due to a reduction in forecasted revenues over the measurement period and to a lesser extent an increase in the discount rate from higher market interest rates.", 0.4], ["As discussed above, we recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 related to our SSI ultrasound imaging assets to record the asset group to fair value less the costs to sell.", -0.6], ["We have implemented various cost reduction initiatives to align our cost structure with our operations and related to integration activities.", 0.1], ["These actions have primarily resulted in the termination of employees.", -0.5], ["$12.0 million in fiscal 2023 and $2.4 million in fiscal 2022, primarily related to severance benefits.", -0.4], ["Interest income in fiscal 2023 increased significantly compared to fiscal 2022 due to the significant increase in market interest rates over the past eighteen months as the U.S. Federal Reserve began periodically raising its Federal Funds Rate starting in March 2022.", -0.1], ["To a lesser extent, the increase in interest income was due to higher average cash balances in the current year compared to the prior year.", 0.1], ["Interest expense increased in fiscal 2023 compared to fiscal 2022 primarily due to an increase in the variable interest rate under our 2021 Credit Agreement based on SOFR, partially offset by $35.4 million received under an interest rate swap agreement, which hedges the benchmark interest rate, versus payments of $4.9 million under the interest rate swap in the prior year period.", -0.2], ["In fiscal 2023, this account primarily consisted of net foreign currency exchange losses of $7.9 million, primarily from the mark-to- market of foreign currency contracts used to hedge operating results, partially offset by a gain of $5.6 million from", -0.3], ["the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market gains.", 0.2], ["In fiscal 2022, this account primarily consisted of net foreign currency exchange gains of $48.5 million, primarily from settling forward foreign currency hedging transactions and mark-to-market of outstanding foreign currency contracts, and a $2.4 million gain on life insurance proceeds as a result of the death of a former employee, partially offset by a loss of $12.2 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan primarily driven by stock market losses, a $4.0 million impairment charge of an equity investment and a charge of $4.3 million to write-off an equity method investment acquired in the Mobidiag acquisition.", -0.4], ["Diagnostics revenues decreased in fiscal 2023 compared to fiscal 2022 primarily due to the decrease in product revenues discussed above, partially offset by higher lab testing revenue from our Biotheranostics business.", -0.5], ["Operating income for this business segment decreased in fiscal 2023 compared to fiscal 2022 primarily due to a decrease in gross profit from lower SARS-CoV-2 assay sales and the Mobidiag impairment charges of $197.4 million recorded in the third quarter discussed above.", -0.6], ["Gross margin was 44.7% in the current year compared to 67.1% in the prior year.", -0.7], ["The decrease in gross margin was primarily due to decreased sales of our SARS-CoV-2 assays which have a higher margin, a slight decline in average selling prices of certain assays, the impairment charges discussed above of which $162.8 million was included in costs of revenues, a $24.7 million charge to write-off inventory related to a product line discontinuance, unfavorable manufacturing variances at certain of our manufacturing facilities and higher field service costs from our expanded instrument installed base, partially offset by increases in core Aptima assay and ThinPrep Pap Test volumes, higher lab testing revenue and a $41.4 million decrease in intangible asset amortization expense as assets acquired in the Cytyc acquisition became fully amortized in the current year.", -0.8], ["Also partially offsetting the decrease was an increase in Fusion respiratory and Quant Viral assay volumes in the current fiscal year and lower freight costs internationally.", -0.1], ["Operating expenses decreased in fiscal 2023 compared to fiscal 2022 primarily due to a decrease in marketing expenses and allocated advertising and charitable donations, a decrease in intangible asset amortization expense, and a decrease in commissions and bonus as well as lower consulting costs.", 0.2], ["Partially offsetting these decreases was the impairment charge discussed above of which $34.6 million was included in operating expenses, a settlement charge of $8.9 million related to the termination of the Mobidiag joint venture in China, an increase in compensation and benefits from the extra week in the current fiscal year, an increase in facilities cost and an increase in travel expenses.", -0.4], ["Breast Health revenues increased in fiscal 2023 compared to fiscal 2022 primarily due to an increase in product and service revenue discussed above.", 0.5], ["Operating income for this business segment increased in fiscal 2023 compared to fiscal 2022 primarily due to an increase in gross profit from both product sales and services, partially offset by an increase in operating expenses.", 0.4], ["Gross margin was 54.8% in the current year compared to 51.9% in the prior year.", 0.3], ["The increase in gross margin is primarily due to higher volumes of our capital equipment and related software sales, and interventional breast solutions devices, an increase in service margin from the continued conversion of digital mammography systems to service contracts and to a lesser extent the extra week in the current fiscal year and an increase in the average selling prices and attachment rates of our service contracts.", 0.4], ["These increases were partially offset by the impairment charges related to our SSI ultrasound imaging business discussed above, of which $16.7 million was included in cost of revenues, and higher costs for raw materials and components from supply chain constraints and inflation, and a slight decline in average selling prices of our biopsy disposables.", -0.3], ["We also had an increase in inventory reserves and freight in the current year.", -0.2], ["Operating expenses increased in fiscal 2023 compared to fiscal 2022 primarily due to the loss on assets-held-for-sale of $51.7 million and impairment charges related to our SSI ultrasound imaging business discussed above, of which $9.7 million was included in operating expenses, an increase in commissions from higher sales, an increase in travel and meeting expense and higher restructuring costs, partially offset by a decrease due to the release of the research and development credit reserve related to the SSI acquisition and a decrease in marketing initiatives, allocated advertising and charitable contributions.", -0.5], ["In addition, there was an increase in compensation and benefits from the extra week in the current year.", 0.2], ["GYN Surgical revenues increased in fiscal 2023 compared to fiscal 2022 due to the increase in product revenues discussed above.", 0.5], ["Operating income for this business segment increased in fiscal 2023 compared to fiscal 2022 primarily due to an increase in gross profit offset by an increase in operating expenses.", 0.4], ["Gross margin was 67.7% in the current year, compared to 59.2% in the prior year.", 0.6], ["The increase in gross margin was primarily due to a decrease in intangible asset amortization expense of $41.2 million in the current year as assets acquired in the Cytyc acquisition became fully amortized, an increase in volume of higher margin products, primarily MyoSure and NovaSure, as procedure rates continue to recover from the impact of the COVID-19 pandemic and higher average selling prices of our NovaSure V5 device.", 0.7], ["These increases were partially offset by higher volumes of lower margin products, mostly attributable to sales of our Fluent Fluid Management systems, CoolSeal vessel sealers and scopes.", -0.1], ["Operating expenses increased in fiscal 2023 compared to fiscal 2022 primarily due to a gain of $39.5 million recorded in the prior fiscal year compared to a gain of $14.9 million recorded in the current year to decrease the Acessa contingent consideration liability to fair value.", -0.3], ["In addition, we had an increase in compensation and benefits primarily due to an increase in commissions and higher salaries from an increase in headcount as well as an increase in travel expenses.", 0.1], ["Partially offsetting these increases was a gain of $7.4 million for infringement damages from the Minerva litigation, which was recorded as a credit to general and administrative expenses, a decrease in intangible asset amortization expense, lower R&D project spend, and lower marketing initiative spend and allocated advertising and charitable donations.", 0.2], ["Skeletal Health revenues increased in fiscal 2023 compared to fiscal 2022 primarily due to the increase in product revenues as discussed above and to a lesser extent the increase in service contract revenue from the extra week in the current fiscal year.", 0.5], ["Operating income increased in fiscal 2023 compared to fiscal 2022 primarily due to an increase in gross profit and a decrease in operating expenses.", 0.8], ["Gross margin was 32.2% in the current year compared to 28.2% in the prior year.", 0.7], ["The increase in gross margin was primarily due to higher sales volumes of our Horizon DXA, Insight FD systems, and system upgrades and an increase in the average selling prices of our Horizon DXA systems, partially offset by increased costs from supply chain constraints and inflation.", 0.5], ["Operating expenses decreased in fiscal 2023 compared to fiscal 2022 primarily due to a decrease in marketing initiatives and research and development project spend.", 0.6], ["Our cash and cash equivalents balance increased by $416.2 million during fiscal 2023 principally due to cash generated from operating activities partially offset by cash used in investing and financing activities primarily related to repurchases of our common stock and capital expenditures.", 0.7], ["In fiscal 2023, our operating activities provided cash of $1,051.2 million, primarily due to net income of $456.0 million, non-cash charges for depreciation and amortization aggregating $323.4 million, intangible asset equipment impairment charges of $223.8 million, stock- based compensation expense of $79.6 million, and a loss on assets held-for-sale related to the SSI ultrasound imaging business of $51.7 million.", 0.3], ["These adjustments to net income were partially offset by a decrease in net deferred taxes of $109.1 million primarily due to the capitalization of research expenditures under the tax rules and to a lesser extent the amortization and impairments of intangible assets.", -0.2], ["Cash provided by operations included a net cash inflow of $11.8 million from changes in our operating assets and liabilities.", 0.4], ["The net cash inflow was primarily driven by a decrease in prepaid expenses and other assets of $23.6 million primarily due to normal amortization related to the Women’s Tennis Association sponsorship and service and software subscriptions, a decrease in prepaid income taxes of $17.4 million primarily due to the timing of tax payments relative to the provision for income taxes, and an increase in deferred revenue of $14.4 million primarily due to billings for annual service contracts under our expanded installed base of digital mammography systems.", 0.5], ["These cash inflows were partially offset by a decrease in accounts payable of $23.0 million primarily due to timing of payments and a decrease in accrued expenses of $14.2 million primarily due to a decrease in accrued compensation and benefits for annual bonuses and timing of payroll versus the prior year, and a decrease in professional services partially offset by an increase of value-added tax payments primarily due to timing.", 0.1], ["In fiscal 2023, our investing activities used cash of $152.1 million primarily due to capital expenditures of $150.2 million, which primarily consisted of the placement of equipment under customer usage agreements and purchase of", -0.5], ["These uses of cash were partially offset by a final reimbursement of $20.5 million received from the Department of Defense under a grant to increase production capacity of our two SARS-CoV-2 assays.", 0.2], ["In fiscal 2023, our financing activities used cash of $483.2 million, primarily due to $474.8 million for repurchases of our common stock, $24.0 million for the payment of employee taxes withheld for the net share settlement of vested restricted stock units, $15.0 million for debt principal payments under our 2021 Credit Agreement and a $7.6 million contingent consideration payment related to the Acessa Health acquisition.", -0.7], ["Partially offsetting these uses of cash was $43.0 million from our equity plans from the exercise of stock options and issuance of shares under our employee stock purchase plan.", 0.3], ["We are required to make scheduled principal payments under the 2021 Term Loan in increasing amounts ranging from $3.75 million per three-month period commencing with the three-month period ending on December 29, 2022 to $18.75 million per three-month period commencing with the three-month period ending on December 26, 2025.", -0.4], ["On October 27, 2023 (in the first quarter of fiscal 2024), we made a $250.0 million voluntary prepayment on the 2021 Term Loan.", -0.2], ["In connection with certain of our acquisitions, we have incurred the obligation to make contingent earn-out payments tied to performance criteria, principally revenue growth of the acquired business over a specified period.", -0.5], ["Our obligation to make contingent payments may also result in significant operating expenses.", -0.6], ["Increases or decreases in the fair value of contingent consideration liabilities can result from changes in discount rates, changes in the timing, probabilities and amount of revenue estimates, and accretion of the liability for the passage of time.", -0.4], ["We have an obligation to the former Acessa shareholders to make contingent payments based on a multiple of annual incremental revenue growth over a three-year period ending annually in December.", -0.5], ["The second earn-out period was completed in December 2022, resulting in a payment amount of $7.6 million in the second quarter of fiscal 2023.", -0.1], ["During fiscal 2023, we updated our forecasted revenue and recorded a gain of $14.9 million to record the liability to fair value.", 0.5], ["The reduction in fair value was primarily due to a decrease in forecasted revenues.", -0.6], ["On November 6, 2023, the Board of Directors authorized the Company to repurchase up to $500 million of our outstanding shares pursuant to an accelerated share repurchase (ASR) agreement.", 0.8], ["Subject to the “Risk Factors” set forth in Part I, Item 1A of this Annual Report and the general disclaimers set forth in our Special Note Regarding Forward-Looking Statements at the outset of this Annual Report, we believe that our cash and cash equivalents, cash flows from operations, and the cash available under our 2021 Revolver will provide us with sufficient funds in order to fund our expected normal operations and debt payments over the next twelve months.", 0.3], ["These risks, trends and uncertainties may also adversely affect our long-term liquidity.", -0.7], ["It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings.", -0.5], ["Any differences may have a material impact on our financial condition and results of operations.", -0.4], ["Although considerable effort is made to ensure the accuracy of our forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of our inventory and our operating results.", -0.8], ["Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator.", -0.9], ["As a result of this simplified approach the goodwill impairment is calculated as the amount by which the carrying value of the reporting unit exceeds its fair value to the extent of the goodwill balance.", -0.2], ["As a result of completing this analysis, all of our reporting units had fair values exceeding their carrying values.", 0.5], ["If the current economic environment were to deteriorate, this would likely result in a higher WACC because market participants would require a higher rate of return.", -0.7], ["In the DCF as the WACC increases, the fair value decreases.", -0.5], ["The other significant factor in the DCF is our projected financial information (i.e., amount and timing of expected future cash flows and growth rates) and if these assumptions were to be adversely impacted, this could result in a reduction of the fair value of a reporting unit.", -0.6], ["We generate revenue from the sale of our products, primarily medical imaging systems and diagnostic and surgical disposable products, and related services, which are primarily support and maintenance services on our medical imaging systems.", 0.7], ["We have recognized $36.4 million in net deferred tax assets at September 30, 2023 and $74.6 million in net deferred tax liabilities at September 24, 2022.", 0.3], ["The change was primarily due to recording a deferred tax asset on capitalized research and development costs and intangible asset impairments in fiscal 2023.", 0.1], ["Any change in these factors could result in the recognition of a tax benefit or an additional charge to the tax provision.", -0.3], ["If our assumptions are incorrect, the differences could have a material impact on our income tax provision and operating results in the period in which such determination is made.", -0.4], ["We incur interest expense on borrowings outstanding under our 2028 and 2029 Senior Notes, and 2021 Credit Agreement.", -0.5], ["A hypothetical 10% adverse movement (increase in the SOFR rate) would increase annual interest expense by approximately $5.2 million, which is net of the impact of our interest rate swap hedge.", -0.7], ["A hypothetical 10% increase in market rates would increase annual interest income by approximately $13.0 million based on our current cash balances.", 0.5], ["Accordingly, our future results could be materially adversely impacted by changes in these or other factors.", -0.9], ["Our revenues denominated in foreign currencies are positively affected when the U.S. dollar weakens against them and adversely affected when the", -0.3], ["Fluctuations in foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses.", -0.6], ["In addition, currency devaluations can result in a loss if we hold deposits of that currency.", -0.8], ["As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of unrealized gains and losses reported in other income, net on the mark-to-market of outstanding contracts and", -0.4], ["(ii) realized gains and losses recognized in other income, net, whereas the offsetting economic gains and losses are reported in the line item of the underlying cash flow, for example, revenue.", -0.2], ["Our operating results and certain assets and liabilities that are denominated in foreign currencies are affected by changes in the relative strength of the U.S. dollar against those currencies.", -0.4], ["Our expenses, denominated in foreign currencies, are positively affected when the U.S. dollar strengthens against those currencies and adversely affected when the U.S. dollar weakens.", -0.2], ["We believe a hypothetical 10% increase or decrease in foreign currencies that we transact in would not have a material adverse impact on our financial condition or results of operations.", 0.1], ["During fiscal 2023, we incurred net foreign exchange losses of $7.9 million, net foreign exchange gains of $48.5 million in fiscal 2022 and net foreign exchange losses of $15.1 million in fiscal 2021.", -0.3], ["Subject to the foregoing, based on management’s assessment, we believe that, as of September 30, 2023, our internal control over financial reporting is effective at a reasonable assurance level based on these criteria.", 0.3], ["As discussed in Note 3 to the consolidated financial statements, the Company generates capital equipment rev from the sale of medical imaging systems.", 0.2], ["Net income per common share attributable to Hologic:", 0.0], ["Gain (loss) recognized, net of tax of $(2.9) in 2023, $13.7 in 2022, and $2.5 in 2021 for interest rate swaps", -0.1], ["Loss reclassified from accumulated other comprehensive loss to the statement of operations, net", -0.4], ["2020              295,107  $  2.9  $  5,904.8  $   (1,573.2) $     (49.7)    37,609  $ (1,579.6) $      2.1  $   2,707.3", -0.5], ["Net income (loss)          —    —      —     1,871.5        —      —      —       (1.8)     1,869.7", 0.0], ["stock                —    —      —       —        —     6,044    (409.8)       —     (409.8)", -0.5], ["rate swap              —    —      —       —        9.4      —      —        —       9.4", 0.2], ["interest               —    —     (8.2)       —        —      —      —       (0.3)      (8.5)", -0.7], ["Exercise of stock options       336    —     13.8       —        —      —      —        —      13.8", 0.5], ["Net income             —    —      —     1,302.0        —      —      —        —     1,302.0", 1.0], ["Net income             —    —      —      456.0        —      —      —        —      456.0", 0.8], ["299,940 $  3.0 $  6,141.2 $   2,056.3 $", 0.3], ["stock                —    —      —       —        —     6,830    (504.5)       —     (504.5)", -0.6], ["On October 27, 2023, the Company made a $250.0 million voluntary prepayment on the term loan outstanding under the 2021 Credit Agreement.", 0.4], ["On November 15, 2023, the Company executed an accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. (“Goldman Sachs”) pursuant to which the Company agreed to repurchase $500 million of the Company’s common stock.", 0.7], ["A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations.", -0.8], ["The fiscal year 2023 and 2021 refunds received primarily related to tax filings and over-payments made in the ordinary course of business, while the fiscal 2022 refunds were primarily related to federal and state loss carryback claims.", 0.1], ["A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future.", -0.7], ["The Company records charges for excess and obsolete inventory within cost of product revenues.", -0.5], ["Less - accumulated depreciation and amortization                            (714.0)          (705.6)", -0.6], ["In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force (“DOD”) to expand production capacity for the Company's two SARS-CoV-2 assays.", 0.8], ["During the second quarter of fiscal 2023, the Company received the final DOD approvals and the final payment from the DOD of $20.5 million, which was recorded as a reduction of the cost basis of the purchased equipment.", 0.7], ["In fiscal 2022 and 2021, the Company received $75.0 million and $21.5 million, respectively, from the DOD for reimbursement of capital equipment, which was recorded as a reduction of the cost basis of the purchased equipment.", 0.7], ["In addition, a portion of the DOD grant funded expenditures in connection with the project that did not qualify for capitalization and was recorded as a reduction to expenses, which was $7.6 million and $1.3 million in fiscal 2022 and 2021, respectively.", 0.6], ["During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its Mobidiag", -0.9]], "ogn22_sentences.json": [["The aggregate market value of the voting common equity held by non-affiliates of the registrant, computed by reference to the closing price at which the", -0.1], ["A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time, yet still contribute meaningful profitability.", 0.2], ["Organon believes its established brands products will, over time, continue to deliver meaningful revenue and operating profit that can be redirected into organic and inorganic growth opportunities in key product areas and geographies.", 0.5], ["Led by the women's health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows to support investments in innovation and future growth opportunities", 0.8], ["Organon's sales for each of its product groups are as follows:", 0.0], ["In 2022, Organon recorded revenues of $6.2 billion.", 0.3], ["Organon operates on a global scale and Organon's global network enables it to distribute products to patients in more than 140 countries and territories, with approximately 77% of 2022 revenues, or $4.7 billion, generated outside the United States.", 0.4], ["In 2022, Organon's women's health portfolio accounted for $1.7 billion, or approximately 27%, of Organon's revenues, with $774 million, or approximately 46%, generated outside the United States.", 0.3], ["Marvelon and Mercilon are not approved or marketed in the United States but are available in certain countries outside the United States, including now in China and Vietnam as a result of a recent transaction with Bayer Healthcare where Organon gained rights to Marvelon and Mercilon in these markets.", 0.2], ["In 2022, Organon's biosimilars portfolio accounted for $481 million, or approximately 8%, of revenues, with $237 million, or approximately 49%, generated outside the United States.", 0.3], ["The assets in Organon's biosimilars portfolio and Organon's commercial experience in biosimilars provides an opportunity to benefit from future growth anticipated in this area.", 0.8], ["Organon's established brands portfolio contributed approximately $3.9 billion of revenues in 2022, of which approximately 92%, or $3.6 billion, generated outside the United States.", 0.5], ["In 2022, Organon's cardiovascular portfolio accounted for $1.5 billion, or approximately 24%, of revenues, nearly all of which were generated outside the United States.", 0.3], ["In 2022, Organon's respiratory portfolio accounted for $1.0 billion, or approximately 17% of revenues, with approximately 80%, or $826 million, generated outside the United States.", 0.3], ["In 2022, Organon's dermatology, bone health and non-opioid pain management portfolios accounted for $788 million, or approximately 13%, of revenues, nearly all of which were generated outside the United States.", 0.3], ["Proscar, used for the treatment of symptomatic benign prostatic hyperplasia (\"BPH\") in men with an enlarged prostate, accounted for $101 million of revenues in 2022.", 0.1], ["In addition, Propecia, used for the treatment of male pattern hair loss, accounted for $125 million of revenues in 2022.", 0.1], ["Organon does not have any single customer that, if such customer were lost, would have a material adverse effect on Organon's business.", -0.5], ["Organon's global commercial and manufacturing teams collaborate on various operational efficiency initiatives, including yield improvements, procurement savings, site synergies, manufacturing support rationalization and supply chain distribution optimization, each intended to improve Organon's leverage position.", 0.7], ["Additionally, in December 2021, Organon signed a supplemental license with Merck that provides a limited expansion of the fields in which it may use the underlying technology of Nexplanon / Implanon NXT beyond contraception in exchange for milestone payments.", 0.6], ["While the expiration of a product patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from: (i) later-granted patents on processes and intermediates related to the", -0.2], ["Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products.", -0.1], ["Royalty income in 2022 on patent and know-how licenses and other rights amounted to $3 million.", 0.3], ["Organon also incurred royalty expenses totaling $13 million in 2022 under patent and know-how licenses Organon holds.", -0.3], ["These changing requirements could cause Organon to incur substantial costs or require it to change its business practices or compliance procedures in a manner adverse to Organon's business.", -0.7], ["Organon's operations may be adversely affected by generic and biosimilar competition as Organon's products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors' branded products and new information from clinical trials of marketed products or post-marketing surveillance.", -0.8], ["An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.", -0.9], ["However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents.", -0.5], ["Global efforts toward health care cost containment continue to exert pressure on product pricing and market access.", -0.6], ["The ACA, among other things, increased the mandated Medicaid drug rebate from 15.1% to 23.1%, expanded the rebate to Medicaid-managed care utilization, and increased the types of entities eligible for the federal 340B drug discount program.", -0.4], ["The ACA, together with the Bipartisan Budget Act of 2018, also requires pharmaceutical manufacturers to pay 70% (up from 50% from the ACA effective 2019) of the negotiated price of the medicine, including biosimilar products, when Medicare Part D beneficiaries are in the Medicare Part D coverage gap (i.e., the so-called \"donut hole provision\").", -0.2], ["Organon's cost-sharing responsibility for any approved product covered by Medicare Part D could be significantly greater under the newly designed Part D benefit structure compared to the pre-IRA benefit design.", -0.5], ["Organon recorded approximately $16 million, $17 million and $24 million as a reduction to revenue in 2022, 2021 and 2020, respectively, related to the coverage gap or \"donut hole\" provision.", -0.3], ["Furthermore, the IRA, among other reforms, allows Medicare to, beginning in 2026, establish a \"maximum fair price\" for certain high expenditure pharmaceutical and biological products covered under Medicare Parts B and D. Organon's products could be selected for negotiation and become subject to prices representing a significant discount from average prices to wholesalers and direct purchasers.", -0.6], ["The IRA also allows Medicare to, beginning in 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation through establishing a rebate obligation for those companies.", -0.4], ["Organon recorded approximately $3 million, $10 million and $4 million of costs within selling, general and administrative expenses in 2022,", -0.3], ["This expanded definition may result in certain of Organon's drugs being subject to a higher Medicaid rebate liability.", -0.4], ["Finally, the provisions of this December 2020 Final Rule also may affect rebates owed under the Medicaid Drug Rebate Program in certain circumstances where accumulator adjustment or similar programs are applied to Organon's drugs and the value of Organon's assistance programs, which is intended for patients, is not counted towards the patient's deductible or other out-of-pocket costs.", -0.4], ["In addition, other legislative changes include automatic 2% aggregate reductions in Medicare payments to providers, which results in an overall reduction in physician-administered drug reimbursement from 106% of Average Sales Price (\"ASP\") to approximately 104.3% of ASP.", -0.5], ["The sequestration was temporarily halted from May 1, 2020 to March 31, 2022 as a result of various legislation, and later reduced to 1% from April 2022 to June 2022.", -0.2], ["Organon cannot predict how these and future adjustments to sequestration, and the way in which these laws impact physician reimbursement for Organon's products, will affect Organon's profitability.", -0.5], ["Organon also faces increasing pricing pressure globally from managed care organizations, government agencies and programs that could negatively affect Organon's sales and profit margins, including, in the United States (i) practices of managed care organizations, federal and state exchanges and institutional and governmental purchasers, and (ii) federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement and Modernization Act of 2003 and the ACA.", -0.8], ["While Organon cannot anticipate the effects of these changes on the way Organon currently contracts, the new framework could significantly alter the way Organon does business with Part D Plan Sponsors and PBMs on behalf of such plans.", -0.6], ["On August 16, 2022, President Biden signed the IRA into law, which sets forth meaningful changes to drug product reimbursements by Medicare, which may reduce the prices Organon can charge and reimbursement Organon can receive for its products, among other effects.", -0.7], ["In addition, several recently passed state laws require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes.", -0.4], ["These changes could have a material adverse effect on Organon's business, cash flow, results of operations, financial condition, and prospects.", -0.9], ["Failure to obtain timely or adequate pricing or formulary placement for Organon's products or obtaining such placement at unfavorable pricing could adversely affect revenue.", -0.7], ["As the United States payor market concentrates further and as more drugs become available in generic form, pharmaceutical companies may face greater pricing pressure from private third-party payors.", -0.6], ["The downward pressure on health care costs in general, particularly prescription drugs, has become intense.", -0.8], ["In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.", -0.5], ["Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement.", -0.5], ["A negative HTA of one of Organon's products may mean that the product is not reimbursable or may force Organon to reduce Organon's reimbursement price or offer discounts or rebates.", -0.8], ["A negative HTA by a leading and recognized HTA body could also undermine Organon's ability to obtain reimbursement for the relevant product outside a jurisdiction.", -0.7], ["HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.", -0.6], ["As a result of the TCA, Organon believes its operations will not be materially adversely affected by Brexit.", 0.2], ["In Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products.", -0.6], ["Organon's business in China has grown rapidly in the past few years, and the importance of China to Organon's overall pharmaceutical business has increased accordingly.", 0.7], ["This has led to a significant increase in the number of new products being approved each year.", 0.8], ["Though at the same time this regular innovative products access has been coupled with significant price reductions to ensure public access to NRDL and periodical-biannual price reviews for NRDL products.", -0.3], ["While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume-based procurement (\"VBP\").", -0.4], ["Mature products that have entered into the first seven rounds of VBP have had, on average, a price reduction of approximately 50%.", -0.2], ["Organon expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward, which Organon expects to increase pricing pressure on its products in China.", -0.5], ["Governments in many other markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine.", -0.7], ["Organon anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in such markets.", -0.6], ["Beyond pricing and market access challenges, other conditions in certain countries outside the United States can affect Organon's efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, credit worthiness of health care partners such as hospitals due to COVID-19, and other developments that may adversely impact the business environment for Organon.", -0.8], ["In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the United States.", -0.4], ["At the same time, the FDA has committed to expediting the development and review of products bearing the ''breakthrough therapy\" designation, and established other expedited programs to support the development, review, and approval of medicines where there is unmet medical need in serious and life-threatening conditions.", 0.3], ["Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties.", -0.6], ["This can potentially lead to a faster and less costly approval process for these products because it generally means that the biosimilar manufacturer does not need to conduct as many clinical trials.", 0.4], ["Non-compliance can lead to informal or formal enforcement action, including Untitled Letters, Warning Letters, fines, injunctions, consent decrees, civil penalties, recalls, detention or seizure of Organon's products, import refusals, and criminal prosecution.", -0.7], ["Other federal, state or foreign enforcement authorities can also take action under other laws and regulations, such as false claims laws, if they consider Organon's business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, and exclusion from participation in government health care programs.", -0.9], ["Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.", -0.8], ["As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor's generic, hybrid or biosimilar product (in the case of marketing exclusivity, even if the pharmaceutical product has already received an MA) and for data exclusivity, prohibiting another applicant from relying on the MA holder's pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application.", 0.2], ["New medicinal products authorized in the EU on the basis of a standalone application (i.e., on the basis of a dossier containing a complete suite of pre-clinical tests and clinical trials) qualify for eight years of data exclusivity and 10 years of marketing exclusivity.", 0.5], ["An additional noncumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.", 0.6], ["These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.", -0.9], ["These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed pharmaceutical products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine's safety, or to measure the effectiveness of risk-management measures, which may be time consuming, expensive and could impact Organon's profitability.", -0.7], ["can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied.", -0.8], ["More generally, noncompliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.", -0.8], ["The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.", -0.9], ["Companies may be subject to civil, criminal or administrative sanctions if they fail to comply with these practices.", -1.0], ["These include suspension of manufacturing authorization in case of non-compliance with the EU or EU Member States' requirements governing the manufacturing of pharmaceutical products.", -0.8], ["Violation of these laws could result in substantial fines and imprisonment.", -1.0], ["Some of the potential effects of climate change to Organon's business could include increased operating costs due to additional regulatory requirements, changes in supply due to regulatory requirements, physical risks to Organon's facilities, water limitations and disruptions to Organon's supply chain.", -0.9], ["Expenditures for remediation and environmental liabilities are estimated to be approximately $16 million in the aggregate for the years 2023 through 2027.", -0.7], ["The Samsung Bioepis Agreement provides that gross profits are shared equally in all markets except for certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to Organon.", 0.2], ["The Samsung Bioepis Agreement also provides for payment of certain milestone license fees associated with pre-specified clinical and regulatory milestones to Samsung Bioepis, payment of the supply price for each product to Samsung Bioepis, and an upfront payment to Samsung Bioepis that was completed by Merck at the commencement of the agreement.", 0.3], ["As of December 31, 2022, there were $25 million in potential future regulatory milestone payments remaining under the agreement.", 0.1], ["Any of the following risks could materially and adversely affect Organon’s results of operations, financial condition and the price of the Common Stock.", -1.0], ["The following is a summary of the principal risks that could significantly and negatively affect Organon's business, prospects, financial conditions, or operating results.", -1.0], ["•       Key products generate a significant amount of Organon's profits and cash flows, and any events that adversely affect the markets for Organon's leading products could adversely affect its results of operations and financial condition.", -1], ["•       Organon faces continued pricing pressure with respect to its products.", -1], ["•       Organon faces intense competition from competitors' products.", -1], ["•       Organon has limited in-house discovery and early research capabilities and will continue to rely on future acquisitions, partnerships and collaborations to expand its innovative pipeline and early discovery and research capabilities, which may limit its ability to discover or develop new products or expand its existing products into new markets to replace the sales of products that lose patent protection and therefore Organon may not be able to maintain its current levels of profitability.", -1], ["•       Developments following regulatory approval or marketing authorization may adversely affect sales of Organon's pharmaceutical products or medical devices.", -1], ["•       Issues with product quality could have an adverse effect on our business or cause a loss of customer confidence in us or our products, among other negative consequences.", -1], ["When the patent protection and market exclusivity periods for such products expire, a significant and rapid loss of sales from those products is generally experienced.", -1], ["Expiry of patent protection and market exclusivity for products that contribute significantly to Organon's sales will adversely affect its business.", -1], ["•       Organon depends on its patent rights for the marketing of certain of its products, and invalidation or circumvention of Organon's patent rights would adversely affect its business.", -1], ["•       Organon is subject to minimum purchase obligations under certain supply agreements, and if Organon fails to meet those minimum purchase requirements, its financial results may be unfavorably impacted.", -1], ["•       Organon has incurred substantial indebtedness, which could adversely affect its financial condition and results of operations.", -1.0], ["•       Organon is subject to a number of restrictive covenants under its indebtedness, including customary operating restrictions and financial covenants, which could restrict Organon's ability to pay dividends or adversely affect its financing options and liquidity position.", -1.0], ["•       As Organon builds its information technology infrastructure and transitions its data to its own systems, Organon could incur substantial additional costs and experience temporary business interruptions.", -1.0], ["•       Potential indemnification liabilities to Merck pursuant to the Separation and Distribution Agreement could adversely affect Organon.", -1.0], ["•       There could be significant income tax liability if the spinoff or certain related transactions are determined to be taxable for U.S.", -1.0], ["•       The price and trading volume of Organon's Common Stock may be volatile, and stockholders could lose all or part of their investment in Organon.", -1.0], ["•       Certain provisions in Organon's amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of Organon, which could decrease the trading price of the Common Stock.", -1.0], ["Key products generate a significant amount of Organon's profits and cash flows, and any events that adversely affect the markets for Organon's leading products could adversely affect its results of operations and financial condition.", -1.0], ["Organon's ability to generate profits and operating cash flow depends largely upon the continued profitability of its key products, such as Nexplanon, Cozaar/Hyzaar, Singulair and the Ezetimibe family of products.", -0.5], ["As a result of Organon's dependence on key products, any event that adversely affects any of these products or the markets for any of these products could adversely affect Organon's sales, results of operations or cash flows.", -1.0], ["These adverse events could include increased costs associated with manufacturing, product shortages, increased generic or over-the-counter availability of Organon's products or competitive products, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of these products for any reason.", -1], ["Organon also expects that competition will continue to adversely affect the sales of these products.", -1], ["Organon faces continued pricing pressure with respect to its products.", -1], ["Organon faces continued pricing pressure globally and, particularly in mature markets from managed care organizations, government agencies and programs that could adversely affect its sales and profit margins.", -1], ["Exclusion of a product from a formulary can lead to reduced usage in the population covered by the managed care organization or other payor.", -1], ["For instance, pricing pressure from the Chinese government has recently increased, including through a series of health care reforms to accelerate generic substitution through the government's VBP and GQCE programs.", -1], ["Mature products that have entered into the first seven rounds of VBP have had, on average, a price reduction of approximately 50%.", -1], ["Organon expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.", -1], ["Under the URPS, the government will usually determine the reimbursement prices by referring to the prices of the lowest-priced VBP winning products, with any remaining costs are then passed along to the patients in the form of a co-pay, which reduces the affordability of certain products with prices that exceed the lowest-priced VBP- winning products.", -1], ["The URPS policy will create additional pricing and volume pressure for pharmaceutical products that are subject to the program and may adversely affect Organon's business and results of operations.", -1], ["Organon's efforts to compete with other companies or Organon's failure to maintain its competitive position could adversely affect its business, cash flow, results of operations, financial condition or prospects.", -1.0], ["Organon has limited in-house discovery and early research capabilities and will continue to rely on future acquisitions, partnerships and collaborations to expand its innovative pipeline and early discovery and research capabilities, which may limit its ability to discover or develop new products or expand its existing products into new markets to replace the sales of products that lose patent protection, and therefore Organon may not be able to maintain its current levels of profitability.", -0.8], ["Organon intends to grow its business through new indications or formulations of its existing products or expansion of existing products into new markets or new geographies.", 0.5], ["Organon may not be able to offset any sales losses for products that lose or do not have exclusivity by growing sales in other markets.", -0.9], ["If Organon cannot produce sufficient revenues from expansion into new products, new indications or formulations of its existing products or expansion of existing products into new markets or new geographies, then Organon may not be able to maintain its current levels of profitability, and this could adversely affect Organon's business, cash flow, results of operations, financial condition or prospects.", -1.0], ["This may hinder or delay efforts to successfully commercialize Organon's product candidates.", -0.7], ["Organon may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and Organon may not realize the expected benefits of any acquisition, license arrangement or strategic partnerships.", -0.8], ["Organon could experience negative effects on its results of operations and financial condition from acquisition-related charges, amortization of intangible assets and asset impairment charges.", -0.9], ["If an acquired business fails to operate as anticipated or cannot be successfully integrated with Organon's existing business, its business, financial condition, results of operations or cash flows could be materially and adversely affected.", -1.0], ["Organon's failure to obtain approval, significant delays in the approval or marketing authorization process or its failure to maintain approval or marketing authorization in any jurisdiction will prevent Organon from selling the products in that jurisdiction.", -1.0], ["Organon would not be able to realize revenues for its pharmaceutical products or medical devices in any jurisdiction where it does not have approval or marketing authorization.", -1], ["Organon or its partners may fail to adequately demonstrate the safety and efficacy of any of Organon's pharmaceutical product candidates or medical devices in pre-clinical studies and clinical trials, which would prevent or delay development, regulatory approval or marketing authorization and commercialization of Organon's product candidates.", -1], ["Accordingly, there is a high risk of failure and Organon may never succeed in obtaining regulatory approval or marketing authorization of its product candidates.", -1], ["If the results of these studies, trials or tests are not positive (or are only modestly positive), or if there are safety concerns, Organon may incur unplanned costs, as well as delays in its efforts to obtain regulatory approval or marketing authorization.", -1], ["Developments following regulatory approval or marketing authorization may adversely affect sales of Organon's pharmaceutical products or medical devices.", -1], ["Failure to comply with any of these requirements could subject Organon to a variety of formal or informal enforcement actions by the FDA or other regulators, result in a recall or market withdrawal of Organon's products, require Organon to cease manufacturing and distribution of the products, trigger product liability or other litigation, or otherwise impact Organon's ability to realize revenues for its products.", -1], ["As previously disclosed, Organon voluntarily initiated market actions, including recalls, in certain markets with respect to the Company's suspension injections Diprospan, Celestone Chronodose® (betamethasone), and Celestone Soluspan® (betamethasone) related to a non-conforming component of a manufacturing line at Organon's Heist, Belgium plant.", -1], ["It is possible that future recalls or similar developments could materially and adversely impact Organon's business, result of operations, and financial condition.", -1], ["Likewise, if previously unknown side effects, adverse events, malfunctions or other quality or safety concerns are discovered or if there is an increase in negative publicity regarding known side effects of any of Organon's products, it could significantly reduce demand for the product or require it to take actions that could negatively affect sales, including initiating corrections of a marketed product or removing the product from the market, restricting Organon's distribution or applying for marketing authorization for labeling changes.", -1], ["Certain developments may decrease demand for Organon's products, including the following:", -1], ["•       negative results in post-approval Phase 4 trials or other studies;", -1.0], ["•       review by regulatory authorities or other expert bodies of Organon's products that are already marketed based on new data or other developments in the field;", -0.5], ["Issues with product quality could have an adverse effect on our business or cause a loss of customer confidence in us or our products, among other negative consequences.", -1.0], ["A quality or safety issue may result in adverse inspection reports, voluntary or official action indicated, warning letters, import bans, product recalls (either voluntary or required by FDA or similar governmental authorities in other countries) or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions (which may include corporate integrity agreements), costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses.", -1.0], ["An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.", -1.0], ["This, in turn, may result in the loss of confidence in our products' reputation and integrity, and potentially impact our business through lost sales, product recalls, and possible litigation.", -1.0], ["When the patent protection and market exclusivity periods for such products expire, a significant and rapid loss of sales from those products is generally experienced.", -1.0], ["Expiry of patent protection and market exclusivity for products that contribute significantly to Organon's sales will adversely affect its business.", -1.0], ["Loss of patent protection typically leads to a significant and rapid loss of sales for that product where lower priced generic versions of that drug become available.", -1.0], ["In the case of current or future products that contribute significantly to Organon's sales, a loss of market exclusivity could materially adversely affect its business, cash flow, results of operations, financial condition or prospects.", -1.0], ["Organon experienced a rapid and substantial decline in NuvaRing sales in the United States in 2020 as a result of this generic competition.", -0.9], ["Organon depends on its patent rights for the marketing of certain of its products, and invalidation or circumvention of Organon's patent rights would adversely affect its business.", -0.8], ["Even if Organon succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent Organon's patents and patent applications.", -0.7], ["It is important for Organon's business to successfully defend the patent rights that provide market exclusivity for its products.", -0.2], ["Patent litigation and other challenges to Organon's patents are costly and unpredictable and may deprive it of market exclusivity for a patented product or, in some cases, third-party patents may prevent Organon from marketing and selling a product in a particular geographic area, negatively affecting its business and results of operations.", -0.8], ["Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect Organon's business and results of operations.", -0.7], ["If one or more of Organon's important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available.", -0.9], ["Organon's results of operations may be adversely affected by the lost sales unless and until it has launched commercially successful products that replace the lost sales.", -0.8], ["In addition, if products with intangible assets that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, Organon may recognize material non-cash impairment charges with respect to the value of those products.", -0.8], ["Organon is subject to minimum purchase obligations under certain supply agreements, and if Organon fails to meet those minimum purchase requirements, its financial results may be unfavorably impacted.", -0.7], ["If Organon is unable to offset these payments, it could result in a lower margin.", -0.8], ["During the year ended December 31, 2022 and 2021, Organon recognized $5 million and $24 million, respectively, in Cost of Sales pertaining to estimated unavoidable losses associated with a long-term vendor supply contract conveyed as part of the spinoff.", -0.2], ["Organon does not currently expect these payments to be material; however, in the aggregate they may become material if additional amounts are identified in the future, and they could have a material adverse effect on Organon's financial condition, results of operations or cash flows.", -0.9], ["The ACA also increased the mandated Medicaid rebate applicable to most branded drugs from 15.1% to 23.1% of the product's Average Manufacturer Price, expanded the rebate to Medicaid managed care utilization, and increased the types of entities eligible for the federal 340B drug discount program.", -0.5], ["For example, efforts to repeal, modify, or invalidate some or all of the provisions of the ACA, some of which have been successful, create considerable uncertainties for Organon's business and other pharmaceutical manufacturers.", -0.7], ["On August 16, 2022, President Biden signed into law the IRA, which, among other reforms, allows Medicare to: beginning in 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation.", -0.3], ["This expanded definition may result in certain of Organon's drugs being subject to a higher Medicaid rebate liability.", -0.6], ["These changes could have a material adverse effect on Organon's business, cash flow, results of operations, financial condition and prospects.", -0.9], ["Changes to the health care system enacted as part of health care reform in the United States, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid and private sector beneficiaries, could result in further pricing pressures.", -0.8], ["As an example, health care reform has contributed to an increase in the number of patients in the Medicaid program under which sales of pharmaceutical products are subject to substantial rebates.", -0.7], ["While Organon cannot anticipate the effects of these changes to the way that it currently contracts, the new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans.", -0.2], ["Organon cannot predict the likelihood of additional future changes in the health care industry in general, the pharmaceutical industry in particular, or what impact they may have on its business, cash flow, results of operations, financial condition or prospects.", -0.5], ["The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect Organon's business, cash flow, results of operations, financial condition or prospects.", -0.8], ["The costs of compliance and penalties for noncompliance may be particularly significant with respect to health care reform initiatives in the United States or in other countries, including additional mandatory discounts or fees; new laws, regulations and judicial or other governmental decisions affecting pricing, reimbursement, and market access or marketing within or across jurisdictions; new and increasing data privacy regulations and enforcement, particularly in the EU, the UK, the United States, and China; legislative mandates or preferences for local manufacturing of medical products; emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals and health care organizations; environmental regulations; and emerging and new regulations on human rights and environmental matters in the supply chain and importation restrictions, embargoes, trade sanctions and legislative or other regulatory changes.", -0.7], ["Recent years have seen substantial increase in the global enforcement of anti-corruption laws.", -0.3], ["Organon has significant global operations, which expose it to additional risks, and any adverse event could adversely affect Organon's results of operations and financial condition.", -0.6], ["For example, in 2022, Organon generated $4.7 billion in revenues outside the United States, representing approximately 77% of its total revenues.", 0.3], ["•       financial risks, such as foreign currency exchange fluctuations, longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for Organon's products;", -0.4], ["•       volatility of commodity prices, fuel, shipping rates that impact the costs and/or ability to supply Organon's products;", -0.5], ["As a result of global economic conditions, some parties may delay or be unable to satisfy their payment or reimbursement obligations.", -0.6], ["Job losses or other economic hardships may also affect patients' ability to afford health care as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost health care insurance coverage or for other reasons.", -0.8], ["Further, with rising international trade tensions or sanctions, Organon's business may be adversely affected following new or increased tariffs, as well as the costs of materials, products, and commodities upon which Organon rely.", -0.7], ["As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect Organon's results of operations and financial condition.", -0.8], ["In particular, in February 2022, the armed conflict between Ukraine and Russia escalated, which may adversely impact Organon's business.", -0.9], ["Specifically, trade sanctions, travel bans and asset/financial freezes announced by the United States, European Union and other countries against Russian entities and designated individual restrictions have impacted and may continue to impact many global businesses in direct and indirect ways (including, but not limited to, product shipping delays, supply shortages, delays in regulatory approvals and audits and currency exchange rates).", -0.8], ["Such actions may negatively impact the financial institutions, vendors, manufacturers, suppliers, partners and other third parties with whom Organon conducts business and therefore may negatively impact Organon.", -0.8], ["Failing to comply with these obligations could lead to government enforcement actions and significant penalties against Organon, harm to its reputation, and adversely impact its business and operating results.", -0.9], ["Cyberattacks affecting Organon's IT systems could result in exposure of confidential information, the modification of critical data or the disruption of its worldwide operations, including manufacturing and sales operations.", -0.8], ["Disruption, degradation, destruction or manipulation of these IT systems through intentional or accidental means by Organon's employees, third parties with authorized access or cyber threat actors could adversely affect key business processes.", -0.8], ["These attacks could lead to loss of confidentiality, integrity and/or availability of Organon's data, applications or systems.", -0.8], ["Further, any such interruption, security breach, or loss, misappropriation, and/or unauthorized access, use or disclosure of confidential information, including personal information regarding Organon's patients and employees, or the modification of critical data, could result in financial, legal, business, and reputational harm to Organon and could result in loss of revenue, or the loss of critical or sensitive information from Organon's or its third-party providers' databases or IT systems, or result in financial, legal, business or reputational harm to Organon and substantial remediation and recovery costs.", -1.0], ["Organon or its suppliers and other manufacturing partners may experience difficulties, delays or expenses in connection with manufacturing Organon's products, such as: failure to comply with applicable regulations and quality assurance guidelines; delays related to the construction of new facilities or the expansion of existing facilities; delays related to the supply of key ingredients or other components of Organon's products; increased costs of key materials, packaging, or operational procedures; and other manufacturing or distribution problems, including, but not limited to, changes in manufacturing production sites and limits to manufacturing capacity resulting from regulatory requirements, changes in types of products produced and physical limitations that could impact supply.", -0.8], ["Manufacturing difficulties, delays or shutdowns, as well as difficulties obtaining materials of adequate quality and quantity, can result in product shortages, leading to lost sales, a significant short- or long-term financial impact, government agency actions, and reputational harm to Organon, which are difficult to predict.", -0.9], ["Ongoing and future epidemics and pandemics, including the ongoing COVID-19 pandemic, may adversely impact Organon's business, operations, financial performance, results of operations, and financial condition.", -0.9], ["Organon's business and financial results were negatively impacted by the outbreak of COVID-19.", -1.0], ["During 2022, our product sales in China declined by approximately $46 million, primarily as a result of lockdowns and clinic closures in selected cities, as well as a decline in patient visits to the remaining in-patient and out-patient clinics.", -0.8], ["A significant amount of Organon's revenue is comprised of physician prescribed products, which, despite underlying demand, have been affected by reduced access, fewer medical visits and delays in elective procedures.", -0.7], ["Additionally, our portfolio in women's health includes products that are physician administered, which have been affected by reduced access to physicians and health care centers.", -0.7], ["These impacts, have resulted in reduced prescription of many products within established brands and women's health, such as Nexplanon, in some countries outside the U.S., as well as our Fertility brands.", -0.8], ["Organon may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or Organon may experience other supply difficulties that could adversely affect both its ability to deliver its products and its results of operations and financial condition.", -0.9], ["For instance, Follistim AQ and Atozet¹ have been challenged by intermittent supply disruptions.", -0.8], ["Further, if Organon does seek recovery or damages from such supplier for any supply shortages or disruptions, such recovery or damages may be limited and not include indirect or consequential losses or any loss of revenue or lost profits.", -0.7], ["A reduction or interruption in supply and an inability to quickly develop acceptable alternative sources for such supply could adversely affect Organon's ability to manufacture and distribute its products in a timely or cost-effective manner, negatively impacting Organon's ability to sell its products.", -0.9], ["Organon may not realize benefits from its investments in emerging markets.", -0.6], ["Organon has been taking steps to increase its sales in emerging markets; however, Organon's efforts to expand sales in these markets may not succeed.", -0.5], ["Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care.", -0.7], ["In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and Organon cannot offset the devaluations, its financial performance within such countries could be adversely affected.", -0.8], ["For example, Organon's business in China is growing, and China is now Organon's second largest market, thereby increasing the importance of China to Organon's overall pharmaceutical business.", 0.3], ["Pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available.", -0.6], ["While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government's VBP and GQCE programs.", -0.7], ["Mature products that have entered into the first seven rounds of VBP have had, on average, a price reduction of approximately 50%.", -0.5], ["annual process that will have a significant impact on mature products moving forward, which Organon expects to increase pricing pressure on its products in China.", -0.7], ["The URPS policy will create additional pricing and volume pressure for pharmaceutical products that are subject to the program and may adversely affect Organon's business and results of operations.", -0.9], ["These regulatory changes may limit the ability for the third-party manufacturer to continue to sell Organon's products to downstream distributors.", -0.8], ["If Organon fails to identify a pathway forward, its business in China may be adversely affected.", -0.9], ["A failure to make such pivot effectively, or a failure to develop and maintain a presence in emerging markets could adversely affect Organon's business, cash flow, results of operations, financial condition or prospects.", -0.9], ["Any negative impact on economic conditions and international markets, continued volatility or deterioration in the capital markets, inflation, deflation or other adverse economic conditions may adversely affect our liquidity and financial condition.", -0.8], ["It may limit our ability to replace maturing liabilities and to access the capital markets to meet liquidity needs, which could have a material adverse effect on our financial condition and results of operations.", -0.8], ["Ongoing uncertain economic and financial market conditions may also adversely affect the financial condition of our customers, suppliers and other business partners.", -0.7], ["If our customers' financial conditions are adversely affected, those customers may reduce their purchases of our products or we may not be able to collect accounts receivable, each of which could have a material adverse impact on our business operations or financial results, and we may not be able to fully absorb any such additional costs or revenue declines in the prices for our products and services.", -0.9], ["Inflation could materially adversely affect our business and operations.", -1.0], ["Our operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors that impact our cost structure and revenue results.", -1.0], ["Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the war in Ukraine, and steps taken by governments and central banks, as well as other stimulus and spending programs, have led to higher inflation, which is likely to lead to an increase in costs and may cause changes in fiscal and monetary policy, including increased interest rates.", -1.0], ["Since Organon cannot, with certainty, foresee and mitigate against such adverse fluctuations in currency exchange rates, interest rates and inflation could negatively affect Organon's business, cash flow, results of operations, financial condition or prospects.", -1.0], ["While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.", -0.5], ["As a result, currency fluctuations among Organon's reporting currency, the U.S. dollar, and other currencies in which Organon does business will affect its operating results, often in unpredictable ways.", -1.0], ["Reliance on third-party relationships and outsourcing arrangements could materially adversely affect Organon's business.", -1.0], ["Failure of these third parties to meet their contractual, regulatory and other obligations to Organon or the development of factors that materially disrupt the relationships between it and these third parties could adversely affect Organon's business.", -1.0], ["The markets for Organon's products, including the women's health market, may not develop as successfully as expected.", -0.5], ["Organon's ability to successfully execute its growth strategy in this area is subject to numerous risks, including:", -0.5], ["•       uncertainty of the development of a market for such products;", -0.8], ["•       trends relating to, or the introduction or existence of, competing products, technologies or alternative treatments or therapies that may be more effective, safer or easier to use than Organon's products, technologies, treatments or therapies;", -0.6], [" If Organon is unable to successfully commercialize and create a significant market for its women's health products, Organon's business or prospects could be harmed.", -0.9], ["Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business.", -0.9], ["Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, customers, and other business partners, which could cause disruption in our business and operations or increase costs to operate our business.", -0.8], ["Additionally, increased environmental regulation, including to address climate change, may result in increases in our costs to operate our business or restrict certain aspects of our activities.", -0.7], ["Biosimilars carry unique regulatory risks and uncertainties, which could adversely affect Organon's results of operations and financial condition.", -0.8], ["There are unique regulatory risks and uncertainties related to biosimilars.", -0.6], ["Any changes to the regulatory framework governing biosimilars or in the ability of Organon's partners to manufacture an adequate supply of biosimilars may adversely affect Organon's ability to commercialize the biosimilars in its portfolio.", -0.7], ["Organon has incurred substantial indebtedness, which could adversely affect Organon's financial condition and results of operations.", -0.9], ["Current or future levels of indebtedness may increase the possibility that Organon will be unable to generate cash sufficient to pay amounts due in respect of such indebtedness.", -0.8], ["Organon's ability to issue additional debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for Organon's products, if Organon's customers or suppliers are unable to pay amounts due to Organon or there are other significantly unfavorable changes in economic conditions.", -0.9], ["Volatility in the world financial markets could increase borrowing costs or affect Organon's ability to access the capital markets.", -0.7], ["These conditions may adversely affect Organon's ability to obtain and maintain its credit ratings.", -0.8], ["This indebtedness may adversely affect Organon's ability to operate or grow its business or could have other material adverse consequences, including by:", -0.9], ["•       limiting Organon's ability to obtain additional financing in the future for working capital, capital expenditures and acquisitions;", -0.8], ["•       limiting Organon's ability to refinance its indebtedness on terms acceptable to Organon or at all;", -0.8], ["•       requiring Organon to dedicate a significant portion of its cash flows from operations to paying amounts due under its indebtedness, thereby reducing funds available for other corporate purposes;", -0.8], ["•       making Organon more vulnerable to economic downturns; or •   limiting Organon's ability to withstand competitive pressures.", -0.8], ["Any of these restrictions on Organon's ability to operate its business in its discretion could adversely affect its business by, among other things, limiting Organon's ability to adapt to changing economic, financial or industry conditions and to take advantage of corporate opportunities, including opportunities to obtain debt financing, repurchase stock, refinance or pay principal on Organon's outstanding debt, dispose of property, complete acquisitions for cash or debt, or make other investments.", -0.9], ["In addition, events beyond Organon's control, including prevailing economic, financial, and industry conditions, could affect Organon's ability to satisfy applicable financial covenants, and Organon cannot assure you that it will satisfy them.", -0.8], ["Any failure to comply with the restrictions of Organon's current indebtedness, or any future financing agreements, including as a result of events beyond Organon's control, may result in an event of default under these agreements, which in turn may result", -0.9], ["in defaults or acceleration of obligations under these agreements and other agreements, giving Organon's lenders and other debt holders the right to terminate any commitments they may have made to provide Organon with further funds and to require Organon to repay all amounts then outstanding.", -0.9], ["As Organon builds its information technology infrastructure and transition its data to its own systems, Organon could incur substantial additional costs and experience temporary business interruptions.", -0.7], ["Organon may incur temporary interruptions in business operations if it cannot transition effectively from Merck's existing transactional and operational systems, data centers and the transition services that support these functions as Organon replaces these systems.", -0.7], ["Organon may not be successful in implementing new systems and transitioning its data, and Organon may incur substantially higher costs for implementation than currently anticipated.", -0.8], ["Potential operational interruptions impacting Organon as it implements the new systems and replaces Merck's information technology services, or Organon's failure to implement the new systems and replace Merck's services successfully, could disrupt Organon's business or adversely affect its results of operations.", -0.9], ["Merck may not satisfy its obligations under various transaction agreements that have been or will be executed as part of the spinoff, Organon may experience delays with approvals relating to the separation from Merck, or Organon may not have necessary systems and services in place when certain of the transition agreements expire.", -0.8], ["If Merck is unable to satisfy its obligations under these agreements, including its indemnification obligations, Organon could experience operational difficulties or losses.", -0.8], ["Organon may incur additional costs during the period of time before all necessary approvals are granted, which may affect Organon's business and result in additional costs in these markets.", -0.7], ["If Organon does not have its own systems and services in place, or if Organon does not have agreements with other providers of these services, when these agreements terminate, Organon may not be able to operate its business effectively and its profitability may decline.", -0.8], ["Organon may not be successful in effectively or efficiently implementing these systems and services or in transitioning data from Merck's systems to Organon's systems.", -0.7], ["These systems and services may also be more expensive or less efficient than the systems and services Merck is expected to provide during the transition period.", -0.6], ["Potential indemnification liabilities to Merck pursuant to the Separation and Distribution Agreement could adversely affect Organon.", -0.9], ["These indemnification liabilities are intended to ensure that, as between Merck and Organon, Organon is responsible for all liabilities it assumes in connection with the spinoff and that Organon pays for any liability incurred by Merck (including directors, officers, employees and agents) related to Organon's failure to satisfy such obligations or otherwise in respect of the operation of its business, or any breach by Organon of the Separation and Distribution Agreement or any ancillary agreement.", -0.8], ["Organon's indemnity obligations to Merck as set forth in the Separation and Distribution Agreement may be substantial.", -0.7], ["There could be significant income tax liability if the spinoff or certain related transactions are determined to be taxable for U.S. federal income tax purposes.", -0.9], ["If the spinoff is ultimately determined to be taxable, the spinoff could be treated as a taxable dividend to Merck's stockholders for U.S. federal income tax purposes, and Merck's stockholders could incur significant U.S. federal income tax liabilities.", -0.9], ["In addition, Merck would recognize a taxable gain to the extent that the fair market value of Organon Common Stock exceeds Merck's tax basis in such stock on the date of the spinoff.", -0.8], ["Each of Merck and Organon generally will be responsible for any tax-related losses imposed on Merck or Organon as a result of the failure of a transaction to qualify for tax-free treatment, to the extent that the failure to so qualify is attributable to actions, events or transactions relating to Merck's or Organon's respective stock, assets or business, or a breach of the relevant covenants made by Merck or Organon in the tax matters agreement.", -0.8], ["These restrictions may limit Organon's ability to pursue certain strategic transactions or other transactions that Organon may believe to be in the best interests of its stockholders or that might increase the value of Organon's business.", -0.8], ["In the event the spinoff fails to be tax-free as a result of such actions, Organon's indemnity obligation for Merck's tax liability under the tax matters agreement would be substantial and could materially affect its cash flow.", -0.9], ["The price and trading volume of Organon's Common Stock may be volatile, and stockholders could lose all or part of their investment in Organon.", -1.0], ["This volatility could negatively impact Organon's ability to raise additional capital or utilize equity as consideration in any acquisition transactions Organon may seek to pursue, and could make it more difficult for existing stockholders to sell their shares of the Common Stock at a price they consider acceptable or at all.", -0.9], ["•       Organon's liquidity and ability to obtain additional capital, including the market's reaction to any capital-raising transaction Organon may pursue;", -0.7], ["•       declining working capital to fund operations, or other signs of financial uncertainty;", -0.8], ["•       any negative decisions by the FDA or comparable regulatory bodies outside the United States regarding Organon's products and product candidates;", -0.9], ["•       sales of substantial amounts of Organon's Common Stock, or the perception that substantial amounts of Organon's Common Stock may be sold, by stockholders in the public market;", -0.8], ["•       significant advances made by competitors that adversely affect Organon's competitive position.", -0.9], ["This type of litigation, if instituted against Organon, could result in substantial costs and a diversion of its management's attention and resources.", -0.9], ["Organon cannot guarantee the timing, amount or payment of any dividends on the Common Stock.", -0.8], ["Organon currently expects that it will continue to pay quarterly cash dividends.", 0.5], ["Certain provisions in Organon's amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of Organon, which could decrease the trading price of the Common Stock.", -0.7], ["In addition, these limitations may adversely affect the prevailing market price and market for Organon's Common Stock if they are viewed as limiting the liquidity of its stock or discouraging takeover attempts in the future.", -0.9], ["Certain provisions of agreements that Organon entered into with Merck may limit Organon's ability to operate its business.", -0.8], ["It is possible that a court could find these exclusive forum provisions inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, and Organon may incur additional costs associated with resolving such matters in other jurisdictions, which could materially adversely affect Organon's business, financial condition and results of operations and result in a diversion of the time and resources of its management and board of directors.", -1.0], ["The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims.", -0.5], ["During the fourth quarter of 2022, Organon paid cash dividends of $0.28 per share.", 0.7], ["Such forward-looking statements include, but are not limited to, statements relating to Organon's growth and acquisition strategies, financial results, product development, product approvals, product potential and development programs.", 0.3], ["One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from Organon's forward-looking statements.", 0.0], ["No forward-looking statement can be guaranteed and actual future results may vary materially.", -0.8], ["•       difficulties with performance of third parties Organon relies on for its business growth;", -0.7], ["•       the increased cost of supply, manufacturing, packaging, and operations;", -0.7], ["•       difficulties and uncertainties inherent in the implementation of Organon's acquisition strategy or failure to recognize the benefits of such acquisitions;", -0.8], ["•       pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general;", -0.7], ["•       the impact of the global COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat on Organon's business, operations and financial performance;", -0.8], ["•       efficacy, safety or other quality concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales;", -0.8], ["•       delays or failures to demonstrate adequate efficacy and safety of Organon's product candidates in pre-clinical and clinical trials, which may prevent or delay the development, approval, clearance, or commercialization of Organon's product candidates;", -0.8], ["•       future actions of third-parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing health care insurance coverage;", -0.7], ["•       legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental claims and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;", -0.8], ["•       lost market opportunity resulting from delays and uncertainties in clinical trials and the approval or clearance process of the U.S. FDA and other regulatory authorities;", -0.8], ["However, these products continue to represent a valuable opportunity arising from long-term sustainable revenue streams and well-established supply chains that together generate significant operating profit relative to low promotional and development expenses.", 0.9], ["However, the LongActing Reversible Contraceptives (\"LARC\") market segment, which includes Nexplanon, has experienced significant growth in the decade from 2010 through to 2019, driven by a significant shift away from daily oral contraception to LARC.", 0.7], ["The COVID-19 pandemic negatively affected the LARC segment during 2021 and 2020 due to clinic closures and the postponement of non-essential medical procedures during country lockdowns.", -0.7], ["The LARC segment growth did begin to rebound in 2022 during months when clinic restrictions were removed.", 0.5], ["•       Increased Access to Fertility Solutions: We believe governments and payors are implementing favorable policies across major markets that, in turn, drive growth in the market for women's health therapies.", 0.8], ["For example, in the United States, there has been an increase in fertility insurance mandates and employer coverage, albeit subject to certain exemptions.", 0.6], ["•       Growing Acceptance of Biosimilars: Biologics continue to experience strong growth trends.", 0.7], ["Given the high cost of many of these biologics treatments, biosimilars are a more affordable alternative and represent a significant opportunity for patients, providers, and payors once a biologics product loses patent protection.", 0.8], ["Moreover, a significant number of biologics are expected to lose exclusivity over the next decade, representing a large opportunity for more biosimilar approvals.", 0.9], ["•       Increased Competitive Pressures: The markets in which we conduct our business and the pharmaceutical industry in general are highly competitive and highly regulated.", -0.5], ["In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.", 0.5], ["Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for pre-defined terms at a later date.", 0.2], ["The upfront payment will be expensed as Acquired in-process research and development and milestones in our statement of income in the first quarter of 2023.", -0.1], ["Under the terms of the research collaboration and license agreement, Organon recorded a $10 million upfront payment during 2022 as Acquired in-process research and development and milestones.", 0.1], ["Cirqle is eligible to receive potential regulatory and commercial milestone payments of up to $360 million and tiered royalties based on net sales.", 0.6], ["Under the terms of the license agreement, Organon paid a $73 million upfront payment during 2022, of which $3 million was reflected in Other current assets and the remainder was recognized as Acquired in-process research and development and milestones.", 0.1], ["Henlius is eligible to receive potential developmental, regulatory and commercial milestone payments of up to $468 million.", 0.6], ["During the year ended December 31, 2022, the Company paid an additional $27 million related to certain development milestones which were recognized as Acquired in-process research and development and milestones.", 0.1], ["The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.", 0.2], ["Under the terms of the license agreement, Organon paid a $10 million upfront payment during 2022.", -0.1], ["Daré is eligible to receive potential regulatory and commercial milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales.", 0.8], ["During the year ended December 31, 2022 management determined that the first commercial milestone was deemed probable of occurring, and recognized an intangible asset of $12.5 million reflecting the $10 million upfront payment and $2.5 million commercial milestone.", 0.3], ["In February 2022, Organon acquired the product rights and related inventory from Bayer AG to Marvelon and Mercilon, combined oral hormonal daily contraceptive pills, in China, including Hong Kong and Macau, and entered into an agreement to acquire the rights to these products in Vietnam.", 0.2], ["In 2022, Organon paid $95 million to acquire the product rights and inventory in China and Vietnam.", 0.1], ["COVID-19-related disruptions, including patients' inability to access health care providers, prioritization of COVID-19 patients, as well as social distancing measures have negatively affected our results during 2021 and 2022.", -0.9], ["Our product portfolio is comprised of physician prescribed products, mainly in established brands, which have been affected by social distancing measures and fewer medical visits.", -0.7], ["Additionally, our portfolio in women's health includes products that are physician administered, which have been affected by reduced access to physicians and health care centers.", -0.6], ["These impacts, as well as the prioritization of COVID-19 patients at health care providers, resulted in reduced administration of certain products within established brands particularly for respiratory and cardiovascular products and women's health products such as Nexplanon, as well as our fertility brands.", -0.8], ["During 2022, our business was impacted by lockdowns in selective cities across", -0.5], ["Due to the significant uncertainty that exists relative to the duration and overall impact of the COVID-19 pandemic resulting from resurgences in COVID-19 infections or new strains of the virus, our future operating performance, particularly in the short-term, may be subject to volatility.", -0.8], ["Worldwide sales were $6.2 billion for the year ended December 31, 2022, a decrease of 2% compared with 2021.", -0.2], ["Worldwide sales were negatively impacted by approximately 6%, or $383 million, due to unfavorable foreign exchange.", -0.6], ["Excluding foreign exchange, sales increases primarily reflect strong performance of Nexplanon due to favorable pricing and demand uptake in the United States as well as volume growth across Brazil, Latin America and the institutional business in Africa and strong volume growth for products within the established brands business, particularly for respiratory products Nasonex and Singulair primarily in Japan and China.", 0.5], ["Worldwide sales also reflected strong performance in biosimilar products mainly in the United States, resulting from the continued uptake of Renflexis in the United States and the strong performance of cardiovascular products, primarily Atozet, due to increased demand in France and Spain.", 0.6], ["This performance was partially offset by declines due to the generic competition for women's health product NuvaRing and the authorized generic etonogestrel/ethinyl estradiol vaginal ring in the United States and unfavorable discount rates and lower volume growth in the United States related to Dulera.", -0.3], ["The loss of exclusivity (\"LOE\") negatively impacted sales by approximately $30 million during the year ended December 31, 2022, compared to the year ended December 31, 2021, based on the decrease in volume period over period, mainly impacting NuvaRing in the United States.", -0.7], ["Volume-based procurement (\"VBP\") in China had a $20 million negative impact on sales during the year ended December 31, 2022, compared to the year ended December 31, 2021.", -0.7], ["Organon expects VBP to impact the Company's established brands product portfolio for the next several quarters.", -0.5], ["Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, increased 8% for the year ended December 31, 2022 compared to 2021, primarily due to the impact of favorable pricing and demand uptake in the United States, the favorable impact from the timing of tenders in Brazil and Latin America and volume growth from the institutional business in Africa.", 0.7], ["Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 9% for the year ended December 31, 2022, compared to 2021, due to ongoing generic competition in the United States.", -0.7], ["We expect a continued decline in NuvaRing sales as a result of generic competition.", -0.8], ["Under the terms of the agreement, our share in the profits declines over time as new participants enter the market.", -0.6], ["The decline in revenue for the year ended December 31, 2022, is due to the entry of a new market participant.", -0.7], ["Worldwide sales of Marvelon and Mercilon, combined oral hormonal daily contraceptive pills not approved or marketed in the United States but available in certain countries outside the United States, increased 12% for the year ended December 31, 2022, compared to 2021 as a result of the recent transaction with Bayer Healthcare where Organon gained full rights in the China and Vietnam markets.", 0.8], ["Worldwide sales of Follistim AQ® (marketed in most countries outside the United States as Puregon), a fertility treatment, declined 3% for the year ended December 31, 2022 compared to 2021, as continuous demand growth in the United States and China was offset by the unfavorable impact of foreign exchange and the negative impact of COVID in China.", -0.3], ["Worldwide sales of Ganirelix Acetate Injection (marketed in certain countries outside the United States as Orgalutran), a fertility treatment, increased 11% for the year ended December 31, 2022, compared to 2021, driven by demand uptake in the international markets.", 0.7], ["Sales growth of 21% for the year ended December 31, 2022, was driven primarily by continued demand growth, favorable channel mix and favorable discount rates in the United States.", 0.9], ["Sales in the year ended December 31, 2022 declined 4%, driven by the competitive pressures in Europe and the unfavorable impact of foreign exchange offset by the continued uptake in the United States since its launch in July 2020.", -0.4], ["Sales in the year ended December 31, 2022 increased 19%, primarily driven by volume growth in Canada.", 0.9], ["We recorded sales of $19 million during the year ended December 31, 2022, reflecting an increase of 51% from modest sales during the year ended December 31, 2021 in markets outside of the US.", -0.1], ["Combined global sales of Zetia (marketed in most countries outside of the United States as Ezetrol) and Vytorin (marketed outside of the United States as Inegy), medicines for lowering LDL cholesterol, declined 10% for the year ended December 31, 2022, compared to 2021, primarily driven by increased competition, lower performance in Europe, the impact of VBP in China and the unfavorable impact of foreign exchange offset by increased demand resulting from competitors' supply disruptions in Japan and growing demand in China across retail and public sectors.", -0.5], ["Sales of Atozet, a medicine for lowering LDL cholesterol, remained consistent for the year ended December 31, 2022, compared to 2021, primarily due to increased demand in France and Spain offset by the unfavorable impact of foreign exchange.", 0.0], ["Sales of Rosuzet, a medicine for lowering LDL cholesterol, increased 5% for the year ended December 31, 2022, compared to 2021, primarily due to higher demand in Japan partially offset by the impact of foreign exchange.", 0.1], ["Combined global sales of Cozaar, and Hyzaar (a combination of losartan potassium and hydrochlorothiazide that is marketed in Japan as Preminent™1), a medicine for the treatment of hypertension, declined 10% for the year ended December 31, 2022, compared to 2021, primarily due to lower volume growth in Japan and China and the unfavorable impact of foreign exchange.", -0.5], ["Worldwide sales of Singulair, a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, declined 1% for the year ended December 31, 2022, compared to 2021, primarily attributable the unfavorable impact of foreign exchange offset by volume recovery from the COVID-19 pandemic and demand resulting from competitors' supply disruptions in Japan.", -0.1], ["Global sales of Nasonex, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 16% during the year ended December 31, 2022, primarily driven by higher demand resulting from competitors' supply disruptions in Japan and increased demand across several markets, partially offset by the unfavorable impact of foreign exchange.", 0.3], ["In addition, sales during the year ended December 31, 2022 included a $10 million milestone payment related to a regulatory approval in the United States.", 0.2], ["Global sales of Dulera, a combination medicine for the treatment of asthma, declined 5% for the year ended December 31, 2022, compared to 2021, primarily due to lower volume growth in the United States.", -0.3], ["Sales of Arcoxia, a medicine for the treatment of arthritis and pain, declined 1% during the year ended December 31, 2022 compared to 2021, primarily due to the unfavorable impact of foreign exchange offset by higher demand in China and the South East Asia region.", -0.1], ["Worldwide sales of Proscar, a medicine for the treatment of symptomatic benign prostate enlargement, declined 14% for the year ended December 31, 2022, compared to 2021, primarily due to lower demand in China and the unfavorable impact of foreign exchange.", -0.7], ["Cost of sales decreased 4% compared to the same period in 2021, primarily due to the impact of lower supply sales compared to the prior year, pre-spin allocated costs related to the Separation in the prior year and a $24 million charge pertaining to unavoidable losses associated with a long-term vendor supply contract incurred during the prior year, offset by inventory charges of $36 million relating to a regulatory inspection finding at the Heist manufacturing location which impacts selected injectable steroids brands.", -0.2], ["During the year ended December 31, 2022 and 2021, the Company recorded impairment charges of $9 million and $7 million, respectively, related to a product right for a biosimilar product.", -0.5], ["Selling, general and administrative expenses increased 2% for the year ended December 31, 2022 due to selling and promotional costs related to our women's health portfolio, including costs related to our recent acquisitions, partially offset by pre-spin allocated costs related to the Separation during the prior year which were not incurred during the year ended December 31, 2022.", -0.1], ["Research and development expenses increased 39% for the year ended December 31, 2022, primarily due to higher costs associated with the Company's recent acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.", 0.1], ["The restructuring charges primarily relate to targeted reduction in headcount in selective territories outside of the U.S. in our commercial organizations.", -0.6], ["For the year ended December 31, 2022, the Company incurred $28 million related to headcount related restructuring activities.", -0.4], ["For the year ended December 31, 2022, interest expense increased, due to the $9.5 billion of debt, which was incurred by the Company during the second quarter of 2021, increased interest rates and the impact of exchange rates.", -0.8], ["For the year ended December 31, 2022, the change in exchanges losses (gains) was driven by the exchange rate impact on the portion of Eurodenominated debt not designated as a net investment hedge and the fluctuations in foreign exchange.", -0.3], ["Therefore, for the year ended December 31, 2021, we reflected a $29 million net tax benefit.", 0.2], ["This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.", -0.1], ["The Company has historically generated and expects to continue to generate positive cash flow from operations.", 0.8], ["The increase in working capital of continuing operations was primarily driven by a decrease in trade accounts payable.", 0.2], ["Net cash provided by operating activities was $858 million for the year ended December 31, 2022 compared to $2.2 billion for the same period in the prior year.", -0.3], ["The decrease in cash provided by operating activities in 2022 was primarily attributable to the decrease in trade payables, including balances with Merck.", -0.5], ["Net cash used in investing activities was $420 million for the year ended December 31, 2022 compared to $481 million for the same period in the prior year, primarily reflecting the asset acquisition of Marvelon and Mercilon and licensing agreements with Daré, Henlius and Cirqle in the year ended December 31, 2022 and the asset acquisitions of Alydia Health and Forendo Pharma and the ebopiprant license in the year ended December 31, 2021.", -0.2], ["Net cash used in financing activities was $433 million for the year ended December 31, 2022 compared to $977 million for the same period in the prior year.", 0.1], ["Capital expenditures were $196 million and $192 million for the years ended December 31, 2022 and 2021, respectively.", 0.0], ["In 2022, the armed conflict between Ukraine and Russia escalated, which may adversely impact Organon's business.", -0.8], ["Specifically, trade sanctions, travel bans and asset and financial freezes announced by the United States, European Union and other countries against Russian entities and designated individuals, as well as counter-measures announced by Russia, have impacted and may continue to impact many global businesses in direct and indirect ways (including, but not limited to, product shipping delays, supply shortages, delays in regulatory approvals and audits, constraints in energy supply, currency exchange rates and exchange controls).", -0.7], ["Such actions may negatively impact the financial institutions, vendors, manufacturers, suppliers, partners and other third parties with whom Organon conducts business.", -0.8], ["Organon will continue to monitor the impacts of the conflict, which may negatively impact Organon's operations, financial position or cash flows.", -0.7], ["As of December 31, 2022, total potential payments due for contractual milestones are $2.4 billion.", 0.1], ["Organon is responsible for settlement of certain tax matters, of which the Company expects to pay approximately $19 million within the next year.", -0.2], ["During 2022, Organon paid cash dividends of $1.12 per share.", 0.3], ["On February 16, 2023, the Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the Company's common stock.", 0.5], ["The accrued balances relative to these provisions included in accounts receivable and accrued and other current liabilities were $78 million and $307 million, respectively, at December 31, 2022, $54 million and $275 million, respectively, at December 31, 2021 and $41 million and $302 million, respectively, at December 31, 2020.", 0.0], ["Expenditures for remediation and environmental liabilities were $4 million in 2022, and are estimated at $16 million in the aggregate for the years 2023 through 2027.", -0.3], ["In management's opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $20 million and $24 million at December 31, 2022 and 2021, respectively.", -0.1], ["The judgments made in evaluating impairment of long-lived intangibles can materially affect our results of operations.", -0.6]], "ogn23_sentences.json": [["The aggregate market value of the voting common equity held by non-affiliates of the registrant, computed by reference to the closing price at which the Common Stock was sold as of the end of the second fiscal quarter ended June 30, 2023, was $5.3 billion.", -0.1], ["A number of our established brands lost exclusivity years ago and have faced generic competition for some time.", -0.7], ["Led by the women's health portfolio, coupled with an expanding biosimilars business and stable franchise of established medicines, our products produce sufficient cash flows to support investments in innovation and future growth opportunities in women's health.", 0.8], ["In 2023, we recorded revenues of $6.3 billion.", 0.2], ["We operate on a global scale and our global network enables us to distribute products to patients in more than 140 countries and territories, with approximately 76% of 2023 revenues, or $4.8 billion, generated outside the United States.", 0.5], ["In 2023, our women's health portfolio accounted for $1.7 billion, or approximately 27%, of our total revenues, with $805 million, or approximately 47%, generated outside the United States.", 0.3], ["Marvelon and Mercilon are not approved or marketed in the United States but are available in certain countries outside the United States, including in China and Vietnam as a result of the transaction with Bayer Healthcare in which we gained rights to Marvelon and Mercilon in these markets.", 0.1], ["We acquired Jada as part of our acquisition of Alydia Health in June 2021.", 0.0], ["We launched Xaciato in the United States in the fourth quarter of 2023, and currently plan to assess opportunities to seek potential further marketing authorizations for countries outside the United States.", 0.4], ["In 2023, our biosimilars portfolio accounted for $593 million, or approximately 9%, of our total revenues, with $295 million, or approximately 50%, generated outside the United States.", 0.3], ["The assets in our biosimilars portfolio, coupled with our commercial experience in biosimilars, provide an opportunity to benefit from future growth anticipated in this area.", 0.8], ["Our established brands portfolio contributed approximately $3.8 billion of our total revenues in 2023, with approximately 93%, or $3.6 billion, generated outside the United States.", 0.5], ["In 2023, our cardiovascular portfolio accounted for $1.5 billion, or approximately 23%, of our total revenues, nearly all of which were generated outside the United States.", 0.5], ["In 2023, our respiratory portfolio accounted for $1.1 billion, or approximately 17% of our total revenues, with approximately 79%, or $843 million, generated outside the United States.", 0.5], ["In 2023, our dermatology, bone health and non-opioid pain management portfolios accounted for $782 million, or approximately 12%, of our total revenues, nearly all of which were generated outside the United States.", 0.5], ["Proscar, used for the treatment of symptomatic benign prostatic hyperplasia (\"BPH\") in men with an enlarged prostate, accounted for $97 million of revenues in 2023.", 0.2], ["In addition, Propecia, used for the treatment of male pattern hair loss, accounted for $125 million of revenues in 2023.", 0.2], ["We obtained exclusive worldwide rights to develop and commercialize the product.", 0.7], ["In December 2021, we also signed a supplemental license with Merck that provides a limited expansion of the fields in which it may use the underlying technology of Nexplanon / Implanon NXT beyond contraception in exchange for milestone payments.", 0.3], ["While the expiration of a product patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from, for example: (i) later-granted patents on processes and intermediates related to the most economical method of manufacture of the active ingredient of such product; (ii) patents relating to the use or delivery of such product; and (iii) patents relating to novel compositions and formulations.", -0.2], ["Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products.", -0.2], ["Royalty income in 2023 on patent and know-how licenses and other rights amounted to $6 million.", 0.2], ["We also incurred royalty expenses totaling $6 million in 2023 under patent and know-how licenses we hold.", -0.1], ["These changing requirements could cause us to incur substantial costs or require us to change our business practices or compliance procedures in a manner adverse to our business.", -0.8], ["Our operations may be adversely affected by generic and biosimilar competition as our products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors' branded products and new information from clinical trials of marketed products or postmarketing surveillance.", -0.9], ["An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.", -0.9], ["Competitive pressures continue to intensify as the industry grows.", -0.5], ["As the United States payor market further concentrates, and as more drugs become available in generic form, pharmaceutical companies may face greater pricing pressure from private third-party payors.", -0.7], ["We face increasing pricing pressure globally from managed care organizations and government agencies and programs.", -0.7], ["This pricing pressure could negatively affect our sales and profit margins.", -0.8], ["In the United States, we are impacted by expanded Medicaid rebates, Medicaid-managed care utilization, and increases in the types of entities eligible for the federal 340B drug discount program.", -0.5], ["Increases in these percentages or changes in the timing of their implementation could increase our cost-sharing responsibility for any approved product.", -0.7], ["We recorded approximately $15 million, $16 million and $17 million revenue reduction in 2023, 2022 and 2021, respectively.", -0.6], ["We recorded approximately $3 million, $3 million and $10 million of costs within selling, general and administrative expenses in 2023, 2022 and 2021, respectively, for the annual health care reform fee.", -0.6], ["In the future, our drugs could be subject to a higher Medicaid rebate liability.", -0.8], ["The downward pressure on health care costs in general, particularly prescription drugs, has intensified.", -0.9], ["In Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products.", -0.7], ["Furthermore, the government can order re-pricings for specific products if it determines that use of such products will exceed certain thresholds defined under applicable re-pricing rules.", -0.7], ["Our business in China has grown rapidly in the past few years, and the importance of China to our overall pharmaceutical business has increased accordingly.", 0.5], ["In recent years, the Chinese government has introduced and implemented several structural reforms to accelerate the shift to innovative products and reduce costs.", 0.3], ["The Chinese government updated the National Reimbursement Drug List (\"NRDL\") for the governmentadministered insurance plans; however, every two years regular access to the NRDL is coupled with significant price reductions and price reviews for NRDL products.", -0.2], ["Mature products that have entered into the first nine rounds of VBP have had, on average, a price reduction of over 50%.", -0.5], ["has been a roughly semi-annual process that will have a significant impact on mature products moving forward, which we expect to increase pricing pressure on our products in China.", -0.4], ["Under the URPS, the government may determine the reimbursement prices by referring to the prices of the lowest-priced VBP winning products, with any remaining costs then passed along to the patients in the form of a co-pay, which reduces the affordability of certain products with prices that exceed the lowest-priced VBP-winning products.", -0.6], ["The URPS policy will create additional pricing and volume pressure for pharmaceutical products that are subject to the program and may adversely affect our business and results of operations.", -0.7], ["The campaign caused disruptions to academic activities across the health care industry, which negatively affected our business in late 2023.", -0.8], ["Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors, to comply with laws governing the conduct of clinical trials, manufacturing approval, marketing authorization of pharmaceutical products and marketing of such products, both before and after grant of marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements, may result in administrative, civil or criminal penalties.", -0.9], ["These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.", -0.9], ["Companies may be subject to civil, criminal or administrative sanctions if they fail to comply with these practices.", -0.8], ["Expenditures for remediation and environmental liabilities are estimated to be approximately $15 million in the aggregate for the years 2024 through 2028.", -0.5], ["The Samsung Bioepis Agreement provides that gross profits are shared equally in all markets except for certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to us.", -0.1], ["Any of the following risks could materially and adversely affect our results of operations, financial condition and the price of our Common Stock.", -0.9], ["The following is a summary of the principal risks that could significantly and negatively affect our business, prospects, financial conditions, or operating results.", -0.9], ["•       Key products generate a significant amount of our profits and cash flows, and any events that adversely affect the markets for our leading products could adversely affect our results of operations and financial condition.", -0.8], ["•       We face continued pricing pressure with respect to our products.", -0.7], ["•       We face intense competition from competitors' products.", -0.7], ["•       We have limited in-house discovery and early research capabilities and will continue to rely on future acquisitions, partnerships and collaborations to expand our innovative pipeline and early discovery and research capabilities, which may limit our ability to discover or develop new products or expand our existing products into new markets to replace the sales of products that lose patent protection and therefore we may not be able to maintain our current levels of profitability.", -0.8], ["•       Our growth could be limited by the scope of our intellectual property licenses for certain women's health care products.", -0.7], ["•       We may experience difficulties identifying acquisition opportunities or completing such transactions.", -0.7], ["•       Developments following regulatory approval or marketing authorization may adversely affect sales of our pharmaceutical products or medical devices.", -0.8], ["•       Issues with product quality could have an adverse effect on our business or cause a loss of customer confidence in us or our products, among other negative consequences.", -0.9], ["When the patent protection and market exclusivity periods for such products expire, a significant and rapid loss of sales from those products is generally experienced.", -0.8], ["Expiry of patent protection and market exclusivity for products that contribute significantly to our sales will adversely affect our business.", -0.9], ["•       We depend on our patent rights for the marketing of certain of our products, and invalidation or circumvention of our patent rights would adversely affect our business.", -0.8], ["•       We have incurred substantial indebtedness, which could adversely affect our financial condition and results of operations.", -0.9], ["•       We are subject to minimum purchase obligations under certain supply agreements, and if we fail to meet those minimum purchase requirements, our financial results may be unfavorably impacted.", -0.8], ["•       Potential indemnification liabilities to Merck pursuant to the Separation and Distribution Agreement could adversely affect us.", -0.8], ["•       There could be significant income tax liability to us if the spinoff or certain related transactions are determined to be taxable for U.S.", -0.7], ["•       The price and trading volume of our Common Stock may be volatile, and stockholders could lose all or part of their investment.", -0.9], ["•       Certain provisions in our amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of Organon, which could decrease the trading price of our Common Stock.", -0.7], ["Key products generate a significant amount of our profits and cash flows, and any events that adversely affect the markets for our leading products could adversely affect our results of operations and financial condition.", -0.8], ["As a result of our dependence on key products, any event that adversely affects any of these products or the markets for any of these products could adversely affect our sales, results of operations or cash flows.", -0.8], ["These adverse events could include increased costs associated with manufacturing, product shortages, increased generic or over-the-counter availability of our products or competitive products, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of these products for any reason.", -0.9], ["We also expect that competition will continue to adversely affect the sales of these products.", -0.9], ["We face continued pricing pressure with respect to our products.", -0.8], ["We face continued pricing pressure in the United States and globally and, particularly in the EU, the UK, China and Japan, from managed care organizations, government agencies and programs that could adversely affect our sales and profit margins.", -0.8], ["We expect pricing pressure to continue in the future.", -0.7], ["Our products face intense competition from competitors' products, including lower cost generic versions of our products that have lost market exclusivity.", -0.8], ["Competitors' products may be equally safe and as effective as our products but sold at a substantially lower price than our products.", -0.7], ["Alternatively, our competitors' products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than our products.", -0.7], ["Our efforts to compete with other companies or our failure to maintain our competitive position could adversely affect our business, cash flow, results of operations, financial condition or prospects.", -1.0], ["We have limited in-house discovery and early research capabilities and will continue to rely on future acquisitions, partnerships and collaborations to expand our innovative pipeline and early discovery and research capabilities, which may limit our ability to discover or develop new products or expand our existing products into new markets to replace the sales of products that lose patent protection, and therefore we may not be able to maintain our current levels of profitability.", -1.0], ["Our growth could be limited by the scope of our intellectual property licenses for certain women's health care products.", -0.8], ["However, we expect that our ability to do so could be limited by the scope of our limited intellectual property licenses for certain women's health products.", -0.8], ["Additionally, in December 2021, we signed a supplemental license with Merck that provides a limited expansion of the fields in which we may use the underlying technology of Nexplanon beyond contraception in exchange for milestone payments.", 0.2], ["We may not be able to offset any sales losses for products that lose or do not have exclusivity by growing sales in other markets.", -1.0], ["If we cannot produce sufficient revenues from expansion into new products, new indications or formulations of our existing products or expansion of existing products into new markets or new geographies, then we may not be able to maintain our current levels of profitability, and this could adversely affect our business, cash flow, results of operations, financial condition or prospects.", -1.0], ["Our failures, or the failure of third parties, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions.", -1.0], ["Further, issues related to manufacture of product, preclinical testing, and/or clinical testing may affect our ability to obtain or maintain marketing approval for our products in a timely manner, or at all.", -1.0], ["This may hinder or delay efforts to successfully commercialize our product candidates.", -1.0], ["We may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the expected benefits of any acquisition, license arrangement or strategic partnerships.", -0.8], ["Even if we are successful in making acquisitions, the products and technologies we acquire may not be successful or may require significantly greater resources and investments than we originally anticipated.", -0.7], ["We could experience negative effects on our results of operations and financial condition from acquisition-related charges, amortization of intangible assets and asset impairment charges.", -0.9], ["If an acquired business fails to operate as anticipated or cannot be successfully integrated with our existing business, our business, financial condition, results of operations or cash flows could be materially and adversely affected.", -0.9], ["Our failure to obtain approval or marketing authorization, significant delays in the approval or marketing authorization process or our failure to maintain approval or marketing authorization in any jurisdiction will prevent us from selling the products in that jurisdiction.", -0.9], ["We would not be able to realize revenues for our pharmaceutical products or medical devices in any jurisdiction where we do not have required approval or marketing authorization.", -0.8], ["We or our partners may fail to adequately demonstrate the safety and efficacy of any of our pharmaceutical product candidates or medical devices in pre-clinical studies and clinical trials, which would prevent or delay development, regulatory approval or marketing authorization and commercialization of our product candidates.", -0.8], ["Accordingly, there is a high risk of failure and we may never succeed in obtaining regulatory approval or marketing authorization of our product candidates.", -0.9], ["We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of regulatory approval or marketing authorization, or our ability to commercialize our product candidates, including for example, issues with study execution including timely access to study drugs; inability to recruit and enroll study subjects; failure of our product candidates in pre-clinical studies or clinical trials to demonstrate safety and efficacy; receipt of feedback from the FDA or other regulatory authorities that require us to modify the design of our clinical trials; and negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain research and/or development programs.", -0.9], ["We may be required to conduct additional pre-clinical studies, clinical trials or other testing of our product candidates beyond those that we currently contemplate, or we may be unable to successfully complete pre-clinical studies or clinical trials of our product candidates or other testing in a timely manner.", -0.8], ["If the results of these studies, trials or tests are not positive (or are only modestly positive), or if there are safety concerns, we may incur unplanned costs, as well as delays in our efforts to obtain regulatory approval or marketing authorization.", -0.8], ["Even if we receive such approval, we may be more limited or restrictive than anticipated, or be subject to additional post-marketing testing requirements.", -0.7], ["Developments following regulatory approval or marketing authorization may adversely affect sales of our pharmaceutical products or medical devices.", -0.9], ["Failure to comply with any of these requirements could subject us to a variety of formal or informal enforcement actions by the FDA or other regulators, result in a recall or market withdrawal of our products, require us to cease manufacturing and distribution of the products, trigger product liability or other litigation, or otherwise impact our ability to realize revenues for our products.", -1.0], ["As previously disclosed, we voluntarily initiated market actions, including recalls, in certain markets with respect to our suspension injections Diprospan, Celestone, ChronodoseTM 1 (betamethasone), and Celestone Soluspan® (betamethasone) related to a non-conforming component of a manufacturing line at our Heist, Belgium plant.", -0.8], ["It is possible that future recalls or similar developments could materially and adversely impact our business, result of operations, and financial condition.", -0.9], ["Likewise, if previously unknown side effects, adverse events, malfunctions or other quality or safety concerns are discovered or if there is an increase in negative publicity regarding known side effects of any of our products, it could significantly reduce demand for the product or require us to take actions that could negatively affect sales, including initiating corrections of a marketed product or removing the product from the market, restricting our distribution of the product or applying for marketing authorization for labeling changes.", -0.9], ["Further, we are at risk for product liability and consumer protection claims and civil and criminal governmental actions related to our products, research and marketing activities.", -0.8], ["•       negative results in post-approval Phase 4 trials or other studies;", -0.9], ["•       the recall, loss or modification of regulatory approval or marketing authorization of products that are already marketed; and", -0.9], ["Issues with product quality could have an adverse effect on our business or cause a loss of customer confidence in us or our products, among other negative consequences.", -1.0], ["While we have a quality system that covers the lifecycle of our products, quality and safety issues have and may in the future occur with respect to our products.", -0.8], ["A quality or safety issue may result in adverse inspection reports, voluntary or official action indicated, warning letters, import bans, product recalls (either voluntary or required by FDA or similar governmental authorities in other countries) or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions (which may include corporate integrity agreements), costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses.", -1.0], ["An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity or a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.", -1.0], ["When the patent protection and market exclusivity periods for such products expire, a significant and rapid loss of sales from those products is generally experienced.", -0.9], ["Expiry of patent protection and market exclusivity for products that contribute significantly to our sales will adversely affect our business.", -1.0], ["Loss of patent protection typically leads to a significant and rapid loss of sales for that product where lower priced generic versions of that drug or other competitors become available.", -0.9], ["In the case of current or future products that contribute significantly to our sales, a loss of market exclusivity could materially adversely affect our business, cash flow, results of operations, financial condition or prospects.", -1.0], ["We depend on our patent rights for the marketing of certain of our products, and invalidation or circumvention of our patent rights would adversely affect our business.", -1.0], ["Patents covering products that we have introduced normally provide market exclusivity, which is important for the successful marketing and sale of certain of our products.", 0.2], ["Patent litigation and other challenges to our patents are costly and unpredictable and may deprive us of market exclusivity for a patented product or, in some cases, thirdparty patents may prevent us from marketing and selling a product in a particular geographic area, negatively affecting our business and results of operations.", -1], ["Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect our business and results of operations.", -1], ["If one or more of our important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available.", -1], ["Our results of operations may be adversely affected by the lost sales unless and until we have launched commercially successful products that replace the lost sales.", -1], ["In addition, if products with intangible assets that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, we may recognize material non-cash impairment charges with respect to the value of those products.", -1], ["We have incurred substantial indebtedness, which could adversely affect our financial condition and results of operations.", -1], ["Current or future levels of indebtedness may increase the possibility that we will be unable to generate cash sufficient to pay amounts due in respect of such indebtedness.", -1], ["Our ability to issue additional debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products, if our customers or suppliers are unable to pay amounts due to us or there are other significantly unfavorable changes in economic conditions.", -1], ["Volatility in the world financial markets could increase borrowing costs or affect our ability to access the capital markets.", -1], ["These conditions may adversely affect our ability to obtain and maintain our credit ratings.", -1], ["We are subject to minimum purchase obligations under certain supply agreements, and if we fail to meet those minimum purchase requirements, our financial results may be unfavorably impacted.", -0.8], ["If we are unable to offset these payments, it could result in a lower margin.", -0.7], ["During the year ended December 31, 2022 and 2021, we recognized $5 million and $24 million, respectively, in Cost of Sales pertaining to estimated unavoidable losses associated with a long-term vendor supply contract conveyed as part of the spinoff.", -0.5], ["We do not currently expect these payments to be material; however, in the aggregate they may become material if additional amounts are identified in the future, and they could have a material adverse effect on our financial condition, results of operations or cash flows.", -0.9], ["Changes to the health care system enacted as part of health care reform in the United States, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid and private sector beneficiaries, could result in further pricing pressures.", -0.6], ["As an example, health care reform has contributed to an increase in the number of patients in the Medicaid program under which sales of pharmaceutical products are subject to substantial rebates.", -0.4], ["The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect our business, cash flow, results of operations, financial condition or prospects.", -0.8], ["Recent years have seen substantial increase in the global enforcement of anti-corruption laws.", -0.3], ["The failure to comply with the FCPA and similar such laws could result in civil or criminal sanctions or other adverse consequences.", -0.7], ["Enforcement activities under the laws and regulations described above may subject us to administrative and legal proceedings and actions, which could result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, preclusion from participating in public tenders, breach of contract and fraud litigation, reputational harm, and other consequences.", -0.9], ["We have significant global operations, which expose us to additional risks, and any adverse event could adversely affect our results of operations and financial condition.", -0.9], ["For example, in 2023, we generated $4.8 billion in revenues outside the United States, representing approximately 76% of our total revenues.", 0.5], ["As a result of global economic conditions, some parties may delay or be unable to satisfy their payment or reimbursement obligations.", -0.8], ["In addition, patients' ability to afford health care may also be affected by job losses or other economic hardships, increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, and lost health care insurance coverage.", -0.7], ["Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs, as well as increased costs of materials, products, and commodities upon which we rely.", -0.9], ["As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.", -0.9], ["In February 2022, in response to the armed conflict between Ukraine and Russia, trade sanctions, travel bans and asset/financial freezes were announced by the United States, European Union and other countries against Russian entities and designated individual restrictions have impacted, and may continue to impact, many global businesses in direct and indirect ways (including, but not limited to, product shipping delays, supply shortages, delays in regulatory approvals and audits and currency exchange rates).", -0.8], ["Such actions may negatively impact the financial institutions, vendors, manufacturers, suppliers, partners and other third parties with whom we conduct business and therefore may negatively impact us.", -0.8], ["Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results.", -0.9], ["Disruption, degradation, destruction or manipulation of these IT systems through intentional or accidental means by our employees, third parties with authorized access or cyber threat actors could adversely affect key business processes.", -0.9], ["In addition, we and our third-party providers have experienced and expect to continue to experience phishing attempts, scanning attempts of our network, and other attempts of unauthorized access to our computer environment.", -0.8], ["These attacks could lead to loss of confidentiality, integrity and/or availability of our data, applications or systems.", -0.9], ["A breach of our IT systems or our third-party providers' IT systems, such as cloud-based systems, or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud, trickery, other forms of deception, or any other cause, could enable others to produce competing products, use our proprietary technology or information, and/or adversely affect our business position.", -1.0], ["Further, any such interruption, security breach, or loss, misappropriation, and/or unauthorized access, use or disclosure of confidential information, including personal information regarding our patients and employees, or the modification of critical data, could result in financial, legal, business, and reputational harm to us, including loss of revenue, loss of critical or sensitive information from our or our third-party providers' databases or IT systems, and substantial remediation and recovery costs.", -0.9], ["We may experience difficulties or delays, or incur unforeseen expenses in connection with the manufacturing certain of our products.", -0.7], ["We or our suppliers and other manufacturing partners may experience difficulties or delays in connection with manufacturing our products that may lead to increased costs, such as: failure to comply with applicable regulations and quality assurance guidelines; delays related to the construction of new facilities or the expansion of existing facilities; delays related to the supply of key ingredients or other components of our products; increased costs of key materials, packaging, or operational procedures; difficulties obtaining materials of adequate quality and quantity and other manufacturing or distribution problems, including, but not limited to, changes in manufacturing production sites and limits to manufacturing capacity resulting from regulatory requirements and changes in types of products produced and physical limitations that could impact supply.", -0.8], ["Any of the foregoing could result in product shortages, lost sales, government agency actions, and reputational harm to us, which could have a material adverse effect on our business, results of operations, and financial condition.", -0.9], ["We may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or we may experience other supply difficulties that could adversely affect both our ability to deliver our products and our results of operations and financial condition.", -0.8], ["Further, if we do seek recovery or damages from such supplier for any supply shortages or disruptions, such recovery or damages may be limited and not include indirect or consequential losses or any loss of revenue or lost profits.", -0.8], ["Our ability to achieve continuity of our supply may also be affected by public health crises and epidemics/pandemics.", -0.7], ["A reduction or interruption in supply and an inability to quickly develop acceptable alternative sources for such supply could adversely affect our ability to manufacture and distribute our products in a timely or cost-effective manner, negatively impacting our ability to sell our products.", -1.0], ["In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and we cannot offset the devaluations, our financial performance within such countries could be adversely affected.", -1.0], ["For example, our business in China is growing, and China is now our second largest market, thereby increasing the importance of China to our overall pharmaceutical business.", 0.5], ["Continued growth of our business in China depends upon ongoing development of a favorable regulatory environment, sustained availability of our currently marketed products within China, and our ability to mitigate the impact of any trade impediments or adverse pricing controls.", 0.0], ["These programs regularly reduce the price and/or reimbursement rate for drugs by over 50%.", -0.5], ["These and other such programs could adversely affect our business in China.", -1.0], ["If these trends and the related changes to the requirements for development, importation, registration, distribution, and manufacturing of our drugs disrupt our business model that would adversely affect our business in China.", -1.0], ["A failure to make such pivot effectively, or a failure to develop and maintain a presence in China or emerging markets could adversely affect our business, cash flow, results of operations, financial condition or prospects.", -1.0], ["Current market conditions and recessionary pressures in one or more of our markets could impact our ability to grow our business.", -1.0], ["Any negative impact on economic conditions and international markets, continued volatility or deterioration in the capital markets, inflation, deflation or other adverse economic conditions may limit our ability to replace maturing liabilities and to access the capital markets to meet liquidity needs, which could have a material adverse effect on our financial condition and results of operations.", -1.0], ["If our customers' financial conditions are adversely affected, those customers may reduce their purchases of our products or we may not be able to collect accounts receivable, each of which could have a material adverse impact on our business operations or financial results, and we may not be able to fully absorb any such additional costs or revenue declines in the prices for our products and services.", -1], ["This, in turn, may result in the loss of confidence in our products' reputation and integrity, and potentially impact our business through lost sales, product recalls, and possible litigation.", -1], ["Inflation could materially adversely affect our business and operations.", -1], ["Our operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors that impact our cost structure and revenue results.", -1], ["Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the war in Ukraine, and steps taken by governments and central banks, as well as other stimulus and spending programs, have led to higher inflation, which is likely to lead to an increase in costs and may cause changes in fiscal and monetary policy, including increased interest rates.", -1], ["In a higher inflationary environment, we may be unable to raise the prices of our products and services sufficiently to keep up with the rate of inflation.", -1], ["We are exposed to market risk from fluctuations in currency exchange rates and interest rates.", -1], ["Since we cannot, with certainty, foresee and mitigate against such adverse fluctuations in currency exchange rates, interest rates and inflation could negatively affect our business, cash flow, results of operations, financial condition or prospects.", -1], ["While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.", -1], ["As a result, currency fluctuations among our reporting currency, the U.S. dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways.", -1], ["Reliance on third-party relationships and outsourcing arrangements could materially adversely affect our business.", -1], ["Failure of these third parties to meet their contractual, regulatory and other obligations to us or the development of factors that materially disrupt the relationships between us and these third parties could adversely affect our business.", -1], ["Cyberattacks affecting our IT systems could result in exposure of confidential information, the modification of critical data or the disruption of our worldwide operations, including manufacturing and sales operations,\" for a description of additional risks relating to our third-party providers that collect, store and transmit large amounts of confidential information.", -1], ["If we are unable to successfully commercialize and create a significant market for our women's health products, our business or prospects could be harmed.", -1], ["Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, customers, and other business partners, which could cause disruption in our business and operations or increase costs to operate our business.", -1], ["Additionally, increased environmental, social and governance regulations, including to address climate change, may result in increases in our costs to operate our business or restrict certain aspects of our activities.", -1], ["Additional potential effects of climate change to our business could include increased operating costs due to additional regulatory requirements, changes in supply and suppliers due to regulatory requirements, water limitations and disruptions to our supply chain.", -1], ["Biosimilars carry unique regulatory risks and uncertainties, which could adversely affect our results of operations and financial condition.", -1], ["Any changes to the regulatory framework governing biosimilars or in the ability of our partners to manufacture an adequate supply of biosimilars may adversely affect our ability to commercialize the biosimilars in our portfolio.", -1], ["If we fail to achieve the benefits of our collaborations, our business, financial condition, and results of operations could be adversely impacted.", -1], ["We or our suppliers may not be able to obtain materials or supplies or capacity necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.", -0.8], ["If we or our suppliers are unable to purchase enough of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.", -0.7], ["We are subject to a number of restrictive covenants under our indebtedness, including customary operating restrictions and financial covenants, which could restrict our ability to pay dividends or adversely affect our financing options and liquidity position.", -0.9], ["This indebtedness may adversely affect our ability to operate or grow our business or could have other material adverse consequences, including by:", -0.9], ["•      limiting our ability to obtain additional financing in the future for working capital, capital expenditures and acquisitions; •       limiting our ability to refinance our indebtedness on terms acceptable to us or at all;", -0.8], ["•       requiring us to dedicate a significant portion of our cash flows from operations to paying amounts due under our indebtedness, thereby reducing funds available for other corporate purposes;", -0.8], ["Any of these restrictions on our ability to operate our business in our discretion could adversely affect our business by, among other things, limiting our ability to adapt to changing economic, financial or industry conditions and to take advantage of corporate opportunities, including opportunities to obtain debt financing, repurchase stock, refinance or pay principal on our outstanding debt, dispose of property, complete acquisitions for cash or debt, or make other investments.", -0.8], ["Any failure to comply with the restrictions of our current indebtedness, or any future financing agreements, including as a result of events beyond our control, may result in an event of default under these agreements, which in turn may result in defaults or acceleration of obligations under these agreements and other agreements, giving our lenders and other debt holders the right to terminate any commitments they may have made to provide us with further funds and to require us to repay all amounts then outstanding.", -0.9], ["Changes in tax laws or other tax guidance could adversely affect our effective tax rates, financial condition and results of operations.", -0.7], ["We expect recent changes in tax laws around the world, including as led by the Organization for Economic Cooperation and Development (\"OECD\"), such as the adoption by the EU and the enactment by additional countries of a global minimum tax, to negatively impact our effective tax rate and results of operations.", -0.7], ["Other changes in tax laws or regulations around the world, including in the United States, could negatively impact our cash tax liability, and will likely have a negative impact on our effective tax rate, and results of operations.", -0.8], ["Merck may not satisfy its obligations under various transaction agreements that have been or will be executed as part of the spinoff, we may experience delays with approvals relating to the separation from Merck, or we may not have necessary systems and services in place when certain of the transition agreements expire.", -0.7], ["If Merck is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could experience operational difficulties or losses.", -0.8], ["may incur additional costs during the period of time before all necessary approvals are granted, which may affect our business and result in additional costs in these markets.", -0.6], ["If we do not have our own systems and services in place, or if we do not have agreements with other providers of these services, when these agreements terminate, we may not be able to operate our business effectively and our profitability may decline.", -0.7], ["We may not be successful in effectively or efficiently implementing these systems and services or in transitioning data from Merck's systems to our systems.", -0.7], ["These systems and services may also be more expensive or less efficient than the systems and services Merck is expected to provide during the transition period.", -0.6], ["Potential indemnification liabilities to Merck pursuant to the Separation and Distribution Agreement could adversely affect us.", -0.8], ["These liabilities, which could be material to us, include a general obligation to indemnify Merck for litigation or governmental proceedings relating to our products, including, but not limited to, currently pending litigation relating to Fosamax, Nexplanon, and Propecia / Proscar.", -0.7], ["Our indemnity obligations to Merck as set forth in the Separation and Distribution Agreement may be substantial.", -0.7], ["There could be significant income tax liability if the spinoff or certain related transactions are determined to be taxable for U.S. federal income tax purposes.", -0.8], ["If the spinoff is ultimately determined to be taxable, the spinoff could be treated as a taxable dividend to Merck's stockholders for U.S. federal income tax purposes, and Merck's stockholders could incur significant U.S. federal income tax liabilities.", -0.9], ["In addition, Merck would recognize a taxable gain to the extent that the fair market value of our Common Stock exceeds Merck's tax basis in such stock on the date of the spinoff.", -0.7], ["Each of Merck and Organon generally will be responsible for any tax-related losses imposed on Merck or Organon, respectively, as a result of the failure of a transaction to qualify for tax-free treatment, to the extent that the failure to so qualify is attributable to actions, events or transactions relating to Merck's or Organon's respective stock, assets or business, or a breach of the relevant covenants made by Merck or Organon in the tax matters agreement.", -0.6], ["In the event the spinoff fails to be tax-free as a result of such actions, our indemnity obligation for Merck's tax liability under the tax matters agreement would be substantial and could materially affect our cash flow.", -0.9], ["The price and trading volume of our Common Stock may be volatile, and stockholders could lose all or part of their investment in us.", -1.0], ["This volatility could negatively impact our ability to raise additional capital or utilize equity as consideration in any acquisition transactions we may seek to pursue, and could make it more difficult for existing stockholders to sell their shares of our Common Stock at a price they consider acceptable or at all.", -0.9], ["•       our liquidity and ability to obtain additional capital, including the market's reaction to any capital-raising transaction we may pursue;", -0.7], ["•       declining working capital to fund operations, or other signs of financial uncertainty;", -0.8], ["•       any negative decisions by the FDA or comparable regulatory bodies outside the United States regarding our products and product candidates;", -0.8], ["•       sales of substantial amounts of our Common Stock, or the perception that substantial amounts of our Common Stock may be sold, by stockholders in the public market;", -0.8], ["•       changes in earnings estimated by securities analysts or our ability to meet those estimates;", -0.5], ["•       significant advances made by competitors that adversely affect our competitive position.", -0.9], ["This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management's attention and resources.", -0.9], ["Certain provisions in our amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of us, which could decrease the trading price of our Common Stock.", -0.7], ["In addition, these limitations may adversely affect the prevailing market price and market for our Common Stock if they are viewed as limiting the liquidity of our stock or discouraging takeover attempts in the future.", -0.7], ["that a court could find these exclusive forum provisions inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, and we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors.", -0.9], ["We implement processes for the assessment, identification, and management of material risks from cybersecurity threats; however, disruption, degradation, destruction or manipulation of our Information Systems through intentional or accidental means by our employees, third parties with authorized access or cyber threat actors could adversely affect key business processes.", -0.8], ["The size and complexity of our Information Systems, and those of our third-party providers with whom we contract, make such systems potentially vulnerable to service interruptions.", -0.6], ["In addition, we and our third-party providers have experienced and expect to continue to experience phishing attempts, scanning attempts of our network, and other attempts of unauthorized access to our computers, digital systems, networks, or devices.", -0.7], ["These attacks could lead to loss of confidentiality, integrity and/or availability of our data and Information Systems.", -0.8], ["While we have processes to protect such information, and to ensure that the third-party providers on which we rely have taken adequate steps to protect such information, a breach of our Information Systems or those of our third-party providers, such as cloud-based systems, or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud, trickery, other forms of deception, or any other cause, could enable others to produce competing products, use our proprietary technology or information, and/or adversely affect our business position.", -0.9], ["Further, any such interruption, security breach, or loss, misappropriation, and/or unauthorized access, use or disclosure of confidential information, including personal information regarding our patients and employees, or the modification of critical data, could result in financial, legal, business, and reputational harm to us, including loss of revenue, loss of critical or sensitive information from our or our third-party providers' databases or Information Systems, and substantial remediation and recovery costs.", -0.9], ["During the fourth quarter of 2023, we paid cash dividends of $0.28 per share.", 0.5], ["On February 15, 2024, our Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of our Common Stock.", 0.5], ["The dividend is payable on March 14, 2024, to stockholders of record at the close of business on February 26, 2024.", 0.5], ["Effective October 18, 2023, we were deleted from the S&P 500 index and added to the S&P SmallCap 600 index.", -0.5], ["No forward-looking statement can be guaranteed and actual future results may vary materially.", -0.6], ["Risk Factors of this report or otherwise described in our filings with the SEC, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations expressed in our forward-looking statements, including, but not limited to:", -0.7], ["•       expanded brand and class competition in the markets in which we operate;", -0.6], ["•       difficulties with performance of third parties we rely on for our business growth;", -1], ["•       the failure of any supplier to provide substances, materials, or services as agreed;", -1], ["•       the increased cost of supply, manufacturing, packaging, and operations;", -1], ["•       competition from generic products as our products lose patent protection;", -1], ["•       any failure by us to obtain an additional period of market exclusivity in the United States for Nexplanon subsequent to the expiration of certain key patents in 2027;", -1], ["•       difficulties and uncertainties inherent in the implementation of our acquisition strategy or failure to recognize the benefits of such acquisitions;", -1], ["•       pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general;", -1], ["•       the impact of higher selling and promotional costs;", -1], ["•       delays or failures to demonstrate adequate efficacy and safety of our product candidates in pre-clinical and clinical trials, which may prevent or delay the development, approval, clearance, or commercialization of our product candidates;", -1], ["•       legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental claims and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;", -1], ["•       lost market opportunity resulting from delays and uncertainties in clinical trials and the approval or clearance process of the U.S. FDA and other regulatory authorities;", -0.8], ["•       the impact of any future pandemic, epidemic, or similar public health threat on our business, operations and financial performance;", -0.7], ["However, these products continue to represent a valuable opportunity arising from long-term sustainable revenue streams and well-established supply chains that together generate significant operating profit relative to low promotional and development expenses.", 0.8], ["However, the Long-Acting Reversible Contraceptives (\"LARC\") market segment, which includes Nexplanon, has experienced significant growth in the decade from 2010 through to 2019, driven by a significant shift away from daily oral contraception to LARC.", 0.7], ["The COVID-19 pandemic negatively affected the LARC segment during 2020 and 2021 due to clinic closures and the postponement of non-essential medical procedures during country lockdowns.", -0.6], ["The LARC segment began to rebound in 2021 and 2022, during months when clinic restrictions were removed.", 0.6], ["•       Increased Access to Fertility Solutions: With the global trend toward declining birthrates, governments and payors are implementing favorable policies across major markets that, in turn, improve access to care and drives growth for infertility therapies.", 0.9], ["•       Growing Acceptance of Biosimilars: Biologics continue to experience strong growth trends.", 0.7], ["• Increased Competitive Pressures: The markets in which we conduct our business and the pharmaceutical industry in general are highly competitive and highly regulated.", -0.5], ["Under the terms of the agreement, we paid an upfront payment of $50 million, upon closing of the transaction in January 2024, and will pay sales-based milestone payments.", 0.2], ["The upfront payment and certain sales-based milestone payments, which were deemed probable of being achieved, are recognized as an intangible asset in the first quarter of 2024.", -0.1], ["Under the terms of the agreement, we paid $8 million upfront and have the option to acquire Claria for an additional $47 million, payable if and when the option is exercised.", 0.2], ["The $8 million was expensed as Acquired in-process research and development and milestones in our Condensed Consolidated Statement of Income for the year ended December 31, 2023.", -0.3], ["COVID-19 related disruptions, including patients' inability to access health care providers, negatively affected our results during 2022 and the first half of 2023, specifically, in China.", -0.8], ["The China economy has had a slower recovery from COVID-19 and this, coupled with healthcare budget deficits, has created cost containment measures post-COVID that have primarily impacted our retail business, and to a lesser extent has impacted the hospital side.", -0.7], ["Worldwide sales were $6.3 billion for the year ended December 31, 2023, an increase of 1% compared with 2022.", 0.1], ["Worldwide sales were negatively impacted by approximately 2%, or $117 million, due to unfavorable foreign exchange.", -0.4], ["Excluding foreign exchange, sales increases primarily reflect the performance of; Atozet due to increased demand in various international markets; Renflexis driven primarily by continued patient growth in the United States and Canada; Follistim AQ due to a one-time buy-in as a result of the exit of the IOM in the United States, increased patient demand in the United States and volume recovery in China related to the COVID-19 negative impact during the first half of the year; Ontruzant driven by the timing of tenders and increased demand; Jada due to continued uptake in the United States following the launch; and Marvelon and Mercilon, resulting from the transaction with Bayer Healthcare where we gained rights in China during the second quarter of 2022 and in Vietnam during the third quarter of 2022.", 0.3], ["This performance was offset by: decreased sales of Zetia and Vytorin driven by the negative impact of VBP in China; the impact of the Diprospan regulatory inspection finding at the Heist manufacturing location", -0.5], ["that impacted the manufacturing of selected injectable steroid brands in the first quarter of 2023 (the \"Market Action\"); and decreased sales of Cozaar and Hyzaar (a combination of losartan potassium and hydrochlorothiazide that is marketed in Japan as Preminent™), primarily due to ongoing generic competition.", -0.6], ["The loss of exclusivity negatively impacted sales of certain of our products by approximately $18 million during the year ended December 31, 2023, compared to the year ended December 31, 2022, due to the decrease in volume period over period, which mainly impacted NuvaRing in the United States.", -0.8], ["VBP in China had a $95 million negative impact on our sales during the year ended December 31, 2023, compared to the year ended December 31, 2022.", -0.9], ["Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, declined 1% for the year ended December 31, 2023, compared to 2022, primarily due to the impact of foreign exchange, unfavorable discount rates, the result of distributor purchasing patterns associated with the timing of the increase in Nexplanon list price in the United States and the impact of the limited participation of a tender in Mexico.", -0.5], ["Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 12% for the year ended December 31, 2023, compared to 2022, due to ongoing generic competition in the United States.", -0.7], ["We expect a continued decline in NuvaRing sales as a result of generic competition.", -0.9], ["Worldwide sales of Marvelon and Mercilon, combined oral hormonal daily contraceptive pills not approved or marketed in the United States but available in certain countries outside the United States, increased 22% for the year ended December 31, 2023, compared to 2022, as a result of the transaction with Bayer Healthcare where we gained rights in China during the second quarter of 2022 and in Vietnam during the third quarter of 2022.", 0.8], ["Worldwide sales of Follistim AQ, a fertility treatment, increased 14% for the year ended December 31, 2023, compared to 2022, due to a onetime buy-in as a result of the exit of the IOM in the United States, increased patient demand in the United States and volume recovery in China related to the COVID-19 negative impact during the first half of the year.", 0.7], ["This was partially offset by the negative impact of unfavorable discount rates in the United States.", -0.4], ["Worldwide sales of ganirelix acetate injection, a fertility treatment, declined 10% for the year ended December 31, 2023, compared to 2022, primarily due to unfavorable discount rates in the United States and increased generic competition in Europe.", -0.6], ["Worldwide sales of Jada, a device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, increased 113% for the year ended December 31, 2023, compared to 2022.", 1.0], ["Sales increased 23% for the year ended December 31, 2023, compared to 2022, driven primarily by continued demand growth in the United States and Canada.", 0.8], ["Sales for the year ended December 31, 2023, compared to 2022, increased 28% driven by the timing of tenders in Brazil and increased demand partially offset by the competitive pressures in Europe.", 0.7], ["We recorded sales of $44 million during the year ended December 31, 2023, reflecting an increase from modest sales during 2022 in markets outside of the United States and the launch in the United States in July 2023.", 0.6], ["Combined global sales of Zetia and Vytorin, medicines for lowering LDL cholesterol, declined 11% for the year ended December 31, 2023, compared to 2022, primarily driven by the negative impact of VBP in China.", -0.6], ["Sales of Atozet, a medicine for lowering LDL cholesterol, increased 14% for the year ended December 31, 2023, compared to 2022, primarily due to increased demand in various international markets.", 0.5], ["Combined global sales of Cozaar and Hyzaar, medicines for the treatment of hypertension, declined 13% for the year ended December 31, 2023, compared to 2022, primarily due to ongoing generic competition.", -0.7], ["Worldwide sales of Singulair, a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, declined 2% for the year ended December 31, 2023, compared to 2022, due to the impact of foreign exchange partially offset by increased demand due to higher incidences of respiratory conditions across many international markets during the fourth quarter of 2023 compared to 2022.", -0.2], ["Global sales of Nasonex, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 6% for the year ended December 31, 2023, compared to 2022, due to increased demand across several markets partially offset by a $10 million milestone related to a regulatory approval received during the first quarter of 2022.", 0.3], ["Global sales of Dulera, a combination medicine for the treatment of asthma, increased 8% for the year ended December 31, 2023, compared to 2022, primarily due to the favorable impact from price and increased demand in the United States.", 0.4], ["Sales of Arcoxia, a medicine for the treatment of arthritis and pain, increased 7% for the year ended December 31, 2023, compared to 2022, primarily due to customers buying patterns and higher demand in various international markets.", 0.4], ["Sales of Diprospan, a corticosteroid approved for treatment of a wide range of inflammatory conditions, declined 25% for the year ended December 31, 2023, compared to 2022, due to manufacturing issues resulting from the Market Action.", -0.8], ["Sales have not yet recovered.", -0.7], ["We expect the sales recovery to continue over the next twelve months.", 0.5], ["Worldwide sales of Proscar, a medicine for the treatment of symptomatic benign prostate enlargement, for the year ended December 31, 2023, compared to 2022 were substantially consistent.", 0.1], ["Cost of sales increased 10% for the year ended December 31, 2023, compared to 2022, primarily due to foreign exchange translation, higher employee-related and material and distribution related costs, which increased as a result of inflationary pressures, and product mix.", -0.6], ["During the year ended December 31, 2022, we recorded a $36 million inventory charge relating to the Market Action and an impairment charge of $9 million related to a product right for a biosimilar product.", -0.9], ["Cost of sales includes amortization of intangible assets which totaled $116 million in 2023, $116 million in 2022 and $103 million in 2021.", 0.0], ["\"Contingencies\" to the Consolidated Financial Statements.", 0.0], ["Research and development expenses increased 12% for the year ended December 31, 2023, compared to 2022, primarily due to higher costs associated with our acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.", -0.4], ["For the year ended December 31, 2023, we incurred $62 million of headcount-related restructuring expense, of which $58 million is due to activities initiated in the fourth quarter related to the ongoing optimization of our internal operations.", -0.5], ["Interest expense increased 25% for the year ended December 31, 2023, compared to 2022, due to increased interest rates, and debt fees and discounts expensed as part of the prepayment on the U.S.", -0.5], ["For the year ended December 31, 2023, the change in exchange losses was driven by foreign currency exchange translation losses and the impact of the portion of Euro-denominated debt not designated as a net investment hedge in the prior year period.", -0.7], ["In the fourth quarter of 2023, we recorded a $476 million tax benefit comprised of a gross benefit of $686 million, net of a $210 million valuation allowance, resulting from the termination of a Swiss tax arrangement.", 0.3], ["We have historically generated and expect to continue to generate positive cash flow from operations.", 0.8], ["The increase in working capital was primarily driven by an increase in inventory and the timing of collection of receivables.", 0.1], ["Net cash provided by operating activities was $799 million for the year ended December 31, 2023 compared to $858 million for the same period in the prior year.", -0.2], ["The decrease in cash provided by operating activities was primarily attributable to the changes in working capital balances, offset by an increase in net income.", -0.3], ["Net cash used in investing activities was $260 million for the year ended December 31, 2023 compared to $420 million for the same period in the prior year, primarily reflecting lower investment in business development transactions in the year ended December 31, 2023 compared to the prior year, partially offset by an increase in capital expenditures.", 0.2], ["Net cash used in financing activities was $569 million for the year ended December 31, 2023 compared to $433 million for the same period in the prior year.", -0.4], ["The increase in cash used in financing activities was driven by the $250 million voluntary prepayment on the U.S. Dollardenominated term loan in 2023 compared to the $100 million voluntary prepayment in 2022.", -0.5], ["We anticipate we will incur costs associated with this separation, including but not limited to accelerated depreciation, exit premiums and fees, technology transfer costs, stability and qualification batch costs, one-time resourcing costs, regulatory and filing costs, capital investment, and inventory stock bridges.", -0.8], ["During the 2024 fiscal year, we anticipate paying higher cash taxes than the 2023 fiscal year.", -0.6], ["During 2023, we paid cash dividends of $1.12 per share.", 0.2], ["In the United States, revenue is reduced by sales discounts issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebate amounts owed based upon definitive contractual agreements or", -0.5], ["There were no material adjustments to estimates associated with the aggregate customer discount provision in 2023, 2022, or 2021.", 0.1], ["The accrued balances relative to these provisions included in accounts receivable and accrued and other current liabilities were $87 million and $417 million, respectively, at December 31, 2023, $78 million and $307 million, respectively, at December 31, 2022 and $54 million and $275 million, respectively, at December 31, 2021.", 0.0], ["The increase in accrued rebates in 2023 is attributable to a wholesaler buy-in in conjunction with the exit of the IOM with Merck for the Follistim product.", -0.3], ["We believe that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on us.", 0.5], ["Expenditures for remediation and environmental liabilities were $2 million in 2023, and are estimated at $15 million in the aggregate for the years 2024 through 2028.", -0.4], ["Liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $19 million and $20 million at December 31, 2023 and 2022, respectively.", -0.2], ["The judgments made in evaluating impairment of long-lived intangibles can materially affect our results of operations.", -0.5], ["If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value.", -0.5], ["If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).", -0.7], ["We recorded impairment charges of $9 million and $7 million as of December 31, 2022 and 2021 respectively.", -0.8], ["Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales.", -0.6], ["Product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable of being achieved.", 0.2], ["Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill.", 0.3], ["We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely affected by fluctuations in foreign exchange rates.", -0.7], ["We estimate a hypothetical 10% adverse movement in interest rates of our variable rate debt would not materially change annual interest expense.", -0.2], ["Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.", -0.6], ["Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.", -0.5], ["In 2023, the Company recorded a $476 million tax benefit comprised of a gross benefit of $686 million, net of a $210 million valuation allowance, resulting from the termination of a tax arrangement in Switzerland.", 0.5], ["Amounts accrued, included in accrued and other current liabilities, for aggregate customer discounts as of December 31, 2023 in the United States was $417 million, of which the majority related to U.S. rebate accruals for Medicaid and Managed Care.", 0.0], ["Loss From Discontinued Operations -   Net of Tax", -1.0], ["Benefit plan net (loss) gain and prior service   (cost) credit, net of amortization", -0.5], ["Cash dividends declared on common stock ($1.12 per share)", 0.0], ["Cash dividends declared on common stock ($1.12 per share)", 0.0], ["Net Cash Flows Provided by Operating Activities from Continuing Operations", 0.5], ["Proceeds from sale of property, plant and equipment", 0.5], ["Net Cash Provided by (Used in) Operating Activities", 0.5], ["Net (Decrease) Increase in Cash and Cash Equivalents", -0.5], ["Organon's oncology biosimilars; Ontruzant® (trastuzumab-dttb) and AybintioTM 1 (bevacizumab), have been launched in more than 20 countries and Organon's immunology biosimilars; BrenzysTM 1 (etarnarcept), Renflexis® (infliximab-abda) and Hadlima® (adalimumab-bwwd), have been launched in five countries.", 0.8], ["All five biosimilars in Organon's portfolio have launched in Canada, and three biosimilars; Ontruzant, Renflexis and Hadlima have been launched in the United States.", 0.7], ["A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time.", -0.7], ["(v)   restructuring costs (see Note 8 \"Restructuring\") and stock-based compensation expenses (see Note 7 \"Stock-Based Compensation Plans\"); and", -0.3], ["The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company.", -0.4], ["There were no material adjustments to estimates associated with the aggregate customer discount provision in 2023, 2022, or 2021.", 0.0], ["The accrued balances relative to the provisions for chargebacks and rebates in the United States included in Accounts receivable and Accrued and other current liabilities were $87 million and $417 million, respectively, at December 31, 2023 and $78 million and $307 million, respectively, at December 31, 2022.", -0.2], ["At December 31, 2023 and 2022, the accrued balances related to the provision for rebates and discounts included in other current liabilities were approximately $126 million and $109 million, respectively.", -0.1], ["Depreciation expense was $120 million in 2023, $96 million in 2022, and $92 million in 2021.", -0.2], ["The Company recorded advertising and promotion expenses of $209 million, $255 million, and $236 million in 2023, 2022 and 2021, respectively.", -0.1], ["If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).", -0.5], ["The Company completed the annual qualitative goodwill impairment test as of October 1, 2023 and concluded that there was no impairment to goodwill as the fair value of the reporting unit was significantly in excess of the carrying value.", 0.5], ["If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.", -0.4], ["If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.", -0.6], ["The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated other comprehensive loss and reflected as a separate component of equity.", -0.3], ["For those operations that operate in highly inflationary economies and for those operations where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Exchange losses.", -0.7], ["The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.", 0.2], ["Restructuring Costs — Costs associated with exit or disposal activities are recognized in the period in which they are incurred.", -0.4], ["Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.", -0.5], ["The amounts of the deferred tax asset considered realizable, however, could be adjusted in future periods if estimates of future income are reduced or increased.", -0.1], ["The Company applied this guidance to the Senior Credit Agreement, as amended on June 30, 2023.", 0.0], ["The $8 million was expensed as Acquired in-process research and development and milestones in the Consolidated Statement of Income for the year ended December 31, 2023.", -0.2], ["Under the terms of the research collaboration and license agreement, Organon recorded a $10 million upfront payment during 2022 as Acquired in-process research and development and milestones.", -0.1], ["Under the terms of the license agreement, Organon paid a $73 million upfront payment during 2022, of which $3 million was reflected in Other current assets and the remainder was recognized as Acquired in-process research and development and milestones.", -0.1], ["Henlius is eligible to receive potential developmental, regulatory and commercial milestone payments of up to $468 million.", 0.5], ["During the year ended December 31, 2022, the Company paid an additional $27 million related to certain development milestones which were recognized as Acquired in-process research and development and milestones.", -0.1], ["Under the terms of the license agreement, Organon paid a $10 million upfront payment during 2022.", -0.1], ["Daré is eligible to receive potential regulatory and commercial milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales.", 0.5], ["During the year ended December 31, 2022 management determined that the first commercial milestone was deemed probable of occurring, and recognized an intangible asset of $12.5 million reflecting the $10 million upfront payment and $2.5 million commercial milestone.", 0.2], ["This resulted in Organon recognizing an intangible asset of $72 million in total related to the product rights with the remainder of the consideration recorded to Inventories for the fair value of acquired inventory during 2022.", 0.2], ["Due to the conversion, Organon incurred $17 million of incremental stock-based compensation expense in 2021.", -0.5], ["Of this amount, $4 million was related to vested option awards and was recognized immediately into earnings in connection with the Separation, and the remainder is recognized ratably over the option awards' remaining weighted average vesting period.", 0.1], ["For PSUs with a performance-based FCF goal, stock-based compensation expense is recognized based on the probability of the achievement of the financial performance metric for the respective vesting period and is assessed at each reporting date.", 0.0], ["In connection with the Separation, in 2021, Merck's PSUs and RSUs were converted into 3.3 million Organon RSUs at a weighted average grant date fair value of $36.77 and Merck's stock options were converted into 4.1 million Organon stock options at a weighted average grant date fair value of $8.55.", 0.3], ["At December 31, 2023, the unrecognized portion of the incremental stock-based expense was $1 million.", 0.0], ["In 2022, Organon initiated restructuring activities to optimize its internal operations by reducing headcount through selected markets and functions.", -0.3], ["As a result of this program, the Company restructured approximately 130 positions, with the majority of the position eliminations occurring in selected markets outside of the United States in the commercial organizations.", -0.4], ["In the fourth quarter of 2023, Organon implemented additional restructuring activities related to the ongoing optimization of its internal operations by reducing headcount in certain markets and functions.", -0.3], ["As a result of these activities, the Company's headcount will be reduced by approximately 3% over the next twelve months.", -0.4], ["Organon expects the remaining severance payments associated with the restructuring activities to be paid by the end of 2024.", -0.2], ["The components of Loss from discontinued operations, net of tax for the Merck Retained Products business are as follows:", -0.5], ["Discontinued operations include related party sales of $12 million for the year ended December 31, 2021.", -0.3], ["Costs for inventory purchases from related parties were $53 million for the year ended December 31, 2021.", -0.3], ["The tax effects of foreign earnings in the tax rate reconciliation above primarily reflect the effects of operations in jurisdictions with different tax rates than the United States thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%.", 0.2], ["The favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active legal entity.", 0.3], ["The effective income tax rates were (52.2)%, 18.3% and 11.7% for 2023, 2022 and 2021, respectively.", -0.1], ["These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense, as well as a $476 million tax benefit comprised of a gross benefit of $686 million, net of a $210 million valuation allowance, resulting from the termination of a tax arrangement in Switzerland recorded in the fourth quarter 2023.", 0.1], ["During 2021, the Company recorded a $75 million tax benefit relating to a portion of the non-U.S. step-up of tax basis associated with the Company's Separation from Merck.", 0.2], ["The Company has recognized $35 million and $65 million deferred taxes on net operating loss (\"NOL\") carryforwards in multiple jurisdictions as of December 31, 2023 and 2022, respectively.", 0.1]], "tsla22_sentences.json": [["The aggregate market value of voting stock held by non-affiliates of the registrant, as of June 30, 2022, the last day of the registrant’s most recently completed second fiscal quarter, was", -0.1], ["$580.48 billion (based on the closing price for shares of the registrant’s Common Stock as reported by the NASDAQ Global Select Market on June 30, 2022).", 0.2], ["These forward-looking statements include, but are not limited to, statements concerning any potential future impact of the coronavirus disease (“COVID-19”) pandemic on our business, supply chain constraints, our strategy, competition, future operations and production capacity, future financial position, future revenues, projected costs, profitability, expected cost reductions, capital adequacy, expectations regarding demand and acceptance for our technologies, growth opportunities and trends in the markets in which we operate, prospects and plans and objectives of management.", -0.5], ["We also strive to lower the cost of ownership for our customers through continuous efforts to reduce manufacturing costs and by offering financial and other services tailored to our products.", 0.5], ["In order to enable a greater supply of cells for our products with higher energy density at lower costs, we have developed a new proprietary lithium-ion battery cell and improved manufacturing processes.", 0.7], ["We intend to establish in the future an autonomous Tesla ride-hailing network, which we expect would also allow us to access a new customer base even as modes of transportation evolve.", 0.8], ["We have also achieved complex engineering feats in stamping, casting and thermal systems, and developed a method to integrate batteries directly with vehicle body structures without separate battery packs to optimize manufacturability, weight, range and cost characteristics.", 0.6], ["Historically, we have been able to generate significant media coverage of our company and our products, and we believe we will continue to do so.", 0.4], ["Such media coverage and word of mouth are the current primary drivers of our sales leads and have helped us achieve sales without traditional advertising and at relatively low marketing costs.", 0.3], ["We believe this infrastructure enables us to better control costs of inventory, manage warranty service and pricing, educate consumers about electric vehicles, maintain and strengthen the Tesla brand and obtain rapid customer feedback.", 0.6], ["However, sales of vehicles in the automobile industry tend to be cyclical in many markets, which may expose us to volatility from time to time.", -0.2], ["Internationally, we also have manufacturing facilities in China (Gigafactory Shanghai) and Germany (Gigafactory Berlin- Brandenburg), which allows us to increase the affordability of our vehicles for customers in local markets by reducing transportation and manufacturing costs and eliminating the impact of unfavorable tariffs.", 0.8], ["We also intend to further increase cost-competitiveness in our significant markets by strategically adding local manufacturing.", 0.7], ["Certain components purchased from these suppliers are shared or are similar across many product lines, allowing us to take advantage of pricing efficiencies from economies of scale.", 0.6], ["The IRA includes multiple incentives to promote clean energy, electric vehicles, battery and energy storage manufacture or purchase, including through providing tax credits to consumers.", 0.9], ["For example, qualifying Tesla customers may receive up to $7,500 in federal tax credits for the purchase of qualified electric vehicles in the U.S through 2032.", 1.0], ["Sales of these credits are recognized within automotive regulatory credits revenue in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.", 0.3], ["In such transactions, they are included as a component of energy generation and storage revenues in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.", 0.3], ["Sales of electricity and non-sale equipment leases by third parties, such as our leases and PPAs, have faced regulatory challenges in some states and jurisdictions.", -0.5], ["In certain jurisdictions, regulators or utilities have reduced or eliminated the benefit available under net metering or have proposed to do so.", -0.7], ["We believe that there is also increasing competition for our vehicle offerings as a platform for delivering self-driving technologies, charging solutions and other features and services, and we expect to compete in this developing market through continued progress on our Autopilot, FSD and neural network capabilities, Supercharger network and our infotainment offerings.", 0.5], ["We believe that the specifications and features of our products, our strong brand and the modular, scalable nature of our energy storage products give us a competitive advantage in our markets.", 0.8], ["We compete with these traditional utility companies primarily based on price and the ease by which customers can switch to electricity generated by our solar energy systems.", 0.3], ["We believe we have a significant expansion opportunity with our offerings and that the regulatory environment is increasingly conducive to the adoption of renewable energy systems.", 0.7], ["Our incidents per vehicle continue to drop even as our production volumes increase.", 0.6], ["As of December 31, 2022, our full-time count for our and our subsidiaries’ employees worldwide was 127,855, a 29,000 year over year increase.", 0.4], ["In 2022, we had over 200 graduates from Tesla START programs, with an additional 100+ graduating in the coming weeks from our winter classes.", 0.5], ["We hired 144 graduates through this program in 2022, and our goal in 2023 is to grow this program 2.5X to over 360 students annually across our Fremont Factory, Gigafactory Nevada, Gigafactory Texas, and Gigafactory New York.", 0.6], ["You should carefully consider the risks described below together with the other information set forth in this report, which could materially affect our business, financial condition and future results.", -0.7], ["Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results.", -0.8], ["Government regulations and shifting social behaviors have, at times, limited or closed non-essential transportation, government functions, business activities and person-to-person interactions.", -0.8], ["Global trade conditions and consumer trends that originated during the pandemic continue to persist and may also have long-lasting adverse impact on us and our industries independently of the progress of the pandemic.", -0.9], ["For example, pandemic-related issues have exacerbated port congestion and intermittent supplier shutdowns and delays, resulting in additional expenses to expedite delivery of critical parts.", -0.7], ["Similarly, increased demand for personal electronics has created a shortfall of semiconductors, which has caused challenges in our supply chain and production.", -0.7], ["In addition, labor shortages resulting from the pandemic, including worker absenteeism, has led to increased difficulty in hiring and retaining manufacturing and service workers, as well as increased labor costs and supplier delays.", -0.8], ["For example, in 2022, spikes in COVID-19 cases in Shanghai resulted in the temporary shutdown of Gigafactory Shanghai, as well as parts of our supply chain, and impacted our ability to deliver cars.", -0.8], ["Lastly, rising interest rates may lead to consumers to increasingly pull back spending, including on our products, which may harm our demand, business and operating results.", -0.9], ["If we experience unfavorable global market conditions, or if we cannot or do not maintain operations at a scope that is commensurate with such conditions or are later required to or choose to suspend such operations again, our business, prospects, financial condition and operating results may be harmed.", -0.9], ["We have previously experienced and may in the future experience launch and production ramp delays for new products and features.", -0.7], ["For example, we encountered unanticipated supplier issues that led to delays during the initial ramp of our first Model X and experienced challenges with a supplier and with ramping full automation for certain of our initial Model 3 manufacturing processes.", -0.8], ["There is no guarantee that we will be able to successfully and timely introduce and scale such processes or features.", -0.8], ["In particular, our future business depends in large part on increasing the production of mass-market vehicles including Model 3 and Model Y.", 0.2], ["In order to be successful, we will need to implement, maintain and ramp efficient and cost-effective manufacturing capabilities, processes and supply chains and achieve the design tolerances, high quality and output rates we have planned at our manufacturing facilities in California, Nevada, Texas, China, Germany and any future sites.", 0.5], ["Bottlenecks and other unexpected challenges such as those we experienced in the past may arise during our production ramps, and we must address them promptly while continuing to improve manufacturing processes and reducing costs.", -0.6], ["If we are not successful in achieving these goals, we could face delays in establishing and/or sustaining our Model 3 and Model Y ramps or be unable to meet our related cost and profitability targets.", -0.9], ["Any delay or other complication in ramping the production of our current products or the development, manufacture, launch and production ramp of our future products, features and services, or in doing so cost-effectively and with high quality, may harm our brand, business, prospects, financial condition and operating results.", -0.9], ["For example, a global shortage of semiconductors has been reported since early 2021 and has caused challenges in the manufacturing industry and impacted our supply chain and production.", -0.7], ["We have used alternative parts and programmed software to mitigate certain challenges caused by these shortages, but there is no guarantee we may be able to continually do so as we scale production to meet our growth targets.", -0.8], ["Additionally, if our suppliers do not accurately forecast and effectively allocate production or if they are not willing to allocate sufficient production to us, it may reduce our access to components and require us to search for new suppliers.", -0.7], ["The unavailability of any component or supplier could result in production delays, idle manufacturing facilities, product design changes and loss of access to important technology and tools for producing and supporting our products, as well as impact our capacity expansion and our ability to fulfill our obligations under customer contracts.", -0.9], ["Moreover, significant increases in our production, such as for Model 3 and Model Y, or product design changes by us have required and may in the future require us to procure additional components in a short amount of time.", -0.1], ["We have faced in the past, and may face suppliers who are unwilling or unable to sustainably meet our timelines or our cost, quality and volume needs, or to do so may cost us more, which may require us to replace them with other sources.", -0.7], ["Additionally, we may be unsuccessful in our continuous efforts to negotiate with existing suppliers to obtain cost reductions and avoid unfavorable changes to terms, source less expensive suppliers for certain parts and redesign certain parts to make them less expensive to produce, especially in light of the increases in materials pricing.", -0.6], ["Any of these occurrences may harm our business, prospects, financial condition and operating results.", -0.8], ["management and other systems to accommodate the increased complexity in our supply chain and parts management, we may incur unexpected production disruption, storage, transportation and write-off costs, which may harm our business and operating results.", -0.7], ["If we experience any issues or delays in meeting our projected timelines, costs, capital efficiency and production capacity for our new factories, expanding and managing teams to implement iterative design and production changes there, maintaining and complying with the terms of any debt financing that we obtain to fund them or generating and maintaining demand for the vehicles we manufacture there, our business, prospects, operating results and financial condition may be harmed.", -0.9], ["We currently produce numerous international variants at a limited number of factories, and if our specific demand expectations for these variants prove inaccurate, we may not be able to timely generate deliveries matched to the vehicles that we produce in the same timeframe or that are commensurate with the size of our operations in a given region.", -0.6], ["As our production volumes continue to grow, we have faced in the past, and may face challenges with deliveries at increasing volumes, particularly in international markets requiring significant transit times.", -0.7], ["If we experience production delays or inaccurately forecast demand, our business, financial condition and operating results may be harmed.", -0.8], ["If we experience delays in adding servicing capacity or servicing our vehicles efficiently, or experience unforeseen issues with the reliability of our vehicles, particularly higher-volume additions to our fleet such as Model 3 and Model Y, it could overburden our servicing capabilities and parts inventory.", -0.7], ["There is no assurance that we will be able to ramp our business to meet our sales, delivery, installation, servicing and vehicle charging targets globally, that our projections on which such targets are based will prove accurate or that the pace of growth or coverage of our customer infrastructure network will meet customer expectations.", -0.8], ["These plans require significant cash investments and management resources and there is no guarantee that they will generate additional sales or installations of our products, or that we will be able to avoid cost overruns or be able to hire additional personnel to support them.", -0.7], ["If we fail to manage our growth effectively, it may harm our brand, business, prospects, financial condition and operating results.", -0.9], ["In the long term, we intend to supplement cells from our suppliers with cells manufactured by us, which we believe will be more efficient, manufacturable at greater volumes and more cost-effective", 0.5], ["However, our efforts to develop and manufacture such battery cells have required, and may continue to require, significant investments, and there can be no assurance that we will be able to achieve these targets in the timeframes that we have planned or at all.", -0.6], ["If we are unable to do so, we may have to curtail our planned vehicle and energy storage product production or procure additional cells from suppliers at potentially greater costs, either of which may harm our business and operating results.", -0.8], ["Any reduced availability of these materials may impact our access to cells and our growth, and any increases in their prices may reduce our profitability if we cannot recoup such costs through increased prices.", -0.7], ["Moreover, our inability to meet demand and any product price increases may harm our brand, growth, prospects and operating results.", -0.8], ["Though we continue to see increased interest and adoption of electric vehicles, if the market for electric vehicles in general and Tesla vehicles in particular does not develop as we expect, develops more slowly than we expect, or if demand for our vehicles decreases in our markets or our vehicles compete with each other, our business, prospects, financial condition and operating results may be harmed.", -0.9], ["Sales of vehicles in the automotive industry tend to be cyclical in many markets, which may expose us to further volatility.", -0.7], ["Increased competition could result in our lower vehicle unit sales, price reductions, revenue shortfalls, loss of customers and loss of market share, which may harm our business, financial condition and operating results.", -1.0], ["Decreases in the retail or wholesale prices of electricity from utilities or other renewable energy sources could make our products less attractive to customers and lead to an increased rate of customer defaults.", -1.0], ["In the past, some of the manufacturing lines for certain product components took longer than anticipated to ramp to their full capacity, and additional bottlenecks may arise in the future as we continue to increase the production rate and introduce new lines.", -0.5], ["If we are unable to or otherwise do not maintain and grow our respective operations, or if we are unable to do so cost-effectively or hire and retain highly-skilled personnel there, our ability to manufacture our products profitably would be limited, which may harm our business and operating results.", -1.0], ["Any such disruptions or issues may harm our brand and business.", -1.0], ["Such conditions may increase our costs, impact our ability to sell our products and require significant management attention, and may harm our business if we are unable to manage them effectively.", -1.0], ["If our products contain design or manufacturing defects that cause them not to perform as expected or that require repair, or certain features of our vehicles such as new Autopilot or FSD features take longer than expected to become enabled, are legally restricted or become subject to onerous regulation, our ability to develop, market and sell our products and services may be harmed, and we may experience delivery delays, product recalls, product liability, breach of warranty and consumer protection claims and significant warranty and other expenses.", -1.0], ["Likewise, as our solar energy systems and energy storage products generate and store electricity, they have the potential to fail or cause injury to people or property.", -1.0], ["Any product liability claim may subject us to lawsuits and substantial monetary damages, product recalls or redesign efforts, and even a meritless claim may require us to defend it, all of which may generate negative publicity and be expensive and time-consuming.", -1.0], ["In most jurisdictions, we generally self-insure against the risk of product liability claims for vehicle exposure, meaning that any product liability claims will likely have to be paid from company funds and not by insurance.", -1.0], ["Any such negative perceptions, whether caused by us or not, may harm our business and make it more difficult to raise additional funds if needed.", -0.8], ["The profitability of any directly-leased vehicles returned to us at the end of their leases depends on our ability to accurately project our vehicles’ residual values at the outset of the leases, and such values may fluctuate prior to the end of their terms depending on various factors such as supply and demand of our used vehicles, economic cycles and the pricing of new vehicles.", -0.2], ["We have made in the past and may make in the future certain adjustments to our prices from time to time in the ordinary course of business, which may impact the residual values of our vehicles and reduce the profitability of our vehicle leasing program.", -0.4], ["If we are unable to adequately fund our leasing program through internal funds, partners or other financing sources, and compelling alternative financing programs are not available for our customers who may expect or need such options, we may be unable to grow our vehicle deliveries.", -0.9], ["Furthermore, if our vehicle leasing business grows substantially, our business may suffer if we cannot effectively manage the resulting greater levels of residual risk.", -0.7], ["Similarly, we have provided resale value guarantees to vehicle customers and partners for certain financing programs, under which such counterparties may sell their vehicles back to us at certain points in time at pre-determined amounts.", -0.3], ["However, actual resale values are subject to fluctuations over the term of the financing arrangements, such as from the vehicle pricing changes discussed above.", -0.5], ["If the actual resale values of any vehicles resold or returned to us pursuant to these programs are materially lower than the pre- determined amounts we have offered, our financial condition and operating results may be harmed.", -0.8], ["In the event of a widespread economic downturn or other catastrophic event, our customers may be unable or unwilling to satisfy their payment obligations to us on a timely basis or at all.", -1.0], ["If a significant number of our customers default, we may incur substantial credit losses and/or impairment charges with respect to the underlying assets.", -0.9], ["As of December 31, 2022, we are currently in excess of such targets relating to investments and personnel in the State of New York and Buffalo.", -0.1], ["While we expect to have and grow significant operations at Gigafactory New York and the surrounding Buffalo area, any failure by us in any year over the course of the term of the agreement to meet all applicable future obligations may result in our obligation to pay a “program payment” of $41 million to the SUNY Foundation for such year, the termination of our lease at Gigafactory New York which may require us to pay additional penalties, and/or the need to adjust certain of our operations, in particular our production ramp of the Solar Roof or other components.", -0.8], ["Any of the foregoing events may harm our business, financial condition and operating results.", -0.9], ["If we are not successful in managing these risks, our business, financial condition and operating results may be harmed.", -0.9], ["Employees may leave Tesla or choose other employers over Tesla due to various factors, such as a very competitive labor market for talented individuals with automotive or technology experience, or any negative publicity related to us.", -0.7], ["Moreover, we may be impacted by perceptions relating to reductions in force that we have conducted in the past in order to optimize our organizational structure and reduce costs and the departure of certain senior personnel for various reasons.", -0.6], ["We also compete with both mature and prosperous companies that have far greater financial resources than we do and start-ups and emerging companies that promise short-term growth opportunities.", -0.5], ["If we are unable to obtain the requisite stockholder approvals for such future increases, we may have to expend additional cash to compensate our employees and our ability to retain and hire qualified personnel may be harmed.", -0.7], ["To the extent any security incident results in unauthorized access or damage to or acquisition, use, corruption, loss, destruction, alteration or dissemination of our data, including intellectual property and personal information, or our products or vehicles, or for it to be believed or reported that any of these occurred, it could disrupt our business, harm our reputation, compel us to comply with applicable data breach notification laws, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information.", -0.9], ["This could result in increased costs to us and result in significant legal and financial exposure and/or reputational harm.", -0.8], ["We also rely on service providers, and similar incidents relating to their information technology systems could also have a material adverse effect on our business.", -1.0], ["Further, the implementation, maintenance, segregation and improvement of these systems require significant management time, support and cost, and there are inherent risks associated with developing, improving and expanding our core systems as well as implementing new systems and updating current systems, including disruptions to the related areas of business operation.", -0.8], ["These risks may affect our ability to manage our data and inventory, procure parts or supplies or manufacture, sell, deliver and service products, adequately protect our intellectual property or achieve and maintain compliance with, or realize available benefits under, tax laws and other applicable regulations.", -0.9], ["Moreover, if we do not successfully implement, maintain or expand these systems as planned, our operations may be disrupted, our ability to accurately and/or timely report our financial results could be impaired and deficiencies may arise in our internal control over financial reporting, which may impact our ability to certify our financial results.", -0.9], ["If these systems or their functionality do not operate as we expect them to, we may be required to expend significant resources to make corrections or find alternative sources for performing these functions.", -0.8], ["Any unauthorized access to or control of our products or their systems or any loss of data could result in legal claims or government investigations.", -1.0], ["In addition, regardless of their veracity, reports of unauthorized access to our products, their systems or data, as well as other factors that may result in the perception that our products, their systems or data are capable of being hacked, may harm our brand, prospects and operating results.", -0.9], ["It is not uncommon for employees of certain trades at companies such as ours to belong to a union, which can result in higher employee costs and increased risk of work stoppages.", -0.7], ["Any unfavorable ultimate outcome for Tesla may have a negative impact on the perception of Tesla’s treatment of our employees.", -0.9], ["Any work stoppages or strikes organized by such unions could delay the manufacture and sale of our products and may harm our business and operating results.", -0.9], ["Recalls for our vehicles have resulted from various hardware and software-related safety defect or non-compliance determinations.", -0.8], ["Such recalls, whether voluntary or involuntary or caused by systems or components engineered or manufactured by us or our suppliers, could result in significant expense, supply chain complications and service burdens, and may harm our brand, business, prospects, financial condition and operating results.", -0.9], ["If our warranty reserves are inadequate to cover future warranty claims on our products, our financial condition and operating results may be harmed.", -0.7], ["We may be subject, in the ordinary course of business, to losses resulting from products liability, accidents, acts of God and other claims against us, for which we may have no insurance coverage.", -0.6], ["A loss that is uninsured or which exceeds policy limits may require us to pay substantial amounts, which may harm our financial condition and operating results.", -0.7], ["Furthermore, our failure to comply with our debt covenants could result in a default under our debt agreements, which could permit the holders to accelerate our obligation to repay the debt.", -0.8], ["If any of our debt is accelerated, we may not have sufficient funds available to repay it.", -0.8], ["If we cannot raise additional funds when we need them, our financial condition, results of operations, business and prospects could be materially and adversely affected.", -0.9], ["The useful life of any equipment that would be retired early as a result would be shortened, causing the depreciation on such equipment to be accelerated, and our results of operations may be harmed.", -0.7], ["Our consolidated indebtedness may increase our vulnerability to any generally adverse economic and industry conditions.", -0.8], ["Our business may not continue to generate cash flow from operations in the future sufficient to satisfy our obligations under our existing indebtedness and any future indebtedness we may incur, and to make necessary capital expenditures.", -0.8], ["If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as reducing or delaying investments or capital expenditures, selling assets, refinancing or obtaining additional equity capital on terms that may be onerous or highly dilutive.", -0.9], ["We may not be able to engage in these activities on desirable terms or at all, which may result in a default on our existing or future indebtedness and harm our financial condition and operating results.", -0.9], ["To the extent we have significant revenues denominated in such foreign currencies, any strengthening of the U.S. dollar would tend to reduce our revenues as measured in U.S. dollars, as we have historically experienced, and are currently experiencing.", -0.7], ["If we do not have fully offsetting revenues in these currencies and if the value of the U.S. dollar depreciates significantly against these currencies, our costs as measured in U.S. dollars as a percent of our revenues will correspondingly increase and our margins will suffer.", -0.8], ["As a result, our operating results may be harmed.", -0.9], ["Our competitors or other third parties may hold or obtain patents, copyrights, trademarks or other proprietary rights that could prevent, limit or interfere with our ability to make, use, develop, sell or market our products and services, which could make it more difficult for us to operate our business.", -0.8], ["From time to time, the holders of such intellectual property rights may assert their rights and urge us to take licenses and/or may bring suits alleging infringement or misappropriation of such rights, which could result in substantial costs, negative publicity and management attention, regardless of merit.", -0.8], ["Accordingly, we may consider the entering into licensing agreements with respect to such rights, although no assurance can be given that such licenses can be obtained on acceptable terms or that litigation will not occur, and such licenses and associated litigation could significantly increase our operating expenses.", -0.8], ["In addition, if we are determined to have or believe there is a high likelihood that we have infringed upon a third party’s intellectual property rights, we may be required to cease making, selling or incorporating certain components or intellectual property into the goods and services we offer, to pay substantial damages and/or license royalties, to redesign our products and services and/or to establish and maintain alternative branding for our products and services.", -0.9], ["In the event that we are required to take one or more such actions, our brand, business, financial condition and operating results may be harmed.", -1.0], ["While our mission is to accelerate the world’s transition to sustainable energy, if our ESG practices do not meet investor or other industry stakeholder expectations, which continue to evolve, we may incur additional costs and our brand, ability to attract and retain qualified employees and business may be harmed.", -0.8], ["If major disasters such as earthquakes, floods or other climate-related events occur, or our information system or communication breaks down or operates improperly, our headquarters and production facilities may be seriously damaged, or we may have to stop or delay production and shipment of our products.", -1.0], ["In addition, the global COVID-19 pandemic has impacted economic markets, manufacturing operations, supply chains, employment and consumer behavior in nearly every geographic region and industry across the world, and we have been, and may in the future be, adversely affected as a result.", -0.9], ["Also, the broader consequences in the current conflict between Russia and Ukraine, which may include further embargoes, regional instability and geopolitical shifts; airspace bans relating to certain routes, or strategic decisions to alter certain routes; and potential retaliatory action by the Russian government against companies, and the extent of the conflict on our business and operating results cannot be predicted.", -0.9], ["We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.", -1.0], ["For example, previously available incentives favoring electric vehicles in areas including Ontario, Canada, Netherlands, Italy, Hong Kong and California have expired or were cancelled or temporarily unavailable, and in some cases were not eventually replaced or reinstituted, which may have negatively impacted sales.", -0.8], ["Such developments could negatively impact demand for our vehicles, and we and our customers may have to adjust to them, including through pricing modifications.", -0.8], ["In addition, certain governmental rebates, tax credits and other financial incentives that are currently available with respect to our solar and energy storage product businesses allow us to lower our costs and encourage customers to buy our products and investors to invest in our solar financing funds.", 0.5], ["Any reductions or terminations of such incentives may harm our business, prospects, financial condition and operating results by making our products less competitive for customers, increasing our cost of capital and adversely impacting our ability to attract investment partners and to form new financing funds for our solar and energy storage assets.", -0.9], ["Such determinations may result in adverse tax consequences and/or our obligation to make indemnification or other payments to our funds or fund investors.", -1], ["New, or changes in, environmental and climate change laws, regulations or rules could also lead to increased costs of compliance, including remediations of any discovered issues, and changes to our operations, which may be significant, and any failures to comply could result in significant expenses, delays or fines.", -1], ["If we are unable to successfully defend ourselves in such litigation or government investigations, it may harm our brand, ability to attract and retain qualified employees, business and financial condition.", -1], ["Such regulations continue to rapidly change, which increases the likelihood of a patchwork of complex or conflicting regulations, or may delay, restrict or prohibit the availability of certain functionalities and vehicle designs, which could adversely affect our business.", -1], ["If regulations and policies are introduced that adversely impact the import or export of components, or the interconnection, maintenance or use of our solar and energy storage systems, they could deter potential customers from purchasing our solar and energy storage products and services, threaten the economics of our existing contracts and cause us to cease solar and energy storage system sales and services in the relevant jurisdictions, which may harm our business, financial condition and operating results.", -1], ["Substantial expenses and operational changes may be required in connection with maintaining compliance with such laws, and even an unsuccessful challenge by customers or regulatory authorities of our activities could result in adverse publicity and could require a costly response from and defense by us.", -1], ["In addition, certain emerging privacy laws are still subject to a high degree of uncertainty as to their interpretation, application and impact, and may require extensive system and operational changes, be difficult to implement, increase our operating costs, adversely impact the cost or attractiveness of the products or services we offer, or result in adverse publicity and harm our reputation.", -1], ["Notwithstanding our efforts to protect the security and integrity of our customers’ personal information, we may be required to expend significant resources to comply with data breach requirements if, for example, third parties improperly obtain and use the personal information of our customers or we otherwise experience a data loss with respect to customers’ personal information.", -1], ["A major breach of our network security and systems may result in fines, penalties and damages and harm our brand, prospects and operating results.", -1], ["However, we cannot predict the outcome or impact of any such ongoing matters, and there exists the possibility that we could be subject to liability, penalties and other restrictive sanctions and adverse consequences if the SEC, the U.S. Department of Justice or any other government agency were to pursue legal action in the future.", -1], ["Moreover, we expect to incur costs in responding to related requests for information and subpoenas, and if instituted, in defending against any governmental proceedings.", -0.8], ["Pursuant to the settlement, we, among other things, paid a civil penalty of $20 million, appointed an independent director as the chair of our board of directors, appointed two additional independent directors to our board of directors and made further enhancements to our disclosure controls and other corporate governance-related matters.", -0.2], ["Although we intend to continue to comply with the terms and requirements of the settlement, if there is a lack of compliance or an alleged lack of compliance, additional enforcement actions or other legal proceedings may be instituted against us.", -0.7], ["While we intend to continue to leverage our most effective sales strategies, including sales through our website, we may not be able to sell our vehicles through our own stores in certain states in the U.S. with laws that may be interpreted to impose limitations on this direct-to-consumer sales model.", -0.5], ["We have prevailed in many of these lawsuits and such results have reinforced our continuing belief that state franchise laws were not intended to apply to a manufacturer that does not have franchise dealers anywhere in the world.", 0.5], ["Continued regulatory limitations and other obstacles interfering with our ability to sell vehicles directly to consumers may harm our financial condition and operating results.", -0.6], ["The trading price of our common stock has been highly volatile and could continue to be subject to wide fluctuations in response to various factors, some of which are beyond our control.", -0.7], ["While we defend such actions vigorously, any judgment against us or any future stockholder litigation could result in substantial costs and a diversion of our management’s attention and resources.", -0.8], ["We expect our period-to-period financial results to vary based on our operating costs, which we anticipate will fluctuate as the pace at which we continue to design, develop and manufacture new products and increase production capacity by expanding our current manufacturing facilities and adding future facilities, may not be consistent or linear between periods.", 0.2], ["Additionally, our revenues from period to period may fluctuate as we introduce existing products to new markets for the first time and as we develop and introduce new products.", 0.3], ["As a result of these factors, we believe that quarter-to-quarter comparisons of our financial results, especially in the short term, are not necessarily meaningful and that these comparisons cannot be relied upon as indicators of future performance.", -0.5], ["Moreover, our financial results may not meet expectations of equity research analysts, ratings agencies or investors, who may be focused only on short-term quarterly financial results.", -0.7], ["If any of this occurs, the trading price of our stock could fall substantially, either suddenly or over time.", -0.9], ["If our guidance varies from actual results, such as due to our assumptions not being met or the impact on our financial performance that could occur as a result of various risks and uncertainties, the market value of our common stock could decline significantly.", -0.8], ["If the price of our common stock were to decline substantially, Mr. Musk may be forced by one or more of the banking institutions to sell shares of Tesla common stock to satisfy his loan obligations if he could not do so through other means.", -0.9], ["Any such sales could cause the price of our common stock to decline further.", -0.8], ["Further, Mr. Musk from time to time may commit to investing in significant business or other ventures, and as a result, be required to sell shares of our common stock in satisfaction of such commitments.", -0.7], ["Any of the foregoing provisions and terms that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.", -0.8], ["We believe that any proceeding that is material to our business or financial condition is likely to have potential penalties far in excess of such amount.", -0.6], ["The German Umweltbundesamt issued our subsidiary in Germany a notice and fine in the amount of 12 million euro alleging its non-compliance under applicable laws relating to market participation notifications and take-back obligations with respect to end-of- life battery products required thereunder.", -0.7], ["In response to Tesla’s objection, the German Umweltbundesamt issued Tesla a revised fine notice dated April 29, 2021 in which it reduced the original fine amount to 1.45 million euro.", 0.2], ["A hearing took place on November 24, 2022, and the parties reached a settlement which resulted in a further reduction of the fine to 600,000 euro.", 0.5], ["While the outcome of this matter cannot be determined at this time, it is not currently expected to have a material adverse impact on our business.", 0.0], ["In 2022, we produced 1,369,611 consumer vehicles and delivered 1,313,851 consumer vehicles, despite ongoing supply chain and logistics challenges and factory shutdowns.", 0.3], ["In 2022, we recognized total revenues of $81.46 billion, respectively, representing an increase of $27.64 billion, compared to the prior year.", 0.8], ["In 2022, our net income attributable to common stockholders was $12.56 billion, representing a favorable change of $7.04 billion, compared to the prior year.", 0.9], ["We ended 2022 with $22.19 billion in cash and cash equivalents and investments, representing an increase of $4.48 billion from the end of 2021.", 0.7], ["Our cash flows provided by operating activities during 2022 and 2021 were $14.72 billion and $11.50 billion, respectively, representing an increase of $3.23 billion.", 0.7], ["Sustained growth has allowed our business to generally fund itself, and we will continue investing in a number of capital-intensive projects in upcoming periods.", 0.6], ["Our goals are to improve vehicle performance, decrease production costs and increase affordability.", 0.7], ["Our cost reduction efforts, cost innovation strategies, and additional localized procurement and manufacturing are key to our vehicles’ affordability, and for example, have allowed us to competitively price our vehicles in China.", 0.8], ["We will also continue to generate demand and brand awareness by improving our vehicles’ performance and functionality, including through products based on artificial intelligence such as Autopilot and FSD, and other software features, and delivering new vehicles, such as the Tesla Semi in December 2022.", 0.9], ["For example, in the earlier part of 2022, the automotive industry in general experienced part shortages and supplier disruptions which impacted production leading to a general increase in vehicle pricing.", -0.3], ["As the year progressed, inflationary pressures increased across the markets in which we operate.", -0.5], ["In an effort to curb this trend, central banks in developed countries raised interest rates rapidly and substantially, impacting the affordability of vehicle lease and finance arrangements.", -0.7], ["These macroeconomic and industry trends have had, and will likely continue to have, an impact on the pricing of, and order rate for our vehicles, and we will continue to adjust accordingly to such developments.", -0.6], ["As our production increases, we must work constantly to similarly increase vehicle delivery capability so that it does not become a bottleneck on our total deliveries.", 0.2], ["Beginning the second half of 2022, due to continuing challenges caused by vehicle transportation capacity during peak delivery periods, we began transitioning to a more even regional mix of vehicle builds each week, which led to an increase in cars in transit at the end of the year.", 0.1], ["Increasing the exports of vehicles manufactured at Gigafactory Shanghai has also been effective in mitigating the strain on our deliveries in markets outside of the United States, and we expect to benefit further from situating additional factories closer to local markets, including the production launch at Gigafactory Berlin-Brandenburg and Gigafactory Austin.", 0.7], ["The long-term success of this business is dependent upon increasing margins through greater volumes.", 0.5], ["We continue to increase the production of our energy storage products to meet high levels of demand.", 0.8], ["For Powerwall, better availability and growing grid stability concerns drive higher customer interest.", 0.7], ["We remain committed to growing our retrofit solar energy business by offering a low-cost and simplified online ordering experience.", 0.9], ["Our business has recently been consistently generating cash flow from operations in excess of our level of capital spend, and with better working capital management resulting in shorter days sales outstanding than days payable outstanding, our sales growth is also facilitating positive cash generation.", 0.9], ["On the other hand, we are likely to see heightened levels of capital expenditures during certain periods depending on the specific pace of our capital-intensive projects and rising material prices and increasing supply chain and labor expenses resulting from changes in global trade conditions and labor availability associated with the COVID-19 pandemic.", -0.3], ["Overall, we expect our ability to be self-funding to continue as long as macroeconomic factors support current trends in our sales.", 0.5], ["As long as we see expanding sales, and excluding the potential impact of macroeconomic conditions including increased labor costs and impairment charges on certain assets as explained below, we generally expect operating expenses relative to revenues to decrease as we continue to increase operational efficiency and process automation.", 0.4], ["We expect operating expenses to continue to grow in 2023 as we are expanding our operations globally.", -0.2], ["In the first quarter of 2021, we invested an aggregate $1.50 billion in bitcoin.", 0.2], ["Accordingly, any decrease in their fair values below our carrying values for such assets at any time subsequent to their acquisition will require us to recognize impairment charges, whereas we may make no upward revisions for any market price increases until a sale.", -0.7], ["For any digital assets held now or in the future, these charges may negatively impact our profitability in the periods in which such impairments occur even if the overall market values of these assets increase.", -0.8], ["For example, in the year ended December 31, 2022, we recorded $204 million of impairment losses resulting from changes to the carrying value of our bitcoin and gains of $64 million on certain conversions of bitcoin into fiat currency by us.", -0.5], ["To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows may be affected.", -0.7], ["Actual results could differ materially from these estimates under different assumptions or conditions.", -0.6], ["Any fees that are paid or payable by us to a customer’s lender when we arrange the financing are recognized as an offset against automotive sales revenue.", -0.4], ["On a quarterly basis, we assess the estimated market values of vehicles sold with resale value guarantees to determine whether there have been changes to the likelihood of future product returns.", -0.3], ["As we accumulate more data related to the resale values of our vehicles or as market conditions change, there may be material changes to their estimated values.", -0.5], ["We record inventory write-downs for excess or obsolete inventories based upon assumptions about current and future demand forecasts.", -0.7], ["If our inventory on-hand is in excess of our future demand forecast, the excess amounts are written-off.", -0.8], ["Once inventory is written-down, a new, lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.", -0.9], ["Should our estimates of future selling prices or production costs change, additional and potentially material write-downs may be required.", -0.8], ["A small change in our estimates may result in a material charge to our reported financial results.", -0.7], ["These estimates are inherently uncertain given our relatively short history of sales, and changes to our historical or projected warranty experience may cause material changes to the warranty reserve in the future.", -0.6], ["As we accumulate additional employee stock-based awards data over time and as we incorporate market data related to our common stock, we may calculate significantly different volatilities and expected lives, which could materially impact the valuation of our stock-based awards and the stock-based compensation expense that we will recognize in future periods.", -0.7], ["As of December 31, 2022, we had recorded a full valuation allowance on our net U.S. deferred tax assets because we expect that it is more likely than not that our U.S. deferred tax assets will not be realized.", -0.9], ["Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted.", -0.8], ["To the extent that the final tax outcome of these matters differs from our expectations, such differences may impact income tax expense in the period in which such determination is made.", -0.7], ["Automotive sales                   $ 67,210  $ 44,125  $ 24,604  $ 23,085      52 % $ 19,521       79 %", 0.8], ["Automotive regulatory credits               1,776    1,465    1,580    311      21 %   (115 )      (7 )%", 0.2], ["Total automotive revenues               71,462    47,232    27,236   24,230      51 %  19,996       73 %", 0.7], ["Automotive sales revenue increased $23.09 billion, or 52%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to an increase of 347,024 Model 3 and Model Y deliveries, and an increase of 38,183 Model S and Model X deliveries year over year.", 1.0], ["This was achieved from production ramping of Model Y at Gigafactory Shanghai and the Fremont Factory as well as the start of production at Gigafactory Berlin-Brandenburg and Gigafactory Texas in 2022, at a higher combined average selling price from a higher proportion of Model Y sales despite a negative impact from the United States dollar strengthening against other foreign currencies in 2022 compared to the prior period.", 0.5], ["There was also an increase in production of Model S and Model X and an increase in the combined average selling price of Model S and Model X with a higher proportion of Model X sales, compared to the prior period as deliveries of the new versions of Model S and Model X began ramping in the second and fourth quarters of 2021, respectively.", 0.5], ["Further, during the fourth quarter of 2022, we recognized $324 million in revenue related to the general FSD feature release in North America.", 1.0], ["Automotive regulatory credits revenue increased $311 million, or 21%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to changes in regulation which entitled us to additional consideration of $288 million in revenue in the first quarter of 2022 for credits sold previously, in the absence of which we had only an immaterial increase in automotive regulatory credits revenue.", 0.0], ["Automotive leasing revenue increased $834 million, or 51%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 1.0], ["Services and other revenue increased $2.29 billion, or 60%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 1.0], ["Energy generation and storage revenue increased $1.12 billion, or 40%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to an increase in energy storage deployments of Megapack, Powerwall and higher average selling price of Megapack, as well as on solar cash and loan deployments driven by price increases in 2022.", 1.0], ["Automotive sales                     $  49,599  $   32,415  $ 19,696  $ 17,184      53 %$ 12,719      65 %", 0.5], ["Gross profit total automotive Gross margin total automotive", 0.0], ["segment cost of revenues                  56,988     37,299   22,930   19,689      53 %  14,369      63 % Energy generation and storage segment  3,621    2,918    1,976  703 24 %    942 48 % Total cost of revenues                  $  60,609  $   40,217  $ 24,906  $ 20,392      51 %$ 15,311      61 %", -0.2], ["Gross profit total automotive & services and other segment", 0.1], ["Gross margin total automotive & services and other segment", 0.1], ["Cost of automotive sales revenue increased $17.18 billion, or 53%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, in line with the growth in revenue year over year, as discussed above.", 0.0], ["The average combined cost per unit of Model 3 and Model Y increased year over year due to rising raw material, logistics and warranty costs.", -0.5], ["There were also idle capacity charges of $306 million primarily related to the temporary suspension of production at Gigafactory Shanghai as well as the ramping up of production in Gigafactory Texas and our proprietary battery cells manufacturing during the year ended December 31, 2022.", -0.6], ["These increases were partially offset by a decrease in combined average Model S and Model X costs per unit driven by lower average cost for the new versions from ramping up production.", 0.2], ["Further, these increases in costs of revenue were positively impacted by the United States dollar strengthening against other foreign currencies in 2022 compared to the prior period.", 0.3], ["Cost of automotive leasing revenue increased $531 million, or 54%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to an increase in cumulative vehicles under our direct operating lease program and an increase in direct sales-type leasing cost of revenues from more activities in the current year.", -0.3], ["Cost of services and other revenue increased $1.97 billion, or 51%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", -0.3], ["The change is primarily due to an increase in used vehicle cost of revenue driven by increases in volume and costs of used Tesla and non-Tesla vehicle sales, an increase in non-warranty maintenance service revenue, and an increase in costs of paid Supercharging, insurance services and retail merchandise.", -0.2], ["Gross margin for total automotive decreased from 29.3% to 28.5% in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", -0.3], ["Gross margin for total automotive & services and other segment decreased from 26.9% to 26.5% in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to the automotive gross margin decrease discussed above, partially offset by an improvement in our services and other gross margin.", -0.2], ["Cost of energy generation and storage revenue increased $703 million, or 24%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to increases in energy storage deployments of Megapack and Powerwall, as well as higher average cost of solar cash and loan deployments due to increased component costs.", -0.1], ["Gross margin for energy generation and storage increased from -4.6% to 7.4% in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.5], ["R&D expenses increased $482 million, or 19%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", -0.2], ["The increase was primarily due to a $175 million increase in employee and labor related expenses, a $132 million increase in facilities, outside services, freight and depreciation expense, a $101 million increase in R&D expensed materials and an $87 million increase in stock-based compensation expense.", -0.1], ["R&D expenses as a percentage of revenue decreased from 5% to 4% in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.1], ["Our R&D expenses have decreased as a proportion of total revenues despite expanding product roadmap and technologies.", 0.2], ["(Dollars in millions)                       2022      2021     2020     $      %      $      % Selling, general and administrative             $   3,946  $   4,517  $   3,145  $  (571 )     (13 )%$  1,372      44 % As a percentage of revenues                      5 %      8 %     10 %", -0.1], ["SG&A expenses decreased $571 million, or 13%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", -0.1], ["There was also a decrease of $87 million in overall employee and labor related expenses driven by a decrease of $340 million of additional payroll tax due to our CEO's option exercises from the 2012 CEO Performance Award in 2021, partially offset by an increase in other employee and labor costs from increased headcount.", -0.2], ["These decreases were partially offset by an increase of $222 million in facilities-related expenses, and an increase of $117 million in professional services, sales and marketing activities and other costs.", -0.3], ["SG&A expenses as a percentage of revenue decreased from 8% to 5% in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.2], ["Our SG&A expenses have decreased as a proportion of total revenues due to the decrease in expenses as discussed above, in addition to operational efficiencies.", 0.3], ["During the years ended December 31, 2022 and 2021, we recorded $204 million and $101 million, respectively, of impairment losses on digital assets, respectively.", -0.5], ["During the years ended December 31, 2022 and 2021, we also realized gains of $64 million and", 0.4], ["$128 million, respectively, in connection with converting our holdings of digital assets into fiat currency.", 0.5], ["we recorded other expenses of $36 million during the second quarter of the year ended December 31, 2022, related to employee terminations.", -0.4], ["Interest income increased $241 million, or 430%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.8], ["This increase was primarily due to higher interest earned on our cash and cash equivalents and short-term investments during the year ended 2022 compared to the prior period.", 0.5], ["This was driven by an increase in our average cash and cash equivalents and short- term investments balance and rising interest rates.", 0.5], ["$   (191 )  $   (371 ) $   (748 ) $  180", -0.5], ["Interest expense decreased $180 million, or 49%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.5], ["This decrease was primarily due to the continued reduction in our overall debt balance offset by lower capitalized interest.", 0.0], ["Other (expense) income, net, consists primarily of foreign exchange gains and losses related to our foreign currency-denominated monetary assets and liabilities.", 0.0], ["Other (expense) income, net, changed unfavorably by $178 million in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", -0.5], ["Our provision for income taxes increased by $433 million, or 62%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to the increase in our pre-tax income year over year.", 0.5], ["Our effective tax rate decreased from 11% to 8% in the year ended December 31, 2022 as compared to the year ended December 31, 2021, primarily due to changes in mix of jurisdictional earnings.", 0.5], ["Net income attributable to noncontrolling interests and redeemable noncontrolling interests decreased by $94 million, or 75%, in the year ended December 31, 2022 as compared to the year ended December 31, 2021.", 0.5], ["We expect to continue to generate net positive operating cash flow as we have done in the last four fiscal years.", 0.8], ["For example, if our near-term manufacturing operations decrease in scale or ramp more slowly than expected, including due to global economic or business conditions, we may choose to correspondingly slow the pace of our capital expenditures.", -0.5], ["As discussed in and subject to the considerations referenced in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations—Management Opportunities, Challenges and Risks and 2023 Outlook—Cash Flow and Capital Expenditure Trends in this Annual Report on Form 10-K, we currently expect our capital expenditures to support our projects globally to be between $6.00 to $8.00 billion in 2023 and between $7.00 to $9.00 billion in each of the following two fiscal years.", 0.2], ["As of December 31, 2022, we and our subsidiaries had outstanding $2.06 billion in aggregate principal amount of indebtedness, of which $1.02 billion is scheduled to become due in the succeeding 12 months.", -0.7], ["Net cash provided by operating activities increased by $3.23 billion to $14.72 billion during the year ended December 31, 2022 from $11.50 billion during the year ended December 31, 2021.", 0.9], ["This increase was primarily due to the increase in net income excluding non-cash expenses, gains and losses of $7.65 billion, offset by the overall increase in net operating assets and liabilities of $4.43 billion.", 0.3], ["The increase in our net operating assets and liabilities was mainly driven by a larger increase of inventory in the year ended December 31, 2022 as compared to the year ended December 31, 2021, partially offset by a larger increase of accounts payable and accrued liabilities, to support the ramp up in production at our factories and larger increases in other non-current assets and prepaid expenses and other current assets.", 0.1], ["Additionally, cash inflows related to sales of digital assets were $936 million in the year ended December 31, 2022, and net cash outflows related to digital assets were $1.23 billion in the year ended December 31, 2021 from purchases of digital assets for $1.50 billion offset by proceeds from sales of digital assets of $272 million.", -0.2], ["Net cash used in financing activities decreased by $1.68 billion to $3.53 billion during the year ended December 31, 2022 from", 0.4], ["The decrease was primarily due to a $1.92 billion decrease in repayments of convertible and other debt, net of proceeds from issuances of debt.", 0.5], ["We have also experienced, and will continue to experience, fluctuations in our net income as a result of gains (losses) on the settlement and the re-measurement of monetary assets and liabilities denominated in currencies that are not the local currency (primarily consisting of our intercompany and cash and cash equivalents balances).", -0.5], ["These changes would have resulted in a gain or loss of $473 million at December 31, 2022 and $277 million at December 31, 2021, assuming no foreign currency hedging.", -0.3], ["Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.", -0.7], ["(1)  Prior period results have been adjusted to reflect the three-for-one stock split effected in the form of a stock dividend in August 2022.", 0.1], ["Buy-outs of noncontrolling interests                        (4 )     —      —    (31 )     —      —     (31 )      —   (31 )", -0.4], ["Buy-outs of noncontrolling interests                        (11 )     —      —    27      —      —      27      (61 )   (34 )", -0.4], ["Proceeds from issuances of common stock in public offerings, net of issuance costs", 0.5], ["Proceeds from exercises of stock options and other stock issuances", 0.5], ["Proceeds from investments by noncontrolling interests in subsidiaries", 0.5], ["Net cash (used in) provided by financing activities", -0.2], ["Net (decrease) increase in cash and cash equivalents and restricted cash", -0.5], ["There are ongoing global impacts resulting from the pandemic, and we have been affected by temporary manufacturing closures, employment and compensation adjustments and impediments to administrative activities supporting our product deliveries and deployments.", -0.8], ["In addition, we have experienced and are experiencing the impacts of varying levels of inflation caused by the COVID‐19 pandemic and general global economic conditions.", -0.7], ["On August 5, 2022, we increased the number of authorized shares of common stock by 4,000,000,000 shares and our Board of Directors declared the 2022 Stock Split.", 0.5], ["Each stockholder of record on August 17, 2022 received a dividend of two additional shares of common stock for each then-held share, distributed after close of trading on August 24, 2022.", 0.7], ["(1)  Pricing adjustments on our vehicle offerings can impact the estimate of likelihood that customers would exercise their resale value guarantees, resulting in an adjustment of our sales return reserve on vehicles sold with resale value guarantees.", -0.3], ["Actual return rates being lower than expected and increases in resale values of our vehicles in 2021 resulted in a net release of our reserve of $365 million for the year ended December 31, 2021, which represented increases in automotive sales revenue.", 0.6], ["Further, $324 million of the total revenue recognized as of December 31, 2022 is related to the general FSD feature release in North America in the fourth quarter of 2022.", 0.4], ["As we accumulate more data related to the resale values of our vehicles or as market conditions change, there may be material changes to their estimated values.", -0.4], ["The total sales return reserve on vehicles sold with resale value guarantees was $91 million and $223 million as of December 31, 2022 and 2021, respectively, of which $40 million and $91 million was short-term, respectively.", -0.2], ["$472 million as of December 31, 2022, primarily related to the general FSD feature release in North America in the fourth quarter of 2022.", 0.3], ["We had recognized revenue of $312 million from the deferred revenue balance as of December 31, 2020, for the year ended December 31, 2021.", 0.2], ["During the year ended December 31, 2022, we had also recognized $288 million in revenue due to changes in regulation which entitled us to additional consideration for credits sold previously.", 0.4], ["For the years ended December 31, 2022, 2021 and 2020, we recognized $1.75 billion, $1.25 billion and $752 million of direct vehicle leasing revenue, respectively.", 0.5], ["For the years ended December 31, 2022, 2021 and 2020, we recognized $683 million, $369 million and $120 million, respectively, of sales-type leasing revenue and $427 million, $234 million and $87 million, respectively, of sales-type leasing cost of revenue.", 0.4], ["In certain instances, we may receive a bonus payment if the system performs above a specified level.", 0.1], ["Conversely, if a solar energy system or energy storage system does not meet the performance guarantee requirements, we may be required to pay liquidated damages.", -0.3], ["As of December 31, 2022 and 2021, deferred revenue related to such customer payments amounted to $863 million and $399 million, respectively, mainly due to milestone payments.", 0.2], ["Revenue recognized from the deferred revenue balance as of December 31, 2021 and 2020 was $171 million and $93 million for the years ended December 31, 2022 and 2021, respectively.", 0.2], ["As of December 31, 2022 and 2021, deferred revenue related to such customer payments amounted to $191 million and $198 million, respectively.", 0.1], ["As of December 31, 2022 and 2021, deferred revenue from rebates and incentives amounted to $25 million and $27 million, respectively.", -0.1], ["Cost of energy generation and storage revenue also includes charges to write down the carrying value of our inventory when it exceeds its estimated net realizable value and to provide for obsolete and on-hand inventory in excess of forecasted demand.", -0.8], ["Comprehensive income is comprised of net income and other comprehensive (loss) income.", -0.5], ["Other comprehensive (loss) income consists of foreign currency translation adjustments and unrealized net gains and losses on investments that have been excluded from the determination of net income.", -0.5], ["We have determined that the contractual provisions of the funds represent substantive profit-sharing arrangements.", 0.2], ["For certain funds, there may be significant fluctuations in net income attributable to noncontrolling interests and redeemable noncontrolling interests in subsidiaries due to changes in the liquidation provisions as time-based milestones are reached.", -0.3], ["We recognize goodwill if the fair value of the total purchase consideration and any noncontrolling interests is in excess of the net fair value of the identifiable assets acquired and the liabilities assumed.", 0.1], ["We recognize a bargain purchase gain within Other (expense) income, net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration and any noncontrolling interests.", 0.1], ["Investments may be comprised of a combination of marketable securities, including U.S. government securities, corporate debt securities, time deposit, and certain certificates of deposit, which are all designated as available-for-sale and reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive income which is included within stockholders’ equity.", 0.0], ["Realized gains and losses on the sale of available-for-sale investments are recorded in Other (expense) income, net.", 0.0], ["These various factors may have a significant impact on our accounts receivable balance from period to period.", -0.2], ["As of December 31, 2022 and December 31, 2021, we had $753 million and $627 million, respectively, of long-term government rebates receivable in Other non-current assets in our consolidated balance sheets.", 0.3], ["Provisions for loan losses are charged to operations in amounts sufficient to maintain the allowance for loan losses at levels considered adequate to cover expected credit losses on the financing receivables.", -0.1], ["As of December 31, 2022 and 2021, the total outstanding balance of MyPower customer notes receivable, net of allowance for expected credit losses, was $280 million and $299 million, respectively, of which $7 million and $11 million were due in the next 12 months as of December 31, 2022 and 2021, respectively.", 0.2], ["As of December 31, 2022 and 2021, the allowance for expected credit losses was $37 million and $41 million, respectively.", 0.1], ["We are dependent on our suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of our products in a timely manner at prices, quality levels and volumes acceptable to us, or our inability to efficiently manage these components from these suppliers, could have a material adverse effect on our business, prospects, financial condition and operating results.", -0.8], ["We record inventory write-downs for excess or obsolete inventories based upon assumptions about current and future demand forecasts.", -0.4], ["If our inventory on-hand is in excess of our future demand forecast, the excess amounts are written-off.", -0.5], ["Should our estimates of future selling prices or production costs change, additional and potentially material write-downs may be required.", -0.6], ["A small change in our estimates may result in a material charge to our reported financial results.", -0.7], ["The gross cost of operating lease vehicles as of December 31, 2022 and December 31, 2021 was $6.08 billion and $5.28 billion, respectively.", -0.1], ["Operating lease vehicles on the consolidated balance sheets are presented net of accumulated depreciation of $1.04 billion and $773 million as of December 31, 2022 and December 31, 2021, respectively.", -0.1], ["We perform an analysis each quarter to identify whether events or changes in circumstances, principally decreases in the quoted prices on active exchanges, indicate that it is more likely than not that our digital assets are impaired.", -0.3], ["When the then current carrying value of a digital asset exceeds the fair value determined each quarter, an impairment loss has occurred with respect to those digital assets in the amount equal to the difference between their carrying values and the prices determined.", -0.5], ["Impairment losses are recognized within Restructuring and other in the consolidated statements of operations in the period in which the impairment is identified.", -0.4], ["Gains are not recorded until realized upon sale(s), at which point they are presented net of any impairment losses for the same digital assets held within Restructuring and other.", 0.2], ["In determining the gain to be recognized upon sale, we calculate the difference between the sales price and carrying value of the digital assets sold immediately prior to sale.", 0.1], ["Upon the retirement or sale of our property, plant and equipment, the cost and associated accumulated depreciation are removed from the consolidated balance sheet, and the resulting gain or loss is reflected on the consolidated statement of operations.", 0.0], ["We review our property, plant and equipment, solar energy systems, long-term prepayments and intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable.", -0.2], ["If the asset is not recoverable, its carrying amount would be adjusted down to its fair value.", -0.3], ["For the years ended December 31, 2022, 2021 and 2020, we have recognized no material impairments of our long-lived assets.", -0.1], ["For the years ended December 31, 2022, 2021 and 2020, we recorded a net foreign currency transaction loss of $89 million, gain of $97 million and loss of $114 million, respectively.", -0.2], ["The government incentives received by us are immaterial in all periods presented since the adoption of ASU 2021-10.", 0.0], ["Under the terms of the arrangement, the SUNY Foundation paid for a majority of the construction costs related to the manufacturing facility and the acquisition and commissioning of certain manufacturing equipment; and we are responsible for any construction or equipment costs in excess of such amount (refer to Note 15, Commitments and Contingencies).", 0.0], ["This incentive reduces the related lease costs of the facility within the Energy generation and storage cost of revenues and operating expense line items in our consolidated statements of operations.", 0.1], ["For the years ended December 31, 2022 and 2021, we received grant funding of $76 million and $6 million, respectively.", 0.2], ["These incentives offset the related costs of our facilities and are recorded as a reduction of the cost of the capital investment within the Property, plant and equipment, net line item in our consolidated balance sheets.", 0.1], ["The incentive therefore reduces the depreciation expense over the useful lives of the related equipment.", 0.1], ["In connection with the construction of Gigafactory Nevada, we entered into agreements with the State of Nevada and Storey County in Nevada that provide abatements for specified taxes, discounts to the base tariff energy rates and transferable tax credits of up to $195 million in consideration of capital investment and hiring targets that were met at Gigafactory Nevada.", 0.3], ["In connection with the construction of Gigafactory Texas, we entered into a 20-year agreement with Travis County in Texas pursuant to which we would receive grant funding equal to 70-80% of property taxes paid by us to Travis County and a separate 10- year agreement with the Del Valle Independent School District in Texas pursuant to which a portion of the taxable value of our property would be capped at a specified amount, in each case subject to our meeting certain minimum economic development metrics through our construction and operations at Gigafactory Texas.", 0.4], ["This incentive is recorded as a reduction of the related expenses within the Cost of automotive revenues and operating expense line items of our consolidated statements of operations.", -0.2], ["We recognized $91 million of expenses related to employer contributions for the 401(k) savings plan during the year ended December 31, 2022.", -0.3], ["The IRA includes multiple incentives to promote clean energy, electric vehicles, battery and energy storage manufacture or purchase, in addition to a new corporate alternative minimum tax of 15% on adjusted financial statement income of corporations with profits greater", 0.2], ["These measures may materially affect our consolidated financial statements, and we will continue to evaluate the applicability and effect of the IRA as more guidance is issued.", -0.4], ["Due to the recombination of the equity conversion component of our convertible debt remaining outstanding, additional paid in capital and convertible senior notes (mezzanine equity) were reduced.", -0.5], ["The removal of the remaining debt discounts recorded for this previous separation had the effect of increasing our net debt balance and the reduction of property, plant and equipment was related to previously capitalized interest.", -0.4], ["During the years ended December 31, 2022 and 2021, we purchased and/or received an immaterial amount and $1.50 billion, respectively, of digital assets.", 0.1], ["During the years ended December 31, 2022 and 2021, we recorded $204 million and $101 million of impairment losses on such digital assets, respectively.", -0.6], ["During the years ended December 31, 2022 and 2021, we realized gains of $64 million and $128 million, respectively, in connection with converting our holdings of digital assets into fiat currency.", 0.3], ["As of December 31, 2022 and 2021, the carrying value of our digital assets held was $184 million and $1.26 billion, which reflects cumulative impairments of $204 million and $101 million, each period, respectively.", -0.5], ["Goodwill decreased $6 million within the automotive segment from $200 million as of December 31, 2021 to $194 million as of December 31, 2022.", -0.5], ["The net carrying value of our intangible assets decreased from $257 million as of December 31, 2021 to $215 million as of December 31, 2022 mainly from amortization.", -0.5], ["We record gross realized gains, losses and credit losses as a component of Other (expense) income, net in the consolidated statements of operations.", -0.2], ["For the years ended December 31, 2022 and 2021, we did not recognize any material gross realized gains, losses or credit losses.", 0.0], ["The ending allowance balances for credit losses were immaterial as of December 31, 2022 and December 31, 2021.", 0.0], ["We have determined that the gross unrealized losses on our investments as of December 31, 2022 and December 31, 2021 were temporary in nature.", 0.1], ["We write-down inventory for any excess or obsolete inventories or when we believe that the net realizable value of inventories is less than the carrying value.", -0.6], ["During the years ended December 31, 2022, 2021 and 2020 we recorded write-downs of $144 million,", -0.7], ["$106 million and $145 million, respectively, in Cost of revenues in the consolidated statements of operations.", -0.7], ["Depreciation and amortization expense during the years ended December 31, 2022, 2021 and 2020 was $235 million, $236 million and $232 million, respectively.", -0.3], ["As of December 31, 2022 and 2021, there were $802 million and $1.02 billion, respectively, of gross solar energy systems under lease pass-through fund arrangements with accumulated depreciation of $148 million and $165 million, respectively.", -0.2], ["Depreciation expense during the years ended December 31, 2022, 2021 and 2020 was $2.42 billion, $1.91 billion and $1.57 billion, respectively.", -0.3], ["For the year ended December 31, 2022, accrued purchases increased as we continued construction and expansion of our facilities and operations.", 0.1], ["During the first quarter of 2022, the remaining $29 million in aggregate principal amount of the 2022 Notes was converted and settled in cash for their par amount, and 1.2 million shares of our common stock were issued for the applicable conversion premium, as adjusted to give effect to the 2022 Stock Split.", 0.2], ["we fully settled the warrants entered into in connection with the issuance of the 2022 Notes, resulting in the issuance of 37.0 million shares of our common stock, as adjusted to give effect to the 2022 Stock Split.", 0.1], ["In May 2019, we issued $1.84 billion in aggregate principal amount of our 2024 Notes in a public offering.", 0.3], ["The net proceeds from the issuance, after deducting transaction costs, were $1.82 billion.", 0.4], ["We received $174 million in cash proceeds from the sale of these warrants.", 0.5], ["The closing price of our common stock exceeded 130% of the applicable conversion price on at least 20 of the last 30 consecutive trading days of each quarter in 2022, causing the 2024 Notes to be convertible by their holders in the subsequent quarter.", 0.3], ["During the year ended December 31, 2022, $54 million in aggregate principal amount of the 2024 Notes was converted and settled in cash for their par amount, and 2.4 million shares of our common stock were issued for the applicable conversion premium, as adjusted to give effect to the 2022 Stock Split.", 0.2], ["The note hedges we entered into in connection with the issuance of the 2024 Notes were automatically settled with the respective conversions of the 2024 Notes, resulting in the receipt of 2.4 million shares of our common stock during the same period, as adjusted to give effect to the 2022 Stock Split.", -0.1], ["As of December 31, 2022, the if-converted value of the notes exceeds the outstanding principal amount by $186 million.", 0.2], ["$69 million and are included within Solar energy systems, net, on the consolidated balance sheet.", 0.0], ["During the year ended December 31, 2022, we early repaid $819 million in aggregate principal of the Solar Asset and Loan- backed Notes and recorded an extinguishment of debt charge of $24 million related to the early repayments in Interest expense in the consolidated statement of operations.", -0.3], ["In connection with the cash equity financing deals closed in 2016, our subsidiaries issued $502 million in aggregate principal amount of debt that bears interest at fixed rates.", 0.1], ["Tranche 12 of the 2018 CEO Performance Award, which represents 25.3 million stock options, was achieved in the fourth quarter of 2022 and will vest upon expected certification following the filing of this Annual Report on Form 10-K.", 0.3], ["The aggregate release date fair value of RSUs in the years ended December 31, 2022, 2021 and 2020 was $4.32 billion, $5.70 billion and $3.25 billion, respectively.", 0.2], ["The aggregate intrinsic value of options exercised in the years ended December 31, 2022, 2021, and 2020 was $1.90 billion,", 0.2], ["$26.88 billion and $1.55 billion, respectively.", 0.2], ["During the year ended December 31, 2021, our CEO exercised all of the remaining vested options from the 2012 CEO Performance Award, which amounted to an intrinsic value of $23.45 billion.", 0.3]], "tsla23_sentences.json": [["The aggregate market value of voting stock held by non-affiliates of the registrant, as of June 30, 2023, the last day of the registrant’s most recently completed second fiscal quarter, was $722.52 billion (based on the closing price for shares of the registrant’s Common Stock as reported by the NASDAQ Global Select Market on June 30, 2023).", 0.5], ["We intend to establish in the future an autonomous Tesla ride-hailing network, which we expect would also allow us to access a new customer base even as modes of transportation evolve.", 0.8], ["Historically, we have been able to achieve sales without traditional advertising and at relatively low marketing costs.", 0.7], ["In 2021, we launched our insurance product using real-time driving behavior in select states, which offers rates that are often better than other alternatives and promotes safer driving.", 0.9], ["Internationally, we also have manufacturing facilities in China (Gigafactory Shanghai) and Germany (Gigafactory Berlin- Brandenburg), which allows us to increase the affordability of our vehicles for customers in local markets by reducing transportation and manufacturing costs and eliminating the impact of unfavorable tariffs.", 0.6], ["For example, qualifying Tesla customers may receive up to $7,500 in federal tax credits for the purchase of qualified electric vehicles in the U.S. through 2032.", 0.7], ["We earn tradable credits in the operation of our business under various regulations related to zero-emission vehicles (“ZEVs”), greenhouse gas, fuel economy and clean fuel.", 0.6], ["Certain dealer associations have also actively lobbied state licensing agencies and legislators to interpret existing laws or enact new laws in ways not favorable to our ownership and operation of our own retail and service locations.", -0.7], ["Sales of electricity and non-sale equipment leases by third parties, such as our leases and PPAs, have faced regulatory challenges in some states and jurisdictions.", -0.6], ["In certain jurisdictions, regulators or utilities have reduced or eliminated the benefit available under net metering or have proposed to do so.", -0.5], ["Overall, we believe these announcements and vehicle introductions, including the introduction of electric vehicles into rental car company fleets, promote the development of the electric vehicle market by highlighting the attractiveness of electric vehicles relative to the internal combustion vehicle.", 0.8], ["Our incidents per vehicle continue to drop even as our production volumes increase.", 0.7], ["During the past year, Tesla made substantial investments in its workforce, further strengthening its standing as one of the most desirable and innovative companies to work for.", 0.9], ["Tesla’s growth of 35% over the past two years has offered internal career development to our employees as well as the ability to make a meaningful contribution to a sustainable future.", 0.9], ["In 2023, we hired over 1,900 Technician Trainees across the U.S., Germany and China.", 0.7], ["In 2023, we hired over 350 trainees for manufacturing and service roles through this program, providing an opportunity to transition into full- time employment.", 0.7], ["Our interns engage in meaningful work from day one, and we often offer them full-time positions post-internship.", 0.8], ["These programs aim to convert high-performing individuals to full-time roles and create a veteran talent pipeline.", 0.7], ["We hired 373 graduates through this program in 2023, and our goal in 2024 is grow this program to over 600 students annually across our Fremont Factory, Gigafactory Nevada, Gigafactory Texas and Gigafactory New York.", 0.8], ["You should carefully consider the risks described below together with the other information set forth in this report, which could materially affect our business, financial condition and future results.", -0.8], ["Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results.", -0.9], ["We have previously experienced and may in the future experience launch and production ramp delays for new products and features.", -0.7], ["For example, we encountered unanticipated supplier issues that led to delays during the initial ramp of our first Model X and experienced challenges with a supplier and with ramping full automation for certain of our initial Model 3 manufacturing processes.", -0.6], ["Bottlenecks and other unexpected challenges such as those we experienced in the past may arise during our production ramps, and we must address them promptly while continuing to improve manufacturing processes and reducing costs.", -0.8], ["If we are not successful in achieving these goals, we could face delays in establishing and/or sustaining our product ramps or be unable to meet our related cost and profitability targets.", -0.9], ["Any delay or other complication in ramping the production of our current products or the development, manufacture, launch and production ramp of our future products, features and services, or in doing so cost-effectively and with high quality, may harm our brand, business, prospects, financial condition and operating results.", -0.9], ["For example, a global shortage of semiconductors beginning in early 2021 has caused challenges in the manufacturing industry and impacted our supply chain and production.", -0.8], ["The unavailability of any component or supplier could result in production delays, idle manufacturing facilities, product design changes and loss of access to important technology and tools for producing and supporting our products, as well as impact our capacity expansion and our ability to fulfill our obligations under customer contracts.", -0.9], ["We have faced in the past, and may face suppliers who are unwilling or unable to sustainably meet our timelines or our cost, quality and volume needs, which may increase our costs or require us to replace them with other sources.", -0.8], ["Additionally, we may be unsuccessful in our continuous efforts to negotiate with existing suppliers to obtain cost reductions and avoid unfavorable changes to terms, source less expensive suppliers for certain parts and redesign certain parts to make them less expensive to produce, especially in the case of increases in materials pricing.", -0.8], ["Any of these occurrences may harm our business, prospects, financial condition and operating results.", -1.0], ["If we are unable to accurately match the timing and quantities of component purchases to our actual needs or successfully implement automation, inventory management and other systems to accommodate the increased complexity in our supply chain and parts management, we may incur unexpected production disruption, storage, transportation and write-off costs, which may harm our business and operating results.", -1.0], ["If we experience any issues or delays in meeting our projected timelines, costs, capital efficiency and production capacity for our new factories, expanding and managing teams to implement iterative design and production changes there, maintaining and complying with the terms of any debt financing that we obtain to fund them or generating and maintaining demand for the vehicles we manufacture there, our business, prospects, operating results and financial condition may be harmed.", -1.0], ["If we experience production delays or inaccurately forecast demand, our business, financial condition and operating results may be harmed.", -1.0], ["If we experience delays in adding servicing capacity or servicing our vehicles efficiently, or experience unforeseen issues with the reliability of our vehicles, particularly higher-volume additions to our fleet such as Model 3 and Model Y, it could overburden our servicing capabilities and parts inventory.", -0.8], ["These plans require significant cash investments and management resources and there is no guarantee that they will generate additional sales or installations of our products, or that we will be able to avoid cost overruns or be able to hire additional personnel to support them.", -0.7], ["If we fail to manage our growth effectively, it may harm our brand, business, prospects, financial condition and operating results.", -1.0], ["We are dependent on the continued supply of lithium-ion battery cells for our vehicles and energy storage products, and we will require substantially more cells to grow our business according to our plans.", -0.8], ["Any disruption in the supply of battery cells from our suppliers could limit production of our vehicles and energy storage products.", -0.9], ["In the long term, we intend to supplement cells from our suppliers with cells manufactured by us, which we believe will be more efficient, manufacturable at greater volumes and more cost-effective than currently available cells.", 0.5], ["However, our efforts to develop and manufacture such battery cells have required, and may continue to require, significant investments, and there can be no assurance that we will be able to achieve these targets in the timeframes that we have planned or at all.", -0.8], ["unable to do so, we may have to curtail our planned vehicle and energy storage product production or procure additional cells from suppliers at potentially greater costs, either of which may harm our business and operating results.", -0.9], ["Any reduced availability of these materials may impact our access to cells and our growth, and any increases in their prices may reduce our profitability if we cannot recoup such costs through increased prices.", -0.7], ["Moreover, our inability to meet demand and any product price increases may harm our brand, growth, prospects and operating results.", -0.8], ["Though we continue to see increased interest and adoption of electric vehicles, if the market for electric vehicles in general and Tesla vehicles in particular does not develop as we expect, develops more slowly than we expect, or if demand for our vehicles decreases in our markets or our vehicles compete with each other, our business, prospects, financial condition and operating results may be harmed.", -0.7], ["As a result, the market for our vehicles could be negatively affected by numerous factors, such as:", -0.6], ["The target demographics for our vehicles are highly competitive.", -0.5], ["Sales of vehicles in the automotive industry tend to be cyclical in many markets, which may expose us to further volatility.", -0.6], ["Rising interest rates may lead to consumers to increasingly pull back spending, including on our products, which may harm our demand, business and operating results.", -0.7], ["If we experience unfavorable global market conditions, or if we cannot or do not maintain operations at a scope that is commensurate with such conditions or are later required to or choose to suspend such operations again, our business, prospects, financial condition and operating results may be harmed.", -0.8], ["In addition, certain government and economic incentives which provide benefits to manufacturers who assemble domestically or have local suppliers, may provide a greater benefit to our competitors, which could negatively impact our profitability.", -0.8], ["Increased", -0.2], ["competition could result in our lower vehicle unit sales, price reductions, revenue shortfalls, loss of customers and loss of market share, which may harm our business, financial condition and operating results.", -0.9], ["Decreases in the retail or wholesale prices of electricity from utilities or other renewable energy sources could make our products less attractive to customers and lead to an increased rate of customer defaults.", -0.8], ["Our plan to grow the volume and profitability of our vehicles and energy storage products depends on significant lithium-ion battery cell production, including by our partner Panasonic at Gigafactory Nevada.", 0.5], ["If we are unable to or otherwise do not maintain and grow our respective operations, or if we are unable to do so cost-effectively or hire and retain highly- skilled personnel there, our ability to manufacture our products profitably would be limited, which may harm our business and operating results.", -0.7], ["Any such disruptions or issues may harm our brand and business.", -0.6], ["Such conditions may increase our costs, impact our ability to sell our products and require significant management attention, and may harm our business if we are unable to manage them effectively.", -0.7], ["If our products contain design or manufacturing defects, whether relating to our software or hardware, that cause them not to perform as designed or intended or that require repair, or certain features of our vehicles such as new Autopilot or FSD Capability features take longer than expected to become enabled, are legally restricted or become subject to onerous regulation, our ability to develop, market and sell our products and services may be harmed, and we may experience delivery delays, product recalls, allegations of product liability, breach of warranty and related consumer protection claims and significant warranty and other expenses.", -0.9], ["The automobile industry generally experiences significant product liability claims, and as such we face the risk of such claims in the event our vehicles do not perform or are claimed to not have performed as expected.", -0.8], ["As is true for other automakers, our vehicles have been involved and we expect in the future will be involved in accidents resulting in death or personal injury, and such accidents where Autopilot, Enhanced Autopilot or FSD Capability features are engaged are the subject of significant public attention, especially in light of NHTSA’s Standing General Order requiring reports regarding crashes involving vehicles with advanced driver assistance systems.", -0.8], ["We have experienced, and we expect to continue to face, claims and regulatory scrutiny arising from or related to misuse or claimed failures or alleged misrepresentations of such new technologies that we are pioneering.", -0.7], ["Any product liability claim may subject us to lawsuits and substantial monetary damages, product recalls or redesign efforts, and even a meritless claim may require us to defend it, all of which may generate negative publicity and be expensive and time-consuming.", -0.9], ["Maintaining such confidence may be challenging due to our limited operating history relative to established competitors; customer unfamiliarity with our products; any delays we may experience in scaling manufacturing, delivery and service operations to meet demand; competition and uncertainty regarding the future of electric vehicles or our other products and services; our quarterly production and sales performance compared with market expectations; and other factors including those over which we have no control.", -0.6], ["Any such negative perceptions, whether caused by us or not, may harm our business and make it more difficult to raise additional funds if needed.", -0.8], ["If we do not successfully monitor and comply with applicable national, state and/or local financial regulations and consumer protection laws governing these transactions, we may become subject to enforcement actions or penalties.", -0.7], ["The profitability of any directly-leased vehicles returned to us at the end of their leases depends on our ability to accurately project our vehicles’ residual values at the outset of the leases, and such values may fluctuate prior to the end of their terms depending on various factors such as supply and demand of our used vehicles, economic cycles and the pricing of new vehicles.", -0.6], ["We have made in the past and may make in the future certain adjustments to our prices from time to time in the ordinary course of business, which may impact the residual values of our vehicles and reduce the profitability of our vehicle leasing program.", -0.5], ["If we are unable to adequately fund our leasing program through internal funds, partners or other financing sources, and compelling alternative financing programs are not available for our customers who may expect or need such options, we may be unable to grow our vehicle deliveries.", -0.7], ["If the actual resale values of any vehicles resold or returned to us pursuant to these programs are materially lower than the pre- determined amounts we have offered, our financial condition and operating results may be harmed.", -0.8], ["In the event of a widespread economic downturn or other catastrophic event, our customers may be unable or unwilling to satisfy their payment obligations to us on a timely basis or at all.", -0.9], ["If a significant number of our customers default, we may incur substantial credit losses and/or impairment charges with respect to the underlying assets.", -0.8], ["While we expect to have and grow significant operations at Gigafactory New York and the surrounding Buffalo area, any failure by us in any year over the course of the term of the agreement to meet all applicable future obligations may result in our obligation to pay a “program payment” of $41 million to the SUNY Foundation for such year, the termination of our lease at Gigafactory New York which may require us to pay additional penalties, and/or the need to adjust certain of our operations.", -0.7], ["Any of the foregoing events may harm our business, financial condition and operating results.", -0.9], ["The loss of the services of any of our key employees or any significant portion of our workforce could disrupt our operations or delay the development, introduction and ramp of our products and services.", -0.8], ["If we are not successful in managing these risks, our business, financial condition and operating results may be harmed.", -0.8], ["Employees may leave Tesla or choose other employers over Tesla due to various factors, such as a very competitive labor market for talented individuals with automotive or technology experience, or any negative publicity related to us.", -0.7], ["If we are unable to obtain the requisite stockholder approvals for such future increases, we may have to expend additional cash to compensate our employees and our ability to retain and hire qualified personnel may be harmed.", -0.8], ["To the extent any security incident results in unauthorized access or damage to or acquisition, use, corruption, loss, destruction, alteration or dissemination of our data, including intellectual property and personal information, or our products or vehicles, or for it to be believed or reported that any of these occurred, it could disrupt our business, harm our reputation, compel us to comply with applicable data breach notification laws, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information.", -0.9], ["This could result in increased costs to us and result in significant legal and financial exposure and/or reputational harm.", -0.8], ["Moreover, if we do not successfully implement, maintain or expand these systems as planned, our operations may be disrupted, our ability to accurately and/or timely report our financial results could be impaired and deficiencies may arise in our internal control over financial reporting, which may impact our ability to certify our financial results.", -0.8], ["Any unauthorized access to or control of our products or their systems or any loss of data could result in legal claims or government investigations.", -0.9], ["In addition, regardless of their veracity, reports of unauthorized access to our products, their systems or data, as well as other factors that may result in the perception that our products, their systems or data are capable of being hacked, may harm our brand, prospects and operating results.", -0.7], ["Any unfavorable ultimate outcome for Tesla may have a negative impact on the perception of Tesla’s treatment of our employees.", -0.8], ["Any work stoppages or strikes organized by such unions could delay the manufacture and sale of our products and may harm our business and operating results.", -0.7], ["Recalls for our vehicles have resulted from various hardware and software-related safety concerns or non-compliance determinations.", -0.6], ["In addition to recalls initiated by us for various causes, testing of or investigations into our products by government regulators or industry groups may compel us to initiate product recalls or may result in negative public perceptions about the safety of our products, even if we disagree with the defect determination or have data that contradicts it.", -0.7], ["Such recalls, whether voluntary or involuntary or caused by systems or components engineered or manufactured by us or our suppliers, could result in significant expense, supply chain complications and service burdens, and may harm our brand, business, prospects, financial condition and operating results.", -0.8], ["If our warranty reserves are inadequate to cover future warranty claims on our products, our financial condition and operating results may be harmed.", -0.7], ["We may be subject, in the ordinary course of business, to losses resulting from products liability, accidents, acts of God and other claims against us, for which we may have no insurance coverage.", -0.9], ["A loss that is uninsured or which exceeds policy limits may require us to pay substantial amounts, which may harm our financial condition and operating results.", -1], ["Furthermore, our failure to comply with our debt covenants could result in a default under our debt agreements, which could permit the holders to accelerate our obligation to repay the debt.", -1], ["If any of our debt is accelerated, we may not have sufficient funds available to repay it.", -1], ["If we cannot raise additional funds when we need them, our financial condition, results of operations, business and prospects could be materially and adversely affected.", -1], ["The useful life of any equipment that would be retired early as a result would be shortened, causing the depreciation on such equipment to be accelerated, and our results of operations may be harmed.", -1], ["Our consolidated indebtedness may increase our vulnerability to any generally adverse economic and industry conditions.", -1], ["Our business may not continue to generate cash flow from operations in the future sufficient to satisfy our obligations under our existing indebtedness and any future indebtedness we may incur, and to make necessary capital expenditures.", -1], ["If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as reducing or delaying investments or capital expenditures, selling assets, refinancing or obtaining additional equity capital on terms that may be onerous or highly dilutive.", -1], ["We may not be able to engage in these activities on desirable terms or at all, which may result in a default on our existing or future indebtedness and harm our financial condition and operating results.", -1], ["To the extent we have significant revenues denominated in such foreign currencies, any strengthening of the U.S. dollar would tend to reduce our revenues as measured in U.S. dollars, as we have historically experienced, and are currently experiencing.", -1], ["If we do not have fully offsetting revenues in these currencies and if the value of the U.S. dollar depreciates significantly against these currencies, our costs as measured in U.S. dollars as a percent of our revenues will correspondingly increase and our margins will suffer.", -1], ["As a result, our operating results may be harmed.", -1], ["Our competitors or other third parties may hold or obtain patents, copyrights, trademarks or other proprietary rights that could prevent, limit or interfere with our ability to make, use, develop, sell or market our products and services, which could make it more difficult for us to operate our business.", -1], ["From time to time, the holders of such intellectual property rights may assert their rights and urge us to take licenses and/or may bring suits alleging infringement or misappropriation of such rights, which could result in substantial costs, negative publicity and management attention, regardless of merit.", -1], ["The theft or unauthorized use or publication of our trade secrets and confidential information could affect our competitive position.", -1], ["While we endeavor to obtain and protect the intellectual property rights that we expect will allow us to retain or advance our strategic initiatives in these circumstances, there can be no assurance that we will be able to adequately identify and protect the portions of intellectual property that are strategic to our business, or mitigate the risk of potential suits or other legal demands by third parties.", -1], ["Accordingly, we may consider the entering into licensing agreements with respect to such rights, although no assurance can be given that such licenses can be obtained on acceptable terms or that litigation will not occur, and such licenses and associated litigation could significantly increase our operating expenses.", -1], ["In the event that we are required to take one or more such actions, our brand, business, financial condition and operating results may be harmed.", -1], ["While our mission is to accelerate the world’s transition to sustainable energy, if our ESG practices do not meet investor or other industry stakeholder expectations, which continue to evolve, we may incur additional costs and our brand, ability to attract and retain qualified employees and business may be harmed.", -1], ["If major disasters such as earthquakes, floods or other climate-related events occur, or our information system or communication breaks down or operates improperly, our headquarters and production facilities may be seriously damaged, or we may have to stop or delay production and shipment of our products.", -1], ["In addition, the global COVID-19 pandemic has impacted economic markets, manufacturing operations, supply chains, employment and consumer behavior in nearly every geographic region and industry across the world, and we have been, and may in the future be, adversely affected as a result.", -0.8], ["We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.", -0.9], ["For example, previously available incentives favoring electric vehicles in certain areas have expired or were cancelled or temporarily unavailable, and in some cases were not eventually replaced or reinstituted, which may have negatively impacted sales.", -0.7], ["Such developments could negatively impact demand for our vehicles, and we and our customers may have to adjust to them, including through pricing modifications.", -0.6], ["In addition, certain governmental rebates, tax credits and other financial incentives that are currently available with respect to our solar and energy storage product businesses allow us to lower our costs and encourage customers to buy our products and investors to invest in our solar financing funds.", 0.5], ["However, these incentives may expire when the allocated funding is exhausted, reduced or terminated as renewable energy adoption rates increase, sometimes without warning.", -0.4], ["The benefit available under net metering has been or has been proposed to be reduced, altered or eliminated in several jurisdictions, and has also been contested and may continue to be contested before the Federal Energy Regulatory Commission.", -0.5], ["Any reductions or terminations of such incentives may harm our business, prospects, financial condition and operating results by making our products less competitive for customers, increasing our cost of capital and adversely impacting our ability to attract investment partners and to form new financing funds for our solar and energy storage assets.", -0.8], ["Such determinations may result in adverse tax consequences and/or our obligation to make indemnification or other payments to our funds or fund investors.", -0.7], ["remediations of any discovered issues, and changes to our operations, which may be significant, and any failures to comply could result in significant expenses, delays or fines.", -0.9], ["If we are unable to successfully defend ourselves in such litigation or government investigations, it may harm our brand, ability to attract and retain qualified employees, business and financial condition.", -0.9], ["Such regulations continue to rapidly change, which increases the likelihood of a patchwork of complex or conflicting regulations, or may delay, restrict or prohibit the availability of certain functionalities and vehicle designs, which could adversely affect our business.", -0.8], ["If regulations and policies are introduced that adversely impact the import or export of components, or the interconnection, maintenance or use of our solar and energy storage systems, they could deter potential customers from purchasing our solar and energy storage products and services, threaten the economics of our existing contracts and cause us to cease solar and energy storage system sales and services in the relevant jurisdictions, which may harm our business, financial condition and operating results.", -0.9], ["Any failure by us or our vendors or other business partners to comply with our public privacy notice or with federal, state or international privacy, data protection or security laws or regulations relating to the processing, collection, use, retention, security and transfer of personally identifiable information could result in regulatory or litigation-related actions against us, legal liability, fines, damages, ongoing audit requirements and other significant costs.", -0.9], ["Substantial expenses and operational changes may be required in connection with maintaining compliance with such laws, and even an unsuccessful challenge by customers or regulatory authorities of our activities could result in adverse publicity and could require a costly response from and defense by us.", -0.8], ["In addition, certain privacy laws are still subject to a high degree of uncertainty as to their interpretation, application and impact, and may require extensive system and operational changes, be difficult to implement, increase our operating costs, adversely impact the cost or attractiveness of the products or services we offer, or result in adverse publicity and harm our reputation.", -0.8], ["Complying with emerging and changing requirements may cause us to incur substantial costs and make enhancements to relevant data practices.", -0.7], ["Noncompliance could result in significant penalties or legal liability.", -0.8], ["A major breach of our network security and systems may occur despite defensive measures, and may result in fines, penalties and damages and harm our brand, prospects and operating results.", -0.9], ["However, we cannot predict the outcome or impact of any such ongoing matters, and there exists the possibility that we could be subject to liability, penalties and other restrictive sanctions and adverse consequences if the SEC, the U.S. Department of Justice or any other government agency were to pursue legal action in the future.", -0.8], ["Moreover, we expect to incur costs in responding to related requests for information and subpoenas, and if instituted, in defending against any governmental proceedings.", -0.8], ["Continued regulatory limitations and other obstacles interfering with our ability to sell vehicles directly to consumers may harm our financial condition and operating results.", -0.9], ["The trading price of our common stock has been highly volatile and could continue to be subject to wide fluctuations in response to various factors, some of which are beyond our control.", -0.7], ["Our common stock has experienced over the last 52 weeks an intra-day trading high of $299.29 per share and a low of $152.37 per share.", 0.1], ["In particular, a large proportion of our common stock has been historically and may in the future be traded by short sellers which may put pressure on the supply and demand for our common stock, further influencing volatility in its market price.", -0.6], ["While we defend such actions vigorously, any judgment against us or any future stockholder litigation could result in substantial costs and a diversion of our management’s attention and resources.", -0.8], ["We expect our period-to-period financial results to vary based on our operating costs, which we anticipate will fluctuate as the pace at which we continue to design, develop and manufacture new products and increase production capacity by expanding our current manufacturing facilities and adding future facilities, may not be consistent or linear between periods.", 0.2], ["Additionally, our revenues from period to period may fluctuate as we introduce existing products to new markets for the first time and as we develop and introduce new products.", 0.3], ["Moreover, our financial results may not meet expectations of equity research analysts, ratings agencies or investors, who may be focused only on short-term quarterly financial results.", -0.5], ["If any of this occurs, the trading price of our stock could fall substantially, either suddenly or over time.", -0.9], ["If our guidance varies from actual results, such as due to our assumptions not being met or the impact on our financial performance that could occur as a result of various risks and uncertainties, the market value of our common stock could decline significantly.", -0.9], ["If the price of our common stock were to decline substantially, Mr. Musk may be forced by one or more of the banking institutions to sell shares of Tesla common stock to satisfy his loan obligations if he could not do so through other means.", -0.8], ["Any such sales could cause the price of our common stock to decline further.", -0.7], ["Further, Mr. Musk from time to time may commit to investing in significant business or other ventures, and as a result, be required to sell shares of our common stock in satisfaction of such commitments.", -0.6], ["Any of the foregoing provisions and terms that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.", -0.8], ["We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading “Our information technology systems or data, or those of our service providers or customers or users could be subject to cyber-attacks or other security incidents, which could result in data breaches, intellectual property theft, claims, litigation, regulatory investigations, significant liability, reputational damage and other adverse consequences” included as part of our risk factor disclosures at Item 1A of this Annual Report on Form 10-K.", -0.7], ["We believe that any proceeding that is material to our business or financial condition is likely to have potential penalties far in excess of such amount.", -0.8], ["We have never declared or paid cash dividends on our common stock.", -0.9], ["We currently do not anticipate paying any cash dividends in the foreseeable future.", -0.9], ["We have never declared or paid cash dividends on our common stock nor do we anticipate paying any such cash dividends in the foreseeable future.", -0.9], ["In 2023, we recognized total revenues of $96.77 billion, representing an increase of $15.31 billion, compared to the prior year.", 0.8], ["In 2023, our net income attributable to common stockholders was $15.00 billion, representing a favorable change of $2.44 billion, compared to the prior year.", 0.7], ["This included a one-time non-cash tax benefit of $5.93 billion for the release of valuation allowance on certain deferred tax assets.", 0.3], ["We ended 2023 with $29.09 billion in cash and cash equivalents and investments, representing an increase of $6.91 billion from the end of 2022.", 0.6], ["Our cash flows provided by operating activities in 2023 and 2022 were $13.26 billion and $14.72 billion, respectively, representing a decrease of $1.47 billion.", -0.3], ["Capital expenditures amounted to $8.90 billion in 2023, compared to $7.16 billion in 2022, representing an increase of $1.74 billion.", 0.2], ["For example, during the third quarter of 2023, we experienced a sequential decline in production volumes due to pre-planned shutdowns for upgrades at various factories.", -0.5], ["Our cost reduction efforts, cost innovation strategies, and additional localized procurement and manufacturing are key to our vehicles’ affordability and have allowed us to competitively price our vehicles.", 0.5], ["Moreover, we expect to continue to benefit from ongoing electrification of the automotive sector and increasing environmental regulations and initiatives.", 0.7], ["However, we operate in a cyclical industry that is sensitive to political and regulatory uncertainty, including with respect to trade and the environment, all of which can be compounded by inflationary pressures, rising energy prices, interest rate fluctuations and the liquidity of enterprise customers.", -0.6], ["For example, inflationary pressures have increased across the markets in which we operate.", -0.5], ["In an effort to curb this trend, central banks in developed countries raised interest rates rapidly and substantially, impacting the affordability of vehicle lease and finance arrangements.", -0.7], ["Further, sales of vehicles in the automotive industry also tend to be cyclical in many markets, which may expose us to increased volatility as we expand and adjust our operations.", -0.6], ["Additionally, our suppliers’ liquidity and allocation plans may be affected by current challenges in the North American automotive industry, which could reduce our access to components or result in unfavorable changes to cost.", -0.8], ["These macroeconomic and industry trends have had, and will likely continue to have, an impact on the pricing of, and order rate for our vehicles, and in turn our operating margin.", -0.7], ["Changes in government and economic incentives in relation to electric vehicles may also impact our sales.", -0.4], ["We will continue to adjust accordingly to such developments, and we believe our ongoing cost reduction, including improved production innovation and efficiency at our newest factories and lower logistics costs, and focus on operating leverage will continue to benefit us in relation to our competitors, while our new products will help enable future growth.", 0.6], ["We are also committed to reducing the percentage of vehicles delivered in the third month of each quarter, which will help to reduce the cost per vehicle.", 0.5], ["The long-term success of this business is dependent upon increasing margins through greater volumes.", 0.3], ["We continue to increase the production of our energy storage products to meet high levels of demand, including the construction of a new Megafactory in Shanghai and the ongoing ramp at our Megafactory in Lathrop, California.", 0.7], ["Owing and subject to the foregoing as well as the pipeline of announced projects under development, all other continuing infrastructure growth and varying levels of inflation, we currently expect our capital expenditures to exceed $10.00 billion in 2024 and be between $8.00 to $10.00 billion in each of the following two fiscal years.", -0.1], ["Our business has been consistently generating cash flow from operations in excess of our level of capital spend, and with better working capital management resulting in shorter days sales outstanding than days payable outstanding, our sales growth is also generally facilitating positive cash generation.", 0.8], ["At the same time, we are likely to see heightened levels of capital expenditures during certain periods depending on the specific pace of our capital-intensive projects and other potential variables such as rising material prices and increases in supply chain and labor expenses resulting from changes in global trade conditions and labor availability.", -0.2], ["Overall, we expect our ability to be self-funding to continue as long as macroeconomic factors support current trends in our sales.", 0.5], ["To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows may be affected.", -0.5], ["We record inventory write-downs for excess or obsolete inventories based upon assumptions about current and future demand forecasts.", -0.6], ["If our inventory on-hand is in excess of our future demand forecast, the excess amounts are written-off.", -0.7], ["Once inventory is written-down, a new, lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.", -0.6], ["Should our estimates of future selling prices or production costs change, additional and potentially material write-downs may be required.", -0.8], ["A small change in our estimates may result in a material charge to our reported financial results.", -0.9], ["These estimates are inherently uncertain and changes to our historical or projected warranty experience may cause material changes to the warranty reserve in the future.", -0.5], ["As we accumulate additional employee stock-based awards data over time and as we incorporate market data related to our common stock, we may calculate significantly different volatilities and expected lives, which could materially impact the valuation of our stock-based awards and the stock-based compensation expense that we will recognize in future periods.", -0.5], ["To the extent that the final tax outcome of these matters differs from our expectations, such differences may impact income tax expense in the period in which such determination is made.", -0.5], ["Our revenue from automotive regulatory credits is directly related to our new vehicle production, sales and pricing negotiated with our customers.", 0.0], ["Automotive sales revenue increased $11.30 billion, or 17%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to an increase of 473,382 combined Model 3 and Model Y cash deliveries from production ramping of Model Y globally.", 0.8], ["The increase was partially offset by a lower average selling price on our vehicles driven by overall price reductions year over year, sales mix, and a negative impact from the United States dollar strengthening against other foreign currencies in the year ended December 31, 2023 compared to the prior year.", -0.2], ["Automotive regulatory credits revenue increased $14 million, or 1%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.1], ["Automotive leasing revenue decreased $356 million, or 14%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", -0.3], ["The decrease was primarily due to a decrease in direct sales-type leasing revenue driven by lower deliveries year over year, partially offset by an increase from our growing direct operating lease portfolio.", -0.2], ["Services and other revenue increased $2.23 billion, or 37%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.7], ["The increase was primarily due to higher used vehicle revenue driven by increases in volume, body shop and part sales revenue, non-warranty maintenance services revenue, paid Supercharging revenue and insurance services revenue, all of which are primarily attributable to our growing fleet.", 0.8], ["The increases were partially offset by a decrease in the average selling price of used vehicles.", -0.3], ["Energy generation and storage revenue increased $2.13 billion, or 54%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.9], ["The increase was primarily due to an increase in deployments of Megapack.", 0.7], ["Cost of automotive sales revenues also includes adjustments to warranty expense and charges to write down the carrying value of our inventory when it exceeds its estimated net realizable value and to provide for obsolete and on-hand inventory in excess of forecasted demand.", -0.6], ["Additionally, cost of automotive sales revenue benefits from manufacturing credits earned.", 0.5], ["Cost of automotive sales revenue increased $15.52 billion, or 31%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", -0.4], ["The increase was partially offset by a decrease in the average combined cost per unit of our vehicles primarily due to sales mix, lower inbound freight, a decrease in material costs and lower manufacturing costs from better fixed cost absorption.", 0.2], ["Our costs of revenue were also positively impacted by the United States dollar strengthening against our foreign currencies as compared to the prior periods and by the IRA manufacturing credits earned during the current year.", 0.6], ["Cost of automotive leasing revenue decreased $241 million, or 16%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.4], ["The decrease was primarily due to a decrease in direct sales-type leasing cost of revenue driven by lower deliveries year over year.", -0.5], ["Cost of services and other revenue increased $1.95 billion, or 33%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.3], ["Gross margin for total automotive decreased from 28.5% to 19.4% in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", -0.7], ["The decrease was primarily due to a lower average selling price on our vehicles partially offset by the favorable change in our average combined cost per unit of our vehicles and IRA manufacturing credits earned as discussed above.", -0.4], ["Gross margin for total automotive & services and other segment decreased from 26.5% to 18.2% in the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to the automotive gross margin decrease discussed above.", -0.6], ["Cost of energy generation and storage revenue increased $1.27 billion, or 35%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022, in line with the increase in Megapack deployments year over year, as discussed above.", 0.2], ["This increase was partially offset by an improvement in production ramping that drove down the average cost per MWh of Megapack as well as IRA manufacturing credits earned during the current year.", 0.1], ["Gross margin for energy generation and storage increased from 7.4% to 18.9% in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.8], ["The increase was driven by an improvement in our Megapack gross margin from lower average cost per MWh and a higher proportion of Megapack, which operated at a higher gross margin, within the segment as compared to the prior year periods.", 0.7], ["Additionally, there was a margin benefit from IRA manufacturing credits earned.", 0.5], ["R&D expenses increased $894 million, or 29%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", -0.1], ["The overall increase was primarily driven by additional costs in the current year related to the pre-production phase for Cybertruck, AI and other programs.", -0.1], ["Our R&D expenses have increased proportionately with total revenues as we continue to expand our product roadmap and technologies.", 0.2], ["SG&A expenses increased $854 million, or 22%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", -0.2], ["This was driven by a $447 million increase in employee and labor costs primarily from increased headcount, including professional services and a $363 million increase in facilities related expenses.", -0.3], ["During the year ended December 31, 2022, we recorded an impairment loss of $204 million as well as realized gains of $64 million in connection with converting our holdings of digital assets into fiat currency.", -0.4], ["We also recorded other expenses of $36 million during the second quarter of the year ended December 31, 2022, related to employee terminations.", -0.5], ["Interest income increased $769 million, or 259%, in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.5], ["This increase was primarily due to higher interest earned on our cash and cash equivalents and short-term investments in the year ended December 31, 2023 as compared to the prior year due to rising interest rates and our increasing portfolio balance.", 0.4], ["Other income, net, changed favorably by $215 million in the year ended December 31, 2023 as compared to the year ended December 31, 2022.", 0.3], ["The favorable change was primarily due to fluctuations in foreign currency exchange rates on our intercompany balances.", -0.1], ["As such, we released $6.54 billion of our valuation allowance associated with the U.S. federal and state deferred tax assets, with the exception of our California deferred tax assets.", 0.2], ["Approximately $5.93 billion of the total valuation allowance release was related to deferred tax assets to be realized in the future years and the remainder benefited us during the year ended December 31, 2023.", 0.3], ["Our (benefit from) provision for income taxes changed by $6.13 billion in the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to the release of $6.54 billion of our valuation allowance associated with the U.S. federal and certain state deferred tax assets.", 0.1], ["Our effective tax rate changed from an expense of 8% to a benefit of 50% in the year ended December 31, 2023 as compared to the year ended December 31, 2022, primarily due to the release of the valuation allowance regarding our U.S. federal and certain state deferred tax assets.", 0.2], ["We expect to continue to generate net positive operating cash flow as we have done in the last five fiscal years.", 0.8], ["The cash we generate from our core operations enables us to fund ongoing operations and production, our research and development projects for new products and technologies including our proprietary battery cells, additional manufacturing ramps at existing manufacturing facilities, the construction of future factories, and the continued expansion of our retail and service locations, body shops, Mobile Service fleet, Supercharger, including to support NACS, energy product installation capabilities and autonomy and other artificial intelligence enabled products.", 0.7], ["For example, if our near-term manufacturing operations decrease in scale or ramp more slowly than expected, including due to global economic or business conditions, we may choose to correspondingly slow the pace of our capital expenditures.", -0.3], ["As discussed in and subject to the considerations referenced in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations—Management Opportunities, Challenges and Uncertainties and 2023 Outlook—Cash Flow and Capital Expenditure Trends in this Annual Report on Form 10-K, we currently expect our capital expenditures to support our projects globally to exceed $10.00 billion in 2024 and be between $8.00 to $10.00 billion in each of the following two fiscal years.", 0.1], ["As of December 31, 2023, we and our subsidiaries had outstanding $4.68 billion in aggregate principal amount of indebtedness, of which $1.98 billion is scheduled to become due in the succeeding 12 months.", -0.4], ["As of December 31, 2023, our total minimum lease payments was $5.96 billion, of which $1.31 billion is due in the succeeding 12 months.", -0.2], ["Net cash provided by operating activities decreased by $1.47 billion to $13.26 billion during the year ended December 31, 2023 from $14.72 billion during the year ended December 31, 2022.", -0.5], ["This decrease was primarily due to the decrease in net income excluding non-cash expenses, gains and losses of $2.93 billion, partially offset by favorable changes in net operating assets and liabilities of $1.46 billion.", -0.4], ["$8.90 billion for the year ended December 31, 2023 and $7.16 billion for the year ended December 31, 2022, mainly for global factory expansion and machinery and equipment as we expand our product roadmap.", 0.3], ["Net cash from financing activities changed by $6.12 billion to $2.59 billion net cash provided by financing activities during the year ended December 31, 2023 from $3.53 billion net cash used in financing activities during the year ended December 31, 2022.", 0.4], ["The change was primarily due to a $3.93 billion increase in proceeds from issuances of debt and a $2.01 billion decrease in repayments of debt.", 0.2], ["We have also experienced, and will continue to experience, fluctuations in our net income as a result of gains (losses) on the settlement and the re-measurement of monetary assets and liabilities denominated in currencies that are not the local currency (primarily consisting of our intercompany and cash and cash equivalents balances).", -0.3], ["We considered the historical trends in foreign currency exchange rates and determined that it is reasonably possible that adverse changes in foreign currency exchange rates of 10% for all currencies could be experienced in the near-term.", -0.6], ["These changes would have resulted in a gain or loss of $1.01 billion at December 31, 2023 and $473 million at December 31, 2022, assuming no foreign currency hedging.", -0.4], ["In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.", 0.5], ["Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interests in subsidiaries", -0.5], ["Net income per share of common stock attributable to common stockholders", 0.5], ["Adjustment for net loss realized and included in net income", -0.5], ["Less: Comprehensive (loss) income attributable to noncontrolling interests and redeemable noncontrolling interests in subsidiaries", -0.5], ["Net cash provided by (used in) financing activities", 0.0], ["Net increase (decrease) in cash and cash equivalents and restricted cash", 0.0], ["Revenue recognized from the deferred revenue balance as of December 31, 2022 was", 0.5], ["$469 million for the year ended December 31, 2023.", 0.5], ["We had recognized revenue of $472 million from the deferred revenue balance as of December 31, 2021, for the year ended December 31, 2022, primarily related to the general FSD Capability feature release in North America in the fourth quarter of 2022.", 0.5], ["Of the total deferred revenue balance as of December 31, 2023, we expect to recognize $926 million of revenue in the next 12 months.", 1.0], ["During the year ended December 31, 2022, we had also recognized $288 million in revenue due to changes in regulation which entitled us to additional consideration for credits sold previously.", 0.5], ["For the years ended December 31, 2023, 2022 and 2021, we recognized $1.86 billion, $1.75 billion and $1.25 billion of direct vehicle leasing revenue, respectively.", 0.8], ["For the years ended December 31, 2023, 2022 and 2021, we recognized $215 million, $683 million and $369 million, respectively, of sales-type leasing revenue and $164 million, $427 million and $234 million, respectively, of sales-type leasing cost of revenue.", 0.3], ["If an energy storage system does not meet the performance guarantee requirements, we may be required to pay liquidated damages.", -0.7], ["Additionally, cost of automotive sales revenue benefits from manufacturing credits earned.", 0.2], ["Additionally, cost of energy generation and storage revenue benefits from manufacturing credits earned.", 0.2], ["We have determined that the contractual provisions of the funds represent substantive profit-sharing arrangements.", 0.1], ["For certain funds, there have been significant fluctuations in net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interests in subsidiaries due to changes in the liquidation provisions as time-based milestones have been reached.", -0.5], ["We recognize a bargain purchase gain within Other income (expense), net, in the consolidated statement of operations if the net fair value of the identifiable assets acquired and the liabilities assumed is in excess of the fair value of the total purchase consideration and any noncontrolling interests.", 0.4], ["Investments may be comprised of a combination of marketable securities, including U.S. government securities, corporate debt securities, commercial paper, time deposits, and certain certificates of deposit, which are all designated as available-for-sale and reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive income which is included within stockholders’ equity.", 0.0], ["Realized gains and losses on the sale of available-for-sale investments are recorded in Other income (expense), net.", -0.1], ["We regularly review all of our investments for declines in fair value.", 0.0], ["The review includes but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers.", 0.0], ["These various factors may have a significant impact on our accounts receivable balance from period to period.", -0.2], ["As of December 31, 2023 and 2022, we had $207 million and $753 million, respectively, of long-term government rebates receivable in Other non-current assets in our consolidated balance sheets.", 0.1], ["Provisions for loan losses are charged to operations in amounts sufficient to maintain the allowance for loan losses at levels considered adequate to cover expected credit losses on the financing receivables.", -0.3], ["As of December 31, 2023 and 2022, the total outstanding balance of MyPower customer notes receivable, net of allowance for expected credit losses, was $266 million and $280 million, respectively, of which $5 million and $7 million were due in the next 12 months as of December 31, 2023 and 2022, respectively.", 0.0], ["We are dependent on our suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of our products in a timely manner at prices, quality levels and volumes acceptable to us, or our inability to efficiently manage these components from these suppliers, could have a material adverse effect on our business, prospects, financial condition and operating results.", -0.8], ["Once inventory is written-down, a new, lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.", -0.4], ["Should our estimates of future selling prices or production costs change, additional and potentially material write-downs may be required.", -0.5], ["A small change in our estimates may result in a material charge to our reported financial results.", -0.5], ["The gross cost of operating lease vehicles as of December 31, 2023 and 2022 was $7.36 billion and $6.08 billion, respectively.", 0.0], ["Operating lease vehicles on the consolidated balance sheets are presented net of accumulated depreciation of $1.38 billion and $1.04 billion as of December 31, 2023 and 2022, respectively.", 0.0], ["The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated balance sheet at cost, net of any impairment losses incurred since acquisition.", 0.0], ["We perform an analysis each quarter to identify whether events or changes in circumstances, principally decreases in the quoted prices on active exchanges, indicate that it is more likely than not that our digital assets are impaired.", -0.3], ["In determining if an impairment has occurred, we consider the lowest market price of one unit of digital asset quoted on the active exchange since acquiring the digital asset.", -0.2], ["When the then current carrying value of a digital asset exceeds the fair value determined each quarter, an impairment loss has occurred with respect to those digital assets in the amount equal to the difference between their carrying values and the prices determined.", -0.4], ["Impairment losses are recognized within Restructuring and other in the consolidated statements of operations in the period in which the impairment is identified.", -0.6], ["Gains are not recorded until realized upon sale(s), at which point they are presented net of any impairment losses for the same digital assets held within Restructuring and other.", 0.1], ["In determining the gain to be recognized upon sale, we calculate the difference between the sales price and carrying value of the digital assets sold immediately prior to sale.", 0.2], ["Upon the retirement or sale of our property, plant and equipment, the cost and associated accumulated depreciation are removed from the consolidated balance sheet, and the resulting gain or loss is reflected on the consolidated statement of operations.", -0.2], ["If the asset is not recoverable, its carrying amount would be adjusted down to its fair value.", -0.5], ["For the years ended December 31, 2023, 2022 and 2021, we have recognized no material impairments of our long-lived assets.", 0.5], ["For the years ended December 31, 2023, 2022, and 2021, we did not recognize any impairment of goodwill.", 0.5], ["For the years ended December 31, 2023, 2022, and 2021, we have recognized no impairments of capitalized software costs.", 0.5], ["For the years ended December 31, 2023, 2022 and 2021, we recorded a net foreign currency transaction gain of $122 million, loss of $89 million and gain of $97 million, respectively.", 0.1], ["For the year ended December 31, 2023, the impact from our IRA incentive was primarily a reduction of our material costs in our consolidated statement of operations.", 0.3], ["For the year ended December 31, 2022, we received grant funding of $76 million.", 0.4], ["In connection with the construction of Gigafactory Nevada, we entered into agreements with the State of Nevada and Storey County in Nevada that provide abatements for specified taxes, discounts to the base tariff energy rates and transferable tax credits of up to $195 million in consideration of capital investment and hiring targets that were met at Gigafactory Nevada.", 0.6], ["In connection with the construction of Gigafactory Texas, we entered into a 20-year agreement with Travis County in Texas pursuant to which we would receive grant funding equal to 70-80% of property taxes paid by us to Travis County and a separate 10- year agreement with the Del Valle Independent School District in Texas pursuant to which a portion of the taxable value of our property would be capped at a specified amount, in each case subject to our meeting certain minimum economic development metrics through our construction and operations at Gigafactory Texas.", 0.6], ["This ASU will result in gains and losses", -0.1], ["recorded in the consolidated financial statements of operations and additional disclosures when adopted.", 0.0], ["We are currently evaluating the adoption of this ASU and it will affect the carrying value of our crypto assets held and the gains and losses relating thereto, once adopted.", -0.2], ["This ASU has not and is currently not expected to have a material impact on our consolidated financial statements.", 0.1], ["We recognized a favorable $211 million cumulative effect of initially applying the ASU as an adjustment to the January 1, 2021 opening balance of accumulated deficit.", 0.5], ["Due to the recombination of the equity conversion component of our convertible debt remaining outstanding, additional paid in capital was reduced by $474 million and convertible senior notes (mezzanine equity) was reduced by $51 million.", -0.3], ["The removal of the remaining debt discounts recorded for this previous separation had the effect of increasing our net debt balance by $269 million and we reduced property, plant and equipment by $45 million related to previously capitalized interest.", -0.4], ["During the year ended December 31, 2023, we recorded an immaterial amount of impairment losses on digital assets.", -0.2], ["During the year ended December 31, 2022, we recorded $204 million of impairment losses on digital assets and realized gains of $64 million in connection with converting our holdings of digital assets into fiat currency.", -0.1], ["As of December 31, 2023 and 2022, the carrying value of our digital assets held reflects cumulative impairment of $204 million.", -0.3], ["Goodwill increased $59 million within the automotive segment from $194 million as of December 31, 2022 to $253 million as of December 31, 2023 primarily from a business combination, net of the impact of a divestiture.", 0.5], ["The net carrying value of our intangible assets decreased from $215 million as of December 31, 2022 to $178 million as of December 31, 2023 mainly from amortization.", -0.3], ["We record gross realized gains, losses and credit losses as a component of Other income (expense), net in the consolidated statements of operations.", 0.0], ["We write-down inventory for any excess or obsolete inventories or when we believe that the net realizable value of inventories is less than the carrying value.", -0.7], ["During the years ended December 31, 2023, 2022 and 2021 we recorded write-downs of $233 million,", -0.8], ["Depreciation expense during the years ended December 31, 2023, 2022 and 2021 was $3.33 billion, $2.42 billion and $1.91 billion, respectively.", -0.2], ["$3.93 billion in aggregate principal amount of Automotive Asset-backed Notes, with terms similar to our other previously issued Automotive Asset-backed Notes.", 0.4], ["The proceeds from the issuance, net of debt issuance costs, were $3.92 billion.", 0.6], ["In connection with the cash equity financing deals closed in 2016, our subsidiaries issued $502 million in aggregate principal amount of debt that bears interest at fixed rates.", 0.2], ["In the third quarter of 2023, we terminated our Automotive Lease-backed Credit Facilities and the previously committed funds are no longer available for future borrowings.", -0.5], ["Operating lease expense (1)                         $     1,153  $      798  $      627", -0.2], ["The aggregate release date fair value of RSUs in the years ended December 31, 2023, 2022 and 2021 was $2.50 billion, $4.32 billion and $5.70 billion, respectively.", -0.1], ["The aggregate intrinsic value of options exercised in the years ended December 31, 2023, 2022, and 2021 was $1.33 billion,", 0.1], ["$1.90 billion and $26.88 billion, respectively.", 0.1], ["During the year ended December 31, 2021, our CEO exercised all of the remaining vested options from the 2012 CEO Performance Award, which amounted to an intrinsic value of $23.45 billion.", 0.2], ["Each of the 12 vesting tranches of the 2018 CEO Performance Award vested upon certification by the Board of Directors that both (i) the market capitalization milestone for such tranche, which began at $100.0 billion for the first tranche and increases by increments of $50.0 billion thereafter (based on both a six calendar month trailing average and a 30 calendar day trailing average, counting only trading days), had been achieved, and (ii) any one of the following eight operational milestones focused on total revenue or any one of the eight operational milestones focused on Adjusted EBITDA had been achieved for the four consecutive fiscal quarters on an annualized basis and subsequently reported by us in our consolidated financial statements filed with our Forms 10-Q and/or 10-K.", 0.3], ["$66 million and $910 million, respectively, related to the 2018 CEO Performance Award.", 0.2], ["For the years ended December 31, 2023 and 2022, we recorded $57 million and $159 million, respectively, of stock-based compensation expense related to these grants, net of forfeitures.", -0.1], ["A (benefit from) provision for income taxes of $(5.00) billion, $1.13 billion and $699 million has been recognized for the years ended December 31, 2023, 2022 and 2021, respectively.", 0.0], ["As such, we released $6.54 billion of our valuation allowance associated with the U.S. federal and state deferred tax assets, with the exception of our California deferred tax assets.", 0.1], ["We continue to maintain a full valuation allowance against our California deferred tax assets as of December 31, 2023, because we concluded they are not more likely than not to be realized as we expect our California deferred tax assets generation in future years to exceed our ability to use these deferred tax assets.", -0.5], ["As of December 31, 2023, we maintained valuation allowances of $892 million for deferred tax assets that are not more likely than not to be realized, which primarily included deferred tax assets in the state of California and certain foreign operating losses.", -0.5], ["The valuation allowance on our net deferred tax assets decreased by $6.46 billion and $1.73 billion during the years ended December 31, 2023 and 2022, respectively, and increased by $6.14 billion during the year ended December 31, 2021.", 0.1], ["The valuation allowance decrease during the year ended December 31, 2023 was primarily due to the release of our valuation allowance with respect to our U.S. federal and certain state deferred tax assets.", 0.3], ["Among our deferred tax assets in foreign jurisdictions, we recorded a valuation allowance on certain foreign net operating losses that are not more likely than not to be realized.", -0.4], ["The remainder of our foreign deferred tax assets are more likely than not to be realized given the expectation of future earnings in these jurisdictions.", 0.4], ["As of December 31, 2023, we had $10.31 billion of federal and $10.36 billion of state net operating loss carry-forwards available to offset future taxable income, some of which, if not utilized, will begin to expire in 2024 for federal and state purposes.", 0.2], ["The local government of Shanghai granted a beneficial corporate income tax rate of 15% to certain eligible enterprises, compared to the 25% statutory corporate income tax rate in China.", 0.5], ["Our Gigafactory Shanghai subsidiary was granted this beneficial income tax rate of 15% for 2019 through 2023.", 0.5], ["Starting in 2024, Gigafactory Shanghai is subject to 25% statutory corporate income tax rate in China.", -0.2], ["Increases in balances related to prior year tax positions", 0.0], ["Decreases in balances related to prior year tax positions", -0.5], ["Increases in balances related to current year tax positions", 0.5], ["Increases in balances related to prior year tax positions", 0.0], ["Decreases in balances related to prior year tax positions", -0.5], ["Increases in balances related to current year tax positions", 0.5], ["Decreases in balances related to expiration of the statute of limitations", 0.5], ["Increases in balances related to prior year tax positions", 0.0], ["Increases in balances related to current year tax positions", 0.5], ["Decreases in balances related to expiration of the statute of limitations", 0.5], ["$17 million, $27 million and $4 million for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.1], ["As of December 31, 2023, and 2022, we have accrued $47 million and $31 million, respectively, related to interest and penalties on our unrecognized tax benefits.", -0.2], ["Unrecognized tax benefits of $901 million, if recognized, would affect our effective tax rate.", -0.3], ["On an annual basis during the initial lease term, as measured on each anniversary of such date, if we fail to meet these specified investment and job creation requirements, then we would be obligated to pay a $41 million “program payment” to the SUNY Foundation for each year that we fail to meet these requirements.", -0.5], ["Furthermore, if the arrangement is terminated due to a material breach by us, then additional amounts may become payable by us.", -0.6], ["On February 1, 2022, we reported to the State of New York that we had met and exceeded our annual requirements for jobs and investment in Buffalo and New York State.", 0.5], ["However, if our expectations as to the costs and timelines of our investment and operations at Buffalo prove incorrect, we may incur additional expenses or be required to make substantial payments to the SUNY Foundation.", -0.4], ["14.08 billion in capital expenditures by the end of 2023, which has been achieved in 2023, and to generate RMB 2.23 billion of annual tax revenues starting at the end of 2023.", 0.6], ["As of December 31, 2023, we have met and expect to meet the tax revenue requirements based on our current level of spend and sales.", 0.7], ["The settlement is not expected to have an adverse impact on our results of operations, cash flows or financial position.", 0.4], ["JP Morgan now alleges that it is owed approximately $162 million as the value of additional shares that it claims should have been delivered as a result of the adjustment to the strike price in 2018.", -0.8], ["A retrial was held starting on March 27, 2023, after which a jury returned a verdict of $3,175,000.", -0.5], ["As a result, the damages awarded against Tesla were reduced from an initial $136.9 million (October 4, 2021) down to $15 million (April 13, 2022), and then further down to $3.175 million (April 3, 2023).", -0.6], ["Should the government decide to pursue an enforcement action, there exists the possibility of a material adverse impact on our business, results of operation, prospects, cash flows, financial position or brand.", -0.9], ["If an unfavorable ruling or development were to occur in these or other possible legal proceedings, risks and claims, there exists the possibility of a material adverse impact on our business, results of operations, prospects, cash flows, financial position or brand.", -0.9], ["During the years ended December 31, 2022 and 2021, we recorded $204 million and $101 million, respectively, of impairment losses on digital assets.", -0.7], ["During the years ended December 31, 2022 and 2021 we also realized gains of $64 million and $128 million, respectively, in connection with converting our holdings of digital assets into fiat currency.", 0.5], ["$36 million during the second quarter of the year ended December 31, 2022, related to employee terminations.", -0.4], ["Our management concluded that our internal control over financial reporting was effective as of December 31, 2023.", 0.7], ["27 Thirty-First Supplemental Indenture, dated as of April 9, 2015, by and between SolarCity and the Trustee, related to SolarCity’s 5.45% Solar Bonds, Series 2015/C20-15.", 0.1], ["Thirty-Fifth Supplemental Indenture, dated as of April 14, 2015, by and between SolarCity and the Trustee, related to SolarCity’s 4.70% Solar Bonds, Series 2015/C24-10.", 0], ["Thirty-Sixth Supplemental Indenture, dated as of April 14, 2015, by and between SolarCity and the Trustee, related to SolarCity’s 5.45% Solar Bonds, Series 2015/C25-15.", 0], ["† Agreement for Tax Abatement and Incentives, dated as of May 7, 2015, by and between Tesla Motors, Inc. and the State of Nevada, acting by and through the Nevada Governor’s Office of Economic Development.", 0]], "ups22_sentences.json": [["If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.", 0.0], ["Total revenue in 2022 was $100.3 billion.", 0.5], ["Innovation Driven is designed to optimize the volume that flows through our network to focus on increasing value share and to drive business growth from higher-yielding opportunities in our target markets.", 0.8], ["We are a global leader in developing technologies that help our customers enhance their shipping and logistics business processes to lower costs, improve service and increase efficiency.", 0.9], ["Financial Strength.", 0.2], ["Our financial strength allows us to continue investing in digital technology, transportation equipment, facilities and employee development to generate value for shareholders.", 0.7], ["We pursue strategic opportunities that facilitate our growth and seek to maintain a strong credit rating to give us flexibility in running the business.", 0.6], ["These services are driven by the continued growth of e- commerce that has increased our customers' need for efficient and reliable returns, and are designed to promote efficiency and a friction-free consumer experience.", 0.7], ["We also offer a selection of returns technologies, such as UPS Returns Manager, that promote systems integration, increase customer ease of use and visibility of inbound merchandise.", 0.6], ["These technologies help reduce costs and improve efficiency in our customers' reverse logistics processes.", 0.7], ["International markets are one of our identified growth opportunities.", 0.8], ["We have recently expanded hubs and gateways in France, Germany and Italy to increase efficiency for cross-border ground shipments and provide capacity for future growth.", 0.9], ["During 2022, we acquired Bomi Group to accelerate our growth by expanding our international presence and increasing our cold chain capabilities in major European and Latin American markets.", 0.9], ["By leveraging diversity with respect to gender, age, ethnicity, skills and other factors, and creating inclusive environments, we believe we can improve organizational effectiveness, cultivate innovation and drive growth.", 0.7], ["We are investing in capabilities that we believe will transform our business, including investments in employee opportunities to support growth.", 0.8], ["For the year ended December 31, 2022, one customer, Amazon.com, Inc. and its affiliates, represented approximately 11.3% of our consolidated revenues, substantially all of which was within our U.S.", 0.2], ["We expect to continue to face significant competition, which could materially adversely affect us\".", -0.7], ["Continued compliance with increasingly stringent laws, regulations and policies in the U.S. and in the other countries in which we operate may result in materially increased costs, or we could be subject to substantial fines or possible revocation of our authority to conduct our operations.", -0.8], ["Compliance with changing laws and regulations from time to time, including those promulgated by the U.S. Occupational Safety and Health Administration, could result in materially increased operating costs and capital expenditures, and negatively impact our ability to attract and retain employees.", -0.8], ["The consequences of the COVID-19 pandemic have had a substantial impact on business and consumer activity, including contributing to a curtailment of certain business activities (including a decrease in demand for a broad variety of goods and services), significant ongoing supply chain disruptions, economic uncertainty and volatility in global financial markets.", -0.9], ["These consequences have significantly impacted, and may continue to significantly impact us, and have had, and may continue to have, a material adverse impact on the operations, financial performance and liquidity of many of our customers.", -1.0], ["Because of ongoing uncertainty with respect to the consequences of the COVID-19 pandemic, the future impact on our operations, financial condition and liquidity also remains uncertain and difficult to predict.", -0.8], ["These risks include, but are not limited to: a significant reduction in revenue due to renewed or extended curtailment of business activities; a significant increase in our expenses or a reduction in our operating margins due to long-term changes in the mix of our products and services; effects from governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic (including workforce pressures); reductions in operating effectiveness due to employees working remotely or in hybrid models; unavailability of personnel; the delay or cancellation of capital projects and related delays in, or loss of, expected benefits therefrom; limited access to liquidity; increased volatility and pricing in the capital markets; further disruption of global supply chains; impairments in the fair value of our assets; increases in pension funding obligations; and reductions in our customers’ credit- worthiness.", -1.0], ["We could be materially affected by adverse developments in these aspects of the economy.", -1.0], ["We have also been, and may in the future be, adversely impacted by changes in general economic conditions as a result of geopolitical uncertainty and/or conflicts in or arising from the countries and/or regions where we operate, including the United Kingdom, the European Union, the Ukraine, the Russian Federation and the Trans-Pacific region.", -1.0], ["Changes in general economic conditions, or our inability to accurately forecast these changes or mitigate the impact of these conditions on our business, could materially adversely affect us.", -1.0], ["If we do not timely and appropriately respond to competitive pressures, including replacing any lost volume or maintaining our profitability, we could be materially adversely affected.", -1.0], ["Business combinations could also result in competitors providing a wider variety of services and products at competitive prices, which could materially adversely affect us.", -1.0], ["If all or a portion of our business relationships with one or more significant customers were to terminate or significantly change, this could materially adversely affect us.", -1.0], ["If we are unable to hire, properly train or retain qualified employees, we could experience higher labor costs, reduced revenues, further increased workers' compensation and automobile liability claims, regulatory noncompliance, customer losses and diminution of our brand value or company culture, which could materially adversely affect us.", -1.0], ["Our ability to control labor costs has in the past been, and is expected to continue to be, subject to numerous factors, including turnover, training costs, regulatory changes, market pressures, inflation, unemployment levels and healthcare and other benefit costs.", -0.2], ["In addition, our strategic initiatives, including transformation, have led and are expected to continue to lead to the creation of fewer, but more impactful, jobs as we strive to lower our cost to serve.", -0.1], ["Our inability to continue to retain experienced and motivated employees may also materially adversely affect us.", -0.8], ["Actual or threatened strikes, work stoppages or slowdowns by our employees could adversely affect our ability to meet our customers' needs.", -0.9], ["Customers may reduce their business or stop doing business with us if they believe that such actions or threatened actions may adversely affect our ability to provide services.", -0.7], ["We may permanently lose customers if we are unable to provide uninterrupted service, and this could materially adversely affect us.", -0.8], ["The terms of future collective bargaining agreements also may affect our competitive position and results of operations.", -0.5], ["Furthermore, our actions or responses to any such negotiations, labor disputes, strikes or work stoppages could negatively impact how our brand is perceived and our corporate reputation and have adverse effects on our business, including our results of operations.", -0.6], ["As a result of concerns about global terrorism and homeland security, various governments have adopted and may continue to adopt stricter security requirements, resulting in increased operating costs.", -0.4], ["We cannot determine the effect that any new requirements will have on our operations, cost structure or operating results, and new rules or other future security requirements may increase our operating costs and reduce operating efficiencies.", -0.5], ["Regardless of our compliance with security requirements or the steps we take to secure our facilities or fleet, we could also be the target of an attack or security breaches could occur, which could materially adversely affect us.", -1.0], ["law, and adds a broad array of requirements for handling personal data, including the public disclosure of significant data breaches.", -0.8], ["IT systems (ours, as well as those of our franchisees, acquired businesses, and third-party service providers) are susceptible to damage, disruptions and shutdowns due to programming errors, defects or other vulnerabilities, power outages, hardware failures, computer viruses, cyber-attacks, ransomware or malware attacks, attacks by foreign governments and state-sponsored actors, theft, misconduct by employees or other insiders, telecommunications failures, misuse, human errors or other catastrophic events.", -1.0], ["These events, which have become more frequent and sophisticated, could, from time to time, cause material service outages, allow inappropriate or block legitimate access to systems or information, or result in other material interruptions in our business.", -0.9], ["The costs and operational consequences of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly frequent, complex and sophisticated cyber threats and regulatory requirements.", -0.9], ["The occurrence of any of the events described above could result in material disruptions in our business, the loss of existing or potential customers, damage to our brand and reputation, additional regulatory scrutiny, litigation and other potential material liability.", -1.0], ["In addition, our customers’ confidence in our ability to protect data and systems and to provide services consistent with their expectations could be impacted, further disrupting our operations.", -0.9], ["U.S. and foreign data protection regulations or other data protection standards may expose us to litigation, fines, sanctions or other penalties.", -0.9], ["While we maintain cyber insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred, that insurance will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim.", -0.8], ["Although to date we are unaware of any material data breach or system disruption, including a cyber-attack, we cannot provide any assurances that such events and impacts will not occur and be material in the future.", -0.7], ["Our efforts to deter, identify, mitigate and/or eliminate future breaches may require significant additional effort and expense and may not be successful.", -0.8], ["Also, adverse publicity or public sentiment surrounding labor relations, environmental, sustainability and governance (\"ESG\") concerns, physical or cyber security matters, political activities and similar matters, or attempts to connect our company to such issues, either in the U.S. or elsewhere, could materially adversely affect us.", -0.9], ["The effects of climate change present financial and operational risks to our business, both directly and indirectly.", -0.7], ["While we remain committed to being responsive to the effects of climate change and reducing our carbon footprint, there can be no assurances that our goals and strategic plans to achieve those goals will be successful, that the costs related to climate transition will not be higher than expected, that the necessary technological advancements will occur in the timeframe we expect, or at all, that the severity of and or the pace of negative climate-related effects will not accelerate faster than expected, or that proposed regulation or deregulation related to climate change will not have a negative competitive impact, any one of which could have a material adverse effect on our capital expenditures or other expenses, revenue or results of operations.", -0.8], ["Changes in regulation or technology impacting our business could require us to write down the carrying value of assets, which could result in material impairment charges.", -0.8], ["If we do not meet these goals or there is perception that we failed to meet these goals, then, in addition to regulatory and legal risks related to compliance, we could incur adverse publicity and reaction, which could adversely impact our reputation, and in turn adversely impact our results of operations.", -0.8], ["Customers may reduce shipments, supply chains may be disrupted, demand may be negatively impacted or our costs to operate our business may increase, any of which could have a material adverse effect on us.", -0.9], ["To the extent such weather events or natural disasters do become more frequent or severe, disruptions to our business and costs to repair damaged facilities or maintain or resume operations could increase.", -0.8], ["Emerging markets are often more volatile than those in other countries, and any broad-based downturn in these markets from any of those developments could reduce our revenues and materially adversely affect our business, financial condition and results of operations.", -0.9], ["Our failure to manage and anticipate these and other risks associated with our international operations could materially adversely affect us.", -0.8], ["Accordingly, our financial results could be materially adversely affected by our failure to effectively integrate acquired operations, unanticipated performance or other issues or transaction-related charges.", -1], ["If we are unable to maintain or increase our fuel surcharges, higher fuel costs could materially adversely impact our operating results.", -1], ["Even if we are able to offset changes in fuel costs with surcharges, high fuel surcharges have in the past, and may in the future result in a shift from our higher-yielding products to lower-yielding products or an overall reduction in volume, revenue and profitability.", -1], ["Moreover, we could experience a disruption in energy supplies as a result of new or increased regulation, war or other conflicts, weather-related events or natural disasters, actions by producers (including as part of their own sustainability efforts) or other factors beyond our control, which could have a material adverse effect on us.", -1], ["We monitor and manage foreign currency exchange rate and interest rate exposures, and use derivative instruments to mitigate the impact of changes in these rates on our financial condition and results of operations; however, changes in foreign currency exchange rates and interest rates cannot always be predicted or effectively hedged, and may have a material adverse effect on us.", -1], ["If we do not accurately forecast our future capital investment needs, we could under- or over- invest, or have excess capacity or insufficient capacity, any of which would negatively affect our revenues and profitability.", -1], ["In recent years, we have experienced significant increases in some of these costs, in particular, ongoing increases in healthcare costs in excess of the rate of inflation and historically low discount rates that we use to value our company-sponsored defined benefit plan obligations.", -1], ["Increasing healthcare costs, volatility in investment returns and discount rates, as well as changes in laws, regulations and assumptions used to calculate retiree health and pension benefit expenses, may materially adversely affect our business, financial condition, or results of operations, and have required, and may in the future require significant contributions to our benefit plans.", -1], ["Our national master agreement with the Teamsters includes provisions that are designed to mitigate certain healthcare expenses, but there can be no assurance that our efforts will be successful or that these efforts will not materially adversely affect us.", -1], ["However, in future collective bargaining negotiations, we could agree to make significantly higher future contributions to one or more of these plans.", -1], ["In addition to our ongoing multiemployer pension plan obligations, we may have an obligation in the future to pay significant coordinating benefits previously earned by UPS employees in the Central States Pension Fund (the \"CSPF\").", -0.5], ["If the number or severity of claims for which we are retaining risk continues to increase, our financial condition and results of operations could be materially adversely affected.", -0.8], ["If we lose our ability to, or decide not to, self-insure these risks, our insurance cost could materially increase and we may find it difficult to obtain adequate levels of insurance coverage.", -0.7], ["Our estimates of fair value have resulted from time to time, and may in the future result, in substantial impairments of our assets.", -0.6], ["In addition, we have been and may be required in the future to recognize increased depreciation and amortization charges if we determine the useful lives or salvage values of our assets are less than we originally estimated.", -0.5], ["Such changes have in the past, and may in the future, reduce our net income.", -0.4], ["In addition, changes in U.S. federal and state or international tax laws, other fundamental law changes currently being considered by many countries, and changes in taxing jurisdictions’ administrative interpretations, decisions, policies and positions may materially adversely impact our tax expense and cash flows.", -0.7], ["Compliance with any new laws, regulations or policies may increase our operating costs or require significant capital expenditures.", -0.6], ["Any failure to comply with applicable laws, regulations or policies in the U.S. or other countries could result in substantial fines or possible revocation of our authority to conduct our operations, which could materially adversely affect us.", -0.8], ["Regulation of greenhouse gas (\"GHG\") emissions exposes us to potentially significant new taxes, fees and other costs.", -0.7], ["ICAO continues to develop details regarding implementation, but compliance with CORSIA will increase our operating costs.", -0.5], ["Even in the absence of such legislation, the Environmental Protection Agency could determine to regulate GHG emissions, especially aircraft or diesel engine emissions, and this could impose substantial costs on us.", -0.7], ["The extent to which other countries implement that accord could also have a material adverse effect on us.", -0.8], ["Increased regulation relating to GHG emissions in the U.S. or abroad, especially aircraft or diesel engine emissions, could, among other things, increase the cost of fuel and other energy we purchase and the capital costs associated with updating or replacing our aircraft or vehicles prematurely.", -0.6], ["It is likely that such regulation could significantly increase our operating costs and that we may not be willing or able to pass such costs along to our customers.", -0.9], ["Any material litigation or a catastrophic accident or series of accidents could result in significant expenditures and have a material adverse effect on us.", -0.9], ["(1) Six MD-11 aircraft are expected to be retired from operational use during 2023.", -0.3], ["During the fourth quarter of 2022, we reduced the estimated salvage value of our MD-11 fleet.", -0.4], ["On January 25, 2023, our Board declared a dividend of $1.62 per share, which is payable on March 10, 2023 to shareowners of record on February 21, 2023.", 0.8], ["During the year ended December 31, 2022, we repurchased 19.0 million shares of class B common stock for $3.5 billion under this program.", 0.7], ["We anticipate repurchasing approximately $3.0 billion in shares in 2023.", 0.8], ["These factors resulted in disruptions to certain parts of our business, negatively impacted demand for our services and contributed to increases in certain of our operating costs.", -0.8], ["Despite the challenging macroeconomic environment, our strategic execution strengthened our balance sheet and resulted in the generation of strong cash flows for the year.", 0.6], ["We retired $2.0 billion of debt, reinvested in the business and returned cash to shareowners through dividends and share repurchases.", 0.7], ["We also completed the acquisition of Delivery Solutions, a digital platform that optimizes customer deliveries across multiple networks, and the acquisition of Bomi Group, which will accelerate our growth in healthcare logistics by expanding our footprint and bringing additional expertise in cold chain logistics.", 0.7], ["Average daily package volume in our global small package operations decreased, primarily due to lower levels of business-to- consumer shipping.", -0.6], ["Revenue increased due to strong revenue per piece growth, with most of the increase in our U.S.", 0.5], ["Revenue in Supply Chain Solutions decreased.", -0.5], ["Operating expenses increased, driven by higher fuel prices and higher compensation and benefits expense, primarily in our", -0.7], ["Operating profit and operating margin increased, with the increases coming from the U.S.", 0.6], ["Domestic Package segment and Supply Chain Solutions, while operating profit and operating margin declined in the International Package segment.", -0.2], ["We reported net income of $11.5 billion and diluted earnings per share of $13.20.", 0.8], ["defined benefit pension and postretirement medical benefit plan mark-to-market gains outside of a 10% corridor, together with defined benefit pension plan curtailment gains, totaling $806 million, or $0.92 per diluted share;", 0.3], ["a one-time, non-cash charge related to the accelerated vesting of certain equity awards in connection with an incentive compensation program design change of $384 million, or $0.44 per diluted share;", -0.1], ["a one-time, non-cash charge in connection with a reduction in the estimated residual value of our MD-11 aircraft of $58 million, or $0.07 per diluted share; and", -0.3], ["transformation strategy costs of $142 million, or $0.15 per diluted share.", -0.4], ["Domestic Package segment, revenue growth resulted from higher fuel revenue, driven by increases in both price per gallon and in fuel surcharge rates as part of our pricing initiatives, as well as improvements in revenue quality and customer mix.", 0.5], ["Expenses increased due to higher fuel prices and higher compensation and benefits costs, which were partially offset by declines in purchased transportation costs and higher productivity as we executed our strategy.", -0.1], ["In our International Package segment, revenue increased slightly, driven by fuel revenue, revenue quality actions and favorable shifts in customer and product mix.", 0.2], ["These increases were mostly offset by lower volume, the impact of the strengthening U.S. Dollar and reductions in demand-related surcharges, primarily in the fourth quarter.", -0.2], ["Expense increases were primarily driven by higher fuel prices, partially offset by favorable currency impacts and volume declines.", -0.3], ["In Supply Chain Solutions, the decrease in revenue was driven by volume and market rate declines in Forwarding, as well as the impact of divesting UPS Freight in 2021.", -0.5], ["These decreases were partially offset by growth in our healthcare operations and in a number of our other businesses.", 0.2], ["Expenses decreased, driven by lower transportation costs in Forwarding and a reduction in operating expenses due to the divestiture of UPS Freight.", 0.4], ["These decreases were partially offset by higher operating costs in Logistics.", -0.2], ["Defined Benefit Pension and Postretirement Medical Plan (Gains) and Losses", 0.0], ["Defined Benefit Pension and Postretirement Medical Plan (Gains) and Losses", 0.0], ["The blended average effective income tax rates for the years ended December 31, 2022 and 2021 were 26.5% and 23.8%, respectively.", -0.1], ["During 2022, we completed certain structural changes to the design of our incentive compensation programs that resulted in a one-time, non-cash charge in connection with the accelerated vesting of certain equity incentive awards that we do not expect to repeat.", -0.4], ["During the fourth quarter of 2022, we determined to retire six of our existing MD-11 aircraft from operational use in 2023.", -0.3], ["In connection therewith, we reduced the estimated residual value of our MD-11 fleet, incurring a one-time, non-cash charge on our fully- depreciated aircraft.", -0.5], ["We supplement the presentation of our operating profit, operating margin, income before income taxes, net income and earnings per share with non-GAAP measures that exclude the impact of charges related to transformation activities, and goodwill, asset impairment and divestiture charges.", 0.0], ["We supplement the reporting of revenue, revenue per piece and operating profit with adjusted measures that exclude the period over period impact of foreign currency exchange rate changes and hedging activities.", 0.0], ["Defined Benefit Pension and Postretirement Medical Plan Gains and Losses", 0.0], ["We recognize changes in the fair value of plan assets and net actuarial gains and losses in excess of a 10% corridor (defined as 10% of the greater of the fair value of plan assets or the plan's projected benefit obligation), as well as gains and losses resulting from plan curtailments and settlements, for our defined benefit pension and postretirement medical plans immediately as part of Investment income (expense) and other in the statements of consolidated income.", 0.0], ["The remeasurement of our defined benefit pension and postretirement medical plans' assets and liabilities resulted in gains of", 0.5], ["$1.1 and $3.3 billion for the years ended December 31, 2022 and 2021, respectively.", 0.5], ["The pre-tax defined benefit plan gains and losses for the years ended December 31, 2022 and 2021 consisted of the following: 2022 - $1.1 billion pre-tax defined benefit plan gain:", 0.5], ["Discount Rates ($5.2 billion pre-tax gain): The weighted-average discount rate for our pension and postretirement medical plans increased from 3.11% as of December 31, 2021 to 5.77% as of December 31, 2022, primarily due to an increase in U.S. treasury yields as well as an increase in credit spreads on AA-rated corporate bonds in 2022.", 0.5], ["Return on Assets ($4.1 billion pre-tax loss): In 2022, the actual rate of return on plan assets was lower than our expected rate of return, primarily due to weaker global equity and U.S. bond market performance.", -0.5], ["Demographic and Other Assumption Changes ($0.1 billion pre-tax loss): This loss was due to the differences between actual and estimated participant data and demographic factors, including healthcare cost trends, compensation rate increases and rates of termination, retirement and mortality.", -0.5], ["2021 - $3.3 billion pre-tax defined benefit plan gain, primarily due to the impact of the interim remeasurement of the UPS/IBT Plan in the first quarter of 2021 as described in note 5 to the audited, consolidated financial statements:", 0.8], ["Discount Rates ($1.9 billion pre-tax gain): This gain was largely attributable to an increase in the discount rate for the UPS/IBT Plan from 2.98% as of December 31, 2020 to 3.70% as of March 31, 2021, driven by an increase in U.S. treasury yields in 2021.", 0.7], ["Return on Assets ($0.3 billion pre-tax loss): This loss was driven by the actual rate of return on plan assets being approximately 220 basis points lower than our expected rate of return as of March 31, 2021, primarily due to weak global equity and U.S. bond market performance.", -0.4], ["Demographic and Other Assumption Changes ($0.1 billion pre-tax loss): This loss was due to the differences between actual and estimated participant data and demographic factors, including healthcare cost trends, compensation rate increases and rates of termination, retirement and mortality.", -0.5], ["Coordinating benefits attributable to the Central States Pension Fund ($1.8 billion pre-tax gain): This represents a reduction of the liability for potential coordinating benefits that may be required to be paid related to the Central States Pension Fund.", 0.7], ["Changes in these estimates directly impact the amount of expense allocated to each segment and therefore the operating profit of each reporting segment.", 0.0], ["2022 vs. 2021                           (2.8)%         4.3 %         5.0 %         6.5 %", 0.0], ["Revenue also benefited from one additional operating day in 2022 compared to 2021.", 0.3], ["Average daily volume decreased, driven by a 5.1% reduction in residential shipments.", -0.3], ["The decline in residential shipments was driven by declines from our largest customer in accordance with our agreed upon contract terms as we continued to execute within our strategy.", -0.5], ["This decline was slightly offset by growth from small- and medium-sized businesses (\"SMBs\"), including the expansion of our Digital Access Program.", 0.2], ["Commercial activity increased in the first half of the year, but declined in the second half of 2022, primarily from industry sectors that are more sensitive to the macroeconomic factors discussed above.", -0.3], ["We anticipate overall average daily volume year-over-year growth rates will continue to decline in the first half of 2023 and then grow through the remainder of the year as economic conditions improve.", 0.1], ["Within our Air products, average daily volume decreases were driven by lower volumes from certain large customers, as well as shifts in product preferences during the second half of the year.", -0.4], ["Ground residential average daily volume decreased 4.3%, driven by the declines discussed above.", -0.5], ["Ground commercial volume increased 0.6%, driven by growth from SMBs and large customers in the first half of 2022 that was largely offset by volume declines in the second half of the year.", -0.1], ["Revenue per piece in our Air and Ground products increased for the full year, driven by base rate increases and other pricing actions, and favorable changes in customer mix.", 0.4], ["A shift in product mix during the second half of the year, and declines in demand- related surcharges, slightly offset these increases.", -0.2], ["Rates for Air and Ground products increased an average of 5.9% in December 2021.", 0.3], ["In our Next Day Air and Deferred products, revenue per piece growth was negatively impacted by a reduction in average billable weight per piece.", -0.5], ["We anticipate moderate revenue per piece growth in 2023 as we continue to execute on pricing initiatives within our strategy.", 0.5], ["Fuel surcharge revenue increased $3.0 billion, driven by increases in price per gallon and increases in fuel surcharges as part of our pricing initiatives.", 0.7], ["We expect a reduction in fuel surcharge revenue in 2023 based on the current commodity market outlook.", -0.3], ["Operating expenses and adjusted operating expenses increased year over year.", -0.6], ["The cost of operating our integrated air and ground network increased $858 million and pickup and delivery costs increased $1.5 billion.", -0.7], ["Other indirect operating costs increased $498 million and package sorting costs increased $163 million.", -0.6], ["Higher fuel costs, primarily attributable to increases in the price of jet fuel, diesel and gasoline.", -0.8], ["Increases in employee benefits expense for our union workforce, driven by contractual rate increases for contributions to multiemployer benefit plans, as well as higher year-over-year service cost for our company-sponsored pension plans.", -0.7], ["Higher compensation expense due to contractual rate increases and cost of living and market-rate adjustments for our union workforce, that were partially offset by a decrease in union labor hours.", -0.4], ["Inflationary pressures that contributed to cost increases in repairs and maintenance and facility operating costs.", -0.7], ["These increases were partially offset by lower purchased transportation costs due to a reduction in ground volume handled by third-party carriers and continued productivity initiatives as we executed within our strategy.", 0.2], ["Total cost per piece increased 9.2% for the year and adjusted cost per piece increased 8.6%, for the reasons described above.", -0.3], ["We anticipate that the cost per piece growth rate will be elevated in the first quarter of 2023 and will then moderate throughout the remainder of the year.", -0.2], ["As a result of the factors described above, operating profit increased $561 million, with operating margin increasing 20 basis points to 10.9%.", 0.5], ["Adjusted operating profit increased $857 million, with adjusted operating margin increasing 70 basis points to 11.8%.", 0.7], ["Average daily volume decreased for both domestic and export products.", -0.6], ["Volume from both large customers and SMBs declined, driven by declines in the retail and technology sectors.", -0.5], ["Business-to-consumer volume decreased 17.2%, as challenging global economic conditions, including high inflation, high energy costs, COVID-19 lockdowns in China and geopolitical uncertainty, impacted consumer demand.", -0.8], ["In the first half of the year, volume growth was also impacted by the year-over-year effect of COVID-19 restrictions on consumer e-commerce spending.", -0.4], ["These global economic conditions also impacted business-to-business volume, which decreased 2.9%.", -0.7], ["We expect year-over-year volume growth in the first half of 2023 to be negative, with economic conditions and volume growth rates improving in the second half of the year.", 0.1], ["Export volume decreased for the year driven by reduced intra-Europe activity, as well as lower volumes on the Asia and U.S. export trade lanes.", -0.8], ["The decline in Asia export trade lanes was also driven by COVID-19 lockdowns, which resulted in fewer flights being operated throughout the year and reduced business activity within China and Hong Kong.", -0.9], ["We experienced lower volumes from certain large customers on U.S. export trade lanes, due to the strength of the U.S. Dollar and the economic factors discussed above.", -0.8], ["Our premium products saw volume decline 3.0%, primarily from our Express Saver product which was impacted by lower volumes from certain large customers as a result of the economic factors and COVID-19 disruptions discussed above.", -0.8], ["Volume in our non-premium products decreased 1.4%, driven by declines in our Worldwide products.", -0.6], ["Domestic volume declines were largest in Europe and Canada, where macroeconomic conditions and the year-over-year impact of COVID-19 restrictions on e-commerce spending resulted in lower residential deliveries.", -0.7], ["In December 2021, we implemented an average 5.9% net increase in base and accessorial rates for international shipments originating in the United States.", 0.2], ["Total revenue per piece increased 7.6%, primarily due to fuel surcharges and favorable shifts in customer and product mix as we executed on revenue quality initiatives.", 0.5], ["Demand-related surcharges contributed slightly to the growth in revenue per piece, although we experienced a decline in these surcharges during the latter part of the year.", -0.1], ["Unfavorable currency movements partially offset these increases.", -0.5], ["Excluding the impact of currency, revenue per piece increased 13.5%.", 0.5], ["Export revenue per piece increased 5.0% for the reasons described above.", 0.3], ["Excluding the impact of currency, export revenue per piece increased 9.6%.", 0.4], ["Domestic revenue per piece increased 2.1% for the reasons described above.", 0.2], ["Excluding the impact of currency, domestic revenue per piece increased 13.3%.", 0.5], ["We expect overall revenue per piece to be relatively flat in 2023, with a decline in demand-related surcharges relative to 2022.", -0.3], ["Total international fuel surcharge revenue increased by $1.2 billion, driven primarily by increases in price per gallon as well as changes in fuel surcharge rates as part of our pricing strategy.", 0.6], ["These increases were slightly offset by unfavorable currency movements and volume declines.", -0.4], ["Based on commodity forecasts, we expect declining fuel prices will drive a decrease in fuel surcharge revenue in 2023.", -0.5], ["Operating expenses, and adjusted operating expenses, increased year over year.", -0.3], ["The costs of operating our integrated international air and ground network increased $1.1 billion, primarily due to higher fuel prices.", -0.6], ["As noted above, we expect fuel prices to decrease in 2023.", 0.2], ["Pickup and delivery costs decreased $333 million, other indirect costs, including compensation and benefits, decreased $319 million and package sorting costs decreased $20 million as inflationary pressures were more than offset by favorable currency movements and volume declines.", 0.4], ["We expect volume declines and inflationary pressures will continue to impact our costs in 2023.", -0.4], ["As a result of the factors described above, operating profit decreased $320 million, with operating margin decreasing 180 basis points to 22.0%.", -0.7], ["Adjusted operating profit decreased $301 million and adjusted operating margin decreased 180 basis points to 22.4%.", -0.6], ["**  Excludes the $46 million pre-tax gain recognized as part of the divestiture of UPS Freight for the year ended December 31, 2021.", 0.0], ["Total revenue within Supply Chain Solutions decreased for the year.", -0.5], ["Lower volume and revenue in forwarding and the impact of divesting UPS Freight in the second quarter of 2021 more than offset strong revenue growth in logistics and a number of our other businesses.", -0.5], ["International airfreight revenue decreased approximately $480 million, as challenging economic conditions and lockdowns in China drove a decline in customer demand during the year.", -0.8], ["Lower demand coupled with higher capacity, particularly in the fourth quarter of 2022, resulted in a decline in the market rates we charge for services, including demand-related surcharges that were elevated in the first quarter of the year.", -0.7], ["Revenue in our truckload brokerage business decreased approximately $300 million, as volume and market rates declined.", -0.6], ["These declines were partly offset by successful revenue quality initiatives.", 0.2], ["The remaining reduction in revenue was attributable to ocean freight forwarding as a result of a significant decline in market rates in the second half of the year, particularly on the Asia to U.S. lane.", -0.7], ["Volume also declined during the year, driven by lower customer demand.", -0.6], ["As a result of expected market conditions, we anticipate that volume will remain challenged and that market rates within all of our Forwarding businesses during the first half of 2023 will be lower than the first half of 2022.", -0.8], ["Rates in our airfreight and truckload brokerage businesses are expected to stabilize in the latter half of 2023.", 0.1], ["Revenue within our Logistics businesses increased as a result of the following factors:", 0.3], ["Healthcare logistics revenue increased approximately $360 million, driven by clinical trials and pharmaceuticals.", 1.0], ["Revenue in our mail services business increased approximately $160 million as a result of volume from new customers, rate increases and a favorable shift in product characteristics.", 1.0], ["We experienced year-over-year revenue increases, driven by customer expansion, revenue quality initiatives and increased demand for warehousing services.", 1.0], ["Revenue from the other businesses within Supply Chain Solutions increased, partly due to the acquisition of Roadie, Inc. in the fourth quarter of 2021.", 0.5], ["Revenue from transition services provided to the acquirer of UPS Freight increased and revenue from our service contracts with the U.S.", 0.5], ["We expect our transition services revenue to decline in 2023 as the acquirer of UPS Freight begins to exit these arrangements.", -0.5], ["Total operating expenses and total adjusted operating expenses for Supply Chain Solutions decreased for the year.", 0.0], ["This included a decrease of $952 million due to the divestiture of UPS Freight in 2021.", 0.0], ["Forwarding operating expenses decreased $1.1 billion, driven by a reduction in purchased transportation costs.", 0.5], ["Elevated market rates in the first half of 2022 were more than offset by declines in the latter part of the year.", -0.5], ["We expect market volume and rates will remain low through at least mid-2023, which will reduce our purchased transportation costs.", -0.2], ["Logistics operating expenses increased $485 million, including the impact of the Bomi Group acquisition.", -0.5], ["Compensation and benefits expense increased, driven by business growth and inflationary pressures across our logistics businesses.", -0.4], ["Purchased transportation costs increased in our healthcare and mail services businesses due to business growth.", -0.3], ["Mail services expenses were also impacted by transportation rate increases and higher fuel surcharges.", -0.4], ["As a result of the factors described above, total operating profit increased $43 million, with operating margin increasing 90 basis points to 10.8%.", 0.5], ["On an adjusted basis, operating profit increased $153 million and operating margin increased 150 basis points to 11.3%.", 0.7], ["Total compensation and benefits and adjusted total compensation and benefits increased.", 0.1], ["Compensation costs increased $495 million.", -0.3], ["On an adjusted basis, compensation costs decreased $16 million.", 0.2], ["Domestic direct labor costs increased $422 million due to annual contractual rate increases for our union workforce that occur in August, as well as cost of living adjustments driven by inflation and other market factors.", -0.5], ["These increases were partially offset by a reduction in labor hours, driven by volume declines and productivity improvements.", 0.1], ["International compensation decreased $245 million, primarily due to volume declines and favorable currency movements.", 0.2], ["Supply Chain Solutions' compensation costs increased $95 million, driven by business growth and inflationary pressures across our logistics operations.", 0.1], ["Management compensation increased $466 million, primarily due to the accelerated vesting of certain equity incentive awards in connection with a one-time change to the design of our incentive compensation programs.", -0.3], ["On an adjusted basis, management compensation increased $42 million due to salary growth, which was partially offset by reductions in other incentive awards and sales commissions.", 0.1], ["The UPS Freight divestiture in 2021 resulted in a $328 million decrease in compensation costs.", 0.3], ["Benefits costs increased $579 million and increased $745 million on an adjusted basis, primarily as a result of:", -0.4], ["Health and welfare costs increased $195 million, driven by increased contributions to multiemployer plans as a result of contractual rate increases that occur annually in August.", -0.2], ["The UPS Freight divestiture in 2021 reduced expense by $75 million.", 0.3], ["Pension and postretirement benefits increased $215 million due to contractually-mandated contribution increases to multiemployer plans and higher service costs for company-sponsored plans.", -0.2], ["The UPS Freight divestiture in 2021 reduced expense by $53 million.", 0.3], ["Vacation, excused absence, payroll taxes and other expenses increased $248 million, driven by wage growth and additional discretionary payments.", -0.3], ["The UPS Freight divestiture in 2021 reduced expense by $54 million.", 0.3], ["Workers' compensation expense increased $88 million due to an increase in current year claims, partially offset by favorable developments in reserves for existing claims.", -0.4], ["The increase in repairs and maintenance expense was due to an increase in planned building maintenance as well as increases in the cost of materials and supplies, which we expect to persist in 2023.", -0.3], ["We also incurred higher costs for aircraft engine and airframe maintenance due to the timing of scheduled maintenance events.", -0.4], ["Depreciation and amortization expense increased, primarily due to the reduction in the estimated residual value of our fully- depreciated MD-11 aircraft, facility automation and expansion projects, investments in internally developed software and the amortization of acquired intangible assets.", -0.3], ["Excluding the impact of the estimated residual value change, adjusted depreciation and amortization expense increased due to the aforementioned factors.", -0.2], ["The reduction in estimated residual value of our MD-11 aircraft will result in additional depreciation expense for the remainder of these aircraft in 2023 and thereafter.", -0.4], ["Supply Chain Solutions expense decreased $957 million, resulting from volume declines in our international air and ocean freight and truckload brokerage businesses and declining market rates paid for services in the latter half of the year.", -0.5], ["These impacts were slightly offset by expense increases in our logistics operations due to business growth and third-party rate increases in our mail services business.", 0.0], ["The UPS Freight divestiture in 2021 drove a decrease of $260 million.", -0.3], ["Domestic expense decreased $254 million, driven by a reduction in ground volume handled by third-party carriers as a result of network optimization initiatives.", 0.2], ["International expense decreased $194 million, primarily due to a reduction in air charter expense in the second half of the year and favorable currency movements.", 0.1], ["The increase in fuel expense was primarily driven by higher prices for jet fuel, diesel and gasoline.", -0.4], ["The increase in other occupancy expense, and adjusted other occupancy expense, was due to additional facilities coming into service, higher utilities costs and rent and property tax increases.", -0.3], ["An increase of $170 million in commissions paid for certain online shipments.", -0.2], ["Hosted software application fees and other technology costs increased $115 million in support of ongoing investments in our digital transformation.", -0.1], ["Professional fees increased $72 million, driven by an increase in support services provided to various business units and information technology consulting to support ongoing strategic initiatives.", -0.1], ["Other increases included the cost of goods provided under transitional service agreements to the acquirer of UPS Freight, allowances for credit losses, facility security expenses and self-insured automobile liability expense, driven by increases in the frequency and severity of claims.", -0.8], ["These increases were partially offset by favorable developments in certain legal and tax contingencies and reductions in asset impairment charges and customer claims.", 0.2], ["Investment and other income decreased $2.0 billion, primarily due to a reduction in mark-to-market gains recognized on remeasurements of our defined benefit pension and postretirement plans.", -0.9], ["Excluding the impact of these gains, adjusted investment and other income increased $167 million, driven by higher yields on higher average invested balances and foreign currency gains.", 0.5], ["These increases were partially offset by declines in the fair values of certain non-current investments.", -0.3], ["Interest expense increased due to the impact of higher effective interest rates on floating rate debt, partially offset by lower average outstanding debt balances, higher capitalized interest and favorable foreign currency exchange rate impacts on foreign currency-denominated debt.", -0.6], ["Defined Benefit Pension and Postretirement Medical Plan (Gains) and Losses", 0.0], ["Net cash from operating activities decreased $903 million in 2022, driven by higher contributions to our company-sponsored defined benefit pension and postretirement medical plans.", -0.7], ["$1.9 billion in 2022 compared to $0.2 billion in 2021.", -0.5], ["Our working capital benefited from an improvement in collections that was partially offset by increases in duty and tax settlements on behalf of our customers due to the timing of payments.", 0.1], ["Cash payments for income taxes were $2.6 billion and $1.9 billion for the years ended December 31, 2022 and 2021, respectively, with changes driven by the timing of deductions related to pension contributions and depreciation.", -0.1], ["We have been informed by the participating financial institutions that as of December 31, 2022 and 2021, suppliers sold them", 0.0], ["The amounts settled through the SCF program were approximately $2.3 and $1.7 billion for the years ended December 31, 2022 and 2021, respectively.", 0.1], ["Capital Expenditures as a % of revenue                                       4.8 %        4.3 %", 0.1], ["(1) In addition to capital expenditures of $4.8 and $4.2 billion for the years ended December 31, 2022 and 2021, respectively, there were principal repayments of finance lease obligations of $149 and $208 million, respectively.", 0.0], ["Total capital expenditures increased in 2022, primarily due to:", 0.2], ["Spending on buildings, facilities and plant equipment increased, largely due to facility automation and capacity expansion projects in our global small package business.", 0.3], ["Expenditures in the fourth quarter more than offset the impact of supply chain disruptions that we experienced earlier in the year.", 0.2], ["Aircraft and parts expenditures increased due to higher contract deposits on open aircraft orders, partially offset by fewer payments associated with the delivery of aircraft.", 0.1], ["Vehicles expenditures increased as supply chain constraints eased in the latter half of 2022 relative to 2021.", 0.3], ["Information technology expenditures increased due to additional deployments of technology equipment and continuing investments in our digital capabilities and network automation.", -0.1], ["Proceeds from the disposal of businesses, property, plant and equipment decreased, primarily due to the 2021 divestiture of UPS Freight for cash proceeds of $848 million.", -0.5], ["Net purchases of marketable securities increased due to a shift to longer duration investments.", 0.1], ["The increase in cash paid for acquisitions in 2022 was primarily attributable to the acquisitions of Bomi Group and Delivery Solutions, and the purchase of development areas for The UPS Store.", 0.0], ["The increase in other investing activities was driven by our investment of $252 million in the parent company of CommerceHub, Inc., as well as changes in our other non-current investments and various other items.", 0.0], ["We repurchased 19.0 and 2.6 million shares of class B common stock for $3.5 billion and $500 million under our stock repurchase program for the years ended December 31, 2022 and 2021, respectively.", 0.2], ["We anticipate our share repurchases will total $3.0 billion for 2023.", 0.3], ["For the years ended December 31, 2022 and 2021, dividends reported within shareowners' equity include $249 and $167 million, respectively, of non-cash dividends that were settled in shares of class A common stock.", 0.1], ["In the first quarter of 2023, we increased our quarterly dividend from $1.52 to $1.62 per share.", 0.5], ["Cash outflows for this purpose were $516 and $358 million for the years ended December 31, 2022 and 2021, respectively.", -0.2], ["The increase was driven by changes in required repurchase amounts.", -0.1], ["The amount of any minimum funding requirement, as applicable, for these plans could change significantly in future periods depending on many factors, including plan asset returns, discount rates, other actuarial assumptions, changes to pension plan funding regulations and the discretionary contributions that we make.", -0.2], ["As a result of the amendments to the UPS 401(k) Savings Plan discussed in note 5 to the audited, consolidated financial statements, we expect contributions to this plan will increase by approximately $450 million beginning in 2024.", 0.2], ["We record a liability for a loss when the loss is probable of occurring and reasonably estimable.", -0.5], ["For such accruals, we record the amount we consider to be the best estimate within a range of potential losses; however, when there appears to be a range of equally possible losses, our accrual is based on the low end of this range.", -0.4], ["Additionally, events may arise that were not anticipated and, as a result, the outcome of a contingency may result in a loss that differs materially from our previously estimated liability.", -0.6], ["Except as disclosed in note 10 to the audited, consolidated financial statements, contingent losses that were probable and estimable were not material to our financial position or results of operations as of, or for the year ended, December 31, 2022.", 0.1], ["We did not incur goodwill impairment charges in 2022 or 2021.", 0.3], ["During 2020, we recognized a goodwill impairment charge of $494 million in our former UPS Freight reporting unit.", -0.7], ["Goodwill impairment charges could have a material impact on our results of operations.", -0.8], ["As of our July 1st testing date, we concluded the fair value of each reporting unit exceeded its carrying value; however, the excess of fair value over the carrying value for our Roadie reporting unit was less than 10 percent.", -0.1], ["If the cost of capital used in our July 1st test increased by 150 basis points, it is reasonably possible that the reporting unit would be impaired.", -0.7], ["We believe the fair value of the Roadie reporting unit continues to exceed its carrying value; however, if the cost of capital increases or the business does not meet forecasts, we may incur an impairment charge in the future.", -0.5], ["If the carrying value of the trade name exceeded its estimated fair value, an impairment charge would be recognized for the excess amount.", -0.6], ["However, if near-term economic conditions change our assumptions unfavorably, or result in the reporting unit being unable to meet forecasts, there could be a more significant decrease in the estimated fair value of the trade name, which may result in an impairment.", -0.8], ["If the carrying amount of the intangible is determined not to be recoverable, a write-down to fair value is recorded.", -0.7], ["If impairment indicators are present, the resulting impairment charges could have a material impact on our results of operations.", -0.8], ["All these factors can result in revisions to actuarial projections and produce a material difference between estimated and actual operating results.", -0.6], ["We believe our estimated reserves for such claims are adequate; however, actual experience in claims frequency and/or severity of claims could materially differ from our estimates and affect our results of operations.", -0.5], ["Actual experience may differ materially from these estimates and, therefore, produce a material difference between estimated and actual operating results.", -0.6], ["Our total reserves related to prior year claims decreased by $5 million in 2022 and increased by $34 million in 2021.", -0.1], ["A five percent deterioration or improvement in both the assumed claim severity and claim frequency rates used to estimate our self-insurance reserves would result in an increase or decrease of approximately $290 million, respectively, in our reserves and expenses as of, and for the year ended, December 31, 2022.", 0.0], ["We recognize changes in the fair value of plan assets and net actuarial gains or losses in excess of a corridor (defined as 10% of the greater of the fair value of plan assets or the plans' projected benefit obligations) immediately within income upon remeasurement of a plan.", 0.0], ["Other components of pension expense (referred to as \"ongoing net periodic benefit cost\"), primarily service and interest costs and the expected return on plan assets, are reported on a quarterly basis.", 0.0], ["The following sensitivity analysis shows the impact of a 25 basis point change in the assumed discount rate and return on assets for our pension and postretirement benefit plans, and the resulting increase (decrease) in our obligations and expense as of, and for the year ended, December 31, 2022 (in millions):", 0.0], ["(1) Amount calculated based on 25 basis point increase / decrease in the expected return on assets.", 0.0], ["(2) Amount calculated based on 25 basis point increase / decrease in the actual return on assets.", 0.0], ["We monitor our long-lived assets for indicators of impairment which may include, but are not limited to, a significant change in the extent to which an asset is utilized and operating or cash flow losses associated with the use of the asset.", -0.2], ["If circumstances are present that indicate the carrying value of our long-lived assets may not be recoverable, we then perform impairment testing at the asset group level.", -0.3], ["If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded.", -0.4], ["Adverse changes in volume forecasts, or a shortfall in our actual volume compared with our projections, could result in our current aircraft capacity exceeding current or projected demand.", -0.8], ["This situation could lead to an excess of aircraft, resulting in an impairment charge or reduction in expected useful life that may result in increased depreciation expense.", -0.7], ["In the fourth quarter of 2022, we reduced the estimated residual value of our MD-11 aircraft and associated engines to zero based on updated operational plans for these aircraft and our expectations for their eventual disposal.", -0.6], ["In connection with this change in estimate, during the fourth quarter of 2022 we recorded a one-time depreciation charge to adjust the residual value of our fully- depreciated MD-11 aircraft.", -0.7], ["Changes in the fixed income, foreign currency exchange and commodity markets will impact our estimates of fair value in the future, potentially affecting our results of operations.", -0.5], ["If our estimates of activity changed, this could have a material impact on the reported value of these investments and on the return on assets that we report.", -0.6], ["Changes in any of these assumptions may materially impact the amount we recognize for identifiable assets and liabilities, in addition to the residual amount allocated to goodwill.", -0.5], ["Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.", -0.4], ["If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable.", -0.7], ["We believe that we will ultimately recover a substantial majority of the deferred tax assets recorded on our consolidated balance sheets.", 0.5], ["However, should there be a change in our ability to recover our deferred tax assets, our tax provision would increase in the period in which we determined that the recovery was not likely.", -0.5], ["Such a change in recognition or measurement could result in the recognition of a tax benefit or an additional charge to the tax provision.", -0.3], ["We are exposed to market risk from changes in certain commodity prices, foreign currency exchange rates, interest rates and equity prices.", -0.7], ["Because of this, our operating results may be affected should the market price of fuel suddenly change by a significant amount or change by amounts that do not result in an adjustment in our fuel surcharges, which can significantly affect our results either positively or negatively in the short-term.", -0.6], ["Our floating-rate debt and interest rate swaps subject us to risk resulting from changes in short-term interest rates.", -0.6], ["We are also subject to interest rate risk with respect to our defined benefit pension and postretirement medical plan obligations, as changes in interest rates will effectively increase or decrease the obligations associated with these plans.", -0.6], ["This will result in changes to the amount of pension and postretirement benefit expense recognized in future periods and may also result in us being required to make contributions to the plans.", -0.4], ["We adjust the fixed and floating interest rate mix of our interest-rate-sensitive assets and liabilities in response to changes in market conditions.", 0.2], ["Additionally, changes in the fair value of foreign currency derivatives and commodity derivatives are offset by changes in the cash flows of the underlying hedged foreign currency and commodity transactions.", 0.1], ["(1) The potential change in fair value from a hypothetical 10% weakening of the U.S. Dollar against foreign currency exchange rates across all maturities.", -0.2], ["In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.", 0.8], ["Change in unrealized gain (loss) on marketable securities, net of tax", -0.2], ["Change in unrealized gain (loss) on cash flow hedges, net of tax", -0.2], ["Change in unrecognized pension and postretirement benefit costs, net of tax", -0.2], ["Proceeds from disposal of businesses, property, plant and equipment", 0.5], ["Net Increase (Decrease) In Cash, Cash Equivalents and Restricted Cash", 0.1], ["In particular, a number of estimates have been and will continue to be affected by the ongoing COVID-19 pandemic.", -0.5], ["Unrealized gains and losses on trading securities are reported as Investment income (expense) and other on the statements of consolidated income.", 0.0], ["Unrealized gains and losses on available-for-sale securities are reported as other comprehensive income, a separate component of shareowners’ equity.", 0.0], ["The cost of securities sold is based on the specific identification method; realized gains and losses resulting from such sales are included in Investment income (expense) and other.", 0.0], ["Impairment of available-for-sale securities results in a charge to income when a market decline below cost is other-than-temporary.", -0.8], ["If a decline in fair value is determined to be the result of a credit loss, then the decrease is recognized in income through an allowance for credit losses.", -0.7], ["We record the investment at cost and subsequently increase or decrease the carrying amount of the investment by our proportionate share of the net earnings or losses and other comprehensive income of the investee.", 0.2], ["Gains and losses from equity method investments are reported in Investment income (expense) and other on the statements of consolidated income.", 0.1], ["Total inventories were $889 and $717 million as of December 31, 2022 and 2021, respectively, and are included in Other current assets in the consolidated balance sheets.", 0.3], ["Capitalized interest was $60 and $58 million for the years ended December 31, 2022 and 2021, respectively.", 0.2], ["If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded.", -0.9], ["If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, we record the excess amount as goodwill impairment, not to exceed the total amount of goodwill allocated to the reporting unit.", -0.8], ["If the carrying value of the asset exceeds its estimated fair value, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds its fair value.", -0.9], ["We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell and recognize any loss in the period in which the held for sale criteria are met.", -0.7], ["Gains are not recognized until the date of sale.", -0.1], ["We paid $341 million to transfer a portfolio of claims for which we carried reserves of $332 million, recognizing a pre-tax loss of $9 million that was recorded in Other expenses in the statement of consolidated income for the year ended December 31, 2022.", -0.8], ["Such a change in recognition or measurement could result in the recognition of a tax benefit or an additional charge to the tax provision.", -0.5], ["Pre-tax foreign currency transaction gains (losses) from remeasurement, net of hedging, included in Investment income (expense) and other were $72, $(36) and $9 million in 2022, 2021 and 2020, respectively.", 0.1], ["These assets are subject to fair value adjustments in certain circumstances, such as when there is an impairment.", -0.4], ["Following the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.", 0.0], ["For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is reported as a component of other comprehensive income, and reclassified into earnings in the period during which the hedged transaction affects earnings.", 0.2], ["For derivative instruments that are designated and qualify as fair value hedges, the gain or loss on the derivative instrument is recognized in earnings during the current period, together with the gain or loss on the hedged item.", 0.3], ["For instruments that meet the hedge accounting requirements, the net gains or losses attributable to changes in spot exchange rates are recorded in the foreign currency translation adjustment within other comprehensive income, and are recorded in the income statement when the hedged item affects earnings.", 0.2], ["We are evaluating the potential impacts of reference rate reform on our various contractual positions to determine whether we may apply any of the practical expedients set forth in this standard; however, we do not expect reference rate reform to have a material impact on our consolidated financial position, results of operations, cash flows, or internal controls.", 0.0], ["Other accounting pronouncements adopted during the periods covered by the consolidated financial statements did not have a material impact on our consolidated financial position, results of operations, cash flows or internal controls.", -0.1], ["We are evaluating the impact of its adoption on our consolidated financial statements and internal control over financial reporting environment but do not expect this ASU to have a material impact on our consolidated financial position, results of operations, cash flows or internal controls.", -0.1], ["Other accounting pronouncements issued, but not effective until after December 31, 2022, are not expected to have a material impact on our consolidated financial position, results of operations, cash flows or internal controls.", -0.1], ["Our contracts commonly contain customer incentives, guaranteed service refunds or other provisions that can either increase or decrease the rates paid for services.", -0.2], ["Losses on accounts receivable are recognized when reasonable and supportable forecasts affect the expected collectability.", -0.3], ["We increased our allowance for expected credit losses by $18 million during 2022 based upon current forecasts that reflect changes in the economic outlook.", -0.4], ["Our allowance for credit losses as of December 31, 2022 and 2021 was $146 and $128 million, respectively.", -0.3], ["Amounts for credit losses charged to expense before recoveries during the twelve months ended December 31, 2022 and 2021 were $214 and $175 million, respectively.", -0.4], ["The gross realized gains on sales of available-for-sale marketable securities totaled $0, $7 and $5 million in 2022, 2021 and 2020, respectively.", 0.1], ["The gross realized losses on sales of available-for-sale marketable securities totaled $3, $2 and $0 million in 2022, 2021 and 2020, respectively.", -0.2], ["Equity method investments: During the fourth quarter of 2022 we invested $252 million in the parent company of CommerceHub, Inc., a software provider connecting retailers and brands with marketplaces, drop ship solutions and delivery providers.", -0.1], ["Property, plant and equipment purchased on account was $176 and $248 million as of December 31, 2022 and 2021, respectively.", 0.0], ["There were no material impairment charges during the year ended December 31, 2022.", 0.2], ["We recognized impairment charges of", -0.5], ["$71 million during the year ended December 31, 2021, due to the reevaluation of certain facility projects.", -0.6], ["During 2022, we reduced the estimated residual value of our MD-11 aircraft to zero, incurring a one-time charge on our fully- depreciated aircraft during the fourth quarter.", -0.8], ["This resulted in an increase in depreciation expense of $76 million, and a decrease in net income of $58 million, or $0.07 per share on a basic and diluted basis.", -0.7], ["The UPS Retirement Plan and the UPS Excess Coordinating Benefit Plan ceased accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023.", -0.3], ["The divestiture of UPS Freight in 2021 triggered an interim remeasurement of the plan assets and benefit obligations of the UPS Pension Plan, UPS Retirement Plan and UPS Retired Employee Health Care Plan as of April 30, 2021.", 0.1], ["The interim remeasurement resulted in an actuarial gain of $2.1 billion, reflecting updated actuarial assumptions, and was recorded in other comprehensive income within the equity section of the consolidated balance sheet.", 0.5]], "ups23_sentences.json": [["The aggregate market value of the class B common stock held by non-affiliates of the registrant was $129,730,366,499 as of June 30, 2023.", 0.5], ["In 2023, we delivered an average of 22.3 million packages per day, totaling 5.7 billion packages during the year.", 0.5], ["Total revenue in 2023 was $91.0 billion.", 0.5], ["Innovation Driven is designed to optimize the volume that flows through our network to focus on increasing value share and to drive business growth from higher-yielding opportunities in our target markets.", 0.7], ["We continue to leverage data and automation to deliver improvements to our network and unlock additional value for our customers through innovation.", 0.8], ["We are a global leader in developing technologies that help customers enhance their shipping and logistics business processes to lower costs, improve service and increase efficiency.", 0.9], ["Increasingly, our customers benefit from UPS business solutions that integrate our services beyond package delivery.", 0.8], ["For example, our supply chain services are designed to improve the efficiency and resilience of customers’ entire supply chain management process.", 0.7], ["Our financial strength allows us to continue to pursue strategic opportunities that facilitate our growth.", 0.9], ["These services are driven by the continued growth of e- commerce that has increased our customers' need for efficient and reliable returns, and are designed to promote efficiency and a friction-free consumer experience.", 0.8], ["To accelerate growth of this portfolio, in the fourth quarter of 2023 we acquired Happy Returns, a technology-focused company that is managed and reported within Supply Chain Solutions, to provide innovative end-to-end return services and a consolidated returns solution for our enterprise retail customers.", 0.8], ["With a strategic focus on serving the unique, priority-handling needs of healthcare and life sciences customers, we continue to increase our complex cold-chain logistics capabilities both in the U.S. and internationally.", 0.7], ["In furtherance of this strategy and to broaden our reach and services, we recently acquired Bomi Group and MNX Global Logistics.", 0.6], ["For the year ended December 31, 2023, one customer, Amazon.com, Inc. and its affiliates, represented approximately 11.8% of our consolidated revenues, substantially all of which was within our U.S.", 0.1], ["For additional information on our customers, see \"Risk Factors - Business and Operating Risks - Changes in our relationships with any of our significant customers, including the loss or reduction in business from one or more of them, could have a material adverse effect on us\" and note 14 to the audited, consolidated financial statements.", -0.7], ["We expect to continue to face significant competition, which could materially adversely affect us\".", -0.9], ["Continued compliance with increasingly stringent laws, regulations and policies in the U.S. and in the other countries in which we operate may result in materially increased costs, or we could be subject to substantial fines or possible revocation of our authority to conduct our operations.", -0.8], ["The DOD is required to compensate us for any use of aircraft under the CRAF program.", 0.3], ["In addition, participation in the CRAF program entitles us to bid for other U.S. Government opportunities including small package and airfreight.", 0.5], ["Increases in operational security requirements impose substantial costs on us and we could be the target of an attack or have a security breach, which could materially adversely affect us\".", -0.9], ["Compliance with changing laws and regulations from time to time, including those promulgated by the U.S. Occupational Safety and Health Administration and state agencies, could result in materially increased operating costs and capital expenditures, and negatively impact our ability to attract and retain employees.", -0.9], ["Based on our most recent review, from August 2018 to the date of this filing, in addition to previously disclosed deliveries we inadvertently delivered to: Bank Melli – 2 shipments (revenue of $18.84, loss of $3.98); the Embassy of Iran (revenue of $7.81, loss of", -0.5], ["$0.65); Syrian Airlines (revenue of $7.70, profit of $0.72); Irasco SRL – 2 shipments (revenue of $11.59, loss of $1.08); Stark 1 (revenue of $7.33, profit of $2.02); Fanreach (revenue of $9.74, profit of $2.76); and Wael Bazzi (revenue of $4.74, loss of $2.29).", 0.1], ["Changes in general economic conditions, in the U.S. and internationally, may adversely affect us.", -0.8], ["Changes in general economic conditions are beyond our control, and it may be difficult for us to adjust our business model.", -0.7], ["We have been, and may in the future be, materially affected by adverse developments in these aspects of the economy.", -0.8], ["We have also been, and may in the future be, adversely impacted by changes in general economic conditions resulting from geopolitical uncertainty and/or conflicts in or arising from the countries and regions where we operate, including the United Kingdom, the European Union, Ukraine, the Russian Federation, the Middle East and the Trans-Pacific region.", -0.8], ["Changes in general economic conditions, or our inability to accurately forecast these changes or mitigate the impact of these conditions on our business, could materially adversely affect us.", -0.9], ["We expect to continue to face significant competition, which could materially adversely affect us.", -0.9], ["Additionally, from time to time we have raised, and may in the future raise, prices and our customers may not be willing to accept these higher prices.", -0.7], ["If we do not appropriately respond to competitive pressures, including replacing any lost volume or maintaining our profitability, we could be materially adversely affected.", -1], ["Business combinations could also result in competitors providing a wider variety of services and products at competitive prices, which could also materially adversely affect us.", -1], ["Changes in our relationships with any of our significant customers, including the loss or reduction in business from one or more of them, could have a material adverse effect on us.", -1], ["Customers could choose, and have in the past chosen, to divert all or a portion of their business with us to one of our competitors, demand pricing concessions, request enhanced services that increase our costs, or develop their own logistics capabilities.", -1], ["If all or a portion of our business relationships with one or more significant customers were to terminate or significantly change, this could materially adversely affect us.", -1], ["Failure to attract or retain qualified employees could materially adversely affect us.", -1], ["If we are unable to hire, properly train or retain qualified employees, we could experience higher labor costs, reduced revenues, further increased workers' compensation and automobile liability claims costs, regulatory noncompliance, customer losses and diminution of our brand value or company culture, which could materially adversely affect us.", -1], ["In addition, we strive to lower our cost to serve, including labor costs, through various strategic initiatives.", 0], ["Our inability to continue to retain experienced and motivated employees through the execution of these initiatives may also materially adversely affect us.", -1], ["Strikes, work stoppages or slowdowns by our employees could materially adversely affect us.", -1], ["Actual or threatened strikes, work stoppages or slowdowns by our employees could adversely affect our ability to meet our customers' needs.", -1.0], ["As a result, customers have reduced, and in the future may reduce, their business or stop doing business with us if they believe that such actions or threatened actions may adversely affect our ability to provide services.", -1.0], ["We may permanently lose customers if we are unable to provide uninterrupted service, and this could materially adversely affect us.", -1.0], ["The terms of collective bargaining agreements also may affect our competitive position and results of operations.", -0.5], ["Furthermore, our actions or responses to any such negotiations, labor disputes, strikes or work stoppages could negatively impact how our brand is perceived and our reputation and have adverse effects on our business, including our results of operations.", -1.0], ["Increases in operational security requirements impose substantial costs on us and we could be the target of an attack or have a security breach, which could materially adversely affect us.", -1.0], ["As a result of concerns about global terrorism and homeland security, various governments have adopted and may adopt additional heightened security requirements, resulting in significantly increased operating costs.", -1.0], ["We cannot determine the effect that any new requirements will have on our operations, cost structure or operating results, and new rules or other future security requirements may significantly increase our operating costs and reduce operating efficiencies.", -1.0], ["Regardless of our compliance with security requirements or our own security measures, we could also be the target of an attack or security breaches could occur, which could materially adversely affect one or more of our operations, or our business.", -1.0], ["A significant cybersecurity incident, or increased data protection regulations, could materially adversely affect us.", -1.0], ["However, cybersecurity incidents have in the past and may in the future expose us, our customers, franchisees, service providers or others, to loss, disclosure or misuse of proprietary information and sensitive or confidential data or result in disruptions to our operations or those of our customers,", -0.8], ["The occurrence of any of the events described above could result in material disruptions in our business, the loss of existing or potential customers, damage to our brand and reputation, additional regulatory scrutiny, litigation and other potential material liability.", -0.9], ["The costs and operational consequences of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly frequent, complex and sophisticated cyber threats and regulatory requirements.", -0.7], ["In addition, our customers’ confidence in our ability to protect data and systems and to provide services consistent with their expectations could be impacted, further disrupting our operations.", -0.8], ["An actual or alleged failure to comply with applicable data protection laws, regulations, or other data protection standards has in the past and may in the future expose us to litigation, fines, sanctions, or other penalties, which could harm our reputation and adversely affect our business, results of operations, and financial condition.", -0.9], ["Consequently, compliance with applicable regulations in the various jurisdictions in which we do business may present material obligations and risks to our business, including significantly expanded compliance burdens, costs, and enforcement risks which are expected to increase over time; require us to make extensive system or operational changes; or adversely affect the cost or attractiveness of the services we offer.", -0.8], ["Failure to maintain our brand image and corporate reputation could materially adversely affect us.", -0.9], ["Service quality issues, actual or perceived, could tarnish the image of our brand and may cause customers not to use UPS services.", -0.8], ["Also, adverse publicity or public sentiment surrounding labor relations, environmental, sustainability and governance concerns, physical or cyber security matters, political activities and similar matters, or attempts to connect our company to such issues, either in the U.S. or elsewhere, could materially adversely affect us.", -0.9], ["For example, damage to our reputation or loss of brand equity could require the allocation of resources to rebuild our reputation and restore the value of our brand.", -0.8], ["The proliferation of social media may increase the likelihood, speed, and magnitude of negative brand events.", -0.8], ["Global climate change could materially adversely affect us.", -0.9], ["The effects of climate change present financial and operational risks to our business, both directly and indirectly.", -0.7], ["While we remain committed to being responsive to the effects of climate change and reducing our carbon footprint, there can be no assurances that our goals and strategic plans to achieve those goals will be successful, that the costs related to climate transition will not be higher than expected, that the necessary technological advancements will occur in the timeframe we expect, or at all, that the severity of and or the pace of negative climate-related effects will not accelerate faster than expected, or that proposed regulation or deregulation related to climate change will not have a negative competitive impact, any one of which could have a material adverse effect on our capital expenditures or other expenses, revenue or results of operations.", -0.9], ["Changes in regulation or technology impacting our business could require us to write down the carrying value of assets, which could result in material impairment charges.", -0.8], ["If we do not meet these goals or there is perception that we failed to meet these goals, then, in addition to regulatory and legal risks related to compliance, we could incur adverse publicity and reaction, which could adversely impact our reputation, and in turn adversely impact our results of operations.", -0.8], ["Severe weather or other natural or man-made disasters could materially adversely affect us.", -0.9], ["Customers may reduce shipments, supply chains may be disrupted, demand may be negatively impacted or our costs to operate our business may increase, any of which could have a material adverse effect on us.", -0.8], ["Any such event affecting one of our major facilities could result in a significant interruption in or disruption of our business.", -0.7], ["To the extent such weather events or natural disasters do become more frequent or severe, disruptions to our business and those of our customers and costs to repair damaged facilities or maintain or resume operations could increase.", -0.8], ["Economic, political, or social developments and other risks associated with international operations could materially adversely affect us.", -1], ["Emerging markets are often more volatile than those in other countries, and any broad-based downturn in these markets could reduce our revenues and materially adversely affect our business, financial condition and results of operations.", -1], ["Our failure to manage and anticipate these and other risks associated with our international operations could materially adversely affect us.", -1], ["Our inability to effectively integrate any acquired businesses and realize the anticipated benefits of any acquisitions, joint ventures, strategic alliances or dispositions could materially adversely affect us.", -1], ["Accordingly, our financial results could be materially adversely affected by our failure to effectively integrate acquired operations, unanticipated performance or other issues or transaction-related charges.", -1], ["Changing fuel and energy prices, including gasoline, diesel and jet fuel, and interruptions in supplies of these commodities could materially adversely affect us.", -1], ["If we are unable to maintain or increase our fuel surcharges, higher fuel costs could materially adversely impact our operating results.", -1], ["Even if we are able to offset changes in fuel costs with surcharges, high fuel surcharges have in the past, and may in the future result in a shift from our higher-yielding products to lower-yielding products or an overall reduction in volume, revenue and profitability.", -1], ["Moreover, we could experience a disruption in energy supplies as a result of new or increased regulation, war or other conflicts, weather-related events or natural disasters, actions by producers (including as part of their own sustainability efforts) or other factors beyond our control, which could have a material adverse effect on us.", -1], ["Changes in foreign currency exchange rates or interest rates may have a material adverse effect on us.", -1], ["We monitor and manage foreign currency exchange rate and interest rate exposures, and use derivative instruments to mitigate the impact of changes in these rates on our financial condition and results of operations; however, changes in foreign currency exchange rates and interest rates cannot always be predicted or effectively hedged, and may have a material adverse effect on us.", -0.8], ["Our business requires significant capital and other investments; if we do not accurately forecast our future investment needs, we could be materially adversely affected.", -0.7], ["If we do not accurately forecast our future capital investment needs, we could under- or over-invest, or have excess capacity or insufficient capacity, any of which could negatively affect our revenues and profitability.", -0.7], ["Employee health and retiree health and pension benefit costs represent a significant expense to us; further cost increases could materially adversely affect us.", -0.8], ["In recent years, we have experienced increases in some of these costs, in particular, ongoing increases in healthcare costs in excess of the rate of inflation and historically low discount rates that we use to value our company-sponsored defined benefit plan obligations.", -0.6], ["Increasing healthcare costs, volatility in investment returns and discount rates, as well as changes in laws, regulations and assumptions used to calculate retiree health and pension benefit expenses, may materially adversely affect our business, financial condition, or results of operations, and have required, and may in the future require significant contributions to our benefit plans.", -0.8], ["Our national master agreement with the Teamsters includes provisions that are designed to mitigate certain healthcare expenses, but there can be no assurance that our efforts will be successful or that these efforts will not materially adversely affect us.", -0.7], ["Insurance and claims expense could materially adversely affect us.", -0.8], ["If the number, severity or cost of claims for which we retain risk continues to increase, our financial condition and results of operations could be materially adversely affected.", -0.8], ["If we lose our ability to, or decide not to, self-insure these risks, our insurance cost could materially increase and we may find it difficult to obtain adequate levels of insurance coverage.", -0.7], ["Changes in markets and our business plans have resulted, and may in the future result, in substantial impairments of the carrying value of our assets, thereby reducing our net income.", -0.8], ["If the carrying value of an asset exceeds its estimated fair value, we may be required to incur charges to reduce the carrying value thereof.", -0.7], ["Our estimates of fair value have resulted from time to time, and may in the future result, in substantial impairments of our assets.", -0.7], ["For example, during the year ended December 31, 2023, as a result of a number of factors including changes in business strategy and challenging macroeconomic conditions such as increases in the risk-free interest rate and volatility of the stock prices of market comparables, we incurred impairment charges of $125 and $111 million in respect of goodwill and indefinite-lived intangible assets, respectively.", -0.6], ["In addition, we have been and may be required in the future to recognize increased depreciation and amortization charges if we determine the useful lives or salvage values of our assets are less than we originally estimated.", -0.7], ["Such changes have in the past, and may in the future, reduce our net income.", -0.8], ["We may have significant additional tax liabilities that could materially adversely affect us.", -0.9], ["The final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.", -0.8], ["In addition, changes in U.S. federal and state or international tax laws, other fundamental law changes currently being considered by many countries, and changes in taxing jurisdictions’ administrative interpretations, decisions, policies and positions may materially adversely impact our tax expense and cash flows.", -0.9], ["Increasingly complex and stringent laws, regulations and policies could materially increase our operating costs.", -0.8], ["Compliance with any new laws, regulations or policies may increase our operating costs or require significant capital expenditures.", -0.5], ["Any failure to comply with applicable laws, regulations or policies in the U.S. or other countries could result in substantial fines or possible revocation of our authority to conduct our operations, which could materially adversely affect us.", -1.0], ["Increasingly stringent regulations related to climate change, including reporting obligations, could materially increase our operating costs.", -0.7], ["Regulation and required disclosures of greenhouse gas (\"GHG\") emissions and related matters exposes us to potentially significant new taxes, fees, disclosure and compliance obligations and other costs.", -0.8], ["The International Civil Aviation Organization, which adopted CORSIA, continues to develop details regarding implementation, but compliance with CORSIA is expected to increase our operating costs, potentially significantly.", -0.6], ["Even in the absence of such legislation, the Environmental Protection Agency could determine to regulate GHG emissions, especially aircraft or diesel engine emissions, and this could impose substantial costs on us.", -0.9], ["The extent to which other countries implement that accord could also have a material adverse effect on us.", -0.8], ["Increased regulation relating to GHG emissions in the U.S. or abroad, especially aircraft or diesel engine emissions, could, among other things, increase the cost of fuel and other energy we purchase and the capital costs associated with updating or replacing our aircraft or vehicles prematurely.", -0.7], ["It is likely that such regulation could significantly increase our operating costs and that we may not be willing or able to pass such costs along to our customers.", -0.9], ["Moreover, even without such regulation, increased awareness and any adverse publicity in the global marketplace about the GHGs emitted by companies in the airline and transportation industries could harm our reputation and reduce customer demand for our services, especially our air services.", -0.8], ["Compliance with these disclosure requirements may increase our operating costs or require significant management time and attention.", -0.5], ["Any failure to comply with applicable disclosure regulations in the U.S. (at either the federal or state level) or other countries could result in substantial fines or other penalties, which could materially adversely affect us.", -1.0], ["We may be subject to various claims and lawsuits that could result in significant expenditures which may materially adversely affect us.", -1.0], ["Any material litigation or a catastrophic accident or series of accidents could result in significant expenditures and have a material adverse effect on us.", -1.0], ["The Company maintains an enterprise risk management process designed to identify potential events that may affect the achievement of the Company's objectives or have a material adverse effect on the Company.", -0.8], ["Two of the MD-11 aircraft shown above have been retired from operational use as of December 31, 2023.", 0.0], ["We anticipate retiring an additional nine of these aircraft during 2024.", 0.0], ["On January 25, 2024, our Board declared a dividend of $1.63 per share, which is payable on March 8, 2024 to shareowners of record on February 20, 2024.", 0.8], ["In August 2021, the Board of Directors approved a share repurchase authorization of $5.0 billion of class A and class B common stock.", 0.9], ["During the year ended December 31, 2023, we repurchased 0.5 million shares of class B common stock for $0.1 billion under this authorization.", 0.7], ["$5.0 billion of class A and class B common stock.", -0.1], ["During the year ended December 31, 2023, we repurchased 12.3 million shares of class B common stock for $2.2 billion under this authorization.", 0.2], ["We did not repurchase any shares during the fourth quarter of 2023 and do not anticipate repurchasing any shares in 2024.", -0.5], ["During the year, macroeconomic headwinds, including inflationary pressures and changes in consumer behavior, together with volume diversion resulting from our labor negotiations with the International Brotherhood of Teamsters (\"Teamsters\"), contributed to volume declines in our U.S. small package business.", -0.8], ["Internationally, the challenging macroeconomic environment, coupled with geopolitical tensions, drove a decline in demand for our small package services in Europe and Asia.", -0.7], ["Our freight forwarding businesses, including truckload brokerage, were negatively impacted by soft demand and market overcapacity.", -0.6], ["We expect global economic conditions to improve gradually during 2024, and therefore expect volume and revenue growth to increase in the second half of the year.", 0.5], ["Under the agreement, wage and benefit rates, combined with all other contract provisions, will increase union cost at a 3.3% compounded annual growth rate over the five-year term of the contract, with the majority of the increase in the first and fifth years.", -0.2], ["We experienced higher year-over-year labor costs in the second half of the year as a result of these contractual increases, which we expect to persist through the first half of 2024.", -0.4], ["These moves include exploring strategic alternatives for our truckload brokerage business and reducing headcount through our \"fit to serve\" initiative to create a more efficient operating model and enhance responsiveness to changing market dynamics.", 0.3], ["Revenue and average daily package volume in our global small package operations decreased for the year, with declines in both commercial and residential shipments across all of our products.", -0.8], ["These declines were primarily the result of the macroeconomic conditions and union labor-related uncertainties described above, as well as reductions in fuel and demand- related surcharges.", -0.7], ["Operating expenses decreased for the year, driven by a reduction in purchased transportation in Supply Chain Solutions and reductions in fuel expense in our small package operations, as well as the impact of our ongoing productivity initiatives and reductions in operating costs; these reductions were partially offset by U.S.", 0.2], ["Domestic Package segment wage rate increases in the second half of 2023 due to the new Teamsters contract.", -0.3], ["Operating profit and operating margin decreased, as revenue declines were greater than operating expense reductions.", -0.6], ["We reported net income of $6.7 billion and diluted earnings per share of $7.80.", 0.7], ["Adjusted diluted earnings per share were $8.78 after adjusting for the after-tax impacts of:", 0.5], ["Domestic Package segment, revenue declines for the year were driven by lower volume, a shift in product mix, and lower fuel and demand-related surcharges.", -0.5], ["These were somewhat offset by revenue per piece growth due to increases in base rates and changes in customer mix.", 0.1], ["Expenses decreased for the year, primarily due to declines in fuel prices and reductions in purchased transportation.", 0.3], ["In our International Package segment, revenue declines for the year were driven by lower volume and declines in fuel and demand-related surcharges.", -0.7], ["Expenses decreased year over year, driven by lower fuel and third-party transportation expense as a result of volume declines and lower fuel prices.", 0.3], ["In Supply Chain Solutions, revenue decreases for the year were driven by volume and market rate declines in Forwarding.", -0.6], ["Expenses decreased for the year, primarily due to a reduction in purchased transportation in Forwarding.", 0.4], ["Defined Benefit Pension and Postretirement Medical Plan (Gains) and Losses", 0.0], ["Defined Benefit Pension and Postretirement Medical Plan (Gains) and Losses", 0.0], ["Transformation Charges, and Goodwill and Asset Impairment Charges", -0.5], ["During 2022, we completed certain structural changes to the design of our incentive compensation programs that resulted in a one-time, non-cash charge in connection with the accelerated vesting of certain equity incentive awards that we do not expect to repeat.", -0.2], ["In connection therewith, we reduced the estimated residual value of our MD-11 fleet, incurring a one-time, non-cash charge on our fully-depreciated aircraft.", -0.3], ["We supplement the reporting of revenue, revenue per piece and operating profit with adjusted measures that exclude the period over period impact of foreign currency exchange rate changes and hedging activities.", 0.1], ["Defined Benefit Pension and Postretirement Medical Plan Gains and Losses", -0.1], ["The remeasurement of our defined benefit pension and postretirement medical plans' assets and liabilities resulted in a loss of $0.4 billion and a gain of $1.1 billion for the years ended December 31, 2023 and 2022, respectively.", 0.2], ["The pre-tax defined benefit plan gains and losses for the years ended December 31, 2023 and 2022 consisted of the following: 2023 - $0.4 billion pre-tax defined benefit plan loss:", -0.4], ["Discount Rates ($384 million pre-tax loss): The weighted-average discount rate for our pension and postretirement medical plans decreased from 5.77% as of December 31, 2022 to 5.40% as of December 31, 2023, primarily due to a decrease in credit spreads on AA-rated corporate bonds in 2023.", -0.3], ["Return on Assets ($37 million pre-tax gain): The actual rate of return on plan assets in certain of our international pension plans was higher than our expected rate of return, primarily due to strong global equity market performance.", 0.3], ["Demographic and Other Assumption Changes ($4 million pre-tax loss): This loss was due to differences between actual and estimated participant data and demographic factors, including healthcare cost trends, compensation rate increases and rates of termination, retirement and mortality.", -0.1], ["Discount Rates ($5.2 billion pre-tax gain): The weighted-average discount rate for our pension and postretirement medical plans increased from 3.11% as of December 31, 2021 to 5.77% as of December 31, 2022, primarily due to an increase in U.S. treasury yields as well as an increase in credit spreads on AA-rated corporate bonds in 2022.", 0.5], ["Return on Assets ($4.1 billion pre-tax loss): The actual rate of return on plan assets was lower than our expected rate of return, primarily due to weaker global equity and U.S. bond market performance.", -0.5], ["Demographic and Other Assumption Changes ($0.1 billion pre-tax loss): This loss was due to differences between actual and estimated participant data and demographic factors, including healthcare cost trends, compensation rate increases and rates of termination, retirement and mortality.", -0.1], ["The change in revenue was due to the following factors:", 0.0], ["2023 vs. 2022                            (8.0)%         3.0 %        (1.6)%        (6.6)%", -0.5], ["Revenue was also negatively impacted by having one less operating day in 2023 compared to 2022.", -0.8], ["Average daily volume decreased, with reductions in both residential and commercial volume.", -0.7], ["Challenging external conditions, including inflationary pressures and changes in consumer spending behavior contributed to overall volume declines.", -0.9], ["Also contributing to the decline was diverted volume associated with our labor negotiations with the Teamsters.", -0.8], ["Following ratification of the Teamsters contract in the third quarter of 2023, we regained approximately 60% of diverted U.S. volume and gained volume from new customers.", 0.6], ["We anticipate overall year-over-year volume growth rates will be flat in the first half of 2024, with moderate growth expected in the second half of the year dependent upon improving macroeconomic conditions.", 0.2], ["Business-to-consumer volume declined 9.3% during the year, driven by changes in consumer spending behavior, as well as the impact of our labor negotiations with the Teamsters.", -0.7], ["Business-to-consumer volume declines from SMBs were less than those from our large customers, which was partially due to continued growth in our Digital Access Program.", 0.1], ["Volume from our largest customer declined for the year as planned under our contract terms.", -0.6], ["Business-to-business volume declined 7.2%, primarily as a result of declines from large customers in industry sectors that are sensitive to the macroeconomic factors discussed above.", -0.7], ["Uncertainty around our Teamsters contract also negatively impacted volume, primarily during the first nine months of the year.", -0.8], ["Average daily returns volume increased slightly during the year, benefiting from our acquisition of Happy Returns during the fourth quarter.", 0.2], ["Within our Air products, average daily volume decreases were driven by continued execution under the contract terms with our largest customer as planned, as well as by other customers making cost trade-offs and utilizing the enhanced speed in our ground network.", -0.5], ["We expect moderate volume decreases in 2024 as we continue to execute contract terms with our largest customer.", -0.3], ["Ground residential and Ground commercial average daily volume decreases of 7.1% and 6.7%, respectively, were primarily attributable to volume declines from a number of large customers due to the factors discussed above.", -0.6], ["We expect volume growth in 2024 to be aligned with overall market growth.", 0.4], ["In December 2022, we implemented an average 6.9% net increase in base and accessorial rates for our Air and Ground products.", 0.3], ["Revenue per piece in Air and Ground products increased for the full year, driven by base rate increases and other pricing actions, and favorable changes in customer mix.", 0.5], ["A shift in product mix, declines in fuel and demand-related surcharges, and a reduction in average billable weight per piece slightly offset these increases.", -0.1], ["In 2023, fuel surcharge revenue decreased $1.0 billion, driven by reductions in price per gallon and the impact of lower volumes.", -0.8], ["Based on current commodity market forecasts, we anticipate a further decline in fuel prices will be offset in part by higher surcharge modifiers.", -0.2], ["Operating expenses and adjusted operating expenses decreased year over year.", 0.5], ["The costs of operating our integrated air and ground network decreased $1.5 billion, our pickup and delivery costs decreased $641 million and our package sorting costs decreased", 0.6], ["Lower compensation expense due to a reduction in direct labor hours resulting from volume declines, as well as the impact of incentive compensation program design changes implemented in the fourth quarter of 2022 and reductions in management headcount.", 0.3], ["A reduction in purchased transportation costs, resulting from lower volumes and a reduction in ground volume handled by third-party carriers, as well as the impact of continued strategic initiatives.", 0.4], ["Lower fuel expense driven by lower volumes and decreases in the price of jet fuel, diesel and gasoline.", 0.5], ["These decreases were slightly offset by an increase of $259 million in other operating costs.", -0.1], ["Notwithstanding the factors discussed above, total cost per piece increased 5.2% for the year and adjusted cost per piece increased 5.7%, driven by overall reductions in volume while maintaining industry leading service levels.", -0.6], ["As a result of the factors described above, operating profit decreased $1.9 billion, with operating margin decreasing 240 basis points to 8.5%.", -0.9], ["Adjusted operating profit decreased $2.2 billion, with adjusted operating margin decreasing 280 basis points to 9.0%.", -1], ["Average daily volume decreased for both domestic and export products.", -1], ["Business-to-consumer volume decreased 10.0%, as geopolitical tensions and global macroeconomic headwinds, including persistent inflation and high interest rates, negatively impacted consumer demand.", -1], ["These factors, coupled with higher U.S. inventory levels, also negatively impacted business-to-business volume, driving a decrease of 5.8%.", -1], ["Volume from both large customers and SMBs declined, driven by declines in the retail, technology and manufacturing sectors.", -1], ["Export volume decreased for the year, driven by declines on intra-Europe and Asia trade lanes that were slightly offset by volume growth in the Americas.", -1], ["Volume on intra-Europe and Asia trade lanes was negatively impacted by overall economic conditions, with Asia to U.S. volumes also impacted by higher inventory levels in the United States.", -1], ["Our premium products experienced a volume decline of 10.6%, primarily from our Transborder and Worldwide Express Saver products.", -1], ["These declines resulted from shifts in customer product preferences, macroeconomic conditions and lower import demand from U.S. consumers.", -1], ["Volume in our non-premium products decreased 1.9%, driven by declines in our Transborder Standard product in Europe and our Worldwide Expedited product.", -1], ["Domestic volume declines were largest in Europe and Canada, resulting from an overall reduction in customer demand for all of the reasons discussed above.", -0.8], ["In December 2022, we implemented an average 6.9% net increase in base and accessorial rates for international shipments originating in the United States.", 0.3], ["Total revenue per piece decreased 1.0%, primarily due to declines in fuel and demand-related surcharges, as well as unfavorable currency movements during the first half of the year.", -0.6], ["Base rate increases and favorable shifts in customer and product mix largely offset these declines.", 0.2], ["Excluding the impact of currency, revenue per piece decreased 0.3%.", -0.2], ["We expect overall revenue per piece to decline in 2024 driven by a continued shift to non-premium products as the challenging economic outlook persists.", -0.7], ["Export revenue per piece decreased 4.2%, driven by declines in our Worldwide products.", -0.7], ["These declines were slightly offset by base rate increases.", 0.1], ["Excluding the impact of currency, export revenue per piece decreased 3.7%.", -0.5], ["Domestic revenue per piece increased 4.3%, primarily due to base rate increases and favorable shifts in customer mix.", 0.5], ["Excluding the impact of currency, domestic revenue per piece increased 5.2%.", -0.1], ["Total international fuel surcharge revenue decreased by $532 million, driven primarily by a decrease in the fuel price per gallon and the impact of volume declines.", -0.6], ["Based on current commodity pricing forecasts, we anticipate a decline in fuel prices to impact fuel surcharge revenue negatively in the first half of 2024.", -0.7], ["Operating expenses, and adjusted operating expenses, decreased year over year.", 0.2], ["This was primarily due to a reduction of $730 million in the cost of operating our integrated international air and ground network, driven by lower fuel prices and reductions in air charters and aircraft block hours as a result of lower volumes.", 0.3], ["As a result of the factors described above, operating profit decreased $1.1 billion, with operating margin decreasing 390 basis points to 18.1%.", -0.8], ["Adjusted operating profit decreased $1.1 billion and adjusted operating margin decreased 400 basis points to 18.4%.", -0.8], ["Total revenue within Supply Chain Solutions decreased for the year, primarily due to lower revenue and volumes across our forwarding businesses.", -0.5], ["The declines in forwarding and certain of our other businesses more than offset the impact of revenue growth in logistics and our digital businesses.", -0.4], ["International airfreight revenue decreased approximately $1.2 billion.", -0.9], ["Market rates declined during the year as customer demand remained weak and capacity continued to outpace demand.", -0.8], ["As a result, Asia export lanes experienced significant pressure during the first half of the year.", -0.6], ["Year-over-year revenue declines began to moderate in the fourth quarter and we experienced volume growth on Asia export lanes.", 0.2], ["We expect limited improvements in 2024, primarily from the continued volume growth in Asia.", 0.3], ["Revenue in our truckload brokerage business decreased $1.3 billion due to declines in volume and market rates.", -0.7], ["We focused on revenue quality initiatives for this business during the year and, as a result, were able to grow volume from SMBs.", 0.4], ["The remaining reduction in revenue was attributable to declines in ocean freight forwarding, driven by lower market rates.", -0.6], ["While volume in this business also declined for the year, we experienced year-over-year growth during the second half of the year.", 0.1], ["We anticipate ocean freight forwarding revenue will remain challenged in 2024 as market overcapacity continues to adversely impact rates.", -0.5], ["Within our Logistics businesses, healthcare logistics revenue increased $439 million, primarily due to the acquisition of Bomi Group in the fourth quarter of 2022.", 0.5], ["Additionally, we experienced growth within our other healthcare operations.", 0.7], ["Revenue in mail services increased $130 million as a result of volume growth, rate increases and a favorable shift in product characteristics.", 0.8], ["The impact of acquiring MNX Global Logistics during the fourth quarter of 2023 was largely offset by declines in our distribution and post sales operations.", -0.2], ["Within our other Supply Chain Solutions businesses, we experienced higher revenue from our digital businesses, including the acquisition of Happy Returns during the fourth quarter of 2023.", 0.6], ["Growth in our digital businesses was more than offset by a reduction of $386 million in transition services provided to the acquirer of UPS Freight.", -0.5], ["Revenue was also negatively impacted by $155 million due to lower volumes from our service contracts with the U.S.", -0.7], ["Total operating expenses and total adjusted operating expenses for Supply Chain Solutions decreased for the year.", 0.3], ["Forwarding operating expenses decreased $2.7 billion, including charges of $119 million related to impairments of goodwill and an indefinite-lived trade name.", -0.4], ["On an adjusted basis, operating expenses decreased $2.8 billion, driven by a reduction in purchased transportation expense as a result of lower market rates and volume declines.", 0.2], ["Overall, we expect market conditions will improve during 2024, leading to increases in our purchased transportation costs, particularly for airfreight.", 0.5], ["Logistics operating expenses increased $532 million primarily due to the acquisitions of Bomi Group and MNX Global Logistics.", -0.5], ["Returns, were more than offset by reductions in other businesses.", -0.3], ["In total, operating expenses decreased $176 million, including", 0.1], ["goodwill impairment charges of $117 million.", -0.7], ["On an adjusted basis, operating expenses decreased $295 million driven by a reduction of", 0.2], ["$363 million in costs incurred to procure transportation for, and provide transition services to, the acquirer of UPS Freight.", 0.3], ["Postal Service also decreased for the year as a result of lower volumes.", -0.4], ["As a result of the factors described above, total operating profit decreased $937 million, with operating margin decreasing 450 basis points to 6.3%.", -0.8], ["On an adjusted basis, operating profit decreased $672 million and operating margin decreased 230 basis points to 9.0%.", -0.6], ["Total compensation and benefits and adjusted total compensation and benefits decreased in 2023 compared to 2022.", -0.2], ["Compensation costs decreased $1.2 billion.", -0.5], ["On an adjusted basis, compensation costs decreased $676 million.", -0.3], ["Management compensation decreased $1.2 billion, including the effect of a 2022 one-time charge related to incentive compensation program design changes.", -0.4], ["Adjusted management compensation decreased $639 million, driven by lower incentive compensation accruals and lower overall headcount.", -0.3], ["The acquisition of Bomi Group in the fourth quarter of 2022 and the acquisitions of MNX Global Logistics and Happy Returns in the fourth quarter of 2023 resulted in additional compensation cost of $116 million within Supply Chain Solutions.", 0.1], ["Reductions in U.S. direct labor hours due to volume declines and lower administrative headcount resulted in a reduction in compensation cost of $1.2 billion that was offset by an increase of $1.3 billion due to contractual wage rate increases for our Teamsters workforce.", -0.1], ["Benefits costs increased $566 million and increased $197 million on an adjusted basis, primarily due to:", -0.2], ["Other benefits costs increased $348 million, driven by employee separation costs of $303 million as we reduced headcount to create a more efficient operating model and enhance responsiveness to changing market dynamics.", -0.4], ["On an adjusted basis, other benefits costs decreased $6 million.", 0.0], ["Health and welfare costs increased $294 million, driven by increased contributions to multiemployer plans as a result of contractually-mandated rate increases.", -0.2], ["Costs related to Company-sponsored health and welfare plans increased $51 million due to claims experience and medical cost inflation, partially offset by lower overall headcount.", -0.5], ["Accruals for paid time off, payroll taxes and other costs increased $250 million, including payroll taxes associated with the one-time payment discussed above.", -0.5], ["On an adjusted basis, these accruals increased $240 million, primarily due to contractual wage growth.", -0.3], ["Workers' compensation expense increased $61 million due to adverse claims trends, partially offset by the impact from a reduction in hours worked.", -0.4], ["Partially offsetting these increases, pension and other postretirement benefits expense decreased $392 million, primarily impacted", 0.2], ["A reduction of $887 million in the cost of Company-sponsored defined benefit plans, driven by a reduction in service cost due to higher discount rates and the cessation of accruals for future service in the UPS Retirement Plan.", 0.5], ["An expense increase of $445 million for the UPS 401(k) Savings Plan, primarily due to the impact of replacement contributions for the UPS Retirement Plan.", -0.4], ["The decrease in repairs and maintenance expense was primarily due to a reduction in aircraft engine maintenance as the declines in volume we experienced in 2023 resulted in the temporary idling of certain aircraft to better match capacity with demand.", 0.1], ["We incurred higher depreciation expense during 2023, primarily as a result of new facilities coming into service.", -0.3], ["We incurred higher amortization expense on capitalized software investments in support of our strategic initiatives, as well as on intangible assets due to the addition of assets arising from the acquisitions of Bomi Group in the fourth quarter of 2022 and MNX Global Logistics and Happy Returns in the fourth quarter of 2023.", -0.2], ["Supply Chain Solutions expense decreased $2.8 billion resulting from volume declines and a reduction in market rates paid for services in our forwarding businesses.", -0.2], ["Domestic Package expense decreased $783 million, driven by reduced utilization of third-party ground carriers as a result of volume declines and network optimization initiatives.", -0.1], ["International Package expense decreased $382 million, primarily due to a reduction in air charters and ground transportation expense as a result of volume declines.", -0.1], ["The decrease in fuel expense was driven by lower prices for jet fuel, diesel and gasoline and the impact of lower volumes.", 0.0], ["Based on current commodity market forecasts, we anticipate a decline in fuel prices in the first half of 2024.", 0.1], ["The increase in other occupancy expense was primarily the result of leased operating facilities coming into service, increases in rental rates due to market demand and inflationary pressures, and higher utility costs.", -0.3], ["We expect market factors may continue to increase rent and utility costs in 2024.", -0.2], ["Other expenses increased $176 million for the year, driven by goodwill impairment charges of $125 million in certain Supply Chain Solutions reporting units and a $111 million indefinite-lived trade name impairment charge in our truckload brokerage business.", -0.5], ["On an adjusted basis, other expenses decreased $25 million.", 0.1], ["Reductions in vehicle lease expense of $144 million due to volume declines.", 0.0], ["Gains on the sale of surplus real estate of $98 million.", -0.1], ["A reduction of $74 million in costs incurred under the transition service agreements with the acquirer of UPS Freight as we reach the termination of these agreements in the first half of 2024.", 0.2], ["Purchases of supplies for our Smart Package Smart Facility initiative, which increased costs $109 million.", -0.3], ["An increase of $85 million in commissions paid for certain online shipments.", -0.2], ["An increase of $78 million in hosted software application fees and other technology costs in support of ongoing investments in our digital transformation.", -0.1], ["Investment income and other decreased $2.2 billion.", -0.8], ["Remeasurements of our defined benefit plans resulted in a $359 million mark-to-market loss in 2023 compared to a $1.1 billion gain in 2022.", -0.9], ["Excluding the impact of these remeasurements, adjusted investment income and other decreased $798 million, driven by a reduction in other pension income.", -0.7], ["Expected returns on pension assets decreased, primarily due to a lower asset base resulting from negative returns in 2022, while pension interest cost increased as a result of higher discount rates and ongoing plan growth.", -0.6], ["Interest expense increased due to higher effective interest rates on floating rate debt.", -0.5], ["Net cash from operating activities decreased $3.9 billion in 2023, primarily due to the reduction in net income.", -0.8], ["A decrease in our hedge margin collateral position due to changes in the fair value of derivative contracts used in our foreign currency hedging program.", -0.6], ["A payment of $323 million in 2023 for employer payroll taxes that were deferred under the Coronavirus Aid, Recovery and Economic Security Act in 2020, compared to a payment of $234 million in 2022.", -0.4], ["A decrease in income taxes payable, primarily due to changes in our uncertain tax positions.", -0.5], ["We made discretionary contributions to our qualified U.S. pension plans of $1.2 billion in 2023 compared to $1.9 billion in 2022.", -0.3], ["Cash payments for income taxes were $2.0 and $2.6 billion for the years ended December 31, 2023 and 2022, respectively, with the decrease corresponding to the reduction in net income.", -0.7], ["Capital Expenditures as a % of revenue                                       5.7 %        4.8 %", 0.1], ["(1)  In addition to capital expenditures of $5.2 and $4.8 billion for the years ended December 31, 2023 and 2022, respectively, there were principal repayments of finance lease obligations of $126 and $149 million, respectively.", 0.0], ["enhancement of existing capacity and targeted growth.", 0.5], ["Total capital expenditures increased in 2023 compared to 2022 as a result of:", 0.2], ["Spending on buildings, facilities and plant equipment increased due to network enhancements, capacity expansion projects and facility maintenance.", 0.5], ["Vehicles expenditures increased, driven by the timing and availability of vehicle replacements and continuing investments in our network.", 0.5], ["Information technology expenditures increased as a result of continuing investments in our digital capabilities and network automation.", 0.5], ["Aircraft expenditures decreased as a result of lower payments on open aircraft orders and final delivery of aircraft.", -0.2], ["Proceeds from the disposal of businesses, property, plant and equipment were higher in 2023 relative to 2022, primarily due to the sale of surplus real estate during 2023.", 0.3], ["Net purchases of marketable securities increased in 2023 due to a shift to longer duration investments.", -0.1], ["Cash used in other investing activities decreased, primarily due to our 2022 investment of $252 million in the parent company of CommerceHub, Inc. and changes in other non-current investments.", 0.2], ["We repurchased 12.8 and 19.0 million shares of class B common stock for $2.3 and $3.5 billion under our stock repurchase program for the years ended December 31, 2023 and 2022, respectively.", -0.3], ["We do not anticipate repurchasing any shares in 2024.", -0.5], ["We paid quarterly cash dividends of $1.62 and $1.52 per share in 2023 and 2022, respectively.", 0.1], ["In the first quarter of 2024, we declared a quarterly cash dividend of $1.63 per share.", -0.1], ["Repayments of debt in 2023 included $23 million of debt assumed in the Bomi Group acquisition, scheduled principal payments on our finance lease obligations and reductions in our commercial paper balances.", -0.3], ["Cash outflows for this purpose were $402 and $516 million for the years ended December 31, 2023 and 2022, respectively.", -0.4], ["The decrease was due to changes in required repurchase amounts.", -0.5], ["We anticipate this balance will increase by approximately $61 million in 2024.", 0.2], ["Actual results could differ materially from our estimates, which would affect the related amounts reported in our consolidated financial statements.", -0.7], ["Except as disclosed in note 10 to the audited, consolidated financial statements, contingent losses that were probable and estimable were not material to our financial position or results of operations as of, or for the year ended, December 31, 2023.", 0.1], ["Changes in any of our assumptions could significantly impact the fair value of one or more of our reporting units.", -0.6], ["The projections that we use in our DCF model are updated annually, or more often if necessary, and will change over time based on the historical performance and changing business conditions for each of our reporting units.", 0.0], ["Changes to our selection of comparable companies or market multiples may result in changes to the estimates of fair value of our reporting units.", -0.2], ["In developing our valuation assumptions underlying the quantitative annual impairment testing, we determined that the cost of capital for our Roadie and Delivery Solutions reporting units had increased, driven by increases in the risk-free interest rate and volatility of the stock prices of market comparables.", -0.5], ["As a result, during the third quarter of 2023 we recorded and disclosed goodwill impairment charges of $56 million related to Roadie and $61 million related to Delivery Solutions.", -0.8], ["Our annual testing as of July 1 indicated that the fair value of the Coyote trade name was in excess of its carrying value, although the excess was less than 10 percent.", 0.1], ["Since the annual testing date, our truckload brokerage business continued to be negatively impacted by market conditions, which resulted in revenue declines.", -0.7], ["Based on the results of this testing, we concluded that the carrying value of the Coyote trade name exceeded its estimated fair value and recorded an impairment charge of $111 million.", -0.9], ["A decrease of 10 percent in forecasted cash flows, a decrease of 40 basis points in our selected royalty rate or an increase of 100 basis points in the cost of capital would each result in an incremental impairment charge of $10 million.", -0.6], ["If the cost of capital were increased by 100 basis points or our projected cash flows were reduced by 10 percent, it is reasonably possible that these reporting units would be impaired.", -0.7], ["In addition, a reduction in expected useful life, or a decision to sell or abandon an intangible asset before the end of its useful life, may increase amortization expense, which could have a material impact on our results of operations.", -0.6], ["All these factors can result in revisions to actuarial projections and produce a material difference between estimated and actual operating results.", -0.5], ["We believe our estimated reserves for such claims are adequate; however, actual experience in claims frequency and/or severity of claims could materially differ from our estimates and affect our results of operations.", -0.4], ["Our total reserves related to prior year claims increased by $39 million in 2023 and decreased by $5 million in 2022 as a result of", -0.2], ["A five percent deterioration or improvement in both the assumed claim severity and claim frequency rates used to estimate our self-insurance reserves would result in an increase or a decrease, respectively, of approximately $300 million in our reserves and expenses as of, and for the year ended, December 31, 2023.", 0.0], ["We recognize changes in the fair value of plan assets and net actuarial gains or losses in excess of a corridor (defined as 10% of the greater of the fair value of plan assets or the plans' projected benefit obligations) immediately within income upon remeasurement of a plan.", 0.0], ["The following sensitivity analysis shows the impact of a 25 basis point change in the assumed discount rate and return on assets for our pension and postretirement benefit plans, and the resulting increase (decrease) in our obligations and expense as of, and for the year ended, December 31, 2023 (in millions):", 0.0], ["(1) Amount calculated based on 25 basis point increase / decrease in the expected return on assets.", 0.0], ["(2) Amount calculated based on 25 basis point increase / decrease in the actual return on assets.", 0.0], ["A reduction in expected useful life, or a decision to sell or abandon a long-lived asset before the end of its useful life, may increase depreciation expense.", -0.5], ["We monitor our long-lived assets for indicators of impairment which may include, but are not limited to, a significant change in the extent to which an asset is utilized and operating or cash flow losses associated with the use of the asset.", -0.3], ["If circumstances are present that indicate the carrying value of our long-lived assets may not be recoverable, we perform impairment testing at the asset group level.", -0.4], ["Determining asset groups requires judgment and changes in the way asset groups are defined could have a material impact on the results of impairment testing.", -0.3], ["If the carrying amount of the asset group is determined not to be recoverable, a write-down to fair value is recorded.", -0.8], ["Adverse changes in volume could result in our current aircraft capacity exceeding projected demand, which may result in temporary idling of aircraft to better match capacity with demand.", -0.9], ["As a result of the reduction in volumes experienced during 2023, we temporarily idled nine aircraft for an average of approximately five months.", -0.7], ["Over a longer period, continued adverse changes in volume forecasts could lead to an excess of aircraft, resulting in an impairment charge or reduction in expected useful life that may result in increased depreciation expense.", -0.9], ["In 2022, we reduced the estimated residual value of our MD-11 aircraft and associated engines to zero based on updated operational plans for these aircraft and our expectations for their eventual disposal.", -0.8], ["In connection with this change in estimate, in 2022 we recorded a one-time depreciation charge to adjust the residual value of our fully-depreciated MD-11 aircraft.", -0.8], ["Changes in the fixed income, foreign currency exchange and commodity markets will impact our estimates of fair value in the future, potentially affecting our results of", -0.6], ["Significant changes in these estimates may result in an increase or decrease to our tax expense in a subsequent period.", -0.7], ["If recovery is not likely, we increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable.", -0.8], ["However, should there be a change in our ability to recover our deferred tax assets, our tax provision would increase in the period in which we determined that the recovery was not likely.", -0.7], ["In 2023, we recognized a net tax benefit of $102 million following resolution of certain global tax audits.", -0.1], ["Because of this, our operating results may be affected should the market price of fuel suddenly change by a significant amount or change by amounts that do not result in an adjustment in our fuel surcharges, which can significantly affect our results either positively or negatively in the short-term.", -0.5], ["These instruments subject us to risk resulting from changes in short-term interest rates.", -0.6], ["We are also subject to interest rate risk with respect to our defined benefit pension and postretirement medical benefit plan obligations, as changes in interest rates will effectively increase or decrease the obligations associated with these plans.", -0.7], ["This will result in changes to the amount of pension and postretirement benefit expense recognized in future periods and may also result in us being required to make contributions to the plans.", -0.4], ["We adjust the fixed and floating interest rate mix of our interest-rate-sensitive assets and liabilities in response to changes in market conditions.", 0.2], ["Additionally, changes in the fair value of foreign currency derivatives and commodity derivatives are offset by changes in the cash flows of the underlying hedged foreign currency and commodity transactions.", 0.1], ["(1) The potential change in fair value from a hypothetical 10% weakening of the U.S. Dollar against foreign currency exchange rates across all maturities.", -0.3], ["(2) The potential change in annual interest expense resulting from a hypothetical 100 basis point increase in short-term interest rates, applied to our variable rate debt.", -0.4], ["(3) The potential change in interest income resulting from a hypothetical 100 basis point increase in short-term interest rates, applied to our variable rate investment holdings.", -0.2], ["In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.", 0.8], ["Change in unrealized gain (loss) on marketable securities, net of tax", -0.2], ["Change in unrealized gain (loss) on cash flow hedges, net of tax", -0.2], ["Change in unrecognized pension and postretirement benefit costs, net of tax", -0.2], ["Proceeds from disposal of businesses, property, plant and equipment", 0.5], ["Net Increase (Decrease) In Cash, Cash Equivalents and Restricted Cash", 0.1], ["Other expenses decreased by $381, $356 and $301 million for 2023, 2022 and 2021, respectively.", 0.3], ["Repairs and maintenance increased by $363, $369 and $326 million for 2023, 2022 and 2021, respectively.", -0.3], ["$37 million of restricted cash related to certain tax and regulatory matters and acquisitions.", 0.0], ["Unrealized gains and losses on trading securities are reported as Investment income and other on the statements of consolidated income.", 0.1], ["Unrealized gains and losses on available-for-sale securities are reported within other comprehensive income, a separate component of shareowners’ equity.", -0.1], ["The cost of securities sold is based on the specific identification method; realized gains and losses resulting from such sales are included in Investment income and other.", 0.1], ["Impairment of available-for-sale securities results in a charge to income when a market decline below cost is other-than-temporary, which includes consideration of whether we have both the intent and ability to hold such securities for the time necessary to recover the cost basis.", -0.5], ["If a decline in fair value is determined to be the result of a credit loss, then the decrease is recognized in income through an allowance for credit losses.", -0.7], ["We record the investment at cost and subsequently increase or decrease the carrying amount of the investment by our proportionate share of the net earnings or losses and other comprehensive income of the investee.", 0.2], ["Gains and losses from equity method investments are reported in Investment income and other on the statements of consolidated income.", 0.1], ["Capitalized interest was $118 and $60 million for the years ended December 31, 2023 and 2022, respectively.", 0.3], ["If the carrying amount of the asset is determined not to be recoverable, a write-down to fair value is recorded.", -0.6], ["Rather, changes to payments due to a change in an index or rate are recognized in our statements of consolidated income in the period of the change.", 0.0], ["Costs of purchased businesses in excess of net identifiable assets acquired (goodwill) and indefinite-lived intangible assets are tested for impairment at least annually, unless changes in circumstances indicate an impairment may have occurred between annual tests.", -0.4], ["If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, we record the excess amount as goodwill impairment, not to exceed the total amount of goodwill allocated to the reporting unit.", -0.5], ["If the carrying value of the indefinite-lived asset exceeds its estimated fair value, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds its fair value.", -0.5], ["Finite-lived intangible assets are assessed for impairment as part of asset groups whenever events or changes in circumstances indicate that their carrying value may not be recoverable.", -0.3], ["We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell and recognize any loss in the period in which the held for sale criteria are met.", -0.4], ["As of December 31, 2023 and 2022, suppliers sold $504 and $806 million, respectively, of our outstanding payment obligations to participating institutions.", 0.2], ["We paid $151 million to transfer a portfolio of claims for which we carried reserves", 0.1], ["of $153 million, recognizing a pre-tax gain of $2 million that was recorded in Other expenses in the statement of consolidated income for the year ended December 31, 2023.", 0.3], ["We paid $341 million to transfer a portfolio of claims for which we carried reserves of $332 million, recognizing a pre-tax loss of $9 million that was recorded in Other expenses in the statement of consolidated income for the year ended December 31, 2022.", -0.2], ["Such a change in recognition or measurement could result in the recognition of a tax benefit or an additional charge to the tax provision.", -0.1], ["Pre-tax foreign currency transaction gains (losses) from remeasurement, net of hedging, included in Investment income and other were $(53), $72 and $(36) million in 2023, 2022 and 2021, respectively.", 0.0]], "zbh22_sentences.json": [["As of February 7, 2023, 208,980,256 shares of the registrant’s $.01 par value common stock were outstanding.", -0.1], ["These risks, uncertainties and changes in circumstances include, but are not limited to: the effects of business disruptions such as the COVID-19 pandemic, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; our ability to attract, retain and develop the highly skilled employees, senior management, independent agents and distributors we need to support our business; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management’s attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; supply and prices of raw materials and products; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration (“FDA”) and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the outcome of government investigations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels and otherwise; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including those expected to occur as a result of the “base erosion and profit shifting” project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. (“ZimVie”) spinoff", -0.9], ["statements.", 0.0], ["Readers of this report are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.", -0.7], ["The transaction was intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders.", 0.8], ["Consignment sales represented approximately 85 percent of our net sales in 2022.", 0.2], ["We allocate resources to achieve our operating profit goals through three regional operating segments.", 0.5], ["Most notably, in 2021 the Chinese government began to implement a nationwide volume-based procurement (“VBP”) process across certain of our product categories that negatively affected our net sales due to distributor inventory reductions, ongoing pricing negotiations with distributor partners, revaluation of channel inventory and volume reductions as patients deferred procedures until after VBP pricing became effective in 2022.", -0.6], ["Our business is seasonal in nature to some extent, as many of our products are used in elective procedures, which typically decline during the summer months and can increase at the end of the year once annual deductibles have been met on health insurance plans.", 0.1], ["The rapid commercialization of innovative new materials, biologics products, implant and instrument designs and surgical techniques remains one of our core strategies and continues to be an important driver of sales growth.", 0.7], ["FDA review may involve substantial delays that adversely affect the marketing and sale of our products.", -0.8], ["Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.", -0.9], ["Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, fines, imprisonment and exclusion from participation in certain government healthcare programs.", -0.9], ["Failure to comply with any such data protection laws and regulations could result in government enforcement actions (which could include civil and/or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.", -0.8], ["Risk Factors – If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -0.8], ["In most of our manufacturing network, we have improved our manufacturing processes to harmonize and optimize our quality systems and to protect our profitability and offset the impact of inflationary costs.", 0.5], ["•        Ensure the company’s return is equivalent to the value we provide our customers and patients", 0.7], ["•        Invest $1 million and provide executive sponsorship to support ongoing programs and elevate the impact of our employee resource groups;", 0.8], ["•        Commit at least $5 million over five years through the Zimmer Biomet Foundation to non-profit organizations dedicated to combating racism and supporting diversity, equality and justice.", 0.8], ["In 2022, our Total Recordable Incident Rate was 0.29 and our Lost Time Incident Rate was 0.11.", 0.6], ["Matters determined to present potential material impacts to our financial results, operations, and/or reputation are required to be immediately reported to the Audit Committee, as appropriate, in accordance with our escalation framework.", -0.2], ["However, as of December 31, 2022, we had not yet detected any material information security breaches.", 0.1], ["Risk Factors - We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from data breaches, our business could be adversely affected.", -0.8], ["Business and economic conditions, including disruptions related to the COVID-19 pandemic, have adversely impacted, and may, either alone or in combination with other risks, in the future adversely impact, our business, results of operations and financial condition, the nature and extent of which are uncertain and unpredictable.", -0.9], ["Our operations expose us to risks from business interruptions that may arise from a variety of sources, including public health crises and outbreaks of diseases, such as the COVID-19 pandemic and its variants, supply chain", -0.7], ["disruptions, trade and tariff disputes and global conflicts, that can, singly or in combination with other factors, adversely affect our business and financial results.", -0.8], ["We experienced a sustained decline in elective surgical procedures globally due to the COVID-19 pandemic and its associated effects, including deferrals of elective surgical procedures and staffing shortages at hospitals.", -0.9], ["Surgical volumes generally recovered over the course of 2022, but may return to lower levels due to future COVID-19 variants and resurgences.", -0.5], ["We expect several of these factors to continue, and there can be no assurance that we will successfully manage these risks without adverse impacts to our business or financial results.", -0.6], ["The occurrence of any one or more risks described in these Risk Factors or otherwise may have unpredictable effects on other risks, our business, operations or financial results which may be comparable to, or more adverse than, those we experienced in connection with the COVID-19 pandemic.", -0.8], ["Our restructuring programs may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our restructuring initiatives.", -0.8], ["In December 2019, our Board of Directors approved, and we initiated, a global restructuring program (the “2019 Restructuring Plan”) with an objective of reducing costs to allow us to further invest in higher priority growth opportunities, which is ongoing.", 0.2], ["In December 2021, our management also initiated a global restructuring program (the “2021 Restructuring Plan”) to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", 0.2], ["Restructuring initiatives involve complex plans and actions that may include, or result in, workforce reductions, global plant closures and/or consolidations, product portfolio rationalizations and asset impairments.", -0.6], ["Additionally, as a result of restructuring initiatives, we may experience a loss of continuity, loss of accumulated knowledge and/or inefficiencies during transitional periods.", -0.7], ["Restructuring initiatives present significant risks that may impair our ability to achieve anticipated operating enhancements and/or cost reductions, or otherwise harm our business, including higher than anticipated costs in implementing our restructuring programs, as well as management distraction.", -0.9], ["If we fail to achieve some or all of the expected benefits of restructuring, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.", -1.0], ["We may not be able to effectively integrate acquired businesses into our operations or achieve expected cost savings or profitability from our acquisitions.", -0.9], ["•           unforeseen difficulties in integrating personnel and sales forces, operations, manufacturing, logistics, research and development, information technology, compliance, vendor management, communications, purchasing, accounting, marketing, administration and other systems and processes;", -0.8], ["•           inability to generate sufficient revenue or realize sufficient cost savings to offset acquisition or investment costs.", -0.9], ["As a result, if we fail to evaluate and execute acquisitions properly, we might not achieve the anticipated benefits of such acquisitions, and we may incur costs in excess of what we anticipate.", -0.8], ["Interruption of manufacturing operations could adversely affect our business, financial condition and results of operations.", -0.9], ["absences, trade impediments or other factors could adversely affect the ability to manufacture our products.", -0.7], ["In the event of an interruption in manufacturing, we may be unable to move quickly to alternate means of producing affected products or to meet customer demand.", -0.8], ["We have experienced such interruptions due to the COVID-19 pandemic, and we may experience such interruptions in the future due to the pandemic or otherwise.", -0.7], ["In the event of a significant interruption, for example, as a result of a failure to follow regulatory protocols and procedures, we may experience lengthy delays in resuming production of affected products due primarily to the need for regulatory approvals.", -0.8], ["The global supply chain has been and continues to be negatively impacted by COVID-19 and a variety of other macro factors which has, in part, resulted in challenges to meet end market demand in some instances.", -0.9], ["We expect similar challenges in 2023.", -0.6], ["As a result, we may experience loss of market share, which we may be unable to recapture, and harm to our reputation, which could adversely affect our business, financial condition and results of operations.", -0.8], ["Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by third-party suppliers could adversely affect our business, financial condition and results of operations.", -0.9], ["A reduction or interruption in the supply of materials or components used in manufacturing our products, such as due to one or more suppliers experiencing reductions in operations and/or worker absences due to a pandemic or otherwise; an inability to timely develop and validate alternative sources if required; or a significant increase in the price of such materials or components could adversely affect our business, financial condition and results of operations.", -0.9], ["To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, or reductions in operations and/or worker absences due to the COVID-19 pandemic or otherwise, we may be unable to transition to other contract sterilizers, sterilizer locations or sterilization methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.", -0.9], ["This rule could adversely affect the sourcing, availability and pricing of materials used in the manufacture of our products, which could adversely affect our manufacturing operations and our profitability.", -0.8], ["In addition, we are incurring additional costs to comply with this rule, including costs related to determining the source of any relevant minerals, metals and other materials used in our products.", -0.7], ["If we fail to maintain or protect our information systems and data integrity effectively, we could:", -0.8], ["•           lose existing customers, vendors and business partners;", -0.8], ["•           have problems in determining product cost estimates and establishing appropriate pricing;", -0.8], ["•           suffer outages or disruptions in our operations or supply chain;", -0.8], ["•           have difficulty preventing, detecting, and controlling fraud;", -0.8], ["•           be subject to issues with product functionality that may result in a loss of data, risk to patient safety, field actions and/or product recalls;", -0.8], ["•           incur expenses or lose revenues as a result of a data privacy breach; or", -0.8], ["Any significant breakdown, intrusion, breach, interruption, corruption or destruction of these systems could have a material adverse effect on our business and reputation and could materially adversely affect our results of operations and financial condition.", -1.0], ["Any of these factors, alone or in combination, could cause us to have difficulty maintaining or increasing sales of our products.", -0.9], ["If we fail to retain the employees, independent agents and distributors upon whom we rely heavily to market our products, customers may not buy our products and our revenue and profitability may decline.", -0.9], ["A loss of a significant number of our agents could have a material adverse effect on our business and results of operations.", -0.9], ["If we do not introduce new products in a timely manner, our products may become obsolete over time, customers may not buy our products and our revenue and profitability may decline.", -0.9], ["Demand for our products may change, in certain cases, in ways we may not anticipate because of evolving customer needs, changing demographics, slowing industry growth rates, declines in the musculoskeletal implant market, the introduction of new products and technologies and evolving surgical philosophies and industry standards.", -0.8], ["If that happens, our revenue and operating results would suffer.", -0.9], ["In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce revenue in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.", -0.9], ["If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed.", -0.9], ["we are subject to cost containment measures in the United States and other countries, resulting in pricing pressures, which could have a material adverse effect on our business, results of operations, and cash flows.", -0.9], ["If third-party payors deny or decline reimbursement, reduce reimbursement levels or change reimbursement models for our products, demand for our products may decline, or we may experience increased pressure to reduce the prices of our products, which could have a material adverse effect on our sales and results of operations.", -0.9], ["If we are not one of the providers selected by a group purchasing organization, affiliated hospitals and other members may be less likely to purchase our products, and, if the group purchasing organization has negotiated a strict compliance contract for another manufacturer’s products, we may be precluded from making sales to members of the group purchasing organization for the duration of the contractual arrangement.", -0.8], ["Our failure to respond to the cost-containment efforts of group purchasing organizations may cause us to lose market share to our competitors and could have a material adverse effect on our sales and results of operations.", -0.8], ["Initiatives to limit the growth of general healthcare expenses and hospital costs are ongoing in the markets in which we do business, and we have experienced downward pressure on product pricing and other effects of healthcare reform in our international markets.", -0.7], ["For example, China has implemented a volume-based procurement (“VBP”) process designed to reduce medical spending, which has in the past resulted in, and could in the future result in, reduced margins on covered devices and products, required renegotiation of distributor arrangements, and incurrence of inventory-related charges.", -0.7], ["In cases where our product is not selected in VBP, sales of that product are substantially impacted.", -0.8], ["If key participants in government healthcare systems reduce the reimbursement levels for our products, including through political changes or transitions, our business, financial condition, results of operations and cash flows may be adversely affected.", -0.9], ["We incurred substantial additional indebtedness in connection with previous mergers and acquisitions and may not be able to meet all of our debt obligations, and interest rate risk could adversely affect our indebtedness.", -0.9], ["As a result of the increase in our debt, demands on our cash resources have increased.", -0.8], ["•           require us to dedicate a large portion of our cash flow from operations to the servicing and repayment of our debt, thereby reducing funds available for working capital, capital expenditures, research and development expenditures and other general corporate requirements;", -1.0], ["•           limit our ability to obtain additional financing to fund future working capital, capital expenditures, research and development expenditures and other general corporate requirements;", -1.0], ["•           adversely affect our credit rating, with the result that the cost of servicing our indebtedness might increase and our ability to obtain surety bonds could be impaired;", -1.0], ["•           adversely affect the market price of our common stock; and", -1.0], ["Any increase in interest rates applicable to our debt obligations would increase our cost of borrowing and could adversely affect our financial position, results of operations or cash flows.", -1.0], ["The results of an audit or litigation could have a material effect on our financial statements in the period or periods for which that determination is made.", -1.0], ["Proposed changes in tax laws in countries in which we do business, if enacted, could lead to changes in tax laws that could negatively impact our effective tax rate.", -1.0], ["Changes in the tax laws and regulations of the jurisdictions where we do business, including an increase in tax rates or an adverse change in the treatment of an item of income or expense, could result in a material increase in our tax expense and/or tax payments, could increase tax uncertainty and could have a material adverse impact on our business, financial condition or results of operations.", -1.0], ["For example, changes in the tax laws of foreign jurisdictions are expected to occur as a result of pillar two of the base erosion and profit shifting plan (“Pillar Two”) undertaken by the Organisation for Economic Co-operation and Development, which would require profits earned in jurisdictions in which we operate to be subject to a minimum 15 percent income tax rate.", -0.5], ["The spinoff of ZimVie Inc. and the divestiture of our retained interest in ZimVie Inc. could result in substantial tax liability.", -1.0], ["If the spinoff, or the subsequent divestiture of our retained interest in ZimVie, does not qualify for tax-free treatment for U.S. federal income tax purposes, the resulting tax liability to us, to our stockholders and to ZimVie stockholders could be substantial.", -0.9], ["If our independent agents and distributors are characterized as employees, we would be subject to additional tax and other liabilities.", -0.8], ["Changes in classification from independent contractor to employee can result in a change to various requirements associated with the payment of wages, tax withholding, and the provision of unemployment, health, and other traditional employer-employee related benefits.", -0.7], ["As a result, any determination that our independent agents and distributors are our employees could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["Future material impairments in the carrying value of our intangible assets, including goodwill, would negatively affect our operating results.", -0.8], ["As discussed further in Note 11 to our consolidated financial statements, in the fourth quarter of 2022, we recorded goodwill impairment charges of $289.8 million as a result of, among other factors, changes in foreign currency exchange rates in our European-based currencies, inflation and a higher interest rate environment; in the first quarter of 2020, we recorded goodwill impairment charges of $470.0 million as a result of the adverse impacts from the COVID-19 pandemic and a change in our reportable segments; and in the second quarter of 2022 and 2021, we recorded $3.0 million and $16.3 million, respectively, of in-process research and development (“IPR&D”) intangible asset impairments on certain IPR&D projects.", -0.9], ["If the operating performance at one or more of our reporting units falls significantly below current levels, including if elective surgical procedures return to lower levels due to a resurgence of the COVID-19 pandemic or otherwise, if competing or alternative technologies emerge, if market conditions or future cash flow estimates for one or more of our businesses decline, or as a result of restructuring initiatives pursuant to which we reorganize our reporting units, we could be required to record additional impairment charges.", -0.8], ["Any write-off of a material portion of our goodwill or unamortized intangible assets would negatively affect our results of operations.", -0.8], ["We conduct a significant amount of our sales activity outside of the U.S., which subjects us to additional business risks and may cause our profitability to decline due to increased costs.", -0.7], ["•           the effects of inflation, including the effects of different rates of inflation in different countries, on our costs and the costs of our products;", -0.6], ["•           trade protection measures, import or export requirements, new or increased tariffs, trade embargoes and sanctions and other trade barriers, which may prevent us from shipping products to or receiving products from a particular market, restrict our access to certain sources of raw materials and other inputs, increase our operating costs and disrupt our ability to collect payment for our products and services in particular markets;", -0.9], ["•           potentially negative consequences from changes in tax laws; and", -0.8], ["Violations of foreign laws or regulations could result in fines, criminal sanctions against us, our officers or our employees, prohibitions on the conduct of our business and damage to our reputation.", -0.9], ["Wars and other conflicts may increase certain of these risks and may adversely affect our business and financial performance, including by limiting our ability to operate in, or export from, certain markets.", -0.9], ["Losing access to such markets or exports may have a material adverse effect on our business in the affected market and may limit our ability to operate some of our businesses globally.", -0.8], ["We anticipate that the effects of emerging, expanding and new conflicts, such as a possible expansion of the Russian-Ukrainian conflict or a conflict involving China and Taiwan, would not be limited to the specific markets involved.", -0.7], ["Sanctions, and other civil, political and economic effects of such conflicts may have adverse impacts globally, including supply chain continuity disruption; inflationary pressures and increased costs of raw materials and inputs; manufacturing or shipping delays; increased shipping costs; inability to ship products to or from certain countries potentially resulting in an inability to sell certain products globally; and increased disruptions and delays on our ability to collect payment for our products and services in particular markets.", -0.9], ["While Russia and Ukraine do not constitute material portions of our business, a significant escalation or expansion of economic disruption or of the conflict’s current scope, or the emergence of new conflicts involving other countries, could adversely affect our results of operations.", -0.8], ["We are subject to risks arising from currency exchange rate fluctuations, which can increase our costs, cause our profitability to decline and expose us to counterparty risks.", -0.8], ["Significant increases in the value of the U.S. Dollar relative to the Euro, the Japanese Yen, the Swiss Franc or other currencies could have a material adverse effect on our results of operations.", -0.8], ["Although we address currency risk management through regular operating and financing activities, and, on a limited basis, through the use of derivative financial instruments, those actions may not prove to be fully effective or may create additional financial obligations for us.", -0.5], ["Further, if the counterparties to the derivative financial instrument transactions fail to honor their obligations due to financial distress or otherwise, we would be exposed to potential losses or the inability to recover anticipated gains from those transactions.", -0.7], ["We are subject to costly and complex laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, postmarket surveillance, manufacturing, labeling and marketing of our products, noncompliance with which could adversely affect our business, financial condition and results of operations.", -0.8], ["Delays in receipt of, or failure to obtain, approvals for future products, or loss of approval for current products, could result in delayed realization of product revenues or in substantial additional costs.", -0.6], ["Complying with the requirements of this regulation requires us to incur significant expense.", -0.4], ["If a regulator were to conclude that we are not in compliance with applicable laws or regulations, that any of our products are ineffective or pose an unreasonable health risk, or that we have marketed or promoted a product for use other than as indicated in labelling approved by the regulator, the regulator could ban such products; detain or seize adulterated or misbranded products; order a recall, repair, replacement, or refund of payment of such products; refuse to grant pending premarket approval applications; refuse to provide certificates for exports; require us to notify healthcare professionals and others that the products present unreasonable risks of substantial harm to the public health; and subject us to fines, injunctions or other penalties.", -0.9], ["Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.", -0.8], ["In August 2018, we received a warning letter from the FDA related to observed non-conformities with current good manufacturing practice requirements of the QSR at our Warsaw North Campus manufacturing facility.", -0.7], ["Until the violations are corrected, we may become subject to additional regulatory action by the FDA as described above, the FDA may refuse to grant premarket approval applications and/or the FDA may refuse to grant export certificates, any of which could have a material adverse effect on our business, financial condition and results of operations.", -0.8], ["If we fail to adequately address any of these regulations, our business could be harmed.", -0.7], ["If we fail to comply with healthcare fraud and abuse laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -1], ["If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -1], ["Failure to comply with U.S. and international data protection laws and regulations, and the disclosure of any data or related breach, could result in government enforcement actions (which could include substantial civil and/or criminal penalties and injunctive relief), private litigation and/or adverse publicity and could have a material adverse impact on our business, financial condition or results of operations.", -1], ["Pending and future product liability claims and litigation could adversely impact our financial condition and results of operations and impair our reputation.", -1], ["Product liability lawsuits and claims, safety alerts or product recalls, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation and on our ability to attract and retain customers.", -1], ["We are substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and other proprietary rights against others.", -1], ["While it is not possible to predict the outcome of patent and other intellectual property litigation, such litigation has in the past resulted in, and could in the future result in, our payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and proprietary rights against others, which could have a material adverse effect on our business and results of operations.", -1], ["To prevent or respond to unauthorized uses of our intellectual property, we might be required to engage in costly and time-consuming litigation or other proceedings and we may not ultimately prevail.", -1], ["Any failure to establish, maintain or protect our intellectual property or proprietary rights could have a material adverse effect on our business, financial condition, or results of operations.", -1], ["We are involved in legal proceedings that may result in adverse outcomes.", -1], ["We could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.", -0.8], ["As a result, our stockholders may be limited in their ability to obtain a premium for their shares.", -0.7], ["Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.", -0.9], ["We expect to continue paying cash dividends on a quarterly basis; however, future dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.", 0.2], ["On March 1, 2022, we completed the spinoff of our spine and dental businesses into ZimVie.", 0.5], ["Our results continue to be impacted by the COVID-19 global pandemic.", -0.6], ["The vast majority of our net sales are derived from products used in elective surgical procedures that have typically declined during surges of the virus as governments and healthcare systems take actions in an effort to prevent the spread and provide sufficient hospital beds and other resources for COVID-19 patients.", -0.7], ["Additionally, we believe that staffing shortages at hospitals have contributed to the deferral of elective surgical procedures.", -0.6], ["In the year ended December 31, 2022, the Omicron variant resulted in fewer elective surgical procedures earlier in the year with recovery in procedures as the surge began to subside later in the first quarter and through the second quarter.", -0.4], ["In the second half of 2022, procedural volumes continued to improve across most markets relative to the first half of the year.", 0.3], ["In 2022, our net sales increased by 1.6 percent compared to 2021.", -0.1], ["Our net sales in 2022 were tempered by a negative 5.0 percent effect from changes in foreign currency exchange rates.", -0.5], ["Our net earnings, including discontinued operations, were $231.4 million in 2022 compared to $401.6 million in 2021.", -0.7], ["In 2022, we recognized a goodwill impairment charge of $289.8 million, which was the primary driver for lower net earnings in 2022 when compared to 2021.", -0.8], ["Other significant unfavorable items in 2022 when compared to 2021 include an unrealized investment loss of $116.6 million due to a decline in the value of our investment in ZimVie, higher restructuring-related costs as we continued to execute on our 2019 and 2021 Restructuring Plans, and higher spending on travel and other activities which started to return to pre-pandemic levels.", -0.9], ["These unfavorable factors to net earnings were partially offset by higher net sales, hedge gains recognized from our hedging program, the favorable effects of our restructuring programs, lower litigation-related expenses, and the fact the 2021 period included a $165.1 million charge for the early extinguishment of debt and $65.0 million of charges related to certain agreements we entered into to gain access to or acquire third-party in-process research and development (“IPR&D”) projects.", 0.2], ["We expect revenue growth in 2023 to be driven by a combination of market growth, procedure volume recovery from COVID-19 and new product introductions.", 0.7], ["In addition, based on foreign currency exchange rates at the end of 2022 we expect foreign currency to negatively affect net sales growth in 2023, but at a lower level than experienced in 2022.", -0.2], ["We expect that supply chain and inflation pressures will continue into 2023, but with supply chain pressure easing in the second half of the year and with inflation stable to the level experienced at the end of 2022.", -0.1], ["We estimate our operating expenses in 2023 will be impacted by the expected non-reoccurrence of goodwill impairment charges, lower quality remediation expenses due to the completion of our remediation milestones, and lower restructuring-related expenses related to our 2019 and 2021 Restructuring Plans.", 0.3], ["We expect our interest expense, net, will increase primarily due to higher interest rates.", -0.5], ["We also expect our non-operating other (expense) income, net, will decline in 2023 since the 2022 expense was primarily driven by an investment loss in the shares of ZimVie that we held following the spinoff, which shares we disposed of in February 2023.", -0.2], ["Changes in volume and mix of product sales had a positive effect of 7.6 percent and 12.3 percent on year-over-year sales during the years ended December 31, 2022 and 2021, respectively.", 0.8], ["Volume trends were positive in 2022 as we saw recovery of elective surgical procedures, most notably in international markets, driving volume growth in tandem with new product introductions.", 0.9], ["In 2022, sales were negatively impacted by limitations due to global supply chain challenges.", -0.7], ["The volume increases in 2022 were largely a product of how much the COVID-19 pandemic negatively affected the various regions in 2021.", -0.4], ["Additionally, in Asia Pacific in 2021, China sales were negatively impacted from a combination of variables related to the implementation of a nationwide volume-based procurement (“VBP”) process.", -0.6], ["The China VBP had a negative effect on volume due to inventory reductions by distributors and short-term deferral of procedures as patients waited to have a surgical procedure performed until after VBP pricing was effective in 2022.", -0.6], ["Global selling prices had negative effects of 1.0 percent and 2.1 percent on year-over-year sales during 2022 and 2021, respectively.", -0.5], ["However, we have had some success in reducing the negative effects of pricing in 2022 due to internal initiatives and being able to pass some inflationary impacts on to customers.", 0.2], ["In 2022 and 2021, changes in foreign currency exchange rates had a negative effect of 5.0 percent and a positive effect of 1.2 percent, respectively, on year-over-year sales.", -0.1], ["The 4.1 percent and 9.9 percent net sales growth in the U.S. in 2022 and 2021, respectively, when compared to the prior year in each case was primarily driven by recovery in surgical procedures as COVID-19 cases subsided, especially in the Knees and Hips categories.", 0.7], ["Internationally, net sales declined by 1.5 percent in 2022 when compared to 2021 and increased 13.5 percent in 2021 when compared to 2020.", -0.2], ["The decline in 2022 was driven by the negative impacts on International sales of 11.2 percent due to changes in foreign currency exchange rates.", -0.5], ["In 2021, our International markets experienced net sales growth from recovery in elective surgical procedures.", 0.6], ["In 2022, our Knees and Hips net sales increased by 4.9 percent and 2.1 percent, respectively, when compared to 2021 due to the recovery in elective surgical procedures and new product introductions.", 0.5], ["The increase was despite the impact of changes in foreign currency exchange rates having a negative effect of 5.0 percent and 5.9 percent on", -0.3], ["net sales decreased by 1.8 percent in 2022 when compared to 2021 due to the negative effects of changes in foreign currency exchange rates, lower trauma product net sales partially due to VBP implementation and unfavorable changes in reimbursement for certain restorative therapy products.", -0.6], ["Other product category net sales decreased by 4.3 percent in 2022 when compared to 2021 due to the negative effects of changes in foreign currency exchange rates and lower unit sales of our ROSA robots as some customers shifted to operating lease arrangements for our robots instead of purchasing them.", -0.7], ["In 2021, all our product categories experienced net sales growth when compared to 2020 due to the recovery of elective surgical procedures.", 0.6], ["The decline in gross margin percentage in 2022 compared to 2021 was primarily due to inflationary cost pressures, lower average selling prices and inventory charges related to products we plan to discontinue.", -0.8], ["These unfavorable items were partially offset by hedge gains recognized in 2022 as part of our hedging program compared to hedge losses in 2021, operating leverage from volume increases, a mix shift to higher margin product sales, as well as the fact that the 2021 period experienced lower than normal production at certain facilities which resulted in fixed overhead costs being expensed immediately.", 0.2], ["Research & development (“R&D”) expenses decreased in both amount and as a percentage of net sales in 2022 compared to 2021, primarily due to the fact that in 2021 we entered into certain agreements to gain access to or acquire third-party IPR&D projects that resulted in charges of $65.0 million.", 0.1], ["That favorability was partially offset by higher personnel-related costs and higher spending on our initial compliance with the EU MDR in 2022.", -0.1], ["Selling, general & administrative (“SG&A”) expenses decreased in both amount and as a percentage of net sales in 2022 compared to 2021 primarily due to litigation-related expenses declining by $135.1 million and savings from our restructuring plans.", 0.5], ["These favorable items were partially offset by higher bad debt charges partially related to the Russia/Ukraine conflict and higher expenses for travel and other activities as we started to return to pre-pandemic levels in 2022.", -0.3], ["The bad debt charges for expected credit losses in Russia resulted in a significant portion of our accounts receivable from customers in this country being impaired.", -0.7], ["In addition to accounts receivable, we also have inventory and instruments that could require impairment if our business in Russia deteriorates more than our current expectations; however, any such amounts are not expected to be material.", -0.4], ["In 2022, we recognized a goodwill impairment charge of $289.8 million related to our EMEA reporting unit.", -0.9], ["In 2022 and 2021, we recognized intangible asset impairment charges of $3.0 million and $16.3 million, respectively, related to IPR&D projects that we discontinued.", -0.6], ["The 2021 Restructuring Plan is intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", -0.1], ["The 2019 Restructuring Plan has an objective of reducing costs to allow us to invest in higher priority growth opportunities.", 0.2], ["We also have other cost reduction and optimization initiatives that have the goal of reducing costs across the organization.", 0.1], ["We recognized expenses of $191.6 million and $125.7 million in 2022 and 2021, respectively, primarily related to employee termination benefits, sales agent contract terminations, and consulting and project management expenses associated with these programs.", -0.3], ["The expenses were higher in 2022 primarily due to additional expenses related to the 2021 Restructuring Plan that had just been initiated at the end of 2021.", -0.4], ["We incurred quality remediation expenses of $33.8 million and $52.8 million in 2022 and 2021, respectively.", -0.5], ["The decline in expenses in 2022 when compared to 2021 was due to the natural regression as various remediation milestones were completed.", 0.1], ["We do not expect to incur any significant quality remediation expenses related to these inspectional observations in 2023.", 0.3], ["In 2022, we incurred a loss of $128.0 million in our other (expense) income, net compared to a gain of $12.2 million in 2021.", -0.8], ["The expense in 2022 was primarily due to a $116.6 million loss on our investment in ZimVie.", -0.7], ["Interest expense, net, decreased in 2022 when compared to 2021 primarily from using debt that we issued in the fourth quarter of 2021, along with cash on hand, to repurchase portions of outstanding notes with higher interest rates.", -0.1], ["Additionally, interest expense, net was lower due to additional debt paydown.", 0.2], ["In 2021, we recognized a $165.1 million loss on the early extinguishment of debt.", -0.8], ["In 2022, the ETR was primarily driven by the $289.8 million goodwill impairment charge and the $116.6 million loss on our investment in ZimVie, which have no corresponding tax benefits, partially offset by favorable tax audit settlements and finalization of Switzerland's Federal Act on Tax Reform and AHV Financing (“TRAF”) step-up.", -0.7], ["In the Americas, operating profit and operating profit as a percentage of net sales increased in 2022 when compared to 2021 due to higher net sales driven by continued recovery of elective surgical procedures, lower excess and obsolete inventory charges and savings from our restructuring programs.", 0.7], ["In EMEA, operating profit and operating profit as a percentage of net sales increased in 2022 when compared to 2021.", 0.5], ["Our net sales declined in EMEA due to the negative effects of changes in foreign currency exchange rates.", -0.5], ["However, our operating profit increased slightly due to our hedging program as we recognized hedge gains, which minimized the negative effects from net sales, and we realized savings from our restructuring programs.", 0.1], ["In Asia Pacific, operating profit and operating profit as a percentage of net sales increased in 2022 when compared to 2021.", 0.5], ["Our net sales declined in Asia Pacific due to the negative effects of changes in foreign currency exchange rates and by the China government implementing a nationwide volume-based procurement process that became effective in 2022.", -0.6], ["However, our operating profit increased slightly due to our hedging program as we recognized hedge gains, which minimized these negative effects from net sales, and we realized savings from our restructuring programs.", -0.1], ["Cash flows provided by operating activities from continuing operations were $1,356.2 million in 2022 compared to $1,404.3 million in 2021.", -0.1], ["The decrease in cash flows from operating activities in 2022 when compared to 2021 was primarily the result of higher tax payments and increased payments under our restructuring programs.", -0.5], ["These unfavorable items were partially offset by lower interest payments and lower investments in inventory, as well as the fact that the 2021 period included payments related to certain IPR&D agreements.", -0.2], ["Cash flows used in investing activities from continuing operations were $522.0 million in 2022 compared to $443.3 million in 2021.", -0.3], ["These cash outflows were partially offset by favorable settlements of our net investment hedges as they matured.", 0.1], ["Cash flows used in financing activities from continuing operations were $775.7 million in 2022 compared to $1,306.0 million in 2021.", -0.4], ["We used these proceeds, together with borrowings on our five-year revolving facility and cash on hand to redeem the full $750.0 million senior notes that were due April 1, 2022.", 0.2], ["We also repaid $242.9 million outstanding on our Japanese term loans and $525.8 million outstanding on our 1.414% Euro senior notes at their maturity date of December 13, 2022.", 0.1], ["In addition, in 2022 we expended $126.4 million to repurchase shares of our common stock.", -0.2], ["In 2021, we issued senior notes and received $1,599.8 million in proceeds, which, along with cash on hand, were used to extinguish $1,993.2 million aggregate outstanding principal amount of our senior notes pursuant to cash tender offers for certain outstanding series of our senior notes, at a total reacquisition price of $2,154.8 million.", -0.2], ["Additionally, we used cash on hand to redeem $500.0 million of other senior notes that matured in 2021.", -0.1], ["We also had deferred business combination payments of $145.0 million that were paid in 2021 under the terms of the purchase agreements.", -0.1], ["At December 31, 2022, we had outstanding debt of $5,696.5 million, of which $544.3 million was classified as current debt.", -0.3], ["Of our current debt, we settled the full amount of our $83.0 million of our short-term term loan in February 2023 using $33.9 million in cash and the transfer of all the ZimVie shares that we owned, $86.3 million of senior notes mature on March 19, 2023 and the remaining $375.0 million is outstanding under our five-year revolving facility which we expect to repay during 2023.", -0.2], ["We believe we can satisfy these debt obligations with cash generated from our operations.", 0.3], ["In February, May, August and December 2022, our Board of Directors declared cash dividends of $0.24 per share.", 0.2], ["We expect to continue paying cash dividends on a quarterly basis; however, future dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.", 0.1], ["In February 2016, our Board of Directors authorized a $1.0 billion share repurchase program effective March 1, 2016, with no expiration date.", 0.4], ["We had not repurchased any shares under this program until the fourth quarter of 2022, when we entered into transactions to repurchase $150.0 million in shares of our common stock.", 0.3], ["2021 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $220 million, of which", -0.2], ["approximately $130 million was incurred through December 31, 2022.", -0.1], ["We expect to reduce gross annual pre-tax operating expenses by approximately $190 million relative to the 2021 baseline expenses by the end of 2024 as program benefits under the 2021 Restructuring Plan are realized.", 0.3], ["The 2019 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $350 million to $400 million, of which approximately $280 million was incurred through December 31, 2022.", -0.2], ["In our original estimates, we expected to reduce gross annual pre-tax operating expenses by approximately $180 million to $280 million relative to the 2019 baseline expenses by the end of 2023 as program benefits under the 2019 Restructuring Plan are realized.", 0.2], ["Although the ultimate timing for resolution of the disputed tax issues is uncertain, future payments may be significant to our operating cash flows.", -0.7], ["We estimate the total liabilities for all litigation matters was $349.2 million as of December 31, 2022.", -0.6], ["Critical accounting estimates are those that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition and results of operations.", -0.5], ["We believe that the accounting estimates and assumptions described below involve significant subjectivity and judgment, and changes to such estimates or assumptions could have a material impact on our financial condition or operating results.", -0.5], ["Excess Inventory and Instruments - We must determine as of each balance sheet date how much, if any, of our inventory may ultimately prove to be unsaleable or unsaleable at our carrying cost.", -0.8], ["Similarly, we must also determine if instruments on hand will be put to productive use or remain undeployed as a result of excess supply.", -0.5], ["Accordingly, inventory and instruments are written down to their net realizable value.", -0.3], ["Obsolete or discontinued items are generally destroyed and completely written off.", -0.8], ["Realization of deferred tax assets in each taxable jurisdiction is dependent on our ability to generate future taxable income sufficient to realize the benefits.", 0.1], ["Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities.", -0.6], ["These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.", -0.2], ["We establish liabilities for loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated.", -0.4], ["Changes to these assumptions could require us to record impairment charges on these assets.", -0.7], ["In our annual impairment test in the fourth quarter of 2022, we determined our EMEA reporting unit's carrying value was in excess of its estimated fair value.", -0.9], ["As a result of its carrying value being in excess of its estimated fair value, we recorded a goodwill impairment charge of $289.8 million.", -1.0], ["For two of these reporting units, their estimated fair values exceeded their carrying values by more than 35 percent.", 0.35], ["We performed a qualitative test on the other reporting unit and concluded it was more likely than not the fair value of this reporting unit exceeded its carrying value.", 0.4], ["Future impairment in our reporting units could occur if the estimates used in the income and market approaches change.", -0.5], ["If our estimates of profitability in the reporting unit decline, the fair value estimate under the income approach will decline.", -0.6], ["Additionally, changes in the broader economic environment could cause changes to our estimated discount rates and comparable company valuation indicators, which may impact our estimated fair values.", -0.3], ["Further, changes in foreign currency exchange rates could increase the cost of procuring inventory and services from foreign suppliers, which could reduce reporting unit profitability.", -0.4], ["We are exposed to certain market risks as part of our ongoing business operations, including risks from changes in foreign currency exchange rates, interest rates and commodity prices that could affect our financial condition, results of operations and cash flows.", -0.7], ["We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates.", -0.8], ["A sensitivity analysis of changes in the fair value of foreign currency exchange forward contracts outstanding at December 31, 2022 indicated that, if the U.S. Dollar uniformly strengthened or weakened in value by 10 percent relative to all currencies, with no change in the interest differentials, the fair value of those contracts would affect earnings in a range of a decrease of approximately $93 million to an increase of approximately $88 million before income taxes in periods through June 2025.", -0.1], ["To the extent the respective governments’ ability to fund their public hospital programs deteriorates, we may have to record significant bad debt expenses in the future.", -0.9], ["Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.", -0.1], ["The annual goodwill impairment test resulted in an impairment charge of $289.8 million related to the EMEA reporting unit, which represented all of the remaining goodwill.", -0.8], ["As described in Notes 2 and 17 to the consolidated financial statements, the Company has recorded tax liabilities for unrecognized tax benefits with a consolidated balance of $521.0 million as of December 31, 2022.", -0.5], ["Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed.", -0.7], ["Earnings (loss) from   continuing operations before income taxes", -0.6], ["Provision (benefit)   for income taxes from continuing operations", -0.4], ["Net Earnings (Loss) from Continuing Operations of Zimmer Biomet   Holdings, Inc.", -0.6], ["Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.", -0.6], ["Net Earnings (Loss)   of Zimmer Biomet Holdings, Inc.", -0.6], ["Unrealized cash flow   hedge gains/(losses), net of tax", -0.5], ["Comprehensive Income   (Loss) Attributable to Zimmer Biomet Holdings, Inc.", -0.5], ["      (103.9 ) $       (6,720.5 ) $                4.7  $        12,392.8", -0.5], ["      (104.8 ) $       (6,867.2 ) $                6.7  $        12,027.0", -0.5], ["Cash flows provided by   (used in) operating activities from continuing operations:", 0.0], ["Net cash provided by operating activities from continuing   operations", 0.5], ["Cash flows provided by   (used in) investing activities from continuing operations:", 0.0], ["Net cash used in investing   activities from continuing operations", -0.5], ["Cash flows provided by   (used in) financing activities from continuing operations:", 0.0], ["Risks and Uncertainties - Our results have been and may continue to be impacted by the COVID-19 global pandemic.", -1.0], ["The vast majority of our net sales are derived from products used in elective surgical procedures which continue to be deferred to some extent due to precautions in certain markets and staffing shortages.", -0.8], ["Although the effects of the COVID-19 pandemic on our operating results continue to subside, the pandemic could still have an unfavorable effect on our financial position, results of operations and cash flows in the near term.", -0.5], ["The historical results of our spine and dental businesses that were contributed to ZimVie in the spinoff have been reflected as discontinued operations in our consolidated financial statements as the spinoff represents a strategic shift in our business that has a major effect on operations and financial results.", 0.2], ["These estimates have considered the impact the COVID-19 pandemic may have on our financial position, results of operations and cash flows.", -0.3], ["Unrealized translation gains and losses are included in accumulated other comprehensive loss in stockholders’ equity.", -0.1], ["When a transaction is denominated in a currency other than the subsidiary’s functional currency, we remeasure the transaction into the functional currency and recognize any transactional gains or losses in earnings.", 0.0], ["general and administrative (“SG&A”) expenses and were $254.4 million, $255.4 million and $235.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.", -0.1], ["Litigation - We record an undiscounted liability for contingent losses, including future legal costs, settlements and judgments, when we consider it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", -0.4], ["In December 2021, our management approved a new global restructuring program intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", 0.3], ["In December 2019, our Board of Directors approved, and we initiated, a new global restructuring program with an objective of reducing costs to allow us to further invest in higher priority growth opportunities.", 0.2], ["Restructuring charges for the years ended December 31, 2022, 2021 and 2020 were primarily attributable to these programs.", -0.2], ["•        Employee termination benefits related to terminating employees with overlapping responsibilities in various areas of our business.", -0.8], ["•        Dedicated project personnel expenses which include the salary, benefits, travel expenses and other costs directly associated with employees who are 100 percent dedicated to our integration of acquired businesses and employees who have been notified of termination, but are continuing to work on transferring their responsibilities.", -0.6], ["•        Contract termination expenses related to terminated contracts, primarily with sales agents and distribution agreements.", -0.7], ["•        Changes to our contingent consideration liabilities related to our mergers and acquisitions.", -0.2], ["•        Other various expenses to relocate facilities, integrate information technology, losses incurred on assets resulting from the applicable acquisition, and other various expenses.", -0.5], ["We make concerted efforts to collect all accounts receivable, but sometimes we have to write-off the account against the allowance when we determine the account is uncollectible.", -0.9], ["The allowance for credit losses was $78.4 million and $60.1 million as of December 31, 2022 and 2021, respectively.", -0.4], ["Net expenses include any resulting gains or losses from the sales of receivables, credit insurance and factoring fees.", -0.5], ["Under the previous arrangement in the U.S. and Japan, any initial collections of cash and remittances to the third parties were recognized in our consolidated statements of cash flows in financing activities which resulted in an outflow of $53.0 million for the year ended December 31, 2020.", -0.3], ["An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount.", -0.9], ["If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded in the amount that the carrying value of the reporting unit exceeds the fair value.", -0.8], ["An impairment loss is recognized if the carrying amount exceeds the estimated fair value of the asset.", -0.7], ["The amount of the impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value.", -0.7], ["We reduce our deferred tax assets by a valuation allowance if it is more likely than not that we will not realize some portion or all of the deferred tax assets.", -0.6], ["In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes.", 0.2], ["In the year ended December 31, 2022, we recognized losses of $116.6 million related to our investment in ZimVie.", -0.9], ["For sales-type or direct financing leases, this could result in the recognition of a dayone loss for leases with entire or partial variable payments.", -0.8], ["ASU 2021-05 requires lessors to classify leases with entire or partial variable payments as operating leases if otherwise a day-one loss would be recognized.", -0.7], ["The adoption of this standard did not have a material impact on our financial position, results of operations or cash flows.", 0.1], ["In the fourth quarter of 2021, ZimVie entered into a credit agreement with a financial institution providing for revolving loans of up to $175.0 million and term loan borrowings of up to $595.0 million.", 0.5], ["On February 28, 2022, prior to separation, ZimVie borrowed the entire $595.0 million available under the term loan.", -0.2], ["Approximately $540.6 million of this amount was paid by ZimVie to Zimmer Biomet in the form of a dividend at separation which is included in our cash flows from financing activities in the consolidated statements of cash flows.", -0.1], ["We used proceeds from the dividend, along with cash on hand and proceeds from a draw on our revolving credit facility, to repay our 3.150% Senior Notes due 2022 which had an outstanding principal balance of $750.0 million.", 0.1], ["We recognize any gains or losses from the TSA and TMA agreements in Acquisition, integration, divestiture and related expense in our consolidated statements of earnings.", 0.0], ["In the year ended December 31, 2022, we recognized losses of $116.6 million related to our investment in ZimVie.", -0.8], ["In February 2023, we repaid in full the Short-Term Term Loan by transferring our ZimVie common shares to the financial institution counterparty to settle the Forward Exchange Agreement and by paying $33.9 million in cash, representing an amount determined by the difference between the average daily volume-weighted average price of the ZimVie shares over the outstanding term of the Forward Exchange Agreement and the principal amount of $83.0 million.", -0.5], ["For the year ended December 31, 2022, an unrealized gain of $1.1 million related to the change in fair value of the Forward Exchange Agreement was recorded in non-operating other (expense) income, net in our consolidated statements of earnings.", 0.2], ["Consignment sales represented approximately 85 percent of our net sales in 2022.", 0.0], ["At negotiated thresholds within a contract buying period, price discounts may increase.", 0.0], ["We estimate sales recognized in this manner represented approximately 15 percent of our net sales in 2022.", 0.0], ["These customers may purchase items in large quantities if incentives are offered or if there are new product offerings in a market, which could cause period-to-period differences in sales.", -0.1], ["If sales incentives may be earned by a customer for purchasing a specified amount of our product, we estimate whether such incentives will be achieved and recognize these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized.", -0.3], ["Occasionally, products are returned and, accordingly, we maintain an estimated refund liability based upon the expected value method that is recorded as a reduction in revenue.", -0.4], ["In December 2021, our management approved a new global restructuring program (the “2021 Restructuring Plan”) intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", 0.2], ["The 2021 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $220 million.", -0.5], ["The pre-tax restructuring charges consist of employee termination benefits; contract terminations for sales agents; and other charges, such as consulting fees and project management.", -0.5], ["Plan”) with an objective of reducing costs to allow us to further invest in higher priority growth opportunities.", 0.3], ["The 2019 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $350 million to $400 million.", -0.6], ["The restructuring charges incurred in the year ended December 31, 2022, primarily related to employee termination benefits, consulting fees and project management expenses.", -0.5], ["For the expense estimated to be recognized for the 2019 Restructuring Plan, we have disclosed the midpoint in our estimated range of expenses.", -0.4], ["Amounts charged to the consolidated statements of earnings for excess and obsolete inventory, including certain product lines we intend to discontinue, in the years ended December 31, 2022, 2021 and 2020 were $137.3 million, $117.3 million and $230.0 million, respectively.", -0.8], ["The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and changes as revenue estimates increase or decrease.", 0.0], ["The total aggregate cash consideration paid at closing was $100.0 million, with an additional $11.0 million of deferred payments to be made over the next two years.", 0.2], ["In addition, we revised our estimates related to net operating loss carryforwards based on updated tax calculations which reduced our deferred income tax liability and goodwill correspondingly.", 0.3], ["In the annual 2022 test, each of the Americas Orthopedics and Americas CMFT reporting units exceeded their carrying values by more than 35 percent.", 0.5], ["We determined the goodwill related to our EMEA reporting unit was fully impaired and recognized an impairment charge of $289.8 million for the year ended December 31, 2022.", -0.9], ["The impairment charge of $289.8 million in our EMEA reporting unit was primarily due to the impacts from macroeconomic factors.", -0.7], ["The weakening of major foreign currencies in our EMEA reporting unit against the U.S. Dollar significantly impacted forecasted cash flows used in our analysis.", -0.6], ["In addition, inflationary pressures have also caused our forecasted expenses to increase.", -0.5], ["We had previously taken goodwill impairment charges related to this reporting unit in prior years so when these negative macroeconomic factors occurred in 2022, the remaining goodwill was determined to be fully impaired.", -0.9], ["If our estimated cash flows decrease, we may have to record further impairment charges in the future.", -0.8], ["Factors that could result in our cash flows being lower than our current estimates include: 1) additional recurrence of the COVID-19 virus, including variants, causing hospitals to defer elective surgical procedures, 2) decreased revenues caused by unforeseen changes in the healthcare market, or our inability to generate new product revenue from our research and development activities, 3) our inability to achieve the estimated operating margins in our forecasts from our restructuring programs, cost saving initiatives, and other unforeseen factors, and 4) the weakening of foreign currencies against the U.S. Dollar.", -0.9], ["During the year ended December 31, 2020, we recorded a goodwill charge related to our EMEA reporting unit of $470.0 million.", -0.7], ["The impairment charge was primarily due to the COVID-19 pandemic and a reportable segment change.", -0.6], ["The COVID-19 pandemic had a significant adverse effect on both the operational and non-operational assumptions used to estimate the fair value of our EMEA reporting unit.", -0.9], ["The significant decline in our share price and that of most other publicly-traded companies resulted in us utilizing a higher risk-adjusted discount rate compared to the rate used in the previous annual goodwill impairment test to discount our future estimated cash flows to present value.", -0.8], ["On an operational basis, due to the deferral of elective surgical procedures, we estimated that our cash flows would be significantly lower than previously estimated in the prior annual goodwill impairment test.", -0.8], ["The change in reportable segments resulted in additional impairment due to additional assets being allocated to the EMEA reporting unit.", -0.7], ["We recognized IPR&D intangible asset impairment charges of $3.0 million, $16.3 million and $33.0 million in the years ended December 31, 2022, 2021 and 2020, respectively, in “Goodwill and intangible asset impairment” on our consolidated statements of earnings.", -0.8], ["We received net proceeds of $1,599.8 million.", 0.5], ["As a result, we recorded a loss on the extinguishment of debt in the amount of $165.1 million in our consolidated statement of earnings for the year ended December 31, 2021.", -0.8], ["The components of this loss were the reacquisition price of $2,154.8 million minus the carrying value of the debt of $1,982.7 million (including debt discount and issuance costs) plus debt tender fees of $5.0 million minus a gain of $12.0 million on a reverse treasury lock that we entered into to offset any increases or decreases to the premium associated with the tender offer from the date we entered into the lock.", -0.7], ["As of December 31, 2022, there were outstanding borrowings of $375.0 million under the 2022 Five-Year Revolving Facility.", -0.5], ["As of December 31, 2022, there were no outstanding borrowings under the 2022 364-Day Revolving Credit Agreement.", 0.2], ["We paid $161.7 million, $219.0 million, and $193.1 million in interest during 2022, 2021, and 2020, respectively.", -0.6], ["Changes in the fair value of the derivative instrument are recorded in current earnings and are offset by gains or losses on the underlying debt instrument.", 0.0], ["The interest rate swaps were settled, and the remaining loss to be recognized at December 31, 2022 was $24.6 million, which will be recognized using the effective interest rate method over the remaining maturity period of the hedged notes.", -0.4], ["We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates.", -0.9], ["In the year ended December 31, 2022, Euro 575 million of these cross-currency interest rate swaps matured at a gain of $56.2 million.", 0.7], ["In the year ended December 31, 2022, ¥7 billion of these cross-currency swaps were terminated at a gain of $12.8 million.", 0.6], ["For derivatives which qualify as hedges of future cash flows, the gains and losses are temporarily recorded in AOCI and then recognized in cost of products sold when the hedged item affects net earnings.", -0.1], ["Any foreign currency remeasurement gains/losses recognized in earnings are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period.", 0.0], ["The amount of these gains/losses is recorded in other (expense) income, net.", -0.2], ["As discussed in Note 13, in 2021 we entered into a reverse treasury lock related to our bond tender offer to offset any increases or decreases to the premium associated with the tender offer from the date we entered into the lock.", 0.0], ["We recognized a gain of $12.0 million that was included in the loss on early extinguishment of debt.", 0.2], ["                                                                                          Amount of Gain / (Loss)                                                                                                                                                Amount of Gain / (Loss)", 0.0], ["100.5  $           102.5  $       (42.7)   Cost of products sold", -0.3], ["December 31, 2022, together with settled derivatives where the hedged item has not yet affected earnings, was a net unrealized gain of $80.3 million, or $69.6 million after taxes, which is deferred in AOCI.", 0.3], ["A gain of $82.9 million, or $68.6 million after taxes, is expected to be reclassified to earnings in cost of products sold and a loss of $0.7 million, or $0.5 million after taxes, is expected to be reclassified to earnings in interest expense, net over the next twelve months.", 0.4], ["Location and Amount of Gain/(Loss) Recognized in Income on Fair Value, Cash Flow and", 0.0], ["The following gains/(losses) from these derivative instruments were recognized on our consolidated statements of earnings (in millions):", -0.1], ["These gains/(losses) do not reflect gains of $5.3 million and losses of $3.7 million and $22.8 million in 2022, 2021 and 2020, respectively, recognized in other (expense) income, net as a result of foreign currency re-measurement of monetary assets and liabilities denominated in a currency other than an entity’s functional currency.", -0.2], ["The following net investment hedge gains (losses) were recognized on our consolidated statements of comprehensive income (loss) (in millions):", -0.1], ["The U.S. and Puerto Rico plans are frozen; meaning there are no new participants that can join the plan and participants in the plan do not accrue additional years of service or compensation.", -0.3], ["Service cost                                       $                  0.7  $                   0.9  $                  0.7  $                22.7  $", 0.1], ["Expected return on   plan assets                         (30.8)                  (29.8)                  (32.9)                 (14.3)", 0.2], ["expense                                             $              (10.3) $                 (3.1) $               (10.3)   $                 5.5  $", -0.1], ["Changes in projected benefit obligations and plan assets were (in millions):", 0.0], ["of year                                                                $                  499.5  $                   474.1  $                  821.2  $", 0.1], ["year                                                                    $                  396.2  $                   499.5  $                  667.2  $", -0.2], ["Total accumulated benefit obligations and plans with accumulated benefit obligations in excess of plan assets were as follows (in millions):", 0.0], ["We expensed $48.5 million, $46.3 million and $43.5 million related to these plans for the years ended December 31, 2022, 2021 and 2020, respectively.", -0.1], ["The components of earnings (loss) from continuing operations before income taxes consisted of the following (in millions):", 0.0], ["Valuation allowances are recorded to reduce deferred income tax assets when it is more likely than not that an income tax benefit will not be realized.", -0.5], ["The remaining valuation allowances booked against deferred tax assets of $8.4 million relate primarily to accrued liabilities and intangible assets that management believes, more likely than not, will not be realized.", -0.4], ["Decreases   related to lapse of statute of limitations", 0.1], ["During 2022, we accrued interest and penalties of $18.1 million, and as of December 31, 2022, had a recognized liability for interest and penalties of $134.5 million, which does not include any increase related to business combinations.", -0.6], ["During 2021, we accrued interest and penalties of $8.9 million, and as of December 31, 2021 had a recognized liability for interest and penalties of $116.2 million, which does not include any increase related to business combinations.", -0.5], ["During 2020, we released interest and penalties of $1.7 million, and as of December 31, 2020, had a recognized liability for interest and penalties of $107.4 million, which does not include any increase related to business combinations.", -0.3], ["Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed.", -0.8], ["Management’s best estimate of such change is within the range of a $400 million decrease to a $20 million increase.", -0.1], ["Therefore, there is a possibility that an adverse outcome in these audits could have a material effect on our results of operations and financial condition.", -0.9], ["In October 2020, we reached agreement with the IRS for tax years 2006-2012 primarily related to the reallocation of profits between the U.S. and Puerto Rico.", 0.2], ["This includes a proposed increase to our U.S. federal taxable income related to our cost sharing agreement, which would result in additional tax expense related to 2013 of approximately $370 million, subject to interest and penalties.", -0.7], ["This resulted in recording a deferred tax asset for future deductions of tax goodwill.", 0.1], ["In 2022, we reached final agreement with Swiss authorities for certain tax years, resulting in an increase of the TRAF deferred tax asset and a corresponding net $59 million tax benefit.", 0.5], ["We also recognized a net $22 million tax benefit associated with closing certain tax years.", 0.4], ["For the years ended December 31, 2022 and 2021, an average of 4.4 million options and 1.3 million options, respectively, to purchase shares of common stock were not included in the computation of diluted earnings per share as the exercise prices of these options were greater than the average market price of the common stock.", -0.2], ["Since we incurred a net loss in the year ended December 31, 2020, no dilutive stock options or other equity awards were included as diluted shares.", -0.5]], "zbh23_sentences.json": [["Yes  ☐    No  ☒", -1.0], ["The transaction was intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders.", 0.8], ["Consignment sales represented approximately 85 percent of our net sales in 2023.", 0.0], ["In most European countries, healthcare is sponsored by the government and therefore government budgets impact healthcare spending, which can affect our sales in this segment.", -0.2], ["Japan is the largest market within this segment, accounting for approximately 50 percent of the region’s sales in 2023.", 0.1], ["Our business is seasonal in nature to some extent, as many of our products are used in elective procedures, which typically decline during the summer months and can increase at the end of the year once annual deductibles have been met on health insurance plans.", 0.0], ["Additionally, with sales to customers where title to product passes upon shipment, these customers may purchase items in large quantities if incentives are offered or if there are new product offerings in a market, which could cause period-to-period differences in sales.", 0.0], ["Since most of our sales occur at the time of an elective procedure, we generally do not have firm orders.", -0.1], ["Sports medicine products represented 11 percent of our S.E.T.", 0.0], ["Biologics products represented 8 percent of our S.E.T.", 0.0], ["Our foot and ankle products represented 4 percent of our S.E.T.", -0.1], ["The rapid commercialization of new data solutions, surgical techniques,  innovative new materials, biologics products, and implant and instrument designs remains one of our core strategies and continues to be an important driver of sales growth.", 0.8], ["The FDA review may involve substantial delays that adversely affect the marketing and sale of our products.", -0.9], ["Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.", -1.0], ["We do not expect that the ongoing costs of compliance with these environmental requirements will have a material impact on our consolidated earnings, capital expenditures or competitive position.", 0.2], ["Failure to comply with any such data protection laws, regulations and guidance could result in government enforcement actions (which could include civil and/or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.", -0.8], ["Risk Factors – If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -0.9], ["In most of our manufacturing network, we have improved our manufacturing processes to harmonize and optimize our quality systems and to protect our profitability and offset the impact of inflationary costs.", 0.7], ["We have, for example, employed computer-assisted robots and multi-axis grinders to precision polish medical devices; automated certain manufacturing and inspection processes, including onmachine inspection and process controls; purchased state-of-the-art equipment; in-sourced core products and processes; and negotiated cost reductions from third-party suppliers.", 0.9], ["For example, we have experienced elevated charges for excess and obsolete inventory while also facing increased backorders due to unpredictable demand fluctuations across our various markets, and there can be no assurance that production mix planning or inventory allocation will match end market demand.", -0.5], ["Any of these factors, alone or in combination, could cause us to have difficulty maintaining or increasing sales of our products or otherwise have an adverse effect on our business and financial results.", -0.9], ["Our products may become obsolete, customers may not buy our products, and our revenue and profitability may decline without the timely introduction of new products and enhancements, due to changes in markets, or due to changes in applicable standards of care.", -0.8], ["Demand for our products may change, in certain cases, in ways we may not anticipate because of evolving customer needs, changing demographics, changing industry growth rates, declines in the musculoskeletal implant market, the introduction of competing products and technologies, the emergence of alternative treatment methods, and evolving surgical philosophies and industry standards.", -0.7], ["Our products may become obsolete without the timely introduction of new products and enhancements, or due to changes in applicable standards of care.", -0.8], ["If that happens, our revenue and operating results would suffer.", -0.9], ["In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce revenue in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.", -0.8], ["Our restructuring programs may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our restructuring initiatives.", -0.8], ["We have initiated a series of restructuring programs to reduce costs, improve efficiency, spin off certain businesses, and prioritize investments in higher-priority growth operations.", 0.2], ["Restructuring initiatives involve complex plans and actions that may include, or result in, workforce reductions, plant closures and/or consolidations, product portfolio rationalizations and asset impairments.", -0.7], ["Additionally, as a result of restructuring initiatives, we may experience a loss of continuity, loss of accumulated knowledge and/or inefficiencies during transitional periods.", -0.8], ["Restructuring initiatives present risks that may impair our ability to achieve anticipated operating enhancements and/or cost reductions, or otherwise harm our business, including higher than anticipated costs in implementing our restructuring programs, as well as management distraction.", -0.8], ["If we fail to achieve some or all of the expected benefits of our restructuring programs, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.", -0.9], ["We may not be able to effectively integrate acquired businesses into our operations or achieve expected cost savings or profitability from our acquisitions.", -0.7], ["•           unforeseen difficulties related to entering markets for which or geographic regions where we do not have prior experience; •         potential loss of key employees;", -0.6], ["•           inability to generate sufficient revenue or realize sufficient cost savings to offset acquisition or investment costs.", -0.7], ["As a result, if we fail to evaluate and execute acquisitions properly, we might not achieve the anticipated benefits of such acquisitions, and we may incur costs in excess of what we anticipate.", -0.8], ["Interruption of manufacturing operations could adversely affect our business, financial condition and results of operations.", -0.9], ["Damage to one or more facilities from weather or natural disaster-related events, vulnerabilities in technology, cyber-attacks against our information systems or the information systems of our business partners (such as ransomware attacks), issues in manufacturing arising from failure to follow specific internal protocols and procedures, compliance concerns relating to the Quality System Regulation (“QSR”) and Good Manufacturing Practice requirements, equipment breakdown or malfunction, reductions in operations and/or worker absences, trade impediments, international sanctions, wars or other factors could adversely affect the ability to manufacture and distribute our products.", -0.9], ["In the event of an interruption in manufacturing or involving a critical supplier, we may be unable to move quickly to alternate means of producing or acquiring affected products or to meet customer demand, and alternative sources of supply may not be adequate to accommodate sudden increases in demand.", -0.8], ["The global supply chain has been and continues to be negatively impacted by a variety of macro factors which have, in part, resulted in challenges to meet end market demand in some instances.", -0.9], ["As a result, we may experience lost sales, which we may be unable to recover, loss of market share, which we may be unable to recapture, and/or harm to our reputation, which could adversely affect our business, financial condition and results of operations.", -1], ["Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by us or third-party suppliers could adversely affect our business, financial condition and results of operations.", -1], ["A reduction or interruption in the supply of materials or components used in manufacturing our products, such as due to loss of access to one or more suppliers; an inability to timely develop and validate alternative sources if required; or a significant increase in the price of such materials or components could adversely affect our business, financial condition and results of operations.", -1], ["To the extent we or our contract sterilizers are unable to sterilize our products or provide sterilization services to our customers, whether caused by capacity, availability of materials for sterilization, and regulatory or other restrictions on the use of ethylene oxide or otherwise, we may be unable to transition to other contract sterilizers, sterilizer locations or sterilization methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.", -1], ["This rule could adversely affect the sourcing, availability and pricing of materials used in the manufacture of our products, which could adversely affect our manufacturing operations and our profitability.", -1], ["•           suffer a loss of access to or alteration of all or a portion of our Confidential Information;", -1], ["•           lose existing customers, suppliers and business partners;", -1], ["•           have problems in determining product cost estimates and establishing appropriate pricing;", -1], ["•           suffer outages or disruptions in our operations, supply chain, products and/or services, including our ZBEdgeTM ecosystem; •      have difficulty preventing, detecting, and controlling fraud;", -1], ["•           be subject to issues with product functionality that may result in a loss of data, risk to patient safety, field actions and/or product recalls;", -1], ["•           incur expenses or lose revenues as a result of a data privacy breach; or", -0.8], ["Any significant breakdown, intrusion, breach, interruption, corruption or destruction of these systems could have a material adverse effect on our business and reputation and could materially adversely affect our results of operations and financial condition.", -1.0], ["Business and economic conditions have adversely impacted, and may, either alone or in combination with other risks, in the future adversely impact, our business, results of operations and financial condition, the nature and extent of which impacts are uncertain and unpredictable.", -1.0], ["Our operations expose us to risks from business interruptions that may arise from a variety of sources, including public health crises; supply chain disruptions; loss of or limitations on access to certain markets due to trade and tariff disputes and disruptions or national, regional and global conflicts; adverse economic developments; healthcare staffing challenges; government shutdowns; natural disasters; and other events that can, singly or in combination with other factors, adversely affect our business and financial results.", -1.0], ["There can be no assurance that we will successfully manage risks, such as experienced during the COVID-19 pandemic, without adverse impacts to our business or financial results.", -0.9], ["otherwise may have unpredictable effects on other risks, our business, financial or operational results which may be comparable to, or more adverse than, those we experienced in connection with the COVID-19 pandemic.", -0.9], ["If we fail to retain the employees, independent agents and distributors upon whom we rely heavily to market our products, customers may not buy our products and our revenue and profitability may decline.", -0.8], ["A loss of a significant number of our marketing employees, agents or distributors could have a material adverse effect on our business and results of operations.", -0.9], ["If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed.", -0.9], ["In addition, we are subject to cost containment measures in the United States and other countries, resulting in pricing pressures, which could have a material adverse effect on our business, results of operations, and cash flows.", -0.9], ["If third-party payors deny or decline reimbursement, reduce reimbursement levels or change reimbursement models for our products, demand for our products may decline, or we may experience increased pressure to reduce the prices of our products, which could have a material adverse effect on our sales and results of operations.", -1], ["If we are not one of the providers selected by a group purchasing organization, affiliated hospitals and other members may be less likely to purchase our products, and, if the group purchasing organization has negotiated a strict compliance contract for another manufacturer’s products, we may be precluded from making sales to members of the group purchasing organization for the duration of the contractual arrangement.", -1], ["Our failure to respond to the cost-containment efforts of group purchasing organizations may cause us to lose market share to our competitors and could have a material adverse effect on our sales and results of operations.", -1], ["Initiatives to limit the growth of general healthcare expenses and hospital costs are ongoing in the markets in which we do business, and we have experienced downward pressure on product pricing and other effects of healthcare reform in our international markets.", -1], ["For example, China has implemented a volume-based procurement (“VBP”) process designed to reduce medical spending, which has in the past resulted in, and could in the future result in, reduced margins on covered devices and products, required renegotiation of distributor arrangements, and incurrence of inventory-related charges.", -1], ["In cases where our product is not selected in VBP, sales of that product are substantially impacted.", -1], ["Similarly, the Italian Public Administration has implemented a Pay Back Law to obtain reimbursement from the medical device industry to contribute to government overspending on medical devices beginning in 2015, which assessments we are challenging.", -1], ["Additional cost reduction and recovery strategies are likely to be proposed in various jurisdictions, the effects of which are difficult to predict, but may have a material adverse effect on our sales and results of operations.", -1], ["Pricing pressure continues due to consolidation among healthcare providers, trends toward managed care, the shift toward governments becoming the primary payors of healthcare expenses, reductions in reimbursement levels and government laws and regulations relating to reimbursement and pricing generally.", -1], ["If key participants in government healthcare systems reduce the reimbursement levels for our products, including through regulatory changes, elections and other political changes, our business, financial condition, results of operations and cash flows may be adversely affected.", -1], ["We incurred substantial additional indebtedness in connection with previous mergers and acquisitions and may not be able to meet all of our debt obligations, and interest rate risk could adversely affect our indebtedness.", -1.0], ["As a result of the increase in our debt, demands on our cash resources have increased; such demand would further amplify if we fund future mergers and acquisitions using debt financing.", -1.0], ["Our current and future increased level of debt could, among other things:", -0.5], ["•           require us to dedicate a large portion of our cash flow from operations to the servicing and repayment of our debt, thereby reducing funds available for working capital, capital expenditures, research and development expenditures and other general corporate requirements;", -0.5], ["•           adversely affect our credit rating, with the result that the cost of servicing our indebtedness might increase and our ability to obtain surety bonds could be impaired;", -0.5], ["•           adversely affect the market price of our common stock; and", -0.5], ["SOFR and such other rates have increased from recent lows, which has increased our cost of borrowing.", -1.0], ["Any further increase in interest rates applicable to our debt obligations would increase our cost of borrowing and could adversely affect our financial position, results of operations or cash flows.", -1.0], ["Changes in tax laws in countries in which we do business are expected to negatively impact our effective tax rate; further changes in tax laws may have a further negative impact.", -1.0], ["Changes in the tax laws and regulations of the jurisdictions where we do business, including an increase in tax rates or an adverse change in the treatment of an item of income or expense, could result in a material increase in our tax expense and/or tax payments, could increase tax uncertainty and could have a material adverse impact on our business, financial condition or results of operations.", -1.0], ["We expect the implementation and interpretation of Pillar Two across all jurisdictions where we do business will have an adverse effect on our effective tax rate, results of operations and cash flows.", -0.9], ["Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.", -0.7], ["an audit or litigation could have a material effect on our financial statements in the period or periods for which that determination is made.", -0.8], ["If our independent agents and distributors are characterized as employees, we would be subject to additional tax and other liabilities.", -0.8], ["Although we believe that our independent agents and distributors are properly characterized as independent contractors, tax, labor or other regulatory authorities may in the future challenge our characterization of these relationships.", -0.6], ["Changes in classification from independent contractor to employee can result in a change to various requirements associated with the payment of wages, tax withholding, and the provision of unemployment, health, and other traditional employer-employee related benefits.", -0.7], ["If regulatory authorities or state, federal or foreign courts were to determine our independent agents or distributors are employees and not independent contractors, we would be required to withhold income taxes, to withhold and pay social security, Medicare and similar taxes and to pay unemployment and other related payroll taxes, as well as provide other employer-employee related benefits.", -0.9], ["We would also be liable for unpaid past taxes and subject to penalties.", -0.9], ["As a result, any determination that our independent agents and distributors are our employees could have a material adverse effect on our business, financial condition or results of operations.", -0.9], ["Future material impairments in the carrying value of our intangible assets, including goodwill, would negatively affect our operating results.", -0.9], ["As discussed further in Note 11 to our consolidated financial statements, in the fourth quarter of 2022, we recorded goodwill impairment charges of $289.8 million as a result of, among other factors, changes in foreign currency exchange rates in our European-based currencies, inflation and a higher interest rate environment; and in the second quarter of 2022 and 2021, we recorded $3.0 million and $16.3 million, respectively, of in-process research and development (“IPR&D”) intangible asset impairments on certain IPR&D projects.", -0.8], ["There were no impairment charges during the year ended December 31, 2023, but if the operating performance at one or more of our reporting units significantly declines, including if competing or alternative technologies or pharmacological treatments, emerge, if market conditions or future cash flow estimates for one or more of our businesses decline, or as a result of restructuring initiatives pursuant to which we reorganize our reporting units, we could be required to record additional impairment charges.", -0.7], ["Any write-off of a material portion of our goodwill or unamortized intangible assets would negatively affect our results of operations.", -0.9], ["The spinoff of ZimVie Inc. and the divestiture of our retained interest in ZimVie Inc. could result in substantial tax liability.", -0.6], ["If the spinoff, or the subsequent divestiture of our retained interest in ZimVie, does not qualify for tax-free treatment for U.S. federal income tax purposes, the resulting tax liability to us, to our stockholders and to ZimVie stockholders could be substantial.", -0.7], ["We conduct a significant amount of our sales and manufacturing activities outside of the U.S., which subjects us to additional business risks and may cause our profitability to decline due to increased costs.", -0.6], ["•           changes to trade restrictions and protection measures, new import or export requirements, new or increased tariffs, trade embargoes and sanctions and other trade barriers, which may prevent us from shipping products to or from a particular market, restrict our access to certain sources of raw materials and other inputs, increase our operating costs and disrupt our ability to collect payment for our products and services in particular markets;", -0.7], ["•           the effects of inflation, including the effects of different rates of inflation in different countries, on our costs and expenses, and the costs of our products;", -0.7], ["Wars and other conflicts may increase certain of these risks and may adversely affect our business and financial performance, including by limiting our ability to operate in, or export from, certain markets.", -0.8], ["Losing access to such markets or to exports from such markets may have a material adverse effect on our business, and may limit our ability to operate, both in the affected market and globally.", -0.8], ["Sanctions and other civil, political and economic effects of such conflicts are likely to have adverse impacts upon us.", -1], ["For example, we produced implants and instruments in China that supported a significant portion of our global total profit in 2023; if trade restrictions or other barriers arose that limited our ability to export from China and we are unable to fully mitigate the risk or find alternative sources of supply, such trade restrictions could have a material and adverse effect on our sales and results of operations.", -1], ["Additionally, other trade disruptions include supply chain continuity disruption; inflationary pressures and increased costs of raw materials and inputs; manufacturing or shipping delays; increased shipping costs and transit delays (such as experienced due to attacks on shipping transiting the Red Sea); and increased disruptions and delays affecting our ability to operate in and to collect payment for our products and services in particular markets.", -1], ["We are subject to risks arising from currency exchange rate fluctuations, which can increase our costs, cause our profitability to decline and expose us to counterparty risks.", -1], ["Significant increases in the value of the U.S. Dollar relative to the Euro, the Japanese Yen, the Swiss Franc or other currencies could have a material adverse effect on our results of operations.", -1], ["Further, if the counterparties to the derivative financial instrument transactions fail to honor their obligations due to financial distress or otherwise, we would be exposed to potential losses or the inability to recover anticipated gains from those transactions.", -1], ["We are subject to complex and expensive laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of our products, noncompliance with which could adversely affect our business, financial condition and results of operations.", -1], ["Delays in receipt of, or failure to obtain, approvals for future products or product enhancements, or loss of approval for current products, could result in delayed realization of product revenues or in substantial additional costs.", -1], ["If a regulator were to conclude that we are not in compliance with applicable laws or regulations, that any of our products are ineffective or pose an unreasonable health risk, or that we have marketed or promoted a product for use other than as indicated in the product labelling approved by the regulator, the regulator may ban such products; detain or seize adulterated or misbranded products; order a recall, repair, replacement, or refund of payment of such products; refuse to grant pending premarket approval applications; refuse to provide certificates for exports; require us to notify healthcare professionals and others that the products present unreasonable risks of substantial harm to the public health; and subject us to fines, injunctions or other penalties.", -1], ["The regulator may also impose operating restrictions, including a ceasing of operations at one or more facilities, enjoining and restraining certain violations of applicable law pertaining to our products, seizing our products, and/or assessing civil or criminal penalties against our officers, employees or us.", -1], ["Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.", -1], ["If we fail to adequately address any of these regulations, our business could be harmed.", -1], ["If we fail to comply with healthcare fraud and abuse laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -1], ["If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.", -1], ["Failure to comply with U.S. and international data protection laws and regulations, and the disclosure of any data or related breach, could result in government enforcement actions (which could include substantial civil and/or criminal penalties and injunctive relief), private litigation and/or adverse publicity and could have a material adverse impact on our business, financial condition or results of operations.", -1], ["Pending and future product liability claims and litigation could adversely impact our financial condition and results of operations and impair our reputation.", -1], ["Product liability lawsuits and claims, safety alerts or product recalls, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation and on our ability to attract and retain customers.", -1], ["We are substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in the payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and other proprietary rights against others.", -1], ["property litigation, such litigation has in the past resulted in, and could in the future result in, our payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and proprietary rights against others, which could have a material adverse effect on our business, finances and results of operations.", -1], ["Any failure to establish, maintain or protect our intellectual property or proprietary rights could have a material adverse effect on our business, financial condition, or results of operations.", -1], ["We are involved in legal proceedings that may result in adverse outcomes.", -0.8], ["We could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our financial results in any particular period.", -0.9], ["Certain provisions of our Restated Certificate of Incorporation, our Restated By-Laws and the Delaware General Corporation Law may have an anti-takeover effect and may delay, complicate, defer or prevent a merger, acquisition, tender offer, takeover attempt or other change of control transaction, including those that a stockholder might consider in its best interest, that might result in a premium over the market price for the shares held by our stockholders, or that may be considered beneficial by many of our stockholders.", -0.7], ["As a result, our stockholders may be limited in their ability to obtain a premium for their shares.", -0.8], ["This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees.", -0.7], ["specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.", -0.8], ["However, we are subject to ongoing risks from cybersecurity threats that could materially affect us, including our business strategy, results of operations, or financial condition, as further described in Item 1A.", -0.6], ["Risk Factors - We are dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from data breaches and cybersecurity events, our business could be adversely affected.", -0.7], ["(1)   In February 2016, our Board of Directors authorized a $1.0 billion share repurchase program effective March 1, 2016, with no expiration date.", 0.7], ["On March 1, 2022, we completed the spinoff of our spine and dental businesses into ZimVie.", 0.5], ["In addition, improvements in our supply chain, procedure volume recovery from patients who deferred surgical procedures related to the pandemic, new product introductions and commercial execution have contributed to our net sales growth.", 0.8], ["As a result, in 2023 our net sales increased by 6.5 percent compared to 2022.", 0.7], ["Our net sales in 2023 were tempered by a negative 1.0 percent effect from changes in foreign currency exchange rates.", -0.2], ["Our net earnings from continuing operations were $1,024.0 million in 2023 compared to $290.2 million in 2022.", 0.9], ["Our net earnings increased in 2023 driven by the higher net sales, favorable tax settlements and lower operating expenses.", 0.8], ["Operating expenses declined primarily due to lower litigation-related, restructuring-related and quality remediation-related charges.", 0.5], ["In addition, 2022 included $292.8 million of goodwill and intangible asset impairments, and a $116.6 million loss on our investment in ZimVie.", -0.7], ["We expect year-over-year revenue growth of mid-single digits in 2024 to be driven by a combination of market growth, new product introductions, commercial execution and continued improvements in product supply.", 0.6], ["Based on foreign currency exchange rates at the end of 2023, we expect foreign currency to negatively affect year-over-year net sales by approximately 0.5 percent.", -0.3], ["We estimate operating profit will increase in 2024 when compared to 2023 due to higher net sales, leverage from fixed operating expenses and savings from our restructuring plans.", 0.7], ["However, we estimate these favorable items may be partially offset by higher intangible asset amortization and increased restructuring-related costs to implement our plans.", -0.5], ["We estimate our net interest expense will increase slightly due to higher interest rates.", -0.2], ["We expect our provision for income taxes will increase in 2024 when compared to 2023 due to the European Union adoption of Pillar Two and the non-reoccurrence of favorable tax settlements.", -0.3], ["Changes in volume and mix of product sales had positive effects of 8.1 percent and 7.6 percent on year-over-year sales during the years ended December 31, 2023 and 2022, respectively.", 0.7], ["We saw recovery of elective surgical procedures across most of our major markets driving volume growth.", 0.8], ["In addition, new product introductions and commercial execution contributed positively to volume and mix trends.", 0.9], ["Global selling prices had negative effects of 0.6 percent and 1.0 percent on year-over-year sales during 2023 and 2022, respectively.", -0.4], ["The majority of countries in which we operate continue to experience pricing pressure from local hospitals, health systems, and governmental healthcare cost containment efforts.", -0.6], ["However, we have had some success in reducing the negative effects of pricing due to internal initiatives and being able to pass some inflationary impacts on to customers.", 0.2], ["In 2023 and 2022, changes in foreign currency exchange rates had negative effects of 1.0 percent and 5.0 percent, respectively, on yearover-year sales.", -0.5], ["The 6.9 percent net sales growth in the U.S. in 2023 when compared to 2022 was primarily driven by recovery in surgical procedures as", 0.8], ["Internationally, net sales increased by 6.1 percent in", 0.5], ["The 2023 International net sales increase was similarly driven by recovery in surgical procedures as COVID-19 caused fewer disruptions across most of our major markets, but volume increases were partially offset by the negative impacts of changes in foreign currency exchange rates of 2.1 percent.", 0.2], ["In 2023, our Knees and Hips net sales increased by 9.4 percent and 3.8 percent, respectively, when compared to 2022 due to the recovery in elective surgical procedures, improvements in our supply chain and new product introductions.", 0.9], ["Changes in foreign currency exchange rates had negative effects of 0.8 percent and 1.3 percent on 2023 Knees and Hips net sales, respectively.", -0.3], ["net sales increased by 3.3 percent in 2023 when compared to 2022.", 0.3], ["Changes in foreign currency exchange rates had a negative effect of 0.5 percent on 2023 S.E.T.", -0.2], ["net sales growth was primarily driven by growth in CMFT, sports medicine and upper extremities products of 12.9 percent, 10.6 percent and 9.4 percent, respectively, partially offset by a 5.5 percent decline in trauma.", 0.4], ["S.E.T.’s performance was also negatively impacted by unfavorable changes in reimbursement for certain restorative therapy products.", -0.6], ["Other product category net sales increased by 11.6 percent in 2023 when compared to 2022 primarily due to higher net sales for our ROSA robot.", 0.7], ["Cost of products sold, excluding intangible asset amortization, increased in 2023 compared to 2022 primarily due to higher sales.", -0.2], ["However, as a percentage of net sales costs of products sold, excluding intangible asset amortization, declined in 2023 compared to 2022.", 0.1], ["This decline was primarily due to volume and mix shift to higher margin products and markets, higher hedge gains recognized in the current year period as part of our hedging program and lower royalty expense.", 0.3], ["These favorable items were partially offset by higher excess and obsolete inventory charges, inflationary cost pressures and lower average selling prices.", -0.3], ["Intangible asset amortization expense increased in 2023 when compared to 2022 due to acquisitions we made in 2023, including intangible assets acquired from the buyout of certain royalty-related licensing agreements as described above.", -0.2], ["However, as a percentage of net sales intangible asset amortization in 2023 was similar to 2022 as amortization expense and net sales increased by a similar percentage.", 0.0], ["Research & development (“R&D”) expenses increased in both amount and as a percentage of net sales in 2023 compared to 2022.", -0.2], ["The increases were driven by higher personnel-related costs, higher spending on our initial compliance with the European Union Medical Device Regulation, additional R&D expenses from acquisitions we made in 2023, and other R&D investments.", -0.1], ["Selling, general & administrative (“SG&A”) expenses increased in amount, but decreased as a percentage of net sales in 2023 compared to 2022.", 0.1], ["The increase in expenses was due to selling and distribution costs that are variable expenses which increase as net sales increase.", 0.0], ["Additionally, personnel-related costs were higher due to additional headcount investments and annual merit increases, and travel and entertainment costs were higher as we have increased these activities from lower pandemic levels.", -0.2], ["These higher costs were partially offset by lower litigation-related charges in 2023, lower bad debt charges in 2023 as we recognized higher bad debt charges in 2022 that were partially related to the beginning of the Russia/Ukraine conflict, lower share-based compensation expense in 2023 due to the forfeiture of awards related to employee departures, and a gain recognized in 2023 from the sale of an asset.", 0.1], ["In 2022, we recognized a goodwill impairment charge of $289.8 million related to our EMEA reporting unit.", -0.8], ["In 2022 and 2021, we recognized intangible asset impairment charges of $3.0 million and $16.3 million, respectively, related to IPR&D projects that we discontinued.", -0.7], ["The 2023 Restructuring Plan is intended to further streamline the organization, to better align it with our go-to-market strategies and to reduce costs across the organization.", 0.3], ["The 2021 Restructuring Plan is intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", 0.2], ["We recognized expenses of $151.9 million and $191.6 million in 2023 and 2022, respectively, primarily related to employee termination benefits, sales agent contract terminations, and consulting and project management expenses associated with these programs.", -0.5], ["The expenses were higher in 2022 when compared to 2023 primarily due to additional expenses related to the 2021 Restructuring Plan that had just been initiated at the end of 2021.", -0.3], ["We expect restructuring and other cost reduction initiatives expense to increase in 2024 as we further implement our 2023 Restructuring Plan.", -0.4], ["In 2023, we did not recognize any significant quality remediation expenses as we completed our remediation milestones in late 2022 that addressed inspectional observations on Form 483 and a warning letter issued by the FDA at our Warsaw North Campus facility, among other matters.", 0.2], ["Acquisition, integration, divestiture and related expenses relate to acquisitions made in 2023 and 2022, as well as costs related to our separation with ZimVie.", -0.5], ["The increase in these expenses in 2023 was primarily due to higher contingent consideration charges from our various acquisitions.", -0.3], ["In 2023, we incurred a loss of $9.3 million in our other (expense) income, net compared to a loss of $128.0 million in 2022.", -0.7], ["The yearover-year change was primarily due to a loss of $116.6 million recognized in 2022 related to our investment in ZimVie, while in 2023 we recognized a gain of $2.5 million prior to disposing of our ZimVie shares in February 2023.", 0.2], ["Interest expense, net, increased in 2023 when compared to 2022, primarily from higher interest rates on borrowings in 2023.", -0.4], ["In addition, in 2023 we incurred losses of $38.9 million on our fixed-to-variable interest rate swaps compared to losses of $4.0 million in 2022.", -0.6], ["In 2022, the ETR was primarily driven by the $289.8 million goodwill impairment charge and the $116.6 million loss on our investment in ZimVie, which have no corresponding tax benefits, partially offset by favorable tax settlements and finalization of Switzerland's Federal Act on Tax Reform and AHV Financing (“TRAF”) step-up.", -0.8], ["In the Americas, operating profit increased, but operating profit as a percentage of net sales decreased, in 2023  compared to 2022.", 0.1], ["The increase in operating profit in 2023 was primarily due to higher net sales driven by continued recovery of elective surgical procedures and new product introductions.", 0.5], ["However, operating profit as a percentage of net sales decreased in 2023 due to higher carrying expenses from inventory at consigned locations, and continued investments in R&D, including personnel-related costs, which were partially offset by lower royalty expenses as a result of agreements we entered into to acquire intellectual property through the buyout of certain licensing arrangements.", 0.0], ["In EMEA, operating profit and operating profit as a percentage of net sales increased in 2023 when compared to 2022.", 0.8], ["The increases were due to higher net sales driven by continued recovery of elective surgical procedures and", 0.5], ["improved pricing, lower bad debt charges and operating profit leverage from certain costs that do not increase as net sales increase.", 0.7], ["In Asia Pacific, operating profit and operating profit as a percentage of net sales increased in 2023 when compared to 2022.", 0.8], ["While net sales declined in 2023 when compared to 2022 due to changes in foreign currency exchange rates, the negative net sales impact was partially offset by higher hedge gains recognized in 2023 from our hedging program.", -0.2], ["As a result, net sales volume growth and operating leverage from certain costs that do not increase as net sales increase resulted in operating profit and operating profit as a percentage of sales increasing in 2023.", 0.6], ["Cash flows provided by operating activities from continuing operations were $1,581.6 million in 2023 compared to $1,356.2 million in 2022.", 0.9], ["The increase in 2023 was primarily driven by higher earnings, lower restructuring-related payments and lower tax payments.", 0.7], ["These favorable items were partially offset by higher investments in inventory in 2023 when compared to 2022, as well as higher bonus payments in 2023.", -0.1], ["Cash flows used in investing activities from continuing operations were $778.9 million in 2023 compared to $522.0 million in 2022.", -0.3], ["In 2023, we used the proceeds from draws on our existing credit facilities, along with cash on hand, to repurchase $692.2 million of our common stock.", -0.1], ["At December 31, 2023, we had outstanding debt of $5,767.9 million, of which $900.0 million was classified as current debt.", -0.5], ["Of our current debt, $850.0 million of senior notes mature on November 22, 2024 and the remaining $50.0 million is outstanding under an uncommitted credit facility which we expect to repay during 2024.", -0.2], ["In March, May, August and December 2023, our Board of Directors declared cash dividends of $0.24 per share.", 0.3], ["In February 2016, our Board of Directors authorized a $1.0 billion share repurchase program effective March 1, 2016, with no expiration date.", 0.2], ["In 2023, we executed share repurchases to return cash to investors as well as to limit ownership dilution from the issuance of common stock under our share-based compensation programs and in connection with our acquisition of Embody, Inc.  As of December 31, 2023, $155.8 million remained authorized under this program.", 0.1], ["An additional 0.5 million shares were repurchased in early January 2024 for $64.1 million.", 0.1], ["The 2023 Restructuring Plan along with other related initiatives is expected to result in total pretax charges of $120 million to $135 million by the end of 2025, of which approximately $13 million was incurred through December 31, 2023.", -0.4], ["We expect to reduce gross annual pre-tax operating expenses by $175 million to $200 million relative to the 2023 baseline expenses by the end of 2025 as program benefits under the 2023 Restructuring Plan are realized.", 0.4], ["The 2021 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $180 million by the end of 2024, of which approximately $170 million was incurred through December 31, 2023.", -0.3], ["We expect to reduce gross annual pre-tax operating expenses by approximately $190 million relative to the 2021 baseline expenses by the end of 2024 as program benefits under the 2021 Restructuring Plan are realized.", -0.1], ["The 2019 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $370 million by the end of 2025, of which approximately $320 million was incurred through December 31, 2023.", -0.2], ["In our original estimates, we expected to reduce gross annual pre-tax operating expenses by approximately $180 million to $280 million relative to the 2019 baseline expenses by the end of 2023 as benefits under the 2019 Restructuring Plan were realized.", 0.1], ["We estimate the total liabilities for all litigation matters was $244.1 million as of December 31, 2023.", -0.5], ["We expect to pay these liabilities over the next few years.", -0.3], ["We have entered into development, distribution and other contractual arrangements that may result in future payments dependent upon various events such as the achievement of certain product R&D milestones, sales milestones, or exclusive rights to distribute a product.", 0.0], ["These estimated payments related to these agreements could range from $0 to $440 million.", -0.1], ["Critical accounting estimates are those that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition and results of operations.", -0.4], ["We believe that the accounting estimates and assumptions described below involve significant subjectivity and judgment, and changes to such estimates or assumptions could have a material impact on our financial condition or operating results.", -0.4], ["Excess Inventory and Instruments - We must determine as of each balance sheet date how much, if any, of our inventory may ultimately prove to be unsaleable or unsaleable at our carrying cost.", -0.6], ["Accordingly, inventory and instruments are written down to their net realizable value.", -0.2], ["Obsolete or discontinued items are generally destroyed and completely written off.", -0.8], ["Management evaluates the need for changes to the net realizable values of inventory and instruments based on market conditions, competitive offerings and other factors on a regular basis.", 0.0], ["Income Taxes - Our income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid.", 0.2], ["Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities.", -0.6], ["These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.", 0.0], ["Changes to these assumptions could require us to record impairment charges on these assets.", -0.4], ["During our annual goodwill impairment testing in the fourth quarter of 2023, for two of these reporting units their estimated fair values exceeded their carrying values by more than 50 percent.", 0.5], ["If our estimates of profitability in the reporting unit decline, the fair value estimate under the income approach will decline.", -0.4], ["Further, changes in foreign currency exchange rates could increase the cost of procuring inventory and services from foreign suppliers, which could reduce reporting unit profitability.", -0.4], ["We are exposed to certain market risks as part of our ongoing business operations, including risks from changes in foreign currency exchange rates, interest rates and commodity prices that could affect our financial condition, results of operations and cash flows.", -0.5], ["We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates.", -0.6], ["A sensitivity analysis of changes in the fair value of foreign currency exchange forward contracts outstanding at December 31, 2023 indicated that, if the U.S. Dollar uniformly strengthened or weakened in value by 10 percent relative to all currencies, with no change in the interest differentials, the fair value of those contracts would affect earnings in a range of a decrease of approximately $114 million to an increase of approximately $105 million before income taxes in periods through June 2026.", -0.2], ["foreign currency exchange contracts would not subject us to material risk due to exchange rate movements because gains and losses on these contracts offset gains and losses on the assets, liabilities and transactions being hedged.", 0.2], ["As a result, foreign currency remeasurement gains/losses recognized in earnings are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period.", 0.1], ["To the extent the respective governments’ ability to fund their public hospital programs deteriorates, we may have to record significant bad debt expenses in the future.", -0.8], ["         Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2023, 2022 and 2021                                                                           44", 0.0], ["As described in Notes 2 and 17 to the consolidated financial statements, the Company has recorded tax liabilities for unrecognized tax benefits with a consolidated balance of $391.9 million as of December 31, 2023.", -0.4], ["Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed.", -0.7], ["The principal considerations for our determination that performing procedures relating to tax liabilities for certain unrecognized tax benefits is a critical audit matter are (i) the significant judgment by management when determining the tax liabilities for certain unrecognized tax benefits due to a high degree of estimation uncertainty related to management’s application of complex tax laws and regulations, the result of income tax audits, and potential for significant adjustments as a result of such audits; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures to evaluate the timely identification and accurate measurement of tax liabilities for certain unrecognized tax benefits and evaluating audit evidence available to support the estimates; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.", -0.6], ["Net Earnings from Continuing Operations of Zimmer Biomet Holdings,   Inc.", -0.1], ["Unrealized cash flow   hedge gains, net of tax", 0.2], ["Comprehensive Income   Attributable to Zimmer Biomet Holdings, Inc.", 0.3], ["                Net cash provided by   operating activities from continuing operations", 0.4], ["                 Net cash   used in investing activities from continuing operations", -0.4], ["                 Net cash   used in financing activities from continuing operations", -0.4], ["    Net cash (used in) provided by   operating activities", 0.0], ["                Net cash (used in) provided   by discontinued operations", 0.0], ["Spinoff - On March 1, 2022, we completed the previously announced separation of our spine and dental businesses into a new public company through the distribution by Zimmer Biomet Holdings of 80.3% of the outstanding shares of common stock of ZimVie Inc. (“ZimVie”) to Zimmer Biomet Holding’s stockholders.", 0.1], ["The historical results of our spine and dental businesses that were contributed to ZimVie in the spinoff have been reflected as discontinued operations in our consolidated financial statements through the date of the spinoff in 2022 and in 2021 as the spinoff represents a strategic shift in our business that has a major effect on operations and financial results.", 0.0], ["Unrealized translation gains and losses are included in accumulated other comprehensive loss in stockholders’ equity.", -0.5], ["When a transaction is denominated in a currency other than the subsidiary’s functional currency, we remeasure the transaction into the functional currency and recognize any transactional gains or losses in earnings.", -0.2], ["Expenses incurred related to shipping and handling of products are reflected in selling, general and administrative (“SG&A”) expenses and were $272.7 million, $254.4 million and $255.4 million for the years ended December 31, 2023, 2022 and 2021, respectively.", 0.0], ["Quality remediation - We used the financial statement line item “Quality remediation” to recognize expenses related to addressing inspectional observations on Form 483 and a warning letter issued by the FDA following its inspections of our Warsaw North Campus facility, among other matters.", -0.7], ["Restructuring and other cost reduction initiatives - A restructuring is defined as a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted.", -0.3], ["Restructuring charges include (i) employee termination benefits, (ii) contract termination costs and (iii) other related costs associated with exit or disposal activities.", -0.4], ["In December 2023, 2021 and 2019, we approved separate new global restructuring programs intended to further reduce costs and to reorganize our global operations.", 0.1], ["Restructuring charges for the years ended December 31, 2023, 2022 and 2021 were primarily attributable to these programs.", -0.3], ["We have also initiated other cost reduction and optimization projects that have the goal of reducing costs across the organization.", 0.2], ["•        Employee termination benefits related to terminating employees with overlapping responsibilities in various areas of our business.", -0.4], ["•        Dedicated project personnel expenses which include the salary, benefits, travel expenses and other costs directly associated with employees who are 100 percent dedicated to our integration of acquired businesses and employees who have been notified of termination, but are continuing to work on transferring their responsibilities.", -0.5], ["•        Contract termination expenses related to terminated contracts, primarily with sales agents and distribution agreements.", -0.6], ["•        Other various expenses to relocate facilities, integrate information technology, losses incurred on assets resulting from the applicable acquisition, and other various expenses.", -0.5], ["The allowance for credit losses was $75.1 million and $78.4 million as of December 31, 2023 and 2022, respectively.", -0.2], ["An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount.", -0.7], ["An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value.", -0.7], ["If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded in the amount that the carrying value of the reporting unit exceeds the fair value.", -0.7], ["An impairment loss is recognized if the carrying amount exceeds the estimated fair value of the asset.", -0.7], ["The amount of the impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value.", -0.7], ["The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the new tax rate is enacted.", -0.3], ["We reduce our deferred tax assets by a valuation allowance if it is more likely than not that we will not realize some portion or all of the deferred tax assets.", -0.5], ["In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes.", 0.2], ["Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed.", -0.7], ["For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.", -0.6], ["In the years ended December 31, 2023 and 2022, we recognized a gain of $2.5 and a loss of $116.6 million, respectively, related to our investment in ZimVie.", 0.1], ["On March 1, 2022, we completed the previously announced separation of our spine and dental businesses through the distribution of", 0.0], ["In the fourth quarter of 2021, ZimVie entered into a credit agreement with a financial institution providing for revolving loans of up to $175.0 million and term loan borrowings of up to $595.0 million.", 0.3], ["We used proceeds from the dividend, along with cash on hand and proceeds from a draw on our revolving credit facility, to repay senior notes due in 2022 which had an outstanding principal balance of $750.0 million.", 0.1], ["We recognize any gains or losses from the TSA and TMA agreements in Acquisition, integration, divestiture and related expense in our consolidated statements of earnings.", 0.0], ["In the years ended December 31, 2023 and 2022, we recognized a gain of $2.5 and a loss of $116.6 million, respectively, related to our investment in ZimVie.", 0.1], ["On August 31, 2022, we borrowed an aggregate principal amount of $83.0 million under a short-term credit agreement (the “ShortTerm Term Loan”) with a third-party financial institution, the proceeds of which were used to repay certain of our existing", -0.2], ["In February 2023, we repaid in full the Short-Term Term Loan by transferring our ZimVie common shares to the financial institution counterparty to settle the Forward Exchange Agreement and by paying $33.9 million in cash, representing an amount determined by the difference between the average daily volume-weighted average price of the ZimVie shares over the outstanding term of the Forward Exchange Agreement and the principal amount of $83.0 million.", 0.1], ["The transfer of our ZimVie common shares as part of the settlement resulted in a $49.1 million noncash financing activity for the year ended December 31, 2023.", -0.3], ["For the year ended December 31, 2022, an unrealized gain of $1.1 million related to the change in fair value of the Forward Exchange Agreement was recorded in non-operating other (expense) income, net in our consolidated statements of earnings.", 0.2], ["Details of earnings (loss) from discontinued operations included in our consolidated statements of earnings are as follows (in millions):", -0.5], ["Consignment sales represented approximately 85 percent of our net sales in 2023.", 0.3], ["At negotiated thresholds within a contract buying period, price discounts may increase.", -0.1], ["We estimate sales recognized in this manner represented approximately 15 percent of our net sales in 2023.", 0.2], ["These customers may purchase items in large quantities if incentives are offered or if there are new product offerings in a market, which could cause period-to-period differences in sales.", 0.0], ["If sales incentives may be earned by a customer for purchasing a specified amount of our product, we estimate whether such incentives will be achieved and recognize these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized.", -0.2], ["Occasionally, products are returned and, accordingly, we maintain an estimated refund liability based upon the expected value method that is recorded as a reduction in revenue.", -0.2], ["In December 2023, our management approved a new global restructuring program (the “2023 Restructuring Plan”) intended to optimize our cost base and drive greater efficiencies throughout the company.", 0.3], ["The 2023 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $100 million.", -0.4], ["The pre-tax restructuring charges consist of employee termination benefits, and other charges, such as consulting fees.", -0.3], ["In December 2021, our management approved a new global restructuring program (the “2021 Restructuring Plan”) intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie.", 0.2], ["The 2021 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $180 million.", -0.4], ["The pre-tax restructuring charges consist of employee termination benefits; contract terminations for sales agents; and other charges, such as consulting fees and project management expenses.", -0.3], ["Expense estimated to be   recognized for the 2021 Restructuring Plan", -0.2], ["Plan”) with an objective of reducing costs to allow us to further invest in higher priority growth opportunities.", 0.4], ["The 2019 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $370 million.", -0.5], ["The pre-tax restructuring charges consist of employee termination benefits; contract terminations for facilities and sales agents; and other charges, such as consulting fees, project management and relocation costs, including costs to close a manufacturing facility.", -0.8], ["In the years ended December 31, 2022 and 2021, all expenses related to the 2019 Restructuring Plan were recognized in “Restructuring and other cost reduction initiatives”.", -0.5], ["Based upon the number of RSUs that we expect to vest, the unrecognized share-based payment expense as of December 31, 2023 was $84.5 million and is expected to be recognized over a weighted-average period of 1.8 years.", 0.2], ["The fair value of RSUs that vested during the years ended December 31, 2023, 2022 and 2021 based upon our stock price on the date of vesting was $26.9 million, $20.3 million, and $40.0 million, respectively.", 0.3], ["Amounts charged to the consolidated statements of earnings for excess and obsolete inventory, including certain product lines we intend to discontinue, in the years ended December 31, 2023, 2022 and 2021 were $155.2 million, $137.3 million and $117.3 million, respectively.", -0.7], ["The fair value of sales-based payments is based upon significant unobservable inputs such as probabilityweighted future revenue estimates and simulating the numerous potential outcomes, and changes as revenue estimates increase or decrease.", -0.4], ["During the year ended December 31, 2023, we issued 0.1 million shares of our common stock valued at $15.5 million and paid $0.7 million of cash as the regulatory milestone related to the Embody acquisition was achieved.", 0.4], ["To minimize dilution from issuing shares for the milestone settlement, we repurchased 0.1 million shares of our common stock in June of 2023.", 0.1], ["To minimize dilution from issuing shares for the Embody acquisition, we repurchased 1.9 million shares of our common stock in the three-month period ended March 31, 2023.", 0.1], ["The total aggregate cash consideration paid at closing was $100.0 million, with an additional $11.0 million of deferred payments to be made over the following two years, of which $4.0 million was paid in the year ended December 31, 2023.", 0.0], ["We have not included pro forma information and certain other information under GAAP for these acquisitions because they did not have a material impact on our financial position or results of operations.", -0.1], ["We fully impaired the goodwill related to our EMEA reporting unit during the fourth quarter of 2022, as discussed below.", -0.7], ["During the year ended December 31, 2022, we recorded a goodwill impairment charge of $289.8 million in our EMEA reporting unit, primarily due to the impacts from macroeconomic factors.", -0.8], ["For the EMEA reporting unit, operating expenses did not decline proportionally to revenue as many inventory-related and certain expenses are based on the U.S. Dollar.", -0.5], ["We had previously taken goodwill impairment charges related to this reporting unit in prior years so when these negative macroeconomic factors occurred in 2022, the remaining goodwill was determined to be fully impaired.", -0.6], ["There were no goodwill impairment charges for the year ended December 31, 2021.", 0.1], ["If our estimated cash flows decrease, we may have to record further impairment charges in the future.", -0.6], ["Factors that could result in our cash flows being lower than our current estimates include: 1) additional recurrence of the COVID-19 virus, including variants, causing hospitals to defer elective surgical procedures, 2) decreased revenues caused by unforeseen changes in the healthcare market, or our inability to generate new product revenue from our research and development activities, 3) our inability to achieve the estimated operating margins in our forecasts from our restructuring programs, cost saving initiatives, and other unforeseen factors, and 4) the weakening of foreign currencies against the U.S. Dollar.", -0.9], ["We recognized IPR&D intangible asset impairment charges of $3.0 million and $16.3 million in the years ended December 31, 2022 and 2021, respectively, in “Goodwill and intangible asset impairment” on our consolidated statements of earnings.", -0.4], ["These impairments were the result of terminated projects or delays and additional costs related to a project.", -0.5], ["There were no IPR&D intangible asset impairment charges in the year ended December 31, 2023.", -0.1], ["At December 31, 2023, our total current and non-current debt of $5.8 billion consisted of $5.9 billion aggregate principal amount of senior notes, which included €1.0 billion of Euro-denominated senior notes (“Euro Notes”), and $50.0 million of outstanding borrowings under the Uncommitted Facility Letter (defined below), partially offset by fair value adjustments relating to interest rate swaps totaling $144.7 million and debt discount and issuance costs of $29.1 million.", -0.5], ["In 2023, we redeemed the $83.0 million outstanding principal amount of our Short-Term Term Loan and the $86.3 million outstanding principal amount of our 3.700% Senior Notes due 2023.", -0.3], ["On November 28, 2023, we completed the offering of $500.0 million aggregate principal amount of our 5.350% Senior Notes due December 1, 2028.", 0.2], ["We received net proceeds of $499.8 million.", 0.3], ["There was approximately $520.0 million in aggregate outstanding borrowings under the 2022 Five-Year Credit Agreement at the time it was terminated, which borrowings were repaid in full through borrowings under the 2023 Five-Year Credit Agreement on July 7, 2023 in the same amount and on the same interest rate and margin terms.", 0.1], ["We were in compliance with all covenants under the 2023 Five-Year Credit Agreement as of December 31, 2023.", 0.4], ["As of December 31, 2023, there were no outstanding borrowings under the 2023 Five-Year Credit Agreement.", 0.5], ["There were no borrowings outstanding under the 2022 364-Day Revolving Facility when it was terminated.", 0.2], ["As a result, we recorded a loss on the extinguishment of debt in the amount of $165.1 million in our consolidated statement of earnings for the year ended December 31, 2021.", -0.7], ["The components of this loss were the reacquisition price of $2,154.8 million minus the carrying value of the debt of $1,982.7 million (including debt discount and issuance costs) plus debt tender fees of $5.0 million minus a gain of $12.0 million on a reverse treasury lock that we entered into to offset any increases or decreases to the premium associated with the tender offer from the date we entered into the lock.", -0.5], ["We reclassified the portion of the net investment hedge gains (losses) deferred in foreign currency translation adjustments related to those entities to retained earnings.", 0.0], ["Unrealized gains and losses on cash flow hedges are reclassified to net earnings when the hedged item affects net earnings.", 0.0], ["           Balance December 31, 2022                                                          $    (169.3) $                             69.6  $                                                                      (79.6) $  (179.3)", -0.8], ["           Reclassifications to statements of earnings                                                      -                                           (77.4)                                                           (5.8)         (83.2)", -0.7], ["           Balance December 31, 2023                                                          $    (159.4) $                             63.3  $                                                                      (94.9) $  (191.0)", -0.7], ["     45.1  $                 9.9  $ (123.3 ) $ (99.9 )", -0.3], ["Changes in the fair value of the derivative instrument are recorded in current earnings and are offset by gains or losses on the underlying debt instrument.", 0.2], ["In June 2021, we entered into $1 billion of fixed-to-variable interest rate swaps that we have designated as fair value hedges of $1 billion of our fixed rate debt obligations.", 0.1], ["Long-term debt                                  $                          851.3  $                     823.9   $                                                     (144.7) $                     (172.0)", -0.4], ["The interest rate swaps were settled, and the remaining loss to be recognized at December 31, 2023 was $23.9 million, which will be recognized using the effective interest rate method over the remaining maturity period of the hedged notes.", -0.5], ["We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates.", -0.8], ["In the year ended December 31, 2023, Euro 100 million and Swiss Franc 50 million of these cross-currency interest rate swaps matured at a gain of $6.0 million and a loss of $3.0 million, respectively.", 0.1], ["The settlement of these gains with the counterparties is reflected in investing cash flows in our consolidated statements of cash flows and will remain in AOCI on our consolidated balance sheet until the hedged net investment is sold or substantially liquidated.", 0.0], ["For derivatives which qualify as hedges of future cash flows, the gains and losses are temporarily recorded in AOCI and then recognized in cost of products sold when the hedged item affects net earnings.", 0.0], ["Any foreign currency re-measurement gains/losses recognized in earnings are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period.", 0.0], ["The amount of these gains/losses is recorded in other (expense) income, net.", -0.2], ["In 2021 we entered into a reverse treasury lock related to our bond tender offer to offset any increases or decreases to the premium associated with the tender offer from the date we entered into the lock.", 0.0], ["We recognized a gain of $12.0 million that was included in the loss on early extinguishment of debt.", 0.5], ["Derivative instruments designated as cash flow hedges had the following effects, before taxes, on AOCI and net earnings on our consolidated statements of earnings, consolidated statements of comprehensive income (loss) and consolidated balance sheets (in millions):", 0.0], ["                                                                                               Amount of Gain / (Loss)                                                                                                                                                       Amount of Gain / (Loss)", -0.5], ["                                                                                                  Recognized in AOCI                                                                                       Location on                                                Reclassified from AOCI", 0.2], ["December 31, 2023, together with settled derivatives where the hedged item has not yet affected earnings, was a net unrealized gain of $71.6 million, or $63.3 million after taxes, which is deferred in AOCI.", 0.8], ["A gain of $68.2 million, or $56.4 million after taxes, is expected to be reclassified to earnings in cost of products sold and a loss of $0.7 million, or $0.5 million after taxes, is expected to be reclassified to earnings in interest expense, net over the next twelve months.", 0.6], ["Plans with projected benefit obligations in excess of plan assets were as follows (in millions):", -0.3], ["Total accumulated benefit obligations and plans with accumulated benefit obligations in excess of plan assets were as follows (in millions):", -0.3], ["Plans with accumulated   benefit obligations in excess    of   plan assets:", -0.3], ["We expensed $60.4 million, $48.5 million and $46.3 million related to these plans for the years ended December 31, 2023, 2022 and 2021, respectively.", -0.2], ["Valuation allowances are recorded to reduce deferred income tax assets when it is more likely than not that an income tax benefit will not be realized.", -0.7], ["Decreases related to   lapse of statute of limitations", -0.6], ["During 2023, we released interest and penalties of $45.3 million, and as of December 31, 2023, had a recognized liability for interest and penalties of $89.1 million, which does not include any increase related to business combinations.", -0.5], ["The $206.2 million decrease related to prior periods and the $45.3 million release of interest and penalties primarily resulted from unrecognized tax benefits determined to be effectively settled during 2023.", -0.3], ["During 2022, we accrued interest and penalties of $18.1 million, and as of December 31, 2022 had a recognized liability for interest and penalties of $134.5 million, which does not include any increase related to business combinations.", -0.4], ["During 2021, we accrued interest and penalties of $8.9 million, and as of December 31, 2021, had a recognized liability for interest and penalties of $116.2 million, which does not include any increase related to business combinations.", -0.4], ["Management’s best estimate of such change is within the range of a $270 million decrease to a $20 million increase.", -0.2], ["During the course of these audits, we receive proposed adjustments from taxing authorities that may be material.", -0.6], ["Therefore, there is a possibility that an adverse outcome in these audits could have a material effect on our results of operations and financial condition.", -0.8], ["This includes a proposed increase to our U.S. federal taxable income related to our cost sharing agreement, which would result in additional tax expense related to 2013 of approximately $370 million, subject to interest and penalties.", -0.7], ["The IRS has proposed adjustments for tax years 2016-2019, primarily related to the U.S. taxation of foreign earnings and profits, which could result in additional material tax expense if we are unsuccessful in defending our position.", -0.7], ["For the years ended December 31, 2023, 2022 and 2021, an average of 2.7 million options, 4.4 million options and 1.3 million options, respectively, to purchase shares of common stock were not included in the computation of diluted earnings per share as the exercise prices of these options were greater than the average market price of the common stock.", -0.3], ["Since the Americas segment includes additional costs related to centralized product category headquarter expenses, profitability metrics in this operating segment are not comparable to the EMEA and Asia Pacific operating segments.", -0.2], ["U.S. sales were $4,288.8 million, $4,012.4 million, and $3,853.9 million for the years ended December 31, 2023, 2022 and 2021, respectively.", 0.5], ["On a quarterly and annual basis, we review relevant information with respect to loss contingencies and update our accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.", 0.1], ["Actions involving intellectual property could result in a loss of patent protection or the ability to market products, which could lead to significant sales reductions or cost increases, or otherwise materially affect the results of our operations.", -0.8], ["During the years ended December 31, 2023, 2022, and 2021, we recognized $21.6 million, $65.9 million and $201.0 million, respectively, of net litigation-related charges.", -0.5], ["At December 31, 2023 and 2022, accrued litigation liabilities were $244.1 million and $349.2 million, respectively.", -0.4], ["The ultimate cost of litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on our financial condition and results of operations.", -0.9], ["We accrued a litigation-related charge in this matter based on an estimate of the reasonably possible loss, as discussed above.", -0.6], ["We accrued a litigation-related charge in this matter based on an estimate of the reasonably possible loss, as discussed above.", -0.6], ["Trials may still occur in the future, and although each case will be tried on its particular facts, a verdict and subsequent final judgment for the plaintiff in one or more of these cases could have a substantial impact on our potential liability.", -0.7], ["We accrued a litigation-related charge in this matter based on an estimate of the reasonably possible loss, as discussed above.", -0.5], ["On December 27, 2023, the FDA notified us that the warning letter relating to the Warsaw North Campus had been resolved.", 0.8], ["Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.", -0.9], ["Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of December 31, 2023, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.", 0.7], ["Based on their assessment, management has concluded that, as of December 31, 2023, the Company’s internal control over financial reporting is effective based on those criteria.", 0.7], ["The Executives’ underlying Change in Control Severance Agreements provide for certain payments to an Executive if their employment is terminated in certain circumstances in connection with a change in control of the Company, and also imposes limits on such payments.", 0.2]]}
